| Public title (as per ICTRP) | Scientific title (as per ICTRP) | Trial identifier |
|---|---|---|
| Efficacy observation for sequential first-line treatment of advanced metastatic pancreatic cancer with albumin combined with paclitaxel + teggio/gemcitabine + oxaliplatin: a single-arm prospective study | Metastatic pancreatic cancer with albumin combined with paclitaxel + teggio /gemcitabine + oxaliplatin: a single-arm prospective study | ChiCTR1900024867 |
| A Multinational, Multicenter, Open-label, Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of Oral Paclitaxel (DHP107) Compared to IV Paclitaxel as First-line Therapy in Patients with Recurrent or metastatic HER2 negative Breast Cancer | A Multinational, Multicenter, Open-label, Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of Oral Paclitaxel (DHP107) Compared to IV Paclitaxel as First-line Therapy in Patients with Recurrent or metastatic HER2 negative Breast Cancer | EUCTR2020-000954-86-BG |
| Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer | A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC) | NCT04499924 |
| Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinum | A Phase II Trial of Paclitaxel (Taxol) Administered as a Weekly One Hour Infusion in Patients With Taxol/Platinum-Refractory Stage III and IV Ovarian Cancer | NCT00003160 |
| Open-label, multi -center, single-arm, phase II clinical study for sintilimab combined with weekly paclitaxel and anlotinib in the treatment of platinum-resistant recurrent epithelial ovarian cancer/fallopian tube cancer/primary peritoneal adenocarcinoma | Open-label, multi -center, single-arm, phase II clinical study for sintilimab combined with weekly paclitaxel and anlotinib in the treatment of platinum-resistant recurrent epithelial ovarian cancer/fallopian tube cancer/primary peritoneal adenocarcinoma | ChiCTR2000035072 |
| PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer | A Phase I-II Study of PTX-200 Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients With Metastatic and Locally Advanced Breast Cancer | NCT01697293 |
| Clinical trial of first line treatment with carboplatin and paclitaxel plus bevacizumab for advanced ovarian cancer patients. | A multicenter study in patients with stage III-IV epithelial ovarian cancer treated with carboplatin/paclitaxel with bevacizumab: clinical and biological prognostic factors | EUCTR2012-003043-29-IT |
| Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer | Phase II Study of Lapatinib and Trastuzumab Followed by Concurrent Lapatinib, Trastuzumab, and Paclitaxel Followed by Surgery for Primary HER2-positive (HER2+) Breast Cancer | NCT01688609 |
| Cohort Study of Prospective Validation of Predictive Factors and Biological Imaging of Response to Bevacizumab and Paclitaxel in Patients With Metastatic Breast Cancer | Cohort Study of Prospective Validation of Predictive Factors and Biological Imaging of Response to Bevacizumab (AVASTIN ®) in Combination With Weekly Paclitaxel Chemotherapy in First Line Treatment Patients With Metastatic Breast Cancer | NCT01745757 |
| Gemcitabine, plus nab-paclitaxel, pirfenidone for pancreatic cancer with liver metastasis: a phase II, single center, single arm study | Gemcitabine, plus nab-paclitaxel, pirfenidone for pancreatic cancer with liver metastasis: a phase II, single center, single arm study | ChiCTR2000034397 |
| Gemcitabine plus nab-paclitaxel, paricalcitol and PD-1 antibody for locally advanced pancreatic cancer: a phase II, single center, single arm study | Gemcitabine plus nab-paclitaxel, paricalcitol and PD-1 antibody for locally advanced pancreatic cancer: a phase II, single center, single arm study | ChiCTR2000034398 |
| To evaluate the efficacy and safety of albumin paclitaxel in first-line and maintenance therapy in patients with advanced lung squamous cell carcinoma | To evaluate the efficacy and safety of albumin paclitaxel in first-line and maintenance therapy in patients with advanced lung squamous cell carcinoma | ChiCTR2000034444 |
| Efficacy and safety of albumin-bound paclitaxel combined with PD-1 antibody in the treatment of recurrent, metastatic or refractory cervical cancer | Efficacy and safety of albumin-bound paclitaxel combined with PD-1 antibody in the treatment of recurrent, metastatic or refractory cervical cancer | ChiCTR2000034427 |
| Efficacy and safety of albumin bound paclitaxel combined with pegylated liposome doxorubicin in the treatment of platinum resistant or refractory ovarian cancer: an open, single arm, phase II prospective study | Efficacy and safety of albumin bound paclitaxel combined with pegylated liposome doxorubicin in the treatment of platinum resistant or refractory ovarian cancer: an open, single arm, phase II prospective study | ChiCTR2000034609 |
| Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2). | A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) | NCT04472429 |
| Sirolimus- vs. Paclitaxel-Drug Coated Ballons in Patients With Peripheral Artery Disease | Head-to-Head Comparison of SIROlimus Versus Paclitaxel Drug-Eluting BallooN Angioplasty in the Femoropopliteal Artery | NCT04475783 |
| Paclitaxel with biweekly cetuximab for platinum- and immune checkpoint inhibitor-refractory head and neck cancer | Paclitaxel with biweekly cetuximab for platinum- and immune checkpoint inhibitor-refractory head and neck cancer | JPRN-jRCTs051200040 |
| Randomized phase 2 study comparing maintenance treatments with paclitaxel plus bevacizumab and endocrine agent in patients with inoperable or recurrent breast cancer who received prior endocrine treatment and achieved non progressive disease during induction treatment with paclitaxel plus bevacizumab. | Randomized phase 2 study comparing maintenance treatments with paclitaxel plus bevacizumab and endocrine agent in patients with inoperable or recurrent breast cancer who received prior endocrine treatment and achieved non progressive disease during induction treatment with paclitaxel plus bevacizumab. - CAPTURE | JPRN-UMIN000008955 |
| Phase II Trial of capsaicin gel application for prevent paclitaxel-induced peripheral neuropathy | Phase II Trial of capsaicin gel application for prevent paclitaxel-induced peripheral neuropathy | TCTR20150626002 |
| Development and clinical activity of low dose metronomic chemotherapy with oral paclitaxel. | Development and clinical activity of low dose metronomic chemotherapy with oral paclitaxel. | NL-OMON21795 |
| A randomized phase II study of TEC (Paclitaxel+Epirubicin+Carboplatin) therapy, TAC (Paclitaxel+Doxorubicin+Carboplatin)therapy, and ddTC (Dose-dense Paclitaxel+Carboplatin) therapy as adjuvant chemotherapy for the patients with intermediate or high risk group of endometrial carcinoma | A randomized phase II study of TEC (Paclitaxel+Epirubicin+Carboplatin) therapy, TAC (Paclitaxel+Doxorubicin+Carboplatin)therapy, and ddTC (Dose-dense Paclitaxel+Carboplatin) therapy as adjuvant chemotherapy for the patients with intermediate or high risk group of endometrial carcinoma - ACE trial (GOGO-EM3 / Intergroup Study) | JPRN-UMIN000008911 |
| Randomized phase II study of eribulin versus nab-paclitaxel in patients with relapsed HER2-negative breast cancer previously treated with anthracycline and peri-operative taxane | Randomized phase II study of eribulin versus nab-paclitaxel in patients with relapsed HER2-negative breast cancer previously treated with anthracycline and peri-operative taxane - EVA study | JPRN-UMIN000008839 |
| A Study of RO5083945 in Combination With Cisplatin and Gemcitabine or Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer of Squamous Histology Who Have Not Received Prior Chemotherapy for The Metastatic Disease | A MULTICENTER, OPEN-LABEL PHASE IB STUDY OF RO5083945 IN COMBINATION WITH CISPLATIN AND GEMCITABINE OR CARBOPLATIN AND PACLITAXEL IN PATIENTS WITH ADVANCED OR RECURRENT NON SMALL CELL LUNG CANCER OF SQUAMOUS HISTOLOGY WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR THE METASTATIC DISEASE. | NCT01702714 |
| A prospective, randomized controlled study of mFOLFIRINOX versus gemcitabine combined with albumin paclitaxel in the treatment of patients with unresectable pancreatic cancer | A prospective, randomized controlled study of mFOLFIRINOX versus gemcitabine combined with albumin paclitaxel in the treatment of patients with unresectable pancreatic cancer | ChiCTR2000034870 |
| Efficacy and Safety of Nab-Paclitaxel /Carboplatin for First-Line Chemotherapy of Advanced Ovarian Cancer | Efficacy and Safety of Nab-Paclitaxel /Carboplatin for First-Line Chemotherapy of Advanced Ovarian Cancer | ChiCTR2000034944 |
| A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10) | A Phase 4, Single-arm, Open-label Clinical Study of Pembrolizumab (MK-3475) to Evaluate the Efficacy and Safety of MK-3475 Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE B10). | NCT04489888 |
| Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery | A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma | NCT04498117 |
| A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) | A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) | EUCTR2020-000826-24-GB |
| A Multi-national, Multi-center, Open-label, Phase 2 Clinical Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DHP107 (Liporaxel®, Oral Paclitaxel) Compared to IV Paclitaxel in Patients with Recurrent or Metastatic Breast Cancer | A Multi-national, Multi-center, Open-label, Phase 2 Clinical Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DHP107 (Liporaxel®, Oral Paclitaxel) Compared to IV Paclitaxel in Patients with Recurrent or Metastatic Breast Cancer | EUCTR2020-000960-52-CZ |
| Single Arm on the Tolerability of Weekly Nab-paclitaxel | LCCC 1210 - Phase II, Multicenter, Single Arm Study of the Tolerability of Weekly Nab-paclitaxel as Second Line Treatment for Elderly Patients With Advanced Lung Cancer | NCT01702844 |
| TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer | A Single Center and Single Arm Study of TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer | NCT04475016 |
| A study of low intensity chemotherapy in relapsed and refractory lymphoma patients | Efficacy of weekly paclitaxel in combination with daily oral sodium valproate in relapsed and refractory lymphoma patients- A phase II study | CTRI/2020/08/026992 |
| A phase IB/II study of abemaciclib with paclitaxel for CDK4/6 pathway activated tumors | An open-label, multi-center phase IB/II study of abemaciclib with paclitaxel for CDK4/6 pathway activated tumors | KCT0005293 |
| To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer | An Open Label Phase II Study to Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer | NCT04561817 |
| Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients | A Phase II Clinical Study of the Efficacy and Safety of Preoperative Sintilimab in Combination With Nab-paclitaxel and Cisplatin in Borderline Resectable Esophageal Squamous Carcinoma | NCT04548440 |
| Nab-PTX, Ifosfamide and Cisplatin in the Treatment of Pediatric Extracranial Germ Cell Tumor. | A Multicenter Phase II Clinical Study of Albumin-bound Paclitaxel (Nab-PTX), Ifosfamide and Cisplatin in the Treatment of Pediatric Advanced, Recurrent or Refractory Extracranial Germ Cell Tumor. | NCT04581265 |
| Endoscopic Abraxane Injection Into Pancreatic Cysts | EUS Guided Injection of Albumin Bound Paclitaxel Into Pancreatic Cysts | NCT01698710 |
| A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic PC Patients | A Phase 1B Study to Determine the Safety and Tolerability and Confirm the Dose of Canakinumab and Spartalizumab in Combination With Nab-paclitaxel and Gemcitabine for Patients With Metastatic Pancreatic Cancer | NCT04581343 |
| An exploratory study of Camrelizumab combined with nab-paclitaxel in the treatment of platinum-resistant recurrent ovarian cancer | An exploratory study of Camrelizumab combined with nab-paclitaxel in the treatment of platinum-resistant recurrent ovarian cancer | ChiCTR2000038254 |
| Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer | Efficacy and Safety of Dose-dense Epirubicin and Cyclophosphamide Plus Paclitaxel as Neoadjuvant Chemotherapy for HER2-negative Early Breast Cancer:a Multicenter Randomized Controlled Trial | NCT04576143 |
| Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer | Toripalimab Combined With Docetaxel or Nab-paclitaxel in the Treatment of Advanced Gastric Cancer : a Single-arm, Open Label, Prospective Phase II Clinical Trial | NCT04563975 |
| Evaluation of efficacy and safety of Paclitaxel Lipid Suspension for Injection in patients with recurrent metastatic ovarian carcinoma | A multicenter, open-label, randomized, study to evaluate the efficacy and safety of Paclitaxel Lipid Suspension for Injection in patients with recurrent metastatic ovarian carcinoma | CTRI/2020/09/028042 |
| A randomized controlled trial for the efficacy and side effects of paclitaxel liposomes compared with paclitaxel in first-line chemotherapy for ovarian cancer | A randomized controlled trial for the efficacy and side effects of paclitaxel liposomes compared with paclitaxel in first-line chemotherapy for ovarian cancer | ChiCTR2000038555 |
| Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer | Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer: a Single-arm, Multicenter, Prospective Phase II Study | NCT04572542 |
| A study to compare two forms/formulations of Paclitaxel Injectable Suspension in metastatic Breast cancer patients | A randomized, multicenter, single dose, two-treatment, two-period, crossover, bioequivalence study of Mylanâ??s Paclitaxel protein bound particles for Injectable Suspension (albumin-bound) and Abraxis Bioscienceâ??s Abraxane® for Injectable Suspension in 110 breast cancer patients after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy | CTRI/2020/09/028155 |
| ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL | A Randomized, 2-Arm, Open-Label, Ph-II Study of Abemaciclib Combined With ET w/ or w/o CT With Paclitaxel as 1L in Patients With Unresectable Locally Advanced or Metastatic HR(+)/HER2(-) BC With Aggressive Disease Criteria | NCT04603183 |
| A PHASE III DOUBLE-BLIND RANDOMISED STUDY ASSESSING THE EFFICACY AND SAFETY OF CAPIVASERTIB + PACLITAXEL VERSUS PLACEBO + PACLITAXEL AS FIRST-LINE TREATMENT FOR PATIENTS WITH HISTOLOGICALLY CONFIRMED, LOCALLY ADVANCED (INOPERABLE) OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER (TNBC) (CAPITELLO-290) | A PHASE III DOUBLE-BLIND RANDOMISED STUDY ASSESSING THE EFFICACY AND SAFETY OF CAPIVASERTIB + PACLITAXEL VERSUS PLACEBO + PACLITAXEL AS FIRST-LINE TREATMENT FOR PATIENTS WITH HISTOLOGICALLY CONFIRMED, LOCALLY ADVANCED (INOPERABLE) OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER (TNBC) (CAPITELLO-290) | PER-039-20 |
| The exploratory study for IV period single peritoneal metastasis with ascites in gastric cancer treated with Injected red cartesian bacteria's cell wall skeleton (N-CWS) combine Paclitaxel and tigio | The exploratory study for IV period single peritoneal metastasis with ascites in gastric cancer treated with Injected red cartesian bacteria's cell wall skeleton (N-CWS) combine Paclitaxel and tigio | ChiCTR2000038902 |
| A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial Carcinoma | A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial Carcinoma | NCT04603846 |
| A Single-arm Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk IHCC in Korea | A Single-arm Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk Intrahepatic Cholangiocarcinoma in Korea | NCT04546828 |
| Paclitaxel-coated Balloon for Treatment of De-novo Non-complex Coronary Artery Lesions | Paclitaxel-coated Balloon for the Treatment of De-novo Non-complex Coronary Artery Lesions: an Open-label, Multicentre, Randomised, Non-inferiority Trial | NCT04561739 |
| A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma | A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Patients With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma | NCT04540211 |
| Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy | A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2 Study of Weekly Paclitaxel With or Without KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine | NCT04555304 |
| An exploratory study on the safety and efficacy of Paclitaxel for injee in (Albumin Bound) combined with Nedaplatin arterial perfusion in the treatment of stage IIIb non-small cell lung cancer | An exploratory study on the safety and efficacy of Paclitaxel for injee in (Albumin Bound) combined with Nedaplatin arterial perfusion in the treatment of stage IIIb non-small cell lung cancer | ChiCTR2000035359 |
| Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma | A Phase 2 Study With Combination Chemotherapy (Gemcitabine and Nab-Paclitaxel), Chemokine (C-X-C) Motif Receptor 4 Inhibitor (BL-8040), and Immune Checkpoint Blockade (Cemiplimab) in METastatic Treatment naïve PANCreas Adenocarcinoma | NCT04543071 |
| Pyrotinib Plus Paclitaxel in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer | Pyrotinib Plus Paclitaxel in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer | ChiCTR2000035412 |
| Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer | Phase II Trial of Paricalcitol and Hydroxychloroquine (PH) Combination With Gemcitabine and Nab-Paclitaxel in Advanced or Metastatic Pancreatic Cancer | NCT04524702 |
| Phase II clinical trial of acc006 combined with albumin bound paclitaxel and carboplatin in the treatment of advanced squamous non-small cell lung cancer | Acc006 combined with albumin bound paclitaxel and carboplatin (NAB PC) in the treatment of advanced squamous non-small cell lung cancer | ChiCTR2000035558 |
| Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer | Phase IB/II Study of Alpelisib in Combination With Paclitaxel in Patients With PIK3CA-altered Metastatic/Recurrent Gastric Cancer | NCT04526470 |
| A single arm, single center clinical study of Toripalimab combined with paclitaxel and platinum as neoadjuvant therapy on patients with esophageal squamous cell carcinoma at clinical stage of T2-T3/N0-N1/M0 | A single arm, single center clinical study of Toripalimab combined with paclitaxel and platinum as neoadjuvant therapy on patients with esophageal squamous cell carcinoma at clinical stage of T2-T3/N0-N1/M0 | ChiCTR2000035237 |
| Feasibility study of ABCP therapy and an exploratory study of microbiota in Japanese patients with advanced non-squamous non-small-cell lung cancer | Feasibility study of ABCP (Atezolizumab+Bevacizumab+Carboplatin+Paclitaxel) therapy and an exploratory study of microbiota in Japanese patients with advanced non-squamous non-small-cell lung cancer - Keihin area's next generation research for checkpoint inhibitor and immuno-oncology (Kangaroo-Tail: K-TAIL) 201 | JPRN-jRCTs031200088 |
| Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma | Phase 1 / 2 Trial of Blood-brain Barrier Opening With an Implantable Ultrasound Device SonoCloud-9 and Treatment With Albumin-bound Paclitaxel and Carboplatin in Patients With Recurrent Glioblastoma | NCT04528680 |
| The exploratory study of albumin binding paclitaxel intraperitoneal neoadjuvant chemotherapy in the evaluation of unresectable stage III primary ovarian serous adenocarcinoma by laparoscopic exploration | The exploratory study of albumin binding paclitaxel intraperitoneal neoadjuvant chemotherapy in the evaluation of unresectable stage III primary ovarian serous adenocarcinoma by laparoscopic exploration | ChiCTR2000036809 |
| Phase II, open-label study for efficacy and safety of consolidation paclitaxel/ifosfamide/cisplatin (TIP) chemotherapy for high risk pediatric germ cell tumor | Non-randomized, phase II, open-label study for efficacy and safety of consolidation paclitaxel/ifosfamide/cisplatin (TIP) chemotherapy for high risk pediatric germ cell tumor | KCT0005355 |
| First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC Patients | A Prospective, Single-arm, Open-Label, Phase II Study of Nab-paclitaxel Plus Cisplatin Plus Carilizumab as First-line Treatment in Patients With Metastatic Triple-negative Breast Cancer | NCT04537286 |
| Efficacy and safety of Antinib hydrochloride capsule combined with Paclitaxel for Injection (Albumin Bound) for first-line treatment of triple negative breast cancer | Efficacy and safety of Antinib combined with Paclitaxel for Injection (Albumin Bound) for first-line treatment of triple-negative breast cancer | ChiCTR2000037592 |
| A prospective, randomized, double-blinded, multi-center clinical trial to evaluate the efficiency and safety of anti-PD1 antibody (Camrelizumab) combined with Paclitaxel(Albumin Bound) and Gemcitabine versus Paclitaxel(Albumin Bound) and Gemcitabine as first-line therapy in patients with metastatic pancreatic cancer | A prospective, randomized, double-blinded, multi-center clinical trial to evaluate the efficiency and safety of anti-PD1 antibody (Camrelizumab) combined with Paclitaxel(Albumin Bound) and Gemcitabine versus Paclitaxel(Albumin Bound) and Gemcitabine as first-line therapy in patients with metastatic pancreatic cancer | ChiCTR2000037723 |
| A phase II neoadjuvant trial of sequential nab-paclitaxel followed by dose dense epirubicine/cyclophosphamide (ddEC) in operable breast cancer | A phase II neoadjuvant trial of sequential nab-paclitaxel followed by dose dense epirubicine/cyclophosphamide (ddEC) in operable breast cancer - A phase II neoadjuvant trial of sequential nab-paclitaxel followed by ddEC in operable breast cancer | JPRN-UMIN000041509 |
| A clinical study of intraperitoneal and intravenous Nab-Paclitaxel plus S-1 for gastric cancer with peritoneal metastasis complicated with malignant ascites | A clinical study of intraperitoneal and intravenous Nab-Paclitaxel plus S-1 for gastric cancer with peritoneal metastasis complicated with malignant ascites | ChiCTR2000036223 |
| A randomized trial to identify markers for personalized treatment in patients treated with bevacizumab and paclitaxel for advanced breast cancer | A prospective randomized Phase II study to identify predictive biomarkers and mechanisms of therapy resistance in patients with HER2-negative metastatic breast cancer (MBC) treated with the combination of bevacizumab and paclitaxel. | EUCTR2012-003743-30-SE |
| Combination of Gemcitabine and Paclitaxel for urothelial carcinoma | Combination of Gemcitabine and Paclitaxel for urothelial carcinoma - Gemcitabine and Paclitaxel for Urothelial carcinoma | JPRN-UMIN000008357 |
| Phase II study of weekly nanoparticle albumin-bound paclitaxel for patients with metastatic breast cancer (KSCOG-BC04) | Phase II study of weekly nanoparticle albumin-bound paclitaxel for patients with metastatic breast cancer (KSCOG-BC04) - Phase II study of weekly nanoparticle albumin-bound paclitaxel (KSCOG-BC04) | JPRN-UMIN000008861 |
| Phase I/II study of Chemotherapy with Nab-paclitaxel, Carboplatin and Trastuzumab in HER2-positive Locally Advanced Breast Cancer | Phase I/II study of Chemotherapy with Nab-paclitaxel, Carboplatin and Trastuzumab in HER2-positive Locally Advanced Breast Cancer - Phase I/II study of Chemotherapy with Nab-paclitaxel, Carboplatin and Trastuzumab in HER2-positive Locally Advanced Breast Cancer | JPRN-UMIN000007600 |
| A randomized phase III trial comparing nanoparticle-based paclitaxel with solvent-based paclitaxel as part of neoadjuvant chemotherapy for patients with early breast cancer(GeparSepto) - GeparSepto | A randomized phase III trial comparing nanoparticle-based paclitaxel with solvent-based paclitaxel as part of neoadjuvant chemotherapy for patients with early breast cancer(GeparSepto) - GeparSepto | EUCTR2011-004714-41-DE |
| A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation | A Randomized, Double-blind, Placebo Controlled, Phase II/III Study of BKM120 Plus Paclitaxel in Patients With HER2 Negative Inoperable Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Pathway Activation. | NCT01572727 |
| Feasibility study of adjuvant nab-paclitaxel in breast cancer | Feasibility study of adjuvant nab-paclitaxel in breast cancer - FANAP-BC Study | JPRN-UMIN000007725 |
| Primary systemic therapy of nab-paclitaxel in breast cancer patients | Primary systemic therapy of nab-paclitaxel in breast cancer patients - PINC-BC study | JPRN-UMIN000007724 |
| Efficacy and Safety of AZD8931 in Combination with Paclitaxel versus Paclitaxel alone in Patients with Metastatic Gastric Cancer, 2nd line, ineligible for Treatment with trastuzumab by HER2 Status | A Phase IIa Multi-centre Randomised Double-Blind Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of AZD8931 in Combination with Paclitaxel versus Paclitaxel alone in Patients with Metastatic, Gastric or Gastro-oesophageal Junction, Cancer who progress following First Line Therapy and are Ineligible for Treatment with trastuzumab by HER2 Status (SAGE) | KCT0000401 |
| Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma. | A Randomized Phase II Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Previously Untreated Advanced/Metastatic Pulmonary Adenocarcinoma | NCT01578551 |
| Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer | A Phase IIa Multi-centre Randomised Double-Blind Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Metastatic, Gastric or Gastro-oesophageal Junction, Cancer Who Progress Following First Line Therapy and Are Ineligible for Treatment With Trastuzumab by HER2 Status (SAGE) | NCT01579578 |
| A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma | A Phase III Randomized Clinical Trial of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma | NCT01591135 |
| Randomized trial of Legflow® Paclitaxel eluting balloon (LPEB) with stentplacement vs. standard PTA with stentplacement for the treatment of intermediate (>5 cm and < 15 cm) and long (>15 cm) lesions of the superficial femoral artery (SFA). The RAPID trial. | Randomized trial of Legflow® Paclitaxel eluting balloon (LPEB) with stentplacement vs. standard PTA with stentplacement for the treatment of intermediate (>5 cm and < 15 cm) and long (>15 cm) lesions of the superficial femoral artery (SFA). The RAPID trial. - The RAPID trial | NL-OMON40039 |
| Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2 | A Randomized Phase II Neoadjuvant Study of Sequential Eribulin Followed by FAC/FEC-regimen Compared to Sequential Paclitaxel Followed by FAC/FEC-Regimen in Women With Early Stage Breast Cancer Not Overexpressing HER-2 | NCT01593020 |
| Concurrent Chemoradiotherapy With Weekly Cisplatin Versus Concurrent Chemoradiotherapy With Weekly Cisplatin and Paclitaxel in Locally Advanced Carcinoma Cervix | NCT01593306 | |
| A Phase I/Ib, Multicentre, Study Comprising a Safety Run-In of AZD5363 when Combined with Paclitaxel in Patients with Advanced or Metastatic Breast Cancer; Followed by a Randomised Expansion of AZD5363 when Combined with Paclitaxel vs. Paclitaxel plus Placebo in Patients with ER-Positive Advanced or Metastatic Breast Cancer, Stratified by PIK3CA Mutation Status (BEECH). | A Phase I/Ib, Multicentre, Study Comprising a Safety Run-In of AZD5363 when Combined with Paclitaxel in Patients with Advanced or Metastatic Breast Cancer; Followed by a Randomised Expansion of AZD5363 when Combined with Paclitaxel vs. Paclitaxel plus Placebo in Patients with ER-Positive Advanced or Metastatic Breast Cancer, Stratified by PIK3CA Mutation Status (BEECH). - BEECH | NL-OMON37581 |
| Local Delivery of Paclitaxel Via the TAPAS Catheter to Prevent Restenosis From Percutaneous Femoropopliteal Intervention | Local Delivery of Paclitaxel Via the TAPAS Catheter to Prevent Restenosis From Percutaneous Femoropopliteal Intervention (PacTAP Study): A Double Blind, Randomized Control Study | NCT01599078 |
| An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors | An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors | NCT01618136 |
| Breast Cancer Study of Clinical Efficacy and Safty of Avastin with Paclitaxel in the 1st-taxane-line | Breast Cancer Study of Clinical Efficacy and Safty of Avastin with Paclitaxel in the 1st-taxane-line - BRAVE study | JPRN-UMIN000007948 |
| Randomized Phase II trial of Docetaxel treatment vs Paclitaxel Treatment for advanced/metastatic esophageal cancer resistant to fluoropyrimidine and/or platinum compound (OGSG1201) | Randomized Phase II trial of Docetaxel treatment vs Paclitaxel Treatment for advanced/metastatic esophageal cancer resistant to fluoropyrimidine and/or platinum compound (OGSG1201) - Second line treatment using taxan in esophageal cancer (OGSG1201) | JPRN-UMIN000007940 |
| TIP (paclitaxel + ifosfamide + cisplatin) Combined with Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer | A Single center and Single arm Study of TIP (paclitaxel + ifosfamide + cisplatin) Combine with Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Patients with locally advanced penile cancer | ChiCTR2000034375 |
| Evaluation of the efficacy of Frozen Glove to prevent peripheral neuropathy in patients who receive nab-paclitaxel treatment | Evaluation of the efficacy of Frozen Glove to prevent peripheral neuropathy in patients who receive nab-paclitaxel treatment - TBCRG05 | JPRN-UMIN000007907 |
| Piolt study of usefulness of analysis of genetic polymorphism of aldehyde dehydrogenase 2 (ALDH2) in safety of paclitaxel for the patients with alcohol intolerance | Piolt study of usefulness of analysis of genetic polymorphism of aldehyde dehydrogenase 2 (ALDH2) in safety of paclitaxel for the patients with alcohol intolerance - Role of genetic polymorphism of aldehyde dehydrogenase 2 (ALDH2) in the alcohol-related toxicity of paclitaxel | JPRN-UMIN000007624 |
| Concurrent Chemoradiotherapy for Cervical Cancer in Elderly Women | Weekly Cisplatin or Weekly Liposome Paclitaxel Concurrent Radiation Therapy in Treating Elderly People With Cervical Cancer | NCT01594099 |
| Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck Cancer | Phase II Trial of Nab-Paclitaxel, Cisplatin, and 5-FU (ACF) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC) | NCT01566435 |
| [18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer | Phase 1b Exploratory Study of [18F]Fluciclatide-PET as a Marker of Angiogenic Response to Combination Therapy With the Pan-VEGF Inhibitor, Pazopanib, and Weekly Paclitaxel in Platinum Resistant Ovarian Cancer | NCT01608009 |
| Determination of Dose of Antiangiogenic Multitargeted DOVITINIB (TKI258) Plus Paclitaxel in Patients With Solid Tumors | Phase I/II Randomized Clinical Trial of Neoadjuvant Paclitaxel Versus Priming With BIBF 1120 BIBF 1120 Followed by Plus Paclitaxel in Breast Cancer With HER-2 Negative Correlative Proteomic Studies. and Dynamic Image | NCT01548924 |
| PacLitaxel Eluting Balloon Application In Sfa In Stent Restenosis | PacLitaxel Eluting Balloon Application In Sfa In Stent Restenosis | NCT01587482 |
| Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer | A Phase II Trial of Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer Previously Treated With Docetaxel | NCT01558492 |
| A study for Subjects with Advanced Non-Small Cell Lung Cancer cured with either Tamibarotene or placebo plus Paclitaxel and Carboplatin as First Line Treatment. | A Randomized, Placebo-Controlled Phase 2b Study of Tamibarotene Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin as First Line Treatment for Subjects with Advanced Non-Small Cell Lung Cancer | EUCTR2011-004982-33-BG |
| Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients (SHINE) | A Randomised Open-Label Phase II Study to Assess the Efficacy and Safety of AZD4547 Monotherapy versus Paclitaxel in Patients with Advanced Gastric Adenocarcinoma (including Adenocarcinoma of the Lower Third of the Oesophagus or the Gastro-Oesophageal Junction) with FGFR2Polysomy or Gene Amplification (Shine study) - SHINE | CTRI/2012/02/002432 |
| ovarian cancer treatment with intraabdominal chemotherapy (paclitaxel) | Closed abdomen hyperthermic intraperitoneal chemotherapy with paclitaxel for advanced epithelial ovarian cancer - Hipecovario | EUCTR2011-006319-69-ES |
| Phase II study of tri-weekly administration of nanoparticle albumin-bound-paclitaxel for first-line chemotherapy in advanced and metastatic HER2- negative breast cancer | Phase II study of tri-weekly administration of nanoparticle albumin-bound-paclitaxel for first-line chemotherapy in advanced and metastatic HER2- negative breast cancer - Phase II study of Nab-paclitaxel treatment in HER2-negative breast cancer | JPRN-UMIN000007342 |
| Feasibility study of weekly paclitaxel plus gemcitabine for metastatic and recurrent breast cancer with negative HER2 | Feasibility study of weekly paclitaxel plus gemcitabine for metastatic and recurrent breast cancer with negative HER2 - KBC-SG1104 | JPRN-UMIN000007445 |
| Cetuximab and Cisplatin with or without Paclitaxel in recurrent/metastatic head and neck cancer | Cetuximab and Cisplatin with or without Paclitaxel in recurrent/metastatic head and neck cancer | EUCTR2011-002564-24-IT |
| A study to evaluate the efficacy and safety of bevacizumab in combination with chemotherapy in patients with breast cancer that spread to other tissues. | A phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of bevacizumab, and associated biomarkers, in combination with paclitaxel compared with paclitaxel plus placebo as first-line treatment of patients with HER2-negative metastatic breast cancer - Meridian | EUCTR2011-005335-97-DE |
| Preoperative Dose-dense Chemotherapy With Weekly Cisplatin, Epirubicin and Paclitaxel to Treat Patients With Locally Gastric Cancer | Preoperative Chemotherapy With Weekly Cisplatin, Epirubicin and Paclitaxel (Intensified PET) in Patients With Locally Gastric Cancer : a Phase II Proof-of-concept Study. | NCT01830270 |
| A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | A Phase II Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | NCT01570582 |
| A phase 2 study of weekly Nab-Paclitaxel followed by FEC (Fluorouracil, Epirubicin, Cyclophosphamide) as primary therapy for operable breast cancer | A phase 2 study of weekly Nab-Paclitaxel followed by FEC (Fluorouracil, Epirubicin, Cyclophosphamide) as primary therapy for operable breast cancer - A phase 2 study of weekly Nab-Paclitaxel followed by FEC as primary therapy for operable breast cancer | JPRN-UMIN000007510 |
| Pazopanib versus pacLitaxel in relapsed Urothelial TumOurs | A randomised phase II study investigating pazopanib vs weekly paclitaxel in relapsed or progressive transitional cell carcinoma (TCC) of the urothelium | ISRCTN73030316 |
| Feasibility study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced biliary tract cancer with carcinomatous ascites. | Feasibility study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced biliary tract cancer with carcinomatous ascites. - Feasibility study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced biliary tract cancer with carcinomatous ascites. | JPRN-UMIN000007520 |
| Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma | Phase I/II Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma (AI-PCa) | NCT00038246 |
| A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma | A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Patients With Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma | NCT00038545 |
| Combination Chemotherapy Followed by Radiation Therapy With or Without Paclitaxel in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer | Phase III Randomized Study of Paclitaxel and Carboplatin or Cisplatin Followed by Radiotherapy With or Without Concurrent Paclitaxel in Patients With Unresectable Stage III Non-Small Cell Lung Cancer | NCT00039039 |
| Neoadjuvant Treatment With Nab-paclitaxel for Patients With Stage II and III Luminal Breast Cancer | Phase II, Open-label, Non-randomized Study of Nab-paclitaxel for the Neoadjuvant Treatment of Patients With Stage II and III Luminal Breast Cancer | NCT01565499 |
| Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer | ZD1839 (NSC #715055, IND #61187) With Induction Paclitaxel And Carboplatin Followed By Either Radiation Or Concomitant Radiation With Weekly Paclitaxel And Carboplatin In Stage III Non-Small Cell Lung Cancer, A Phase II Study | NCT00040794 |
| Prospective, Randomized, Controlled, Multicentre, Open Study Releas of Paclitaxel during PTA versus PTA alone for the treatment of de-novo occluded, stenotic or reoccluded, restenotic superficial femoral (SFA) or popliteal arteries. | Prospective, Randomized, Controlled, Multicentre, Open Study Releas of Paclitaxel during PTA versus PTA alone for the treatment of de-novo occluded, stenotic or reoccluded, restenotic superficial femoral (SFA) or popliteal arteries. - FREERIDE-STUDY | NL-OMON35958 |
| M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer | A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer | NCT01621243 |
| A Phase 1 Study of veliparib (ABT-888) in Combination with Carboplatin/Paclitaxel in Japanese Subjects with solid tumors | A Phase 1 Study of veliparib (ABT-888) in Combination with Carboplatin/Paclitaxel in Japanese Subjects with solid tumors | JPRN-jRCT2080221796 |
| A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid Tumors | A Phase 1 Study of Veliparib (ABT-888) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Solid Tumors | NCT01617928 |
| Observational Post-authorization Studies Carboplatin, Paclitaxel and Bevacizumab | Observational Studies to Explore the Relation Between Angiogenic Markers and the Treatment Response With Carboplatin, Paclitaxel and Bevacizumab in First Line of Advanced Non-small-cell Lung Cancer With Non- Squamous Histology | NCT01814163 |
| Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors | A Phase Ib Ascending Multi-arm, Dose Escalation Study of BMS-906024 Combined With Several Chemotherapy Regimens in Subjects With Advanced or Metastatic Tumors | NCT01653470 |
| Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer | Phase Ib With Expansion of Patients at the MTD Study of Olaparib Plus Weekly (Metronomic) Carboplatin and Paclitaxel in Relapsed Ovarian Cancer Patients | NCT01650376 |
| A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | NCT01649336 | |
| Neurotoxicity characterization study of nab-paclitaxel versus conventional paclitaxel in metastatic breast cancer. | Neurotoxicity characterization phase II randomized study of nab-paclitaxel versus conventional paclitaxel as first-line therapy of metastatic HER2-negative breast cancer. | EUCTR2012-002361-36-ES |
| Legflow® Paclitaxel Eluting Balloon (LPEB) with stentplacement versus standard percutaneous transluminal angioplasty with stentplacement for the treatment of occlusive disease of the superficial femoral artery | RAndomized trial of Legflow® PaclItaxel Eluting Balloon (LPEB) with stentplacement vs. stanDard percutaneous transluminal angioplasty (PTA) with stentplacement for the treatment of intermediate (>5 cm and < 15 cm) and long (>15 cm) lesions of the superficial femoral artery (SFA): the RAPID trial | ISRCTN47846578 |
| A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer | A Randomized Phase II Study of Reolysin For Patients Receiving Standard Weekly Paclitaxel Therapy as Therapy For Advanced/Metastatic Breast Cancer | NCT01656538 |
| A prospective clinical study to evaluate the feasibility and safeness of the chemotherapy with weekly paclitaxel administration in cases with anaplastic thyroid cancer | A prospective clinical study to evaluate the feasibility and safeness of the chemotherapy with weekly paclitaxel administration in cases with anaplastic thyroid cancer - ATCCJ-TXL-P2 | JPRN-UMIN000008574 |
| A multicenter phase II clinical study of albumin-bound paclitaxel (nab-PTX), ifosfamide and cisplatin in the treatment of pediatric advanced, recurrent or refractory extracranial germ cell tumor. | A multicenter phase II clinical study of albumin-bound paclitaxel (nab-PTX), ifosfamide and cisplatin in the treatment of pediatric advanced, recurrent or refractory extracranial germ cell tumor. | ChiCTR2000038919 |
| PhaseII study of neoadjuvant chemotherapy with the nab Paclitaxel And Trastuzumab followed by FEC for the HER2-positive resectable primary breast cancer | PhaseII study of neoadjuvant chemotherapy with the nab Paclitaxel And Trastuzumab followed by FEC for the HER2-positive resectable primary breast cancer - PhaseII study of neoadjuvant chemotherapy with the nab Paclitaxel And Trastuzumab followed by FEC for the HER2-positive resectable primary breast cancer | JPRN-UMIN000008465 |
| Exploratory study of Paclitaxel+Trastuzumab therapy for advanced or recurrent gastric cancer with HER2 positive. | Exploratory study of Paclitaxel+Trastuzumab therapy for advanced or recurrent gastric cancer with HER2 positive. - Exploratory study of Paclitaxel+Trastuzumab therapy for advanced or recurrent gastric cancer with HER2 positive. | JPRN-UMIN000008623 |
| Pilot Study Investigating the Metabolic Activity and Transcriptional Profiling in Vivo in Tumor Biopsies in Melanoma Patients During Treatment With Pazopanib Alone and in Combination With Paclitaxel | NCT01666418 | |
| Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer | OptiHER-Heart: A Prospective, Multicenter, Single-arm, Phase II Study to Evaluate the Safety of Neoadjuvant Liposomal Doxorubicin (Myocet®) Plus Paclitaxel, Trastuzumab, and Pertuzumab in Patients With HER2-positive Breast Cancer | NCT01669239 |
| A study of RO5304020 versus taxane in patients with advanced gastric cancer | A randomized, multicenter, adaptive Phase II/III study to evaluate the efficacy and safety of trastuzumab emtansine (T-DM1) versus Taxane (Docetaxel or Paclitaxel) in patients with previously treated locally advanced or metastatic HER2-positive gastric cancer, including adenocarcinoma of the gastroesophageal junction | JPRN-jRCT2080221881 |
| Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer | Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes:A 2X2 Factorial Phase III Randomized Study | NCT00041119 |
| A Multicenter Randomized Comparison of Paclitaxel-eluting Balloon Catheter with Conventional Balloon Angioplasty in Patients with Bare-metal Stent Restenosis and Drug-eluting Stent Restenosis | A Multicenter Randomized Comparison of Paclitaxel-eluting Balloon Catheter with Conventional Balloon Angioplasty in Patients with Bare-metal Stent Restenosis and Drug-eluting Stent Restenosis - Paclitaxel-eluting Balloon for In-stent restenosis. | JPRN-UMIN000008681 |
| Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies | Phase I Study Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies | NCT01677559 |
| Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma | A Phase II Study of Ipilimumab in Combination With Carboplatin and Paclitaxel in Patients With Unresectable Stage III or Stage IV Melanoma | NCT01676649 |
| Study of Nab-Paclitaxel in High Risk Early Breast Cancer | Neo-/Adjuvant Phase III Trial to Compare Intense Dose-dense Chemotherapy to Tailored Dose-dense Chemotherapy in Patients With High-risk Early Breast Cancer (GAIN-2) | NCT01690702 |
| Phase 1/2 study of weekly paclitaxel and gemcitabine in patient with HER2 negative recurrent breast cancer | Phase 1/2 study of weekly paclitaxel and gemcitabine in patient with HER2 negative recurrent breast cancer - Phase 1/2 study of weekly paclitaxel and gemcitabine in patient with HER2 negative recurrent breast cance | JPRN-UMIN000008848 |
| A Multicenter, Phase II, Single-Arm Clinical Trial of nab-Paclitaxel as salvage treatment for patients with Locally Advanced or Metastatic Adenocarcinomas of the Stomach and Gastro-esophageal junction - N/A | EUCTR2012-002179-32-GR | |
| Phase II study of Paclitaxel and Nedaplatin for previously untreated patients with advanced squamous cell lung cancer. | Phase II study of Paclitaxel and Nedaplatin for previously untreated patients with advanced squamous cell lung cancer. - Phase II study of Paclitaxel and Nedaplatin for previously untreated patients with advanced squamous cell lung cancer. | JPRN-UMIN000008872 |
| A Phase III Study of NK105 in Patients With Breast Cancer | A Multi-national Phase III Clinical Study Comparing NK105 Versus Paclitaxel in Patients With Metastatic or Recurrent Breast Cancer | NCT01644890 |
| A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer | A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic HER2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction | NCT01641939 |
| A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer | A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer | NCT01617668 |
| Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery | Multimodality Risk Adapted Therapy Including Carboplatin/Paclitaxel/Lapatinib as Induction for Squamous Cell Carcinoma of the Head and Neck Amenable to Transoral Surgical Approaches | NCT01612351 |
| A Phase II study of Neoadjuvant chemotherapy in Tri-weekly nab-Paclitaxel followed by FEC with Operable HER2 Negative breast cancer | A Phase II study of Neoadjuvant chemotherapy in Tri-weekly nab-Paclitaxel followed by FEC with Operable HER2 Negative breast cancer - KBCSG-TR1213 | JPRN-UMIN000008085 |
| Paclitaxel Eluting Balloon for SFA In-stent Restenosis | Rug Eluting Balloon With Paclitaxel for Treatment of In-stent Restenosis in Femoropopliteal Arteries | NCT01616888 |
| A phase II study of Paclitaxel combined with Bevacizumab in HER2 negative metastatic Breast Cancer | A phase II study of Paclitaxel combined with Bevacizumab in HER2 negative metastatic Breast Cancer - KBCOG 12 | JPRN-UMIN000008140 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer | A Phase II Study of Weekly Abraxane for Patients With Advanced NSCLC With EGFR Mutations or With Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front Line Therapy With EGFR Tyrosine Kinase Inhibitors | NCT01620190 |
| Phase I study of weekly low dose Paclitaxel for pancreato-biliary cancers after failure of gemcitabine and 5-FU | Phase I study of weekly low dose Paclitaxel for pancreato-biliary cancers after failure of gemcitabine and 5-FU - Palliative chemotherapy with paclitaxel for pancreato-biliary cancers | JPRN-UMIN000008148 |
| AMG 386 Drug-Drug Interaction Study With Paclitaxel | An Open-Label, Pharmacokinetic Drug-Drug Interaction (DDI) Study of AMG 386 in Combination With Paclitaxel in Adult Subjects With Advanced Solid Tumors | NCT01992341 |
| Feasibility study of carboplatin, paclitaxel and bevacizumab in advanced non-squamous non-small-cell lung cancer with idiopathic interstitial pneumonias | Feasibility study of carboplatin, paclitaxel and bevacizumab in advanced non-squamous non-small-cell lung cancer with idiopathic interstitial pneumonias - Feasibility study of carboplatin, paclitaxel and bevacizumab in advanced non-squamous non-small-cell lung cancer with idiopathic interstitial pneumonias | JPRN-UMIN000008189 |
| Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer | A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel versus Weekly Paclitaxel Plus Weekly Carboplatin In Women with Triple Negative Breast Cancer | CTRI/2012/07/002802 |
| Neoadjuvant Study of Nab-paclitaxel Plus Carboplatin in Breast Cancer | A Single-center, Prospective, Phase II Study of Albumin-bound Paclitaxel (Nab-paclitaxel) and Carboplatin With or Without Trastuzumab (Herceptin) as Neoadjuvant Therapy in Locally Advanced Breast Cancer | NCT01625429 |
| Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In-Stent Restenosis 4 | "ISAR-DESIRE 4: Randomized Trial Of Scoring Balloon in Patients With Restenosis in ""Limus""-Eluting Coronary Stents Undergoing Angioplasty With Paclitaxel-Coated Balloon" | NCT01632371 |
| A Phase 2a Multi-centre Randomised Double-Blind Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Metastatic, Gastric or Gastro-oesophageal Junction, Cancer Who Progress Following First Line Therapy and Are Ineligible for Treatment With Trastuzumab by HER2 Status | A Phase 2a Multi-centre Randomised Double-Blind Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Metastatic, Gastric or Gastro-oesophageal Junction, Cancer Who Progress Following First Line Therapy and Are Ineligible for Treatment With Trastuzumab by HER2 Status | JPRN-jRCT2080221824 |
| Comparison the results of combination platinium based neoadjuvant chemotherapy regimens using gemcitabin/ciplatin with carboplatin/paclitaxel in advanced stage ovarian cancer patients; A RCT | Comparison the results of combination platinium based neoadjuvant chemotherapy regimens using gemcitabin/ciplatin with carboplatin/paclitaxel in advanced stage ovarian cancer patients; A RCT | IRCT201203225283N3 |
| A phase II study of additional chemotherapy (neoadjuvant) followed by standard chemoradiation for locally advanced cervical carcinoma | Neoadjuvant chemotherapy with weekly paclitaxel and carboplatin followed by chemoradiation in locally advanced cervical carcinoma: a pilot study. | CTRI/2012/07/002758 |
| Study of Vemurafenib, Carboplatin, and Paclitaxel | Phase I Study of the Combination of Vemurafenib With Carboplatin and Paclitaxel in Patients With Advanced Malignancy | NCT01636622 |
| Paclitaxel plus carboplatin for advanced or recurrent carcinosarcoma of the uterus in Japan. | Paclitaxel plus carboplatin for advanced or recurrent carcinosarcoma of the uterus in Japan. - TC combination chemotherapy for advanced or recurrent carcinosarcoma. | JPRN-UMIN000008390 |
| Clinical Study of Albumin-bound Paclitaxel Plus Nedaplatin in Cervical Cancer | A Single Center, Non-randomized, Open Phase II Clinical Study of Albumin-bound Paclitaxel Plus Nedaplatin in Patients With Advanced, Recurrent Metastatic Cervical Cancer | NCT01667211 |
| A clinical trial to study if GSK2110183 can help ovarian cancers respond to carboplatin and paclitaxel | An Open-Label Phase I/II Study of GSK2110183 in Combination with Carboplatin and Paclitaxel in Subjects with Platinum-Resistant Ovarian Cancer - N/A | EUCTR2012-002483-27-GB |
| A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer | A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer | NCT01647828 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma | Phase II Trial of Nab-paclitaxel (Abraxane®) in Patients With Relapsed or Refractory Multiple Myeloma | NCT01646762 |
| ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer | ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer: A Phase I/Ib Trial | NCT04602117 |
| A randomized phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib in patients with advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian tube cancer preceded by a phase I dose escalation study on Rucaparib-Bevacizumab combination . | A randomized phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib in patients with advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian tube cancer preceded by a phase I dose escalation study on Rucaparib-Bevacizumab combination . - MITO 25 | EUCTR2017-002860-42-IT |
| Phase 1b/2, single arm clinical trial to evaluate the safety and activity of Oregovomab and bevacizumab, paclitaxel, carboplatin as a combination strategy in subjects with BRCA-wild type platinum sensitive recurrent ovarian, tubal and primary peritoneal cancer | Phase 1b/2, single arm clinical trial to evaluate the safety and activity of Oregovomab and bevacizumab, paclitaxel, carboplatin as a combination strategy in subjects with BRCA-wild type platinum sensitive recurrent ovarian, tubal and primary peritoneal cancer | KCT0005461 |
| ATEMPT 2.0: Adjuvant T-DM1 vs TH | A Randomized Phase II Trial of Adjuvant Trastuzumab Emtansine (T-DM1) Followed by Subcutaneous Trastuzumab Versus Paclitaxel in Combination With Subcutaneous Trastuzumab for Stage I HER2-positive Breast Cancer (ATEMPT 2.0) | NCT04893109 |
| Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study) | An Open-label, Multicenter Phase Ib/II Study of Ramucirumab in Combination With Trastuzumab and Weekly Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer | NCT04888663 |
| A prospective single-arm exploratory study of Sintilimab combined with paclitaxel (albumin-bound) and gemcitabine for conversion therapy in patients with locally advanced non-resectable pancreatic cancer | A prospective single-arm exploratory study of Sintilimab combined with paclitaxel (albumin-bound) and gemcitabine for conversion therapy in patients with locally advanced non-resectable pancreatic cancer | ChiCTR2100046345 |
| Camrelizumab combined with paclitaxel and nedaplatin in the treatment of locally advanced/advanced esophageal squamous cell carcinoma: a single arm, prospective study. | Camrelizumab combined with paclitaxel and nedaplatin in the treatment of locally advanced/advanced esophageal squamous cell carcinoma: a single arm, prospective study. | ChiCTR2100046355 |
| A prospective phase II clinical study of albumin-bound paclitaxel plus cisplatin induction chemotherapy followed by concurrent radiotherapy and chemotherapy in patients with locally advanced nasopharyngeal carcinoma | A prospective phase II clinical study of albumin-bound paclitaxel plus cisplatin induction chemotherapy followed by concurrent radiotherapy and chemotherapy in patients with locally advanced nasopharyngeal carcinoma | ChiCTR2100046393 |
| ACOART SCB BIF: Treatment of Coronary Bifurcation Lesion by Sirolimus Coated Balloon vs Paclitaxel Coated Balloon | A Prospective, Multicenter, Random Controlled Clinical Trail to Evaluate the Effectiveness and Safety of Sirolimus Coated Balloon Versus a Paclitaxel Coated Balloon in the Treatment of Coronary Bifurcation Lesion | NCT04899583 |
| Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer | Prospective Exploratory Study of Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Postoperative Recurrence of Pancreatic Cancer | NCT04902261 |
| Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer | Phase 1b/2, Single Arm Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Bevacizumab, Paclitaxel Carboplatin as a Combinatorial Strategy in Subjects With BRCA-wild Type Platinum Sensitive Recurrent Ovarian Cancer | NCT04938583 |
| Clinical study, involving Italian clinical sites, comparing the activity of Paclitaxel (weekly administration) to the activity of Cediranib-Olaparib with continuous administration or to Cediranib-Olaparib with intermittent administration, in patients with advanced ovarian cancer, resistant to previous platinum treatment. | The BAROCCO study (Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib): an Italian multicenter randomized phase II study of weekly paclitaxel vs. Cediranib-Olaparib with continuous schedule vs. Cediranib-Olaparib with intermittent schedule in patients with platinum resistant high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer. - The BAROCCO study | EUCTR2016-003964-38-IT |
| A prospective, single-arm and multicenter clinical study of anlotinib hydrochloride combined with paclitaxel one-week therapy in platinum resistant and recurrent ovarian cancer | A prospective, single-arm and multicenter clinical study of anlotinib hydrochloride combined with paclitaxel one-week therapy in platinum resistant and recurrent ovarian cancer | ChiCTR2100046031 |
| Clinical Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma | A Multi-center, Single-arm, Phase II Clinical Study of Camrelizumab in Combination With Albumin Paclitaxel and Cisplatin for Neoadjuvant Treatment of Operable Locally Advanced Head and Neck Squamous Cell Carcinoma | NCT04922450 |
| A double-blind randomized Control trial to Evaluate mitigation of CIpn by LImb-cooling Apparatus in breast cancer patients who undergo weekly paclitaxel | A double-blind randomized Control trial to Evaluate mitigation of CIpn by LImb-cooling Apparatus in breast cancer patients who undergo weekly paclitaxel - CECILIA | JPRN-jRCT2032210115 |
| A prospective, single-center, observational real-world study: evaluating the efficacy of pembrolizumab combined with standard chemotherapy (cisplatin/carboplatin + paclitaxel) in the first-line treatment of locally recurring head and neck squamous cell carcinoma under different TP53 and PIK3CA states and safety | A prospective, single-center, observational real-world study: evaluating the efficacy of pembrolizumab combined with standard chemotherapy (cisplatin/carboplatin + paclitaxel) in the first-line treatment of locally recurring head and neck squamous cell carcinoma under different TP53 and PIK3CA states and safety | ChiCTR2100046731 |
| Low-dose nab-paclitaxel plus tislelizumab in elderly patients with previously treated advanced non-small cell lung cancer | Efficacy and safety of low-dose nab-paclitaxel plus tislelizumab in elderly patients with previously treated advanced non-small cell lung cancer, a single-arm prospective study | ChiCTR2100046698 |
| Real-world Data (RWD) of Ramucirumab Plus Paclitaxel | A Prospective Study for Real-world Data (RWD) of Ramucirumab Plus Paclitaxel in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | NCT04915807 |
| Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer | Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer | NCT04917900 |
| Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer | A Multi-center, Double-blind, Randomized Phase III Clinical Trial of Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer | NCT04921527 |
| A phase II study of combination of radiotherapy and Atezolizumab/nab-paclitaxel for inoperable or recurrent PD-L1 positive triple negative breast cancer | A phase II study of combination of radiotherapy and Atezolizumab/nab-paclitaxel for inoperable or recurrent PD-L1 positive triple negative breast cancer - IMRad-Br | JPRN-jRCTs021210010 |
| Efficacy and safety of first-line Albumin-Bound Paclitaxel + Anlotinib + Camrelizumab in subjects with locally advanced or metastatic squamous NSCLC: a Multicenter, Randomized, Phase III Clinical Study | Efficacy and safety of first-line Albumin-Bound Paclitaxel + Anlotinib + Camrelizumab in subjects with locally advanced or metastatic squamous NSCLC: a Multicenter, Randomized, Phase III Clinical Study | ChiCTR2100046969 |
| Single-Arm, Multi-Center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-Bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer | Single-Arm, Multi-Center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-Bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer | ChiCTR2100047086 |
| Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) | A Multicenter, Open, Randomized Controlled Study of Camrelizumab+ Nab-paclitaxel + Carboplatin Versus Nab-paclitaxel + Carboplatin as Neoadjuvant Therapy for Triple Negative Breast Cancer (TNBC) | NCT04907344 |
| Phase II Study of Neoadjuvant Chemotherapy With Dose-Dense Paclitaxel In Association With Carboplatin followed by Radical Surgery for Locally Advanced Cervical Cancer (FIGO stage IB2- IIIA) Patients. | Phase II Study of Neoadjuvant Chemotherapy With Dose-Dense Paclitaxel In Association With Carboplatin followed by Radical Surgery for Locally Advanced Cervical Cancer (FIGO stage IB2- IIIA) Patients. - DOSE DENSE | EUCTR2016-003294-18-IT |
| Efficacy and safety of Sintilimab combined with albumin paclitaxel plus platinum chemotherapy versus albumin paclitaxel plus platinum in neoadjuvant chemotherapy for esophageal squamous cell carcinoma: a randomized controlled trial | Efficacy and safety of Sintilimab combined with albumin paclitaxel plus platinum chemotherapy versus albumin paclitaxel plus platinum in neoadjuvant chemotherapy for esophageal squamous cell carcinoma: a randomized controlled trial | ChiCTR2100045992 |
| An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo) | An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer | NCT04876313 |
| Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | A Phase II Trial of the Efficacy and Safety of the Combination of Cemiplimab and Low-Dose Paclitaxel and Carboplatin in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | NCT04862650 |
| Neoadjuvant Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms | Phase II Trial of Toripalimab, an Anti-PD-1 Monoclonal Antibody, in Combination With Combination Carboplatin and Nab-paclitaxel , as a Novel Neoadjuvant Pre-Surgical Therapy for Salivary Gland Malignant Neoplasms | NCT04825938 |
| Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer | Phase Ib/IIa Study to Evaluate Safety and Efficacy of Treatment With the Hedgehog Inhibitor NLM-001 and Chemotherapy (Gemcitabine and Nab-Paclitaxel) Plus Zalifrelimab as First Line Treatment in Patients With Advanced Pancreatic Cancer | NCT04827953 |
| Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC | An Open Label, Single Arm Phase II Study of Camrelizumab in Combination With Cisplatin and Nab-paclitaxel as a Novel Neoadjuvant Pre-Surgical Therapy for Resectable HNSCC | NCT04826679 |
| Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor | Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor: A Single-Arm, Phase 2 Trial | NCT04831320 |
| Study of M7824 and Paclitaxel Combination as a Second-line Treatment in Patients With Recurrent/Metastatic Gastric Cancer | An Open Label, Single-arm, Multi-center Phase 1b/2 Combination Study of M7824 (Bintrafusp Alfa) and Paclitaxel in Recurrent/Metastatic Gastric Cancer as a Second-line Treatment | NCT04835896 |
| A Medical Records Based Observational Study on the Efficacy and Safety of Sintilimab Combined with Albumin, Paclitaxel and Platinum in the Treatment of Relapsed Extensive-stage Small Cell Lung Cancer After First-Line Etoposide-Containing Chemotherapy Failure | Observational Study on the Efficacy and Safety of Sintilimab Combined with Albumin, Paclitaxel and Platinum in the Treatment of Relapsed Extensive-stage Small Cell Lung Cancer After First-Line Etoposide-Containing Chemotherapy Failure | ChiCTR2100045074 |
| Phase Ib/II Study of M7824 and Paclitaxel Combination in Recurrent/Metastatic Gastric Cancer as a Second-line Treatment | An Open Label, Single-arm, Multi-center Phase Ib/II Combination Study of M7824 (bintrafusp alfa) and Paclitaxel in Recurrent/Metastatic Gastric Cancer as a Second-line Treatment | KCT0006078 |
| Nab-paclitaxel Based TPX Neoadjuvant Chemotherapy for NPC Patients: a Dose-escalation Study | Nab-paclitaxel Plus Cisplatin and Capecitabine as Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Locoregionally Advanced Nasopharyngeal Carcinoma: a Phase I Dose-escalation Study | NCT04850235 |
| Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast Cancer | Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast Cancer | NCT04900311 |
| Camrelizumab combined with albumin-bound paclitaxel in the second-line treatment of advanced esophageal squamous cell carcinoma in a single arm, an open phase II clinical trial | Camrelizumab combined with albumin-bound paclitaxel in the second-line treatment of advanced esophageal squamous cell carcinoma in a single arm, an open phase II clinical trial | ChiCTR2100045390 |
| Prevention of paclitaxel-related neurological side effects with lithium to counteract chemotherapy induced neurotoxicity | Prevention of paclitaxel-related neurological side effects with lithium – a randomized, double-blind, placebo-controlled, explorative proof-of-concept phase II clinical trial to counteract chemotherapy induced neurotoxicity | EUCTR2015-004172-30-DE |
| Sintilimab in combination with paclitaxel and cisplatin as neoadjuvant therapy in patients with locally advanced esophageal cancer: a single-center, single-arm, exploratory clinical study | Sintilimab in combination with paclitaxel and cisplatin as neoadjuvant therapy in patients with locally advanced esophageal cancer: a single-center, single-arm, exploratory clinical study | ChiCTR2100045659 |
| Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel | Safely Stopping Pre-Medications in Patients Receiving Paclitaxel: A Randomized Trial | NCT04862585 |
| A prospective, single arm, phase II clinical trial of sindilimab (anti-PD-1 antibody) combined with albumin binding paclitaxel as second-line treatment in patients with unresectable locally advanced / metastatic urothelial carcinoma | A prospective, single arm, phase II clinical trial of sindilimab (anti-PD-1 antibody) combined with albumin binding paclitaxel as second-line treatment in patients with unresectable locally advanced / metastatic urothelial carcinoma | ChiCTR2100045774 |
| A single-arm, prospective, exploratory clinical study of camrelizumab combined with albumin-bound paclitaxel and apatinib mesylate for first-line treatment of unresectable pancreatic cancer | A single-arm, prospective, exploratory clinical study of camrelizumab combined with albumin-bound paclitaxel and apatinib mesylate for first-line treatment of unresectable pancreatic cancer | ChiCTR2100045844 |
| A prospective, single-arm, multicenter clinical study of anlotinib combined with paclitaxel plus carboplatin for platinum-sensitive recurrent ovarian cancer | A phase II prospective, single-arm, multicenter clinical study of evaluating the efficacy and safety of anlotinib combined with paclitaxel plus carboplatin in patients with platinum-sensitive recurrent ovarian cancer | ChiCTR2100045884 |
| Biomarker Discovery in Patients With Advanced Biliary Tract Cancer | Discovery of Molecular Biomarkers for Predicting Response Through RNA Sequencing in Patients With Advanced Biliary Tract Cancer Who Received Nab-paclitaxel Plus Gemcitabine-cisplatin | NCT04871321 |
| Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma | Camrelizumab Combined With Anlotinib and Nab-paclitaxel in Patients With Untreated Advanced Mucosal Melanoma:a Single-arm, Multicenter, Open-label Study | NCT04979585 |
| A Phase I clinical trial to determine the safety of gemcitabine and nab-paclitaxel administered in combination with ATRA in patients with locally advanced or metastatic pancreatic cancer | A Phase 1B study repurposing ATRA as stromal targeting agent along with gemcitabine and nab-paclitaxel for pancreatic cancer (STAR_PAC) | ISRCTN57502371 |
| A study to compare study medication Sacituzumab Govitecan with Standardof Care medications (Paclitaxel, Docetaxel or Vinflunine) in Metastatic (spread to other locations in the body) or Locally Advanced Unresectable (cannot be removed surgically) Urothelial (urinary system) Cancer which has progressed or returned after prior treatments with platinum containing chemotherapy and immunotherapy | A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer | EUCTR2020-002964-29-BE |
| Registry Study of RESTORE DEB Paclitaxel Releasing PTCA Balloon Catheter in China | Evaluation on the Efficacy and Safety of RESTORE Drug-Coated Balloon in Coronary Artery Disease: a Real-World Multicenter Registry Study in China | ChiCTR2100047102 |
| Efficacy and safety of Carrelizumab combined with albumin-bound paclitaxel/nedaratin chemotherapy in the treatment of recurrent/metastatic cervical cancer: a phase II, one-arm, prospective clinical study | Efficacy and safety of Carrelizumab combined with albumin-bound paclitaxel/nedaratin chemotherapy in the treatment of recurrent/metastatic cervical cancer: a phase II, one-arm, prospective clinical study | ChiCTR2100047376 |
| Study on Carboplatin-Paclitaxel-Pembrolizumab in treatment of locally advanced cervical cancer | MITO CERV 3:Phase II study on Carboplatin-Paclitaxel-Pembrolizumab in neoadjuvant treatment of locally advanced cervical cancer - MITO CERV 3 | EUCTR2019-000318-12-IT |
| A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer | A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer | NCT05026905 |
| The ASCEND Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma | A Randomised, Double-blinded Phase II Study of Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma | NCT05042128 |
| Nab-paclitaxel Combined With Oxaliplatin and S-1 for Perioperative Treatment of Advanced Gastric Cancer | Nab-paclitaxel Combined With Oxaliplatin and S-1 for Perioperative Treatment of Advanced Gastric Cancer, a Small-scale, Exploratory Real-world Study | NCT05052931 |
| Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma | A Multicenter, Randomized, Open-lable, Parallel-controlled, Phase II Study to Evaluate the Differences of Safety and Efficacy of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma | NCT05047991 |
| Real world study to evaluate paclitaxel liposome / carboplatin combined with PD-1 monoclonal antibody in the first-line treatment of advanced lung squamous cell carcinoma | Real world study to evaluate paclitaxel liposome / carboplatin combined with PD-1 monoclonal antibody in the first-line treatment of advanced lung squamous cell carcinoma | ChiCTR2100050475 |
| A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer | The OVAL Study: A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer - OVAL | JPRN-jRCT2033210278 |
| A Phase 1 Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules given alone or in combination with Paclitaxel in patients with Advanced Gastric Cancer | A Phase 1 Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules given alone or in combination with Paclitaxel in patients with Advanced Gastric Cancer | KCT0006519 |
| IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors | A Phase 1 Open-Label, Dose-Escalation and Dose-Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-Tumor Activity of IACS-6274 as Monotherapy and in Combination in Patients With Advanced Solid Tumors | NCT05039801 |
| Treatment of abdominal mesothelioma with intra-abdominal chemotherapy - INTERACT MESO | Intraperitoneal Paclitaxel for Patients with Primary Malignant Peritoneal Mesothelioma – a Phase I/II Dose Escalation and Safety Study | NL-OMON26729 |
| Recurrent Stenoses in Arteriovenous Fistula (AVF) for Dialysis Access: CuttIng ballooN angioplaSTy Combined wITh Paclitaxel drUg coaTed Balloon Angioplasty, an observatIONal Clinical Study | Recurrent Stenoses in Arteriovenous Fistula (AVF) for Dialysis Access: CuttIng ballooN angioplaSTy Combined wITh Paclitaxel drUg coaTed Balloon Angioplasty, an observatIONal Clinical Study | NCT05018962 |
| Clinica study evaluating the efficacy and safety of the combination of cisplatin plus nab-paclitaxel and nivolumab with radiotherapy after maximal tumor resection in non-metastatic muscle invasive bladder cancer. | Efficacy and safety of the combination of Cisplatin plus Nab-paclitaxel and Nivolumab with radiotherapy after maximal tumor resection in non-metastatic muscle invasive Bladder Cancer.(CA209-6E8, CNN-BC trial) - CNN-BC | EUCTR2021-001443-27-IT |
| A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC) | A Single-arm, Open-label, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC) | NCT05068141 |
| The BURAN Study of Buparlisib (AN2025) In Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | The BURAN Study of Buparlisib (AN2025) In Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | JPRN-jRCT2011210034 |
| DDP ip Combined With AG in PDAC With Peritoneal Metastasis | Intraperitoneal (IP) Cisplatin Combined With Intravenous Gemcitabine + Nab-paclitaxel in Patients With Pancreatic Cancer With Peritoneal Metastasis | NCT05222204 |
| A study to compare two chemotherapy regimens like cisplatin&etoposide vs paclitaxel&carboplatin with concurrent RT in non small cell lung cancers | A PROSPECTIVE STUDY TO COMPARE TUMOR RESPONSE AND TOXICITIES IN UNRESECTABLE NON SMALL CELL LUNG CANCERS TREATED BY CONCURRENT CHEMO RADIOTHERAPY USING TWO CHEMOTHERAPY REGIMENS SUCH AS CISPLATIN & ETOPOSIDE VS CARBOPLATIN & PACLITAXEL. | CTRI/2021/09/036500 |
| TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT05053750 |
| Intervention study on preoperative application of PD-1 monoclonal antibody combined with gemcitabine and paclitaxel (albumin binding type) in the treatment of borderline resectable and locally advanced pancreatic cancer | Intervention study on preoperative application of PD-1 monoclonal antibody combined with gemcitabine and paclitaxel (albumin binding type) in the treatment of borderline resectable and locally advanced pancreatic cancer | ChiCTR2100051293 |
| Intraperitoneal Paclitaxel for Patients with Primary Malignant Peritoneal Mesothelioma - a Phase I/II Dose Escalation and Safety Study | Intraperitoneal Paclitaxel for Patients with Primary Malignant Peritoneal Mesothelioma - a Phase I/II Dose Escalation and Safety Study - INTERACT MESO | NL-OMON56619 |
| Paclitaxel plus cetuximab for the treatment of recurrentand/or metastatic head and neck cancer after first-line checkpointinhibitor failure: A multicenter, single arm study | Paclitaxel plus cetuximab for the treatment of recurrentand/or metastatic head and neck cancer after first-line checkpointinhibitor failure: A multicenter, single arm study - PACE ACE | EUCTR2019-003114-13-DE |
| Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors | Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors | NCT05075993 |
| Doublet chemotherapy (Gemcitabine and Cisplatin) vs triplet chemotherapy (Gemcitabine, Cisplatin and Nab-paclitaxel) in locally advanced or metastatic gall bladder cancer patients. | Comparing the outcome of doublet therapy (Gemcitabine and Cisplatin) with triplet therapy (Gemcitabine, Cisplatin and nab-paclitaxel) in locally advanced or metastatic gall bladder cancer patients, an open randomized control trial | CTRI/2021/09/036362 |
| A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC | A Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck | NCT05054439 |
| Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID) | A Phase III, Single-arm Study to Evaluate the Efficacy and Safety of ONCOFID-P-B (Paclitaxel-hyaluronic Acid Conjugate) Administered Intravesically to Patients With BCG-unresponsive Carcinoma in Situ of the Bladder With or Without Ta-T1 Papillary Disease (Orion-BC) | NCT05024773 |
| Investigator-initiated Clinical Trial of MIKE-1 | Phase I/II Investigator-initiated Clinical Trial of MIKE-1 With Gemcitabine and Nab-paclitaxel Combination Therapy for Unresectable Pancreatic Cancer | NCT05064618 |
| Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer | Phase II Study of Neoadjuvant Gemcitabine, Nab-paclitaxel, Durvalumab (MEDI4736) (Anti-PD-L1), and Oleclumab (Anti-CD73) in the Treatment of Resectable/Borderline Resectable Primary Pancreatic Adenocarcinoma | NCT04940286 |
| A prospective, single-arm, single-center phase 2 study: to evaluate the efficacy and safety of pembrolizumab combined with cisplatin/carboplatin and albumin paclitaxel for neoadjuvant treatment of IVA-IVB stage locally advanced head and neck squamous cell carcinoma | A prospective, single-arm, single-center phase 2 study: to evaluate the efficacy and safety of pembrolizumab combined with cisplatin/carboplatin and albumin paclitaxel for neoadjuvant treatment of IVA-IVB stage locally advanced head and neck squamous cell carcinoma | ChiCTR2100047437 |
| Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2 | A Randomized, Double-blind, Phase III Study, Comparing NIS793 in Combination With Gemcitabine and Nab-paclitaxel Versus (vs.) Placebo Combined With Gemcitabine and Nab-paclitaxel for First Line Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2 | NCT04935359 |
| Intraperitoneal Paclitaxel With XELOX in Gastric Cancer With Peritoneal Metastasis | Phase I,II Study of First Line Intraperitoneal Paclitaxel With Systemic Capecitabine and Oxaliplatin Combination Therapy in Patients With Advanced Gastric Cancer With Peritoneal Metastasis | NCT04943653 |
| clinical trial to evaluate the safety and efficacy of a drug under investigation called batiraxcept in combination with Paclitaxel in women with ovarian cancer which comes back after a platinum therapy. | A Phase 3, Randomized, Double-Blind, Placebo/Paclitaxel-Controlled Study of Batiraxcept (AVB S6 500) in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer | EUCTR2021-000293-28-PL |
| A single-center, prospective, randomized controlled clinical study of nab-paclitaxel combined with oxaliplatin and S-1 (S-1) regimen and docetaxel combined with oxaliplatin and S-1 (s-1) regimen for neoadjuvant treatment of locally advanced gastric cancer | A single-center, prospective, randomized controlled clinical study of nab-paclitaxel combined with oxaliplatin and S-1 (S-1) regimen and docetaxel combined with oxaliplatin and S-1 (s-1) regimen for neoadjuvant treatment of locally advanced gastric cancer | ChiCTR2100048252 |
| A study to evaluate the safety, tolerability, processing by the body, and antitumor activity of inavolisib and paclitaxel | A Phase Ib, open-label, dose-escalation and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of inavolisib in combination with paclitaxel in patients with locally advanced or metastatic solid tumors | ISRCTN45319897 |
| Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma | A Phase 1b/2 Randomized Study of AVB-S6-500 Plus Nab-paclitaxel and Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma | NCT04983407 |
| Paclitaxel allergic reaction | Role of stepwise titrated paclitaxel infusion schedule in the reduction of acute hypersensitivity reaction: A randomized controlled trial | CTRI/2021/07/034839 |
| First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer | An Open-label, Phase 2 Randomized Trial of Camrelizumab (SHR1210) Plus Apatinib Versus Paclitaxel and Cisplatin/Carboplatin Plus Bevacizumab as a First-line Therapy in Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer | NCT04974944 |
| Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma | A Phase 2, Multi-Center, Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination With Ramucirumab and Paclitaxel in Patients With HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination With Tucatinib in Patients With HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | NCT05190445 |
| Acoart SCB SFA: Sirolimus Coated Balloon Catheter in the Treatment of Femoropopliteal Artery Stenosis | A Prospective, Multicenter, Randomized Controlled Trial Comparing the Efficacy and Safety Between Sirolimus Coated Balloon Catheter and Paclitaxel Coated Balloon Catheter in the Treatment of Femoropopliteal Artery Stenosis. | NCT04982367 |
| PhI to Solid Tumors and PhII to Locally Advanced or mTNBC | A PhI Dose Escalation Study of LAE005+Afuresertib+Nab_Paclitaxel in Advanced Solid Tumors and PhII Study to Evaluate the Safety and Efficacy of LAE005+Afur+Nab_Paclitaxel or LAE005/Afur+Nab-Paclitaxel in Locally Advanced or mTNBC | NCT05390710 |
| A prospective, single-arm, single-center, phase II exploratory study of Sintilimab combined with anlotinib and albumin paclitaxel in the treatment of second-line and above extensive-stage small cell lung cancer | A prospective, single-arm, single-center, phase II exploratory study of Sintilimab combined with anlotinib and albumin paclitaxel in the treatment of second-line and above extensive-stage small cell lung cancer | ChiCTR2100049390 |
| Anlotinib hydrochloride combined with tirelizumab, paclitaxel liposome and nedaplatin in a single-arm, single-center, phase II exploratory clinical study of preoperative neoadjuvant therapy for esophageal squamous cell carcinoma | Anlotinib hydrochloride combined with tirelizumab, paclitaxel liposome and nedaplatin in a single-arm, single-center, phase II exploratory clinical study of preoperative neoadjuvant therapy for esophageal squamous cell carcinoma | ChiCTR2100049693 |
| Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms | Phase II Trial of Sintilimab, an Anti-PD-1 Monoclonal Antibody, in Combination With Combination Carboplatin and Nab-paclitaxel , as a Novel Neoadjuvant Pre-Surgical Therapy for Salivary Gland Malignant Neoplasms | NCT05000892 |
| Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis | Safety and Efficacy of Sintilimab in Combination With Albumin-Paclitaxel/Oxaliplatin/Capecitabine and Radiotherapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis: A Multiple Center Single Arm Trial | NCT05002686 |
| The study is planned to compare Cipla product- Paclitaxel with Innovator product Celgene Corporation product - ABRAXANE�® toestablish that both are equally effective in treating metastatic breast cancer patients. | A multicenter, open label, randomized, balanced, two treatment, two-sequence, four period, replicate crossover, single dose, bioequivalence study of paclitaxel protein-bound particles for injectable suspension (albumin-bound) 100 mg/vial by Cipla Ltd., India with ABRAXANE�® for injectable suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) 100 mg/vial by Celgene Corporation, USA in breast cancer patients after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy - CRD43 | CTRI/2021/08/035583 |
| TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer. | A Multicenter Exploratory Study of Paclitaxel+Cisplatin+TQB2450 Injection Combined With or Without Anlotinib in the First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma | NCT05013697 |
| Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer | Non-inferiority Study of Albumin-bound Paclitaxel Combined With Gemcitabine for Three Weeks Versus Four Weeks for First-line Inoperable Locally Advanced or Metastatic Pancreatic Cancer | NCT05035147 |
| Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer | Apatinib Mesylate Combined with Albumin-bound Paclitaxel for Second-line Treatment of Advanced Triple Negative Breast Cancer:a Single-arm,exploratory Clinical Study | NCT05019690 |
| A Study of Camrelizumab Combined with Paclitaxel-albumin and Platinum-based Chemotherapy in the Treatment of Neoadjuvant and Monotherapy for Locally Advanced Lung Squamous Cell Carcinoma | A Prospective, Single Arm, Clinical Pilot Study of Camrelizumab Combined with Paclitaxel-albumin and Platinum-based Chemotherapy in the Treatment of Neoadjuvant and Monotherapy for Locally Advanced Lung Squamous Cell Carcinoma | ChiCTR2100044645 |
| POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer | A Phase Ib/II Study to Optimize POL6326 (Balixafortide) in Combination With Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer | NCT04826016 |
| Clinical study of albumin paclitaxel combined with cisplatin preoperative chemoradiotherapy for local late esophageal cancer | Clinical study of albumin paclitaxel combined with cisplatin preoperative chemoradiotherapy for local late esophageal cancer | ChiCTR2100044536 |
| hyperthermic intraperitoneal chemotherapy with albumin paclitaxel for the prevention of peritoneal metastasis in patients with locally advanced gastric cancer after surgery: a nonrandomized, open, multicenter study | hyperthermic intraperitoneal chemotherapy with albumin paclitaxel for the prevention of peritoneal metastasis in patients with locally advanced gastric cancer after surgery: a nonrandomized, open, multicenter study | ChiCTR2100044498 |
| Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast Cancer | A Multicenter, Open-label, Single-arm, Phase II Clinical Trial of Nab-paclitaxel in Combination With Pyrotinib in Adjuvant Therapy for Lymph Node-negative and Small Tumor HER2-positive Breast Cancer | NCT04659499 |
| A Multicenter, Randomised, Double blind, Parallel, Phase III Global Study to Assess the Efficacy and Safety of BP01 (Bevacizumab) when compared to Avastin®-EU in Combination with Carboplatin and Paclitaxel during Induction phase and Bevacizumab alone during the Maintenance phase in patients with newly diagnosed or recurrent Stage IIIB/IV Non Squamous (ns) Non-Small Cell Lung Cancer (NSCLC). | A Multicenter, Randomised, Double blind, Parallel, Phase III Global Study to Assess the Efficacy and Safety of BP01 (Bevacizumab) when compared to Avastin®-EU in Combination with Carboplatin and Paclitaxel during Induction phase and Bevacizumab alone during the Maintenance phase in patients with newly diagnosed or recurrent Stage IIIB/IV Non Squamous (ns) Non-Small Cell Lung Cancer (NSCLC). | EUCTR2020-005618-16-HU |
| Study of ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID) | Phase I Exploratory Study of ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID) Administered for 12 Consecutive Weeks Followed by Maintenance Therapy in BCG Unresponsive/ Intolerant Patients With Bladder Carcinoma in Situ (CIS) | NCT04798703 |
| Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer | Ramucirumab Plus Trifluridine/Tipiracil (TAS-102) for Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: An Investigator-Initiated, Randomized Non-Inferiority Phase 2 Study | NCT04660760 |
| Pharmacokinetic variability of paclitaxel in chemotherapy naïve cancer patients | A cross-sectional study on impact of CYP2C8 and CYP3A4 activity on pharmacokinetic variability of paclitaxel in chemotherapy naïve cancer patients | CTRI/2020/12/029534 |
| A Phase Ib/III Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above Chemotherapies | A Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above Chemotherapies | NCT04672928 |
| Clinical study evaluating the activity of the combination of pembrolizumab and nab-paclitaxel in patients with advanced or metastatic urothelial cancer after chemotherapy failure | An open label, single-arm, phase 2 study of pembrolizumab and nanoparticle albumin-bound paclitaxel in patients with metastatic urothelial carcinoma after chemotherapy failure; the PEANUT study - Pembrolizumab and abraxane in locally advanced metastatic urothelial carcinoma after chemotherapy fa | EUCTR2017-000579-10-IT |
| Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data. | Retrospective Study With Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN (Squamous Cell Carcinoma of the Head and Neck): Real World Data. | NCT04672772 |
| A Multicenter, Randomised, Double blind, Parallel, Phase III Global Study to Assess the Efficacy and Safety of BP01 (Bevacizumab) when compared to Avastin®-EU in Combination with Carboplatin and Paclitaxel during Induction phase and Bevacizumab alone during the Maintenance phase in patients with newly diagnosed or recurrent Stage IIIB/IV Non Squamous (ns) Non-Small Cell Lung Cancer (NSCLC). | A Multicenter, Randomised, Double blind, Parallel, Phase III Global Study to Assess the Efficacy and Safety of BP01 (Bevacizumab) when compared to Avastin®-EU in Combination with Carboplatin and Paclitaxel during Induction phase and Bevacizumab alone during the Maintenance phase in patients with newly diagnosed or recurrent Stage IIIB/IV Non Squamous (ns) Non-Small Cell Lung Cancer (NSCLC). | EUCTR2020-005618-16-BG |
| Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer | A Phase II Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin+ Hydroxychlororoquine as Preoperative Treatment in Patients With Untreated Resectable, Borderline Resectable and Locally Advanced Adenocarcinoma of the Pancreas | NCT04669197 |
| Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer | A Phase II Clinical Study of Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the First-line Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma | NCT04675866 |
| A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer | A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine Versus Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer | NCT04674956 |
| Assessment of Ramucirumab plus paclitaxel as switch MANteInance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III Trial | Assessment of Ramucirumab plus paclitaxel as switch MANteInance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III Trial - ARMANI | EUCTR2016-001783-12-IT |
| A Randomized, Multicenter, Multinational, Double-Blind Study to Assess the Efficacy and Safety of MB02 (Bevacizumab Biosimilar Drug) Versus Avastin® in Combination With Carboplatin and Paclitaxel for the Treatment of Subjects With Stage IIIB/IV Non-squamous Non-Small Cell Lung Cancer (NSCLC) | A Randomized, Multicenter, Multinational, Double-Blind Study to Assess the Efficacy and Safety of MB02 (Bevacizumab Biosimilar Drug) Versus Avastin® in Combination With Carboplatin and Paclitaxel for the Treatment of Subjects With Stage IIIB/IV Non-squamous Non-Small Cell Lung Cancer (NSCLC) - STELLA | LBCTR2018120171 |
| Optimizing Ultrasound Enhanced Delivery of Therapeutics | The role of sonoporation-enhanced treatment with Gemcitabine, Nab-Paclitaxel and FOLFIRINOX in patients with inoperable pancreatic cancer. - Optimizing Ultrasound Enhanced Delivery of Therapeutics | EUCTR2019-003735-28-NO |
| First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers. | Ph 1/1B Evaluation of the Safety, Pharmacokinetics and Efficacy of GRN-300, a Salt-inducible Kinase Inhibitor, Alone and in Combination With Paclitaxel, in Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers. | NCT04711161 |
| Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy | Clinical Study of Albumin Paclitaxel With or Without Simvastatin in Treating Extensive-Stage Small Cell Lung Cancer Patients Relapsed From First-line Chemotherapy | NCT04698941 |
| A Single-arm, single-center, open-label clinical study of albumin-bound paclitaxel combined with carrelizumab and apatinib in the treatment of advanced biliary tract cancer | A Single-arm, single-center, open-label clinical study of albumin-bound paclitaxel combined with carrelizumab and apatinib in the treatment of advanced biliary tract cancer | ChiCTR2100041608 |
| Multicenter Clinical Study of Tislelizumab Combined with Nab-Paclitaxel and Carboplatin in Neoadjuvant Therapy Followed by Adjuvant Therapy with Tislelizumab in Triple Negative Breast Cancer (TNBC) | Multicenter Clinical Study of Tislelizumab Combined with Nab-Paclitaxel and Carboplatin in Neoadjuvant Therapy Followed by Adjuvant Therapy with Tislelizumab in Triple Negative Breast Cancer (TNBC) | ChiCTR2100041675 |
| Clinical study of Apatinib combined with paclitaxel in the treatment of gastric cancer | Clinical study of Apatinib combined with paclitaxel in the treatment of gastric cancer | ChiCTR2100041782 |
| Evaluation of the treatment of Cancer of Unknown Primary (CUP) with nab-Paclitaxel in association with gemcitabine or carboplatin | A PHASE II, RANDOMIZED, MULTICENTER STUDY TO ASSESS THE EFFICACY OF NAB-PACLITAXEL-BASED DOUBLET AS FIRST LINE THERAPY IN PATIENTS WITH CANCER OF UNKNOWN PRIMARY (CUP): the AGNOSTOS trial - AGNOSTOS | EUCTR2014-005018-47-IT |
| Observational study of the efficacy and safety of tislelizumab combined with albumin paclitaxel in neoadjuvant MIBC therapy | Observational study of the efficacy and safety of tislelizumab combined with albumin paclitaxel in neoadjuvant MIBC therapy | ChiCTR2000040487 |
| Efficacy and Safety of Paclitaxel (Albumin-bound) Combination With Carboplatin in Ovarian Cancer. | Efficacy and Safety of Paclitaxel (Albumin-bound) Combination With Carboplatin in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer: a Multicenter, Open, Phase 2 Clinical Study | NCT04661696 |
| As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to Biomarkers | As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to Biomarkers | NCT04656002 |
| CDK4/6 Tumor, Abemaciclib, Paclitaxel | An Open-label, Multi-center Phase IB/II Study of Abemaciclib With Paclitaxel for CDK4/6 Pathway Activated Tumors | NCT04594005 |
| Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer | An Open Label, Single-Arm, Multi-center Phase Ib/II Study to Evaluate the Efficacy of Paclitaxel in Combination With Pembrolizumab and Olaparib as a Second Line Treatment in Immune Checkpoint Inhibitor-experienced Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer. | NCT04592211 |
| A trial of ramucirumab plus paclitaxel combined therapy for elderly gastric cancer patients | A phase II trial of ramucirumab plus paclitaxel combined second-line therapy for elderly gastric cancer patients (70 years or more) | JPRN-jRCT1031200158 |
| ATI-450 in Combination With Paclitaxel or Capecitabine in Patients With Hormone Receptor-positive and HER2 Negative Metastatic Breast Cancer With Bone Metastasis | A Phase I/II Trial of ATI-450 in Combination With Paclitaxel or Capecitabine in Patients With Hormone Receptor-positive and HER2 Negative Metastatic Breast Cancer With Bone Metastasis | NCT04606342 |
| A Phase II Study of Toripalimab in Combination with Paclitaxel and Carboplatin in Treatment-Naive Advanced Thymic Carcinoma | A Phase II Study of Toripalimab in Combination with Paclitaxel and Carboplatin in Treatment-Naive Advanced Thymic Carcinoma | ChiCTR2000039155 |
| Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer | A Phase I Dose-Escalation Study on the Safety of Lapatinib With Dose-Dense Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer | NCT04608409 |
| Immunopheresis Alone or in Combination With Paclitaxel or Atezolizumab in Non-small Cell Lung Cancer (NSCLC). | Open-Label Study Evaluating the Safety and Effectiveness of Immunopheresis With the LW-02 Column Alone or in Combination With Paclitaxel or Atezolizumab in Removing Soluble Tumor Necrosis Factor Receptors to Treat Patients With Advanced, Non-Small Cell Lung Cancer (NSCLC) | NCT04690686 |
| Phase II clinical study of carrelizumab combined with albumin-binding paclitaxel in advanced triple negative breast cancer after first-line treatment | Phase II clinical study of carrelizumab combined with albumin-binding paclitaxel in advanced triple negative breast cancer after first-line treatment | ChiCTR2000039442 |
| A prospective, single arm, multicenter, phase II clinical trial of nab-paclitaxel combined with carboplatin in the first-line treatment of epithelial ovarian cancer, tubal cancer, and primary peritoneal cancer | A prospective, single arm, multicenter, phase II clinical trial of nab-paclitaxel combined with carboplatin in the first-line treatment of epithelial ovarian cancer, tubal cancer, and primary peritoneal cancer | ChiCTR2000039581 |
| AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer | A Phase ?, Randomized Controlled Study to Evaluate the Efficacy and Safety of the Combination of Nab-paclitaxel and Gemcitabine Versus mFOLFIRINOX in Treating Patients With Borderline Reseactable and Locally Advanced Pancreatic Cancer | NCT04617821 |
| A Phase 2b study with study drug and carboplatin and paclitaxel for Subjects with Advanced Non-Small Cell Lung Cancer | A Randomized, Placebo-Controlled Phase 2b Study of Tamibarotene Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin as First Line Treatment for Subjects with Advanced Non-Small Cell Lung Cancer - TAMI | CTRI/2012/02/002410 |
| Phase II study of NAB-paclitaxel in SensiTivE and Refractory relapsed SCLC | Phase II study of NAB-paclitaxel in SensiTivE and Refractory relapsed SCLC (NABSTER trial) - NABSTER trial | EUCTR2016-000408-27-IT |
| Clinical research of intraperitoneal and intravenous paclitaxel plus S-1 in patients with recurrence of gastric cancer with peritoneal dissemination | Open-label, non-randomized study to evaluate efficacy and safety of intraperitoneal and intravenous paclitaxel plus S-1 in patients with recurrence of gastric cancer with peritoneal dissemination | JPRN-jRCTs061200027 |
| Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer | Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel in Untreated Metastatic Adenocarcinoma of the Pancreas | NCT04672005 |
| Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer | IIT2020-02-Gong-GlutaPanc: Phase I Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer (GlutaPanc) | NCT04634539 |
| A ClinicalI trial of atezolizumab plus bevacizumab, with carboplatin-paclitaxel or pemetrexed, in EGFR mutant non-small cell lung carcinoma with acquired resistance | A randomised non-comparative open label phase II trial of atezolizumab plus bevacizumab, with carboplatin-paclitaxel or pemetrexed, in EGFR mutant non-small cell lung carcinoma with acquired resistance | KCT0005588 |
| A prospective clinical study of albumin paclitaxel combined with platinum for first-line chemotherapy for advanced or recurrent or metastatic cervical cancer | A prospective clinical study of albumin paclitaxel combined with platinum for first-line chemotherapy for advanced or recurrent or metastatic cervical cancer | ChiCTR2000040042 |
| Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients. | An Open-label Phase Ib Prospective Clinical Trial to Investigate Safety, Tolerability and Maximum Tolerated Dose for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients. | NCT04652206 |
| Real-World Safety Analysis of Paclitaxel Devices Used for the Treatment of Peripheral Arterial Disease | Real-World Safety Analysis of Paclitaxel Devices Used for the Treatment of Peripheral Arterial Disease | NCT04647643 |
| Food Effect on Pharmacokinetics and Safety of DHP107 (Liporaxel®) FEEL Study | A Randomized, Open-label, Two-way Crossover Clinical Trial to Evaluate the Food Effect on Pharmacokinetics and SafEty of DHP107 (Oral Paclitaxel, Liporaxel®) in Patients With Advanced Solid Tumors (FEEL) / EudraCT no : 2020-004976-16 | NCT04675528 |
| Folfox+Irinotecan+Chemort In Esophageal Cancer | A Phase II Study of Neoadjuvant NAPOX Followed by Chemoradiation With Paclitaxel and Carboplatin in Locally Advanced Esophagogastric Cancer | NCT04656041 |
| Nab-paclitaxel Combined with Bevacizumab in the Treatment of Metastatic Extrapulmonary Neuroendocrine Carcinoma | A Prospective, Non-randomized, Multicenter, Phase II Study of Nab-paclitaxel Combined with Bevacizumab for Unresectable Recurrent or Metastatic Extrapulmonary Neuroendocrine Carcinoma | NCT04705519 |
| Phase IB/II study of alpelisib in combination with paclitaxel in patients with PIK3CA-altered metastatic/recurrent gastric cancer | Phase IB/II study of alpelisib in combination with paclitaxel in patients with PIK3CA-altered metastatic/recurrent gastric cancer | KCT0005467 |
| Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma | A Single-arm Exploratory Clinical Study on the Efficacy and Safety of Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma | NCT04725448 |
| A phase II study evaluating the efficacy and safety of conversion surgery after intraperitoneal paclitaxel in combination with systemic capecitabine and oxaliplatin chemotherapy in advanced gastric cancer patients diagnosed with peritoneal dissemination | A phase II study evaluating the efficacy and safety of conversion surgery after intraperitoneal paclitaxel in combination with systemic capecitabine and oxaliplatin chemotherapy in advanced gastric cancer patients diagnosed with peritoneal dissemination | KCT0005750 |
| A clinical study of Apatinib combined with paclitaxel liposome as second line therapy in SLCC | A clinical study of Apatinib combined with paclitaxel liposome as second line therapy in SLCC | ChiCTR2100043483 |
| Single-arm, single-center clinical trial of pyrrottinib in combination with albumin paclitaxel, carboplatin, and trastuzumab neoadjuvant therapy for HER2-positive early or locally advanced breast cancer | Single-arm, single-center clinical trial of pyrrottinib in combination with albumin paclitaxel, carboplatin, and trastuzumab neoadjuvant therapy for HER2-positive early or locally advanced breast cancer | ChiCTR2100043523 |
| Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Phase II Study With Safety Lead-In of Lenvatinib, Pembrolizumab, and Weekly Paclitaxel for Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer | NCT04781088 |
| Efficacy and safety of tislelizumab combined with albumin paclitaxel in the treatment of relapsed and refractory extranodal NK/T cell lymphoma, nasal type: a multi-center, prospective, single-arm, phase II clinical study | Efficacy and safety of tislelizumab combined with albumin paclitaxel in the treatment of relapsed and refractory extranodal NK/T cell lymphoma, nasal type: a multi-center, prospective, single-arm, phase II clinical study | ChiCTR2100043615 |
| LOGIK2002(RESTART) | Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced non-squamous NSCLC with impaired renal function - LOGIK2002(RESTART) | JPRN-jRCTs071200102 |
| Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast Cancer | A Phase II, Single-center, Randomized Study of Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast Cancer | NCT04780347 |
| Pembrolizumab and Paclitaxel in Hormone Receptor-positive, hyperMUTATted Metastatic Breast Cancer Identified by Whole exOme sequeNcing ('MUTATION2') | Phase II Trial of Pembrolizumab and Paclitaxel in Hormone Receptor-positive, hyperMUTATted Metastatic Breast Cancer Identified by Whole exOme sequeNcing ('MUTATION2') | NCT04946227 |
| Anlotinib hydrochloride combined with tirelizumab, paclitaxel liposome and nedaplatin in a single-arm, single-center, phase II exploratory clinical study of preoperative neoadjuvant therapy for esophageal squamous cell carcinoma | Anlotinib hydrochloride combined with tirelizumab, paclitaxel liposome and nedaplatin in a single-arm, single-center, phase II exploratory clinical study of preoperative neoadjuvant therapy for esophageal squamous cell carcinoma | ChiCTR2100043836 |
| Phase II trial of pembrolizumab and paclitaxel in hormone receptor-positive, hyperMUTATted metastatic breast cancer Identified by whole exOme sequeNcing (‘MUTATION2’) | Phase II trial of pembrolizumab and paclitaxel in hormone receptor-positive, hyperMUTATted metastatic breast cancer Identified by whole exOme sequeNcing (‘MUTATION2’) | KCT0005975 |
| Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors. | A Phase I Study of Dose Escalation and Dose Expansion To Evaluate the Safety?Tolerability?Pharmacokinetics and Efficacy of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumor. | NCT04778839 |
| Safety and efficacy of liposomal doxorubicin combined with nab-paclitaxel in the treatment of locally advanced or recurrent/metastatic adenoid cystic carcinoma of head and neck: a prospective, multicenter phase II trial | Safety and efficacy of liposomal doxorubicin combined with nab-paclitaxel in the treatment of locally advanced or recurrent/metastatic adenoid cystic carcinoma of head and neck: a prospective, multicenter phase II trial | ChiCTR2100044076 |
| A prospective phase I clinical trial of paclitaxel for injection (albumin-binding) intraperitoneal perfusion combined with systemic chemotherapy for peritoneal metastasis of pancreatic cancer | A prospective phase I clinical trial of paclitaxel for injection (albumin-binding) intraperitoneal perfusion combined with systemic chemotherapy for peritoneal metastasis of pancreatic cancer | ChiCTR2100044219 |
| Efficacy and Toxicity of Paclitaxel, Cisplatin Combined With Sindilimab in NACT for Locally Advanced Cervical Cancer | Efficacy and Toxicity of Paclitaxel, Cisplatin Combined With Sindilimab in Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer | NCT04799639 |
| Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer | A Prospective, Single-arm, Multicenter, Exploratory Phase II Study to Evaluate the Efficacy and Safety of Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer | NCT04807166 |
| Toripalimab with Paclitaxel and Cisplatin As Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma | Toripalimab with Paclitaxel and Cisplatin As Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma | NCT04804696 |
| A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer | A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 (Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection) + Chemotherapy (Carboplatin/Cisplatin and Paclitaxel) vs Chemotherapy (Carboplatin/Cisplatin and Paclitaxel)in Patients With Advanced Cervical Cancer | NCT04806945 |
| Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic Cancer | A Prospective, Single-center Clinical Study to Explore the Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic Cancer | NCT04814485 |
| Neoadjuvant Nab-Paclitaxel and S-1 in Resectable Pancreatic Cancer | Phase II Single-arm Trial of Nab-Paclitaxel and S-1 as Neoadjuvant Treatment of Patients With Resectable Pancreatic Cancer | NCT04808687 |
| Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002) | An Open Label, Two Arm Phase II Study of Toripalimab Versus Toripalimab in Combination With Carboplatin and Nab-paclitaxel as a Novel Neoadjuvant Pre-Surgical Therapy for HNSCC | NCT04807140 |
| Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Phase I/II Study of the PI3K Inhibitor TL117 Alone and in Combination With Paclitaxel in Patients With Relapsed/Metastatic Squamous Cell Carcinoma of the Head and Neck | NCT04843098 |
| Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002) | A Multicenter Randomized, Controlled Phase III Clinical Trial of Pembrolizumab Plus Paclitaxel and Cisplatin Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Locally Advanced Esophageal Squamous Cell Carcinoma (KEYSTONE-002) | NCT04807673 |
| Comparative Study of Lobaplatin and Paclitaxel in Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy | Comparative Study on the Efficacy of Lobaplatin and Paclitaxel in the Treatment of Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy | NCT04808466 |
| Paclitaxel (Albumin-bound) Combined With Radiotherapy for the Treatment of Early Stage Nasopharyngeal Carcinoma | Paclitaxel (Albumin-bound) Combined With Radiotherapy Compared With Cisplatin Combined With Radiotherapy for the Treatment of Early Stage Nasopharyngeal Carcinoma: a Prospective, Parallel-controlled, Multicenter Phase III Clinical Study | NCT04766359 |
| Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis | Phase II Trial of Sequential Systemic Therapy Plus Intraperitoneal Paclitaxel in Gastric/GEJ Cancer Peritoneal Carcinomatosis (STOPGAP) | NCT04762953 |
| Ntraperitoneal Thermal Perfusion Combined With Chemotherapy Versus Chemotherapy | Peritoneal Perfusion Chemotherapy Combined With Gemcitabine and Albumin Binding Paclitaxel Versus Gemcitabine and Albumin Binding Paclitaxel in the Treatment of Advanced Pancreatic Cancer With Intraperitoneal Metastasis | NCT04707118 |
| Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic Cancer | Anlotinib Plus Toripalimab and Nab-paclitaxel in Patients With Locally Advanced or Metastatic Pancreatic Cancer: an Open-label, Non-randomized, Phase ? Study | NCT04718701 |
| A prospective, open-label, single arm study evaluating the efficacy of anlotinib combined with albumin-bound paclitaxel and carboplatin in neoadjuvant treatment of triple-negative breast cancer | A prospective, open-label, single arm study evaluating the efficacy of anlotinib combined with albumin-bound paclitaxel and carboplatin in neoadjuvant treatment of triple-negative breast cancer | ChiCTR2100042236 |
| A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC) | PD-1 Monoclonal Antibody Camrelizumab Combined With Albumin Paclitaxel and Platinum for Neoadjuvant Treatment of Adcanced Esophageal Squamous Cell Carcinoma (ESCC): A Single-center, Single-arm Phase II Clinical Study | NCT04767295 |
| Second-line treatment of camrelizumab combined with nab-paclitaxel in advanced biliary tract cancer: an exploratory study | Second-line treatment of camrelizumab combined with nab-paclitaxel in advanced biliary tract cancer: an exploratory study - CamPacBTC | ChiCTR2100042316 |
| Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma | Phase II Trial of Sintilimab, an Anti-PD-1 Monoclonal Antibody, in Combination With Carboplatin and Nab-paclitaxel , as a Novel Neoadjuvant Pre-Surgical Therapy for Oral Cavity or Oropharyngeal Squamous Cell Carcinoma | NCT04718415 |
| The aim of this study is to see how well an investigational drug (called BBI-608) works when it is given in combination with paclitaxel, a chemotherapy treatment, or if it is better to receive paclitaxel alone for people with advanced, previously treated lung cancer. To do so, half of the patients in this study will receive paclitaxel plus BBI-608 while the other half will receive paclitaxel alone. | A Phase III Randomized, Open-Label Clinical Trial of BBI-608 plus Weekly Paclitaxel versus Weekly Paclitaxel Alone in Patients with Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer - - | EUCTR2016-002718-32-IT |
| Phase I,II Study of Intraperitoneal Paclitaxel with Capecitabine and Oxaliplatin Combination Therapy in Patients with Gastric Cancer with Peritoneal Metastasis | Phase I,II Study of first line Intraperitoneal Paclitaxel with Systemic Capecitabine and Oxaliplatin Combination Therapy in Patients with Advanced Gastric Cancer with Peritoneal Metastasis | KCT0005802 |
| La crioterapia per le onicopatie indotte da paclitaxel. CRIOP | Cryotherapy for onicopatie induced by paclitaxel. CRIOP - CRIOP | EUCTR2015-002748-16-IT |
| Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma | An Open Label, Single-arm, Phase 2 Study of Perioperative Tislelizumab Combined With Nab-Paclitaxel Before Cystectomy or Complete TURBT for Patients With Muscle-invasive Urothelial Bladder Cancer. | NCT04730219 |
| Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable | An Open Label, Single-arm, Phase 2 Study of Tislelizumab Combined With Nab-Paclitaxel for Patients With High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable | NCT04730232 |
| The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal Carcinoma | A Prospective Phase II Clinical Trial of Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Locally Advanced Nasopharyngeal Carcinoma | NCT04769076 |
| To verify the safety and efficacy of VaSecure paclitaxel drug-coated balloon for the treatment of Peripheral Arterial Disease in a multicentre, random, open, parallel control clinical study. | To verify the safety and efficacy of VaSecure paclitaxel drug-coated balloon for the treatment of Peripheral Arterial Disease in a multicentre, random, open, parallel control clinical study | ChiCTR2100042662 |
| Combination Therapy for First Line Treatment of Advanced Cervical Cancer | Combination of Paclitaxel, Cisplatin\Carboplatin With Toripalimab and Anlotinib for First Line Treatment of Advanced Cervical Cancer | NCT04731038 |
| A Phase III Study of Bevacizumab and Paclitaxel in Combination with Atezolizumab As a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer | A Phase III, Randomized Study of Bevacizumab and Paclitaxel in Combination with Atezolizumab As a Treatment for Patients with Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer | NCT04732598 |
| A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) | A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) | NCT04734262 |
| Albumin-bound Paclitaxel Combined With Cisplatin Versus Docetaxel Combined With Cisplatin Induced Chemotherapy in Advanced Head and Neck Squamous Tummor | A Prospective Randomized Controlled Clinical Study of Albumin-bound Paclitaxel Combined With Cisplatin (AP Regimen) Versus Docetaxel Combined With Cisplatin (TP Regimen) Induced Chemotherapy in Advanced Head and Neck Squamous Tummor | NCT04766827 |
| AMBITION study | A Phase III, Randomized study of Bevacizumab and Paclitaxel in combination with Atezolizumab as a treatment for patients with locally advanced unresectable or metastatic hormone receptor-positive HER2 negative breast cancer - JCOG1919E | JPRN-jRCT2031200335 |
| Comparison of paclitaxel albumin-bound nanoparticles serum level with its original serum brand, Abraxane? in patients with metastatic breast cancer | Comparison of Paclinab serum level with its original serum brand, Abraxane in patients with metastatic breast cancer | IRCT20130603013572N6 |
| Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. | Multi-agent Low Dose Chemotherapy (Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, Irinotecan) Followed by Maintenance Olaparib and Pembrolizumab in Untreated Metastatic Pancreatic Ductal Adenocarcinoma. | NCT04753879 |
| Phase II Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLC | Phase II Study of Pemetrexed or Nab-paclitaxel With Pembrolizumab in Elderly (>/= 75 Years) Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | NCT04754815 |
| Objective to evaluate the feasibility of karelizumab injection combined with dual drug chemotherapy (tegafur / albumin paclitaxel) and / or apatinib in the treatment of advanced unresectable gastric cancer | Objective to evaluate the feasibility of karelizumab injection combined with dual drug chemotherapy (tegafur / albumin paclitaxel) and / or apatinib in the treatment of advanced unresectable gastric cancer | ChiCTR2100041825 |
| A Randomized, Double-Blind, Multicenter, Phase 2 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Metastatic or Advanced Non-Small-Cell Lung Cancer (NSCLC) | Randomized, Double-Blind, Multicenter, Phase 2 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Metastatic or Advanced Non-Small-Cell Lung Cancer (NSCLC) | EUCTR2011-003427-36-DE |
| Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer | A Phase II Trial of Neoadjuvant Paclitaxel - Cisplatin Chemotherapy, Surgery and Adjuvant Radiation Therapy and 5-FU/Leucovorin for Gastric Cancer | NCT00003298 |
| Endoscopic Ultrasound (EUS) Guided Ethanol With Paclitaxel Ablation for Pancreatic Mucinous Cystic Neoplasm | EUS Guided Ethanol With Paclitaxel Ablation for Pancreatic Mucinous Cystic Neoplasm | NCT01525706 |
| Paclitaxel in Treating Patients With Lung Cancer | Phase II Study on TAXOL in Bronchioalveolar Carcinoma | NCT00002972 |
| Combination Chemotherapy With or Without Biological Therapy in Treating Patients With Refractory Solid Tumor or Lymphoma | Phase I Evaluation of Topotecan in Combination With Paclitaxel and Carboplatin | NCT00005021 |
| Tirapazamine, Carboplatin, and Paclitaxel in Treating Patients With Advanced Malignant Solid Tumors | Phase I Dose Escalation Study of Tirapazamine (NSC 130181) in Combination With Carboplatin and Paclitaxel in Advanced Malignant Solid Tumors | NCT00005078 |
| Carboplatin and Paclitaxel in Treating Older Patients With Metastatic or Recurrent Unresectable Non-small Cell Lung Cancer | A Phase II Study of Carboplatin and Paclitaxel in Elderly Patients With Metastatic or Recurrent Unresectable Non-Small Cell Lung Cancer | NCT00005059 |
| Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer | Phase II Study of Weekly Paclitaxel and Bryostatin-1 in Hormone Refractory Prostate Cancer | NCT00005028 |
| SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck | A Phase I Pharmacokinetic, Pharmacodynamic, and Clinical Study of the Combination of the Angiogenesis Inhibitor SU5416 and Paclitaxel in Recurrent or Metastatic Carcinoma of the Head and Neck | NCT00005647 |
| Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2 | A Phase II Trial to Investigate the Pharmacokinetics, Safety, and Tolerability of Herceptin Administered Subcutaneously in Combination With Paclitaxel in Women With HER2 Overexpressing Metastatic Breast Cancer | NCT00005635 |
| Bryostatin 1 Plus Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer or Stomach Cancer | Phase II Trail of Bryostatin-1 and Paclitaxel in Patients With Advanced Esophageal Cancer | NCT00005599 |
| Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis | Phase I Study of Concomitant Chemoradiotherapy With Vinorelbine and Paclitaxel in Patients With Advanced Pelvic Malignancies | NCT00002949 |
| Combination Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer | Epirubicin Plus Paclitaxel Versus Cyclophosphamide, Epirubicin and 5-Fluorouracil as Adjuvant Treatment of Node Positive Breast Cancer Patients: A Controlled Randomized Phase III Study | NCT00005581 |
| Paclitaxel and Capecitabine in Treating Women With Metastatic Breast Cancer | An Open-Label Combination Study of Capecitabine and Standard Paclitaxel Therapy as First or Second Line Therapy in Women With Metastatic Breast Carcinoma | NCT00005649 |
| Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer | Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive Stage Small Cell Lung Cancer | NCT00005646 |
| Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer | Phase I Trial of the Treatment of Advanced Endometrial Cancer With Concurrent Weekly Paclitaxel and Cisplatin and Whole Abdominal Radiation Therapy | NCT00005840 |
| Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer | Phase II Evaluation of Trastuzumab (Herceptin), Paclitaxel, Carboplatin, and Gemcitabine in the Treatment of Advanced Urothelial Cancer | NCT00005831 |
| Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer | A Pilot Trial of Daily Oral ZD1839 (Iressa) With Standard Doses of Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer | NCT00005806 |
| Bryostatin 1 Plus Paclitaxel in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer | Phase II Study of Bryostatin-1 in Combination With Paclitaxel for Non-Small Cell Lung Cancer | NCT00005849 |
| Combination Chemotherapy in Treating Patients With Advanced Solid Tumors | A Phase I Trial of Fenretinide in Combination With Paclitaxel and Cisplatin | NCT00005819 |
| Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | A Randomized Phase II Trial of Mitoxantrone, Estramustine and Navelbine or 13-cis Retinoic Acid, Interferon and Paclitaxel in Patients With Metatstatic Hormone Refractory Prostate Cancer | NCT00005847 |
| Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer | A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma | NCT00006011 |
| Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function | Phase II Trial of Paclitaxel Plus Gemcitabine in Patients With Advanced Urothelial Carcinoma With Renal Insufficiency | NCT00005644 |
| Paclitaxel and BMS-214662 in Treating Patients With Advanced Solid Tumors | Phase I Study of BMS-214662 and Paclitaxel in Patients With Advanced Malignancies | NCT00006018 |
| Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer | A Phase I Trial of Dose Escalated Irinotecan (CPT-11) With Paclitaxel in Patients With Metastatic or Recurrent Malignancies | NCT00002939 |
| Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer | A Phase I Study of Induction Carboplatin / Paclitaxel Chemotherapy, Pre-operative Radiotherapy With Gadolinium Texaphyrin (Gd-Tex), and Surgical Resection in Stage IIIA (N2) Non-small Cell Lung Carcinoma. | NCT00005065 |
| Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancer | A RANDOMISED TRIAL OF PACLITAXEL (TAXOL) IN COMBINATION WITH PLATINUM CHEMOTHERAPY VS. CONVENTIONAL PLATINUM-BASED CHEMOTHERAPY IN THE TREATMENT OF WOMEN WITH RELAPSED OVARIAN CANCER | NCT00002894 |
| Phase II trial of perioperative chemotherapy with cisplatin and dose dense paclitaxel in patients with stage Ib2-IIb uterine cervical cancer (SGSG013) | Phase II trial of perioperative chemotherapy with cisplatin and dose dense paclitaxel in patients with stage Ib2-IIb uterine cervical cancer (SGSG013) - Phase II trial of perioperative dose dense TP in patients with stage Ib2-IIb uterine cervical cancer (SGSG013) | JPRN-UMIN000006440 |
| A Study on Predictive Value of ERCC1 in Esophageal Cancer Patients Treated With Paclitaxel and Cisplatin | A Phase ? Study on Low-expression and High-expression of ERCC1 in Recurrent or Metastastic Esophageal Cancer Patients Treated With Biweekly Paclitaxel and Cisplatin | NCT01444547 |
| Phase II study of FEC followed by Nab-paclitaxel as Neoadjuvant Chemotherapy for Primary Breast Cancer | Phase II study of FEC followed by Nab-paclitaxel as Neoadjuvant Chemotherapy for Primary Breast Cancer - Phase II study of FEC followed by Nab-paclitaxel as Neoadjuvant Chemotherapy for Primary Breast Cancer | JPRN-UMIN000006428 |
| Phese 2 trial of weekly nab-paclitaxel in combination with gemcitabine in partients with metastatic breast cancer | Phese 2 trial of weekly nab-paclitaxel in combination with gemcitabine in partients with metastatic breast cancer - Phese 2 trial of weekly nab-paclitaxel in combination with gemcitabine in partients with metastatic breast cancer | JPRN-UMIN000006427 |
| Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer | A Randomized Phase III Trial of Carboplatin, Paclitaxel and Thoracic Radiotherapy, With or Without Thalidomide, in Patients With Stage III Non-Small Cell Lung Cancer (NSCLC) | NCT00004859 |
| Topotecan and Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Advanced Solid Tumors | Phase I/II Study of Oral Topotecan and Intravenous Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (Phases I and II) and Other Advanced Solid Tumors (Phase I Only) | NCT00004979 |
| Ifosfamide, Teniposide, and Paclitaxel in Treating Patients With Relapsed Non-Hodgkin's Lymphoma | Phase I/II Study of Mesna, Ifosfamide, Teniposide and Weekly Taxol (MITTen) in Relapsed Lymphoma | NCT00004916 |
| Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer | A Phase I Feasibility Trial of Carboplatin and Topotecan Followed by Carboplatin and Paclitaxel (Sequential Doublets) in Patients With Previously Untreated Epithelial Ovarian Carcinoma and Primary Peritoneal Carcinoma | NCT00005026 |
| A phase II study of paclitaxel plus trastuzumab in patients with pretreated recurrent or metastatic gastric cancer. | A phase II study of paclitaxel plus trastuzumab in patients with pretreated recurrent or metastatic gastric cancer. - A phase II study of paclitaxel plus trastuzumab in patients with pretreated recurrent or metastatic gastric cancer. | JPRN-UMIN000006403 |
| Paclitaxel and Irinotecan in Treating Patients With Advanced Non-small Cell Lung Cancer | Phase II Trial of Irinotecan Plus Paclitaxel in Patients With Advanced Nonsmall Cell Lung Cancer | NCT00004924 |
| Paclitaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors | A Phase I Open-Label Safety Study of Escalating Doses of Taxol in Combination With Escalating Doses of GEM231 in Patients With Refractory Solid Tumors | NCT00004863 |
| Estramustine and Paclitaxel in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy | Safety and Efficacy of One Hour Weekly Taxol Infusion and Estramustine in Hormone Refractory Prostate Cancer | NCT00005048 |
| Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer | PHASE I STUDY OF PACLITAXEL COMBINED WITH TOPOTECAN AND CISPLATIN AND G-CSF IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN EPITHELIAL MALIGNANCIES | NCT00002913 |
| Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer | A Phase I/II Study of G3139, a BCL-2 Antisense Oligonucleotide, Combined With Paclitaxel for the Treatment of Recurrent Small Cell Lung Cancer | NCT00005032 |
| Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer | Phase II Study of First-Line Therapy of Ovarian Cancer With Sequential Regimens: Cisplatin-Prolonged Oral Topotecan (C-PORT) Followed by Paclitaxel/Carboplatin (PC) | NCT00005051 |
| Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer | A Phase I Open Label Assessment of the Safety and Pharmacokinetics of Intraperitoneal PACLIMER Microspheres (Polilactofate/Paclitaxel) in Patients With Ovarian Cancer | NCT00005046 |
| Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | A Randomized Trial of Paclitaxel/Epirubicin/Carboplatin Combination (TEC) Versus Paclitaxel/Carboplatin (TC) in the Treatment of Women With Advanced Ovarian Cancer | NCT00004934 |
| TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer | A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers | NCT01493505 |
| ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer | A Randomized, Double-Blind, Phase III Comparative Trial of 2 Doses of ZD1839 (IRESSA) in Combination With Paclitaxel and Carboplatin Versus Placebo in Combination With Paclitaxel and Carboplatin in Chemotherapy-Naive Patients With Advanced (Stage III or IV) Non-Small Cell Lung Cancer | NCT00006049 |
| Chemotherapy Plus Surgery in Treating Women With Breast Cancer | European Cooperative Study of Chemotherapy and Surgery Comparing Adjuvant Doxorubicin Followed by CMF vs. Adjuvant Doxorubicin/Paclitaxel Followed by CMF vs. Primary Doxorubicin/Paclitaxel Followed by CMF in Women With Operable Breast Cancer and T>2 cm | NCT00003013 |
| Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer | Phase III Study of Gemcitabine Plus Paclitaxel Versus Paclitaxel in Patients With Unresectable, Locally Recurrent or Metastatic Breast Cancer | NCT00006459 |
| Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer | Randomized Phase III Trial Of Carboplatin And Paclitaxel Plus Tirapazamine Versus Carboplatin And Paclitaxel In Patients With Advanced Non-Small Cell Lung Cancer | NCT00006484 |
| Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer | Phase III Multicenter Study in Epithelial Ovarian Carcinoma FIGO Stage IIB-IV Comparing Treatment With Paclitaxel and Carboplatin to Paclitaxel and Carboplatin Sequentially Followed by Topotecan | NCT00006454 |
| Combination Chemotherapy and Radiation Therapy Followed By Surgery in Treating Patients With Stage IIB or Stage IIIA Non-Small Cell Lung Cancer | Phase II Trial of Concurrent Paclitaxel, Carboplatin and External Beam Radiotherapy Followed by Surgical Resection in Stage IIIA (N2) Non-small Cell Lung Cancer | NCT00006469 |
| Combination Chemotherapy Plus Radiation Therapy Followed By Surgery in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer | Esophageal Cancer: A Phase II Study of Paclitaxel, Carboplatin and 5-Fluorouracil With Simultaneous Radiotherapy Followed by Surgical Resection | NCT00006472 |
| Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer | A Phase I/II Study of Carboplatin / Paclitaxel / Suramin Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) | NCT00006929 |
| Combination Chemotherapy Combined With Radiation Therapy in Treating Patients Who Have Stage II or Stage III Cancer of the Esophagus | Multicentre Phase II Study Of Concomitant Radio-Chemotherapy Associating Continuous Infusion 5-FU With Hydroxyuree Via Bone Marrow With Or Without Paclitaxel In Treatment Of Inoperable Epidermoid Carcinoma Of Esophagus | NCT00008047 |
| Monoclonal Antibody Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma | A Phase I Study of 90Y-DOTA-Peptide-Lym-1 With Peripheral Blood Stem Cell Support, Paclitaxel And Cyclosporin A In Patients With Non-Hodgkin's Lymphoma | NCT00008021 |
| Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes | A Phase II Study Of Safety And Tolerability Of Adjuvant Chemotherapy With Continuous Infusion Paclitaxel And Dose Intense Cyclophosphamide And Hematopoietic Growth Factor Support Followed By Doxorubicin For Stage II-IIIA Breast Cancer Involving Greater Than or Equal to 10 Lymph Nodes | NCT00007904 |
| Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer | Phase II Study of Weekly Paclitaxel by 1-HR Infusion Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma | NCT00003614 |
| Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma | Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma | NCT00010257 |
| Combination Chemotherapy in Treating Patients With Solid Tumors | A Phase I Study Of Fenretinide Combined With Paclitaxel And Cisplatin For The Treatment Of Refractory Solid Tumors | NCT00009932 |
| Combination Chemotherapy Plus Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Esophagus or Stomach | Non-Operative Therapy Of Local-Regional Carcinoma Of The Esophagus: A Randomizd Phase II Study Of Two Paclitaxel-Based Chemoradiotherapy Regimens | NCT00009880 |
| Paclitaxel Combined With Fluorouracil-Uracil and Leucovorin in Treating Patients With Solid Tumors | Phase I Study Of Weekly Paclitaxel In Combination With ORZEL (UFT + Leucovorin) For Advanced Non-Hematological Malignancies | NCT00009828 |
| Calcitriol Plus Paclitaxel in Treating Patients With Advanced Solid Tumors | A Phase I Trial Of Oral Calcitriol [1,25-(OH)2D3] And Paclitaxel In Advanced Solid Tumors | NCT00009802 |
| Monoclonal Antibody Therapy, Paclitaxel, and Cyclosporine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma | Combined Modality Radioimmunotherapy For Non-Hodgkin's Lymphoma With Three Cycles Of 90Y-DOTA-peptide-Lym-1, Paclitaxel and Cyclosporin A | NCT00009776 |
| Monoclonal Antibody Therapy, Cyclosporine, and Paclitaxel in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer | Combined Modality Radioimmunotherapy For Metastatic Breast Adenocarcinoma With Two Cycles Of Escalating Dose 90Y-DOTA-peptide-m170 and Fixed, Low Dose Paclitaxel With Blood Stem Cell Support And Cyclosporin For HAMA Suppression | NCT00009763 |
| Monoclonal Antibody Therapy Plus Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | Combined Modality Radioimmunotherapy For Hormone Refractory Metastatic Prostate Cancer With Two Cycles Of Escalating Dose 90Y-DOTA-Peptide-m170 And Fixed, Low Dose Paclitaxel With Blood Stem Cell Support And Cyclosporin For HAMA Suppression | NCT00009750 |
| International Collaborative Ovarian Neoplasm studies (3): a trial of paclitaxel with carboplatin in the first-line treatment of ovarian cancer | ISRCTN57157825 | |
| Chemotherapy and Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Stomach Who Have Undergone Surgery | A Randomized Phase II Comparison Of Two Cisplatin-Paclitaxel Containing Chemoradiation Regimens In Resected Gastric Cancers | NCT00011960 |
| Trastuzumab and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer | Herceptin and Paclitaxel in Locally Advanced Breast Cancer With Her-2 Overexpression | NCT00009997 |
| Comparison of Two Combination Chemotherapy Regimens in Treating Non-small Cell Lung Cancer | A Randomized Phase II Trial of Paclitaxel-Carboplatin or Gemicitabine-Cisplatin in ECOG Performance Status 2 Non-Small Cell Lung Cancer Patients | NCT00006004 |
| Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer | An Open-Label, Multicenter, Randomized, Phase II Study of Topotecan/Paclitaxel vs Etoposide/Cisplatin as First-Line Therapy for Patients With Extensive Disease Small Cell Lung Cancer | NCT00006374 |
| Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer | Phase II Randomized Study of Taxol (PACLITAXEL), Paraplatin (Carboplatin), and Radiation Therapy for Locally Advanced Inoperable Non-Small Cell Lung Cancer | NCT00006378 |
| Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer | Phase I-II Study of Topotecan and Paclitaxel Followed by High-Dose Thoracic Radiation Therapy With Concomitant Cisplatin/Etoposide and Amifostine in Limited-Stage Small Cell Lung Cancer | NCT00006012 |
| Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer | A Phase III Study of Adjuvant Postoperative Irradiation With or Without Cisplatin/Taxol Chemotherapy Following TAH/BSO for Patients With Endometrial Cancer | NCT00006027 |
| Combination Chemotherapy, Radiation Therapy and Surgery in Treating Patients With Cancer of the Esophagus | Phase II Trial of Preoperative Combined Modality Therapy for Localized Esophageal Carcinoma: Cisplatin-Paclitaxel Followed by Radiation Therapy With Concurrent Cisplatin and Paclitaxel | NCT00003087 |
| Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer | Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment for Women With HER-2 Over-Expressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer | NCT00005970 |
| Cisplatin, Paclitaxel, and Gemcitabine in Treating Patients With Progressive Unresectable Regional or Metastatic Bladder Cancer | First Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma of the Bladder With a Combination of Cisplatin-Paclitaxel-Gemcitabine | NCT00006118 |
| Combination Chemotherapy in Treating Patients With Unresectable Locally Advanced or Metastatic Stomach Cancer | A Phase II Study of Bryostatin-1 (NSC 339555) Plus Paclitaxel in Patients With Metastatic or Unresectable Locally Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction | NCT00006081 |
| Docetaxel or Paclitaxel in Treating Women With Unresectable Locally Advanced or Metastatic Breast Cancer | Phase II Randomized Study of Two Different Schedules of Docetaxel or Paclitaxel for Metastatic Breast Cancer | NCT00006120 |
| Capecitabine, Paclitaxel, and Trastuzumab in Treating Patients With Metastatic Breast Cancer | A Phase II Trial of Xeloda, Every Three Week Taxol and Herceptin in Metastatic Breast Cancer | NCT00006108 |
| Doxorubicin, Paclitaxel, and Carboplatin in Treating Patients With Primary Stage III, Stage IV, or Recurrent Endometrial Cancer | Phase II Study of Sequential Administration of Doxorubicin, Paclitaxel, and Carboplatin in Patients With Advanced and Recurrent Endometrial Cancer | NCT00006377 |
| Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer | Nonrandomized Ph II Study of Multimodality Therapy for Stg IIB, IIIA/B, or Stg IV Breast Cancer w/4 Cycles of Adriamycin and Cytoxan (AC),Followed by 12 Weeks of Paclitaxel w/ or w/o Herceptin Followed by Local Therapy Followed by Wkly Herceptin or no Additional Therapy | NCT00006110 |
| Paclitaxel Plus Radiation Therapy in Treating Women With Stage II or Stage III Breast Cancer | Concurrent Taxol (Paclitaxel) and Definitive Breast Radiation Therapy in Early Stage Breast Cancer Following Four Cycles of Adriamycin/Cytoxan Chemotherapy | NCT00006256 |
| Flavopiridol and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer That Has Not Responded to Previous Paclitaxel | Phase II Trial of Flavopiridol and Paclitaxel in Patients With Paclitaxel-Refractory Esophageal Cancer | NCT00006245 |
| S0007 - Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer | Evaluation of Three Hour Infusion of Paclitaxel Plus Cisplatin and 5-Fluorouracil in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN) | NCT00006248 |
| SU5416 and Paclitaxel in Treating Patients With Advanced Cancer | Phase I Trial of SU5416 in Combination With Weekly Paclitaxel in Patients With Advanced Malignancies | NCT00006257 |
| Paclitaxel in Treating Patients With Ovarian Stromal Cancer | Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy | NCT00006227 |
| Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer | A Phase II/III Double Blind Randomized Trial of BMS-275291 vs. Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-small Cell Lung Cancer | NCT00006229 |
| Micellar Paclitaxel to Treat Severe Psoriasis | A Pilot Open-Label Single-Dose Study Using Intravenous Micellar Paclitaxel for Patients With Severe Psoriasis | NCT00006276 |
| COMPARATIVE STUDY OF PHASE II OF GEMCITABIN + PACLITAXEL IN PATIENTS WITH ADVANCED BREAST CANCER | COMPARATIVE STUDY OF PHASE II OF GEMCITABIN + PACLITAXEL IN PATIENTS WITH ADVANCED BREAST CANCER | PER-048-00 |
| Chemotherapy and Radiation Therapy Following Surgery in Treating Patients With Head and Neck Cancer | Phase II Early Postoperative Paclitaxel Followed By Paclitaxel And Cisplatin Concurrent With Radiation Therapy For Resected, High Risk Squamous Carcinoma Of The Head And Neck | NCT00011999 |
| Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer | A Dose-finding Phase Ib Study Followed by an Open-label, Randomized Phase II Study of BEZ235 Plus Paclitaxel in Patients With HER2 Negative, Inoperable Locally Advanced or Metastatic Breast Cancer | NCT01495247 |
| This is an early stage breast cancer trial for women who have low expression of a biological protein called Her 2.Patients will have either node positive disease or high risk node negative disease.Patients will be assigned to receive chemotherapy alone or chemotherapy +Trastuzumab in a completely random fashion. | ICORG 11-24-NSABP PROTOCOL B-47A Randomized Phase III Trial of Adjuvant Therapy ComparingChemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide orFour Cycles of Doxorubicin Plus Cyclophosphamide Followed byWeekly Paclitaxel) to Chemotherapy Plus Trastuzumab inWomen with Node-Positive or High-Risk Node-NegativeHER2-Low Invasive Breast Cancer - ICORG11-24NSABPB-47. | EUCTR2011-004943-32-IE |
| Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma | Pilot Study to Evaluate the Potential Interactions Between Paclitaxel and Protease Inhibitors in Patients With AIDS-Related Kaposi's Sarcoma | NCT00003008 |
| Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | A Phase II Trial Using Multiple Cycles of High Dose Sequential Carboplatin, Paclitaxel and Topotecan With Peripheral Blood Stem Cell (PBSC) Support as Initial Chemotherapy in Patients With Suboptimally Debulked Stage III or IV Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma | NCT00003944 |
| S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer | A Comparison of Intensive Sequential Chemotherapy Using Doxorubicin Plus Paclitaxel Plus Cyclophosphamide With High Dose Chemotherapy and Autologous Hematopoietic Progenitor Cell Support for Primary Breast Cancer in Women With 4-9 Involved Axillary Lymph Nodes | NCT00002772 |
| Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus | A Phase III Trial of Ifosfamide (NSC #109274) Versus Ifosfamide Plus Paclitaxel (NSC #125973) in Patients With Advanced, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus | NCT00003128 |
| Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer | Phase I/II Trial of Sequential Doxorubicin/Gemcitabine (AG) and Ifosfamide, Paclitaxel, and Cisplatin (ITP) Chemotherapy (AG-ITP) in Patients With Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium | NCT00003105 |
| Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix | Phase II Investigation of Topotecan and Taxol in Patients With Recurrent/Metastatic Cancer of the Cervix | NCT00003065 |
| Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer | PHASE III COMPARISON OF TAXOTERE (DOCETAXEL) AND TAXOL (PACLITAXEL) IN PATIENTS WITH ADVANCED BREAST CANCER | NCT00002662 |
| Paclitaxel in Treating Patients With Advanced Head and Neck Cancer | Phase II Evaluation of Paclitaxel Infusion in Advanced (Recurrent or Metastatic) Squamous Cell Carcinoma of the Head and Neck | NCT00002922 |
| Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced or Metastatic Cancer of the Esophagus | Paclitaxel Combined With 5-FU and Cisplatin Concomitant With Radiotherapy in the Management of Locally Advanced or Metastatic Esophageal Cancer (Adenocarcinoma and Squamous Histologies) - A Phase I/Modified Phase II Trial | NCT00002984 |
| Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer | A RANDOMIZED, CONTROLLED TRIAL OF SALVAGE THERAPY WITH PACLITAXEL AND CARBOPLATIN VERSU SALVAGE THERAPY WITH STEM CELL SUPPORTED HIGH-DOSE CARBOPLATIN, MITOXANTRONE AND CYCLOPHOSPHAMIDE IN PATIENTS WITH PERSISTENT LOW VOLUME OVARIAN CANCER AND RESPONSE TO PRIMARY THERAPY | NCT00002819 |
| Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy | Phase II Study of Vinorelbine With Paclitaxel in the Treatment of Hormone-Refractory Prostate Cancer | NCT00003622 |
| Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract | Phase II Study of Doxil and Paclitaxel in Patients With Endometrial, Tubal, and Sarcomas of Gynecologic Origin | NCT00003334 |
| Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer | A Phase II/III Trial of Chemotherapy Alone Versus Chemotherapy Plus SCH 58500 in Newly Diagnosed Stage III Ovarian and Primary Peritoneal Cancer Patients With Greater Than or Equal to 0.5 cm and Less Than or Equal to 2 cm Residual Disease Following Surgery | NCT00003880 |
| Paclitaxel in Treating Older Patients With Solid Tumors | Clinical Pharmacology of Paclitaxel in Relation to Patient Age | NCT00003092 |
| Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Stage IIIA Non-small Cell Lung Cancer | A Phase III Study of Surgical Resection and Chemotherapy (Paclitaxel and Carboplatin) With or Without Adjuvant Radiotherapy for Resected Stage IIIA Non-Small Cell Lung Cancer | NCT00003317 |
| Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer | Single-Agent Versus Combination Chemotherapy in Advanced NSCLC: A CALGB Randomized Trial of Efficacy, Quality of Life, and Cost-Effectiveness | NCT00003117 |
| Cisplatin Plus Etoposide With or Without Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer | A Randomized Phase III Study Comparing Etoposide and Cisplatin With Etoposide, Cisplatin and Paclitaxel in Patients With Extensive Small Cell Lung Cancer | NCT00003299 |
| Paclitaxel in Treating Women With Recurrent Solid Tumors | Prospective Evaluation of Body Surface Area (BSA) as a Determinant of Paclitaxel Pharmacokinetics/Pharmacodynamics in Women With Solid Tumors | NCT00003130 |
| High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer | Phase I-II Study of Dose Intense Doxorubicin, Paclitaxel And Cyclophosphamide With Peripheral Blood Progenitor Cells (PBPC) And Cytokine Support In Patients With Metastatic Breast Cancer | NCT00002837 |
| Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery | Concurrent Carboplatin, Paclitaxel, and Radiation Therapy Versus Induction Carboplatin and Paclitaxel Followed by Concurrent Carboplatin, Paclitaxel and Radiation Therapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer: A Phase III Trial | NCT00003387 |
| Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Can Not Be Surgically Removed | A Phase III Trial of Induction Paclitaxel and Carboplatin Followed By Standard Radiotherapy (64 Gy/7 Weeks) vs. Hyperfractionated Accelerated Radiotherapy (HART 57.6 Gy/2.5 Weeks) For Patients With Unresectable Stage IIIA and IIIB Non-Small Cell Lung Cancer | NCT00003235 |
| Paclitaxel in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer | PHASE II TRIAL OF TAXOL IN ADVANCED OR METASTATIC SALIVARY GLAND MALIGNANCIES | NCT00002632 |
| Chemotherapy, Amifostine, and Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer | A Phase II Trial of Induction Paclitaxel Plus Carboplatin Followed by Thoracic Radiation Therapy With Concurrent Weekly Low-Dose Paclitaxel and Twice Weekly Amifostine for Patients With Unresectable Locally Advanced or Partially Resected Non-Small Cell Lung Cancer | NCT00003089 |
| Radiation Therapy Plus Paclitaxel in Treating Patients With Stage IIB or Stage III Breast Cancer | Weekly Paclitaxel During Radiation Therapy for Locally Advanced Breat Cancer | NCT00003050 |
| Doxorubicin and Paclitaxel in Treating Women With Locally Advanced Breast Cancer | A Pilot Trial Comparing Doxorubicin and Paclitaxel Induced Apoptosis in Locally Advanced Breast Cancer | NCT00003035 |
| Combination Chemotherapy for Patients With Brain Cancer | A Phase II Trial of Paclitaxel and Topotecan With Filgrastim in Patients With Recurrent or Refractory Glioblastoma Multiforme or Anaplastic Astrocytoma | NCT00002814 |
| Radiolabeled Monoclonal Antibody, Paclitaxel, and Interferon Alfa in Treating Patients With Recurrent Ovarian Cancer | PHASE I STUDY OF INTERFERON ENHANCED INTRAPERITONEAL RADIOIMMUNO-CHEMOTHERAPY FOR OVARIAN CANCER | NCT00002734 |
| Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer | A Phase III Randomized Trial of Cisplatin (NSC #119875) With Paclitaxel (NSC #125973) Administered by Either 24 Hour Infusion or 96 Hour Infusion in Patients With Selected Stage III and Stage IV Epithelial Ovarian Cancer and Primary Peritoneal Carcinoma | NCT00002717 |
| Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cervical or Vaginal Cancer | EVALUATION OF PACLITAXEL (TAXOL) IN PERSISTENT OR RECURRENT NON-SQUAMOUS CELL CARCINOMA OF THE CERVIX AND VAGINA | NCT00002562 |
| Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer | Phase II Trial of Paclitaxel, Cisplatin and Ifosfamide in Patients With Advanced Urothelial Tumors | NCT00002684 |
| Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer | PHASE I/II TRIAL OF THE ADDITION OF TAXOL TO HIGH DOSE CARBOPLATIN AND CYCLOPHOSPHAMIDE WITH AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELL SUPPORT IN PATIENTS WITH HIGH RISK STAGE II AND III BREAST CANCER | NCT00002627 |
| Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer | A PHASE III RANDOMIZED STUDY OF CISPLATIN (NSC #119875) AND TAXOL (PACLITAXEL) (NSC #125973) WITH INTERVAL SECONDARY CYTOREDUCTION VERSUS CISPLATIN AND PACLITAXEL IN PATIENTS WITH SUBOPTIMAL STAGE III & IV EPITHELIAL OVARIAN CARCINOMA | NCT00002568 |
| Combination Chemotherapy in Treating Patients With Germ Cell Tumors That Have Not Responded to Previous Cisplatin | PHASE I/II TRIAL OF TAXOL, IFOSFAMIDE, AND CISPLATIN FOR CISPLATIN-RESISTANT GERM CELL TUMOR PATIENTS WITH FAVORABLE PROGNOSTIC FEATURES | NCT00002559 |
| Paclitaxel Plus Radiation Therapy in Treating Patients With Untreated Stage III Non-small Cell Lung Cancer | PH I Continuous Infusion Taxol in Combination With Thoracic Radiation Therapy in Untreated Locally Advanced Non-Small Cell Lung Cancer | NCT00002519 |
| Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer | Phase III Randomized Trial of Methotrexate vs. Paclitaxel in Cisplatin-Ineligible Patients With Advanced Squamous Cell Carcinoma of the Head and Neck | NCT00003592 |
| Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors | Phase II Study of Paclitaxel Plus Gemcitabine in Refractory Germ Cell Tumors | NCT00003518 |
| Combination Chemotherapy After Surgery in Treating Patients With Cancer of the Esophagus or Stomach | Phase II Trial of Post-Operative Adjuvant Paclitaxel + Cisplatin in Patients With Adenocarcinoma of the Esophagus, Gastro-Esophageal Junction or Cardia | NCT00003237 |
| A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers | A Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant/ Refractory Advanced Ovarian Cancers | NCT01447706 |
| Topotecan and Paclitaxel in Treating Patients With Recurrent or Refractory Small Cell Lung Cancer | Phase II Trial of Topotecan and Paclitaxel in Previously Treated Patients With Relapsed Small Cell Lung Cancer | NCT00003281 |
| High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer | PHASE I PILOT STUDY OF SEQUENTIAL HIGH DOSE CYCLES OF CISPLATIN, CYCLOPHOSPHAMIDE, ETOPOSIDE AND IFOSFAMIDE, CARBOPLATIN AND TAXOL WITH AUTOLOGOUS STEM CELL SUPPORT | NCT00002854 |
| Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer | High Dose Paclitaxel Added to Cyclophosphamide and Thiotepa Followed by Autologous Stem Cell Rescue: A Phase I Trial in Advanced Breast Cancer | NCT00004174 |
| Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer | A Phase I-II Study of Induction Chemotherapy With Carboplatin and Gemcitabine, Followed by Chemoradiotherapy With Paclitaxel and Vinorelbine for Patients With Locally Advanced Non-Small Cell Lung Cancer | NCT00004093 |
| S9914: Combination Chemotherapy Plus Filgrastim in Untreated Extensive-Stage Small Cell Lung Cancer | Phase II Trial of Paclitaxel, Carboplatin and Topotecan With G-CSF in Untreated Patients With Extensive Small Cell Lung Cancer | NCT00004137 |
| Combination Chemotherapy in Treating Patients With Advanced Cancer | A Phase I/II Study of Paclitaxel, Estramustine Phosphate, and Vinorelbine (PaclEVin) | NCT00004105 |
| Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Advanced Cancer of the Mouth, Pharynx, or Larynx | A Phase II Study of Induction Chemotherapy Followed by Concomitant Paclitaxel (1 Hour Infusion), Fluorouracil, Hydroxyurea and Hyperfractionated Radiotherapy for Advanced Oral, Pharynx and Larynx Cancer | NCT00004094 |
| Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas | A Phase I and Pharmacokinetic Study Evaluating the Safety, Tolerability, and Maximally Tolerated Dose of Combination Therapy With Paclitaxel and L-778,123 in Patients With Recurrent or Refractory Solid Malignancies | NCT00004057 |
| Gemcitabine Plus Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Solid Tumor | Biweekly Gemcitabine and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer and Solid Tumors: A Phase I/IIa Study | NCT00004159 |
| Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Metastatic Testicular Cancer | A Study of Paclitaxel, Cisplatin and Ifosfamide as Induction Therapy in the Treatment of Patients Relapsing After BEP Chemotherapy for Metastatic Germ Cell Tumors | NCT00004077 |
| Paclitaxel and Oxaliplatin in Treating Patients With Recurrent or Advanced Non-small Cell Lung Cancer | A Phase II Study of Oxaliplatin in Combination With Paclitaxel in Non-Small Cell Lung Cancer | NCT00004126 |
| Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer | Randomized Phase II Study of Adriamycin/Cytoxan/Taxol (ACT) vs. Cytoxan, Thiotepa, Carboplatin (STAMP V) in Patients With High-Risk Primary Breast Cancer | NCT00004092 |
| Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes | A Phase III Study of Doxorubicin-Cyclophosphamide Therapy Followed by Paclitaxel or Docetaxel Given Weekly or Every 3 Weeks in Patients With Axillary Node-Positive Breast Cancer | NCT00004125 |
| Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced and/or Recurrent Head and Neck Cancer | A Phase I Study of Concomitant Chemoradiotherapy With Gemcitabine, Paclitaxel, and 5-FU for Patients With Advanced and/or Recurrent Cancer of the Head and Neck | NCT00004097 |
| Topotecan, Paclitaxel, and Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer | Phase II Trial of Oral Topotecan and Paclitaxel With G-CSF (Filgrastim) Support in Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer | NCT00004055 |
| Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer | A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer | NCT00004054 |
| Combination Chemotherapy, Radiation Therapy, and RSR13 in Treating Patients With Stage III Non-small Cell Lung Cancer | A Phase II Study of Induction Chemotherapy With Paclitaxel and Carboplatin Followed by Radiation Therapy With RSR13 for Locally Advanced Inoperable Non-Small Cell Lung Cancer | NCT00004202 |
| Paclitaxel in Treating Patients With Recurrent or Refractory Non-small Cell Lung Cancer | Phase II Study of Weekly Paclitaxel as Second-Line Therapy in Patients With Non-Small Cell Lung Cancer | NCT00004265 |
| Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery | A Phase II Study of 3-Dimensional Conformal Hyperfractionation Radiation Therapy (3D-CHRT) With Dose Escalation and Amifostine Mucosal Protection for Patients With Favorable Prognosis Inoperable Stage II-IIIA/B Non-Small Cell Lung Cancer (NSCLC) Receiving Paclitaxel and Carboplatin | NCT00004253 |
| Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer | A Phase II Trial Using Multiple Cycles of High Dose Sequential Carboplatin, Paclitaxel and Topotecan With Peripheral Blood Stem Cell (PBSC) Support as Initial Chemotherapy in Patients With Optimally Debulked Stage III Ovarian and Primary Peritoneal Carcinoma | NCT00004221 |
| Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy | Phase II Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-Fluorouracil for Peritoneal Carcinomatosis | NCT00004547 |
| Phase IB-II, open label, multicentre feasibility study of pazopanib in combination with Paclitaxel and Carboplatin in patients with platinumrefractory/ resistant ovarian, fallopian tube or peritoneal carcinoma. | Phase IB-II, open label, multicentre feasibility study of pazopanib in combination with Paclitaxel and Carboplatin in patients with platinumrefractory/ resistant ovarian, fallopian tube or peritoneal carcinoma. - Pazopanib and weekly paclitaxel/carboplatin in ovarian cancer | NL-OMON39032 |
| Oxaliplatin and Paclitaxel in Treating Patients With Metastatic or Unresectable Cancer | A Phase I Study of Oxaliplatin in Combination With Paclitaxel | NCT00004173 |
| Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer | Topotecan/Paclitaxel Induction Followed by Consolidation Chemoradiotherapy for Limited Stage Small Cell Lung Cancer: A Phase II Study | NCT00003812 |
| A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer | A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer | NCT00001426 |
| A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy With G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer Patients | A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy With G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer Patients | NCT00001384 |
| Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer | Phase I/II Study to Evaluate Combined Hyperfractionated Radiation Therapy and 5-Fluorouracil, Cisplatin and Paclitaxel (Taxol) and Amifostine (WR 2721, Ethyol) in Stage III and IV Inoperable Head and Neck Carcinomas | NCT00003582 |
| Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer | A Phase I/II Trial in Patients With Muscle-Invading Bladder Cancer of Transurethral Surgery Plus Taxol, Cisplatin and Bid Irradiation Followed by Either Selective Bladder Preservation or Radical Cystectomy and Adjuvant Chemotherapy | NCT00003930 |
| Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer | A Randomized Phase III Trial of IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Low Dose Paclitaxel 40 mg/m2/wk Versus IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Observation in Patients With Early Stage Ovarian Carcinoma | NCT00003644 |
| Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer | Randomized Phase II Trial of Paclitaxel, Carboplatin and rhuMAb Her-2 (Herceptin) as First-Line Chemotherapy in Patients With Metastatic Breast Cancer Who Overexpress Her-2 | NCT00003612 |
| Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma | Autologous Transplantation With High Dose BCNU and Melphalan Followed by Consolidation With DCEP and Taxol/Cisplatin in Patients With Multiple Myeloma and < or = 12 Months of Standard Therapy | NCT00003399 |
| Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia | Autologous Transplantation With and High Dose BCNU and Melphalan Followed by Consolidation With DCEP Plus Taxol/Cisplatin in Patients With Poor Prognosis Low Grade Non-Hodgkin's Lymphoma and Chronic Lymphocyte Leukemia, Who Have Received < or = 12 Months of Standard Therapy | NCT00003402 |
| Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma | Autologous Transplantation With Gemcitabine and High Dose BCNU Plus Melphalan Followed by Consolidation With DCEP Plus Gemcitabine and Taxol/Cisplatin in Patients With Multiple Myeloma and >12 Months of Standard Therapy | NCT00003401 |
| Combination Chemotherapy in Treating Patients With Breast Cancer | A Randomized Phase III Trial of Sequential Chemotherapy Using Doxorubicin, Paclitaxel, and Cyclophosphamide or Concurrent Doxorubicin and Cyclophosphamide Followed by Paclitaxel at 14 or 21 Day Intervals in Women With Node Positive Stage II/IIIA Breast Cancer | NCT00003088 |
| A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833 | A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833 | NCT00001383 |
| Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus | Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus | NCT00003054 |
| Paclitaxel in Advanced Refractory Kaposi's Sarcoma (AIDS-KS): A Phase II Trial of Paclitaxel From Baker Norton Pharmaceuticals | Paclitaxel in Advanced Refractory Kaposi's Sarcoma (AIDS-KS): A Phase II Trial of Paclitaxel From Baker Norton Pharmaceuticals | NCT00002189 |
| A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer | A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer | NCT00001498 |
| Phase II Trial of a 96-Hour Continuous Infusion of Paclitaxel Followed by Cisplatin for Patients With Stage III/IV and Relapsed NSCLC | Phase II Trial of a 96-Hour Continuous Infusion of Paclitaxel Followed by Cisplatin for Patients With Stage III/IV and Relapsed NSCLC | NCT00001450 |
| Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal Carcinomatosis | Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal Carcinomatosis | NCT00001569 |
| Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non-Small Cell Lung Cancer | Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non-Small Cell Lung Cancer | NCT00001499 |
| Phase I and Pharmacokinetic Trial of Paclitaxel (Taxol) Given as a 3-Hour Infusion in Pediatric Patients With Refractory Malignancy | Phase I and Pharmacokinetic Trial of Paclitaxel (Taxol) Given as a 3-Hour Infusion in Pediatric Patients With Refractory Malignancy | NCT00001387 |
| A Pilot Study of Paclitaxel With Radiation Therapy for Locally Advanced Head and Neck Cancer | A Pilot Study of Paclitaxel With Radiation Therapy for Locally Advanced Head and Neck Cancer | NCT00001442 |
| Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer | A Phase III Randomized Trial Of Paclitaxel And Carboplatin Versus Triplet Or Sequential Doublet Combinations In Patients With Epithelial Ovarian Or Primary Peritoneal Carcinoma | NCT00011986 |
| Paclitaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Vulva | Phase II Clinical Trial On Taxol As Single Agent In Locally Advanced And/Or Metastatic Or Recurrent Vulva Cancer Not Amenable For Surgery And/Or Radiotherapy | NCT00014599 |
| High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Lung Cancer | Tandem Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) After High Dose Paclitaxel Followed by Ifosfamide, Carboplatin, and Etoposide (ICE) for the Treatment of Lung Cancer | NCT00003284 |
| Predicting Nerve Damage Induced by Chemotherapy | Biological correlates of chemotherapy-induced neurotoxicity: a prospective cohort study of cancer patients undergoing treatment with cisplatin, oxaliplatin or paclitaxel. Prospectively Investigating Chemotherapy Neurotoxicty | ACTRN12612000029897 |
| Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer | Initial Clinical Evaluation of the Combination of Paclitaxel and Carboplatin With Modulation of Toxicity With GCSF and Amifostine | NCT00003294 |
| Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer | A Phase III Randomized Study of Amifostine Mucosal Protection for Patients With Favorable Performance Inoperable Stage II-III A/B Non-Small Cell Lung Cancer (NSCLC) Receiving Sequential Induction and Concurrent Hyperfractionated Radiotherapy With Paclitaxel and Carboplatin | NCT00003313 |
| Paclitaxel in Treating Patients With Recurrent or Progressive Advanced Ovarian Cancer | A Phase II Trial of Paclitaxel Administered Weekly in Patients With Advanced Ovarian Cancer | NCT00002928 |
| S9714: Paclitaxel in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer | Phase II Trial of Paclitaxel by 96-Hour Infusion in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) | NCT00002969 |
| Combination Chemotherapy in Treating Patients With Metastatic Ovarian Cancer or Non-small Cell Lung Cancer | Amifostine (Ethyol) as a Protectant in Metastatic Ovarian and Non-Small Cell Lung Cancer in Paclitaxel/Carboplatin-Treated Patients: A Comparative Trial | NCT00003072 |
| Paclitaxel in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia | Paclitaxol (Taxol) for Refractory or Relapsed Acute Leukemia in Elderly Patients, and Blast Crisis of Chronic Myelogenous Leukemia: A Multicenter Phase I/II Study | NCT00003230 |
| Paclitaxel and Radiation Therapy Plus Chemoprotection With Amifostine in Treating Patients With Stage III or Stage IV Head and Neck Cancer | Phase I/II Study of Escalating Doses of Taxol Used Concurrently With Ethyol and Accelerated Hyperfractionated Radiotherapy in the Treatment of Stage III and IV Carcinoma of the Head and Neck | NCT00003193 |
| Bryostatin 1 Plus Paclitaxel and Cisplatin in Treating Patients With Advanced Solid Tumors | An Open-Label, Non-Randomized Phase I Study of the Protein Kinase C Inhibitor Bryostatin-1 Administered in Combination With Paclitaxel in Patients With Advanced Solid Tumors | NCT00003242 |
| Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer | Assessment of the Predictive Value of the Extreme Drug Resistance (EDR) Assay in Patients Receiving Paclitaxel for Metastatic Breast Cancer | NCT00003253 |
| Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer | A Phase III Randomized Trial of Intravenous Paclitaxel and Cisplatin Versus Intravenous Paclitaxel, Intraperitoneal Cisplatin and Intraperitoneal Paclitaxel in Patients With Optimal Stage III Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma | NCT00003322 |
| Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus | A Phase II Trial of Paclitaxel (TAXOL) Administered as a Weekly One Hour Infusion in Patients With Advanced Esophageal Cancer | NCT00003326 |
| Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer | A Phase II Trial of Paclitaxel (TAXOL) Administered as a Weekly One Hour Infusion in Previously Treated Patients With Advanced Head and Neck Cancer | NCT00003327 |
| Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma | Phase III Study of Paclitaxel Versus Liposomal Doxorubicin for the Treatment of Advanced AIDS-Associated Kaposi's Sarcoma | NCT00003350 |
| Radiation Therapy Plus Paclitaxel and Cisplatin in Treating Patients With Cervical Cancer | A Phase I/II Study Of Whole Pelvic Radiation Therapy With Concomitant Paclitaxel and Cisplatin Chemotherapy in Patients With Cervical Carcinoma (Stages I-IV) Limited to the Pelvis | NCT00003379 |
| Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer | A Phase I Study of Paclitaxel, Carboplatin, and Increasing Doses of Doxil in Untreated Ovarian, Peritoneal, and Tubal Carcinoma | NCT00003385 |
| Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer | A Pilot Study of Amifostine and Concomitant Cisplatin, Paclitaxel and Radiotherapy in Previously Irradiated, Recurrent Head and Neck Cancer | NCT00003251 |
| S9806: Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer | Randomized Phase II Trial of Carboplatin/Gemcitabine Followed By Paclitaxel or Cisplatin/Vinorelbine Followed by Docetaxel in Advanced Non-Small Cell Lung Cancer | NCT00003587 |
| A PHASE II EVALUATION OF TEMSIROLIMUS (CCI-779) (NCI SUPPLIED AGENT:NSC# 683864, IND# 61010) IN COMBINATION WITH CARBOPLATIN AND PACLITAXEL FOLLOWED BY TEMSIROLIMUS (CCI-779) CONSOLIDATION AS FIRST-LINE THERAPY IN THE TREATMENT OF STAGE III-IV CLEAR CELL CARCINOMA OF THE OVARY | A PHASE II EVALUATION OF TEMSIROLIMUS (CCI-779) (NCI SUPPLIED AGENT:NSC# 683864, IND# 61010) IN COMBINATION WITH CARBOPLATIN AND PACLITAXEL FOLLOWED BY TEMSIROLIMUS (CCI-779) CONSOLIDATION AS FIRST-LINE THERAPY IN THE TREATMENT OF STAGE III-IV CLEAR CELL CARCINOMA OF THE OVARY - GOG-0268 | JPRN-jRCT2091220076 |
| Phase II Study of Paclitaxel and Carboplatin plus Bevacizumab in StageIIIA-N2, IIIB, IV patients with Nonsquamous Non-Small-Cell Lung Cancer | Phase II Study of Paclitaxel and Carboplatin plus Bevacizumab in StageIIIA-N2, IIIB, IV patients with Nonsquamous Non-Small-Cell Lung Cancer - Phase II Study of PTX and CBDCA plus Bevacizumab for Nonsquamous NSCLC | JPRN-UMIN000006809 |
| A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors | Open-Label, Multicenter, Dose Escalation Phase Ia/Ib Study With Expansion Phase to Evaluate Safety, Pharmacokinetics and Activity of RO5509554, Administered as an Intravenous Infusion as Monotherapy and in Combination With Paclitaxel in Patients With Advanced Solid Tumors | NCT01494688 |
| Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer | A Randomized Phase I Trial of Nanoparticle Albumin Bound Paclitaxel (Nab-paclitaxel, Abraxane) With or Without Mifepristone for Advanced Breast Cancer | NCT01493310 |
| EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer | EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial | NCT01485848 |
| Clinical Trial to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of Oral Paclitaxel in Patients With Advanced Solid Cancer | Phase I Clinical Trial to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of Oral Paclitaxel in Patients With Advanced Solid Cancer | NCT01491204 |
| A Study of Oraxol® in Gastric Cancer Patients | A Phase I-II Clinical Trial to Determine Recommended Dose and to Assess the Efficacy, Safety and Pharmacokinetic Profile of Oral Paclitaxel(Oraxol®) in Patients With Advanced/Metastatic or Recurrent Gastric Cancer | NCT01491217 |
| A clinical trial studying Paclitaxel with or without MM-121 for patients with advanced ovarian cancer | A Phase II Randomized Open Label Study of MM-121 incombination with Paclitaxel versus Paclitaxel alone inpatient with Platinum Resistant/Refractory AdvancedOvarian Cancers. | EUCTR2011-003576-36-BE |
| A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen | An Open-Label, One-Arm, One-Sequence Crossover Drug-Drug Interaction Study in Advanced Solid Tumor Subjects Subjects to Evaluate the Potential Effect of Custirsen (OGX-011) on the Pharmacokinetics of Paclitaxel | NCT01497470 |
| Safety and Efficacy of S-8184 in Treatment of Locally Advanced, Metastatic, or Recurrent TCC of the Urothelium | Safety And Efficacy Of Weekly Administration Of S-8184 Paclitaxel Injectable Emulsion In Second Line Treatment Of Patients With Locally Advanced, Metastatic, Or Recurrent Transitional Cell Carcinoma Of The Urothelium | NCT00034177 |
| S9712: Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III Non-small Cell Lung Cancer | A Phase II Trial of Concurrent Carboplatin/VP-16 and Radiation Followed by Paclitaxel (Taxol) for Poor-Risk Stage III Non-Small Cell Lung Cancer | NCT00003158 |
| ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC) | A Two Part, Multiple Dose Clinical Trial of the Safety and Efficacy of ABX-EGF in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non-Small Cell Lung Cancer | NCT00034346 |
| Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer | A Phase II Study of Concurrent Nab-Paclitaxel, Carboplatin and Thoracic Radiotherapy in Local Advanced Squamous Cell Lung Cancer | NCT01494415 |
| Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer | A Phase II, Double-Blind, Placebo-Controlled, Randomized Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer | NCT01493843 |
| Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer | Phase Ib/IIa Study of an Anti-Epidermal Growth Factor Receptor (EGFr) Antibody Cetuximab in Combination With Carboplatin-Paclitaxel in Patients With Chemotherapy-Naive Advanced Non-Small Cell Lung Cancer | NCT00034541 |
| A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer | A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Paclitaxel + Cisplatin or Carboplatin as First-Line Treatment for Patients With Stage IIIb (T4 Disease) or IV Squamous Non-Small Cell Lung Cancer (NSCLC) | NCT01519804 |
| Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer | A Multicenter, Randomized Trial for Stage IIIB or IV NSCLC Comparing Weekly Taxol(Paclitaxel) and Carboplatin(Paraplatin) Regimen Versus Standard Taxol and Carboplatin Administered Every Three Weeks, Followed by Weekly Taxol. | NCT00035152 |
| A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer | A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Metmab Vs. Placebo in Combination With Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum in Patients With Untreated Stage IIIb or IV Non-Squamous NSCLC | NCT01496742 |
| Carboplatin-Paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced (stage III-IV) or recurrent endometrial cancer. | A Randomized Phase II Trial of Carboplatin-Paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced (stage III-IV) or recurrent endometrial cancer. - MITO END2 | EUCTR2011-003301-16-IT |
| A Study of (a) Veliparib and Temozolomide or (b) Veliparib, Carboplatin and Paclitaxel or (c) Placebo, Carboplatin and Paclitaxel in patients with Breast Cancer | A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination with Temozolomide or Veliparib in Combination with Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects with BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer | EUCTR2011-002913-12-HU |
| Pilot study of sequential adjuvant chemotherapy regimen including non-pegylated Liposomal Doxorubicin (MYOCET) in combination with Cyclophosphamide and Paclitaxel in elderly patients with diagnosis of early breast cancer (COLT-ONE study). | Pilot study of sequential adjuvant chemotherapy regimen including non-pegylated Liposomal Doxorubicin (MYOCET) in combination with Cyclophosphamide and Paclitaxel in elderly patients with diagnosis of early breast cancer (COLT-ONE study). - COLTONE | EUCTR2010-024067-41-IT |
| BGOG-OV5:Phase II study of weekly Paclitaxel/Carboplatin in combination with prophylactic G-CSF in the treatment of gynaecological cancers. | BGOG-OV5:Phase II study of weekly Paclitaxel/Carboplatin in combination with prophylactic G-CSF in the treatment of gynaecological cancers. | EUCTR2010-022482-95-BE |
| Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer | A Limited Access Trial Using Amifostine for Protection Against Cisplatin and 3-Hour Paclitaxel-Induced Neurotoxicity | NCT00003624 |
| Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic | A Phase III Study of Paclitaxel Via Weekly 1 Hour Infusion Versus Standard 3 Hour Infusion Every 3 Weeks With Herceptin (Trastuzumab) (NSC #688097) in the Treatment of Patients With/Without HER-2/Neu-Overexpressing Metastatic Breast Cancer | NCT00003440 |
| S9900: Surgery With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer | A Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Paclitaxel/Carboplatin in Clinical Stage IB (T2N0), II (T1-2N1, T3N0) and Selected IIIA (T3N1) Non-Small Cell Lung Cancer (NSCLC) | NCT00004011 |
| Trastuzumab Plus Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer | Phase II Pilot Trial of Carboplatin, Paclitaxel, and Herceptin in HER2/Neu (+) Advanced NSCLC | NCT00003881 |
| Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast Cancer | A PILOT PHASE II TRIAL OF PSC 833 MODULATION OF MULTIDRUG RESISTANCE TO PACLITAXEL IN THE TREATMENT OF METASTATIC CARCINOMA OF THE BREAST | NCT00002826 |
| Carboplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer | A Phase II Trial of Carboplatin Plus Paclitaxel in the Treatment of Locally Recurrent or Metastatic Nasopharyngeal Carcinoma | NCT00003206 |
| Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer | High-Dose Infusional Taxol, Amifostine, Doxorubicin, and Cyclophosphamide Followed by Stem Cell Rescue for High Risk Primary and Responsive Metastatic Breast Cancer | NCT00003927 |
| Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors | PHASE I/II TRIAL OF SEQUENTIAL TAXOL/IFOSFAMIDE AND DOSEINTENSIVE CARBOPLATIN/ETOPOSIDE WITH STEM CELL SUPPORT IN CISPLATIN-RESISTANT GERM CELL TUMOR PATIENTS WITH UNFAVORABLE PROGNOSTIC FEATURES | NCT00002558 |
| Radiation Therapy, Paclitaxel, and Cisplatin in Treating Patients With Cancer of the Cervix | A Phase I Study of Extended Field Radiation Therapy With Concomitant Paclitaxel and Cisplatin Chemotherapy in Patients Cervical Carcinoma Metastatic to the Para-Aortic Lymph Nodes | NCT00003377 |
| S9912 Combination Chemo in Stage III Ovarian Cancer, | Phase II Evaluation of Intravenous Paclitaxel, Intraperitoneal Cisplatin, Intravenous Liposomal Doxorubicin and Intraperitoneal Paclitaxel in Women With Optimally-Debulked Stage III Epithelial Ovarian Cancer | NCT00003896 |
| Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer | A Randomized, Prospective Phase III Comparison of Paclitaxel-Carboplatin Versus Docetaxel-Carboplatin as First Line Chemotherapy in Stage Ic-IV Epithelial Ovarian Cancer | NCT00003998 |
| Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC) | Randomized, Placebo Controlled, Double Blind Phase 1b/2 Study of U3-1287 (AMG 888) in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed HER2 Positive Metastatic Breast Cancer (MBC) | NCT01512199 |
| Feasibility study of weekly nanoparticle albumin-bound paclitaxel for patients with metastatic breast cancer (HBCC1101) | Feasibility study of weekly nanoparticle albumin-bound paclitaxel for patients with metastatic breast cancer (HBCC1101) - Feasibility study of weekly nab-paclitaxel in metastatic breast cancer (HBCC1101) | JPRN-UMIN000007029 |
| A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors | A Study to Evaluate the Potential of Concomitant Ramucirumab to Affect the Pharmacokinetics of Paclitaxel in Patients With Advanced Malignant Solid Tumors | NCT01515306 |
| A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies | Multi-Center, Open-Label Phase 1B Study to Evaluate the Safety and Tolerability of HGS1036 in Combination With Paclitaxel and Carboplatin, Cisplatin and Etoposide, or Docetaxel in Subjects With Advanced Solid Malignancies | NCT01604863 |
| PhaseI/II Study of neoadjuvant therapy with Carboplatin Paclitaxel plus Bevacizumab for stage II/IIIA(>T2) Non-squamous Non-Small-Cell Lung Cancer | PhaseI/II Study of neoadjuvant therapy with Carboplatin Paclitaxel plus Bevacizumab for stage II/IIIA(>T2) Non-squamous Non-Small-Cell Lung Cancer - PhaseI/II Study of neoadjuvant therapy with Carboplatin Paclitaxel plus Bevacizumab for stage II/IIIA(>T2) Non-squamous Non-Small-Cell Lung Cancer | JPRN-UMIN000007129 |
| Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer | A Phase II Study of Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab Refractory Advanced Esophagogastric Cancer | NCT01522768 |
| Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer | Phase II Trial of Neoadjuvant Chemotherapy With Carboplatin and NAB-Paclitaxel in Patients With Locally Advanced and Inflammatory Triple Negative Breast Cancer | NCT01525966 |
| Intermittent administered erlotinib plus carboplatin, paclitaxel, bebacizumab in patients with advanced lung cancer. | Phase II, multicenter, open study , first line treatment of intermittenty administered Erlotinib plus Carboplatin, paclitaxel and bebacizumab in patients with advanced none small and none squamous lung cancer. - avaFAST | EUCTR2011-006313-33-ES |
| Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors | A Phase 1b Study to Assess the Safety of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors | NCT01525602 |
| A phase II neoadjuvant trial of sequential tri-weekly nanoparticle albumin-bound paclitaxel (Abraxane)/cyclophosphamide, with trastuzumab in HER2-positive patients, followed by 5-fluorouracil/epirubicine/cyclophosphamide (FEC) in operable breast cancer | A phase II neoadjuvant trial of sequential tri-weekly nanoparticle albumin-bound paclitaxel (Abraxane)/cyclophosphamide, with trastuzumab in HER2-positive patients, followed by 5-fluorouracil/epirubicine/cyclophosphamide (FEC) in operable breast cancer - TRI-ABC FEC trial | JPRN-UMIN000007180 |
| A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma. | A Randomized, Double-blind, Placebo-controlled Phase Ib/II Clinical Study of Anti-pd-l1 Monoclonal Antibody Injection (ZKAB001) Combined Albumin Binding Paclitaxel, Cisplatin in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma. | NCT04460066 |
| Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer | Phase I Trial of Dose-Dense Gemcitabine, Doxorubicin, Then Paclitaxel Plus Carboplatin In Patients With Transitional Cell Carcinoma of the Urothelium and Impaired Renal Function | NCT00003342 |
| Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2 | Pilot Trial of Paclitaxel-Herceptin Adjuvant Therapy for Early Stage Breast Cancer | NCT00003992 |
| Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Cancer | A Phase I/II Study to Determine the Maximum Tolerated Doses of Oral Topotecan, Carboplatin and Paclitaxel Administered Every 21 Days to Patients With Epithelial Ovarian Cancer Stages IIb, IIc, III and IV | NCT00003732 |
| Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin | A Randomized Phase III Trial of Paclitaxel, Carboplatin and Etoposide Vs. 5-Fluorouracil and Folinic Acid in the Treatment of Patients With Adenocarcinoma of Unknown Primary Site | NCT00003558 |
| Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel | Phase I Trial of Escalating Doses of BNP7787 in Patients With Solid Tumors Undergoing Treatment With Cisplatin and Taxol | NCT00003569 |
| Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901) | A Phase 3 Randomized Study of Lonafarnib in Combination With Paclitaxel and Carboplatin vs. Placebo in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer | PER-035-02 |
| Combination Chemotherapy in Treating Patients With Previously Untreated Stage III or Stage IV Ovarian or Primary Peritoneal Cancer | A Phase I Feasibility Trial of Carboplatin, Paclitaxel, and Gemcitabine in Patients With Previously Untreated Epithelial Ovarian Carcinoma and Primary Peritoneal Carcinoma | NCT00003378 |
| Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer | Phase I/II Study of Weekly Intravenous Estramustine Phosphate in Combination With Paclitaxel and Carboplatin in Patients With Advanced Prostate Cancer | NCT00003394 |
| Combination Chemotherapy in Treating Men With Germ Cell Cancer | Randomized Phase II/III Study of Taxol/Paclitaxel-BEP Versus BEP in Patients With Intermediate Prognosis Germ Cell Cancer | NCT00003643 |
| Combination Chemotherapy in Treating Patients With Platinum-Resistant Recurrent Ovarian Cancer | Phase II Study of Weekly Paclitaxel and Gemcitabine in Platinum-Resistant Ovarian Cancer | NCT00003449 |
| Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors | Phase I Trial of Paclitaxel, Cisplatin, and Irinotecan in Patients With Advanced Solid Tumor Malignancies | NCT00003742 |
| Paclitaxel Plus Monoclonal Antibody Therapy in Treating Women With Recurrent or Metastatic Breast Cancer | Phase II Study of Weekly 1-Hour Paclitaxel (Taxol) Plus Recombinant Humanized Anti-p185HER2 Monoclonal Antibody (Herceptin) in the Treatment of Patients With Metastatic Breast Cancer | NCT00003539 |
| Radiation Therapy Plus Paclitaxel in Treating Patients With Nonmetastatic, Unresectable Pancreatic Cancer | A Phase II Trial of External Irradiation (50.4 GY) and Weekly Paclitaxel (Taxol) for Non-Metastatic, Unresectable Pancreatic Cancer | NCT00003591 |
| Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer | A Phase II Trial of Weekly Paclitaxel Plus Oral Estramustine in Patients With Hormone Refractory Prostate Cancer | NCT00003717 |
| Sequential Chemotherapy in Treating Patients With Residual Disease Following Surgery for Stage IIB, Stage III, or Stage IV Ovarian Cancer | A Phase II Study of Sequential Carboplatin, Paclitaxel and Hycamtin in Patients With Previously Untreated Advanced Ovarian Cancer | NCT00003733 |
| Paclitaxel With or Without Trastuzumab Following Peripheral Stem Cell Transplantation in Treating Patients With Refractory Stage IV Breast Cancer | Treatment of Refractory Stage IV Metastatic Breast Cancer With Weekly Paclitaxel or Weekly Paclitaxel and Herceptin Following Autologous/Syngeneic Stem Cell Transplant | NCT00004013 |
| Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer. | A Phase II Trial of High Dose Paclitaxel, Carboplatin and Topotecan With Peripheral Blood Stem Cell Support in Extensive Stage Small Cell Cancer | NCT00003943 |
| Paclitaxel Plus Chemoprotection With Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors | Use of Weekly One Hour Paclitaxel Infusion With Dose Escalation for Recurrent and Resistant Cancers, Using Amifostine as a Cytoprotector | NCT00003555 |
| Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer | A Randomized Study of Doxorubicin Plus Cisplatin Versus Doxorubicin Plus Cisplatin Plus 3-Hour Paclitaxel With G-CSF Support in Patients With Primary Stage III & IV or Recurrent Endometrial Carcinoma | NCT00003691 |
| Combination Chemotherapy in Treating Patients Who Have Extensive-Stage Small Cell Lung Cancer | Phase III Study of Cyclophosphamide, Doxorubicin and Etoposide Compared to Carboplatin and Taxol in Patients With Extensive Disease Small Cell Lung Cancer | NCT00003696 |
| Phase II study of Carboplatin, Paclitaxel and Bevacizumab in patients with advanced Non-squamous non-small-cell lung cancer with large malignant pleural effusion. | Phase II study of Carboplatin, Paclitaxel and Bevacizumab in patients with advanced Non-squamous non-small-cell lung cancer with large malignant pleural effusion. - Phase II study of Carboplatin, Paclitaxel and Bevacizumab in patients with advanced Non-squamous non-small-cell lung cancer with large malignant pleural effusion. | JPRN-UMIN000006767 |
| A randomised phase 2 study of paclitaxel with or without GSK1120212 in advanced wt BRAF melanoma - Paclitaxel +/- GSK1120212 in Melanoma | A randomised phase 2 study of paclitaxel with or without GSK1120212 in advanced wt BRAF melanoma - Paclitaxel +/- GSK1120212 in Melanoma | EUCTR2011-002545-35-GB |
| Phase 3 clinical trial to determine the treatment of drugs AMG 386 + Paclitaxel is better than paclitaxel + placebo in women with recurrent ovarian cancer. | A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers | CTRI/2011/11/002163 |
| Radiation Therapy and Paclitaxel, Carboplatin, and Fluorouracil Followed by Esophagectomy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction | A Phase II Trial of Preoperative Radiation and Chemotherapy (Paclitaxel, Carboplatin, and Continuous Infusion 5-FU) for Locally Advanced Esophageal Cancer | NCT00022139 |
| Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer | Combination of Chemotherapy With Taxol, Adriamycin, and Cytoxan (TAC), Multiple Infusions of Activated T Cells (ATC), Interleukin-2 (IL-2) and GM-CSF for High Risk Breast Cancer With and Without Her2/Neu Overexpression. (Phase I/II) | NCT00022230 |
| Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas | Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors and Lymphomas | NCT00023166 |
| PHASE III STUDY OF GEMCITABIN WITH PACLITAXEL VERSUS PACLITAXEL IN PATIENTS WITH NON-RESECTIOUS, METASTASIC OR LOCALLY ADVANCED BREAST CANCER | PHASE III STUDY OF GEMCITABIN WITH PACLITAXEL VERSUS PACLITAXEL IN PATIENTS WITH NON-RESECTIOUS, METASTASIC OR LOCALLY ADVANCED BREAST CANCER | PER-059-01 |
| S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer | Phase II Trial of Paclitaxel and Carboplatin With Amifostine in Advanced Recurrent or Refractory Endometrial Adenocarcinoma | NCT00003127 |
| Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer | A Phase I/II Dose Intensification Study Using Three Dimensional Conformal Radiation Therapy And Concurrent Chemotherapy For Patients With Inoperable, Non-Small Cell Lung Cancer | NCT00023673 |
| DHA-Paclitaxel in Treating Patients With Metastatic Colorectal Cancer | Phase II Open-Label Study of Taxoperxin (DHA-Paclitacel) Injection by 2-Hour Intravenous Infusion in Patients With Metastatic Cancer of the Colon/Rectum | NCT00024401 |
| DHA-Paclitaxel in Treating Patients With Metastatic Pancreatic Cancer | Phase II Open-Label Study of Taxoperxin (DHA-Paclitaxel) Injection by 2 Hour Intravenous Infusion in Patients With Metastatic Cancer of the Pancreas | NCT00024375 |
| DHA-Paclitaxel in Treating Patients With Metastatic Prostate Cancer | Phase II Open-Label Study of Taxoprexin (DHA-Paclitaxel) Injection by 2-Hour Intravenous Infusion in Patients With Metastatic Hormone-Refractory Prostate Cancer | NCT00024414 |
| Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer | Phase II Study On Paclitaxel In Recurrent Uterine Papillary Serous Carcinoma (UPSC) | NCT00022620 |
| Chemotherapy in Treating Patients With Metastatic Kidney Cancer | Phase II Open-Label Study of Taxoprexin (DHA-Paclitaxel) Injection by 2-Hour Intravenous Infusion In Patients With Metastatic, Locally Advanced, or Unresectable Renal Cell Carcinoma | NCT00024388 |
| Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer | A Phase II Evaluation of Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum and Paclitaxel-Resistant Ovarian or Primary Peritoneal Cancer | NCT00023907 |
| Bevacizumab, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer | A Phase 2 Study Of Neoadjuvant rhuMAb VEGF (Bevacizumab) In Combination With Paclitaxel And Carboplatin In Surgically Resectable Non-Small Cell Lung Cancer | NCT00025389 |
| Paclitaxel With or Without Carboplatin in Treating Women With Metastatic Breast Cancer | A Randomized, Phase II Trial of Weekly Taxol (Paclitaxel) Versus Weekly Taxol Plus Paraplatin (Carboplatin) as First-Line Chemotherapy in Patients Age 65 Years or Older With Metastatic Breast Cancer | NCT00025688 |
| Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer | A Randomized Phase II Trial of Weekly Gemcitabine, Paclitaxel and External Irradiation (50.4 GY) Followed by the Farnesyl Transferase Inhibitor R115777 (NSC #702818) for Locally Advanced Pancreatic Cancer | NCT00026104 |
| S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer | Phase II Evaluation of Early Oral Estramustine, Oral Etoposide and Intravenous Paclitaxel in Combination With Hormone Therapy in Patients With High-Risk Metastatic Adenocarinoma of the Prostate | NCT00028769 |
| PS-341 and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors | A Phase I and Pharmacologic Study of the Proteasome Inhibitor PS-341 in Combination With Paclitaxel and Carboplatin in Patients With Advanced Malignancies | NCT00028587 |
| Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors | Phase I Trial of Interleukin-12 in Combination With Paclitaxel Plus Herceptin in Patients With Her2-positive Malignancies | NCT00028535 |
| Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer | A Randomized Phase III Tial Of Paclitaxel Versus Paclitaxel Plus Bevacizumab (rhuMAb VEGF) As First-Line Therapy For Locally Recurrent or Metastatic Breast Cancer | NCT00028990 |
| Paclitaxel, Folic Acid, and Lometrexol in Treating Patients With Locally Advanced or Metastatic Solid Tumors | A Phase I Trial of Lometrexol Sodium and Paclitaxel Adminsitered Intravenously Every 21 Days in Conjunction With Oral Folic Acid in Patients With Solid Tumors | NCT00024310 |
| Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | A Phase III Study of Cisplatin Plus Topotecan Followed by Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Carboplatin as First Line Chemotherapy in Women With Newly Diagnosed Advanced Epithelial Ovarian Cancer | NCT00028743 |
| Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer | A Phase II Activity And Safety Study Of IntraDose (Cisplatin/Epinephrine Injectable Gel) When Given In Combination With Systematic Chemotherapy Paclitaxel And Carboplatin In The Treatment Of Patients With Squamous Cell Carcinoma Of The Head And Neck At First Relapse | NCT00022217 |
| S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract | Protocol for Assessment of Gemcitabine and Paclitaxel for Metastatic Urothelial Cancer in Patients Aged 70 Years or Older (and in a Cohort of Patients Younger Than 60 Years) | NCT00022633 |
| Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer | A Phase III Adjuvant Trial Of Sequenced EC + Filgrastim + Epoetin Alfa Followed By Paclitaxel Versus Sequenced AC Followed By Paclitaxel Versus CEF As Therapy For Premenopausal Women And Early Postmenopausal Women Who Have Had Potentially Curative Surgery For Node Positive Or High Risk Node Negative Breast Cancer | NCT00014222 |
| Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer | Pilot and Translational Study of Dasatinib (NSC#732517) Paclitaxel and Carboplatin in Women With Advanced Stage and Recurrent Endometrial Cancer | NCT01440998 |
| Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer | A 2X2X2 Factorial Randomized Phase III Trial Of Multimodality Therapy Comparing 4 Cycles Of Doxorubicin And Cyclophosphamide With Or Without Dexrazoxane (AC+/-Z) Followed By 12 Weeks Of Weekly Paclitaxel With Or Without Trastuzumab (T+/-H) Followed By Local Therapy Followed By 40 Weeks Of Weekly Trastuzumab Or None In Women With HER-2+ STAGE IIIA, IIIB OR REGIONAL STAGE IV BREAST CANCER | NCT00016276 |
| S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer | A Comparative Randomized Study of Standard Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Vs. Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF Followed by Weekly Paclitaxel As Neoadjuvant Therapy For Inflammatory and Locally Advanced Breast Cancer | NCT00016406 |
| Gemcitabine, Carboplatin or Paclitaxel Plus Radiation Therapy in Treating Patients With Stage IIIA or IIIB Non-Small Cell Lung Cancer | A Phase I Study of Gemcitabine, Carboplatin or Gemcitabine, Paclitaxel and Radiation Therapy Followed by Adjuvant Chemotherapy for Patients With Favorable Prognosis Inoperable Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC) | NCT00016315 |
| Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer | Phase II Study Of Neo-Adjuvant Paclitaxel, Estramustine And Carboplatin (TEC) Plus Androgen Ablation Prior To Radiation Therapy In Patients With Poor Prognosis Localized Prostate Cancer | NCT00016913 |
| Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung Cancer | A Prospective, Randomized, Open-label, Phase III Trial of Chemotherapy With Carboplatin And Paclitaxel, Versus Carboplatin And Paclitaxel In Combination With ISIS-3521, An Antisense Inhibitor Of Protein Kinase C Alpha In Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer | NCT00017407 |
| PNU-93914 in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus | A Phase II Multicenter Study of the Efficacy and Safety Study of PNU-93914 (Liposome Encapsulated Paclitaxel) in Patients With Advanced Esophageal Cancer Previously Exposed to Chemotherapy | NCT00016900 |
| Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer | A Phase II Trial Of IM862 Combined With Paclitaxel And Carboplatin In Newly Diagnosed Advanced Epithelial Ovarian Or Primary Peritoneal Carcinoma Followed By IM862 Consolidation Therapy | NCT00017303 |
| Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer | Randomized Phase III Study Comparing Paclitaxel/Cisplatin/Gemcitabine and Cisplatin/Gemcitabine in Patients With Metastatic or Locally Advanced Urothelial Cancer Without Prior Systemic Therapy | NCT00022191 |
| 3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer | A Phase I Study Of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine) In Combination With Cisplatin And Paclitaxel In Patients With Advanced And Metastatic Cancer | NCT00016874 |
| Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer | Phase II Evaluation Of Paclitaxel And Cisplatin In Combination With Split Course Hyperfractionated Radiation Therapy And Granulocyte-Colony Stimulating Factor In Previously Irradiated Patients With Locally Recurrent Carcinoma Of The Head And Neck, And Lung | NCT00021333 |
| Paclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | Phase II Study of Paclitaxel and Estramustine Phosphate in Patients With Relapsed Non-Hodgkin's Lymphoma | NCT00021372 |
| Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer | Phase II Evaluation Of Paclitaxel, Cisplatin And 5-Fluorouracil Given In Combination With Radiation Therapy Prior To Surgery In Patients With Resectable Esophageal Cancer | NCT00021320 |
| Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2 | Study of Trastuzumab (Herceptin) and Paclitaxel in Patients With HER2-Overexpressing Metastatic Breast Cancer | NCT00019812 |
| Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas | A PHASE I STUDY OF THE COMBINATION OF CAI AND PACLITAXEL IN ADULT PATIENTS WITH REFRACTORY CANCERS OR LYMPHOMA | NCT00019019 |
| Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer | Randomized Phase II/III Trial of Paclitaxel Plus Carboplatin With or Without Bevacizumab (NSC #704865) in Patients With Advanced Nonsquamous NSCLC | NCT00021060 |
| Paclitaxel and Hyperthermic Perfusion in Treating Patients With Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery | A Phase I Study of Isolated Lung Perfusion With Paclitaxel and Moderate Hyperthermia in Patients With Unresectable Pulmonary Malignancies | NCT00020007 |
| Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach | A Phase II Study Of Irinotecan (Camptosar) And Paclitaxel (Taxol) In Patients With Adenocarcinoma Of The Upper Gastrointestinal Tract | NCT00020761 |
| A randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin-based, adjuvant chemotherapy for women with early stage breast cancer | A randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin-based, adjuvant chemotherapy for women with early stage breast cancer | ISRCTN51146252 |
| Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors | A Phase I Study of PS-341 in Combination With Paclitaxel in Metastatic Solid Tumors | NCT00030368 |
| Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer | A Phase II Study of Sequential Paclitaxel and Bryostatin-1 for Patients With Advanced Pancreatic Cancer | NCT00031694 |
| Capecitabine and Paclitaxel in Treating Patients With Metastatic Breast Cancer | Phase I/II Trial of Capecitabine With Weekly Paclitaxel for Advanced Breast Cancer | NCT00031876 |
| Phase2 Trial of Carboplatin-Paclitaxel bi-weekly and Bevacizumab combination therapy for Elderly Patients With Nonsquamous Non-Small-Cell Lung Cancer | Phase2 Trial of Carboplatin-Paclitaxel bi-weekly and Bevacizumab combination therapy for Elderly Patients With Nonsquamous Non-Small-Cell Lung Cancer - Phase2 Trial of Carboplatin-Paclitaxel bi-weekly and Bevacizumab combination therapy for Elderly Patients With Nonsquamous Non-Small-Cell Lung Cancer | JPRN-UMIN000006525 |
| Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients | A Randomized Phase II Open Label Study to Assess the Efficacy & Safety of Gemcitabine + Abraxane® With or Without ODSH (2-0, 3-0 Desulfated Heparin) as First Line Treatment of Metastatic Pancreatic Cancer | NCT01461915 |
| RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 TRIAL COMPARING THE EFFICACY OF IPILIMUMAB IN ADDITION TO PACLITAXEL AND CARBOPLATIN VERSUS PLACEBO IN ADDITION TO PACLITAXEL AND CARBOPLATIN IN SUBJECTS WITH STAGE IV/RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC). | RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 TRIAL COMPARING THE EFFICACY OF IPILIMUMAB IN ADDITION TO PACLITAXEL AND CARBOPLATIN VERSUS PLACEBO IN ADDITION TO PACLITAXEL AND CARBOPLATIN IN SUBJECTS WITH STAGE IV/RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC). | PER-050-11 |
| Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates | Phase I/II Randomized Clinical Trial of Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates | NCT01484080 |
| Phase I trial of Albumin-bound paclitaxel plus Cyclophosphamide for metastatic breast cancer | Phase I trial of Albumin-bound paclitaxel plus Cyclophosphamide for metastatic breast cancer - Phase I trial of Albumin-bound paclitaxel plus Cyclophosphamide for metastatic breast cancer | JPRN-UMIN000006597 |
| Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer | Efficacy and Tolerability of Nanoparticle Albumin Bound Paclitaxel (Abraxane) in Patients 65 and Older With Locally Advanced or Metastatic Breast Cancer | NCT01463072 |
| Phase II study of Carboplatin, weekly Paclitaxel and Bevacizumab in elderly patients with advanced non-squamous non-small-cell lung cancer (NEJ 016) | Phase II study of Carboplatin, weekly Paclitaxel and Bevacizumab in elderly patients with advanced non-squamous non-small-cell lung cancer (NEJ 016) - Phase II study of Carboplatin, weekly Paclitaxel and Bevacizumab in elderly patients with advanced non-squamous non-small-cell lung cancer (NEJ 016) | JPRN-UMIN000006622 |
| Sequential HIPEC of Oxaliplatin and Paclitaxel for Gastric Cancer Patients With Peritoneum Metastasis | Phase 2 Study of Sequential Hyperthermic Intraperitoneal Chemotherapy of Oxaliplatin and Paclitaxel for Gastric Cancer Patients With Peritoneum Metastasis or Positive Free Cancer Cells in Abdomen | NCT01471132 |
| Phase I/II study of peptide pulsed dendritic cell vaccination combined with carboplatin and paclitaxel for patients with advanced malignant melanoma | Phase I/II study of peptide pulsed dendritic cell vaccination combined with carboplatin and paclitaxel for patients with advanced malignant melanoma - Phase I/II study of peptide pulsed dendritic cell vaccination combined with carboplatin and paclitaxel for patients with advanced malignant melanoma (DC7) | JPRN-UMIN000006629 |
| Phase II trial of irinotecan, paclitaxel plus bevacizumab for previously untreated patients with non-squamous and non-small cell lung cancer, detected the over-expression of ERCC1 by EBUS-GS. | Phase II trial of irinotecan, paclitaxel plus bevacizumab for previously untreated patients with non-squamous and non-small cell lung cancer, detected the over-expression of ERCC1 by EBUS-GS. - Phase II trial of irinotecan, paclitaxel plus bevacizumab for patients with NSCLC | JPRN-UMIN000006514 |
| Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | A Randomized Phase IIB Evaluation of Weekly Paclitaxel (NSC #673089) Plus Pazopanib (NSC #737754) Versus Weekly Paclitaxel Plus Placebo in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma | NCT01468909 |
| A pharmacokinetic, safety, and tolerability study of paclitaxel administered once a week in subjects with advanced solid malignancies in Indian population. | A phase 1 pharmacokinetic, safety, and tolerability study of paclitaxel injection concentrate for nano-dispersion (PICN) administered once a week in subjects with advanced solid malignancies in Indian population. | CTRI/2011/11/002124 |
| Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer | A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of PD-1 Antibody Camrelizumab in Combination With Nab-paclitaxel Plus Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer | NCT04498689 |
| Safety and Efficacy Study of the DANUBIO Paclitaxel Eluting Balloon in Side Branches of de Novo Bifurcation Lesions (DEBSIDE) | Assessment of the Safety and Efficacy of the Danubio Paclitaxel-Eluting Balloon for the Treatment of Side Branches of de Novo Bifurcation Lesions in Native Coronary Arteries. | NCT01485081 |
| Safety and Efficacy Study of the DANUBIO Paclitaxel Eluting Balloon in In-Stent Restenosis Lesions (DEBREST) | Assessment of the Safety and Efficacy of the Danubio Paclitaxel-Eluting Balloon for the Treatment of In-Stent Restenosis Lesions in Native Coronary Arteries. | NCT01485068 |
| Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer | A Phase II Study of Induction Consolidation and Maintenance Approach for Patients With Advanced Pancreatic Cancer | NCT01488552 |
| TH v THL: A phase III randomized study of TH (Paclitaxel and Trastuzumab) versus THL (Paclitaxel, Trastuzumab and Lapatinib) in first line treatment of HER2-positive metastatic breast cancer. | TH v THL: A phase III randomized study of TH (Paclitaxel and Trastuzumab) versus THL (Paclitaxel, Trastuzumab and Lapatinib) in first line treatment of HER2-positive metastatic breast cancer. - TH v THL | EUCTR2011-005189-39-IE |
| PLUTO - (pazopanib versus paclitaxel in relapsed urothelial tumours) A Randomised Phase II study investigating pazopanib vs weekly paclitaxel in relapsed or progressive Transitional Cell Carcinoma (TCC) of the urothelium | A Randomised Phase II study investigating pazopanib vs weekly paclitaxel in relapsed or progressive Transitional Cell Carcinoma (TCC) of the urothelium. - PLUTO (PAZOPANIB VERSUS PACLITAXEL IN RELAPSED UROTHELIAL TUMOURS) | EUCTR2011-001841-34-GB |
| Phase II, open-label, non-randomized study of nab-paclitaxel for the neoadjuvant treatment of patients with stage II and III luminal breast cancer. | Phase II, open-label, non-randomized study of nab-paclitaxel for the neoadjuvant treatment of patients with stage II and III luminal breast cancer. | EUCTR2011-004476-10-ES |
| Relationship of aberrant DNA hypermethylation of CHFR with sensitivity to paclitaxel in Upper gastrointestinal tumors | Relationship of aberrant DNA hypermethylation of CHFR with sensitivity to paclitaxel in Upper gastrointestinal tumors | ChiCTR-TNC-11001736 |
| A Phase II study of neoadjuvant combination chemotherapy with TS-1, cisplatin and Paclitaxel (PCS) for resectable advanced gastric cancer. | A Phase II study of neoadjuvant combination chemotherapy with TS-1, cisplatin and Paclitaxel (PCS) for resectable advanced gastric cancer. - NECESSIT study | JPRN-UMIN000006674 |
| S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission | Phase III Randomized Trial of 12 Months vs. 3 Months of Paclitaxel in Patients With Advanced Ovarian Cancer Who Attain a Clinically Defined Complete Response (CR) Following Platinum/Paclitaxel-Based Chemotherapy | NCT00003120 |
| Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors | An Open-Label, Non-Randomized Phase I Study of the Protein Kinase C Inhibitor Flavopiridol Administered in Combination With Paclitaxel in Patients With Advanced Solid Tumors | NCT00003004 |
| Combination Chemotherapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | A Phase II Study Of Paclitaxel, Carboplatin And Gemcitabine In Previously Untreated Patients With Epithelial Ovarian Carcinoma FIGO Stage IIB-IV | NCT00031954 |
| Paclitaxel Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma | A Phase I Study Of Taxol And Involved Field Radiation Therapy For Newly Diagnosed Intrinsic Gliomas Of Childhood | NCT00031577 |
| Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer | Randomized Phase II Study of Preoperative Combined Modality Paclitaxel / Cisplatin / RT or Irinotecan / Cisplatin / RT Followed by Postoperative Chemotherapy With the Same Agents in Operable Adenocarcinoma of the Esophagus | NCT00033657 |
| Chemotherapy, Tirapazamine, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer | A Phase I Study Of Tirapazamine (NSC 130181) Paclitaxel And Carboplatin With Concurrent Radiation Followed By Tirapazamine/Paclitaxel/Carboplatin Consolidation For Stage III Non-Small Cell Lung Cancer | NCT00033410 |
| Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer | Paclitaxel/Topotecan/Etoposide (EtopoTax) Induction Followed by Consolidation Chemoradiotherapy for Limited Stage Small Cell Lung Cancer: A Phase II Study | NCT00033696 |
| Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Colorectal Adenocarcinoma | A Phase IIa Multicenter Evaluation of The Safety And Efficacy of Weekly Administration of S-8184 Paclitaxel Injectable Emulsion In Second Line Treatment of Patients With Stage III or IV Colorectal Adenocarcinoma | NCT00034190 |
| Safety and Efficacy of S-8184 in Second Line Treatment of Relapsed Stage IIIB or IV Non Small Cell Lung Cancer | A Phase IIA Multicenter Evaluation of the Safety and Efficacy of Weekly Administration of S-8184 Paclitaxel Injectable Emulsion in Second Line Treatment of Patients With Relapsed Stage IIIB OR IV Non Small Cell Lung Cancer | NCT00034164 |
| Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer | A Phase IIA Evaluation of Safety and Efficacy of Weekly S-8184 Paclitaxel Injectable Emulsion in Second Line Treatment of Stage III or IV Platinum Resistant Ovarian Cancer or Primary Peritoneal Carcinoma | NCT00034151 |
| Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder Cancer | Sequential Gemcitabine, Doxorubicin, Then Paclitaxel Plus Cisplatin Adjuvant Chemotherapy After Complete Resection of Locally Advanced Transitional Cell Carcinoma of the Urothelium | NCT00003133 |
| Paclitaxel Plus Topotecan in Treating Patients With Solid Tumors | A PHASE I STUDY OF PROLONGED LOW-DOSE TOPOTECAN INFUSION COMBINED WITH PACLITAXEL (TAXOL) | NCT00002587 |
| Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Women With Metastatic Breast Cancer | PHASE I/II TRIAL OF THE ADDITION OF TAXOL TO THE HIGH DOSE CARBOPLATIN AND CYCLOPHOSPHAMIDE WITH AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELL SUPPORT IN PATIENTS WITH BREAST CANCER | NCT00002628 |
| Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer | Sequential Adjuvant Chemotherapy With Doxorubicin, Taxol, and Cyclophosphamide for Stage II or III Resectable Breast Cancer With Four or More Involved Axillary Lymph Nodes | NCT00002679 |
| Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus | A PHASE I TRIAL OF COMBINED MODALITY THERAPY FOR LOCALIZED ESOPHAGEAL CANCER: CISPLATIN-PACLITAXEL FOLLOWED BY RADIATION THERAPY WITH CONCURRENT CISPLATIN AND ESCALATING DOSES OF PACLITAXEL | NCT00002711 |
| Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer | A RANDOMIZED PHASE III EVALUATION OF PACLITAXEL + G-CSF + CISPLATIN VERSUS CISPLATIN + 5-FU IN ADVANCED HEAD AND NECK CANCER | NCT00002888 |
| Paclitaxel in Treating Patients With Early-Stage Bladder Cancer | A PHASE I/II INSTITUTIONAL STUDY OF INTRAVESICAL TAXOL (PACLITAXEL) INSTILLATION FOR THE TREATMENT OF SUPERFICIAL BLADDER CANCER | NCT00002917 |
| Paclitaxel With or Without PSC 833 in Treating Patients With Metastatic Breast Cancer | A Phase II Randomized Study of Paclitaxel Versus Paclitaxel + PSC833 for Advanced Breast Cancer (Recurring Less Than 6 Months Since Adjuvant or as Second Line for Advanced Disease | NCT00002937 |
| Epirubicin and Cyclophosphamide Compared With Epirubicin and Paclitaxel in Treating Women With Metastatic Breast Cancer | A Radomized Trial of Epirubicin & Cyclophosphamide vs. Epirubicin & Paclitaxel in the Treatment of Women With Metastatic Breast Cancer | NCT00002953 |
| Paclitaxel-Carboplatin Alone or With M2ES for Non-Small-Cell Lung Cancer | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy of Paclitaxel-Carboplatin Alone or With Pegylated Endostatin for Advanced Non-small Cell Lung Cancer | NCT01527864 |
| Paclitaxel, Cisplatin, and Filgrastim Combined With Radiation Therapy in Treating Patients With Locally Recurrent Head and Neck Cancer | Phase II Study of Paclitaxel and Cisplatin in Combination With Split Course Concomitant Hyperfractionated Re-Irradiation in Patients With Recurrent Squamous Cell Cancer of the Head and Neck | NCT00005087 |
| Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer | Randomized Phase III Crossover Trial of Chemotherapy (Doxorubicin/Cisplatin/Paclitaxel and G-CSF) Versus Hormonal Therapy (Tamoxifen/Megestrol Acetate) in Patients With Stage III & IV or Recurrent Endometrial Cancer | NCT00016341 |
| Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial | Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial | NCT00041470 |
| Phase III study of S-1 plus intravenous and intraperitoneal paclitaxel versus S-1 plus cisplatin for gastric cancer with peritoneal metastasis | Phase III study of S-1 plus intravenous and intraperitoneal paclitaxel versus S-1 plus cisplatin for gastric cancer with peritoneal metastasis - PHOENIX-GC trial | JPRN-UMIN000005930 |
| E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC) | E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC) | NCT00832819 |
| Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811) | NCT01386385 |
| Phase II Study of DMXAA (ASA404) in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer | An Open Label, Randomized, Phase I/II Study of DMXAA in Combination With Carboplatin and Paclitaxel in Patients With Locally Advanced and Metastatic Non-Small Cell Lung Cancer | NCT00832494 |
| Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver | Phase I Study Of Hepatic Arterial Infusion Of Nab-Paclitaxel (Abraxane®) In Patients With Metastatic Melanoma In The Liver | NCT00833807 |
| Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer | A Phase II Multi-Center Study of Concomitant Cetuximab and Cisplatin With Re-Irradiation Using Intensity-Modulated Radiotherapy in Patients With Recurrent Squamous Cell Carcinoma of the Head-and-Neck | NCT00833261 |
| Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin | Phase II Study of Paclitaxel With Imatinib Mesylate (Gleevec) in Taxane-pretreated Ovarian and Other Cancers of Mullerian Origin | NCT00840450 |
| Treatment With Pazopanib for Neoadjuvant Breast Cancer | A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer | NCT00849472 |
| Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas | A Randomized Phase III Study of Weekly ABI-007 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Adenocarcinoma of the Pancreas | NCT00844649 |
| Phase II Trial of Weekly Intravenous Paclitaxel plus Three Weekly Intraperitoneal Carboplatin Administration for Suboptimally Debulked Ovarian and Primary Peritoneal Carcinoma Incorporating Pharmacogenomic Analysis. | Phase II Trial of Weekly Intravenous Paclitaxel plus Three Weekly Intraperitoneal Carboplatin Administration for Suboptimally Debulked Ovarian and Primary Peritoneal Carcinoma Incorporating Pharmacogenomic Analysis. - Phase II Trial of Weekly Paclitaxel plus IP Carboplatin for Ovarian and Peritoneal Cancer | JPRN-UMIN000001713 |
| Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer | A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology | NCT00850577 |
| Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer | A Phase I/II Study of Nab-paclitaxel, Cisplatin and Cetuximab With Concurrent Radiation Therapy for Local-regionally Advanced Head-and-neck Squamous Cell Carcinoma | NCT00851877 |
| Neo-adjuvant therapy with paclitaxel followed by FEC fluoraouracil, epirubicin and cyclophosphamide) for primary breast cancer(KBC-SG0801) | Neo-adjuvant therapy with paclitaxel followed by FEC fluoraouracil, epirubicin and cyclophosphamide) for primary breast cancer(KBC-SG0801) - Neo-adjuvant therapy with paclitaxel followed by FEC fluoraouracil, epirubicin and cyclophosphamide) for primary breast cancer(KBC-SG0801) | JPRN-UMIN000001736 |
| Late Phase II Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Head and Neck Cancer | Late Phase II Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Head and Neck Cancer | NCT00855764 |
| Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity | Phase I Trial of Intraperitoneal Nab-Paclitaxel (Abraxane) in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity | NCT00825201 |
| S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer | A Randomized Phase II Trial of Weekly Nanoparticle Albumin Bound Paclitaxel (Nab-Paclitaxel) (NSC-736631) With or Without Bevacizumab, Either Preceded by or Followed by Q 2 Week Doxorubicin (A)and Cyclophosphamide (C) Plus Pegfilgrastim (PEG-G) as Neoadjuvant Therapy For Inflammatory and Locally Advanced HER-2/NEU Negative Breast Cancer | NCT00856492 |
| Etude de phase II d’intensification de dose dans les tumeurs germinales réfractaires et en rechute de mauvais pronostic Protocole TICE : Paclitaxel et Ifosfamide suivi par une intensification de Carboplatine et Etoposide avec adaptation individuelle de la dose du Carboplatine - Intensification tumeurs germinales | Etude de phase II d’intensification de dose dans les tumeurs germinales réfractaires et en rechute de mauvais pronostic Protocole TICE : Paclitaxel et Ifosfamide suivi par une intensification de Carboplatine et Etoposide avec adaptation individuelle de la dose du Carboplatine - Intensification tumeurs germinales | EUCTR2008-005068-14-FR |
| Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation | Phase 2 Study of Intravenous Administration of Reovirus Serotype 3 - Dearing Strain (REOLYSIN®) in Combination With Paclitaxel and Carboplatin in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer Who Have KRAS or EGFR Activated Tumors | NCT00861627 |
| Phase I/II study of Induction Chemotherapy with weekly RAD001, Carboplatine and Paclitaxel in Unresectable or Inoperable Locally Advanced Head and NeckSquamous Cell Carcinoma (HNSCC) - CAPRA | Phase I/II study of Induction Chemotherapy with weekly RAD001, Carboplatine and Paclitaxel in Unresectable or Inoperable Locally Advanced Head and NeckSquamous Cell Carcinoma (HNSCC) - CAPRA | EUCTR2008-005702-39-FR |
| Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis | Dose Intensification Phase II Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis. TICE Protocol : Paclitaxel and Ifosfamide Followed by Carboplatine and Etoposide Intensification With Individual Carboplatine Dose Adjustment. | NCT00864318 |
| Randomised Phase III Trial of Paclitaxel plus Carboplatin (TC) Therapy versus Irinotecan plus Cisplatin (CPT-P) Therapy as a First Line Chemotherapy for Clear Cell Carcinoma of the Ovary - CCC-1 | Randomised Phase III Trial of Paclitaxel plus Carboplatin (TC) Therapy versus Irinotecan plus Cisplatin (CPT-P) Therapy as a First Line Chemotherapy for Clear Cell Carcinoma of the Ovary - CCC-1 | EUCTR2007-007849-13-FR |
| Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer | An Open-label, Multicenter, Phase I/II Study of Pazopanib in Combination With Paclitaxel in First-line Treatment of Subjects With Stage IIIBwet/IV Non-small Cell Lung Cancer | NCT00866528 |
| A single-arm Phase II clinical study of the combination of carboplatin and weekly paclitaxel plus bevacizumab as first-line treatment in patients with epithelial ovarian cancer - OCTAVIA | A single-arm Phase II clinical study of the combination of carboplatin and weekly paclitaxel plus bevacizumab as first-line treatment in patients with epithelial ovarian cancer - OCTAVIA | EUCTR2008-008336-85-FR |
| PHASE II STUDY OF LIPOSOME-ENCAPSULATED DOXORUBICIN PLUS PACLITAXEL AND TRASTUZUMAB AS PRIMARY SYSTEMIC THERAPY FOR OPERABLE AND LOCALLY-ADVANCED BREAST CANCER - PACLIDOX 07 | PHASE II STUDY OF LIPOSOME-ENCAPSULATED DOXORUBICIN PLUS PACLITAXEL AND TRASTUZUMAB AS PRIMARY SYSTEMIC THERAPY FOR OPERABLE AND LOCALLY-ADVANCED BREAST CANCER - PACLIDOX 07 | EUCTR2008-001369-27-IT |
| Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC) | A Phase 2, Randomized, Efficacy and Safety Study of Imprime PGG® Injection in Combination With Bevacizumab and Concomitant Paclitaxel and Carboplatin Therapy in Patients With Previously Untreated Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer | NCT00874107 |
| Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer | Efficacy and Safety Study of Imprime PGG® Injection in Combination With Cetuximab and Concomitant Paclitaxel and Carboplatin Therapy in Patients With Previously Untreated Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer | NCT00874848 |
| Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer | A Randomized Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Everolimus in Combination With Trastuzumab and Paclitaxel, as First Line Therapy in Women With HER2 Positive Locally Advanced or Metastatic Breast Cancer | NCT00876395 |
| A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors) | A Phase 1/2 Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors) | NCT00889382 |
| A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of MORAb-003 (farletuzumab) in Combination with Paclitaxel Therapy in Subjects with Platinum-Resistant or Refractory Relapsed Ovarian Cancer | A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of MORAb-003 (farletuzumab) in Combination with Paclitaxel Therapy in Subjects with Platinum-Resistant or Refractory Relapsed Ovarian Cancer | EUCTR2008-005449-43-NL |
| Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer | A Phase II Trial of a Vascular Endothelial Growth Factor (VEGF) Monoclonal Antibody, AVASTIN, in Combination With Cytotoxic Chemotherapy CARBOPLATIN and PACLITAXEL for Recurrent/Advanced Endometrial Cancer | NCT00879359 |
| Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery | Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer | NCT00861705 |
| Dose-finding Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and Bulky IIA Cervical Cancer | Phase I Dose Escalation Study Of Weekly Paclitaxel and Cisplatin Followed by Radical Hysterectomy in FIGO IB2 and Bulky IIA Cervical Cancer | NCT00823186 |
| Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194 | A Phase I-II Study of Dasatinib in Combination With Weekly Paclitaxel for Patients With Metastatic Breast Carcinoma | NCT00820170 |
| Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer | Phase II Clinical Trial of Neoadjuvant Weekly Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer | NCT01227408 |
| Phase II Study of Pre-Operative Chemotherapy in Patients With Resectable Local-Regional Carcinoma of Esophagus | Phase II Study of Pre-Operative Chemotherapy With Taxol, Cisplatin, and 5-Fluorouracil Followed by G-CSF in Patients With Resectable Local-Regional Carcinoma of Esophagus | NCT00208936 |
| 6 FEC 100 Vs 4 FEC 100 Followed by 4 Taxol in N+ Breast Cancer | NCT00189644 | |
| Taxol(Paclitaxel),UFT and Leucovorin in Patients With Advanced Gastric Cancer | An Open,Multi-Center,Phase II Clinical Trial tO Evaluate Efficacy and Safety oF TAXOL(PACLITAXEL),UFT,and LEUCOVORIN in Patients With Advanced Gastric Cancer | NCT00154778 |
| Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer | Neoadjuvant Therapy With Herceptin and Taxol for Stage II/III Breast Cancer | NCT00136539 |
| A randomised, multicentre, double-blind, placebo-controlled, 2-arm, Phase III study of oral GW572016 in combination with paclitaxel in subjects previously untreated for advanced or metastatic breast cancer. | A randomised, multicentre, double-blind, placebo-controlled, 2-arm, Phase III study of oral GW572016 in combination with paclitaxel in subjects previously untreated for advanced or metastatic breast cancer. | EUCTR2004-001999-40-AT |
| Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma | Phase I/II Study of Intravenous Estramustine Phosphate Combined With Taxol in Patients With Hormone Refractory Adenocarcinoma of the Prostate | NCT00038168 |
| Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2 | A Randomized Trial Comparing the Safety and Efficacy of Adriamycin and Cyclophosphamide Followed by Taxol (AC-T) to That of Adriamycin and Cyclophosphamide Followed by Taxol Plus Herceptin (AC-T+H) in Node-Positive Breast Cancer Patients Who Have Tumors That Overexpress HER2 | NCT00004067 |
| A Phase I Study of Taxol, Cisplatin, Cyclophosphamide and Granulocyte Colony-Stimulating Factor (G-CSF) in Previously Nontreated Ovarian Cancer Patients | A Phase I Study of Taxol, Cisplatin, Cyclophosphamide and Granulocyte Colony-Stimulating Factor (G-CSF) in Previously Nontreated Ovarian Cancer Patients | NCT00001272 |
| Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant (TECHNO) | Preoperative Therapy With Epirubicin/Cyclophosphamide Followed by Paclitaxel/Trastuzumab and Postoperative Therapy With Trastuzumab in Patients With HER-2 Over Expressed Breast Cancer | NCT00795899 |
| Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine | A Randomized, Parallel, 3-arm Study to Characterize the Effect of Ipilimumab + Chemotherapy in Patients With Untreated Advanced Melanoma | NCT00796991 |
| Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | A Double Blind Randomized Trial of Cediranib Versus Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer | NCT00795340 |
| Drug Eluting Balloon vs conventional balloon predilatation an Open Randomized trial in Acute myocardial infarction. | Safety and efficacy of the Genous Bio-engineered R Stent™ pre-dilated with paclitaxel-eluting balloon (Dior™) versus the Genous Bio-engineered R Stent™ pre-dilated with non drug eluting balloon in Patients undergoing PCI for ST-segment Elevation Myocardial Infarction. | NL-OMON27108 |
| A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis | An Open Label Study to Assess the Effect of Avastin (Bevacizumab) Combined With First Line Paclitaxel-carboplatin or Second Line Tarceva (Erlotinib) on Progression-free Survival in Non-squamous Non-small Cell Lung Cancer Patients With Asymptomatic Untreated Brain Metastasis | NCT00800202 |
| A Phase 2, Randomized, Efficacy and Safety Study of Imprime PGG® Injection in Combination with Cetuximab and Concomitant Paclitaxel and Carboplatin Therapy in Patients with Previously Untreated Advanced (Stage IIIB or IV)Non-Small Cell Lung Cancer | A Phase 2, Randomized, Efficacy and Safety Study of Imprime PGG® Injection in Combination with Cetuximab and Concomitant Paclitaxel and Carboplatin Therapy in Patients with Previously Untreated Advanced (Stage IIIB or IV)Non-Small Cell Lung Cancer | EUCTR2008-006778-14-DE |
| Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy | Phase 1 Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel | NCT00803556 |
| Local Paclitaxel Delivery for SFA Disease | Treatment of Superficial Femoral Artery Atherosclerotic Disease With Local Delivery of Paclitaxel Using an Irrigating Catheter: a Single-center Pilot Study | NCT00821028 |
| Paclitaxel and Cisplatin for Thymic Neoplasm | A Phase II Study of Paclitaxel and Cisplatin in Previously Untreated, Unresectable Invasive Thymoma or Thymic Carcinoma | NCT00818090 |
| Randomized Phase III Trial Comparing Gefitinib with Carboplatin/Paclitaxel in Previously Untreated Advanced Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Gene Mutations | Randomized Phase III Trial Comparing Gefitinib with Carboplatin/Paclitaxel in Previously Untreated Advanced Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Gene Mutations - Gefitinib vs CBDCA/TXL in untreated NSCLC with EGFR mutations | JPRN-C000000376 |
| Efficacy Comparison Study of Combination Regimens to Treat Advanced Esophageal Squamous Cell Carcinoma | A Randomized Phase II Trial of Capecitabine Plus Cisplatin (XP) Versus Capecitabine Plus Paclitaxel (XT) as a First-line Treatment for Advanced or Recurrent Esophageal Squamous Cell Carcinoma | NCT00816634 |
| Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer | A Phase I Feasibility Trial IP Cisplatin and IV Paclitaxel on Day 1 Followed by IP Paclitaxel on Day 8 Every 21 Days as Front-Line Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma | NCT00814086 |
| Postmastectomy chemoradiation therapy(weekly paclitaxel) after adjuvant or neoadjuvant chemothrapy in breast cancer : A phase 1 trial | Postmastectomy chemoradiation therapy(weekly paclitaxel) after adjuvant or neoadjuvant chemothrapy in breast cancer : A phase 1 trial - Phase 1 trial of postmastectomy chemoradiation | JPRN-UMIN000001571 |
| Dose Escalation Study of Liposomal Paclitaxel Plus Capecitabine in Chinese Patients With Advanced Gastric Carcinoma | Phase I Clinical Study of Liposomal Paclitaxel Plus Capecitabine in Chinese Patients With Advanced Gastric Carcinoma | NCT00881816 |
| Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer | A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma | NCT00807768 |
| Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment | A Phase II Trial of Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment | NCT00807573 |
| QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer | A Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer | NCT00807612 |
| Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer | An Open-Label Study of AMG 386 in Combination With Either Paclitaxel and Trastuzumab or Capecitabine and Lapatinib in Subjects With HER2-positive Locally Recurrent or Metastatic Breast Cancer | NCT00807859 |
| Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer | Phase 2 Randomized Study of Carboplatin/Paclitaxel With or Without CS-7017 in Chemotherapy-Naïve Subjects With Metastatic Non-Small Cell Lung Cancer | NCT00806286 |
| Open-labeled, randomized multi-center phase II study evaluating the efficacy and safety of Paclitaxel/ Carboplatin with and without Cetuximab as first-line treatment of adeno- and undifferentiated carcinoma of unknown primary (CUP) | Open-labeled, randomized multi-center phase II study evaluating the efficacy and safety of Paclitaxel/ Carboplatin with and without Cetuximab as first-line treatment of adeno- and undifferentiated carcinoma of unknown primary (CUP) | EUCTR2008-003174-18-DE |
| Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer | A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab (NSC #704865) Versus the Non-platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix | NCT00803062 |
| A Phase 2, Randomized, Efficacy and Safety Study of Imprime PGG® Injection in Combination with Bevacizumab and Concomitant Paclitaxel and Carboplatin Therapy in Patients with Previously Untreated Advanced (Stage IIIb or IV) Non-Small Cell Lung cancer | A Phase 2, Randomized, Efficacy and Safety Study of Imprime PGG® Injection in Combination with Bevacizumab and Concomitant Paclitaxel and Carboplatin Therapy in Patients with Previously Untreated Advanced (Stage IIIb or IV) Non-Small Cell Lung cancer | EUCTR2008-006780-37-DE |
| Clinical Study of Liposomal Paclitaxel in Chinese Patients | Dose Escalation Study of Liposomal Paclitaxel in Chinese Patients With Advanced Solid Tumors | NCT00881101 |
| A Phase II, Double-blind, Placebo-controlled, Multi-centre, Randomised Study of ZD4054 plus Carboplatin and Paclitaxel or Placebo plus Carboplatin and Paclitaxel in Patients with Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy | A Phase II, Double-blind, Placebo-controlled, Multi-centre, Randomised Study of ZD4054 plus Carboplatin and Paclitaxel or Placebo plus Carboplatin and Paclitaxel in Patients with Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy | EUCTR2008-006068-12-DE |
| A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer | A Phase III, Open Label, Randomized, 2 Arm Study of Ixabepilone Administered Every 21 Days Versus Paclitaxel or Doxorubicin Administered Every 21 Days in Women With Advanced Endometrial Cancer Who Have Previously Been Treated With Chemotherapy | NCT00883116 |
| S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer | A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | NCT00946712 |
| ?Fase II study with epirubicin, cisplatin and infusional fluorouracil (ECF) followed by weekly paclitaxel plus metronomic cyclophosphamide ? trastuzumab as preoperative treatment of locally advanced ER and PgR negative breast cancer?. - ND | ?Fase II study with epirubicin, cisplatin and infusional fluorouracil (ECF) followed by weekly paclitaxel plus metronomic cyclophosphamide ? trastuzumab as preoperative treatment of locally advanced ER and PgR negative breast cancer?. - ND | EUCTR2009-012048-18-IT |
| Study of Participants With Advanced Non-Small Cell Lung Cancer | A Study of Pemetrexed Plus Carboplatin Followed by Maintenance Pemetrexed vs Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Advanced NCSLC of Nonsquamous Histology | NCT00948675 |
| Phase I/II study of intravenous and intraperitoneal paclitaxel combined with continuous intraperitoneal cisplatin for advanced gastric cancer with peritoneal metastasis | Phase I/II study of intravenous and intraperitoneal paclitaxel combined with continuous intraperitoneal cisplatin for advanced gastric cancer with peritoneal metastasis - Phase I/II study of intravenous and intraperitoneal paclitaxel combined with continuous intraperitoneal cisplatin for advanced gastric cancer with peritoneal metastasis | JPRN-UMIN000002257 |
| A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer | A Phase Ib-IIa, Open-label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of Trastuzumab Emtansine, Paclitaxel and Pertuzumab Administered Intravenously to Patients With Her2-positive, Locally Advanced or Metastatic Breast Cancer | NCT00951665 |
| A clinical trial to study the pharmacokinetic comparison of two formulations for Intravenous Infusion of Paclitaxel in Indain Patients with Metastatic Breast Cancer. | An open label, balanced, randomized, two period, two treatment, two sequence, and two way crossover study to evaluate safety and pharmacokinetic comparison of intravenous infusion of paclitaxel Lipid Suspension and Taxol® in patients with Metastatic Breast Cancer | CTRI/2009/091/000441 |
| A Study of MNRP1685A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors | A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of MNRP1685A, a Human IgG1 Antibody, in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors | NCT00954642 |
| A Phase 1 Study of Epidermal Growth Factor Receptor (EGFR) Targeted, PaclitaxelLoaded EnGeneIC Delivery Vehicles (Erbitux®EDVsPac) in Patients with Advanced SolidTumours | A Phase 1 Study of Epidermal Growth Factor Receptor (EGFR) Targeted, Paclitaxel Loaded EnGeneIC Delivery Vehicles in Patients with Advanced Solid Tumours | ACTRN12609000672257 |
| Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer | A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary | NCT00954174 |
| Small Coronary Artery Treated by TAXUS Liberté Registry in Japan | Impact of Paclitaxel-eluting Stent for Small Coronary Artery Disease | NCT00955214 |
| Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer | A Phase II Randomized Trial of Paclitaxel, Carboplatin, Bevacizumab With or Without IMC-A12 in Patients With Advanced Non-squamous, Non-small Cell Lung Cancer | NCT00955305 |
| Intek Apollo Paclitaxel Eluting coronary stent study | Clinical success and safety of Intek Apollo coronary drug eluting stent with paclitaxel release in patients with de novo lesion | CTRI/2009/091/000594 |
| A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer | A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of PI3-Kinase Inhibitor GDC-0941 (Pictilisib) in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole in Patients With Locally Recurrent Or Metastatic Breast Cancer | NCT00960960 |
| Paclitaxel Releasing Balloon in Patients Presenting With In-Stent Restenosis | Paclitaxel Releasing Balloon in Patients Presenting With In-Stent Restenosis A Prospective, Multi-centre, Non-randomized Clinical Trial With Follow-up Investigations at 1, 6 and 12 Months | NCT00961181 |
| BIBF 1120 or placebo in combination with paclitaxel and carboplatin in first line treatment of ovarian cancer | Multicenter, randomised, double-blind Phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer - OVAR 12 | EUCTR2008-006831-10-DE |
| Paclitaxel and Cisplatin as First-Line Treatment for Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer | A Phase II Study of Efficacy and Safety of Paclitaxel and Cisplatin Every 2 Weeks as the First-line Treatment of Patients With Ovarian Cancer Stage Ic-IV. | NCT00964626 |
| Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer | The Use of Glutathione (GSH) for Prevention of Paclitaxel/Carboplatin (TAXOL/CBDCA) Induced Peripheral Neuropathy: A Phase III Randomized, Double-Blind Placebo Controlled Study | NCT00979082 |
| Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer | A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab (NSC #704865), Paclitaxel/Carboplatin/Temsirolimus (NSC #683864) and Ixabepilone (NSC #710428)/Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer | NCT00977574 |
| Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer | Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC) | NCT00976677 |
| RCT of TJ-3020 in patients with unresectable advanced or recurrent pancreatic cancer receiving nab-Paclitaxel plus Gemcitabine | Randomized phase II study of TJ-3020 in patients with unresectable advanced or recurrent pancreatic cancer receiving nab-Paclitaxel plus Gemcitabine | JPRN-jRCTs041190040 |
| Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma | A Randomized Phase II Trial of Carboplatin, Paclitaxel, Bevacizumab, With or Without Everolimus for Therapy of Metastatic Malignant Melanoma | NCT00976573 |
| Phase I trial of carboplatin in combination with irinotecan and paclitaxel split-dosed on days 1 and 8 | Phase I study of the maximum dose tolerability of carboplatin-irinotecan-paclitaxel combination (CIP) in patients with advanced refractory solid tumours | ACTRN12609000790246 |
| Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer | Phase 2 Study of CS-1008 in Combination With Chemotherapy (Paclitaxel/Carboplatin) in Locally Advanced or Metastatic Ovarian Cancer | NCT00945191 |
| A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer | A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer | NCT00974584 |
| Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Esophageal Cancer | Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Esophageal Cancer | NCT00971841 |
| Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer | Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer | NCT00971867 |
| Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast Cancer | Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast Cancer | NCT00971945 |
| Capecitabine with/without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer | Phase I/II single-arm interventional pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer | ISRCTN38983527 |
| A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer | A Phase 1b, Open-Label, Dose-Escalation Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Treatment-Naive, Stage IIIB/IV Non-Small Cell Lung Cancer | NCT00970580 |
| Concomitant radiotherapy and weekly cisplatin with or without prior induction chemotherapy with cisplatin, epirubicin and paclitaxel (CEP) in patients with locally advanced nasopharyngeal carcinoma | Induction chemotherapy with cisplatin, epirubicin and paclitaxel (CEP), followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma.A randomized phase II study conducted by the Hellenic Cooperative Oncology Group | ACTRN12609000730202 |
| Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors | A Pharmacodynamic Study of the P-glycoprotein (Pgp) Antagonist, CBT-1(Registered Trademark), Evaluating Pgp Inhibition in Tumors and Normal Tissues | NCT00972205 |
| Phase I/II Study of Paclitaxel Plus CPT-11 in Pts. With 2nd Line Chemotherapy of Inoperable or Recurrent GC. | Phase I/II Study of Biweekly Administration Regimen of Paclitaxel Combined With CPT-11 in Patients With Second Line Chemotherapy of Inoperable or Recurrent Gastric Cancer(GC). | NCT00209612 |
| Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer | A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma | NCT00942357 |
| Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary | A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP) | NCT00936702 |
| A RANDOMIZED PHASE II STUDY OF CARBOPLATIN AND PACLITAXEL +/- CETUXIMAB, IN ADVANCED AND/OR RECURRENT CERVICAL CANCER - Cetuximab in cervical cancer | A RANDOMIZED PHASE II STUDY OF CARBOPLATIN AND PACLITAXEL +/- CETUXIMAB, IN ADVANCED AND/OR RECURRENT CERVICAL CANCER - Cetuximab in cervical cancer | EUCTR2009-010099-74-IT |
| Paclitaxel-Loaded Polymeric Micelle and Carboplatin as First-Line Therapy in Treating Patients With Advanced Ovarian Cancer | Open-label, Multicenter, Phase I/II Trial to Evaluate Efficacy Safety of the Combination Therapy of Genexol-PM and Carboplatin as a Firstline Treatment in Subjects With Advanced Ovarian Cancer | NCT00886717 |
| Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer | Phase I/II Trial of Neoadjuvant Sunitinib Administered With Weekly Paclitaxel/Carboplatin in Patients With Locally Advanced Triple-Negative Breast Cancer | NCT00887575 |
| BEVACIZUMAB Y TRASTUZUMAB PREOPERATORIO JUNTO CON PACLITAXEL SEMANAL SEGUIDO, TRAS CIRUGÍA, DE DOXORUBICINA LIPOSOMAL ENCAPSULADA, CICLOFOSFAMIDA Y TRASTUZUMAB EN MUJERES CON CÁNCER DE MAMA HER2 + - AVANTHER | BEVACIZUMAB Y TRASTUZUMAB PREOPERATORIO JUNTO CON PACLITAXEL SEMANAL SEGUIDO, TRAS CIRUGÍA, DE DOXORUBICINA LIPOSOMAL ENCAPSULADA, CICLOFOSFAMIDA Y TRASTUZUMAB EN MUJERES CON CÁNCER DE MAMA HER2 + - AVANTHER | EUCTR2009-011405-16-ES |
| Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT00888615 |
| Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | A Phase 1 Study of R-(-)-Gossypol (Ascenta's AT-101) in Combination With Paclitaxel and Carboplatin in Solid Tumors | NCT00891072 |
| Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors | A Phase 1 Safety and Pharmacokinetic Study of ABT-263 in Combination With Paclitaxel in the Treatment of Subjects With Solid Tumors | NCT00891605 |
| Study of Blood and Tissue Samples From Patients With Locally Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Treated With Bevacizumab, Carboplatin, and Paclitaxel | Angiogenesis Pathway Gene Polymorphisms Associated With Clinical Outcome in Patients Enrolled in ECOG 4599 | NCT00900172 |
| Biomarker Study of Blood Samples From Patients With Non-Small Cell Lung Cancer Treated With Carboplatin and Paclitaxel With or Without Bevacizumab | Development of a Serum Proteomic Classifier for the Prediction of Benefit From Bevacizumab in Combination With Carboplatin and Paclitaxel | NCT00898417 |
| Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II) | A Phase I/II Multi-centre Study of AZD8931 in Combination With Weekly Paclitaxel to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and in a Selected Population With Low HER2-expressing Locally Recurrent and/or Metastatic Breast Cancer | NCT00900627 |
| An open label, multicenter, Phase I/II study of pazopanib in combination with paclitaxel in first line treatment of subjects with stage IIIBwet/IV non-small cell lung cancer | An open label, multicenter, Phase I/II study of pazopanib in combination with paclitaxel in first line treatment of subjects with stage IIIBwet/IV non-small cell lung cancer | EUCTR2009-010571-24-GB |
| Phase II study of a combined Paclitaxel, Gemcitabine, and Cisplatin chemotherapy regimen for advanced urothelial carcinoma | Phase II study of a combined Paclitaxel, Gemcitabine, and Cisplatin chemotherapy regimen for advanced urothelial carcinoma - Phase II study of a TGP chemotherapy regimen for advanced urothelial carcinoma | JPRN-UMIN000001979 |
| A clinical trial to study the effects of Nanoparticle based Paclitaxel drug, which does not contain the solvent cremophor, in advanced breast cancer | A Multicentre Phase I Study Of Cremophor FreePaclitaxel Nanoparticle In Advanced Breast Cancer. | CTRI/2009/091/000219 |
| A Clinical Trial of Paclitaxel Loaded Polymeric Micelle in Patients With Taxane-Pretreated Recurrent Breast Cancer | A Clinical Trial of Paclitaxel Loaded Polymeric Micelle (Genexol-PM®) in Patients With Taxane-Pretreated Recurrent Breast Cancer | NCT00912639 |
| A Clinical Trial to Study the Effects of Nanoparticle Based Paclitaxel Drug, Which Does Not Contain the Solvent Cremophor, in Advanced Breast Cancer | A Multicentre Phase I Study Of Cremophor FreePaclitaxel Nanoparticle In Advanced Breast Cancer | NCT00915369 |
| Comparison of Neo-adjuvant Weekly Paclitaxel With or Without Carboplatin in Early Breast Cancer | A Phase II Randomized Clinical Trial of Neo-adjuvant Weekly Paclitaxel With or Without Carboplatin in Early Breast Cancer | NCT00919880 |
| PERVIDEO I Registry, The Lutonix Paclitaxel-Coated Balloon Catheter for the Treatment of Coronary In-Stent Restenosis | A Prospective, Multicenter, European Registry Investigating the Lutonix Paclitaxel-Coated Balloon for the Treatment of In-Stent Restenosis Within Bare-Metal Stents | NCT00916279 |
| Infinnium-Core™ Registry for the Treatment of Patients With De Novo Coronary Lesions | Safety and Efficacy of the Infinnium-Core™ Paclitaxel-Eluting Coronary Stent System for the Treatment of Patients With De Novo Coronary Lesions | NCT00936780 |
| De Novo Pilot Study, Lutonix Catheter in Conjunction With Bare Metal Stenting for Treatment of Coronary De Novo Lesions | An Exploratory Study Investigating the Use of the Lutonix Paclitaxel-Coated Balloon in Conjunction With Bare Metal Stenting in Patients With De Novo Coronary Lesions. | NCT00934752 |
| Infinnium-Core(TM) Registry | Safety and Efficacy of the Infinnium-Core(TM) Paclitaxel-Eluting Coronary Stent System for the Treatment of Patients with De novo Coronary Lesions | CTRI/2009/091/000409 |
| A Study of Neoadjuvant Bio-C/T Followed by Concurrent Bio-R/T in High-risk Locally Advanced Oral Squamous Cell Carcinoma | A Phase II Study of Neoadjuvant Bio-chemotherapy With Cetuximab, Paclitaxel, and Cisplatin (CPC) Followed by Cetuximab-based Concurrent Bio-radiotherapy in High-risk Locally Advanced Oral Squamous Cell Carcinoma (OSCC) | NCT00933387 |
| Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma | A Single Arm, Multi-center Phase II Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma After Failure of Prior Platin-based Chemotherapy | NCT00933374 |
| Lenalidomide and Paclitaxel in Prostate Cancer | A Modular Phase I-II Trial of Lenalidomide and Paclitaxel in Men With Castration-Resistant Prostate Cancer and Lymph-Node Dominant Metastases | NCT00933426 |
| Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer | A Phase II Neo-Adjuvant Study of Cisplatin, Paclitaxel With or Without RAD001 in Patients With Triple-negative Locally Advanced Breast Cancer. | NCT00930930 |
| Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology | Randomized, Open Label, Phase III Trial Of CP- 751,871 In Combination With Paclitaxel And Carboplatin Versus Paclitaxel And Carboplatin In Patients With Non Small Cell Lung Cancer | PER-037-09 |
| Feasibility study of 5-fluorouracil, leucovorin and paclitaxel (FLTAX) in peritoneal disseminated gastric cancer with massive ascites or inadequate oral intake | Feasibility study of 5-fluorouracil, leucovorin and paclitaxel (FLTAX) in peritoneal disseminated gastric cancer with massive ascites or inadequate oral intake - Feasibility study of FLTAX in gastric cancer with severe peritoneal metastasis | JPRN-UMIN000002093 |
| Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II) THYME | A Phase I/II Multi-centre Study of AZD8931 in Combination With Weekly Paclitaxel to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and in a Selected Population With Low HER2-expressing Locally Recurrent and/or Metastatic Breast Cancer | PER-046-09 |
| A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | A Randomized Phase 2 Study of Human Anti-PDGFRa Monoclonal Antibody (IMC-3G3) With Paclitaxel/Carboplatin or Paclitaxel/Carboplatin Alone in Previously Untreated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | NCT00918203 |
| Safety, efficacy and pharmacokinetic study of paclitaxel injection concentrate for nano-dispersion in subjects with metastatic breast cancer. | Phase 1 safety, efficacy, and pharmacokinetic study of Paclitaxel nano-dispersion injection in subjects with metastatic breast cancer: A randomized, open label, dose-ranging, active controlled, comparative, parallel group, and multi-centric study. | CTRI/2009/091/000262 |
| Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer | A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC) | NCT00915603 |
| ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer | A Phase II, Double-blind, Placebo-controlled, Multi-centre, Randomised Study of ZD4054 (Zibotentan) Plus Carboplatin and Paclitaxel or Placebo Plus Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy | NCT00929162 |
| Alternating Cycles of Carboplatin/Gemcitabine and Carboplatin/Taxol for Advanced Stage NSCLC | Treatment of Stages IIIB and IV, Non Small Cell Lung Cancer With Alternating Cycles of Carboplatin/Taxol and Carboplatin/Gemcitabine. | NCT00259675 |
| A Randomised Phase II/III Study of Taxol-BEP Versus BEP in Patients with Intermediate Prognosis Germ Cell Cancer | A Randomised Phase II/III Study of Taxol-BEP Versus BEP in Patients with Intermediate Prognosis Germ Cell Cancer | EUCTR2004-000731-28-AT |
| A randomized, multicenter phase II study to explore whether biomarkers correlate with treatment outcome in chemo-naive patients with advanced or recurrent non-squamous non-small cell lung cancer, who receive treatment with bevacizumab (at a dose of either 7.5 mg/kg or 15 mg/kg) in addition to carboplatin based chemotherapy (gemcitabine or paclitaxel) - | EUCTR2008-000662-23-NL | |
| A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of Carboplatin /Paclitaxel in Combination with ABT-869 Versus Carboplatin/Paclitaxel Alone in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) as First-Line Treatment | A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of Carboplatin /Paclitaxel in Combination with ABT-869 Versus Carboplatin/Paclitaxel Alone in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) as First-Line Treatment | EUCTR2007-007107-32-CZ |
| Optical Coherence Tomography for Drug Eluting Stent Safety | In-Vivo Vascular Response of Sirolimus-,Paclitaxel- and Zotarolimus-Eluting Stents in Long Lesions Requiring Overlapping. A Prospective, Randomized, Controlled Study Using Optical Coherence Tomography | NCT00693030 |
| Therapy of Metastatic Breast Cancer With Paclitaxel and Liposomal Doxorubicin | Extended Dose Frequency 1st-line Therapy of Metastatic Breast Cancer With Paclitaxel and Liposomal Doxorubicin (Myocet®) | NCT00691912 |
| A randomized, multicenter phase II study to explore whether biomarkers correlate with treatment outcome in chemo-naive patients with advanced or recurrent non-squamous non-small cell lung cancer, who receive treatment with bevacizumab (at a dose of either 7.5 mg/kg or 15 mg/kg) in addition to carboplatin based chemotherapy (gemcitabine or paclitaxel) | A randomized, multicenter phase II study to explore whether biomarkers correlate with treatment outcome in chemo-naive patients with advanced or recurrent non-squamous non-small cell lung cancer, who receive treatment with bevacizumab (at a dose of either 7.5 mg/kg or 15 mg/kg) in addition to carboplatin based chemotherapy (gemcitabine or paclitaxel) | EUCTR2008-000662-23-HU |
| A randomized, multicenter phase II study to explore whether biomarkers correlate with treatment outcome in chemo-naive patients with advanced or recurrent non-squamous non-small cell lung cancer, who receive treatment with bevacizumab (at a dose of either 7.5 mg/kg or 15 mg/kg) in addition to carboplatin based chemotherapy (gemcitabine or paclitaxel) | A randomized, multicenter phase II study to explore whether biomarkers correlate with treatment outcome in chemo-naive patients with advanced or recurrent non-squamous non-small cell lung cancer, who receive treatment with bevacizumab (at a dose of either 7.5 mg/kg or 15 mg/kg) in addition to carboplatin based chemotherapy (gemcitabine or paclitaxel) | EUCTR2008-000662-23-BE |
| Drug Coated Balloons for Prevention of Restenosis | Paclitaxel Coated Balloons for Prevention of Restenosis in Small Arteries Below the Knee Compared to Angioplasty Using Uncoated Balloons | NCT00696956 |
| Study of Paclitaxel in Patients With Ovarian Cancer | An Open, Randomized, Multicenter Study in Patients with Recurrent Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer to Compare the Efficacy and Safety of paclitaxel (micellar) nanoparticles and paclitaxel(Cremophor® EL) | EUCTR2008-002668-32-SE |
| Hydroxychloroquine + Carboplatin, Paclitaxel and Bevacizumab in Non-Small Cell Lung Cancer (NSCLC) | Modulation of Autophagy With Hydroxychloroquine in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced/Recurrent Non-Small Cell Lung Cancer - A Phase I/II Study | NCT00933803 |
| Phase II randomized trial of combination therapy of paclitaxel and bevacizumab versus paclitaxel, capecitabine and bevacizumab as first-line treatment for locally recurrent or metastatic breast cancer patients with HER2/neu negative tumor | Phase II randomized trial of combination therapy of paclitaxel and bevacizumab versus paclitaxel, capecitabine and bevacizumab as first-line treatment for locally recurrent or metastatic breast cancer patients with HER2/neu negative tumor | NL-OMON20125 |
| A randomized phase II study of concomitant trastuzumab, bevacizumab with paclitaxel versus trastuzumab and bevacizumab followed by the combination of trastuzumab, bevacizumab and paclitaxel at progression as first-line treatment of patients with metastatic breast cancer with HER2-neu overexpression. | A randomized phase II study of concomitant trastuzumab, bevacizumab with paclitaxel versus trastuzumab and bevacizumab followed by the combination of trastuzumab, bevacizumab and paclitaxel at progression as first-line treatment of patients with metastatic breast cancer with HER2-neu overexpression. | NL-OMON25011 |
| Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer | Phase I Open Label Trial of Alimta® Plus Cisplatin and Paclitaxel Given Intraperitoneally (IP) as First Line Treatment for Women With Stage III Ovarian Cancer | NCT00702299 |
| Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer | Phase I Study of Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | NCT00702572 |
| Optical Coherence Tomography Following Paclitaxel Eluting Stent Implantation in Multivessel Coronary Artery Disease | A Prospective Optical Coherence Tomography Study on Completeness of Strut Coverage and Vessel Wall Response at 3-6 and 9 Months Following Paclitaxel Eluting Stent Implantation in Multivessel Coronary Artery Disease | NCT00704145 |
| A study to assess the effect of two chemotherapy drugs (paclitaxel and Cisplatin) along with radiation in treating cancer of the uterine cervix | Phase II study of Concurrent Chemoirradiation with weekly Paclitaxel and Cisplatin in the treatment of Carcinoma of the Cervix | CTRI/2008/091/000029 |
| Paclitaxel Plus Carboplatin With or Without Endostar in Patients With Advanced Non-small Cell Lung Cancer | Paclitaxel Plus Carboplatin (TC) Versus TC Plus Endostar in Patients With Advanced Non-small Cell Lung Cancer(NSCLC): a Randomized, Double-blind, Placebo-controlled, Multicentre Study | NCT00708812 |
| Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC | LPT 111111- A Single-arm, Multicenter Phase II Study to Evaluate The Combination of Weekly Nanoparticle Albumin Bound Paclitaxel (Nab-Paclitaxel or ABRAXANE®) and Lapatinib (TYKERB®) in Women With No More Than One Prior Treatment for ErbB2 Overexpressing Metastatic Breast Cancer | NCT00709761 |
| A RANDOMIZED PHASE II STUDY OF CONCOMITANT TRASTUZUMAB, BEVACIZUMAB WITH PACLITAXEL VERSUS TRASTUZUMAB AND BEVACIZUMAB FOLLOWED BY THE COMBINATION OF TRASTUZUMAB, BEVACIZUMAB AND PACLITAXEL AT PROGRESSION AS FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER WITH HER2-NEU OVEREXPRESSION | A RANDOMIZED PHASE II STUDY OF CONCOMITANT TRASTUZUMAB, BEVACIZUMAB WITH PACLITAXEL VERSUS TRASTUZUMAB AND BEVACIZUMAB FOLLOWED BY THE COMBINATION OF TRASTUZUMAB, BEVACIZUMAB AND PACLITAXEL AT PROGRESSION AS FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER WITH HER2-NEU OVEREXPRESSION - HAT-study | NL-OMON33918 |
| A Phase I/II randomised, double-blind, multi-centre study to assess the efficacy of AZD2281 when given in combination with paclitaxel in the 1st or 2nd line treatment of patients with metastatic Triple Negative Breast Cancer | A Phase I/II randomised, double-blind, multi-centre study to assess the efficacy of AZD2281 when given in combination with paclitaxel in the 1st or 2nd line treatment of patients with metastatic Triple Negative Breast Cancer | EUCTR2008-002608-25-AT |
| A Phase 2, Open-label Study of IMC-1121B in Combination with Paclitaxel and Carboplatin as First-line Therapy in Patients with Stage IIIB/IV Non-small Cell Lung Cancer | A Phase 2, Open-label Study of IMC-1121B in Combination with Paclitaxel and Carboplatin as First-line Therapy in Patients with Stage IIIB/IV Non-small Cell Lung Cancer | EUCTR2007-006715-22-GB |
| Randomized phase III study of CPT-11 versus Weekly Paclitaxel for unresectable or recurrent gastric cancer refractory to combination chemotherapy with fluoropyrimidine plus platinum. | Randomized phase III study of CPT-11 versus Weekly Paclitaxel for unresectable or recurrent gastric cancer refractory to combination chemotherapy with fluoropyrimidine plus platinum. - WJOG4007 | JPRN-UMIN000001252 |
| A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer | A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer | NCT00717340 |
| Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer | A Phase I Study of Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine With Filgrastim Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer | NCT00724386 |
| A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer | A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Patients With Advanced Non-small Cell Lung Cancer | NCT00723957 |
| Sorafenib plus paclitaxel metronomic chemotherapy in adreno-cortical-carcinoma patients progressing after 1st or snd line cytotoxic chemotherapy - PAXO | Sorafenib plus paclitaxel metronomic chemotherapy in adreno-cortical-carcinoma patients progressing after 1st or snd line cytotoxic chemotherapy - PAXO | EUCTR2008-000759-91-IT |
| Phase 2 trial of pemetrexed (Alimta™) combined with paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer - PANTHERA | Phase 2 trial of pemetrexed (Alimta™) combined with paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer - PANTHERA | EUCTR2008-001032-12-DE |
| A GCIG Intergroup multicentre factorial trial of open label carboplatin and paclitaxel +/- bevacizumab compared with oxaliplatin and capecitabine +/- bevacizumab as first line chemotherapy in patients with mucinous Epithelial Ovarian Cancer | A GCIG Intergroup multicentre factorial trial of open label carboplatin and paclitaxel +/- bevacizumab compared with oxaliplatin and capecitabine +/- bevacizumab as first line chemotherapy in patients with mucinous Epithelial Ovarian Cancer (mEOC) | ISRCTN83438782 |
| Sutent + Taxol for Advanced Esophageal Cancer | A Phase II Study of Sunitinib Malate (Sutent®) With Paclitaxel (Taxol®) in Patients With Advanced Esophageal Cancer | NCT00730353 |
| Phase II study of exemestane with doxorubicin plus paclitaxel (AP) followed by weekly paclitaxel (wP) as primary systemic chemotherapy for hormone-sensitive and HER2-negative postmenopausal breast cancer (SBCCSG-13 EAPAC) | Phase II study of exemestane with doxorubicin plus paclitaxel (AP) followed by weekly paclitaxel (wP) as primary systemic chemotherapy for hormone-sensitive and HER2-negative postmenopausal breast cancer (SBCCSG-13 EAPAC) - Phase II study of exemestane with doxorubicin plus paclitaxel (AP) followed by weekly paclitaxel (wP) as primary systemic chemotherapy for hormone-sensitive and HER2-negative postmenopausal breast cancer (SBCCSG-13 EAPAC) | JPRN-UMIN000001298 |
| Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer | Phase I/II Randomised, Double- Blind, Multi-centre Study to Assess the Efficacy of AZD2281 When Given in Combination With Paclitaxel in the 1st or 2nd Line Treatment of Patients With Metastatic Triple Negative Breast Cancer. | NCT00707707 |
| Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer | Weekly Paclitaxel-carboplatin Plus Bevacizumab as First Line Therapy for Patients With Triple Negative (ER-,PR-,HER2-) Metastatic Breast Cancer. A Multicenter Phase I-II Study | NCT00691379 |
| Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma | A Phase II Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma | NCT00687687 |
| Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | Phase IB-II, Open Label, Multicenter Feasibility Study of Pazopanib in Combination With Paclitaxel and Carboplatin in Patients With Platinum-Refractory/Resistant Ovarian, Fallopian Tube or Peritoneal Carcinoma | NCT01402271 |
| A Phase 1b Study With Volociximab in Combination With Carboplatin and Paclitaxel in First-line, Advanced Non-Small Cell Lung Cancer (NSCLC) | A Phase 1b Trial to Evaluate the Safety and Pharmacokinetics of Volociximab (M200) in Combination With Carboplatin and Paclitaxel in Subjects With Previously Untreated Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) | NCT00654758 |
| Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval | Liposomal Doxorubicin Versus Carboplatin/Paclitaxel in Patients With Ovarian Cancer Recurrence Between 6 and 12 Months After Previous Platinum Based Therapy: Phase III Randomized Multicenter Study Amendment Title Protocol Version 2.0: Phase III International Multicenter Randomized Study Testing the Effect on Survival of Prolonging Platinum-free Interval in Patients With Ovarian Cancer Recurring Between 6 and 12 Months After Previous Platinum Based Chemotherapy. | NCT00657878 |
| Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer | A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients With Esophageal Cancer Who Are Treated Without Surgery | NCT00655876 |
| Ensayo Clínico para pacientes con cáncer de mama que compara BIBF 1120 frente BIBF 1120 administrado junto a paclitaxel. | Ensayo clínico de fase I/II, aleatorizado, de paclitaxel neoadyuvante frente a imprimación con BIBF 1120 seguida por BIBF 1120 más paclitaxel en cáncer de mama HER-2 negativo con estudios correlativos proteómicos y de imagen dinámica.Phase I/II Randomized Clinical Trial of Neoadjuvant Paclitaxel vs. BIBF 1120 Priming Followed by BIBF 1120 plus Paclitaxel in Early HER-2 negative Breast Cancer with Pharmacodynamic and Dynamic Imaging Correlates. - NA | EUCTR2011-001649-34-ES |
| Phase II study of EC followed by Nab-paclitaxel as Neoadjuvant Chemotherapy for Early Breast Cancer | Phase II study of EC followed by Nab-paclitaxel as Neoadjuvant Chemotherapy for Early Breast Cancer - Phase II study of EC followed by Nab-paclitaxel as Neoadjuvant Chemotherapy for Early Breast Cancer | JPRN-UMIN000006020 |
| Phase I/II study of Gemcitabine plus weekly Paclitaxel with Metastatic Breast Cancer | Phase I/II study of Gemcitabine plus weekly Paclitaxel with Metastatic Breast Cancer - Phase I/II study of Gemcitabine plus weekly Paclitaxel with Metastatic Breast Cancer | JPRN-UMIN000006019 |
| Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors | Phase I Study of Pazopanib in Combination With Weekly Paclitaxel and Carboplatin to Assess the Safety and Tolerability in Patients With Advanced Solid Tumors | NCT01407562 |
| Randomised phase II study with cetuximab (Erbitux®) in combination with chemotherapy (5-FU and cisplatin or carboplatin) versus cetuximab (Erbitux®) in combination with chemotherapy (paclitaxel and carboplatin) for treatment of patients with relapsed or metastatic head and neck cancer | Randomised phase II study with cetuximab (Erbitux®) in combination with 5-FU and cisplatin or carboplatin versus cetuximab (Erbitux®) in combination with paclitaxel and carboplatin for treatment of patients with relapsed or metastatic squamous cell carcinoma of the head and neck - CETMET | EUCTR2010-022924-57-SE |
| A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer | A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer | NCT00660218 |
| Study Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian Cancer | Weekly Versus Every 3 Week Carboplatin and Paclitaxel in Patients With Ovarian Cancer: a Phase III Randomized Multicenter Study | NCT00660842 |
| A Phase III, randomized, double-blind, placebo-controlled multi-center study of ASA404 in combination with paclitaxel and carboplatin as first-line treatment for locally advanced or metastatic (stage IIIb/IV) non-small cell lung cancer (NSCLC). | A Phase III, randomized, double-blind, placebo-controlled multi-center study of ASA404 in combination with paclitaxel and carboplatin as first-line treatment for locally advanced or metastatic (stage IIIb/IV) non-small cell lung cancer (NSCLC). | EUCTR2007-006072-11-BE |
| ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer | A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of ASA404 in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Locally Advanced or Metastatic (Stage IIIb/IV) Non-Small Cell Lung Cancer (NSCLC) | NCT00662597 |
| S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer | A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2) | NCT00661193 |
| Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By Surgery | Phase I/II Clinical Trial Evaluating the Use of Vorinostat Combined With Paclitaxel and Radiotherapy in Patients With Inoperable Stage III Non-Small Cell Lung Cancer Unable to Tolerate Cisplatin | NCT00662311 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Gemcitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer | Phase II Trial of Albumin-Bound Paclitaxel in Combination With Gemcitabine and Bevacizumab in Patients With Metastatic Breast Cancer | NCT00662129 |
| Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers | A Phase 1 Study of Intraperitoneal Nanoparticle Paclitaxel in Patients With Peritoneal Malignancies | NCT00666991 |
| Study of Bavituximab Plus Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer | A Phase II Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin in Patients With Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | NCT00687817 |
| Concurrent Chemoradiotherapy Containing Paclitaxel&Cisplatin With/Without Tarceva in Locally Advanced Esophageal Cancer | Concurrent Chemoradiotherapy Containing Paclitaxel and Cisplatin With/Without Tarceva in Locally Advanced Esophageal Carcinoma: a Randomized Phase III Multi-center Trial. | NCT00686114 |
| Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC) | Phase IV Study of Concurrent Chemoradiotherapy With Paclitaxel and Cisplatin in Previously Untreated, Inoperable (Stage IIIa or IIIb) Non-small-cell Lung Cancer | NCT00686322 |
| Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer | A Phase I Study of Cisplatin, Paclitaxel, and RAD001 Patients With Metastatic Breast Cancer | NCT00680758 |
| A Study of Mycobacterium w in Combination With Paclitaxel Plus Cisplatin in Advanced Non Small Cell Lung Cancer | Open Label, Randomized Multicentric Phase II Clinical Trial of Mycobacterium w in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel and Cisplatin in Advanced Non Small Cell Lung Cancer. | NCT00680940 |
| Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer | Adjuvant Doxorubicin, Cyclophosphamide Followed by Avastin Given With Paclitaxel and Gemcitabine for Stage II and III Breast Cancer That Does Not Over-express Human Epidermal Growth Factor Receptor 2 (HER-2)/Neu | NCT00679029 |
| Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer | (NJ 1508) Modulation of Autophagy With Hydroxychloroquine in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced/Recurrent Non-Small Cell Lung Cancer - A Phase I/II Study | NCT00728845 |
| Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer | Phase II Trial of Neoadjuvant Chemotherapy [NCT] With Weekly Nanoparticle Albumin-bound Paclitaxel [Nab-paclitaxel; Abraxane®] in Combination With Carboplatin and Bevacizumab in Women With Clinical Stages I-III Breast Cancer | NCT00675259 |
| The Paclitaxel-Eluting Percutaneous Transluminal Coronary Angioplasty (PTCA) - Balloon Catheter in Coronary Artery Disease to Treat Chronic Total Occlusions | The Paclitaxel-Eluting PTCA-Balloon Catheter in Coronary Artery Disease to Treat Chronic Total Occlusions | NCT00670436 |
| A phase II study of carboplatin -paclitaxel with bevacizumab followed by the addition of erlotinib to bevacizumab beyond progression in patients with locally advanced and/or metastatic non-small cell lung cancer (NSCLC) who have not received prior systemic therapy. | A phase II study of carboplatin -paclitaxel with bevacizumab followed by the addition of erlotinib to bevacizumab beyond progression in patients with locally advanced and/or metastatic non-small cell lung cancer (NSCLC) who have not received prior systemic therapy. - ULCN-0107 Bevacizumab plus erlotinib beyond progression | NL-OMON31631 |
| Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors | Phase I Study of Paclitaxel (Taxol) and Bortezomib (Velcade) in Patients With Refractory Solid Tumor Malignancies Involving an Activated MAPK Pathway | NCT00667641 |
| Adjuvant Treatment of Breast Cancer With 1-3 Aflicted Lymph Nodes | Cyclophosphamid + Farmorubicin® With Subsequent Administration of Taxol® (q3w) Versus Intensified Administration of Farmorubicin® Followed by Taxol® (q2w) in the Adjuvant Treatment of Breast Cancer in Patients With 1-3 Afflicted Lymph Nodes (1-3 LK+) | NCT00668616 |
| A Phase 1b Study With Volociximab in Combination With Carboplatin, Paclitaxel, and Bevacizumab in First-line, Advanced Non-small Cell Lung Cancer (NSCLC) | Phase 1b Trial Evaluating the Safety of Volociximab in Combination With Carboplatin, Paclitaxel, and Bevacizumab in Subjects With Previously Untreated Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | NCT00666692 |
| PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer | A Phase I Trial of A SRC Kinase Inhibitor, Dasatinib,in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Recurrent Ovarian, Peritoneal, and Tubal Cancer | NCT00672295 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer | Phase II Trial of Abraxane Plus Carboplatin for Advanced NSCLC for Patients at Risk of Bleeding From VEGF Directed Therapies | NCT00729612 |
| Prevention of Restenosis After Genous Stent Implantation Using a Paclitaxel Eluting Balloon in Coronary Arteries | Prevention of Restenosis After Genous Stent Implantation Using a Paclitaxel Eluting Balloon in Coronary Arteries - a Randomized Clinical Trial. | NCT00732953 |
| Phase I, Pharmacokinetic, Pharmacodynamic Trial of PTK787 and Paclitaxel in Combination for Advanced Solid Tumors | Phase I, Pharmacokinetic, Pharmacodynamic Trial of PTK787 and Paclitaxel in Combination for Advanced Solid Tumors | NCT00731861 |
| A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer | Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer | NCT00789581 |
| Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors | A Phase I Multiple Ascending Dose Study of BMS-754807 in Combination With Paclitaxel and Carboplatin in Subjects With Advanced or Metastatic Solid Tumors | NCT00793897 |
| A phase II randomized trial in completely resected non-small cell lung cancer comparing paclitaxel / carboplatin with TS-1 | A phase II randomized trial in completely resected non-small cell lung cancer comparing paclitaxel / carboplatin with TS-1 - A phase II randomized trial in completely resected non-small cell lung cancer (PTX/CBDCA vs TS-1) | JPRN-UMIN000001510 |
| Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ) | Phase I/II Pilot Study of Lapatinib in Combination With Carboplatin and Paclitaxel in the Treatment of Recurrent/Metastatic Adenocarcinoma of the Esophagus and Gastroesophageal Junction (GEJ) | NCT01395537 |
| A Clinical Trial to evaluate the Efficacy and Safety of of Oral Paclitaxel (DHP107) Compared toIV Paclitaxel as First-line Therapy in Patients with Recurrent orMetastatic HER2 Negative Breast Cancer | A Multinational, Multicenter, Open-label, Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of Oral Paclitaxel (DHP107) Compared to IV Paclitaxel as First-line Therapy in Patients with Recurrent or Metastatic HER2 Negative Breast Cancer | CTIS2024-517090-24-00 |
| A randomized, open, two-cycle, two-cross bioequivalence trial of paclitaxel for injection (albumin-binding) in patients with breast cancer | A randomized, open, two-cycle, two-cross bioequivalence trial of paclitaxel for injection (albumin-binding) in patients with breast cancer | ChiCTR2300071880 |
| Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes | Clinical Efficacy of Albumin Paclitaxel Plus Carrelizumab Versus FLOT in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes--A Multi-center, Randomised, Open, Phase 3 Clinical Trial | NCT05610332 |
| Phase II exploratory clinical study of sintilimab combined with nab-paclitaxel in the second-line treatment of advanced or metastatic esophageal squamous cell carcinoma | Phase II exploratory clinical study of sintilimab combined with nab-paclitaxel in the second-line treatment of advanced or metastatic esophageal squamous cell carcinoma | ChiCTR2200056550 |
| A clinical trial to compare the effects of chemotherapy and trastuzumab combined with radiation therapy followed by surgery versus only chemotherapy and trastuzumab followed by surgery and then radiation therapy in Her 2 neu positive locally advanced breast cancers | Neoadjuvant Concurrent Chemo-radiation with Paclitaxel and Trastuzumab versus Neoadjuvant chemotherapy with trastuzumab followed by sequential radiation in locally advanced Her2 neu positive breast cancers: a phase 2 randomized controlled trial | CTRI/2021/02/031588 |
| effect of dulexetine on paclitaxel- induced peripheral Neuropathy | Effect of duloxetine on paclitaxel- induced peripheral Neuropathy Among women with breast cancer. | IRCT20201115049390N1 |
| A single arm, open, single center phase II clinical study for Anlotinib plus Albumin taxol/Cisplatin in the treatment of recurrent or metastatic cervical cancer. | A single arm, open, single center phase II clinical study for Anlotinib plus Albumin taxol/Cisplatin in the treatment of recurrent or metastatic cervical cancer. | ChiCTR2000037497 |
| Carboplatin-Paclitaxel-Pembrolizumab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer | Phase II Study on Carboplatin-Paclitaxel-Pembrolizumab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer | NCT04238988 |
| Effect of albumin paclitaxel on efficacy, safety and immune function of elderly patients with advanced gastric cancer after first-line treatment failure | Effect of albumin paclitaxel on efficacy, safety and immune function of elderly patients with advanced gastric cancer after first-line treatment failure | ChiCTR1900026165 |
| Open randomized clinical study of Pembrolizumab combination with albumin-bound taxol and cisplatin in the treatment of advanced relapsed metastatic squamous cell carcinoma of the head and neck | Open randomized clinical study of Pembrolizumab combination with albumin-bound taxol and cisplatin in the treatment of advanced relapsed metastatic squamous cell carcinoma of the head and neck | ChiCTR1900024298 |
| Treatment of Advanced Gastrointestinal Tumors With Albumin Taxol | A Retrospective Clinical Study on the Efficacy and Safety of Injection Taxol (Albumin Binding Type) in the Treatment of Patients With Advanced Gastrointestinal Tumors | NCT03977077 |
| A Clinical study for the relationship between ALDH1-positive circulating tumor cells (CTC) and the efficacy of neoadjuvant chemotherapy for breast cancer | A Clinical study for the relationship between ALDH1-positive circulating tumor cells (CTC) and the efficacy of neoadjuvant chemotherapy for breast cancer (containing anthracycline and taxol) | ChiCTR1800019671 |
| Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer | An Open-label, Randomized, Comparative Pilot Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer | NCT00394251 |
| A Randomized Multicenter Phase2 Trial of Neoadjuvant Paclitaxel followed by Fluorouracil,Epirubin,and Cyclophosphamide(FEC)with or without Estrogen Deprivation by LH-RH agonist or Aromatase Inhibitor in Breast Cancer larger than 2 cm. | A Randomized Multicenter Phase2 Trial of Neoadjuvant Paclitaxel followed by Fluorouracil,Epirubin,and Cyclophosphamide(FEC)with or without Estrogen Deprivation by LH-RH agonist or Aromatase Inhibitor in Breast Cancer larger than 2 cm. - A Randomized Multicenter Phase2 Trial of Neoadjuvant Paclitaxel followed by Fluorouracil,Epirubin,and Cyclophosphamide(FEC)with or without Estrogen Deprivation by LH-RH agonist or Aromatase Inhibitor in Breast Cancer larger than 2cm. (NACED Randomized Multicenter Phase2 Trial) | JPRN-UMIN000000748 |
| Organ Preservation: Weekly Carboplatin & Taxol w/Concurrent RT for Locally Advanced Laryngeal & Hypopharyngeal CA | NCT00534729 | |
| Intensive Sequential Chemotherapy With Adriamycin Taxol and Cytoxan in the Treatment of Locally Advanced Breast Cancer | NCT00538395 | |
| Neoadjuvant or Adjuvant Chemotherapy in Patients With Operable Non-small-cell Lung Cancer | Randomized Trial of Surgery With or Without Paclitaxel Plus Carboplatin as Neoadjuvant or Adjuvant Chemotherapy in Patients With Operable, Non-small-cell Lung Cancer | NCT00913705 |
| Study of Paclitaxel in Patients With Ovarian Cancer | An Open, Randomized, Multicenter Study in Patients With Recurrent Epithelian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer to Compare the Efficay and Safety of Paclitaxel (Micellar) Nanoparticles and Paclitaxel (Cremophor® EL) | NCT00989131 |
| A phase III randomized study with Paclitaxel (Taxol) and Gemcitabine or Vinorelbine in patients with stage IIIBw - IV non-operable non-small cell lung cancer (NSCLC), performance status (PS) 0,1. | The comparative effect of combination chemotherapy with Paclitaxel (Taxol) and Gemcitabine vs Taxol and Vinorelbine on survival in non-operable non-small cell lung cancer stage IIIBw and IV, PS : 0, 1. A Phase III randomized study. | ACTRN12609000946213 |
| Combination Anticancer Therapy of Paclitaxel and Everolimus for Relapsed or Refractory Small Cell Lung Cancer | A Phase I Study of Combination Anticancer Therapy of Paclitaxel and Everolimus for Relapsed or Refractory Small Cell Lung Cancer | NCT01079481 |
| Influence of Chemotherapy on Gamma-delta T Cells in Patients With Epithelial Ovarian Cancer | IClyCO Influence of Chemotherapy (Carboplatin and Taxol) on the ex Vivo Expansion and Functional Capacity of Gamma-delta T Cells in Patients With Epithelial Ovarian Cancer | NCT01606358 |
| A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian | SIERRA: A Phase 1b/2 Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer | NCT01952249 |
| Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer | Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer Stage II Randomized Controlled Clinical Studies | NCT02072317 |
| Are people's perceived risks of medicine side effects affected by the words we use to describe them? | What is the effect of two framing variables on perceived risks associated with the medicine Taxol? | ISRCTN39432352 |
| EVALUATION OF AMIFOSTINE FOR MUCOSAL AND HEMOPOETIC PROTECTION AND CARBOPLATIN, TAXOL, RADIOTHERAPY IN THE MANAGEMENT OF PATIENTS WITH HEAD AND NECK CANCER.(GCC 0202) | A SINGLE SITE EVALUATION OF AMIFOSTINE FOR MUCOSAL AND HEMOPOETIC PROTECTION AND CONCURRENT CARBOPLATIN, TAXOL, RADIOTHERAPY IN THE MANAGEMENT OF PATIENTS WITH ADVANCED LOCOREGIONAL SQUAMOUS CELL CARCINOMAS OF THE HEAD AND NECK. | NCT00270790 |
| Pemetrexed + Paclitaxel in Patients With Recurrent/Advanced Thyroid Cancer | Phase 2 Trial of Pemetrexed (Alimta™) Combined With Paclitaxel in Patients With Recurrent/Advanced Follicular, Papillary or Anaplastic Thyroid Cancer | NCT00786552 |
| An open-label randomized phase II trial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BelCaP) compared to carboplatin and paclitaxel in untreated patients with a cancer where the origin of the cancer cannot be established this special cancer is called carcinoma of unknown primary | An open-label randomized phase II trial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BelCaP) compared to carboplatin and paclitaxel in patients with previously untreated carcinoma of unknown primary - BelCaP in CUP | EUCTR2008-005865-67-DK |
| A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Subjects With Advanced Non-Small Cell Lung CancerRevised Protocol 02 incorporating Amendment 03 (version 4.0 dated 01-Sep-09)+ Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 1.0, dated 19-Mar-08) | A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Subjects With Advanced Non-Small Cell Lung CancerRevised Protocol 02 incorporating Amendment 03 (version 4.0 dated 01-Sep-09)+ Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 1.0, dated 19-Mar-08) | EUCTR2008-000977-39-DE |
| An investigational randomized phase II-(III) study on epirubicin plus cyclophospamide (or CMF) vs nab-paclitaxel plus capecitabine as adjuvant chemotherapy for elderly non frail patients with an increased risk for relapse of a primary carcinoma of the breast - ICE II | An investigational randomized phase II-(III) study on epirubicin plus cyclophospamide (or CMF) vs nab-paclitaxel plus capecitabine as adjuvant chemotherapy for elderly non frail patients with an increased risk for relapse of a primary carcinoma of the breast - ICE II | EUCTR2008-003995-23-DE |
| Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer | Combined Targeted Therapies for Triple Negative Advanced Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib | NCT00733408 |
| Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase I Study of Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC) | NCT00736619 |
| An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer | A Randomized, Double Blind, Placebo-Controlled Study of the Efficacy and Safety oF MORAb-003(Farletuzumab) in Combination With Paclitaxel Therapy in Subjects With Platinum-Resistant or Refractory Relapsed Ovarian Cancer | NCT00738699 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery | A Phase 2 Study Of Weekly Infusion Nab-paclitaxel (Paclitaxel Protein-bound Particles for Injectable Suspension) In Patients With Unresectable And Metastatic Uveal Melanoma | NCT00738361 |
| Biweekly Paclitaxel+Carboplatin for elderly patients with untreated nonresectable non-small cell lung cancer | Biweekly Paclitaxel+Carboplatin for elderly patients with untreated nonresectable non-small cell lung cancer - Biweekly Paclitaxel+Carboplatin for elderly patients with untreated nonresectable non-small cell lung cancer | JPRN-UMIN000001328 |
| The efficacy and feasibility of the repeated intraperitoneal Paclitaxel +systemic TS-1 and Paclitaxel for far advanced or recurrent gastric cancer: Phase I/II trial. | The efficacy and feasibility of the repeated intraperitoneal Paclitaxel +systemic TS-1 and Paclitaxel for far advanced or recurrent gastric cancer: Phase I/II trial. - The clinical effects of additional repeated intraperitoneal Paclitaxel for advanced gastric cancer. | JPRN-UMIN000000636 |
| A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast Cancer | A Phase I/II Clinical Trial of the Hypomethylating Agent Azacitidine (Vidaza) With the Nanoparticle Albumin Bound Paclitaxel (Abraxane) in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer | NCT00748553 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer | Phase II Study of ABI-007 Plus Sunitinib as First Line Treatment for Non-Small Cell Lung Cancer | NCT00748163 |
| Paclitaxel-Coated Versus Uncoated Balloon for Treatment of Below-the-Knee In-Stent-Restenosis | Paclitaxel-Coated Versus Uncoated Balloon for Treatment of Below-the-Knee In-Stent-Restenosis | NCT01398033 |
| A Phase II Study of carboplatin plus paclitaxel for advanced thymic cancer | A Phase II Study of carboplatin plus paclitaxel for advanced thymic cancer - Carboplatin plus paclitaxel for advanced thymic cancer | JPRN-UMIN000001358 |
| Paclitaxel and Carboplatin Combination as 1st Line Treatment in Ovarian Carcinomas | Dose Dense Administration of Paclitaxel and Carboplatin Combination as 1st Line Treatment in Patients With Ovarian Carcinoma | NCT00750386 |
| Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma | Phase 2 Study of Intravenous Administration of a Wild-Type Reovirus (REOLYSIN®) in Combination With Paclitaxel and Carboplatin in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck. | NCT00753038 |
| Combination Chemotherapy With Sildenafil Plus Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer | Randomized Phase II Study of Combination Chemotherapy With Sildenafil Plus Carboplatin and Weekly Paclitaxel in Patients With Previously Untreated Advanced Non-small Cell Lung Cancer | NCT00752115 |
| A phase Ib, open-label, two arm study of i.v. and oral panobinostat (LBH589) in combination with i.v. trastuzumab (Herceptin®) and i.v. paclitaxel as treatment for adult female patients with HER2 overexpressing metastatic breast cancer (MBC) | A phase Ib, open-label, two arm study of i.v. and oral panobinostat (LBH589) in combination with i.v. trastuzumab (Herceptin®) and i.v. paclitaxel as treatment for adult female patients with HER2 overexpressing metastatic breast cancer (MBC) - Panobinostat (LBH589) | NL-OMON32569 |
| Paclitaxel, Carboplatin Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer | Paclitaxel, Carboplatin Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer | NCT00753909 |
| Phase II study of weekly Nab-paclitaxel for Metastatic Breast Cancer | Phase II study of weekly Nab-paclitaxel for Metastatic Breast Cancer - Phase II study of weekly Nab-paclitaxel for Metastatic Breast Cancer | JPRN-UMIN000005982 |
| A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer | A Phase Ib, Open-label, Two Arm Study of i.v. and Oral Panobinostat (LBH589) in Combination With i.v. Trastuzumab (Herceptin®) and i.v. Paclitaxel as Treatment for Adult Female Patients With HER2 Overexpressing Metastatic Breast Cancer (MBC) | NCT00788931 |
| Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery. | Neoadjuvant Weekly Nab-paclitaxel (Abraxane®) Plus Carboplatin Followed By Doxorubicin Plus Cyclophosphamide With Bevacizumab Added Concurrently To Chemotherapy For Palpable And Operable Triple Negative Invasive Breast Cancer | NCT00777673 |
| Estudio abierto fase II de bevacizumab en combinación con paclitaxel y gemcitabina como tratamiento de primera línea en pacientes diagnosticados de carcinoma de mama metastasico o localmente avanzado HER-2 negativo - Avaluz | Estudio abierto fase II de bevacizumab en combinación con paclitaxel y gemcitabina como tratamiento de primera línea en pacientes diagnosticados de carcinoma de mama metastasico o localmente avanzado HER-2 negativo - Avaluz | EUCTR2008-003657-32-ES |
| A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian Cancer | A Phase I/II Non-Comparative Study of Paclitaxel Plus Carboplatin in Combination With Vorinostat in Patient With Advanced, Recurrent, Epithelial Ovarian Cancer | NCT00772798 |
| Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery | Randomized Phase III Trial of Paclitaxel +Trastuzumab + Lapatinib Versus Paclitaxel + Trastuzumab as Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer | NCT00770809 |
| Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer | A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-paclitaxel or Ixabepilone With or Without Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer | NCT00785291 |
| Phase II study of weekly Nab-paclitaxel followed by FEC as Neoadjuvant Chemotherapy for Breast Cancer | Phase II study of weekly Nab-paclitaxel followed by FEC as Neoadjuvant Chemotherapy for Breast Cancer - Phase II study of weekly Nab-paclitaxel followed by FEC as Neoadjuvant Chemotherapy for Breast Cancer | JPRN-UMIN000005979 |
| A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel | A Randomized Phase II Trial to Assess the Predictive Value of Increased EGFR Copy Number by FISH in Patients With Advanced / Metastatic NSCLC Treated With Cetuximab and Carboplatin / Paclitaxel | NCT00768131 |
| New therapeutic approaches for anaplastic thyroid cancer: assessment of the benefit-risk profile of the combination valproic acid-paclitaxel. - ND | New therapeutic approaches for anaplastic thyroid cancer: assessment of the benefit-risk profile of the combination valproic acid-paclitaxel. - ND | EUCTR2008-005221-11-IT |
| A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer | Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer | NCT00762034 |
| Phase II Neoadjuvant in Inflammatory Breast Cancer | A Phase II Study of Neoadjuvant Lapatinib Plus Chemotherapy (Sequential FEC75 and Paclitaxel) in Women With Inflammatory Breast Cancer Whose Tumors Overexpress ErbB2 (Her2/Neu) | NCT00756470 |
| Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma | Phase 1/2 Safety and Feasibility of Gemcitabine and Nab-Paclitaxel in Combination With LDE-225 as Neoadjuvant Therapy in Patients With Borderline Resectable Pancreatic Adenocarcinoma. | NCT01431794 |
| Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors | A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL147 (SAR245408) in Combination With Paclitaxel and Carboplatin in Subjects With Solid Tumors | NCT00756847 |
| Study Evaluating Safety And Tolerability, Solid Tumor | A Phase 1 Study Of Neratinib (HKI-272) In Combination With Paclitaxel In Subjects With Solid Tumors | NCT00768469 |
| Cyclosporine A in Combination With Nab-Paclitaxel in Patients With Metastatic Breast Cancer | A Phase I, Open-label, Study of the Safety and Tolerability of Cyclosporine A (CsA) in Combination With Nab-paclitaxel in Patients With Metastatic Breast Cancer | NCT00983424 |
| A Phase II, Open-Label, Randomised, Comparative, Multicentre Study to Compare the Efficacy and tolerability of Oral Olaparib in combination with Carboplatin and Paclitaxel Versus Carboplatin and Paclitaxel Alone in Patients with Platinum Sensitive Advanced Serous Ovarian Cancer | A Phase II, Open-Label, Randomised, Comparative, Multicentre Study to Compare the Efficacy and tolerability of Oral Olaparib in combination with Carboplatin and Paclitaxel Versus Carboplatin and Paclitaxel Alone in Patients with Platinum Sensitive Advanced Serous Ovarian Cancer | EUCTR2009-015970-36-NL |
| Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma | A Phase 2 Study of Intravenous Administration of REOLYSIN (Reovirus Type 3 Dearing) in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma | NCT00984464 |
| Efficacy Study of Paclitaxel Versus Irinotecan in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy | A Randomized, Multicenter Phase III Study to Assess the Efficacy of Paclitaxel Versus Irinotecan in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy | NCT01224652 |
| A Clinical Trial to evaluate the Efficacy and Safety of Intravenous Infusion of Nanosomal Paclitaxel Lipid Suspension and Taxol in Metastatic Breast cancer patients. | An Open Label, Randomized, Multiple-Dose, Parallel Study to Evaluate Efficacy and Safety of Intravenous Infusion of Nanosomal Paclitaxel Lipid Suspension (Intas Pharmaceuticals Ltd.) and Taxol® (Paclitaxel Injection Concentrate, Bristol-Myers Squibb.) in Metastatic Breast Cancer Patients after failure of prior chemotherapy. | CTRI/2010/091/001344 |
| Sealing Moderate Coronary Saphenous VEin Graft Lesions With Paclitaxel-Eluting Stents | Sealing Moderate Coronary Saphenous VEin Graft Lesions With Paclitaxel-Eluting Stents as a New Approach to MainTaining VeIn Graft Patency and Reducing Cardiac Events | NCT01223443 |
| Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer | A Phase 1b Open-Label, Multi-Center Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With High-Risk Stage I and Stages II-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers | NCT01253681 |
| A Phase I study of TSU-68 in patient with non-small cell lung cancer | A Phase I study of TSU-68 in combination with Carboplatin and Paclitaxel in patients with Advanced Non-Small Cell Lung Cancer | JPRN-jRCT2080221286 |
| FEC neo-adjuvant chemotherapy followed by weekly Taxol administration combined with Trastuzumab in II-III stage HER2 positive breast cancer patients.Fase II trial. - ND | FEC neo-adjuvant chemotherapy followed by weekly Taxol administration combined with Trastuzumab in II-III stage HER2 positive breast cancer patients.Fase II trial. - ND | EUCTR2010-021600-24-IT |
| Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel | A Phase 1b/2 Study of Carboplatin-Paclitaxel, With or Without ISIS 183750 (an eIF4E Inhibitor), in Patients With Stage IV Non-Small Cell Lung Cancer | NCT01234038 |
| MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies | A Phase Ib Dose-escalation Trial of the AKT Inhibitor MK2206 in Combination With Weekly Paclitaxel With or Without Trastuzumab | NCT01235897 |
| Feasibility Study of Metronomic Chemotherapy for Locally Advanced HER2-Negative Breast Cancer | Phase II Feasibility Study of Weekly Paclitaxel Followed by Weekly Doxorubicin Plus Daily Oral Cyclophosphamide for Locally Advanced HER2-Negative Breast Cancer | NCT01329627 |
| Feasibility Study of Metronomic Chemotherapy for Locally Advanced Her2- Positive Breast Cancer (TraQ-Me 01) | Phase II Feasibility Study of Weekly Paclitaxel Plus Weekly Trastuzumab Followed by Weekly Doxorubicin Plus Daily Oral Cyclophosphamide Plus Weekly Trastuzumab for Locally Advanced HER2-Positive Breast Cancer | NCT01329640 |
| Nab-Paclitaxel Treatment in Advanced Squamous Cell Carcinoma of Lung | A Randomized Phase II Clinical Trial of Nab-Paclitaxel and Carboplatin Compared With Gemcitabine and Carboplatin as First-line Therapy in Advanced Squamous Cell Carcinoma of Lung | NCT01236716 |
| Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer | A Phase 1 Study of Neoadjuvant Chemotherapy With the Gamma Secretase Inhibitor RO4929097 in Combination With Paclitaxel and Carboplatin in Patients With Clinical Stage II-III Triple Negative Breast Cancer | NCT01238133 |
| A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors | A Phase Ib Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors | NCT01240655 |
| Study of Intraperitoneal Carboplatin with IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer | Phase I Study of Intraperitoneal Carboplatin with Intravenous Paclitaxel and Bevacizumab in Patients with Previously Untreated Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma | NCT01220154 |
| RIBS IV (Restenosis Intra-stent of Drug-eluting Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent) | RIBS IV (Restenosis Intra-stent of Drug-eluting Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent). A Prospective, Multicenter and Randomized Clinical Trial | NCT01239940 |
| Phase II trial of paclitaxel plus bevacizumab for recurrent non-squamous non-small cell lung cancer | Phase II trial of paclitaxel plus bevacizumab for recurrent non-squamous non-small cell lung cancer - Phase II trial of paclitaxel plus bevacizumab for recurrent non-squamous non-small cell lung cancer | JPRN-UMIN000004573 |
| A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy | A Randomized, Double-blind, Multi-center Phase III Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma Who Have Progressed After Therapy With a Fluoropyrimidine-containing Regimen | NCT01248403 |
| Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection | A Phase 1 Study of Paclitaxel and Carboplatin in Solid Tumors (With Focus on Upper Aerodigestive Cancers) in Persons With HIV Infection | NCT01249443 |
| NOT AVAILABLE | PHASE III RANDOMIZED TRIAL OF BIBW 2992 PLUS WEEKLY PACLITAXEL VERSUS INVESTIGATOR´S CHOICE OF CHEMOTHERAPY FOLLOWING BIBW 2992 MONOTHERAPY IN NON-SMALL LUNG CANCER PATIENTS FAILING ERLOTINIB OR GEFITINIB | PER-061-10 |
| Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer | A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer | NCT01254526 |
| Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids | Phase 1A/B Study of Combination Carboplatin, Paclitaxel and Ridaforolimus in Patients With Solid, Endometrial, and Ovarian Cancers | NCT01256268 |
| A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer with Non-Squamous Histology | A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer with Non-Squamous Histology | RBR-48pb9h |
| Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Head and Neck Cancer | """Phase II Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Metastatic or Recurrent Head and Neck Cancer""" | NCT01264328 |
| Assessment Of Stromal Response To Nab-Paclitaxel In Combination With Gemcitabine In Pancreatic Cancer | Assessment Of Stromal Response To Nab-Paclitaxel In Combination With Gemcitabine In Pancreatic Cancer | NCT01442974 |
| CHFR Methylation Status Esophageal Cancer Study | A Phase 2 Study of Paclitaxel With Cisplatin Versus Fluoropyrimidine With a Platinum Agent for Neoadjuvant Therapy in Operable Esophageal Cancer Based on CHFR Methylation Status in Diagnostic Biopsies | NCT01372202 |
| Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer | "A Pilot Trial of Radiation Therapy ""Sandwiched"" Between Paclitaxel and Carboplatin in Patients With Uterine Carcinosarcoma" | NCT01367301 |
| Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE) | A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin , Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease | NCT01366131 |
| Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | An Early Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Patients With Hepatic or Renal Dysfunction and Solid Tumors | NCT01366144 |
| RIBS V (Restenosis Intra-stent of Bare Metal Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent) | RIBS V (Restenosis Intra-stent of Bare Metal Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent). A Prospective, Multicenter and Randomized Clinical Trial | NCT01239953 |
| Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian | Phase I Evaluation of Intravenous Carboplatin With Weekly Paclitaxel and Bevacizumab in Patients Undergoing Neoadjuvant Chemotherapy for Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | NCT01219777 |
| Phase II Study of induction Carboplatin+Paclitaxel+Bevacizumab combination therapy for stage III Non-Small-Cell Lung Cancer (NSCLC) | Phase II Study of induction Carboplatin+Paclitaxel+Bevacizumab combination therapy for stage III Non-Small-Cell Lung Cancer (NSCLC) - Phase II Study of induction Carboplatin+Paclitaxel+Bevacizumab combination therapy for stage III NSCLC (TCOG1002) | JPRN-UMIN000004327 |
| First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma | Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147 | NCT01215136 |
| Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung Cancer | A Randomized Phase II Study of Paclitaxel-carboplatin-bevacizumab With or Without Nitroglycerin Patches in Patients With Stage IV Non-squamous-non-small Cell Lung Cancer: NVALT12 | NCT01171170 |
| A Phase II Study of Dose Density Regimen with Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days with Filgrastim Support followed by Weekly Paclitaxel in Women with Primary Breast Cancer. - ND | A Phase II Study of Dose Density Regimen with Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days with Filgrastim Support followed by Weekly Paclitaxel in Women with Primary Breast Cancer. - ND | EUCTR2010-020772-38-IT |
| A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma | A Two Arm Phase II Trial of Sequential Axitinib and Carboplatin/Paclitaxel in Melanoma With Correlative FLT PET Scans (3'Deoxy-3'-18F-Fluorothymidine Positron Emission Tomography Scans)(CC# 10852) | NCT01174238 |
| A phase II study of Bevacizumab combined with Carboplatin and Weekly Paclitaxel for Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer. North Japan Lung Cancer Study Group Trial 1002 | A phase II study of Bevacizumab combined with Carboplatin and Weekly Paclitaxel for Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer. North Japan Lung Cancer Study Group Trial 1002 - CBDCA+wPTX+BEV Phase II NJLCG1002 | JPRN-UMIN000003949 |
| A randomised placebo-controlled trial of saracatinib (AZD0530) plus weekly paclitaxel in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer. - SaPPrOC | A randomised placebo-controlled trial of saracatinib (AZD0530) plus weekly paclitaxel in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer. - SaPPrOC | EUCTR2009-017171-13-GB |
| Pazopanib and Paclitaxel for Non-Small Cell Lung Cancer | Pazopanib and Weekly Paclitaxel in Stage IIIB/IV Non-small Cell Lung Cancer | NCT01179269 |
| Paclitaxel/Carboplatin (PC) Followed by Gefitinib Versus PC in Advanced Non-small Cell Lung Cancer | Paclitaxel/Carboplatin (PC) Followed by Gefitinib or Paclitaxel/Carboplatin (PC) in Advanced Non-small Cell Lung Cancer (NSCLC): Randomized Phase II Study | NCT01196234 |
| Clinical evaluation of efficacy and safety of paclitaxel-eluting balloon (PEB) for peripheral artery disease patients with femolo-popliteal lesion | Clinical evaluation of efficacy and safety of paclitaxel-eluting balloon (PEB) for peripheral artery disease patients with femolo-popliteal lesion - Clinical evaluation of PEB for peripheral artery disease patients (PADPEB study) | JPRN-UMIN000004031 |
| Japanese Study of Ipilimumab in Combination With Paclitaxel/Carboplatin | Phase 1 Study of Ipilimumab (BMS-734016) in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer | JPRN-jRCT2080221195 |
| Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma | A Phase II Study of Pre-operative Panitumumab, Paclitaxel, Carboplatin and Continuous Infusion 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma | NCT01182610 |
| Randomized Phase II Study Comparing Dose Escalated Weekly Paclitaxel versus Standard Dose Weekly Paclitaxel for Patients with Previously Treated Advanced Gastric Cancer | Randomized Phase II Study Comparing Dose Escalated Weekly Paclitaxel versus Standard Dose Weekly Paclitaxel for Patients with Previously Treated Advanced Gastric Cancer - Randomized Phase II Study Comparing Dose Escalated Weekly Paclitaxel versus Standard Dose Weekly Paclitaxel for AGC | JPRN-UMIN000004055 |
| Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer | Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer | NCT01187199 |
| GLOBAL STUDY TO ASSESS THE ADDITION OF BEVACIZUMAB TO CARBOPLATIN AND PACLITAXEL AS FRONT-LINE TREATMENT OF EPITHELIAL OVARIAN CANCER, FALLOPIAN TUBE CARCINOMA OR PRIMARY PERITONEAL CARCINOMA - ROSiA | GLOBAL STUDY TO ASSESS THE ADDITION OF BEVACIZUMAB TO CARBOPLATIN AND PACLITAXEL AS FRONT-LINE TREATMENT OF EPITHELIAL OVARIAN CANCER, FALLOPIAN TUBE CARCINOMA OR PRIMARY PERITONEAL CARCINOMA - ROSiA | EUCTR2010-019525-34-SK |
| TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer | A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers | NCT01204749 |
| Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel | An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors | NCT01192165 |
| CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC) | Phase 1b Study of CS-7017 in Combination With Carboplatin/Paclitaxel in Chemotherapy-naïve Subjects With Metastatic or Unresectable Locally Advanced Non-small Cell Lung Cancer (NSCLC) | NCT01199055 |
| CP therapy (Carboplatin and Paclitaxel) for advansed malignant melanoma | CP therapy (Carboplatin and Paclitaxel) for advansed malignant melanoma - MMCP | JPRN-UMIN000004073 |
| Phase I study of TS-1 with paclitaxel for gastric carcinomatosa | Phase I study of TS-1 with paclitaxel for gastric carcinomatosa - Phase I study of TS-1 with paclitaxel for gastric carcinomatosa | JPRN-UMIN000002496 |
| A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC) | A Phase 1 Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) as First-Line Treatment | NCT01225302 |
| A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers | A Phase 1, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers | NCT01209195 |
| A clinical trial to study the effect of weekly paclitaxel in advanced epithelial ovarian cancer | WEEKLY PACLITAXEL IN COMBINATION WITH CARBOPLATIN EVERY 3 WEEKS FOR ADVANCED EPITHELIAL OVARIAN CANCER: A PHASE 3 RANDOMIZED STUDY | CTRI/2010/091/000037 |
| Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer | Randomized Study of Efficacy & Safety of Lapatinib & Epirubicin & Cyclophosphamide (EC90) Followed by Paclitaxel & Lapatinib Compared With EC90 Followed by Paclitaxel & Trastuzumab, as Neoadjuvant Therapy in Patients With Previously Untreated ErbB2-overexpressing Stage I - IIIA Breast Cancer. | NCT01205217 |
| A COMparison Between PAClitaxel-coated Balloon and pacliTaxel-eluting Stent in the Treatment of In-Stent Restenosis (COMPACT-ISR) | NCT01204320 | |
| Randomized Phase II trial of Neoadjuvant weekly Nab-paclitaxel followed by FEC compared with Docetaxel followed by FEC for early breast cancer | Randomized Phase II trial of Neoadjuvant weekly Nab-paclitaxel followed by FEC compared with Docetaxel followed by FEC for early breast cancer - ABI-007 Followed by FEC Neoadjuvant Chemotherapy for Breast Cancer (Randomized Phase II Trial) | JPRN-UMIN000005388 |
| Weekly Paclitaxel Plus Carboplatin in Preoperative Treatment of Breast Cancer | Phase 2 Study of Weekly Paclitaxel Plus Carboplatin in Preoperative Treatment of Breast Cancer Patients | NCT01203267 |
| Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma | Phase II Study of Genasense-Carboplatin-Paclitaxel-Combination in Uveal Melanoma | NCT01200342 |
| Randomized Evaluation of Paclitaxel-eluting versus Everolimus-eluting stent Trial | Randomized Evaluation of Paclitaxel-eluting versus Everolimus-eluting stent Trial - Rapeet study | JPRN-UMIN000004177 |
| Efficacy and safety of paclitaxel nano-dispersion concentrate for injection (PICN) in subjects with metastatic breast cancer: A randomized, open label, active controlled, comparative, parallel group, and multi-centric study. | Efficacy and safety of paclitaxel nano-dispersion concentrate for injection (PICN) in subjects with metastatic breast cancer: A randomized, open label, active controlled, comparative, parallel group, and multi-centric study. | CTRI/2010/091/001116 |
| Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer | A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC# 683864,) in Combination With Carboplatin and Paclitaxel Followed by Temsirolimus Consolidation as First-Line Therapy in the Treatment of Clear Cell Carcinoma of the Ovary | NCT01196429 |
| Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer | A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma | NCT01196390 |
| Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer | Phase II Neoadjuvant Trial of Sorafenib in Combination With Cisplatin Followed by Dose Dense Paclitaxel for ER-, PR-, Her2- (Triple Negative) Early-Stage Breast Cancer | NCT01194869 |
| Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | A Randomized Phase II Evaluation of Weekly Paclitaxel (NSC# 673089) Versus Weekly Paclitaxel With Oncolytic Reovirus (Reolysin NSC # 729968) in the Treatment of Recurrent or Persistent Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT01199263 |
| Feasibility study of Nab-paclitaxel followed by FEC as Neoadjuvant Chemotherapy for Primary Breast Cancer | Feasibility study of Nab-paclitaxel followed by FEC as Neoadjuvant Chemotherapy for Primary Breast Cancer - Feasibility study of Nab-paclitaxel followed by FEC as Neoadjuvant Chemotherapy for Primary Breast Cancer | JPRN-UMIN000005704 |
| A RANDOMIZED CONTROLLED STUDY ON THE EFFECTIVENESS OF FIRST-LINE CHEMOTHERAPY (CARBOPLATIN AND PACLITAXEL) VERSUS CHEMO-IMMUNOTHERAPY (CARBOPLATIN-PACLITAXEL-OREGOVOMAB) IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN, ADNEXAL OR PERITONEAL CARCINOMA - ND | A RANDOMIZED CONTROLLED STUDY ON THE EFFECTIVENESS OF FIRST-LINE CHEMOTHERAPY (CARBOPLATIN AND PACLITAXEL) VERSUS CHEMO-IMMUNOTHERAPY (CARBOPLATIN-PACLITAXEL-OREGOVOMAB) IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN, ADNEXAL OR PERITONEAL CARCINOMA - ND | EUCTR2010-024305-13-IT |
| A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy | A Randomized, Double-blinded, Placebo-controlled, Multicenter Phase III Study Comparing Bevacizumab Plus Carboplatin/Paclitaxel Versus Placebo Plus Carboplatin/Paclitaxel in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy For Advanced Disease | NCT01364012 |
| TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | A Phase I Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD; NSC# 712227) or in Combination With Weekly Pactilaxel (NSC #673089) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT01294293 |
| A Dose-escalation Study of Ombrabulin in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors | An Open-label, Dose-escalation, Safety and Pharmacokinetics Phase I Study of Ombrabulin in Combination With Paclitaxel and Carboplatin Every 3 Weeks in Patients With Advanced Solid Tumors | NCT01293630 |
| A randomized phase II study of Pemetrexed plus Carboplatin followed by Pemetrexed versus Paclitaxel plus Carboplatin followed by Pemetrexed in patients with chemotherapy naïve non-squamous non-small cell lung cancer. | A randomized phase II study of Pemetrexed plus Carboplatin followed by Pemetrexed versus Paclitaxel plus Carboplatin followed by Pemetrexed in patients with chemotherapy naïve non-squamous non-small cell lung cancer. - A randomized phase II study of PEM+CBDCA followed by PEM versus PTX+CBDCA followed by PEM in patients with non-squamous NSCLC. | JPRN-UMIN000005008 |
| Phase II trial of trastumab and weekly paclitaxel for breast cancer. -Japan Breast Cancer Research Network (JBCRN) Trial | Phase II trial of trastumab and weekly paclitaxel for breast cancer. -Japan Breast Cancer Research Network (JBCRN) Trial - trastumab and weekly paclitaxel for breast cancer. | JPRN-UMIN000004819 |
| Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Paclitaxel in Triple Negative Breast Cancer (TNBC) | A Phase III, Multicenter, Open-Label, Randomized Study of Gemcitabine Plus Cisplatin (GP) Versus Gemcitabine Plus Paclitaxel (GT) as First-Line Treatment in Patients With Advanced Triple-Negative Breast Cancer | NCT01287624 |
| Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer | A Randomized Phase II Study Of Imetelstat (GRN163L) In Combination With Paclitaxel (With Or Without Bevacizumab) in Patients With Locally Recurrent Or Metastatic Breast Cancer | NCT01256762 |
| Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer | A Phase I Trial of Weekly Paclitaxel in Combination With Bavituximab in Patients With Her-2 Negative Metastatic Breast Cancer | NCT01288261 |
| Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas | A Phase 1b Study of Weekly Paclitaxel With Ramucirumab (IMC-1121B) Drug Product in Patients With Advanced Gastric Adenocarcinomas | NCT01253525 |
| Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin for Stage ?-? Esophageal Cancer Patients | Multicenter,Phase ?Study of Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin for Stage ?-? Esophageal Squamous Cell Carcinoma Patients | NCT01258192 |
| Restenosis Treatment With Rapamycin Eluting Stent or Paclitaxel Eluting Balloon Catheter (RESTENOZA) | Efficacy Evaluation of In-bare Metal Stent Restenosis Treatment With Rapamycin Eluting Stent or Paclitaxel Eluting Balloon Catheter. Study With Intravascular Ultrasound and Optical Coherence Tomography | NCT01255956 |
| Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer | Phase IIb Trial of Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Epirubicin as Neoadjuvant Treatment in Locally Advanced Triple-negative Breast Cancer | NCT01276769 |
| A Randomized, Double-Blind, Placebo-Controlled, Study of the Safety and Efficacy of Farletuzumab in combination with Carboplatin and Paclitaxel or Docetaxel Followed by Pemetrexed in Chemotherapy na?ve Subjects with Stage IV Adenocarcinoma of the Lung with Wild Type EGFR | A Randomized, Double-Blind, Placebo-Controlled, Study of the Safety and Efficacy of Farletuzumab in combination with Carboplatin and Paclitaxel or Docetaxel Followed by Pemetrexed in Chemotherapy na?ve Subjects with Stage IV Adenocarcinoma of the Lung with Wild Type EGFR | EUCTR2010-022229-13-DE |
| European Study of POBA Versus Cotavance(R) Paclitaxel Coated Balloon for the Treatment of Infrapopliteal Lesions in Critical Limb Ischemia (EURO CANAL) | European Study of POBA Versus Cotavance Paclitaxel Coated Balloon for the Treatment of Infrapopliteal Lesions in Critical Limb Ischemia | NCT01260870 |
| A phase 2 study of weekly Paclitaxel plus Gemcitabine Combination Chemotherapy in Patients with advanced or metastatic Breast Cancer | A phase 2 study of weekly Paclitaxel plus Gemcitabine Combination Chemotherapy in Patients with advanced or metastatic Breast Cancer - A Phase 2 study of weekly paclitaxel plus Gemcitabine Combination Chemotherapy in Patients with advanced or metastatic Breast Cancer | JPRN-UMIN000004741 |
| MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer | Phase Ib Dose Escalation and Biomarker Study of MK-2206 in Combination With Standard Doses of Weekly Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors With an Expansion in Advanced Breast Cancer | NCT01263145 |
| A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer | A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer | NCT01268059 |
| ENSAYO EN FASE III ALEATORIZADO DE CISPLATINO MÁS PACLITAXEL CON Y SIN BEVACIZUMAB FRENTE AL DOBLETE SIN PLATINO, TOPOTECAN MÁS PACLITAXEL, CON Y SIN BEVACIZUMAB, EN CARCINOMA DE CÉRVIX EN ESTADIO IVB, RECURRENTE O PERSISTENTE | ENSAYO EN FASE III ALEATORIZADO DE CISPLATINO MÁS PACLITAXEL CON Y SIN BEVACIZUMAB FRENTE AL DOBLETE SIN PLATINO, TOPOTECAN MÁS PACLITAXEL, CON Y SIN BEVACIZUMAB, EN CARCINOMA DE CÉRVIX EN ESTADIO IVB, RECURRENTE O PERSISTENTE | EUCTR2010-023525-38-ES |
| High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors | Vorinostat and Carboplatin or Vorinostat and Paclitaxel in Patients With Advanced Solid Tumors: A Pharmacokinetic and Pharmacodynamic Study | NCT01281176 |
| Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer | A 2-arm Randomized Phase II Study of Carboplatin, Paclitaxel Plus Reovirus Serotype-3 Dearing Strain (Reolysin) vs. Carboplatin and Paclitaxel in the First Line Treatment of Patients With Recurrent or Metastatic Pancreatic Cancer | NCT01280058 |
| Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin | Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin Versus Placebo in Addition to Paclitaxel and Carboplatin in Subjects With Stage IV/Recurrent Non Small Cell Lung Cancer (NSCLC) | NCT01285609 |
| Quality of Life Comparison in Advanced Non-squamous Non Small Cell Lung Cancer | Induction Pemetrexed and Cisplatin Followed by Pemetrexed as Maintenance vs Carboplatin-paclitaxel and Bevacizumab Followed by Bevacizumab as Maintenance:Multicenter Randomized Phase III Study in Patients With Advanced Non-Squamous Non Small-cell Lung Cancer: a Quality of Life Oriented Phase III Trial of the GOIM | NCT01303926 |
| Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery | A Phase I, Open Label, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetic Properties of the Combination of Cilengitide and Paclitaxel in Patients With Advanced Solid Malignancies | NCT01276496 |
| An Open-Label, Randomized, Parallel Group Study of Patients Treated with Paclitaxel with Standard Dosing versus Pharmacokinetic Guided Dose Adjustment in Patients with Advanced NSCLC | An Open-Label, Randomized, Parallel Group Study of Patients Treated with Paclitaxel with Standard Dosing versus Pharmacokinetic Guided Dose Adjustment in Patients with Advanced NSCLC - CEPAC-TDM | EUCTR2010-023688-16-DE |
| Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1º Chemotherapy | Phase II, Randomized Clinical Trial to Assess the Efficacy of Paclitaxel vs Paclitaxel + Cetuximab in Subjects With Recurrent and/or Metastatic Squamous Head & Neck Carcinoma After Failure of a 1º Line Chemotherapy EXTREME Type Treatment | NCT03887442 |
| Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer | A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer | NCT01275677 |
| A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab | A Phase Ib Multi-center, Open-label, 4-arm Dose-escalation Study of Oral BEZ235 and BKM120 in Combination With Weekly Paclitaxel in Patients With Advanced Solid Tumors and Weekly Paclitaxel/Trastuzumab in Patients With HER2+ Metastatic Breast Cancer | NCT01285466 |
| Study to investigate the combination of Afinitor with paclitaxel and carboplatin in advanced large cell lung cancer | A multi-centric, open-label, phase II study investigating the combination of Afinitor with paclitaxel and carboplatin in first line treatment of patients with advanced (stage IV) large cell lung cancer with neuroendocrine differentiation (LC-NEC) | EUCTR2010-022273-34-DE |
| Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer | Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer | NCT01276041 |
| Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx) | A Phase II Clinical Trial of Induction Chemotherapy Regimen Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx) Followed by a Single Cycle of High Dose Chemotherapy (HDC) and Autologous Hematopoietic Stem Cell Rescue (AuHSCR) for Patients With Recurrent or Progressive Intracranial Germ Cell Tumors | NCT01270724 |
| A phase Ib multi-center, open-label, 4-arm dose-escalation study of oral BEZ235 and BKM120 in combination with weekly paclitaxel in patients with advanced solid tumors and weekly paclitaxel/trastuzumab in patients with HER2+ metastatic breast cancer. | A phase Ib multi-center, open-label, 4-arm dose-escalation study of oral BEZ235 and BKM120 in combination with weekly paclitaxel in patients with advanced solid tumors and weekly paclitaxel/trastuzumab in patients with HER2+ metastatic breast cancer. - BEZ235 or BKM120 with paclitaxel or paclitaxel/trastuzumab (phase IB) | NL-OMON34229 |
| Phase II, open label, study of primary chemotherapy with Bevacizumab in association with carboplatin, paclitaxel in early and locally advanced triple negative (ER, PgR and HER2 negative) breast cancer - CaPaBe | Phase II, open label, study of primary chemotherapy with Bevacizumab in association with carboplatin, paclitaxel in early and locally advanced triple negative (ER, PgR and HER2 negative) breast cancer - CaPaBe | EUCTR2010-022077-33-IT |
| Inter-ethnic differences in tolerance of anti-cancer drugs in non-small cell lung cancer patients | Exploration of differences in tolerance between Caucasian and Asian non-small cell lung cancer patients receiving palliative chemotherapy with carboplatin and paclitaxel | ACTRN12611000013965 |
| A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma | A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine | NCT01170663 |
| Cisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage IB-IVA Cervical Cancer | A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes | NCT01295502 |
| BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors | A Phase I Study of BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors | NCT01297452 |
| Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer | Randomized Phase II Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in HER2/Neu+ Patients With Advance/Recurrent Uterine Serous Papillary Carcinoma | NCT01367002 |
| Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors | A Phase Ib, Open-label, Dose-escalation Study of the Safety and Pharmacology of Ipatasertib (GDC-0068) in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors | NCT01362374 |
| Weekly Paclitaxel in Combination with Bevacizumab in Patients with Non-Squamous Non-Small Cell Lung Cancer Who Have Failed Previous Treatments-Phase II study- | Weekly Paclitaxel in Combination with Bevacizumab in Patients with Non-Squamous Non-Small Cell Lung Cancer Who Have Failed Previous Treatments-Phase II study- - Weekly Paclitaxel in Combination with Bevacizumab in Patients with Non-Squamous Non-Small Cell Lung Cancer Who Have Failed Previous Treatments-Phase II study- | JPRN-UMIN000005608 |
| A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004) | A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer | NCT01357161 |
| Epirubicin-Paclitaxel-Cyclophosphamide Methotrexate Fluorouracil (E-T-CMF) versus Epirubicin-Cyclophosphamide Methotrexate Fluorouracil (E-CMF) as adjuvant chemotherapy in high risk patients with operable breast cancer. A phase III study conducted by the Hellenic Cooperative Oncology Group (HE10/97) | High-risk patients with operable breast cancer treated with Epirubicin followed by Paclitaxel followed by Cyclophosphamide-Methotrexate-Fluorouracil (E-T-CMF) or Epirubicin followed by Cyclophosphamide-Methotrexate-Fluorouracil (E-CMF) as adjuvant chemotherapy to investigate the effect of the treatment on disease-free survival and overall survival. | ACTRN12611000506998 |
| To study how efficacious and safe Anastrozole is in women with breast cancer | A Phase IV, Single Arm, Open label, Multi-Centric Study to Evaluate Efficacy, Safety and Tolerability of Anastrozole as an adjuvant to Paclitaxel for Postmenopausal Women with hormone-receptor positive metastatic Breast Cancer . | CTRI/2011/05/001733 |
| Aoxianda (Nedaplati) combined with Paclitaxel for treatment of epithelial ovarian cancer: a randomized, multicenter, parallel-controlled clinical trial | Aoxianda (Nedaplati) combined with Paclitaxel for treatment of epithelial ovarian cancer: a randomized, multicenter, parallel-controlled clinical trial | ChiCTR-TRC-11001333 |
| Treatment of Chinese patients with metastatic gastric cancer where resection is not possible | Treatment of Chinese patients with metastatic gastric cancer where resection is not possible, with a biweekly combination of S-1 and Paclitaxel (SPA) or a combination of S-1 and Oxaliplatin (SOX) | ISRCTN85705844 |
| RESOLUTE China RCT | A Randomized Controlled Trial of the Resolute Zotarolimus-Eluting Stent Versus the Taxus Liberte Paclitaxel-Eluting Stent for Percutaneous Coronary Intervention in a Real-World All-comer Patient Population in China | NCT01334268 |
| Non-interventional study about safety and efficacy of chemo-therapy with Paclitaxel Stragen(R) / Eurotaxel(R) (new name of the prescription) as mono or combined therapy for routine treatment of ovarial or breast cancer with special consideration of age and BMI starting position. | Non-interventional study about safety and efficacy of chemo-therapy with Paclitaxel Stragen(R) / Eurotaxel(R) (new name of the prescription) as mono or combined therapy for routine treatment of ovarial or breast cancer with special consideration of age and BMI starting position. - ET-001 | DRKS00000781 |
| A Multicenter Phase II Study of Tri-weekly Nab-Paclitaxel for Patients with Metastatic Breast Cancer Pretreated with Taxanes (SBCCSG-20) | A Multicenter Phase II Study of Tri-weekly Nab-Paclitaxel for Patients with Metastatic Breast Cancer Pretreated with Taxanes (SBCCSG-20) - Phase II Study of Tri-weekly Nab-Paclitaxel for MBC Pretreated with Taxanes (SBCCSG-20) | JPRN-UMIN000005414 |
| Metformin Plus Paclitaxel for Metastatic or Recurrent Head and Neck Cancer | Randomized Phase II Study of Paclitaxel Plus Metformin or Placebo for the Treatment of Platinum-refractory, Recurrent or Metastatic Head and Neck Neoplasms | NCT01333852 |
| Effects of Paclitaxel on Intimal Hyperplasia | Effects of Paclitaxel on Intimal Hyperplasia Status Post Lower Extremity Revascularization | NCT01454778 |
| The efficacy and the safety of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced pancreatic cancer with carcinomatous ascites. | The efficacy and the safety of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced pancreatic cancer with carcinomatous ascites. - A feasibility study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced pancreatic cancer with carcinomatous ascites. | JPRN-UMIN000005306 |
| A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine | A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine | JPRN-jRCT2080221417 |
| A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies | A Phase Ib/II Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies | NCT01325441 |
| Bevacizumab and Trastuzumab With Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast Cancer | Bevacizumab and Trastuzumab With Paclitaxel on Women With Her2+ Breast Cancer Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast Cancer | NCT01321775 |
| A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors | A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors | NCT01301716 |
| Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies | A Phase I, Open Label, Dose Escalation Study of Oral Administration of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies | NCT01351350 |
| Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas | Phase II Study, Multicenter, Randomized, Stratified, Evaluating the Efficacity of Weekly Paclitaxel, With or Without Bevacizumab in the Treatment of Metastatic or Locally Advanced Angiosarcomas Not Accessible to Surgery Treatment. | NCT01303497 |
| Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients | A Phase I/II Trial of Dasatinib in Combination With Trastuzumab and Paclitaxel in the First Line Treatment of Her2-Positive Metastatic Breast Cancer (MBC) Patients | NCT01306942 |
| MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC | The Maximum Tolerated Dose and to Evaluate Safety and Efficacy of Belinostat (PXD-101) in Combination With Paclitaxel Plus Carboplatin in Chemotherapy-Naive Patients With Stage IV Non-Small-Cell Lung Cancer (NSCLC) | NCT01310244 |
| Phase II trial evaluating gemcitabine + nanoparticle albumin-bound paclitaxel in patients with HER2-negative metastatic breast cancer: GAMBA trial | Phase II trial evaluating gemcitabine + nanoparticle albumin-bound paclitaxel in patients with HER2-negative metastatic breast cancer: GAMBA trial - GAMBA (Gemzar + Abraxane for Metastatic Breast cAncer) trial | JPRN-UMIN000005145 |
| A Phase 2, Multi-Center, Double-Blind, placebo controlled, Randomized Study ofOmbrabulin in Patients with Platinum-Sensitive Recurrent Ovarian Cancer treatedwith Carboplatin/Paclitaxel - OPSALIN | A Phase 2, Multi-Center, Double-Blind, placebo controlled, Randomized Study ofOmbrabulin in Patients with Platinum-Sensitive Recurrent Ovarian Cancer treatedwith Carboplatin/Paclitaxel - OPSALIN | EUCTR2010-024631-16-BE |
| Study of Preoperative Weekly Paclitaxel and Carboplatin With Lapatinib (Tykerb®) in Patients With ErbB2-Positive Stage I-III Breast Cancer | Phase II Open-Label Study of Preoperative Weekly Paclitaxel and Carboplatin With Lapatinib (Tykerb®) in Patients With ErbB2-Positive Stage I-III Breast Cancer | NCT01309607 |
| Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy | Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in HER2-negative Operable Breast Cancer | NCT01314833 |
| PD0332991/Paclitaxel in Advanced Breast Cancer | A Phase 1 Trial of PD0332991 and Paclitaxel in Patients With Rb-Expressing Advanced Breast Cancer | NCT01320592 |
| Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin versus Placebo in Addition to Paclitaxel and Carboplatin in subjects with Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC). | Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin versus Placebo in Addition to Paclitaxel and Carboplatin in subjects with Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC). - IDEATE (078/306) | NL-OMON39194 |
| Phase2 study of Carboplatin / Paclitaxel + Bevacizumab to non-small-cell lung cancer (non-squamous cell carcinoma) with pleural efussion in stage4 | Phase2 study of Carboplatin / Paclitaxel + Bevacizumab to non-small-cell lung cancer (non-squamous cell carcinoma) with pleural efussion in stage4 - Phase2 study of CBDCA / PTX + Bevacizumab to non-small-cell lung cancer with pleural efussion | JPRN-UMIN000005284 |
| A multicenter non-randomized phase II study to evaluate nab-paclitaxel in metastatic breast cancer patients failing a solvent based taxane as (neo-)adjuvant treatment - Tiffany | A multicenter non-randomized phase II study to evaluate nab-paclitaxel in metastatic breast cancer patients failing a solvent based taxane as (neo-)adjuvant treatment - Tiffany | EUCTR2011-000075-13-DE |
| Paclitaxel and Epirubicin as neoadjuvant systemic treatment for locally advanced breast cancer | A phase II study of Paclitaxel and Epirubicin, as neoadjuvant systemic treatment, for women with locally advanced breast cancer to assess response rates | ACTRN12611000307909 |
| Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer | Phase II Trial of Carboplatin/Paclitaxel and Cetuximab, Followed by Carboplatin/Paclitaxel/Cetuximab and Erlotinib, With Correlative Studies in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck. | NCT01316757 |
| Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262 | NCT01167712 |
| Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer | Phase 1 Study of Ipilimumab (BMS-734016) in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer | NCT01165216 |
| A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer | A Phase II Neoadjuvant Study of RAD001 (Everolimus) in Combination With Paclitaxel and Trastuzumab For Operable HER2 Positive Breast Cancer | NCT01163929 |
| Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Breast Cancer | Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Breast Cancer | NCT01023204 |
| A Trial of Paclitaxel (Genexol®) and Cisplatin Versus Paclitaxel Loaded Polymeric Micelle (Genexol-PM®) and Cisplatin in Advanced Non Small Cell Lung Cancer | NCT01023347 | |
| Assessment of Surface Coverage of Two Types of Drug-eluting Stent in Diabetes Mellitus and Non-Diabetes Mellitus | Assessment of Surface Coverage of Polymer-based Sirolimus-eluting Stent( Cypher ) or Polymer-free Paclitaxel-eluting Stent (YinYi )in Diabetes Mellitus and Non- Diabetes Mellitus Patients by Optical Coherence Tomography | NCT01023919 |
| Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer | Paclitaxel/Carboplatin Combined With Intermittent Gefitinib in Patients With Untreated Advanced Non-small Cell Lung Cancer: A Phase ?a Trial | NCT01024712 |
| Epirubicin followed by Paclitaxel followed by Cyclophosphamide-Methotrexate-Fluorouracil (E-T-CMF) versus Epirubicin and Paclitaxel followed by Cyclophosphamide-Methotrexate-Fluorouracil (ET-CMF) as adjuvant chemotherapy in node positive patients with operable breast cancer. A phase III study conducted by the Hellenic Cooperative Oncology Group. | Epirubicin followed by Paclitaxel followed by Cyclophosphamide-Methotrexate-Fluorouracil (E-T-CMF) vs Epirubicin and Paclitaxel followed by Cyclophosphamide-Methotrexate-Fluorouracil (ET-CMF) as adjuvant chemotherapy in node positive patients with operable breast cancer.A phase III study conducted by the Hellenic Cooperative Oncology Group. | ACTRN12609001036202 |
| Phase II study of intravenous and intraperitoneal paclitaxel combined with S-1 for gastric cancer with peritoneal metastasis | Phase II study of intravenous and intraperitoneal paclitaxel combined with S-1 for gastric cancer with peritoneal metastasis - Phase II study of intravenous and intraperitoneal paclitaxel combined with S-1 for gastric cancer with peritoneal metastasis | JPRN-UMIN000002850 |
| ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors | A Phase I Study of ASA 404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Patients With Refractory Solid Tumors | NCT01031212 |
| Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer | A Phase Ib/II Study of Cisplatin, Paclitaxel, and RAD001 in Patients With Metastatic Breast Cancer | NCT01031446 |
| Phase II study of preoperative bevacizumab plus weekly paclitaxel, carboplatin and metronomic cyclophosphamide ? trastuzumab and endocrine therapy for inflammatory breast cancer - ND | Phase II study of preoperative bevacizumab plus weekly paclitaxel, carboplatin and metronomic cyclophosphamide ? trastuzumab and endocrine therapy for inflammatory breast cancer - ND | EUCTR2009-016453-17-IT |
| Cetuximab/Paclitaxel/Cisplatin Concurrent Chemoradiotherapy Followed by Esophagectomy for Loco-regional Esophageal Cancer | A Phase II Study of Combining Cetuximab Plus Twice Weekly Paclitaxel/Cisplatin Concurrent Chemoradiotherapy (TP-CCRT) Followed With or Without Esophagectomy for Loco-regional Esophageal Squamous Cell Carcinoma (ESCC) | NCT01034189 |
| PacCis-RCT | Randomised phase-III-trial of simultaneous radiochemotherapy (RCT) of locally advanced head and neck cancer in the stages III and IV A-B: Comparing dose reduced RCT (63.6 Gy) with Paclitaxel/Cisplatin to standard RCT (70.2 Gy) with 5-Fluorouracil/Cisplatin - PacCis-RCT | EUCTR2005-003484-23-DE |
| Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer | Phase II Study of Panitumumab, Nab-paclitaxel, and Carboplatin for Patients With Primary Inflammatory Breast Cancer (IBC) Without HER2 Overexpression | NCT01036087 |
| A randomized multicentre phase II trial with pazopanib and weekly paclitaxel vs weekly paclitaxel in platinum resistant or refractory ovarian cancer - MITO - 11 | A randomized multicentre phase II trial with pazopanib and weekly paclitaxel vs weekly paclitaxel in platinum resistant or refractory ovarian cancer - MITO - 11 | EUCTR2009-016151-21-IT |
| Study of Weekly LOC-paclitaxel Injection for Melanoma | Phase I Study of Weekly LOC-paclitaxel Injection | NCT01039844 |
| Phase III randomized trial of BIBW 2992 plus weekly paclitaxel versusInvestigator’s choice of chemotherapy following BIBW 2992monotherapy in non-small cell lung cancer patients failing previouserlotinib or gefitinib treatment | Phase III randomized trial of BIBW 2992 plus weekly paclitaxel versusInvestigator’s choice of chemotherapy following BIBW 2992monotherapy in non-small cell lung cancer patients failing previouserlotinib or gefitinib treatment - LuxLung 5 | EUCTR2009-014563-39-DE |
| Phase II study of concurrent chemoradiotherapy with weekly cisplatin and paclitaxel chemotherapy for locally advanced cervical carcinoma (JACCRO GY-01) | Phase II study of concurrent chemoradiotherapy with weekly cisplatin and paclitaxel chemotherapy for locally advanced cervical carcinoma (JACCRO GY-01) - Phase II study of concurrent chemoradiotherapy with weekly cisplatin and paclitaxel chemotherapy for locally advanced cervical carcinoma (JACCRO GY-01) | JPRN-UMIN000002937 |
| Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer | "A Pilot Phase II Trial of Radiation Therapy ""Sandwiched"" Between Paclitaxel and Carboplatin in Patients With High-Risk Endometrial Cancer After Standard Surgical Staging" | NCT01041027 |
| SEDUCE OCT Study in Coronary Artery rEstenosis:an Optical Coherence Tomography (OCT) Study | Healing Responses After Treatment of Bare Metal Stent Restenosis With Implantation of an Everolimus-eluting Xience V Stent Versus Use of a Paclitaxel-eluting Balloon: Optical Coherence Tomography Study | NCT01065532 |
| A multicenter randomized phase III trial to compare weekly usage with triple weekly usage of paclitaxel concurrent with radiotherapy for patients with locally advanced non-small cell lung cancer | A multicenter randomized phase III trial to compare weekly usage with triple weekly usage of paclitaxel concurrent with radiotherapy for patients with locally advanced non-small cell lung cancer | ChiCTR-TRC-10000786 |
| Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients | A Randomised, Double Blinded, Multicentre Phase II Study to Assess the Efficacy of Olaparib (AZD2281, KU-0059436) in Combination With Paclitaxel Versus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy | NCT01063517 |
| Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung Cancer | Carboplatin and Paclitaxel Plus ASA404 as First Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer (ES-SCLC): A Phase II Trial | NCT01057342 |
| The Trial Comparing Dose-dense AC-T With PC as Adjuvant Therapy for TNBC | Randomized Phase ? Trial Comparing Dose-dense Epirubicin and Cyclophosphamide Followed by Paclitaxel With Paclitaxel Plus Carboplatin as Adjuvant Therapy for Triple-negative Breast Cancer. | NCT01378533 |
| Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma | Paclitaxel in Combination With Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma | NCT01055028 |
| Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Non-Small Cell Lung Cancer (NSCLC) | Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Non-Small Cell Lung Cancer (NSCLC) | NCT01024062 |
| Treatment of Lung Adenocarcinoma by Liposomal Cisplatin | Comparison of effectiveness of Liposomal Cisplatin combined with Paclitaxel versus Cisplatin combined with Paclitaxel in patients with adenocarcinoma and undifferentiated carcinoma of the lungs. | ACTRN12610000046000 |
| A phase II randomised study comparing the clinical benefit between Paclitaxel (Taxol) and oral Vinorelbine (Navelbine) in patients with stage IIIBw - IV non-small cell lung cancer (NSCLC), performance status (PS) 2 | A phase II randomised study comparing the clinical benefit between Paclitaxel (Taxol) and oral Vinorelbine (Navelbine) in patients with stage IIIBw - IV non-small cell lung cancer (NSCLC), performance status (PS) 2 | ACTRN12610000020088 |
| Essai multicentrique de phase II évaluant l'efficcacité et la tolérance de l'association de bevacizumab, paclitaxel et capecitabine en première ligne chez des patientes atteintes de cancer du sein métastatique ou localement avancé récepteurs triples negatifs . - A-taxel | Essai multicentrique de phase II évaluant l'efficcacité et la tolérance de l'association de bevacizumab, paclitaxel et capecitabine en première ligne chez des patientes atteintes de cancer du sein métastatique ou localement avancé récepteurs triples negatifs . - A-taxel | EUCTR2009-016708-21-FR |
| A Phase II Study of Paclitaxel+Cisplatin+5-Fluorouracil in Unresectable Advanced or Recurrent Gastric Cancer | A Phase II Study of Paclitaxel+Cisplatin+5-Fluorouracil in Unresectable Advanced or Recurrent Gastric Cancer - TCF-P2 | JPRN-UMIN000002988 |
| Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen | A Phase 1/2 Study of XL147 (SAR245408) Administered in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-Based Regimen | NCT01042925 |
| Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors | A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary | NCT01042522 |
| A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma | A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma | NCT01051934 |
| Efficacy Study of REOLYSIN® in Combination With Paclitaxel andCarboplatin in Platinum-Refractory Head and Neck Cancers | Randomized, Double-blind, Multicenter Phase 3 Study of Intravenous Administration of REOLYSIN® (Reovirus Type 3 Dearing) in Combination with Paclitaxel and Carboplatin versus the Chemotherapy Alone in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck who have Progressed on or after Prior Platinum-Based Chemotherapy | EUCTR2009-016940-38-BE |
| Early Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Advanced or Recurrent Head and Neck Cancer | Early Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Advanced or Recurrent Head and Neck Cancer | NCT01024101 |
| Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC) | A Phase I/II Study of Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC) | NCT01016769 |
| Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer | Three-Arm Randomized Phase II Study of Carboplatin and Paclitaxel in Combination With Cetuximab, IMC-A12 or Both in Patients With Advanced Non-Small Cell Lung Cancer Who Will Not Receive Bevacizumab-Based Therapy | NCT00986674 |
| Gemcitabine Plus Paclitaxel versus Gemcitabine alone in Patients with Recurrent or Advanced Urothelial Cancer previously Treated With Cisplatin-based Chemotherapy: A randomized Phase II study | Gemcitabine Plus Paclitaxel versus Gemcitabine alone in Patients with Recurrent or Advanced Urothelial Cancer previously Treated With Cisplatin-based Chemotherapy: A randomized Phase II study - Study of GP versus G regimen in patients with cisplatin-refractory urothelial cancer | JPRN-UMIN000002450 |
| A Randomized Phase 3 Study of Tasisulam Administered as an Intravenous Infusion on Day 1 of a 28-Day Cycle vs. Paclitaxel as Second-Line Treatment in Patients with Metastatic Melanoma | A Randomized Phase 3 Study of Tasisulam Administered as an Intravenous Infusion on Day 1 of a 28-Day Cycle vs. Paclitaxel as Second-Line Treatment in Patients with Metastatic Melanoma | EUCTR2009-014591-21-DE |
| Clinical trial of Mycobacterium w in Combination withPaclitaxel and Cisplatin in Advanced non small cell lung cancer patients. | Open label, randomized multicentric clinical trial of Mycobacterium w in combination with Paclitaxel plus Cisplatin versus paclitxel and cisplatin in advanced Non Small Cell Lung Cancer. | CTRI/2007/091/000037 |
| Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT00989651 |
| Comparison of multimodality treatment; 2 or 4 courses of Paclitaxel/CDDP or S1/CDDP followed by surgery for locally advanced gastric cancer, a randomized phase II trial (COMPASS) | Comparison of multimodality treatment; 2 or 4 courses of Paclitaxel/CDDP or S1/CDDP followed by surgery for locally advanced gastric cancer, a randomized phase II trial (COMPASS) - Neoadjuvant chemotherapy for advanced gastric cancer | JPRN-UMIN000002595 |
| A Phase III Open Label, Randomized, 2 Arm Study of Ixabepilone Administered Every 21 Days Versus Paclitaxel Or Doxorubicin Administered Every 21 Days in Women with Advanced Endometrial Cancer Who Have Previously Been Treated with Chemotherapy | A Phase III Open Label, Randomized, 2 Arm Study of Ixabepilone Administered Every 21 Days Versus Paclitaxel Or Doxorubicin Administered Every 21 Days in Women with Advanced Endometrial Cancer Who Have Previously Been Treated with Chemotherapy - IXAMPLE2 | RBR-7spw98 |
| ONCOFID-P (Paclitaxel-hyaluronic acid) in the intravesical therapy of patients with non-muscle invasive cancer of the bladder. A phase II marker lesion study - ND | ONCOFID-P (Paclitaxel-hyaluronic acid) in the intravesical therapy of patients with non-muscle invasive cancer of the bladder. A phase II marker lesion study - ND | EUCTR2009-012274-13-IT |
| Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer | A Phase II Study of Intraperitoneal (IP) Plus Intravenous (IV) Chemotherapy Versus IV Carboplatin Plus Paclitaxel in Patients With Epithelial Ovarian Cancer Optimally Debulked at Surgery Following Neoadjuvant Intravenous Chemotherapy | NCT00993655 |
| Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel | A Phase I, Open-Label, Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD0530 in Combination With Carboplatin and Paclitaxel Chemotherapy in Japanese Patients With Advanced Solid Malignancies | NCT01000896 |
| Comparison of Paclitaxel-Eluting Coroflex Please Stent Versus Paclitaxel-Eluting Stent | Comparison of the Efficacy and Safety of Paclitaxel-Eluting CoroflexTM Please Stent Versus Paclitaxel-Eluting Stent in Patients With Coronary Artery Disease | NCT00995423 |
| Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma | Phase II Trial of Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma | NCT01009515 |
| Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer | A Phase II Study of Intermittent Gleevec® (Imatinib Mesylate) and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer | NCT01011075 |
| TAXUS Liberte Post Approval Study | TAXUS Liberte Post Approval Study: A U.S. Post-Approval Study of the TAXUS® Liberté® Paclitaxel-Eluting Coronary Stent System | NCT00997503 |
| A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung | A Phase 2 Study of Intravenous Administration of REOLYSIN® (Reovirus Type 3 Dearing) in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung | NCT00998192 |
| Cisplatin and RT With or Without Gemcitabine, Carboplatin, and Paclitaxel in Treating Patients With Locally Advanced NPC | A Randomised Phase II/III Study of Concurrent Cisplatin-Radiotherapy With or Without Induction Chemotherapy Using Gemcitabine, Carboplatin and Paclitaxel in Locally Advanced Nasopharyngeal Cancer | NCT00997906 |
| Study Assessing Safety and Tolerability of AZD8931 Alone or in Combination With Paclitaxel in Japanese Patients. | A Phase I, Open-label, Multiple-dose, Dose-escalation Study To Assess the Safety and Tolerability of AZD8931 Monotherapy in Japanese Patients With Advanced Solid Malignancies and in Combination With Paclitaxel in Japanese Female Patients With Advanced Breast Cancer | NCT01003158 |
| A Study of Neratinib Plus Paclitaxel VersusTrastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic BreastCancer | A Randomized, Open-Label, Two-Arm Study of Neratinib (HKI-272) Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer - Not applicable | CTRI/2009/091/000942 |
| Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction | A Randomized Multicenter Phase III Study Comparing Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment or Cisplatin Plus Capecitabine in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction | NCT01015339 |
| Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies | A Phase I Trial of Dasatinib (Src Inhibitor), Bevacizumab (Anti-VEGF Monoclonal Antibody) and Metronomic Paclitaxel + or - Methylnaltrexone in Patients With Advanced Malignancies | NCT01015222 |
| A Trial of Everolimus-eluting Stents and Paclitaxel-eluting Stents for Coronary Revascularization in Daily Practice: The COMPARE Trial | A Randomized Controlled Trial of Everolimus-eluting Stents and Paclitaxel-eluting Stents for Coronary Revascularization in Daily Practice: The COMPARE Trial | NCT01016041 |
| Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma | A Phase II Study of Everolimus in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma | NCT01014351 |
| CIRCCa (Cediranib In Recurrent Cervical Cancer): a trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer | CIRCCa (Cediranib In Recurrent Cervical Cancer): a randomised double-blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer | ISRCTN23516549 |
| A Phase I, Open-label, Multiple-dose, Dose-escalation Study To Assess the Safety and Tolerability of AZD8931 Monotherapy in Japanese Patients With Advanced Solid Malignancies and in Combination With Paclitaxel in Japanese Female Patients With Advanced Breast Cancer | A Phase I, Open-label, Multiple-dose, Dose-escalation Study To Assess the Safety and Tolerability of AZD8931 Monotherapy in Japanese Patients With Advanced Solid Malignancies and in Combination With Paclitaxel in Japanese Female Patients With Advanced Breast Cancer | JPRN-jRCT2080220921 |
| Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer | A Phase II Clinical Trial of Weekly Paclitaxel and Carboplatin in Combination With Panitumumab in Metastatic Breast Cancer Patients With Triple Negative Disease | NCT01009983 |
| Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer | A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens With Weekly Paclitaxel Plus Neratinib or Trastuzumab or Neratinib and Trastuzumab Followed by Doxorubicin and Cyclophosphamide With Postoperative Trastuzumab in Women With Locally Advanced HER2-Positive Breast Cancer | NCT01008150 |
| Drug-Eluting Balloon Catheters and the Treatment of Peripheral Arterial Occlusive Disease | An Open-Labeled Multicenter Study to Investigate Plasma Levels and Catheter Tolerability Following Application of Paclitaxel Coated Balloon Catheter in Patients With Stenotic, or Occluded Femoro-Popliteal Arteries Due to Atherosclerosis | NCT01007578 |
| A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma | A Randomized Phase 3 Study of Tasisulam-sodium Administered as an Intravenous Infusion on Day 1 of a 28-Day Cycle Versus Paclitaxel as Second-line Treatment in Patients With Metastatic Melanoma | NCT01006252 |
| Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer | A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer | NCT01005329 |
| Restenosis Following Paclitaxel Eluting Balloon Angioplasty of Hemodialysis Access Stenosis | Local Delivery of Paclitaxel for Prevention of Restenosis in Hemodialysis Access | NCT01001676 |
| Phase I/II trial of neoadjuvant chemotherapy with cisplatin and weekly paclitaxel in patients with stage Ib2- IIb uterine cervical cancer | Phase I/II trial of neoadjuvant chemotherapy with cisplatin and weekly paclitaxel in patients with stage Ib2- IIb uterine cervical cancer - Neoadjuvant chemotherapy with cisplatin and weekly paclitaxel in patients with cervical cancer | JPRN-UMIN000002636 |
| Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer | A Phase Ib Study of Erlotinib in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Previously Untreated Advanced Pancreatic Cancer | NCT01010945 |
| Phase II study of weekly Nab-paclitaxel followed by FEC as Neoadjuvant Chemotherapy for Early Breast Cancer | Phase II study of weekly Nab-paclitaxel followed by FEC as Neoadjuvant Chemotherapy for Early Breast Cancer - Phase II study of weekly Nab-paclitaxel followed by FEC as Neoadjuvant Chemotherapy for Early Breast Cancer | JPRN-UMIN000006053 |
| Genexol-PM Versus Paclitaxel in Anthracycline-pretreated Metastatic Breast Cancer Patients | A Randomized Phase II Trial of Genexol-PM vs Paclitaxel in Anthracycline-pretreated Metastatic Breast Cancer Patients | NCT01169870 |
| A randomized phase III trial with dose-dense sequential chemotherapy with epirubicin/paclitaxel/Cyclophosphamide-Methotrexate-Fluorouracil (CMF) vs epirubicin/CMF/docetaxel or paclitaxel as adjuvant chemotherapy in high-risk patients with operable breast cancer. | A comparison of disease-free and overall survival following dose-dense sequential chemotherapy with epirubicin/paclitaxel/Cyclophosphamide-Methotrexate-Fluorouracil (CMF) vs epirubicin/CMF/weekly docetaxel or weekly paclitaxel as adjuvant chemotherapy in high-risk patients with operable breast cancer. A 3-arm randomized phase III study conducted by the Hellenic Cooperative Oncology Group | ACTRN12610000151033 |
| A Phase II, Open-Label, Randomised, Comparative, Multicentre Study to Compare the Efficacy and tolerability of Oral Olaparib in combination with Carboplatin and Paclitaxel Versus Carboplatin and Paclitaxel Alone in Patients with Platinum Sensitive Advanced Serous Ovarian Cancer | A Phase II, Open-Label, Randomised, Comparative, Multicentre Study to Compare the Efficacy and tolerability of Oral Olaparib in combination with Carboplatin and Paclitaxel Versus Carboplatin and Paclitaxel Alone in Patients with Platinum Sensitive Advanced Serous Ovarian Cancer | PER-143-09 |
| Paclitaxel Plus Bevacizumab for Older Patients With Breast Cancer | Biweekly Paclitaxel Plus Bevacizumab as First Line Treatment for Older Patients With Metastatic Breast Cancer | NCT01120158 |
| Bevacizumab (Avastin) therapy in combination with carboplatin and weekly paclitaxel for advanced non-squamous non-small cell lung cancer | Bevacizumab (Avastin) therapy in combination with carboplatin and weekly paclitaxel for advanced non-squamous non-small cell lung cancer - Bevacizumab (Avastin) therapy in combination with carboplatin and weekly paclitaxel for advanced non-squamous non-small cell lung cancer | JPRN-UMIN000003566 |
| A Phase II Study of Adjuvant Carboplatin and Weekly Paclitaxel in Patients with Completely Resected Stage II-IIIA Non-Small Cell Lung Cancer | A Phase II Study of Adjuvant Carboplatin and Weekly Paclitaxel in Patients with Completely Resected Stage II-IIIA Non-Small Cell Lung Cancer - A Phase II Study of Adjuvant Carboplatin and Weekly Paclitaxel in Patients with Completely Resected Stage II-IIIA Non-Small Cell Lung Cancer | JPRN-UMIN000003586 |
| A phase II study of metronomic paclitaxel + cyclophosphamide + capecitabine (PCX) followed by 5-fluorouracil + epirubicin + cyclophosphamide (FEC) as preoperative chemotherapy for triple negative or low hormone receptors/HER2 negative primary breast cancer (JBCRG-13) | A phase II study of metronomic paclitaxel + cyclophosphamide + capecitabine (PCX) followed by 5-fluorouracil + epirubicin + cyclophosphamide (FEC) as preoperative chemotherapy for triple negative or low hormone receptors/HER2 negative primary breast cancer (JBCRG-13) - JBCRG-13 | JPRN-UMIN000003570 |
| Concurrent Endostar, Paclitaxel/Carboplatin and Radiotherapy for Locally Advanced Non-small Cell Lung (RT0902) | A Phase II Study of Endostar, Paclitaxel/Carboplatin and Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer | NCT01158144 |
| Determinación de la respuesta del estroma a nab-paclitaxel en combinación con gemcitabina en cáncer de páncreas.Assessment of tumor stroma response to nab-placlitaxel (Abraxane) in combination with gemcitabine in pancreatic cancer | Determinación de la respuesta del estroma a nab-paclitaxel en combinación con gemcitabina en cáncer de páncreas.Assessment of tumor stroma response to nab-placlitaxel (Abraxane) in combination with gemcitabine in pancreatic cancer | EUCTR2010-019075-30-ES |
| A Randomized, Open-Label, Two-Arm Study Of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel As First-Line Treatment For ErbB-2-Positive Locally Recurrent Or Metastatic Breast Cancer | A Randomized, Open-Label, Two-Arm Study Of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel As First-Line Treatment For ErbB-2-Positive Locally Recurrent Or Metastatic Breast Cancer | PER-009-10 |
| Neoadjuvant Therapy for Ovarian Cancer | Feasibility of Carboplatin, Paclitaxel and Bevacizumab Neoadjuvant Therapy for Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer | NCT01146795 |
| Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients | Phase Ib/II Study of the Tumour-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Paclitaxel in Patients With Advanced Solid Tumours | NCT01134250 |
| Weekly Paclitaxel and Cyclophosphamide in Metronomic Administration : Dose Escalation Study of Weekly Paclitaxel | Phase I Study : Dose Escalation of Intravenous Weekly Paclitaxel in Association With Metronomic Administration of Cyclophosphamide | NCT01374620 |
| Metronomic Therapy in Metastatic Breast Cancer. | Safety and Tolerability of Bevacizumab Plus Paclitaxel vs. Bevacizumab Plus Metronomic Cyclophosphamide and Capecitabine as First-Line Therapy in Patients With HER2-Negative Metastatic or Locally Recurrent Breast Cancer - A Multicenter, Randomized Phase III Trial. | NCT01131195 |
| A Phase II Study of Carboplatin+weekly Paclitaxel+Bevacizumab in chemo-naive patients with stage IIIB and IV non-squamous, non-small cell lung cancer. | A Phase II Study of Carboplatin+weekly Paclitaxel+Bevacizumab in chemo-naive patients with stage IIIB and IV non-squamous, non-small cell lung cancer. - Phase II study of CBDCA+weekly PTX+Bev in chemo-naive patients with stage IIIB and IV non-sq, non-small cell lung cancer. | JPRN-UMIN000003674 |
| Paclitaxel and Irinotecan in Advanced Gastric Cancer | A Phase I/II Trial of Second-line Chemotherapy With Paclitaxel and Irinotecan in Fluoropyrimidine- and Platinum-Pretreated Advanced Gastric Cancer | NCT01136031 |
| A Phase III randomized controlled clinical trial of CARBOPLATIN and PACLITAXEL(OR GEMCITABINE) alone or in combination with BEVACIZUMAB (NSC #704865, IND #7921) followed by BEVACIZUMAB and secondary cytoredutive surgery in platinum sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer. | A Phase III randomized controlled clinical trial of CARBOPLATIN and PACLITAXEL(OR GEMCITABINE) alone or in combination with BEVACIZUMAB (NSC #704865, IND #7921) followed by BEVACIZUMAB and secondary cytoredutive surgery in platinum sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer. - GOG-0213 | JPRN-UMIN000003682 |
| A Randomized Phase II/III Trial of Tri-weekly Intravenous versus Tri-weekly Intraperitoneal Carboplatin Both in Combination with Weekly Intravenous Paclitaxel for Newly Diagnosed Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | A Randomized Phase II/III Trial of Tri-weekly Intravenous versus Tri-weekly Intraperitoneal Carboplatin Both in Combination with Weekly Intravenous Paclitaxel for Newly Diagnosed Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer - IntraPeritoneal therapy for Ovarian Cancer with Carboplatin Trial | JPRN-UMIN000003670 |
| Estudio fase II, aleatorizado, para valorar la eficacia de paclitaxel en monoterapia vs paclitaxel + cetuximab (ERBITAX) en pacientes con carcinoma escamoso de cabeza y cuello recurrente y/o metastásico que han progresado a una primera línea de quimioterapia tipo EXTREME.Randomized Phase II, study to evaluate the efficacy of Paclitaxel in monotherapy vs Paclitaxel + Cetuximab (Erbitax) in patients with recurrent and/or metastatic head and neck squamous cell carcinoma that has progressed to extreme-type first line chemotherapy - EXTAX | Estudio fase II, aleatorizado, para valorar la eficacia de paclitaxel en monoterapia vs paclitaxel + cetuximab (ERBITAX) en pacientes con carcinoma escamoso de cabeza y cuello recurrente y/o metastásico que han progresado a una primera línea de quimioterapia tipo EXTREME.Randomized Phase II, study to evaluate the efficacy of Paclitaxel in monotherapy vs Paclitaxel + Cetuximab (Erbitax) in patients with recurrent and/or metastatic head and neck squamous cell carcinoma that has progressed to extreme-type first line chemotherapy - EXTAX | EUCTR2010-019061-28-ES |
| A clinical trial to study the effects of a new drug and compare the effect of BIBW 2992 along with paclitaxel and investgators choice chemotherapy in patients with Non-Small Cell Lung Cancer failing previous erlotinib or gefitinib treatment | Phase III randomized trial of BIBW 2992 plus weekly paclitaxel versus Investigator?s choice of chemotherapy following BIBW 2992 monotherapy in non-small cell lung cancer patients failing previous erlotinib or gefitinib treatment | CTRI/2010/091/001098 |
| A Phase II Trial of ProLindac™ and Paclitaxel Combination as Second Line-Treatment in Platinum Pretreated Patients with Advanced Ovarian Cancer | A Phase II Trial of ProLindac™ and Paclitaxel Combination as Second Line-Treatment in Platinum Pretreated Patients with Advanced Ovarian Cancer | EUCTR2010-020030-25-FR |
| Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma | A Phase I Study of Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) (AGX) in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma | NCT01161186 |
| LBH589 Oral in Combination With Carboplatin and Paclitaxel in Advanced Solid Tumors | A Phase IB Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) Given Orally in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumors | NCT01159418 |
| Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer | A Randomized, Open-Label, Phase 2 Trial of Paclitaxel/Carboplatin With or Without Bavituximab in Patients With Previously Untreated Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer | NCT01160601 |
| A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF METMAB IN COMBINATION WITHPACLITAXEL AND BEVACIZUMAB IN PATIENTS WITH METASTATIC, TRIPLE-NEGATIVE BREAST CANCEREstudio aleatorizado, en fase II, multicéntrico, doble ciego y controlado con placebo para evaluar la seguridad y la eficacia de metmab en combinación con paclitaxel y bevacizumab en pacientes con cáncer de mama metastásico triple negativo | A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF METMAB IN COMBINATION WITHPACLITAXEL AND BEVACIZUMAB IN PATIENTS WITH METASTATIC, TRIPLE-NEGATIVE BREAST CANCEREstudio aleatorizado, en fase II, multicéntrico, doble ciego y controlado con placebo para evaluar la seguridad y la eficacia de metmab en combinación con paclitaxel y bevacizumab en pacientes con cáncer de mama metastásico triple negativo | EUCTR2010-020101-32-ES |
| Estudio de fase II de la combinación de panitumumab con paclitaxel como tratamiento de primera línea de sujetos con cáncer de cabeza y cuello recurrente o metastásico - VECTITAX | Estudio de fase II de la combinación de panitumumab con paclitaxel como tratamiento de primera línea de sujetos con cáncer de cabeza y cuello recurrente o metastásico - VECTITAX | EUCTR2010-018898-37-ES |
| A Study of The Safety Profile of First-line Avastin (Bevacizumab) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Her2-negative Breast Cancer (AVATAX) | Post Registration Observational Program for Patients With Locally Recurrent or Metastatic Breast Cancer Who Receive Bevacizumab (Avastin) in Combination With Paclitaxel for the First-line Treatment | NCT01156961 |
| Phase I/II Trial of S-1 plus paclitaxel combination chemotherapy in elderly patients with non-small lung cancer | Phase I/II Trial of S-1 plus paclitaxel combination chemotherapy in elderly patients with non-small lung cancer - Phase I/II Trial of S-1 plus paclitaxel combination chemotherapy in elderly patients with non-small lung cancer | JPRN-UMIN000003782 |
| Effectiveness of Paclitaxel-eluting Balloon Catheter in Patients with Sirolimus-eluting Stent Restenosis | Effectiveness of Paclitaxel-eluting Balloon Catheter in Patients with Sirolimus-eluting Stent Restenosis - Paclitaxel-eluting Balloon for SES Restenosis | JPRN-UMIN000003754 |
| Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer | Randomized Phase II Study of Paclitaxel With or Without the Anti-IGF-IR mAb Cixutumumab (IMC-A12) as Second Line Treatment for Patients With Metastatic Esophageal or GE Junction Cancer | NCT01142388 |
| Drug-Eluting Balloon vs Conventional Balloon Pre-dilatation: An Open Randomized Trial in Acute Myocardial Infarction. | Safety and efficacy of the Genous Bio-engineered R Stent™ pre-dilated with paclitaxel-eluting balloon (Pantera®) versus the Genous Bio-engineered R Stent™ pre-dilated with non drug eluting balloon in Patients undergoing PCI for ST-segment Elevation Myocardial Infarction. | NL-OMON24399 |
| A Phase II Study of Paclitaxel+S-1 for previously treated Non-Small Cell Lung Cancer | A Phase II Study of Paclitaxel+S-1 for previously treated Non-Small Cell Lung Cancer - A Phase II Study of Paclitaxel+S-1 for previously treated Non-Small Cell Lung Cancer | JPRN-UMIN000003719 |
| N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer | Phase I Dose Escalation Study of N-acetylcysteine (NAC) Administered Intravenously (IV) in Conjunction With Intraperitoneal (IP) Administered Cisplatin and IV/IP Paclitaxel in Patients With Stage III or IV Ovarian Cancer | NCT01138137 |
| Phase IIIB randomized trial of BIBW 2992 plus weekly paclitaxel versus Investigator's choise of chemotherapy following BIBW 2992 monotherapy in non-small cell lung cancer patients failing previous erlotinib or gefitinib treatment | Phase IIIB randomized trial of BIBW 2992 plus weekly paclitaxel versus Investigator's choise of chemotherapy following BIBW 2992 monotherapy in non-small cell lung cancer patients failing previous erlotinib or gefitinib treatment - LuxLung 5 | NL-OMON36544 |
| Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC) | Study of BAY43-9006 (Sorafenib) in Combination With Carboplatin, Paclitaxel and Bevacizumab in Previously Untreated Patients With Stage IIIB (With Malignant Pleural Effusions) or Stage IV Non-small Cell Lung Cancer (NSCLC) | NCT01069328 |
| Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies | Phase I Study of Combination of Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies | NCT01113476 |
| Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer | Randomized Phase III Study of Maintenance Therapy With Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC | NCT01107626 |
| Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer | A Multi Phase II Clinical Trials Evaluating the Association of Bevacizumab With Weekly Paclitaxel and Capecitabine in First Line Treatment for Patients With Triple Negative Metastatic or Locally Advanced Cancer | NCT01069796 |
| A phase II study of palliative chemoradiation therapy with paclitaxel and cisplatin for local symptoms due to an unresectable primary advanced or locally recurrent gastric adenocarcinoma | A phase II study of palliative chemoradiation therapy with paclitaxel and cisplatin for local symptoms due to an unresectable primary advanced or locally recurrent gastric adenocarcinoma - chemoradiation therapy for advanced or recurrent gastric adenocarcinoma | JPRN-UMIN000003201 |
| Phase Ib/II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Sunitinib | Phase Ib/II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Sunitinib in Patients With HER2-negative Stage II/III Breast Cancer | NCT01070706 |
| Preoperative Chemotherapy With Paclitaxel, Gemcitabine, and Lapatinib (Tykerb®) (PGT) | Phase Ib Study of Preoperative Chemotherapy With Paclitaxel, Gemcitabine, and Lapatinib (Tykerb®) (PGT) in Patients With HER2 Positive Operable Breast Cancer | NCT01133912 |
| Paclitaxel therapy for angiosarcoma | Paclitaxel therapy for angiosarcoma - Paclitaxel therapy for angiosarcoma | JPRN-UMIN000003243 |
| A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors | A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of MEGF0444A, a Human IgG1 Antibody, in Combination With Bevacizumab and Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors | NCT01075464 |
| Phase II study of second line chemotherapy with carboplatin and paclitaxel for metastatic melanoma | Phase II study of second line chemotherapy with carboplatin and paclitaxel for metastatic melanoma - Phase II study of second line chemotherapy with carboplatin and paclitaxel for metastatic melanoma | JPRN-UMIN000003260 |
| A Phase 2 Study of Bevacizumab in Combination with Carboplatin and Paclitaxel in Patients with Non-Squamous Non-Small-Cell Lung Cancer harboring Mutations of EGFR after failing First-line EGFR-TKIs | A Phase 2 Study of Bevacizumab in Combination with Carboplatin and Paclitaxel in Patients with Non-Squamous Non-Small-Cell Lung Cancer harboring Mutations of EGFR after failing First-line EGFR-TKIs - A Phase 2 Study of Bevacizumab in Combination with Carboplatin and Paclitaxel in Patients with Non-Squamous Non-Small-Cell Lung Cancer harboring Mutations of EGFR after failing First-line EGFR-TKIs | JPRN-UMIN000003263 |
| Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas | A Phase II Study of Gemcitabine and Nab-Paclitaxel in Combination With GDC-0449 (Hedgehog Inhibitor) in Patients With Previously Untreated Metastatic Adenocarcinoma of the Pancreas | NCT01088815 |
| Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction | Phase I/II Trial of Best Supportive Care and Chemotherapy, Either Cisplatin or Paclitaxel, in Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer Presenting With Inoperable Malignant Bowel Obstruction | NCT01083537 |
| Demonstrate Efficacy and Safety of Metastatic Breast Cancer | A Double-blind, Randomised, Parallel Group, Phase III Study to Demonstrate Equivalent Efficacy and Comparable Safety of CT-P6 and Herceptin, Both in Combination With Paclitaxel, in Patients With Metastatic Breast Cancer | NCT01084876 |
| Balloon Elution and Late Loss Optimization (BELLO) Study | Balloon Elution and Late Loss Optimization (BELLO) Study: A Multicentre Randomized Study of the IN.PACT Falcon™ Paclitaxel Drug-eluting Balloon to Reduce Restenosis in Small Coronary Vessels | NCT01086579 |
| Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer | Phase I Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer | NCT01090128 |
| Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer | Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase 1 Portion in Patients With Ovarian or Breast Cancer | NCT01091428 |
| Phase I/II Study of Lapatinib in Combination With Paclitaxel as 1L Chemotherapy for ErbB2-positive MBC | An Open-label, Single-arm, Phase I/II Study of Lapatinib in Combination With Weekly Paclitaxel as First-line Chemotherapy for ErbB2-overexpressing Metastatic Breast Cancer Patients | NCT01138046 |
| Randomized phase II study of preoperative systemic chemotherapy of carboplatin/weekly paclitaxel followed by CEF versus weekly paclitaxel followed by CEF for operable HER2-negative breast cancer | Randomized phase II study of preoperative systemic chemotherapy of carboplatin/weekly paclitaxel followed by CEF versus weekly paclitaxel followed by CEF for operable HER2-negative breast cancer - Randomized phase II study of preoperative systemic chemotherapy of carboplatin/weekly paclitaxel followed by CEF versus weekly paclitaxel followed by CEF for operable HER2-negative breast cancer | JPRN-UMIN000003355 |
| Safety and Efficacy of Belinostat When Used With Standard of Care Chemotherapy for Untreated Non-small Cell Lung Cancer | Phase Ib/II Study to Determine the Recommended Dose, Safety, and Preliminary Efficacy of Belinostat When Used in Combination With Carboplatin, Paclitaxel, and Bevacizumab in Patients With Untreated Non-small Cell Lung Cancer. | NCT01090830 |
| """Estudio de fase II, abierto, aleatorizado para evaluar la eficacia y seguridad de paclitaxel administrado semanalmente como agente único y dos regímenes diferentes de SAR240550 (BSI-201), un inhibidor de PARP-1, en combinación con paclitaxel semanal, como terapia neoadyuvante en pacientes con cáncer de mama triple negativo en estadio II-IIIA (TNBC)""__________________________________________________Randomized, open-label, phase 2 study of the efficacy and safety of weekly paclitaxel single-agent and two different regimens of the PARP-1 inhibitor SAR240550 (BSI-201) in combination with weekly paclitaxel, as neoadjuvant therapy in patients with Stage II-IIIA triple negative breast cancer (TNBC) - SOLTI NEOPARP" | """Estudio de fase II, abierto, aleatorizado para evaluar la eficacia y seguridad de paclitaxel administrado semanalmente como agente único y dos regímenes diferentes de SAR240550 (BSI-201), un inhibidor de PARP-1, en combinación con paclitaxel semanal, como terapia neoadyuvante en pacientes con cáncer de mama triple negativo en estadio II-IIIA (TNBC)""__________________________________________________Randomized, open-label, phase 2 study of the efficacy and safety of weekly paclitaxel single-agent and two different regimens of the PARP-1 inhibitor SAR240550 (BSI-201) in combination with weekly paclitaxel, as neoadjuvant therapy in patients with Stage II-IIIA triple negative breast cancer (TNBC) - SOLTI NEOPARP" | EUCTR2010-018960-17-ES |
| Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma | A Phase II, Single-Arm Study of Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma | NCT01107665 |
| Carboplatin and Paclitaxel (Taxol) versus Carboplatin and Paclitaxel (Taxol) followed by Carboplatin for frontline chemotherapy in advanced ovarian carcinoma. A Hellenic Cooperative Oncology Group Study | Carboplatin and Paclitaxel (Taxol) (8 cycles) versus Carboplatin and Paclitaxel (Taxol) (4 cycles) followed by Carboplatin (4 cycles) for frontline chemotherapy in advanced ovarian carcinoma. A randomised phase III study of overall survival by the Hellenic Cooperative Oncology Group | ACTRN12610000309088 |
| Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer | A Phase II Study of Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer | NCT01108055 |
| Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Who Have Undergone Surgery | A Phase II Study of Adjuvant Therapy Using a Regimen of Cyclophosphamide, Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Patients | NCT01106898 |
| A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1) | A Phase Ib Dose Escalation Study of MK-4827 in Combination With Carboplatin, Carboplatin/Paclitaxel and Carboplatin/Liposomal Doxorubicin in Patients With Advanced Solid Tumors | NCT01110603 |
| Phase II study of Weekly Paclitaxel+Weekly Carboplatin for Platinum/Taxan sensitive recurrent mullerian carcinoma | Phase II study of Weekly Paclitaxel+Weekly Carboplatin for Platinum/Taxan sensitive recurrent mullerian carcinoma - Phase II study of Platinum/Taxan sensitive recurrent mullerian carcinoma | JPRN-UMIN000003476 |
| Breast cancer study | Randomised phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- or third-line treatment of patients with metastatic breast cancer - PASO-Trial | EUCTR2009-018025-73-DE |
| First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | A Phase II Trial of Bevacizumab With Carboplatin and Weekly Paclitaxel as First-Line Treatment in Epithelial Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma | NCT01097746 |
| Randomized Phase II Trial Comparing Docetaxel with weekly Paclitaxel and Carboplatin in Elderly Patients with Non-Small Cell Lung Cancer | Randomized Phase II Trial Comparing Docetaxel with weekly Paclitaxel and Carboplatin in Elderly Patients with Non-Small Cell Lung Cancer - DOC vs wPTX+CBDCA in Elderly NSCLC | JPRN-UMIN000002616 |
| A Phase 1/2 Study of XL147 Administered in Combination with Trastuzumab or Paclitaxel andTrastuzumab in Subjects with Metastatic Breast Cancer who have Progressed on a Previous Trastuzumab-Based Regimen | A Phase 1/2 Study of XL147 Administered in Combination with Trastuzumab or Paclitaxel andTrastuzumab in Subjects with Metastatic Breast Cancer who have Progressed on a Previous Trastuzumab-Based Regimen | EUCTR2009-016862-10-FR |
| A Phase II Open Label Randomised Comparative Multicentre Study to Compare the Efficacy and Tolerability of Olaparib in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Platinum Sensitive Advanced Serous Ovarian Cancer | A Phase II Open Label Randomised Comparative Multicentre Study to Compare the Efficacy and Tolerability of Olaparib in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Platinum Sensitive Advanced Serous Ovarian Cancer | JPRN-jRCT2080221047 |
| Comparison of the Efficacy of Paclitaxel-releasing Balloon Catheter System Versus the Everolimus-Eluting Stent System for Treatment of In-Stent Restenosis Lesions - Harmonizing Optimal Strategy for Treatment of In-Stent Restenosis Lesions (The HOST-ISR Trial) - | NCT01093300 | |
| A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II) | A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II) | NCT01100931 |
| A Randomised, double-blinded phase II study of gemcitabine and nab-paclitaxel with CEND-1 or placebo in patients with untreated metastatic pancreatic ductal adenocarcinoma | A Randomised, double-blinded phase II study of gemcitabine and nab-paclitaxel with CEND-1 or placebo in patients on progression-free survival in patients with untreated metastatic pancreatic ductal adenocarcinoma | ACTRN12621001290886 |
| Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) | A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination With Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in PreviouslyUntreated Subjects With Lung Cancer | CTRI/2007/091/000039 |
| Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin | Pilot Trial of Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Treatment of Women With Newly Diagnosed, Optimally Cytoreduced Carcinoma of Mullerian Origin | NCT00652119 |
| Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer | A Phase 1 Study Of Paclitaxel In Combination With SU011248 For Patients With Breast Cancer As First-Line Treatment In The Advanced Disease Setting | NCT00174434 |
| Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma | Phase II Study of Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in the Treatment of High Grade Neuroendocrine Carcinoma | NCT00193531 |
| Intraperitoneal Paclitaxel and Carboplatin in the Treatment of Women With Carcinoma of Mullerian Origin | A Phase II Trial of Intraperitoneal Paclitaxel and Carboplatin Therapy in the Treatment of Women With Newly Diagnosed, Optimally Cytoreduced Carcinoma of Mullerian Origin | NCT00181701 |
| Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and Vinorelbine for Non-Small Cell Lung Cancer | Phase III Randomized Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and Vinorelbine as First-Line Chemotherapy for Stage IIIB and IV Non-Small Cell Lung Cancer | NCT00193362 |
| Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma | A Phase II Study of a Three-Day Schedule of Topotecan Plus Paclitaxel and Carboplatin on Day Three in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma | NCT00193297 |
| Chemotherapy With or Without Surgical Resection in Locally Advanced Esophageal Cancer | Paclitaxel, Carboplatin, Infusional 5-Fluorouracil, and Radiation Therapy With or Without Surgical Resection in Locally Advanced Esophageal Cancer | NCT00193141 |
| A Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Metastatic Breast Cancer | A Phase II Randomized Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Patients With Metastatic Breast Cancer | NCT00191672 |
| Efficacy Trial of Gemcitabine Containing Regimens As Preoperative Chemotherapy in Non Small Cell Lung Cancer | Randomized Phase II Trial to Outline the Efficacy of Gemcitabine Containing Regimens (Gemcitabine/Carboplatin and Gemcitabine/Paclitaxel) When Used as Preoperative Chemotherapy In Patients With Stage I and II NSCLC | NCT00191256 |
| Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse | National, Randomized, Phase II Study Comparing Efficacy of Weekly Administration of Paclitaxel in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse | NCT00189566 |
| An Open Label, Randomized, Phase I/II Study of DMXAA in Combination with Carboplatin and Paclitaxel in Patients with Locally Advanced and Metastatic Non-Small Cell Lung Cancer. - Not applicable | An Open Label, Randomized, Phase I/II Study of DMXAA in Combination with Carboplatin and Paclitaxel in Patients with Locally Advanced and Metastatic Non-Small Cell Lung Cancer. - Not applicable | EUCTR2004-004340-42-DE |
| VEGF, VEGFR1 and VEGFR2 expression in serous epithelial ovarian carcinoma, and its association to the efficacy of bevacizumab combined with paclitaxel and carboplatin as first line treatment | VEGF, VEGFR1 and VEGFR2 expression in serous epithelial ovarian carcinoma, and its association to the efficacy of bevacizumab combined with paclitaxel and carboplatin as first line treatment | EUCTR2005-003209-10-FI |
| Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma | A Randomized, Phase II Trial of Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin Administered Either Weekly or Every Four Weeks in the Treatment of Hormone Refractory Prostate Carcinoma | NCT00193193 |
| Weekly Taxol Plus Xeloda® vs Taxotere q3wk Plus Xeloda® in the Treatment of Metastatic BC | Weekly Taxol® Plus Xeloda® Versus Taxotere® Every Three Weeks Plus Xeloda® in the Treatment of Metastatic Breast Cancer A Phase II/III Study | NCT00201435 |
| Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable (Stage I/II) Or Unresectable Lung Cancer | A Phase I/II Clinical Trial Of Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable (Stage I/II) Or Unresectable (Stage III) Lung Cancers | NCT00178256 |
| Taxol/ Carboplatin as First Line Therapy in Patients With Epithelial Ovarian Cancer | NCT00170664 | |
| A combination phase II study of paclitaxel and gemcitabine for recurrent or relapsed non-small cell lung cancer previously treated with platinum or docetaxel-based regimen | A combination phase II study of paclitaxel and gemcitabine for recurrent or relapsed non-small cell lung cancer previously treated with platinum or docetaxel-based regimen - Phase II study of paclitaxel and gemcitabine for previously treated non-small cell lung cancer | JPRN-C000000219 |
| Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum | Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum | NCT00189371 |
| Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery | A Study of Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF Followed by Weekly Paclitaxel as Neoadjuvant Therapy for Resectable, Hormone Receptor Negative or Hormone Receptor Positive, HER-2/Neu Positive Breast Cancer Followed by a Novel Regimen of Capecitabine, Methotrexate and Vinorelbine for Patients Who Do Not Have Either a Macroscopic or Microscopic Pathologic Complete Response, a Phase II Study | NCT00194779 |
| Adjuvant Therapy for High-Risk Breast Cancer With Wkly Adriamycin & Oral Cytoxan With G-CSF for 12 Wks; Wkly Taxol x 12 | Adjuvant Therapy for High-Risk Localized Breast Cancer With Weekly Adriamycin +/- Oral Cytoxan With Continuous G-CSF Support for 12 Weeks Followed by Weekly Taxol for 12 Weeks, Phase II | NCT00194753 |
| Randomized Phase III Trial of Conventional Paclitaxel and Carboplatin Versus Dose Dense weekly Paclitaxel and Carboplatin in Patients With Newly Diagnosed Stage II-IV Mullerian Carcinoma (Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer) | Randomized Phase III Trial of Conventional Paclitaxel and Carboplatin Versus Dose Dense weekly Paclitaxel and Carboplatin in Patients With Newly Diagnosed Stage II-IV Mullerian Carcinoma (Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer) - Randomized Trial of tri-weekly TJ vs. weekly TJ for Stage II-IV Mullerian Carcinoma | JPRN-C000000183 |
| Clinical trial of postoperative adjuvant chemotherapy with carboplatin/paclitaxel according to the results of collagen gel droplet embedded culture drug sensitivity test (CD-DST) in completely resected non-small-cell lung cancer | Clinical trial of postoperative adjuvant chemotherapy with carboplatin/paclitaxel according to the results of collagen gel droplet embedded culture drug sensitivity test (CD-DST) in completely resected non-small-cell lung cancer - Postoperative adjuvant chemotherapy according to the results of drug sensitivity test in non-small-cell lung cancer | JPRN-C000000210 |
| A phase II randomized study of DP(Docetaxel+Cisplatin),DJ(Docetaxel+Carboplatin),and TJ(Paclitaxel+Carboplatin) in patients with advanced and recurrent endometrial carcinoma | A phase II randomized study of DP(Docetaxel+Cisplatin),DJ(Docetaxel+Carboplatin),and TJ(Paclitaxel+Carboplatin) in patients with advanced and recurrent endometrial carcinoma - Evaluation of Taxane and Platinum combinations in patients with advanced and recurrent endometrial carcinoma | JPRN-C000000170 |
| A MULTICENTER PHASE 3, RANDOMIZED COMPARISON OF THE SAFETY AND EFFICACY OF WEEKLY TOCOSOL® PACLITAXEL VS. WEEKLY PACLITAXEL INJECTION IN THE TREATMENT OF METASTATIC BREAST CANCER | A MULTICENTER PHASE 3, RANDOMIZED COMPARISON OF THE SAFETY AND EFFICACY OF WEEKLY TOCOSOL® PACLITAXEL VS. WEEKLY PACLITAXEL INJECTION IN THE TREATMENT OF METASTATIC BREAST CANCER | EUCTR2005-002428-33-GB |
| Multi-Center, Phase Ib/IIa Safety and Preliminary Efficacy Study of Phenoxodiol (Intravenous Dosage Form and Oral Dosage Form) as a Chemo-Sensitizing Agent for Cisplatin, Carboplatin and Paclitaxel in Epithelial Ovarian Cancer or Primary Peritoneal Cancer that is Platinum- and/or Taxane-Refractory or Resistant. | Multi-Center, Phase Ib/IIa Safety and Preliminary Efficacy Study of Phenoxodiol (Intravenous Dosage Form and Oral Dosage Form) as a Chemo-Sensitizing Agent for Cisplatin, Carboplatin and Paclitaxel in Epithelial Ovarian Cancer or Primary Peritoneal Cancer that is Platinum- and/or Taxane-Refractory or Resistant. | ACTRN12605000432617 |
| Paclitaxel in Treating Patients With Locally Advanced or Metastatic Soft Tissue Angiosarcoma or Lymphangiosarcoma That Cannot Be Removed By Surgery | Multicentric Phase II Study Evaluating the Efficacy and Toxicity of Weekly Paclitaxel in Locally Advanced or Metastatic Soft Tissue Angiosarcomas That Cannot be Treated by Surgery | NCT00217607 |
| Paclitaxel plus cisplatin and concurrent radiation for unresectable, locally recurrent or remnant gastric cancer in the left upper abdomen – phase I study | Paclitaxel plus cisplatin and concurrent radiation for unresectable, locally recurrent or remnant gastric cancer in the left upper abdomen – phase I study - Paclitaxel plus cisplatin and concurrent radiation for unresectable, locally recurrent or remnant gastric cancer – phase I study(MMTG study) | JPRN-C000000246 |
| CTRG B09/00 A phase I/II study of weekly paclitaxel, UFT, and leucovorin in patients with metastatic breast cancer | CTRG B09/00 A phase I/II study of weekly paclitaxel, UFT, and leucovorin in patients with metastatic breast cancer | ACTRN12605000464662 |
| Induction Gemcitabine & Carboplatin Followed by Paclitaxel & Carboplatin +XRT in NSCLC | Phase II Trial of Induction Gemcitabine and Carboplatin Followed by Paclitaxel and Carboplatin With Concurrent Thoracic Radiation for Patients With Unresectable Stage IIIA/IIIB Non-Small Cell Lung Cancer | NCT00226590 |
| Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer | A Multicenter Phase II Trial of Weekly Gemcitabine, Paclitaxel, and Hyperfractionated External Irradiation (63.80 GY) for Locally Advanced Pancreatic Cancer | NCT00226746 |
| Phase I Trial of Biweekly Gemcitabine & Paclitaxel & Low-Dose Radiation for Metastatic or Recurrent Head & Neck Cancer | A Phase I Trial of Biweekly Gemcitabine & Paclitaxel & Low-Dose Fractionated Radiation in the Treatment of Metastatic or Recurrent Head & Neck Cancer | NCT00176241 |
| Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site | A Randomized, Phase III Comparison of Gemcitabine/Irinotecan Followed by IRESSA Versus Paclitaxel/Carboplatin/Etoposide Followed by IRESSA in the First-Line Treatment of Patients With Carcinoma of Unknown Primary Site | NCT00193596 |
| Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line | Randomized Phase II Study of Biweekly Gemcitabine-Paclitaxel, Biweekly Gemcitabine-Carboplatin and Biweekly Gemcitabine-Cisplatin as First-Line Treatment in Metastatic Breast Cancer After Anthracycline Failure | NCT00191854 |
| An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy | Phase III Randomized Trial of Induction Chemotherapy With Gemcitabine and Carboplatin Followed by Elective Paclitaxel Consolidation Versus Paclitaxel and Carboplatin Followed by Elective Paclitaxel Consolidation in Patients With Primary Epithelial Ovarian, Primary Peritoneal Cancer or Fallopian Tube Carcinoma | NCT00191646 |
| Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients With Advanced Transitional Cell Cancer of the Bladder | Phase II Trial of Paclitaxel, Carboplatin and Gemcitabine in Patients With Locally Advanced Transitional Cell Carcinoma of the Bladder | NCT00136175 |
| Isotretinoin, Interferon Alpha-2b, and Paclitaxel in Stage IV, Recurrent, or Persistent Cervical Cancer | A Phase II Trial of Chemosensitization With Paclitaxel, 13-cis Retinoic Acid and Interferon Alpha-2b in Advanced Uterine Cervical Carcinoma | NCT00138151 |
| Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries | A Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the ZoMaxx Drug Eluting Coronary Stent System as Compared to the TAXUS™ Express2™ Paclitaxel-Eluting Stent in de Novo Coronary Artery Lesions | NCT00140101 |
| A Randomized Phase II study of Carboplatin and Paclitaxel or Gemcitabine and Vinorelbine in ECOG PS2 patients with advanced non-small cell lung cancer | A Randomized Phase II study of Carboplatin and Paclitaxel or Gemcitabine and Vinorelbine in ECOG PS2 patients with advanced non-small cell lung cancer - A Randomized Phase II study of Carboplatin and Paclitaxel or Gemcitabine and Vinorelbine in ECOG PS2 patients with advanced non-small cell lung cancer | JPRN-C000000097 |
| Nonpolymer- and Polymer-Based Drug-Eluting Stents for Restenosis (ISAR-TEST-1) | A Randomized Trial of a Nonpolymer-Based Rapamycin-Eluting Stent Versus a Polymer-Based Paclitaxel-Eluting Stent for the Prevention of Restenosis (ISAR-TEST-1) | NCT00140530 |
| A Phase ? Randomized Study of Mitomycin/Vindesine/Cisplatin Versus Irinotecan/Carboplatin Versus Paclitaxel/Carboplatin With Concurrent Thoracic Radiotherapy for Unresectable Stage ? Non-Small-Cell Lung Cancer | A Phase ? Randomized Study of Mitomycin/Vindesine/Cisplatin Versus Irinotecan/Carboplatin Versus Paclitaxel/Carboplatin With Concurrent Thoracic Radiotherapy for Unresectable Stage ? Non-Small-Cell Lung Cancer | NCT00144053 |
| GAP: Phase II gemcitabine and nab-paclitaxel for resectable pancreas cancer | The effect of preoperative gemcitabine and nab-Paclitaxel compared to historical controls on RO surgical rate in patients with resectable pancreas cancer | ACTRN12611000848909 |
| Randomized multicenter phase III study of weekly paclitaxel versus three weekly paclitaxel in patients with metastatic breast cancer previously treated with anthracyclines. | Randomized multicenter phase III study of weekly paclitaxel versus three weekly paclitaxel in patients with metastatic breast cancer previously treated with anthracyclines. | NL-OMON29217 |
| A randomized phase III trial of postoperative adjuvant oral fluoropyrimidine vs. sequential paclitaxel / oral fluoropyrimidine; and UFT vs. S1 for T3 / T4 gastric carcinoma: the Stomach Cancer Adjuvant Multi-institutional Trial Group (SAMIT) Trial | A randomized phase III trial of postoperative adjuvant oral fluoropyrimidine vs. sequential paclitaxel / oral fluoropyrimidine; and UFT vs. S1 for T3 / T4 gastric carcinoma: the Stomach Cancer Adjuvant Multi-institutional Trial Group (SAMIT) Trial - Phase III trial of postoperative adjuvant oral fluoropyrimidine (UFT or S1) vs. sequential paclitaxel (Factorial Design)for T3/4 gastric carcinoma: the SAMIT Trial | JPRN-C000000082 |
| Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer | A Phase 1b Dose Escalation/Phase 2 Randomized, Non-Comparative, Multiple Center, Open Label Study Of CP 751,871 In Combination With Paclitaxel And Carboplatin And Of Paclitaxel And Carboplatin Alone As First Line Treatment For Advanced Non-Small Cell Lung Cancer | NCT00147537 |
| A Phase II study of Paclitaxel, and Vinorelbine (Pacl-Vin) in Hormone-refractory metastatic prostate cancer: Double Tubulin Targeting | A Phase II study of Paclitaxel and Vinorelbine (PaclVin) in Hormone-refractory metastatic prostate cancer: Double Tubulin Targeting. The outcome measured is PSA response. | ACTRN12605000316606 |
| Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate | Phase II Evaluation of Early Oral Estramustine, Oral Etoposide and Intravenous Paclitaxel in Patients With Hormonally Responsive Adenocarcinoma of the Prostate | NCT00151060 |
| Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer | Phase II Evaluation of Trastuzumab (Herceptin), Paclitaxel, Carboplatin, and Gemcitabine in the Treatment of Advanced Urothelial Cancer | NCT00151034 |
| Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries | A Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the ZoMaxx Drug Eluting Coronary Stent System Compared to the TAXUS™ Express2 Paclitaxel-Eluting Coronary Stent System in de Novo Coronary Artery Lesions | NCT00148356 |
| Uterine Papillary Serous Cancer (UPSC) Trial | Prospective, Non-randomised Phase 2 Clinical Trial of Carboplatin Plus Paclitaxel With Sequential Radical Pelvic Radiotherapy for Uterine Serous Papillary Cancer | NCT00147680 |
| Sirolimus- and Paclitaxel-Eluting Stents for Small Vessels (ISAR-SMART-3) | Randomized Trial of Paclitaxel-Eluting Stent and Sirolimus-Eluting Stent for Restenosis Reduction in Small Coronary Vessels (ISAR-SMART-3) | NCT00146575 |
| CCRT With Twice Weekly Paclitaxel and Cisplatin Followed by Surgery for Locally Advanced Esophageal Cancer | A Phase II Study of Concurrent Chemoradiotherapy With Twice Weekly Paclitaxel and Cisplatin (Twice Weekly TP) Followed by Surgery for Locally Advanced Esophageal Cancer | NCT00154804 |
| Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary | A Phase I Dose Escalation Study of Capecitabine, Carboplatin and Weekly Paclitaxel and a Phase II Trial of the Same Combination in Patients With Adenocarcinoma of Unknown Primary | NCT00201734 |
| Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma | A Phase II Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma | NCT00183820 |
| Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II) | Multi-Center, Single-Blind, Two-Arm, Randomized, Controlled, Non Inferiority Trial of the Conor CoStar Paclitaxel-Eluting Coronary Stent System vs the TAXUS DES in Patients With De Novo Lesions of the Native Coronary Arteries | NCT00165035 |
| Study for Patients With Non Small Cell Lung Cancer (NSCLC) | Randomized Phase II Study to Determine the Efficacy of a Three Weekly vs. Weekly Therapy With Paclitaxel Plus Carboplatin vs. Paclitaxel Plus Vinorelbine for Patients With Non Small Cell Lung Cancer According to UICC Stage IIIB and IV | NCT00168883 |
| Paclitaxel, Carboplatin And Low Dose Radiation As Induction Therapy In Locally Advanced Head And Neck Cancer | Paclitaxel, Carboplatin And Low Dose Radiation As Induction Therapy In Locally Advanced Head And Neck Cancer | NCT00176267 |
| A phase I/II study of weekly intraperitoneal paclitaxel +monthly intravenous carboplatin for mullerian carcinoma (ovarian, tubal, and peritoneal carcinoma) | A phase I/II study of weekly intraperitoneal paclitaxel +monthly intravenous carboplatin for mullerian carcinoma (ovarian, tubal, and peritoneal carcinoma) - Weekly IP PAC+CBDCA for mullerian carcinoma | JPRN-C000000115 |
| A phase II trial of adjuvant chemo-radiation followed by chemotherapy for patients with newly diagnosed endometrial carcinoma at high-risk of relapse | A phase II trial to evaluate the effect on progression-free survival of adjuvant chemo-radiation followed by chemotherapy with carboplatin and paclitaxel for patients with newly diagnosed endometrial carcinoma at high-risk of relapse | ACTRN12605000561684 |
| PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy In NSCLC Patients | A Phase 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel And Carboplatin As First-Line Chemotherapy In Patients With Advanced Non-Small Cell Lung Cancer | NCT00174356 |
| Taxol Carboplatin and Erythropoetin | Carboplatin With Following Taxol® Therapy Under Additional Application of Epoetin Alfa (ERYPO ®) With Female Patients With Advanced Ovarian Cancer FIGO IA/G3 - IV | NCT00158379 |
| Weekly TP-HDFL in the Treatment of Advanced TCC | A Phase II Study of Weekly Paclitaxel, Cisplatin and 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin(Weekly TP-HDFL) in the Treatment of Advanced Transitional Cell Carcinoma(TCC) | NCT00154687 |
| Paclitaxel-HDFL for Locally Advanced and Recurrent/Metastatic Gastric Cancers | A Phase II Study of Weekly Paclitaxel(Taxol)and 24-Hour Infusion High-Dose 5-Fluorouracil and Leucovorin(HDFL)in the Treatment Locally Advanced and Recurrent/Metastatic Gastric Cancers | NCT00154726 |
| Paclitaxel (Phyxol) and Cisplatin as First-line Chemotherapy for Metastatic Breast Cancer | Weekly Low-dose Paclitaxel (Phyxol) Plus 24-Hour Infusion of Cisplatin as First-line Chemotherapy for Metastatic Breast Cancer | NCT00154882 |
| Twice Weekly TP-HDFL for Recurrent or Metastatic Esophageal Cancer | A Phase II Study of Twice Weekly Paclitaxel, Cisplatin and Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Folinic Acid in the Treatment of Recurrent or Metastatic Esophageal Cancer | NCT00154700 |
| Paclitaxel, Carboplatin and Radiotherapy as Induction Therapy in Locally Advanced Head and Neck Cancer | Paclitaxel, Carboplatin and Radiotherapy as Induction Therapy in Locally Advanced Head and Neck Cancer | NCT00176254 |
| Evaluation of the Safety and Efficacy of Paraplatin in Combination With Taxol in Patients of 70 Years and Older With Ovary Cancer F.I.G.O. Stages III-IV | National, Phase II Study Designed to Evaluate the Safety and Efficacy of Paraplatin in Combination With Taxol in Patients of 70 Years and Older With Ovary Cancer F.I.G.O. Stages III and IV. FAG-2 | NCT00231075 |
| randomized phase 2 study of Docetaxel+CBDCA versus weekly Paclitaxel+CBDCA | randomized phase 2 study of Docetaxel+CBDCA versus weekly Paclitaxel+CBDCA - randomized phase 2 study of Docetaxel+CBDCA versus weekly Paclitaxel+CBDCA | JPRN-C000000155 |
| A phase I/II study of weekly paclitaxel therapy for metastatic gastric cancer (Step 2) | A phase I/II study of weekly paclitaxel therapy for metastatic gastric cancer (Step 2) - A phase II study of paclitaxel weekly administration for metastatic gastric cancer | JPRN-C000000101 |
| Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | Phase II Trial of Gemcitabine/Paraplatin® (Carboplatin) Followed by Taxol® (Paclitaxel) in Patients With Performance Status = 2,3 or Other Significant Co-Morbidity (HIV Infection or s/p Organ Transplantation) in Advanced Non-Small Cell Lung Cancer | NCT00276588 |
| Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery | Evaluation of the Clinical Efficacy of Leukine® Administered in Conjunction With Paclitaxel in Patients With Advanced Melanoma | NCT00278122 |
| Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer | A Phase I/II Trial of Neoadjuvant Paclitaxel, Carboplatin and OSI-774 (Tarceva) With Concurrent Accelerated Hyperfractionation Radiation Followed by Maintenance Therapy With OSI-774 for Stage III Non-Small Cell Lung Cancer | NCT00278148 |
| Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim | LCCC 0215: Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim Support Followed by Conformal Radiotherapy and Paclitaxel/Carboplatin/ZD1839 in Locally Advanced Unresectable Stage IIIA/B Non-Small Cell Carcinoma of the Lung | NCT00280787 |
| Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer | Phase I/II Trial of Induction Carboplatin/Paclitaxel With Bevacizumab Followed by Concurrent Thoracic Conformal Radiation Therapy With Carboplatin/Paclitaxel, Bevacizumab and Erlotinib in Stage IIIA/B Non-Small Cell Lung Cancer | NCT00280150 |
| An open label phase 2 study of doxorubicin and cyclophosphamide followed by paclitaxel (AC-T) delivered every 14 days with pegfilgrastim and darbepoetin alfa support for the adjuvant treatment of women with breast cancer | An open label phase 2 study of doxorubicin and cyclophosphamide followed by paclitaxel (AC-T) delivered every 14 days with pegfilgrastim and darbepoetin alfa support for the adjuvant treatment of women with breast cancer | ACTRN12606000030572 |
| Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2 | A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Study of Lapatinib (GW572016) in Combination With Paclitaxel Versus Paclitaxel Plus Placebo in Subjects With ErbB2 Amplified Metastatic Breast Cancer | NCT00281658 |
| Combination Chemotherapy and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer | A Phase I Study of Oral Capecitabine in Combination With Weekly IV Carboplatin/Paclitaxel and Radiation Therapy for Patients | NCT00281788 |
| VINORELBINA CAPECITABIME PACLITAXEL AS FIRST LINE THERAPY IN ADVANCED BREAST CANCER PATIENTS PRETREATED WITH ADJUVANT ANTHRACYCLINES - VNBCAPTAX | VINORELBINA CAPECITABIME PACLITAXEL AS FIRST LINE THERAPY IN ADVANCED BREAST CANCER PATIENTS PRETREATED WITH ADJUVANT ANTHRACYCLINES - VNBCAPTAX | EUCTR2005-005683-87-IT |
| Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid Tumors | Phase I Study Of Suberoylanilide Hydroxamic Acid (SAHA) (NSC 701852) in Combination With Paclitaxel /Carboplatin for Advanced and Refractory Solid Malignancies | NCT00287937 |
| Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma | A Phase II Trial of PS-341 in Combination With Paclitaxel and Carboplatin for the Treatment of Metastatic Melanoma | NCT00288041 |
| An open-label, single-arm, multicentre, Phase II study of oral lapatinib in combination with paclitaxel as first-line treatment for ErbB2-amplified metastatic breast cancer patients - Phase II study of paclitaxel plus lapatinib in patients with ErbB2-amplified metastatic breast cance | An open-label, single-arm, multicentre, Phase II study of oral lapatinib in combination with paclitaxel as first-line treatment for ErbB2-amplified metastatic breast cancer patients - Phase II study of paclitaxel plus lapatinib in patients with ErbB2-amplified metastatic breast cance | EUCTR2005-003945-16-LV |
| Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer | A Randomized Phase II Trial Comparing Two Doses of Pulsed Erlotinib Prechemotherapy (PEP-C) in Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | NCT00287989 |
| Maintenance Chemotherapy in Metastatic Breast Cancer | Maintenance Paclitaxel Vs Control After Anthracycline/Paclitaxel Combined First-Line Chemotherapy in Metastatic Breast Cancer | NCT00289263 |
| Treatment of Moderate Vein Graft Lesions With Paclitaxel Drug Eluting Stents: The VELETI Trial | Sealing Moderate Coronary Saphenous VEin Graft LEsions With the Paclitaxel-eluting Stent (Taxus) as a New Approach to Maintain Vein Graft Patency and Reduce Cardiac Events: a Pilot Intravascular Ultrasound Study. | NCT00289835 |
| Phase II Trial of Dose-dense Paclitaxel and Cisplatin as Neo-adjuvant Chemotherapy for Operable Stage II and IIA NSCLC | Phase II Trial of Dose-dense Paclitaxel and Cisplatin as Neo-adjuvant Chemotherapy for Operable Stage II and IIA Non-Small Cell Lung Cancer | NCT00291850 |
| Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC | A Randomized Phase 2 Trial Of Paclitaxel, Carboplatin And Bevacizumab With Or Without PF-3512676 As First-Line Treatment Of Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer | NCT00313768 |
| Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium | A Phase II Trial of Gemzar (Gemcitabine), Taxol (Paclitaxel), and Platinol (Cisplatin) (GTP) in Treatment of Advanced Transitional Cell Carcinoma of the Urothelium | NCT00310011 |
| Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer | A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial | NCT01414608 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine in Treating Patients With Advanced Metastatic Solid Tumors | Phase I Trial of Abraxane in Combination With Gemcitabine in Patients With Solid Tumors | NCT00307255 |
| A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast cancer | A Randomized Phase 2 Trial of Double- Blind, Placebo Controlled AMG 706 in Combination with Paclitaxel, or Open- Label Bevacizumab in Combination with Paclitaxel, as First Line Therapy in Women with HER2 Negative Locally Recurrent or Metastatic Breast Cancer - AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Brest cancer | EUCTR2006-000091-32-IE |
| Paclitaxel, Topotecan, and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer | A Limited Access Phase II Trial of Weekly Topotecan (NSC #609699), Paclitaxel (NSC #673089), and Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix | NCT00276796 |
| Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stents to Treat De Novo Coronary Lesions | TAXUS V: De Novo Lesion: A Randomized, Double-blind Trial to Assess TAXUS Paclitaxel-Eluting Coronary Stents, SR Formulation, in the Treatment of De Novo Coronary Lesions | NCT00301522 |
| A Randomized, Double-Blind, Controlled Study of the Safety and Performance of the NIRx™ Paclitaxel-Coated Conformer Coronary Stent | TAXUS II: A Randomized, Double-Blind, Controlled Study of the Safety and Performance of the NIRx™ Paclitaxel-Coated Conformer Coronary Stent | NCT00299026 |
| Chemotherapy of Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC) | Phase III Study of Monotherapy by Gemcitabine or Vinorelbine Comparing to Doublet by Carboplatin and Paclitaxel Among Elderly Patients With Stage IIIB/IV NSCLC (Obligatory Second-line by Erlotinib) | NCT00298415 |
| A Randomized, Double-blind Study to Assess Paclitaxel-eluting Stents in Treatment of Longer Lesions | TAXUS VI - A Randomized, Double-blind Study to Assess Paclitaxel-eluting Stents in Treatment of Longer Lesions | NCT00297804 |
| A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel plus or minus Sorafenib (BAY 43-9006) in chemonaive patients with Stage IIIB (with effusion) - IV Non-Small Cell Lung Cancer (NSCLC) - | EUCTR2005-005245-19-SE | |
| Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization | Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization: SIRTAX Trial | NCT00297661 |
| A Randomized Phase III trial of Paclitaxel plus Cisplatin versus Paclitaxel plus Carboplatin in Stage IVB, Persistent, or Recurrent Cervical Cancer (JCOG0505, CC-TPTC-P3) | A Randomized Phase III trial of Paclitaxel plus Cisplatin versus Paclitaxel plus Carboplatin in Stage IVB, Persistent, or Recurrent Cervical Cancer (JCOG0505, CC-TPTC-P3) - A Randomized Phase III trial of Paclitaxel plus Cisplatin versus Paclitaxel plus Carboplatin in Stage IVB, Persistent, or Recurrent Cervical Cancer (JCOG0505, CC-TPTC-P3) | JPRN-C000000335 |
| Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer | Phase II Trial of Induction Therapy With Cetuximab (C225) and Carboplatin/Paclitaxel Chemotherapy in Previously Untreated Patients With Advanced (Stage IV) Head & Neck Squamous Cell Carcinoma | NCT00301028 |
| An open-label, multicenter, randomized Phase II Study to compare the effects of Paclitaxel/Carboplatin and Lonafarnib to those of Paclitaxel/Carboplatin for 1st line Treatment of patients with epithelial ovarian cancer International Federation of Gynecology and Obstetrics (FIGO) Stages IIB-IV | ISRCTN51315091 | |
| ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib | A Randomized, Double Blind, Placebo-Controlled, Multicenter, Phase III Study Comparing the Activity of Paclitaxel Plus Trastuzumab Plus Lapatinib to Paclitaxel Plus Trastuzumab Plus Placebo in Women With ErbB2 Overexpressing Metastatic Breast Cancer | NCT00272987 |
| A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy. | Paclitaxel Poliglumex (CT-2103) vs. Paclitaxel for the Treatment of Women With Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer (NSCLC) Who Are Performance Status 2. | NCT00269828 |
| A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma | "A Pilot Phase II Trial of Radiation Therapy ""Sandwiched"" Between Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma" | NCT00231868 |
| A MULTICENTER PHASE 3, RANDOMIZED COMPARISON OF THE SAFETY AND EFFICACY OF WEEKLY TOCOSOL® PACLITAXEL VS. WEEKLY PACLITAXEL INJECTION IN THE TREATMENT OF METASTATIC BREAST CANCER | A MULTICENTER PHASE 3, RANDOMIZED COMPARISON OF THE SAFETY AND EFFICACY OF WEEKLY TOCOSOL® PACLITAXEL VS. WEEKLY PACLITAXEL INJECTION IN THE TREATMENT OF METASTATIC BREAST CANCER | EUCTR2005-002428-33-SK |
| The REALITY Study - Head-to-Head Comparison Between Cypher and Taxus | A Prospective, Randomized, Multi-Center Comparison of the Cypher Sirolimus-Eluting and the Taxus Paclitaxel-Eluting Stent Systems. | NCT00235092 |
| Phase III Study of Two Different Schedules (Weekly and Tri-weekly) of Combination of Gemcitabine and Two Taxanes in MBC | A Randomized Phase III Trial of Gemcitabine and Docetaxel Versus Gemcitabine and Paclitaxel in Patients With Metastatic Breast Cancer: A Comparison of Different Schedules | NCT00236899 |
| A Controlled, Randomized, Open label Phase II Trial to Evaluate Safety and Efficacy of a 1st line Combination Treatment with Weekly Infusion of Gemcitabine and Twice Weekly Administration of Lipid Complexed Paclitaxel (EndoTAG®-1) in Three Dose Levels Compared with Gemcitabine Monotherapy in Patients with Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas - N/A | A Controlled, Randomized, Open label Phase II Trial to Evaluate Safety and Efficacy of a 1st line Combination Treatment with Weekly Infusion of Gemcitabine and Twice Weekly Administration of Lipid Complexed Paclitaxel (EndoTAG®-1) in Three Dose Levels Compared with Gemcitabine Monotherapy in Patients with Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas - N/A | EUCTR2005-000666-39-DE |
| A Phase III, adjuvant trial comparing three chemotherapy regimens in women with node positive breast cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide followed by DD Paclitaxel (DD AC-P);DD AC followed by DD Paclitaxel plus Gemcitabine (DD AC-PG) - NSABP B-38 | A Phase III, adjuvant trial comparing three chemotherapy regimens in women with node positive breast cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide followed by DD Paclitaxel (DD AC-P);DD AC followed by DD Paclitaxel plus Gemcitabine (DD AC-PG) - NSABP B-38 | EUCTR2005-004822-19-IE |
| A PHASE 1B DOSE ESCALATION/PHASE 2 RANDOMIZED, NON-COMPARATIVE, MULTIPLE CENTER, OPEN LABEL STUDY OF CP-751,871 IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN AND OF PACLITAXEL AND CARBOPLATIN ALONE AS FIRST LINE TREATMENT FOR ADVANCED NON SMAL CELL LUNG CANCER | A PHASE 1B DOSE ESCALATION/PHASE 2 RANDOMIZED, NON-COMPARATIVE, MULTIPLE CENTER, OPEN LABEL STUDY OF CP-751,871 IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN AND OF PACLITAXEL AND CARBOPLATIN ALONE AS FIRST LINE TREATMENT FOR ADVANCED NON SMAL CELL LUNG CANCER | EUCTR2005-002249-38-ES |
| Sequential chemotherapy with FEC(fluoraouracil, epirubicin and cyclophosphamide) and P+H(weekly Paclitaxel+Trastuzumab) as primary systemic therapy for operable breast cancer with HER2 positive disease-a phase 2 study | Sequential chemotherapy with FEC(fluoraouracil, epirubicin and cyclophosphamide) and P+H(weekly Paclitaxel+Trastuzumab) as primary systemic therapy for operable breast cancer with HER2 positive disease-a phase 2 study - Sequential chemotherapy with FEC(fluoraouracil, epirubicin and cyclophosphamide) and P+H(weekly Paclitaxel+Trastuzumab) as primary systemic therapy for operable breast cancer with HER2 positive disease-a phase 2 study(PST0402) | JPRN-C000000265 |
| International, randomized, open-label, Phase 3 trial of paclitaxel/carboplatin plus PF-3512676 versus paclitaxel/carboplatin alone as first-line treatment of patients with advanced non-small cell lung cancer | International, randomized, open-label, Phase 3 trial of paclitaxel/carboplatin plus PF-3512676 versus paclitaxel/carboplatin alone as first-line treatment of patients with advanced non-small cell lung cancer | EUCTR2005-004555-35-GB |
| A phase III randomised, placebo-controlled study of Sorafenib in repeated cycles of 21 days in combination with paclitaxel / carboplatin chemotherapy in patients with unresectable stage III or IV melanoma. | A phase III randomised, placebo-controlled study of Sorafenib in repeated cycles of 21 days in combination with paclitaxel / carboplatin chemotherapy in patients with unresectable stage III or IV melanoma, to compare the anti-tumor activity as measured by progression free survival. | ACTRN12605000684628 |
| Paclitaxel + Carboplatin With/Out Cediranib Maleate in Stage III or Stage IV Non-Small Cell Lung Cancer | A Phase II/III Double Blind Randomized Trial of AZD2171 Versus Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer | NCT00245154 |
| Randomised phase II study of the combination of oral vinorelbine with capecitabine versus gemcitabine in combination with paclitaxel versus gemcitabine in combination with docetaxel as first line chemotherapy in patients with metastatic breast cancer. | Randomised phase II study of the combination of oral vinorelbine with capecitabine versus gemcitabine in combination with paclitaxel versus gemcitabine in combination with docetaxel as first line chemotherapy in patients with metastatic breast cancer. | EUCTR2005-000438-19-ES |
| The SOS (Stenting Of Saphenous Vein Grafts) Trial | The SOS (Stenting Of Saphenous Vein Grafts) Randomized-controlled Trial of a Paclitaxel-eluting Stent vs. a Bare Metal Stent in Saphenous Vein Graft Lesions | NCT00247208 |
| PHASE II TRIAL OF THE SEQUENTIAL ADMINISTRATION OF COMBINATIONS OF GEMCITABINE-CISPLATIN AND CARBOPLATIN-PACLITAXEL FOR THE TREATMENT OF PATIENTS WITH ADVANCED CARCINOMA OF THE OVARY WITH SUB-OPTIMAL CYTOREDUCTION | PHASE II TRIAL OF THE SEQUENTIAL ADMINISTRATION OF COMBINATIONS OF GEMCITABINE-CISPLATIN AND CARBOPLATIN-PACLITAXEL FOR THE TREATMENT OF PATIENTS WITH ADVANCED CARCINOMA OF THE OVARY WITH SUB-OPTIMAL CYTOREDUCTION | EUCTR2004-002473-23-ES |
| Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer | A Multicenter Phase 3, Randomized Comparison of the Safety and Efficacy of Weekly TOCOSOL(R) Paclitaxel vs. Weekly Paclitaxel Injection in the Treatment of Metastatic Breast Cancer | NCT00251095 |
| Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer | International, Randomized, Open-Label, Phase 3 Trial of Paclitaxel/Carboplatin Plus PF-3512676 Versus Paclitaxel/Carboplatin Alone as First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer | NCT00254891 |
| Integration of 3D-conformal, local radiotherapy (3DCRT) to metastatic sites in a paclitaxel weekly chemotherapy regimen in oligometastatic breast cancer patients: a phase I- and randomised phase II-study - Paclitaxel-3DCRT | Integration of 3D-conformal, local radiotherapy (3DCRT) to metastatic sites in a paclitaxel weekly chemotherapy regimen in oligometastatic breast cancer patients: a phase I- and randomised phase II-study - Paclitaxel-3DCRT | EUCTR2005-003327-39-DE |
| Satraplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer | Phase 2 Trial of First-Line Therapy With Satraplatin and Paclitaxel in Patients With Unresectable Stage III or IV Non-small Cell Lung Cancer (NSCLC) | NCT00268970 |
| Late phase II study of weekly paclitaxel (BMS-181339) in patients with advanced head and neck cancer | Late phase II study of weekly paclitaxel (BMS-181339) in patients with advanced head and neck cancer | JPRN-jRCT2080220194 |
| Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery | A Phase II Study of Neo-Adjuvant Cisplatin, Gemcitabine & Bevacizumab, Followed by Radical Cystectomy for Patients With Muscle Invasive, Resectable, Non-Metastatic Transitional Cell Carcinoma (TCC) of the Bladder | NCT00268450 |
| Paclitaxel Poliglumex (CT-2103) vs Paclitaxel for the Treatment of Women with Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer (NSCLC) who are Performance Status 2 | Paclitaxel Poliglumex (CT-2103) vs Paclitaxel for the Treatment of Women with Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer (NSCLC) who are Performance Status 2 | EUCTR2005-005233-35-GB |
| Paclitaxel Poliglumex and Capecitabine in Treating Patients With Metastatic Breast Cancer | Phase II Trial of CT-2103 (Xyotax™) With Capecitabine as First-Line Chemotherapy for Patients With Metastatic Breast Cancer | NCT00265733 |
| Capecitabine Associated With Weekly Paclitaxel in Metastatic Breast Cancer. | A Multicenter Randomized Phase II Study Evaluating Tolerance and Efficacy of Capecitabine 5/7 Days With Weekly Paclitaxel Versus the Recommended Treatment Plan of Weekly Paclitaxel-capecitabine, in Patients With Metastatic Breast Cancer. | NCT00270491 |
| ENSAYO EN FASE I/II DE LA COMBINACIÓN DE GEMCITABINA EN INFUSIÓN PROLONGADA Y PACLITAXEL ADMINISTRADOS DE FORMA QUINCENAL EN EL TRATAMIENTO DE PRIMERA LÍNEA DE PACIENTES CON CÁNCER DE MAMA AVANZADO | ENSAYO EN FASE I/II DE LA COMBINACIÓN DE GEMCITABINA EN INFUSIÓN PROLONGADA Y PACLITAXEL ADMINISTRADOS DE FORMA QUINCENAL EN EL TRATAMIENTO DE PRIMERA LÍNEA DE PACIENTES CON CÁNCER DE MAMA AVANZADO | EUCTR2004-004148-34-ES |
| LOCAL-TAX Trial: Local intracoronary administration of Paclitaxel after stent implantation for prevention of restenosis in comparison with stent implantation alone and with implantation of a Paclitaxel-eluting stent - LOCAL-TAX Trial | LOCAL-TAX Trial: Local intracoronary administration of Paclitaxel after stent implantation for prevention of restenosis in comparison with stent implantation alone and with implantation of a Paclitaxel-eluting stent - LOCAL-TAX Trial | EUCTR2005-001481-14-DE |
| Estudio piloto fase II abierto, no controlado y multicéntrico para evaluar la eficacia y seguridad de cetuximab (Erbitux) en combinación con paclitaxel semanal en primera linea de tratamiento de pacientes con un carcinoma escamoso de cabeza y cuello recurrente y/o metastásico. - ERBITAX | Estudio piloto fase II abierto, no controlado y multicéntrico para evaluar la eficacia y seguridad de cetuximab (Erbitux) en combinación con paclitaxel semanal en primera linea de tratamiento de pacientes con un carcinoma escamoso de cabeza y cuello recurrente y/o metastásico. - ERBITAX | EUCTR2005-003010-15-ES |
| Randomized comparison of paclitaxel eluting stent versus conventional stent in ST-segment elevation myocardial infarction. | Paclitaxel eluting stent versus conventional stent in acute STE-myocardial infarction (PASSION) trial. | NL-OMON25456 |
| Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery | Phase II Trial of Carboplatin, Weekly Paclitaxel and Biweekly Bevacizumab in Patients With Unresectable Stage IV Melanoma | NCT00255762 |
| Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer | A Pilot Study of Neoadjuvant Biweekly Doxorubicin and Cyclophosphamide (AC) With GMCSF Followed by Weekly Carboplatin/Paclitaxel With Plus or Minus Trastuzumab (TC ± H) in the Treatment of Breast Cancer | NCT00256243 |
| Neoadjuvant Treatment of Breast Cancer | Neoadjuvant Biweekly Doxorubicin and Cyclophosphamide With GMCSF Followed by Weekly Carboplatin/Nab-paclitaxel Plus or Minus Trastuzumab and Plus or Minus Bevacizumab in Treatment of Large or Inflammatory Breast Cancer-a Phase II Study | NCT00254592 |
| Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer | NCT00262847 |
| Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors | A Phase I Dose Escalation Study of a 2 Day Oral Lapatinib Chemosensitization Pulse Given Prior To Weekly Intravenous Abraxane™ in Patients With Advanced Solid Tumors | NCT00313599 |
| A Phase II Clinical Trial to Evaluate Intratumoral Injection of a Depot Formulation of Paclitaxel (DTS-301) as Neoadjuvant Therapy of Patients with Breast Cancer | A Phase II Clinical Trial to Evaluate Intratumoral Injection of a Depot Formulation of Paclitaxel (DTS-301) as Neoadjuvant Therapy of Patients with Breast Cancer | EUCTR2005-001417-18-AT |
| A Pharmacogenomics Study for Breast Cancer Patients Undergoing Adjuvant Chemotherapy With Doxorubicin (A)/Cyclophosphamide ©) and/or Weekly Paclitaxel | A Pharmacogenomics Study for Breast Cancer Patients Undergoing Adjuvant Chemotherapy With Doxorubicin (A)/Cyclophosphamide ©) and/or Weekly Paclitaxel | NCT00131963 |
| Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer | A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Phase III Study of Oral GW572016 in Combination With Paclitaxel in Subjects Previously Untreated or Advanced or Metastatic Breast Cancer | NCT00075270 |
| PHASE III RANDOMIZATION OF DOXORUBYCIN AND CYCLOPHOSPHAMID (AC) FOLLOWED BY WEEKLY PACLITAXEL WITH OR WITHOUT TRASTUZUMAB AS AN ADJUVANT TREATMENT FOR WOMEN WITH BREAST CANCER WITH POSITIVE GANGLES ON EXPRESSING HER-2 POSITIVE | PHASE III RANDOMIZATION OF DOXORUBYCIN AND CYCLOPHOSPHAMID (AC) FOLLOWED BY WEEKLY PACLITAXEL WITH OR WITHOUT TRASTUZUMAB AS AN ADJUVANT TREATMENT FOR WOMEN WITH BREAST CANCER WITH POSITIVE GANGLES ON EXPRESSING HER-2 POSITIVE | PER-073-03 |
| RANDOMIZED STUDY OF PHASE III, WITH PACLITAXEL VERSUS PACLITAXEL MAS BEVACIZUMAB (RHU MBA VEGF) AS A FIRST-LINE TREATMENT FOR METASTASIC OR LOCALLY RECURRING BREAST CANCER | RANDOMIZED STUDY OF PHASE III, WITH PACLITAXEL VERSUS PACLITAXEL MAS BEVACIZUMAB (RHU MBA VEGF) AS A FIRST-LINE TREATMENT FOR METASTASIC OR LOCALLY RECURRING BREAST CANCER | PER-072-03 |
| RANDOMIZED STUDY OF PHASE III OF CARBOPLATIN, PACLITAXEL AND THORAXIC RADIOTHERAPY WITH OR WITHOUT TALIDOMIDE IN PATIENTS WITH CLINICAL STAGE III NSCLC | RANDOMIZED STUDY OF PHASE III OF CARBOPLATIN, PACLITAXEL AND THORAXIC RADIOTHERAPY WITH OR WITHOUT TALIDOMIDE IN PATIENTS WITH CLINICAL STAGE III NSCLC | PER-104-03 |
| TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium | A Phase 2 Multicenter Evaluation of the Safety and Efficacy of TOCOSOL(TM) Paclitaxel (S-8184 Paclitaxel Injectable Emulsion) in Patients With Metastatic or Locally Advanced, Unresectable Transitional Cell Carcinoma of the Urothelium | NCT00077688 |
| Paclitaxel and Carboplatin in Treating Patients With Locally Advanced or Metastatic Renal Cell Cancer | Phase II Trial Of Paclitaxel Plus Carboplatin In Patients With Metastatic Or Locally Advanced Collecting Duct Renal Cell Cancer | NCT00077129 |
| Paclitaxel, Carboplatin, and Radiation Therapy With or Without Adjuvant Paclitaxel and Carboplatin in Treating Patients With Stage II or Stage III Unresectable Non-Small Cell Lung Cancer | Phase III Randomised Study Of Adjuvant Paclitaxel And Carboplatin (TAXOL-PARAPLATINE) With Concomittant Radiotherapy In Patients With Stage II or III Non-Metastatic Non-Small Cell Lung Cancer | NCT00077220 |
| ABI-007 in Treating Patients With Chemotherapy-Naïve Stage IV Non-Small Cell Lung Cancer | An Open-Label, Phase I/II Trial Of ABI-007 (A CREMOPHOR® El-Free, Protein Stabilized, Nanoparticle Paclitaxel) Administered Weekly In Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer | NCT00077246 |
| Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer | Phase III Randomized Comparison Study of Vinorelbine, Gemcitabine, and Docetaxel Versus Paclitaxel and Carboplatin in Patients With Advanced Non-Small Cell Lung Cancer | NCT00079287 |
| Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | A Dose-Escalating Phase I Study With an Expanded Cohort to Assess the Feasibility of Intraperitoneal Carboplatin (NSC #214240) and Intravenous Paclitaxel (NSC # 673089) and Intravenous Paclitaxel, Intraperitoneal Carboplatin and NCI Supplied Intravenous Bevacizumab (NSC #704865) in Patients With Previously Untreated Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma | NCT00079430 |
| Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients With Advanced Cancer | Phase I Study of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) Formulation in Patients With Advanced Cancer | NCT00080418 |
| ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma | An Open-Label, Multicenter, Phase II Trial of ABI-007 (A Cremophor® -Free, Protein Stabilized, Nanoparticle Paclitaxel) in Previously Treated Patients With Metastatic Melanoma | NCT00081042 |
| Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer | A Phase II Study Of Cetuximab (C225) In Combination With Chemoradiation In Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC) | NCT00081302 |
| Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer | Pilot Study of Epirubicin and Cyclophosphamide Followed by Paclitaxel at 10-11 Days Interval for Women With Early Breast Carcinoma | NCT00072319 |
| Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck | A Pilot Phase I Dose Escalation Study Of The EGFR Tyrosine Kinase Inhibitor Gefitinib (Iressa) Combined With Paclitaxel (Taxol) And External Beam Radiation Therapy In Patients With Advanced Squamous Cell Carcinoma Of The Head And Neck (SCCHN) | NCT00083057 |
| STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma | A Two-Stage Trial of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Metastatic Melanoma | NCT00084214 |
| S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | Phase II Selection Design Trial Of Concurrent Chemotherapy + Cetuximab Vs. Chemotherapy Followed By Cetuximab In Advanced Non-Small Cell Lung Cancer (NSCLC) | NCT00085501 |
| Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer | Phase II Study of the Activity of Weekly Paclitaxel, Topotecan Plus Oral Estramustine Phosphate in Metastatic Hormone-Refractory Prostate Carcinoma | NCT00084565 |
| Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer | A Phase II Evaluation of Weekly Paclitaxel (NSC #673089) and Celecoxib (Celebrex®, NSC #719627) in the Treatment of Recurrent or Persistent Platinum-Resistant Epithelial Ovarian or Primary Peritoneal Cancer | NCT00084448 |
| Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) | A Phase I Trial of Intravenous Paclitaxel, Intraperitoneal Carboplatin and Intraperitoneal Paclitaxel or Intravenous Docetaxel, Intraperitoneal Carboplatin and Intraperitoneal Paclitaxel or Intravenous Paclitaxel, Intraperitoneal Carboplatin, Intraperitoneal Paclitaxel and CTEP-Supplied Agent Bevacizumab (NSC 704865, IND 7921) in Patients With Previously Untreated Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma | NCT00085358 |
| A Randomized, Partially Blinded, Phase II Study to Assess the Safety, Tolerability, and Efficacy of ZD6474 Alone or in Combination with Paclitaxel and Carboplatin in Subjects with Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) - 6474IL0007 | A Randomized, Partially Blinded, Phase II Study to Assess the Safety, Tolerability, and Efficacy of ZD6474 Alone or in Combination with Paclitaxel and Carboplatin in Subjects with Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) - 6474IL0007 | EUCTR2004-000379-32-FI |
| 17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor | Phase I Study of 17- Allylamino-17 Demethoxygeldanamycin (17-AAG) in Combination With Paclitaxel in Advanced Solid Malignancies | NCT00087217 |
| Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC) | A Phase III Randomized Trial of Gemcitabine/Oxaliplatin (GEMOX) Versus Carboplatin/Paclitaxel (CP) as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | NCT00087802 |
| Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer | CLINICAL STUDY PHASE III RANDOMIZED, MULTICENTER, DOUBLE-BLIND, CONTROLLED WITH PLACEBO, OF 2 ARMS OF GW572016 ORAL IN COMBINATION WITH PACLITAXEL IN PATIENTS NOT TREATED PREVIOUSLY FOR ADVANCED OR METASTATIC BREAST CANCER | PER-045-04 |
| STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC) | A Phase I/II Trial of STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer (NSCLC) | NCT00088088 |
| STA-4783 and Paclitaxel for Treatment of Solid Tumors | A Phase I Trial of STA-4783 in Patients Receiving Paclitaxel for Treatment of Solid Tumors | NCT00088114 |
| Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer | Phase 1-2a Dose-Ranging Study of the Triplet Combination of Carboplatin, Paclitaxel and TLK286 as First-Line Therapy in Advanced Non-Small Cell Lung Cancer | NCT00088556 |
| Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer | Phase II Evaluation of Cetuximab (C225) Combined With Induction Paclitaxel and Carboplatin Followed by C225, Paclitaxel, Carboplatin, and Radiation for Stage III/IV Operable Squamous Cancer of the Head and Neck | NCT00089297 |
| Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer | A Pilot Study to Establish a Standardized Protocol for Gene Microarray Analysis in Patients Receiving Neoadjuvant Chemotherapy for Breast Cancer: Identifying Factors Predictive of a Response to Paclitaxel | NCT00088829 |
| ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | A Randomized, Partially Blinded, Phase II Study to Assess the Safety, Tolerability and Efficacy of ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | NCT00071188 |
| S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer | Phase III Trial of Continuous Schedule AC + G vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer | NCT00070564 |
| Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer | A Phase III Randomized Neoadjuvant Study of Sequential Epirubicin/Cyclophosphamide and Paclitaxel + - Gemcitabine in Poor Risk Early Breast Cancer | NCT00070278 |
| A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Paclitaxel/Carboplatin as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC) | NCT00042302 | |
| Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors | Phase I Study To Determine The Safety, Tolerance And Preliminary Antineoplastic Activity Of Combined EGFR (erbB1) And HER2 (erbB2) Blockade, With OSI-774 And Trastuzumab, In Combination With Weekly Paclitaxel | NCT00042809 |
| S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium | A Sequential Approach to the Treatment of Muscle Invasive, Non-Metastatic Urothelial Carcinoma of the Bladder: A Phase II Trial of Neoadjuvant Gemcitabine, Paclitaxel and Carboplatin With Molecular Correlates | NCT00045630 |
| A randomised trial of maintenance weekly paclitaxel versus observation following remission with first-line induction carboplatin and paclitaxel for patients with ovarian cancer | ISRCTN48397858 | |
| A randomised two-arm, prospective, multi-centre, open-label phase III trial comparing the activity and safety of a weekly versus a three-weekly paclitaxel treatment schedule in patients with advanced or metastatic breast cancer | A randomised two-arm, prospective, multi-centre, open-label phase III trial comparing the activity and safety of a weekly versus a three-weekly paclitaxel treatment schedule in patients with advanced or metastatic breast cancer | ISRCTN52817670 |
| Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | A Phase II Trial of Paclitaxel and Carboplatin in the Treatment of Hormone-Refractory Prostate Cancer (HRPC) | NCT00049257 |
| Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell Lung Cancer | NCT00049790 | |
| Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer | Randomized Phase III Trial Comparing Targretin Capsules/Carboplatin/Paclitaxel Versus Carboplatin/Paclitaxel in Chemotherapy-Naïve Patients With Advanced or Metastatic Non-Small Cell Lung Cancer | NCT00050960 |
| Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer | Randomized Trial Of Adriamycin (A) Cisplatin (P) Chemotherapy Versus Paclitaxel (T) Adriamycin (A) And Cisplatin (P) In Patients With Metastatic/Relapsed Or Locally Advanced Inoperable Endometrial Cancer | NCT00052312 |
| Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer | A Phase I/II Study of Suramin in Combination With Paclitaxel in Advanced (Stage IIIB or IV) Metastatic Breast Cancer | NCT00054028 |
| Combination Chemotherapy Plus Oblimersen in Treating Patients With Advanced Solid Tumors | A Phase I Study of Antisense Bcl-2 Oligonucleotide (G3139) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumors | NCT00054548 |
| Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer | A Randomized, Phase III Multicenter Trial Of Gemcitabine In Combination With Carboplatin Or Paclitaxel Plus Carboplatin In Patients With Metastatic (Stage IIIB, IV) Non-Small Cell Lung Cancer | NCT00054392 |
| Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer | CT-2103 vs Gemcitabine or Vinorelbine for the Treatment of PS = 2 Patients With Chemotherapy Naive Advanced Non-Small Cell Lung Cancer (NSCLC): A Phase III Study | NCT00054197 |
| Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer | CT-2103 vs Docetaxel for the Second-Line Treatment of Non-Small Cell Lung Cancer (NSCLC): A Phase III Study | NCT00054184 |
| Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer | CT-2103/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of PS = 2 Patients With Chemotherapy Naive Advanced Non-Small Cell Lung Cancer (NSCLC): A Phase III Study | NCT00054210 |
| S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium | Phase II Evaluation of Carboplatin, Paclitaxel and Gemcitabine Followed by Concurrent Cisplatin and Radiation Therapy in Patients With Locally Advanced or Recurrent Urothelial Malignancy | NCT00055835 |
| Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer | A Phase II Randomized Trial for Patients With Muscle-Invading Bladder Cancer Evaluating Transurethral Surgery and BID Irradiation Plus Either Paclitaxel and Cisplatin or 5-Fluorouracil and Cisplatin Followed by Selective Bladder Preservation and Gemcitabine/Paclitaxel/Cisplatin Adjuvant Chemotherapy | NCT00055601 |
| Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction | A Phase II Study Of Paclitaxel-Based Chemoradiotherapy Regimen With Selective Surgical Salvage For Resectable Locoregionally Advanced Carcinoma Of The Esophagus | NCT00069953 |
| Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer | Phase I Study of Lonafarnib (SCH66336) in Combination With Herceptin Plus Paclitaxel in HER 2 NEU Overexpressing Breast Cancer | NCT00068757 |
| Celecoxib, Paclitaxel, and Carboplatin in Treating Patients With Cancer of the Esophagus | A Phase II Study Of Preoperative Celecoxib/Paclitaxel/Carboplatin For Squamous Cell And Adenocarcinoma Of The Esophagus | NCT00066716 |
| Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer | Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF Versus Carboplatin/Paclitaxel in Patients With Stage III &Amp; IV or Recurrent Endometrial Cancer | NCT00063999 |
| Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix | A Randomized Phase III Trial Of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Versus Topotecan Plus Cisplatin In Stage IVB, Recurrent Or Persistent Carcinoma of the Cervix | NCT00064077 |
| Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer | A Phase II Study of Cetuximab (C225)/Paclitaxel/Carboplatin for the Initial Treatment of Advanced Stage Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | NCT00063401 |
| Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | Multi-Center, Phase Ib/IIa Safety and Preliminary Efficacy Study of Phenoxodiol (Intravenous) as a Chemo-Sensitizing Agent for Cisplatin and Paclitaxel in Epithelial Ovarian Cancer or Primary Peritoneal Cancer, Platinum- and/or Taxane-Refractory or Resistant | NCT00091377 |
| Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung Cancer | Phase II Randomized Open-Label Trial of the EGFR Tyrosine Kinase Inhibitor OSI-774 (Tarceva™) in Combination With Paclitaxel and Carboplatin Prior to Surgery in Resectable Stage IIIA (N2) and IIIB (T4 N2) NSCLC: A Clinical Outcome and Biological Endpoint Trial | NCT00063258 |
| Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer | Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age | NCT00062062 |
| Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer | Interferon Alpha (NSC# 377523) Plus 13-Cis-Retinoic Acid Modulation Of BCL-2 Plus Paclitaxel For Recurrent Small Cell Lung Cancer | NCT00062010 |
| Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer | A Dose-Escalating Phase I Study With an Expanded Cohort to Assess the Feasibility of CT-2103 and Carboplatin (NSC #214240) in Patients With Previously Untreated Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma | NCT00060359 |
| Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma | Phase II Study of Erlotinib Plus Carboplatin and Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma | NCT00059787 |
| S0227 Cisplatin With Either Paclitaxel or Gemcitabine in Recurrent, Persistent, or Metastatic Cervical Cancer | Phase III Randomized Trial of Cisplatin/Paclitaxel Versus Cisplatin/Gemcitabine in Recurrent, Persistent or Metastatic Carcinoma of the Cervix | NCT00057928 |
| Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer | A Phase II Study of Oxaliplatin in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Cervical Cancer | NCT00057863 |
| Paclitaxel and Carboplatin With or Without Celecoxib Before Surgery in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer | A Randomized Double Blind Phase II Study of Preoperative Celecoxib/Paclitaxel/Carboplatin for Stage IIIA Non-Small Cell Lung Cancer | NCT00062179 |
| A PHASE II, RANDOMIZED STUDY OF CARBOPLATIN-GEMCITABINE PLUS CARBOPLATIN-PACLITAXEL VERSUS CARBOPLATIN-PACLITAXEL IN PLATINUM-SENSITIVE PATIENTS WITH RECURRENT OVARIAN CARCINOMA, PRIMARY PERITONEAL CARCINOMA OR FALLOPIAN TUBE CANCER. | A PHASE II, RANDOMIZED STUDY OF CARBOPLATIN-GEMCITABINE PLUS CARBOPLATIN-PACLITAXEL VERSUS CARBOPLATIN-PACLITAXEL IN PLATINUM-SENSITIVE PATIENTS WITH RECURRENT OVARIAN CARCINOMA, PRIMARY PERITONEAL CARCINOMA OR FALLOPIAN TUBE CANCER. | EUCTR2004-000722-69-ES |
| A Study Extension to Evaluate the Safety and Tolerability of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients that Completed Study LEP-ETU-102A | A Study Extension to Evaluate the Safety and Tolerability of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients that Completed Study LEP-ETU-102A | EUCTR2004-001349-14-DE |
| Pilot study evaluating the efficacy and safety of preoperative ENDOTAG in combination with Paclitaxel in high risk breast cancer | An open-label phase II trial evaluating the efficacy and safety of neoadjuvant EndoTAGTM-1 in combination with paclitaxel in patients with Her2-negative high risk breast cancer - IJBNeoEndoTAG-1 | EUCTR2011-002985-19-BE |
| Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer | A Phase I Dose-Escalation Study Evaluating the Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer | NCT01423123 |
| Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer | A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy | NCT00108745 |
| ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems | An Early Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Patients With Hepatic or Renal Dysfunction and Solid Tumors | NCT01419548 |
| Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma | NCT00110019 |
| ABI-007 (Nab-Paclitaxel) and Gemcitabine in Treating Women With Metastatic Breast Cancer | Phase II Trial of Weekly Nab (Nanoparticle Albumin Bound)-Paclitaxel (Nab-paclitaxel) (Abraxane®) in Combination With Gemcitabine in Patients With Metastatic Breast Cancer | NCT00110084 |
| Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer | A Phase 2 Study of Neoadjuvant Chemotherapy With Sequential Weekly Nanoparticle Albumin Bound Paclitaxel (Abraxane) Followed by 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) in Locally Advanced Breast Cancer | NCT00110695 |
| A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma | Phase III Randomized, Placebo Controlled Study of Sorafenib in Repeated Cycles of 21 Days in Combination With Paclitaxel/Carboplatin Chemotherapy in Subjects With Unresectable Stage III or Stage IV Melanoma. | NCT00111007 |
| """A clinical study comparing the effects of chemotherapy plus Avastin to chemotherapy plus Avastin plus a new drug (MEGF0444A) in patients with non-small cell lung cancer who have not received chemotherapy before""" | A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF MEGF0444A IN COMBINATION WITH CARBOPLATIN, PACLITAXEL ANDBEVACIZUMAB IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR ADVANCED DISEASE | EUCTR2011-000711-85-CZ |
| A Two-Part, Open Label Phase II Trial: Part One, Dose Escalation Safety; Part Two, Randomized/Comparing CDP791 (10 or 20 mg/kg) Plus Carboplatin/Paclitaxel With Carboplatin/Paclitaxel Alone in Subjects With Locally Advanced or Metastatic (Stage IIIb With Pleural Effusion or Stage IV) Non-Squamous Non-Small-Cell Lung Cancer | A Two-Part, Open Label Phase II Trial: Part One, Dose Escalation Safety; Part Two, Randomized/Comparing CDP791 (10 or 20 mg/kg) Plus Carboplatin/Paclitaxel With Carboplatin/Paclitaxel Alone in Subjects With Locally Advanced or Metastatic (Stage IIIb With Pleural Effusion or Stage IV) Non-Squamous Non-Small-Cell Lung Cancer | EUCTR2005-001731-30-HU |
| Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer | A Phase II Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of Lapatinib in Combination With Paclitaxel as Neoadjuvant Therapy in Patients With Newly Diagnosed Inflammatory Breast Cancer | NCT00111787 |
| Paclitaxel in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer | Phase II Clinical Trial of Genexol -PM in Patients With Advanced Pancreatic Cancer | NCT00111904 |
| Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer | A Phase II Evaluation of Paclitaxel (Taxol, NSC # 673089) and Carboplatin (Paraplatin, NSC #241240) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma | NCT00112489 |
| Safety and Effectiveness of Combretastatin A-4 Phosphate Combined With Chemotherapy in Advanced Solid Tumors | A Randomized Open-Labeled Phase II Study of Combretastatin A-4 Phosphate in Combination With Paclitaxel and Carboplatin to Evaluate the Safety and Efficacy in Subjects With Advanced Imageable Malignancies | NCT00113438 |
| The influences of paclitaxel, calcitriol and cinacalcet on hemodialysis patients with CKD-MBD in real-world | The influences of paclitaxel, calcitriol and cinacalcet on hemodialysis patients with CKD-MBD in real-world | ChiCTR1900026679 |
| A Phase II study to evaluate the efficacy, safety and pharmacodynamics of lapatinib in combination with paclitaxel as neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer - Lapatinib combined with paclitaxel in newly diagnosed inflammatory breast cancer (IBC) | A Phase II study to evaluate the efficacy, safety and pharmacodynamics of lapatinib in combination with paclitaxel as neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer - Lapatinib combined with paclitaxel in newly diagnosed inflammatory breast cancer (IBC) | EUCTR2004-001905-93-GB |
| A Study of Carboplatin/Paclitaxel With Pegfilgrastim Supported by Haematopoietic Progenitor Cell Re-Infusion in Whole Blood | An Open-Label, Randomised Study of Multi-Cycle, Dose Intensive Carboplatin/Paclitaxel With Pegfilgrastim Supported by Haematopoietic Progenitor Cell Re-Infusion in Whole Blood | NCT00117442 |
| Phase III Randomized Adjuvant Study of Chemotherapy in Node Positive Breast Cancer Patients -AC(Anthracycline-Cyclophosphamide) 4 cycles followed by Taxane 4 cycles (AC-Tac) versus Taxane 8 cycles and Paclitaxel versus Docetaxel- | Phase III Randomized Adjuvant Study of Chemotherapy in Node Positive Breast Cancer Patients -AC(Anthracycline-Cyclophosphamide) 4 cycles followed by Taxane 4 cycles (AC-Tac) versus Taxane 8 cycles and Paclitaxel versus Docetaxel- - Phase III Randomized Adjuvant Study of chemotherapy in Node Positive Breast Cancer Patients (N-SAS BC 02) | JPRN-C000000055 |
| Intra-Individual Comparison of Sirolimus and Paclitaxel Coated Stent (FRE-RACE Study) | A Prospective, Randomized Intra-Individual Study With the Sirolimus Coated Cypher Select(TM) and the Paclitaxel(TM) Coated Express Balloon Expandable Stents for the Treatment of Patients With Two de Novo Native Coronary Artery Lesions. | NCT00130546 |
| FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients | Multicenter Randomized Phase III Trial to Compare 6 FAC Cycles vs 4 FAC Cycles Followed by 8 Weekly Paclitaxel Administrations, as Adjuvant Treatment for Node Negative Operable Breast Cancer Patients | NCT00129389 |
| Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer | Phase III Study to Compare 6 Courses of FEC (Fluorouracil, Epirubicin and Cyclophosphamide) vs. 4 Courses of FEC Followed by 8 Weekly Paclitaxel Administrations, as Adjuvant Treatment for Node Positive Operable BC Patients | NCT00129922 |
| Carboplatin Taxol Avastin in Ovarian Cancer (OVCA) | Phase II Evaluation of Carboplatin, Paclitaxel and Bevacizumab as First Line Chemotherapy and Consolidation for Advanced Ovarian Cancer | NCT00129727 |
| Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal Junction | A Phase II Trial of PS-341 in Combination With Paclitaxel and Carboplatin for Metastatic Adenocarcinoma of the Lower Esophagus, Gastroesophageal Junction, and Gastric Cardia | NCT00107341 |
| Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients | Phase II Pharmacogenomic and Clinical Trial for the Administration of Gemcitabine-doxorubicin-paclitaxel (GAT) as Neoadjuvant Treatment of Patients With Stage III Breast Cancer | NCT00128856 |
| Weekly maintainance therapy with Paclitaxel vs control arm after first line chemotherapy in patients with metastatic breast carcinoma. Phase III multicentric clinical trial. | Weekly maintainance therapy with Paclitaxel vs control arm after first line chemotherapy in patients with metastatic breast carcinoma. Phase III multicentric clinical trial. | EUCTR2004-004031-59-IT |
| Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis | A Phase I/II Safety Trial of Intracoronary Administration of Systemic Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis | NCT00124943 |
| Comparing Two Chemotherapy Treatments for Late Relapse of Ovarian Cancer: A Global Study | A Multi-National, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX®) and Carboplatin vs. Paclitaxel and Carboplatin in Patients with Epithelial Ovarian Cancer in Late Relapse - Calypso study | EUCTR2004-004456-39-AT |
| A Phase I/II Safety, Pharmacodynamic, and Pharmacokinetic Study of Intravenously Administered PXD101 Plus Carboplatin or Paclitaxel or Both in Patients with Advanced Solid Tumours - PXD101-040-EU Global V4 | A Phase I/II Safety, Pharmacodynamic, and Pharmacokinetic Study of Intravenously Administered PXD101 Plus Carboplatin or Paclitaxel or Both in Patients with Advanced Solid Tumours - PXD101-040-EU Global V4 | EUCTR2005-002338-36-GB |
| Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer | Phase II Feasibility Trial Incorporating Bevacizumab Into Dose Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Patients With Lymph Node Positive Breast Cancer | NCT00119262 |
| Integration of 3D-conformal, local radiotherapy (3DCRT) to metastatic sites in a paclitaxel weekly chemotherapy regimen in oligometastatic breast cancer patients: A phase I- and randomised phase II-study | Integration of 3D-conformal, local radiotherapy (3DCRT) to metastatic sites in a paclitaxel weekly chemotherapy regimen in oligometastatic breast cancer patients: A phase I- and randomised phase II-study | ISRCTN97281381 |
| Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer | A Phase II Randomized Study of OSI-774 (Erlotinib) (NSC #718781) With or Without Carboplatin/Paclitaxel in Patients With Previously Untreated Adenocarcinoma of the Lung Who Never Smoked or Were Former Light Smokers | NCT00126581 |
| Drug-eluting-stents for Unprotected Left Main Stem Disease (ISAR-LEFT-MAIN) | Prospective, Randomized Trial of the Sirolimus-Eluting Stent and Paclitaxel-Eluting Stent for the Treatment of Unprotected Left Main Coronary Artery Disease(ISAR-LEFT-MAIN) | NCT00133237 |
| Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons (PACCOCATH - ISR I) | Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons | NCT00106587 |
| A PHASE 2 MULTICENTER EVALUATION OF THE SAFETY AND EFFICACY OF TOCOSOL ® PACLITAXEL (S-8184 PACLITAXEL INJECTABLE EMULSION) IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED, UNRESECTABLE TRANSITIONAL CELL CARCINOMA OF THE UROTHELIUM | A PHASE 2 MULTICENTER EVALUATION OF THE SAFETY AND EFFICACY OF TOCOSOL ® PACLITAXEL (S-8184 PACLITAXEL INJECTABLE EMULSION) IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED, UNRESECTABLE TRANSITIONAL CELL CARCINOMA OF THE UROTHELIUM | EUCTR2004-003055-40-GB |
| Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer | A Phase II Study of Weekly Dose-Dense Nanoparticle Paclitaxel (ABI-007), Carboplatin With Herceptin® As First-Line Therapy of Advanced HER-2 Positive Breast Cancer | NCT00093145 |
| A Safety Study of ABI-007 for In-Stent Restenosis | A Phase II Safety Study of Systemic Nanoparticle Paclitaxel (ABI-007)for In-Stent Restenosis | NCT00093223 |
| Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer | A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed By DD Paclitaxel (DD AC?P); DD AC Followed By DD Paclitaxel Plus Gemcitabine (DD AC?PG) | NCT00093795 |
| Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) | A Multi-arm Phase I Safety Study of Nivolumab in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) | NCT01454102 |
| Phase II Study of Primary Chemotherapy with Anthracycline-based Regimen Followed by Nab-paclitaxel and Trastuzumab in Patients with HER2 Positive Breast Cancer | Phase II Study of Primary Chemotherapy with Anthracycline-based Regimen Followed by Nab-paclitaxel and Trastuzumab in Patients with HER2 Positive Breast Cancer - Primary Chemotherapy with Anthracycline Followed by Nab-paclitaxel and Trastuzumab | JPRN-UMIN000006288 |
| Epirubicin and Paclitaxel, Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer | Treatment With the Combination of Epirubicin and Paclitaxel Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer. A Multicenter, Randomized Phase III Study | NCT01433614 |
| Phase II study of trastuzumab and paclitaxel in patients with HER2 positive (IHC 3+, IHC 2+ and FISH +) previously treated advanced or recurrent gastric cancer | JPRN-UMIN000006223 | |
| Efficacy and safety of AZD4547 versus paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer patients | A Randomised Open-Label Phase II Study to Assess the Efficacy & Safety of AZD4547 Monotherapy versus Paclitaxel in Patients with Advanced Gastric Adenocarcinoma (inc. Adenocarcinoma of the Lower Third of the Oesophagus or the Gastro-Oesophageal Junction) with FGFR2 Polysomy or Gene Amplification (Shine study) - SHINE | EUCTR2010-023377-19-GB |
| Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer | Multicenter, Randomized, Open-label Phase II Study to Compare the Efficacy and Safety of Trastuzumab and Paclitaxel Based Regimen Plus Carboplatin or Epirubicin as Neoadjuvant Therapy in HER2-positive Breast Cancer Patients | NCT01428414 |
| Weekly Paclitaxel and Trastuzumab in Metastatic Breast Cancer | Weekly Application of Trastuzumab and Paclitaxel in the Treatment of HER2-overexpressing Metastatic Breast Cancer | NCT01423695 |
| A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer | A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer | NCT01421472 |
| Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer | Phase I/II Study of PS-341 in Combination With Paclitaxel, Carboplatin, and Concurrent Thoracic Radiation Therapy for Non-small Cell Lung Cancer (NSCLC) | NCT00093756 |
| Phase II Trial of Dose-Dense Paclitaxel and Cisplatin as Neo-Adjuvant Chemotherapy for Operable Stage II and IIIA Non-Small Cell Lung Cancer - not available | Phase II Trial of Dose-Dense Paclitaxel and Cisplatin as Neo-Adjuvant Chemotherapy for Operable Stage II and IIIA Non-Small Cell Lung Cancer - not available | EUCTR2004-000804-41-HU |
| Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | An Open-label, Dose-finding Study to Evaluate the Safety and Pharmacokinetics (PK) of AMG 706 With Carboplatin/Paclitaxel, AMG 706 With Panitumumab and AMG 706 With Panitumumab and Carboplatin/Paclitaxel in the Treatment of Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC) | NCT00094835 |
| Paclitaxel and ABI-007 in Treating Patients With Locally Advanced or Metastatic Solid Tumors | Randomized, Crossover, Pharmacokinetic Study Of Paclitaxel (Taxol) And ABI-007 (A Cremophor EL-Free, Protein Stabilized, Nanoparticle Paclitaxel) In Patients With Advanced Solid Tumors | NCT00095914 |
| Randomized Amifostine For SCCHN | Phase II, Randomized Study of Concomitant Chemoradiation Using Weekly Carboplatinum/Paclitaxel With (Arm A) or Without (Arm B) Daily Subcutaneous Amifostine in Patients With Newly Diagnosed Locally Advanced Squamous Cell Cancer of the Head and Neck | NCT00095927 |
| GEMZAR AS PROLONGED INFUSION IN COMBINATION WITH PACLITAXEL IN ANTHRACYCLINE PRETREATED METASATTIC BREAST CANCER | GEMZAR AS PROLONGED INFUSION IN COMBINATION WITH PACLITAXEL IN ANTHRACYCLINE PRETREATED METASATTIC BREAST CANCER | EUCTR2004-003999-11-IT |
| AN OPEN LABEL, RANDOMISED, PHASE II STUDY OF AS1404 IN COMBINATION WITH CARBOPLATIN AND PACLITAXEL IN PATIENTS WITH PLATINUM-SENSITIVE RECURRENT OVARIAN EPITHELIAL CANCER - Not available | AN OPEN LABEL, RANDOMISED, PHASE II STUDY OF AS1404 IN COMBINATION WITH CARBOPLATIN AND PACLITAXEL IN PATIENTS WITH PLATINUM-SENSITIVE RECURRENT OVARIAN EPITHELIAL CANCER - Not available | EUCTR2004-004375-11-GB |
| Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer | Phase I of Phase I/II Randomized Study of Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer | NCT00102622 |
| S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer | A Phase II Study of Biweekly Gemcitabine and Paclitaxel (GEMTAX) Combination in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) | NCT00100789 |
| Comparison of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) and Taxol® Pharmacokinetics in Patients With Advanced Cancer | A Randomized Two-Period Crossover, Clinical Bioequivalence Study Comparing the Pharmacokinetics of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) Formulation Versus Taxol® in Patients With Advanced Cancer | NCT00100139 |
| Carboplatin + paclitaxel vs carboplatin + stealth liposomal doxorubicin. A randomised multicentre trial. | Carboplatin + paclitaxel vs carboplatin + stealth liposomal doxorubicin. A randomised multicentre trial. | EUCTR2004-002399-40-DK |
| A multicentre phase I-II study to investigate the combination of bendamustine with weekly paclitaxel as first or second line therapy in patients with metastatic breast cancer - Rita | A multicentre phase I-II study to investigate the combination of bendamustine with weekly paclitaxel as first or second line therapy in patients with metastatic breast cancer - Rita | EUCTR2004-004880-31-DE |
| Evaluation of Safety and Efficacy of TOCOSOL(R) Paclitaxel as Initial Treatment for Metastatic Breast Cancer | A Phase 2 Multicenter Evaluation of the Safety and Efficacy of TOCOSOL(R) Paclitaxel (S-8184 Paclitaxel Injectable Emulsion) as Initial Treatment of Patients With Metastatic Breast Cancer | NCT00096668 |
| Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer | A Phase II Trial Of Neoadjuvant Therapy With Concurrent Chemotherapy And High Dose Radiotherapy Followed By Surgical Resection And Consolidative Therapy For Locally Advanced Non-Small Cell Lung Carcinoma | NCT00096226 |
| Paclitaxel and Carboplatin in Treating Women Who Are Undergoing Surgery for Newly Diagnosed, Locally Advanced Breast Cancer | A Phase II Trial of Pre-Operative Taxol and Carboplatin in Women With Newly Diagnosed Locally Advanced Operable Breast Cancer | NCT00096343 |
| Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | A Phase II Trial Of BAY 43-9006, A Novel Raf Kinase Inhibitor Plus Paclitaxel/Carboplatin In Women With Recurrent Platinum Sensitive Epithelial Ovarian, Peritoneal Or Fallopian Tube Cancer | NCT00096200 |
| Neoadjuvant Chemotherapy Using Doxorubicin and Paclitaxel in Treating Women With Large Breast Cancer | Neoadjuvant Chemotherapy in Palpable Breast Cancer: Evaluation of Physiologic, Radiologic, and Molecular Markers in Predicting Response | NCT00096291 |
| Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) | A Randomized Phase II Trial of Two Dose Schedules of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-small Cell Lung Cancer | NCT00097227 |
| Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer | Cisplatin Induction Followed by Paclitaxel Consolidation for the Treatment of Stage III and IV Epithelial Ovarian Cancer and Primary Peritoneal Cancer With In Vitro Correlates of Response | NCT00314678 |
| Efficacy Study of Gemcitabine-Paclitaxel to Treat Metastatic Breast Cancer | Phase II Study of Gemcitabine-Paclitaxel 3-Weekly Schedule as First-Line Treatment in Metastatic Breast Cancer After Anthracycline Failure | NCT00316199 |
| Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients | Phase I/II Lapatinib Plus Carboplatin and Paclitaxel in Stage III or IV Relapsed Ovarian or Stage IV Breast Cancer Patients | NCT00316407 |
| Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire | A Multicenter Prospective Phase II Study Evaluating Peripheral Neurotoxicity by Using FACT-GOG/NTX Questionnaire in Patients With Ovarian Cancer in Relapse Treated by Paclitaxel +/- EPO. Validation of a French Version of This Questionnaire | NCT00517621 |
| Phase I study of Cisplatin, gemcitabin (+ paclitaxel) and lapatinib as first line treatment in advanced/metastatic urothelial cancer | Phase I study of Cisplatin, gemcitabin (+ paclitaxel) and lapatinib as first line treatment in advanced/metastatic urothelial cancer - EORTC protocol 30061 | NL-OMON31194 |
| A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056) | A Phase II/III Randomized, Double-Blind Study of Paclitaxel Plus Carboplatin in Combination With Vorinostat or Placebo in Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small-Cell Lung Cancer (NSCLC) | PER-050-07 |
| A Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Advanced Breast Cancer (VICTORIA) | Phase III Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Unresectable, Locally Recurrent or Metastatic Breast Cancer After Prior Anthracycline-based Adjuvant Chemotherapy | PER-057-07 |
| Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors | A Randomized Phase II Trial of Avastin (A) or Avastin and Erlotinib (AE) as First Line Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Newly Diagnosed Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors | NCT00520013 |
| Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma | A Randomized, Double-blind, Phase 3 Trial of Elesclomol (STA-4783) in Combination With Paclitaxel Versus Paclitaxel Alone for Treatment of Chemotherapy-Naïve Subjects With Stage IV Metastatic Melanoma (SYMMETRY) | NCT00522834 |
| Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy. | Phase II Randomized Trial of Neoadjuvant Trastuzumab and/or Lapatinib Plus Chemotherapy (Sequential FEC75 and Paclitaxel) in Women With ErbB2- (HER2/Neu-) Overexpressing Invasive Breast Cancer | NCT00524303 |
| "A phase II trial of carboplatin and paclitaxel compared with carboplatin or gemcitabine paclitaxel ""induction"" followed by carboplatin/paclitaxel/gemcitabine in patients with suboptimally resected stage III or IV ovarian carcinoma - ND" | "A phase II trial of carboplatin and paclitaxel compared with carboplatin or gemcitabine paclitaxel ""induction"" followed by carboplatin/paclitaxel/gemcitabine in patients with suboptimally resected stage III or IV ovarian carcinoma - ND" | EUCTR2006-000126-31-IT |
| Carboplatin, Paclitaxel, Selenomethionine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery | Concurrent Carboplatin, Paclitaxel and Selenomethionine in Combination With Radiation for Patients With Unresectable Stage III Non-Small Cell Lung Cancer: A Phase II, Multi-Center Trial | NCT00526890 |
| Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) | A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination With Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer | NCT00527735 |
| A Phase 1 / 2 Study of HKI-272 in combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer - study 203 | A Phase 1 / 2 Study of HKI-272 in combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer - study 203 | EUCTR2006-006412-29-BE |
| Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell Cancer | Phase II Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell Cancer | NCT00531687 |
| Primary Paclitaxel Plus Gemcitabine in Patients With Stage II and III Breast Cancer | Phase II Study of Primary Paclitaxel Plus Gemcitabine in Patients With Stage II and III Breast Cancer | NCT00532285 |
| Phase II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Trastuzumab | Phase II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Trastuzumab in Patients With HER2 Positive Operable Breast Cancer | NCT00532857 |
| Prevention of Restenosis Following Revascularization | A Phase II Trial of ABI-007 (Paclitaxel Albumin-bound Particles) for the Prevention of Restenosis Following Revascularization of the Superficial Femoral Artery (SFA) | NCT00518284 |
| BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC) | Phase I Dose-Escalating, Open-Label, Non-Placebo Controlled Study of BAY 43-9006 (Sorafenib) in Combination With Carboplatin, Paclitaxel and Bevacizumab in Previously Untreated Patients With Stage IIIB (With Malignant Pleural Effusions) or Stage IV Non-Small Cell Lung Cancer (NSCLC) | NCT00533585 |
| Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer | A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by Ixabepilone Compared to Sequential AC Followed by Paclitaxel in Women with Early Stage Breast Cancer Not Overexpressing HER-2 and Estrogen Receptors. | PER-042-07 |
| Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer | A Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Advanced Solid Malignancies | NCT00535119 |
| Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer | Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study | NCT00537173 |
| Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer | A Randomized, Double-Blind, Phase 2 Trial of Paclitaxel Plus Bevacizumab and Enzastaurin Versus Paclitaxel Plus Bevacizumab and Placebo for Locally Recurrent or Metastatic Breast Cancer | NCT00536939 |
| Multi-national, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse. (CALYPSO) | Multi-national, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse. (CALYPSO) | NCT00538603 |
| Phase I/II Study of AZD2171 in Combination With Paclitaxel/Carboplatin in Japanese Non-Small Cell Lung Cancer Patients | A Two-Part Study in Japanese Patients With Advanced or Metastatic NSCLC. Open-Label Phase I to Assess the Safety & Tolerability of AZD2171 in Combination With Pac/Carb, Then a Phase II, Randomised, Double-Blind Study to Assess the Efficacy of Pac/Carb Alone and in Combination With AZD2171 and Pac/Carb | NCT00539331 |
| Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer | A Randomized, Phase III Trial of ABI-007 and Carboplatin Compared With Taxol and Carboplatin as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | NCT00540514 |
| Paclitaxel-Eluting PTCA-Balloon in Combination with the CoroflexTM Blue Stent vs the Sirolimus Coated CypherTM Stent in the Treatment of Advanced Coronary Artery Disease Clnical investigational plan, version 18, 16 october 2006. | Paclitaxel-Eluting PTCA-Balloon in Combination with the CoroflexTM Blue Stent vs the Sirolimus Coated CypherTM Stent in the Treatment of Advanced Coronary Artery Disease Clnical investigational plan, version 18, 16 october 2006. - PEPCAD III | NL-OMON31372 |
| Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer | A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer | NCT00542451 |
| Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC | A Phase I/II Study of Nab-Paclitaxel and Carboplatin With Concurrent Radiation Therapy for Unresectable Stage III Non-Small-Cell Lung Cancer (NSCLC) | NCT00544648 |
| Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer | A Pilot Study of Adjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel Plus Sorafenib in Women With Node Positive or High-Risk Early Stage Breast Cancer | NCT00544167 |
| Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE) | Randomized Comparison of a Preoperative, Dose-Intensified, Interval-Shortened, Sequential Chemotherapy With Epirubicin, Paclitaxel and CMF ± Darbepoetin Alfa Versus a Preoperative, Sequential Chemotherapy With Epirubicin and Cyclophosphamide Followed by Paclitaxel in Standard Dosage ± Darbepoetin Alfa in Patients With Primary Breast Cancer | NCT00544232 |
| Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer | A Phase II Study of Preoperative Dose-dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel (T) With Bevacizumab in ER+ and/or PR+, HER2-negative Operable Breast Cancer | NCT00546156 |
| High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery | A Randomized Phase III Comparison of Standard-Dose (60 Gy) Versus High-Dose (74 Gy) Conformal Radiotherapy With Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab (IND #103444) in Patients With Stage IIIA/IIIB Non-Small Cell Lung Cancer | NCT00533949 |
| Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel | A Phase I, Open-Label Study to Assess the Safety and Tolerability of KU-0059436 in Combination With Carboplatin, KU-0059436 in Combination With a Paclitaxel/Carboplatin T/C Doublet and KU-0059436 in Combination With Paclitaxel in the Treatment of Patients With Advanced Solid Tumours | NCT00516724 |
| PHASE II TRIAL OF PACLITAXEL, GEMCITABINE AND CISPLATIN IN PATIENTS WITH RELAPSING GERM CELL CANCER AFTER FIRST LINE CHEMOTHERAPY - relapse cis-tax-gem | PHASE II TRIAL OF PACLITAXEL, GEMCITABINE AND CISPLATIN IN PATIENTS WITH RELAPSING GERM CELL CANCER AFTER FIRST LINE CHEMOTHERAPY - relapse cis-tax-gem | EUCTR2007-000618-35-NL |
| Papillary Serous Carcinoma of the Endometrium | A Phase II Study: Paclitaxel and Pelvic Radiation for Stage I-IIIA Papillary Serous Carcinoma of the Endometrium | NCT00515073 |
| NeoALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) study A randomized, multicentre open-label phase III study of neoadjuvant lapatinib, trastuzumab and their combination plus paclitaxel in women with HER2/ErbB2 positive primary breast cancer. | A randomised, multicentre, open-label, phase III study of neoadjuvant lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2/ErbB2 positive primary breast cancer - NeoALTTO | EUCTR2006-000564-81-DE |
| Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery | Phase II Study in Operable Adenocarcinoma of the Esophagus to Measure Response Rate and Toxicity of Preoperative Combined Modality Paclitaxel (Taxol®, Bristol-Myers Squibb), Cisplatin (Platinol®, Abbott Laboratories), ZD1839 (IRESSA®) and Radiotherapy Followed by Postoperative ZD1839 | NCT00493025 |
| INTRAPLEURAL PACLITAXEL IN PATIENTS WITH MALIGNANT PLEURAL EFFUSIONS SECONDARY TO OVARIAN CANCER AND OTHER NEOPLASMS - ND | INTRAPLEURAL PACLITAXEL IN PATIENTS WITH MALIGNANT PLEURAL EFFUSIONS SECONDARY TO OVARIAN CANCER AND OTHER NEOPLASMS - ND | EUCTR2007-003664-22-IT |
| Capecitabine plus paclitaxel with sequential capecitabine alone as the firstline therapy in the treatment of recurrent and late gastric cancer | Capecitabine plus paclitaxel with sequential capecitabine alone as the firstline therapy in the treatment of recurrent and late gastric cancer | ChiCTR-TNC-07000014 |
| A Randomized, Double-Blind, Phase III Trial of STA-4783 in Combination with Paclitaxel versus Paclitaxel Alone for Treatment of Chemotherapy-Naïve Subjects with Stage IV Metastatic Melanoma | A Randomized, Double-Blind, Phase III Trial of STA-4783 in Combination with Paclitaxel versus Paclitaxel Alone for Treatment of Chemotherapy-Naïve Subjects with Stage IV Metastatic Melanoma | EUCTR2007-001421-10-BE |
| Phase II randomized trial of combination therapy of paclitaxel and bevacizumab versus paclitaxel, capecitabine and bevacizumab as first-line treatment for locally recurrent or metastatic breast cancer patients with HER2/neu negative tumor (ATX-study) - ATX | Phase II randomized trial of combination therapy of paclitaxel and bevacizumab versus paclitaxel, capecitabine and bevacizumab as first-line treatment for locally recurrent or metastatic breast cancer patients with HER2/neu negative tumor (ATX-study) - ATX | EUCTR2006-006058-83-NL |
| Phase I Study in Patients With Solid Tumours | A Phase I, Open-label Study to Assess the Safety and Tolerability of AZD0530 in Combination With Carboplatin and/or Paclitaxel Chemotherapy in Patients With Solid Tumours | NCT00496028 |
| Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer | Open Label Randomized Clinical Trial of Standard Neoadjuvant Chemotherapy (Paclitaxel Followed by FEC) Versus the Combination of Paclitaxel and RAD001 Followed by FEC in Women With Triple Receptor-Negative Breast Cancer (CRAD001C24101) | NCT00499603 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT00499252 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors | Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Study of Nab-Paclitaxel (Nanoparticle Albumin Bound-Paclitaxel) in Patients With Advanced Solid Tumors | NCT00499291 |
| Paclitaxel, Cyclophosphamide, and Doxorubicin Followed by Autologous Dendritic Cells and Surgery With or Without Radiation Therapy and/or Hormone Therapy in Treating Women With Stage II or Stage III Breast Cancer | Neoadjuvant Intratumoral Injection of Dendritic Cells in Breast Cancer Translation of Biotechnology Into the Clinic | NCT00499083 |
| Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer | A Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Breast Cancer | NCT00499525 |
| Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus | A Phase II Multicenter Trial of Paclitaxel and Carboplatin in Women With Advanced (IIIb, IIIc, IVa and IVb) or Recurrent (All Stages) Malignant Mixed Mullerian Tumors (MMMT) of the Uterus | NCT00502203 |
| Malignant Mixed Mesodermal Tumor (MMMT) - Early Stage With Postoperative XRT/Chemotherapy | A Phase II Study of Adjuvant Postoperative Radiation With Cisplatin Followed by Carboplatin/Paclitaxel Chemotherapy Following Total Abdominal Hysterectomy/Bilateral Salpino-Oophorectomy (TAH/BSO) for Patients With Stage I, II and IIIa Malignant Mixed Mesodermal Tumor (MMMT) of the Uterus. | NCT00505492 |
| Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma | A Phase I/II Study of Gleevec/Taxol in Patients With Newly Diagnosed Stage IIIC or IV or Recurrent (Any Stage) Uterine Papillary Serous Carcinoma (UPSC) | NCT00506779 |
| Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer | A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Maleate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer | NCT00513695 |
| Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer | A Phase 1 Study of BAY80-6946 (Phosphatidylinositol 3?-Kinase Inhibitor) in Combination With Paclitaxel in Subjects With Advanced Solid Malignancy | NCT01411410 |
| PHASE II STUDY ON PACLITAXEL-GEMCITABINE IN RECURRENT OVARIAN CANCER | PHASE II STUDY ON PACLITAXEL-GEMCITABINE IN RECURRENT OVARIAN CANCER | EUCTR2004-004845-17-IT |
| Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma | A Phase II Study of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma | NCT00513786 |
| A PHASE 3 STUDY OF SU011248 IN COMBINATION WITH PACLITAXEL VERSUS BEVACIZUMAB WITH PACLITAXEL IN THE FIRST-LINE ADVANCED DISEASE SETTING IN PATIENTS HAVING BREAST CANCER | A PHASE 3 STUDY OF SU011248 IN COMBINATION WITH PACLITAXEL VERSUS BEVACIZUMAB WITH PACLITAXEL IN THE FIRST-LINE ADVANCED DISEASE SETTING IN PATIENTS HAVING BREAST CANCER | EUCTR2007-002969-12-DE |
| Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery | A Randomized Phase III Trial Comparing a Neoadjuvant Regimen of FEC-75 Followed by Paclitaxel Plus Trastuzumab With a Neoadjuvant Regimen of Paclitaxel Plus Trastuzumab Followed by FEC-75 Plus Trastuzumab in Patients With HER-2 Positive Operable Breast Cancer | NCT00513292 |
| Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer | A Randomized Phase I/II Study Of Sorafenib In Combination With High Does Chemoradiation In Patients With Stage IIIA/B Non-small Cell Lung Cancer (NSCLC) | NCT00547443 |
| Study Of SU011248 In Combination With Paclitaxel/Carboplatin In Patients With Advanced Solid Tumors | Phase I Study Of SU011248 In Combination With Paclitaxel/Carboplatin In Patients With Advanced Solid Malignancies | NCT00511849 |
| Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer | Phase II Study of Paclitaxel (TAXOL), Intraperitoneal Cisplatin and IV Avastin Followed by Avastin Consolidation for Advanced Ovarian and Peritoneal Carcinoma or Fallopian Tube Cancer | NCT00511992 |
| Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients | A Randomized, 4-Arm, Placebo-Controlled Phase 2 Trial of AMG 386 in Combination With Bevacizumab and Paclitaxel or AMG 386 Plus Paclitaxel as First-Line Therapy in Subjects With Her2-Negative, Metastatic or Locally Recurrent Breast Cancer | NCT00511459 |
| NeoALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) study A randomized, multicentre open-label phase III study of neoadjuvant lapatinib, trastuzumab and their combination plus paclitaxel in women with HER2/ErbB2 positive primary breast cancer. | A randomised, multicentre, open-label, phase III study of neoadjuvantlapatinib, trastuzumab, and their combination plus paclitaxel in womenwith HER2/ErbB2 positive primary breast cancer - NeoALTTO | EUCTR2006-000564-81-LT |
| A multicenter, open-label, randomized, phase II/III study to evaluate the safety and efficacy of combretastatin a-4 phosphate in combination with paclitaxel and carboplatin in comparison with paclitaxel and carboplatin against anaplastic thyroid carcinoma - N/A | A multicenter, open-label, randomized, phase II/III study to evaluate the safety and efficacy of combretastatin a-4 phosphate in combination with paclitaxel and carboplatin in comparison with paclitaxel and carboplatin against anaplastic thyroid carcinoma - N/A | EUCTR2007-002846-38-GB |
| Paclitaxel Administered by HAI to Patients With Advanced Cancer and Dominant Liver Involvement | Phase I Study of Paclitaxel Administered by Hepatic Artery Infusion to Patients With Advanced Cancer and Dominant Liver Involvement | NCT00508326 |
| Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer | A Phase II/III Study to Evaluate the Safety and Efficacy of Combretastatin A-4 Phosphate in Combination With Paclitaxel and Carboplatin in Comparison With Paclitaxel and Carboplatin Against Anaplastic Thyroid Carcinoma [FACT] | NCT00507429 |
| Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | Phase I Trial of Tandem Chemotherapy Cycles as Consolidation Therapy for High-Risk Epithelial Ovarian and Primary Peritoneal Cancer Utilizing Intraperitoneal Paclitaxel/IV Cyclophosphamide Followed by IV Topotecan/Intraperitoneal Cisplatin/IV Melphalan Using Hematopoietic Stem Cell Support | NCT00550784 |
| Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors | Phase I/II Multicentre Trial of Salvage Chemotherapy With Gem-TIP for Relapsed Germ Cell Cancer | NCT00551122 |
| Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048) | Randomized Phase II Multinational Trial to Evaluate the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy in Patients With HER2-positive Breast Cancer: Caelyx + Cyclophosphamide + Trastuzumab (C+C+H) or Doxorubicin + Cyclophosphamide (A+C), Each Followed by Paclitaxel + Trastuzumab (T+H) BACH | NCT00550771 |
| 2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab | A Randomized Phase III 2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab for the First-line Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Locally Recurrent or Metastatic Breast Cancer | NCT00600340 |
| A Phase 1/2 Study of CS7017, an Oral PPAR? Agonist, in Combination With Paclitaxel | A Phase 1/2 Study of CS7017, an Oral PPAR? Agonist, in Combination With Paclitaxel in Subjects With Advanced Anaplastic Thyroid Cancer | NCT00603941 |
| Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer | Phase II Study of Weekly Vinorelbine and Paclitaxel in Elderly Patients With Advanced Non-Small Cell Lung Cancer | NCT00602797 |
| Study of CP-751,871 in Combination With Carboplatin and Paclitaxel in Advanced Lung Cancer | Phase 1, Dose Escalation Study of CP-751,871 in Combination With Carboplatin and Paclitaxel in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer | NCT00603538 |
| Comparison of the Conor Sirolimus-eluting Coronary Stent to the Taxus Liberte Paclitaxel-eluting Coronary Stent in the Treatment of Coronary Artery Lesions | A Randomized, Multi-Center, Single-Blind Comparison of the Conor Cobalt Chromium Reservoir Based Stent With Sirolimus Elution Versus the TAXUS Liberte Paclitaxel-eluting Coronary Stent System in De Novo Native Coronary Artery Lesions | NCT00606333 |
| Pharmacokinetics Study of Liposomal Paclitaxel in Humans | A Clinical Trial to Compare the Pharmacokinetics of Two Formulations of Taxane, Paclitaxel Injection and Liposomal Paclitaxel, in Humans | NCT00606515 |
| Dose Finding Study Of CP-870,893, An Immune System Stimulating Antibody, In Combination With Paclitaxel And Carboplatin For Patients With Metastatic Solid Tumors | A Phase 1 Study Of CP- 870,893 In Combination With Paclitaxel And Carboplatin In Patients With Metastatic Solid Tumors | NCT00607048 |
| Phase II Study of Oxaliplatine-Paclitaxel in Patients With Metastatic Germ Cell Tumor Refractory to Cisplatin | Phase II Study of Combined Oxaliplatin and Paclitaxel for Metastatic Germ Cell Tumors | NCT00611962 |
| Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility | Pilot Study of Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in High-Risk Breast Cancer: Feasibility | NCT00617370 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer | Age-Related Changes in Nanoparticle Albumin Bound (Nab) Paclitaxel Pharmacokinetics and Pharmacodynamics | NCT00609791 |
| MnSOD (Esophageal Protectant) to Prevent Esophagitis During Radiation/Chemotherapy Treatment for Non-Small Cell Lung Cancer (NSCLC) | Chemotherapy (Paclitaxel and Carboplatin)and Thoracic Radiotherapy With Swallowed Manganese Superoxide Dismutase (MnSOD) Plasmid Liposome Protection in Patients With Locally Advanced Stage III Non-Small Cell Lung Cancer: A Phase I-II Study | NCT00618917 |
| A Study of Biweekly Gemcitabine, Paclitaxel, and Avastin in Patients With Metastatic Breast Cancer | A Phase II Trial of Biweekly Gemcitabine, Paclitaxel, and Avastin as Frontline Therapy for Metastatic Breast Cancer | NCT00618826 |
| Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting | A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting | NCT00618657 |
| Treatment of Bifurcation Lesions by SINGLE STENT and KISSing Balloon Trial | A Multi-center Trial to Evaluate Paclitaxel- and Sirolimus-eluting Stents in Provisional T-stenting With Kissing Balloon Technique in the Treatment of Bifurcation Lesions | NCT00798954 |
| Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer | A Multi-Institutional Double-Blind Phase II Study Evaluating Response and Surrogate Biomarkers to Carboplatin and Nab-Paclitaxel (CP) With or Without Vorinostat as Preoperative Chemotherapy in HER2-negative Primary Operable Breast Cancer | NCT00616967 |
| Paclitaxel and Carboplatin With or Without Nitroglycerin in Treating Patients With Previously Untreated Stage III or Stage IV Non-Small Cell Lung Cancer | A Phase II, Multinational and Multicenter, Randomized, Controlled Study of Paclitaxel and Carboplatin With vs Without Nitroglycerin in Patients With Untreated Advanced Non-small Cell Lung Cancer | NCT00616031 |
| Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix | A Phase II Evaluation of Bevacizumab and Paclitaxel in Patients With Recurrent Small Cell, Large Cell, and Neuroendocrine Tumors of the Cervix and Uterus | NCT00626561 |
| A phase II study of Conbination therapy of Carboplatin/Paclitaxel/Bavacizumab in previously untreated patients with StageIIIB/IV non-small cell lung cancer | A phase II study of Conbination therapy of Carboplatin/Paclitaxel/Bavacizumab in previously untreated patients with StageIIIB/IV non-small cell lung cancer - A phase II study of Conbination therapy of Carboplatin/Paclitaxel/Bavacizumab in previously untreated patients with StageIIIB/IV non-small cell lung cancer | JPRN-UMIN000006077 |
| Paclitaxel and Radiation Therapy in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer | A Pilot Study of Neoadjuvant Paclitaxel and Concurrent Radiation With Correlative Molecular Studies in Stage II/III Breast Cancer | NCT00647218 |
| A feasibility study of sequential Anthracycline-based regimen and Nab-Paclitaxel / Trastuzumab followed by Trastuzumab as postoperative adjuvant chemotherapy for Her2 positive breast cancer.(SBCCSG-22) | A feasibility study of sequential Anthracycline-based regimen and Nab-Paclitaxel / Trastuzumab followed by Trastuzumab as postoperative adjuvant chemotherapy for Her2 positive breast cancer.(SBCCSG-22) - Anthracycline, Nab-Paclitaxel and Trastuzumab in the adjuvant therapy of HER-2 positive breast cancer.(SBCCSG-22) | JPRN-UMIN000006085 |
| A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer | A Phase II Study to Assess the Safety and Efficacy of the Combination of Carboplatin, Paclitaxel, and Bevacizumab ± Combretastatin A4 Phosphate (CA4P) Followed by Bevacizumab ± CA4P in Subjects With Chemotherapy Naïve Stage IIIB/IV Non-Squamous Cell Histology Non-Small Cell Lung Cancer (NSCLC) | NCT00653939 |
| RANDOMIZED, OPEN LABEL, PHASE III TRIAL OF CP-751,871 IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN VERSUS PACLITAXEL AND CARBOPLATIN IN PATIENTS WITH NON-SMALL CELL LUNG CANCER - CP In Combo | RANDOMIZED, OPEN LABEL, PHASE III TRIAL OF CP-751,871 IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN VERSUS PACLITAXEL AND CARBOPLATIN IN PATIENTS WITH NON-SMALL CELL LUNG CANCER - CP In Combo | EUCTR2008-000345-55-FI |
| Dosisdichte 1st-line Therapie des metastasierten Mammakarzinoms mit Paclitaxel und liposomalem Doxorubicin (Myocet®) | Dosisdichte 1st-line Therapie des metastasierten Mammakarzinoms mit Paclitaxel und liposomalem Doxorubicin (Myocet®) | EUCTR2005-004234-41-DE |
| A Pilot Study of PPX in Women With Metastatic Colorectal Cancer | A Pilot Study of PPX (Paclitaxel Poliglumex, CT-2103) in Women With Metastatic Colorectal Cancer | NCT00598247 |
| Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric Carcinoma | A Phase I Clinical Trial to Investigate the Maximum Tolerated Dose and Pharmacokinetics of Liposomal Paclitaxel With/Without Capecitabine in Chinese Cancer Patients With Advanced Gastric Carcinoma. | NCT00639522 |
| Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin | Phase II Trial of Primary Systemic Therapy for Locally Advanced Breast Cancer Using Sequential Doxil, Paclitaxel, and Cyclophosphamide With Concurrent Avastin | NCT00635050 |
| Trial of E10A in Head and Neck Cancer | A Randomized Phase II Clinical Trial of an Adenovirus-mediated Endostatin Gene (E10A) Combined With Cisplatin and Paclitaxel in Patients With Head and Neck Cancer | NCT00634595 |
| Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery | A Randomized Phase II Trial of Temozolomide (TMZ) and Bevacizumab or ABI-007 (ABX)/Carboplatin (CBDCA) and Bevacizumab in Patients With Unresectable Stage IV Malignant Melanoma | NCT00626405 |
| Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer | Phase II Trial of Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer (With Trastuzumab in HER2 Positive Patients) | NCT00629499 |
| A feasibility study of Nab-Paclitaxel followed by Anthracycline-based regimen as adjuvant chemotherapy for breast cancer.(SBCCSG-21) | A feasibility study of Nab-Paclitaxel followed by Anthracycline-based regimen as adjuvant chemotherapy for breast cancer.(SBCCSG-21) - A feasibility study of Nab-Paclitaxel followed by Anthracycline-based regimen as adjuvant chemotherapy for breast cancer.(SBCCSG-21) | JPRN-UMIN000006084 |
| Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer | Phase II Trial of Sorafenib and Paclitaxel for Measurable Metastatic HER2-Negative Breast Cancer | NCT00622466 |
| A randomized phase III 2-arm trial of paclitaxel plus bevacizumab vs. capecitabine plus bevacizumab for the first-line treatment of HER2-negative locally recurrent or metastatic breast cancer | A randomized phase III 2-arm trial of paclitaxel plus bevacizumab vs. capecitabine plus bevacizumab for the first-line treatment of HER2-negative locally recurrent or metastatic breast cancer | EUCTR2007-005828-32-AT |
| Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis | Phase I Trial of Intraperitoneal Oxaliplatin and Paclitaxel Plus Intravenous Paclitaxel and Bevacizumab in the Treatment of Advanced Peritoneal Carcinomatosis | NCT00491855 |
| Efficacy Study of Two Different Strategies for Restenosis in Sirolimus-Eluting Stents | Randomized Trial of Paclitaxel- vs Sirolimus-eluting Stents for Treatment of Coronary Restenosis in Sirolimus-eluting Stents | NCT00598715 |
| Randomized phase II study of Valproic acid + weekly paclitaxel in unresectable advanced/recurrent gastric cancer | Randomized phase II study of Valproic acid + weekly paclitaxel in unresectable advanced/recurrent gastric cancer - Phase II study of valproic acid + weekly paclitaxel in gastric cancer | JPRN-UMIN000005887 |
| A Phase II Study of Capecitabine plus Paclitaxel Combination Chemotherapy in Patients with Metastatic Breast Cancer | A Phase II Study of Capecitabine plus Paclitaxel Combination Chemotherapy in Patients with Metastatic Breast Cancer - KBCSG 0609 XP PhaseII | JPRN-UMIN000000869 |
| Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer | Paclitaxel Poliglumex (CT-2103)/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer (NSCLC) in Women With Estradiol >30 pg/mL | NCT00551733 |
| Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study | Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study: A Randomised, Multicenter Open-label Phase III Study of Neoadjuvant Lapatinib, Trastuzumab and Their Combination Plus Paclitaxel in Women With HER2/ErbB2 Positive Primary Breast Cancer | NCT00553358 |
| Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery | A Phase II Study of Induction Chemotherapy Followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non-Small Cell Lung Cancer | NCT00553462 |
| Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer | Phase II Randomized Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced Non-small Cell Lung Cancer | NCT01413750 |
| LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors | A Phase I Study of LBH589 in Combination With Paclitaxel and Carboplatin +/- Bevacizumab the Treatment of Solid Tumors | NCT00556088 |
| A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC) | A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC) | NCT00558636 |
| Maintenance Versus Observation After 6 Cycles of Gemcitabine Plus Paclitaxel in Pts With Advanced Breast Cancer | Phase III, Multicenter, Randomized Trial of Maintenance Versus Observation After Achieving Clinical Response in Pts With Metastatic or Recurrent Breast Cancer Who Received 6 Cycles of Gemcitabine Plus Paclitaxel(GP) as 1st-line Chemotherapy | NCT00561119 |
| Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors | A Phase I/II, Open-Label, Multicenter, Two-Arm, Feasibility Study of Pazopanib, Carboplatin, and Paclitaxel in Women With Newly Diagnosed, Previously Untreated, Gynaecological Tumors | NCT00561795 |
| Phase II – Studie P-ICEHochdosischemotherapie mit Paclitaxel, Ifosfamid,Carboplatin und Etoposid mit autologem Stammzellsupport bei männlichen Patienten mit refraktären oder rezidivierten Keimzelltumoren | Phase II – Studie P-ICEHochdosischemotherapie mit Paclitaxel, Ifosfamid,Carboplatin und Etoposid mit autologem Stammzellsupport bei männlichen Patienten mit refraktären oder rezidivierten Keimzelltumoren | EUCTR2006-006004-11-DE |
| RANDOMIZED, MULTICENTER, OPEN, PHASE III,STUDY OF LAPATINIB, TRASTUZUMAB AND ITS COMBINATION IN NEOADYUVANCIA MORE PACLITAXEL IN WOMEN WITH PRIMARY BREAST CANCER HER2 / ERBB2 POSITIVE | RANDOMIZED, MULTICENTER, OPEN, PHASE III,STUDY OF LAPATINIB, TRASTUZUMAB AND ITS COMBINATION IN NEOADYUVANCIA MORE PACLITAXEL IN WOMEN WITH PRIMARY BREAST CANCER HER2 / ERBB2 POSITIVE | PER-089-07 |
| .A clinical trial to study the effects, (side effects and efficacy) of two combinations of chemotherapy drugs, (Paclitaxel, ifosfamide and Cisplatin) with (Paclitaxel, cisplatin and 5-FU) in patients with LocallyAdvanced Head and Neck Cancer | A Phase IIb RCT of Neoadjuvant chemotherapy comparing Paclitaxel, ifosfamide and Cisplatin with Paclitaxel, cisplatin and 5-FU in Patients with LocallyAdvanced Head and Neck (H&N) Cancer . - A Phase IIb RCT of Neoadjuvant chemotherapy comparing Paclitaxel, ifosfamide and Cisplatin with Paclitaxel, cisplatin and 5-FU in Patients with LocallyAdvanced Head and Neck (H&N) Cancer . | CTRI/2007/091/000013 |
| Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865) | NCT00565851 |
| Randomized study of docetaxel or weekly paclitaxel followed by 5FU + epirubicin + cyclophosphamide as preoperative chemotherapy for primary breast cancer | Randomized study of docetaxel or weekly paclitaxel followed by 5FU + epirubicin + cyclophosphamide as preoperative chemotherapy for primary breast cancer - Randomized study of docetaxel or weekly paclitaxel followed by 5FU + epirubicin + cyclophosphamide as preoperative chemotherapy for primary breast cancer(KBCOG-06) | JPRN-UMIN000000916 |
| Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma | Releasing the Cancer Patient's Immune System From Down-regulation With Timed Delivery of Standard Chemotherapy | NCT00568451 |
| A randomised study comparing placebo and a not yet approved drug CS1008, in combination with drugs Carboplatin and Paclitaxel in patients with non small cell lung cancer which has spread or can not be removed by surgery, who have not had chemotherapy treatment before. The study is double-blind (that is when neither the patient nor the investigator know which treatment the patient is receiving). | RANDOMISED, DOUBLE-BLINDED, PLACEBO- CONTROLLED PHASE 2 STUDY OF CS-1008 IN COMBINATION WITH CARBOPLATIN/PACLITAXEL IN CHEMOTHERAPY NAÏVE SUBJECTS WITH METASTATIC OR UNRESECTABLE NON-SMALL CELL LUNG CANCER | EUCTR2007-004574-11-DE |
| A PHASE 2, RANDOMIZED, MULTI-CENTER, OPEN-LABEL STUDY TOEVALUATE THE EFFICACY AND SAFETY OF MAPATUMUMAB ( [HGS1012], AFULLY HUMAN MONOCLONAL ANTIBODY TO TRAIL-R1) IN COMBINATIONWITH CARBOPLATIN AND PACLITAXEL AS FIRST LINE THERAPY INSUBJECTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) | A PHASE 2, RANDOMIZED, MULTI-CENTER, OPEN-LABEL STUDY TOEVALUATE THE EFFICACY AND SAFETY OF MAPATUMUMAB ( [HGS1012], AFULLY HUMAN MONOCLONAL ANTIBODY TO TRAIL-R1) IN COMBINATIONWITH CARBOPLATIN AND PACLITAXEL AS FIRST LINE THERAPY INSUBJECTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) | EUCTR2007-005153-32-DE |
| A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer. | Randomized Phase 2 Trial Of AG013736 Or Bevacizumab In Combination With Paclitaxel And Carboplatin As First Line Treatment For Patients With Advanced Non Small Cell Lung Cancer | NCT00600821 |
| Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology | Randomized, Open Label, Phase III Trial Of CP- 751,871 In Combination With Paclitaxel And Carboplatin Versus Paclitaxel And Carboplatin In Patients With Non Small Cell Lung Cancer | NCT00596830 |
| Randomzied Phase 2 Trial of AG-013736 or Bevacizumab in Combination with Paclitaxel and Carboplatin as First Line Treatment For Patients with Advanced Non-small Cell Lung Cancer | Randomzied Phase 2 Trial of AG-013736 or Bevacizumab in Combination with Paclitaxel and Carboplatin as First Line Treatment For Patients with Advanced Non-small Cell Lung Cancer | EUCTR2007-006682-33-GB |
| Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility | Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility | NCT00591851 |
| Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | A Phase II Study of Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | NCT00588237 |
| A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer | A Phase II Study of the Synergistic Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer | NCT00585052 |
| Paclitaxel, Doxorubicin, and Cyclophosphamide With Or Without Carboplatin in Treating Women With Locally Advanced Breast Cancer That Can Be Removed by Surgery | Randomised Phase II Trial of Neoadjuvant Weekly Paclitaxel Plus Carboplatin Compared to Weekly Paclitaxel Alone Followed in Both Arms by Doxorubicin and Cyclophosphamide for Operable or Locally Advanced Basal-like Subtype Breast Cancer Correlating BRCA-1 mRNA and Protein Expression With Carboplatin Response | NCT00589238 |
| A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer | A Phase II Study of Combination Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Advanced Stage or Recurrent Carcinoma of the Endometrium | NCT00584857 |
| A Phase II Study of Paclitaxel and Carboplatin in Patients With an Elevated-Risk Cancer of the Uterus | A Phase II Study of Paclitaxel and Carboplatin in Patients With Intermediate-Risk Adenocarcinoma of the Endometrium | NCT00584909 |
| Bevacizumab and Carboplatin/Paclitaxel and Radiation in Non-Small Cell Lung Cancer | Bevacizumab and Carboplatin/Paclitaxel and Radiation in Stage III Non-Small Cell Lung Cancer | NCT00578149 |
| CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL | Paclitaxel Poliglumex (CT-2103)/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer (NSCLC) in Women With Estradiol > 25 pg/mL | NCT00576225 |
| Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer | A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure | NCT00575952 |
| Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy | Phase I-II Trial of Vorinostat Plus Weekly Paclitaxel (+/- Trastuzumab) Followed by Doxorubicin-cyclophosphamide in Patients With Locally Advanced Breast Cancer | NCT00574587 |
| New therapeutic approaches in the treatment of anaplastic thyroid cancer: a phase II trial of valproic acid and paclitaxel in solid tumours - ND | New therapeutic approaches in the treatment of anaplastic thyroid cancer: a phase II trial of valproic acid and paclitaxel in solid tumours - ND | EUCTR2007-005090-65-IT |
| Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck | A Phase II Study of Carboplatin, Nab-paclitaxel and Cetuximab for Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck | NCT01412229 |
| A randomised, multicentre, open-label, phase III study of neoadjuvant lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2/ErbB2 positive primary breast cancer - NeoALTTO | A randomised, multicentre, open-label, phase III study of neoadjuvant lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2/ErbB2 positive primary breast cancer - NeoALTTO | EUCTR2006-000564-81-FR |
| Treatment of Paclitaxel Plus Carboplatin Followed by Gemcitabine Plus Carboplatin for Patients With Epithelial Ovarian Cancer | Phase II Study of Sequential Therapy With Paclitaxel Plus Carboplatin Followed by Gemzar Plus Carboplatin in the Treatment of Patients With Epithelial Ovarian Cancer FIGO Stages III-IV | NCT00490711 |
| TAXUS PERSEUS Small Vessel | A Prospective Evaluation in a Non-Randomized Trial of the Safety and Efficacy of the Use of the TAXUS® ElementTM Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions in Small Vessels | NCT00489541 |
| Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer | A Safety and Feasibility Study of Bevacizumab With Paclitaxel, Carboplatin and Chest Radiotherapy in Patients With Locally Advanced Non-Small Lung Cancer | NCT00369551 |
| A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC | A Phase 2, Multicenter, Open Label, Randomized Trial of AMG 706 or Bevacizumab in Combination With Paclitaxel and Carboplatin for Advanced Non-squamous Non-small Cell Lung Cancer | NCT00369070 |
| A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer | A Phase II Open Label, Randomized, 3 Arm Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab as First Line Therapy for Locally Recurrent or Metastatic Breast Cancer | NCT00370552 |
| Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | Evaluation of the Immunogenicity of Vaccination With Synthetic Peptides in Adjuvant in Patients With Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT00373217 |
| A Safety and Efficacy of CCRT With Paclitaxel as Adjuvant Therapy to Post-Operative Advanced Endometrial Cancer Patients | A Phase II Trial of Radiation Therapy With Concurrent Paclitaxel Chemotherapy in High-Risk Endometrial Cancer Patients After Operation. | NCT00373620 |
| A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer | A Phase 3 Study Of SU011248 In Combination With Paclitaxel Versus Bevacizumab With Paclitaxel In The First-Line Advanced Disease Setting In Patients Having Breast Cancer | NCT00373256 |
| A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast Cancer | A Phase 2 Study of Neoadjuvant Chemotherapy With Gemcitabine, Epirubicin and Paclitaxel (Taxol)[GET] in Locally Advanced Breast Cancer | NCT00378313 |
| Randomized Phase III Trial of Paclitaxel plus Carboplatin (TC) Therapy versus Irinotecan plus Cisplatin (CPT-P) Therapy as a First Line Chemotherapy for Clear Cell Carcinoma of the Ovary | Randomized Phase III Trial of Paclitaxel plus Carboplatin (TC) Therapy versus Irinotecan plus Cisplatin (CPT-P) Therapy as a First Line Chemotherapy for Clear Cell Carcinoma of the Ovary - Phase III Trial of (TC) Therapy versus (CPT-P) Therapy for Clear Cell Carcinoma of the Ovary | JPRN-UMIN000000499 |
| Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB) | A Phase I, Open-Label, Study of the Safety, Tolerability, and Pharmacokinetics of Pazopanib in Combination With Paclitaxel on a Weekly Schedule for Three Consecutive Weeks of a 28-Day Cycle, Paclitaxel and Carboplatin on an Every 21 Days Schedule and Lapatinib and Paclitaxel on a Weekly Schedule for Three Consecutive Weeks of a 28- Day Cycle | NCT00388076 |
| Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab | A Phase II Study of Prophylactic Radiation Therapy for the Prevention of Hemoptysis in Advanced Non Small Cell Lung Cancer in Combination With Bevacizumab, Paclitaxel, and Carboplatin in Patients at High Risk for Bevacizumab-Associated Hemoptysis | NCT00387374 |
| Phase I/II study of weekly chemotherapy consisting of 5-FU, leucovorin, and Paclitaxel (FLTAX) in patients with metastatic or recurrent gastric cancer. | Phase I/II study of weekly chemotherapy consisting of 5-FU, leucovorin, and Paclitaxel (FLTAX) in patients with metastatic or recurrent gastric cancer. - Phase I/II study of weekly chemotherapy consisting of 5-FU, leucovorin, and Paclitaxel (FLTAX) in patients with metastatic or recurrent gastric cancer. | JPRN-UMIN000000502 |
| Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer | A Randomized Phase II Study of Paclitaxel/Carboplatin With or Without Sorafenib in the First-Line Treatment of Patients With Stage III/IV Epithelial Ovarian Cancer | NCT00390611 |
| "Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo (""Sugar Pill"")" | A Randomized, Phase 2, Placebo-Controlled, Double-Blinded Study With and Without Enzastaurin in Combination With Paclitaxel and Carboplatin as First-Line Treatment, Followed by Maintenance Treatment in Advanced Ovarian Cancer | NCT00391118 |
| A Phase II Open Label, Randomized, 3 Arm Trial of 2 Schedules of Ixabepilone PlusBevacizumab and Paclitaxel Plus Bevacizumab as first Line Therapy for LocallyRecurrent or Metastatic Breast Cancer. | A Phase II Open Label, Randomized, 3 Arm Trial of 2 Schedules of Ixabepilone PlusBevacizumab and Paclitaxel Plus Bevacizumab as first Line Therapy for LocallyRecurrent or Metastatic Breast Cancer. | EUCTR2006-001921-25-FR |
| P E P C A D II, The Paclitaxel-Eluting PTCA-Balloon Catheter in Coronary Artery Disease to Treat In-Stent Restenoses | P E P C A D II, The Paclitaxel-Eluting PTCA-Balloon Catheter in Coronary Artery Disease to Treat In-Stent Restenoses: A Comparison to the Paclitaxel-Eluting Taxus™ Stent. A Pilot Study | NCT00393315 |
| Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors | Phase I Study of CCI-779 (NSC 683864) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumours | NCT00408655 |
| Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Phase 2 Study of Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma | NCT00408070 |
| Study to determine the possibility of treating women with ovarian and related cancers with chemotherapy, some of which is given directly into the abdomen as well as into the vein. It will also determine how safe it is, what side-effects it causes and how it affects quality of life. | A Single Arm Phase II Trial of Intraperitoneal Chemotherapy with Paclitaxel and Cisplatin after Optimal Debulking Surgery for Ovarian, Peritonuem and Fallopian Tube Cancers assessing the feasibility, toxicity and effects on quality of life of a modified GOG 172 (Gynaecologic Oncology Group) intraperitoneal (IP) regimen. | ACTRN12606000502538 |
| Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery | Adjuvant Therapy for High-Risk Localized Breast Cancer Using Weekly Adriamycin + Daily Oral Cytoxan With Continuous G-CSF Support for 12 Weeks Followed by Weekly Abraxane™ for 12 Weeks With Concurrent Herceptin for Subjects With HER-2/Neu Positive Disease, Phase II | NCT00407888 |
| ICON7 - A randomised, two-arm, multicentre Gynaecologic Cancer InterGroup trial of adding bevacizumab to standard chemotherapy (carboplatin and paclitaxel) in patients with epithelial ovarian cancer. - ICON7 GCIG Trial (International Collaborative Ovarian Neoplasm 7) | ICON7 - A randomised, two-arm, multicentre Gynaecologic Cancer InterGroup trial of adding bevacizumab to standard chemotherapy (carboplatin and paclitaxel) in patients with epithelial ovarian cancer. - ICON7 GCIG Trial (International Collaborative Ovarian Neoplasm 7) | EUCTR2005-003929-22-FR |
| Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer | Phase II Open Label Study of Gemcitabine, Paclitaxel and Bevacizumab Combination as First Line Treatment for Metastatic Breast Cancer | NCT00403130 |
| Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer | Phase I/II Study of a Combination of Suberoylanilide Hydroxamic Acid (Vorinostat) Plus Paclitaxel and Bevacizumab in Patients With Advanced Metastatic and/or Local Chest Wall Recurrent Breast Cancer | NCT00368875 |
| A randomized phase III trial of AP(Doxorubicin+Cisplatin) versus DP(Docetaxel+Cisplatin), TC(Paclitaxel+Carboplatin) as adjuvant chemotherrapy in patients with high risk group of endometrial carcinoma | A randomized phase III trial of AP(Doxorubicin+Cisplatin) versus DP(Docetaxel+Cisplatin), TC(Paclitaxel+Carboplatin) as adjuvant chemotherrapy in patients with high risk group of endometrial carcinoma - A randomized phase III trial of AP versus DP, TC regimens for high risk group of endometrial carcinoma | JPRN-UMIN000000522 |
| Phase I Trial of Paclitaxel With Perifosine | A Phase 1 Trial of the Combination of Perifosine and Paclitaxel Given Either Weekly or Every 3 Weeks | NCT00399126 |
| Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer | A Phase I Trial of Gemcitabine (Gemzar) Plus ABI-007 (ABRAXANE) In Patients With Advanced Metastatic Pancreatic Cancer | NCT00398086 |
| Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer | Combination Capecitabine (Xeloda) and ABI-007 (Abraxane, Nanoparticle Albumin-Bound Paclitaxel) Chemotherapy as Neoadjuvant Treatment of Locally Advanced, Operable Breast Cancer | NCT00397761 |
| Prospecitve study of radiotherapy without surgery after AC followed by weekly paclitaxel and trastuzumab for inflammatory breast cancer with HER2 over expression | Prospecitve study of radiotherapy without surgery after AC followed by weekly paclitaxel and trastuzumab for inflammatory breast cancer with HER2 over expression - Prospecitve study of radiotherapy without surgery after AC followed by weekly paclitaxel and trastuzumab for inflammatory breast cancer with HER2 over expression | JPRN-UMIN000000513 |
| The safety and efficacy trial of sequential administration with AP (Doxorubicin/Paclitaxel) followed by weekly Paclitaxel as preoperative chemotherapy for breast cancer: SBCCSG-07 | The safety and efficacy trial of sequential administration with AP (Doxorubicin/Paclitaxel) followed by weekly Paclitaxel as preoperative chemotherapy for breast cancer: SBCCSG-07 - The safety and efficacy trial of sequential administration with AP (Doxorubicin/Paclitaxel) followed by weekly Paclitaxel as preoperative chemotherapy for breast cancer: SBCCSG-07 | JPRN-UMIN000000504 |
| MITO-5: Weekly Carboplatin and Paclitaxel as First Line Chemotherapy for Elderly Patients With Ovarian Cancer | Phase II Multicenter Study of the Combination of Weekly Carboplatin and Paclitaxel as First-line Chemotherapy for Elderly Patients With Ovarian Cancer. | NCT00401674 |
| Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | A Phase II Study of Intermittent Gleevec® (Imatinib Mesylate) and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-Small Cell Lung Cancer | NCT00408460 |
| S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer | A Phase II Trial of Combination Carboplatin, Paclitaxel, Cetuximab and Bevacizumab (NSC-704865) Followed By Cetuximab and Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer | NCT00368992 |
| En fase I / II forsøg med intraperitoneal Paclitaxel og Carboplatin efter cytoreduktiv operation som behandling af Patienter med ovarie carcinoma med peritoneal carcinose eller primær peritoneal carcinomatose | En fase I / II forsøg med intraperitoneal Paclitaxel og Carboplatin efter cytoreduktiv operation som behandling af Patienter med ovarie carcinoma med peritoneal carcinose eller primær peritoneal carcinomatose | EUCTR2006-002687-26-DK |
| A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer | Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer (SCLC): A Safety, Feasibility and Efficacy Study | NCT00317200 |
| A Phase III Randomized, Controlled Trial of Myocet, Trastuzumab and Paclitaxel versus Trastuzumab and Paclitaxel for First line Therapy of Metastatic Breast Cancer | A Phase III Randomized, Controlled Trial of Myocet, Trastuzumab and Paclitaxel versus Trastuzumab and Paclitaxel for First line Therapy of Metastatic Breast Cancer | EUCTR2005-006109-19-PT |
| A Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer (BRIDGE) | A Pilot Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer | NCT00318136 |
| A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer | A Randomized Phase II Trial of Paclitaxel and Bevacizumab Versus Gemcitabine, Paclitaxel, and Bevacizumab as First Line Treatment for Locally Advanced or Metastatic Breast Cancer | NCT00320541 |
| Validation of genetic diagnosis to predict sensitivity in primary systemic chemotherapy with paclitaxel in women with breast cancer | Validation of genetic diagnosis to predict sensitivity in primary systemic chemotherapy with paclitaxel in women with breast cancer - Validation of genetic diagnosis to predict sensitivity in primary systemic chemotherapy with paclitaxel in women with breast cancer (GENESIS-BC-01) | JPRN-C000000413 |
| Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer | An Open-label, Dose-finding Study to Evaluate the Safety of AMG 706 in Combination With Paclitaxel or Docetaxel as Treatment for Locally Recurrent or Metastatic Breast Cancer | NCT00322400 |
| A Randomized, Multi-Center Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent Systems (GENESIS) | A Randomized, Multi-Center Study of the Pimecrolimus-Eluting (Corio™) and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System (SymBio™) in Patients With De Novo Lesions of the Native Coronary Arteries | NCT00322569 |
| First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia | Open Label, Randomised, Parallel Group, Multicentre, Ph III Study To Assess Efficacy, Safety & Tolerability Of Gefitinib (IRESSA™) Versus Carboplatin/Paclitaxel DC As 1st-Line Treatment In Selected Patients With Stage IIIB / IV NSCLC In Asia | NCT00322452 |
| Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer | Phase II Study of Paclitaxel, Oxaliplatin, Leucovorin and 5-Fluorouracil (POLF) in Gemcitabine-Refractory Advanced Pancreatic Cancer | NCT00323583 |
| Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer | A Phase II Study of Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer | NCT00322881 |
| Ensayo en fase III de vinflunina más gemcitabina frente a paclitaxel más gemcitabina en pacientes con cáncer de mama irresecable, localmente recurrente o metastásico, tras quimioterapia adyuvante previa basada en antraciclinas | Ensayo en fase III de vinflunina más gemcitabina frente a paclitaxel más gemcitabina en pacientes con cáncer de mama irresecable, localmente recurrente o metastásico, tras quimioterapia adyuvante previa basada en antraciclinas | EUCTR2006-001139-23-ES |
| MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer | Phase III Randomized Multicentre Trial of Carboplatin + Liposomal Doxorubicin vs Carboplatin + Paclitaxel in Patients With Ovarian Cancer | NCT00326456 |
| Randomized phase III trial of paclitaxel plus topotecan versus topotecan plus cisplatin in recurrent or persistent cervical cancer stage IVb | ISRCTN77165120 | |
| Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye | Phase II Trial of BAY 43-9006 (Sorafenib; NSC-724772) in Combination With Carboplatin and Paclitaxel in Patients With Metastatic Uveal Melanoma | NCT00329641 |
| Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | A Phase II Study of Carboplatin and Paclitaxel as Neoadjuvant Chemotherapy Followed by Interval Cytoreduction in Women With Advanced Staged Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma for High-Risk Surgical Candidates or Patients Unlikely to be Optimally Surgically Cytoreduced | NCT00331422 |
| Combination Chemotherapy of Gemcitabine and Paclitaxel for Metastatic Breast Cancer | Combination Study of LY188011 and Paclitaxel in Patients With Metastatic/Recurrent Breast Cancer After Neo-adjuvant/Adjuvant Chemotherapy With Anthracycline | NCT00334802 |
| Radiation Therapy, Chemotherapy, and Bevacizumab in Treating Patients With Recurrent, Unresectable or Stage III or Stage IV Non-Small Cell Lung Cancer | Phase II Study of Radiation Followed by Paclitaxel, Carboplatin, and Bevacizumab (PCA) in Patients With Stage IIIB and IV Squamous Non-Small Cell Lung Cancer | NCT00334763 |
| A Randomized, Phase 2, Placebo-Controlled, Double-Blinded Study With and Without Enzastaurin in Combination With Paclitaxel and Carboplatin as First-Line Treatment, Followed by Maintenance Treatment in Advanced Ovarian Cancer - N/A | A Randomized, Phase 2, Placebo-Controlled, Double-Blinded Study With and Without Enzastaurin in Combination With Paclitaxel and Carboplatin as First-Line Treatment, Followed by Maintenance Treatment in Advanced Ovarian Cancer - N/A | EUCTR2006-002316-10-BE |
| Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site | A Phase II Study of Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Patients With Carcinoma of Unknown Primary Site | NCT00360360 |
| Trial of PTK787/ZK 222584 Plus Paclitaxel | Phase I Study of the Oral Vascular Endothelial Growth Factor Inhibitor PTK787/ZK 222584 in Combination With Paclitaxel in Patients With Advanced Solid Tumors. | NCT00358163 |
| Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer | An Open-label, Single-arm, Multi-centre, Phase II Study of Oral Lapatinib in Combination With Paclitaxel as First-line Treatment for ErbB2-amplified Metastatic Breast Cancer Patients | NCT00356811 |
| A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel plus or minus Sorafenib (BAY 43-9006) in chemonaive patients with Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)Bay 43-9006 / 11961 | A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel plus or minus Sorafenib (BAY 43-9006) in chemonaive patients with Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC) | ACTRN12606000316505 |
| Combined Treatment of Cetuximab and Paclitaxel in Basal Like Breast Carcinoma | Phase II of Combined Treatment of Cetuximab and Paclitaxel in Basal Like Breast Carcinoma | NCT00353717 |
| Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer. | A Phase I, Dose Escalation Study to Assess the Safety and Tolerability of Lapatinib in Combination With Carboplatin, Paclitaxel, With and Without Trastuzumab in Subjects With Metastatic Breast Cancer | NCT00367471 |
| A Phase II Study of Radiation Therapy, Paclitaxel Poliglumex, and Carboplatin in Stage III Non-Small Cell Lung Cancer | A Phase II Study of Radiation Therapy, Paclitaxel Poliglumex, and Carboplatin in Stage III Non-Small Cell Lung Cancer | NCT00352690 |
| Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer | Randomized Phase II Trial of Cetuximab With and Without Weekly Paclitaxel in Patients With Previously Treated Advanced Urothelial Cancer | NCT00350025 |
| Phase II Study of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal Cancer | Phase II Study to Evaluate Efficacy and Safety of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal Cancer. This Study is an Extension Study for Japanese Registration Only. | NCT00344552 |
| Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442) | A Phase II Study of Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck | NCT00343083 |
| A Safety and Efficacy of CCRT With Paclitaxel/Carboplatin as Adjuvant Therapy to Post-operative Cervical Cancer Patients | A Phase II Trial of Radiation Therapy With Concurrent Paclitaxel/Carboplatin Chemotherapy in High-risk Cervical Cancer Patients After Radical Hysterectomy | NCT00340184 |
| A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC | Phase II Randomized, Open-Label Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Patients With Stage IIIB/IV Non-Small Cell Lung Cancer | NCT00343291 |
| A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck Cancer | A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck Cancer | NCT00337532 |
| Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer | A Phase I Trial of Dose Dense (Biweekly) Carboplatin Combined With Paclitaxel and Pegfilgrastim (Neulasta): A Feasibility Study in Patients With Untreated Stage III and IV Ovarian, Tubal or Primary Peritoneal Cancer | NCT00352300 |
| CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy | A Phase 3, Randomized, Open-Label, Comparative Study of CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy | NCT00653952 |
| ANZ 0601 / CIRG/TORI 010 | A Randomized Phase 2 Trial of Double-Blind, Placebo Controlled AMG 706 in Combination with Paclitaxel, or Open-Label Bevacizumab in Combination with Paclitaxel, as First Line Therapy in Women with HER2 Negative Locally Recurrent or Metastatic Breast Cancer | ACTRN12606000507583 |
| Abraxane and Temodar Plus Genasense in Advanced Melanoma | "A Pilot Study of Abraxane® (Albumin-bound Paclitaxel) and Temodar® (Temozolomide) Plus Genasense® (Oblimersen Sodium) in Subjects With Advanced Melanoma (""The ATG Study"")." | NCT00409383 |
| Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor | A Phase 1 Dose-Finding Study Of The Anti-Angiogenesis Agent, AG-013736, In Combinations Of Paclitaxel/Carboplatin, Weekly Paclitaxel, Docetaxel, Capecitabine, Gemcitabine/Cisplatin and Pemetrexed/Cisplatin In Patients With Advanced Solid Tumors | NCT00454649 |
| Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer | A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by Ixabepilone Compared to Sequential AC Followed by Paclitaxel in Women With Early Stage Breast Cancer | NCT00455533 |
| Dose-dense treatment with gemcitabine, epirubicin and paclitaxel GET combination in advanced breast cancer a phase II parallel study | Dose-dense treatment with gemcitabine, epirubicin and paclitaxel GET combination in advanced breast cancer a phase II parallel study | EUCTR2005-003582-16-IT |
| Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor | Randomized Fase II Trial: Comparing Cisplatin, Paclitaxel and Gemcitabine Versus Cisplatin, Paclitaxel, Gemcitabine and Avastin in Patients With Unknown Primary Tumors | NCT00458315 |
| Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery | Assessment of Feasibility and Safety of the Addition of ZD6474 (Zactima) to Carboplatin and Paclitaxel Administered Neo-Adjuvantly in Stage IB, II and T3, N1 Non-Small Cell Lung Cancer (NSCLC) | NCT00459121 |
| Paclitaxel Poliglumex and Estradiol in Treating Patients With Stage IV Prostate Cancer | A Phase II Study of Paclitaxel Poliglumex (PPX) in Combination With Transdermal Estradiol for the Treatment of Androgen Independent Prostate Cancer After Docetaxel Chemotherapy | NCT00459810 |
| Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer | Phase II Study of Weekly Neoadjuvant Chemotherapy Followed by Radical Chemoradiation for Locally Advanced Cervical Cancer | NCT00462397 |
| Paclitaxel Eluting Balloon Versus Drug Eluting Stent in Native Coronary Artery Stenoses of Diabetic Patients | Paclitaxel-Eluting Balloon Angioplasty and Cobalt-Chromium Stents Versus Conventional Angioplasty and Paclitaxel-Eluting Stents in the Treatment of Native Coronary Artery Stenoses of Diabetic Patients | NCT00462631 |
| A Phase I, Open label Study to Assess the Safety and Tolerability of KU-0059436 in Combination with Carboplatin and of KU-0059436 in Combination with a Paclitaxel/Carboplatin (TC) doublet and KU-0059436 in combination with Paclitaxel in the Treatment of Patients with Advanced Solid Tumours | A Phase I, Open label Study to Assess the Safety and Tolerability of KU-0059436 in Combination with Carboplatin and of KU-0059436 in Combination with a Paclitaxel/Carboplatin (TC) doublet and KU-0059436 in combination with Paclitaxel in the Treatment of Patients with Advanced Solid Tumours - Safety,Tolerability of KU-0059436,Carboplatin - Paclitaxel in Solid tumours | NL-OMON46952 |
| A phase II study of preoperative S-1 plus Paclitaxel combination therapy and postoperative Paclitaxel followed by S-1 therapy for type 4 gastric cancer (OGSG 0502) | A phase II study of preoperative S-1 plus Paclitaxel combination therapy and postoperative Paclitaxel followed by S-1 therapy for type 4 gastric cancer (OGSG 0502) - OGSG 0502 | JPRN-UMIN000000686 |
| Study of Weekly Paclitaxel, Carboplatin and Irinotecan to Treat Lung Cancer | Phase II Study of Weekly Paclitaxel, Carboplatin and Irinotecan in Patients With Advanced Non-Small Cell Lung Cancer Nad Malignant Pleural Effusion | NCT00465907 |
| Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy | A Phase II Trial of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) With Weekly Protein Bound Paclitaxel (Abraxane™) as Chemoimmunotherapy for Platinum-Refractory/Resistant Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancer | NCT00466960 |
| Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors | Treatment of Recurrent or Resistant Pediatric Malignant Germ Cell Tumors With Paclitaxel, Ifosfamide and Carboplatin | NCT00467051 |
| Phase ? Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast Cancer | Phase ? Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast Cancer | NCT00467012 |
| Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer | A Phase I-II Study of R115777 (Tipifarnib, Zarnestra®) Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients With Stage IIB-IIIC Breast Cancer | NCT00470301 |
| Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors | Phase II Trial of Paclitaxel, Ifosfamide, and Cisplatin in Previously Untreated Intermediate and Poor Risk Germ Cell Tumor Patients | NCT00470366 |
| Phase I/II-Studie zur neoadjuvanten Chemotherapie mit nicht-pegyliertem liposomalem Doxorubicin, Paclitaxel und Lapatinib bei Patientinnen mit HER2-überexprimierenden, primärem Mammakarzinomen | Phase I/II-Studie zur neoadjuvanten Chemotherapie mit nicht-pegyliertem liposomalem Doxorubicin, Paclitaxel und Lapatinib bei Patientinnen mit HER2-überexprimierenden, primärem Mammakarzinomen | EUCTR2007-000924-42-DE |
| Phase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced Non-small Cell Lung Cancer (NSCLC) | Phase II Study of the Combination of Paclitaxel Poliglumex (CT-2103, Xyotax) and Pemetrexed (Alimta) for the Treatment of Patients With Advanced Non-small Cell Lung Cancer. | NCT00487669 |
| A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer | A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response | NCT00486668 |
| Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer | A Randomized, Multicenter, Open-label, Phase III Study of Lapatinib (GW572016) in Combination With Weekly Paclitaxel Versus Weekly Paclitaxel Alone in the Second Line Treatment of ErbB2 Amplified Advanced Gastric Cancer | NCT00486954 |
| A Phase 1b/2 study of AMG 655 Combination with Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer | A Phase 1b/2 study of AMG 655 Combination with Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer | EUCTR2006-006658-89-BE |
| TAXUS PERSEUS Workhorse | A Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions | NCT00484315 |
| Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer | Phase II Study of Dose-Dense Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With Trastuzumab and Lapatinib in HER2/NEU-Overexpressed/Amplified Breast Cancer: Feasibility | NCT00482391 |
| Weekly Paclitaxel Plus Gemcitabine as Second-line in Small Cell Lung Cancer | A Phase II Study of Weekly Paclitaxel and Gemcitabine as Second-line Therapy in Patients With Metastatic or Recurrence Small Cell Lung Cancer | NCT00453167 |
| Feasibility study of weekly paclitaxel patients with pre-treatment (2 regimens) advanced/recurrent gastric cancer (OGSG 0602) | Feasibility study of weekly paclitaxel patients with pre-treatment (2 regimens) advanced/recurrent gastric cancer (OGSG 0602) - OGSG 0602 | JPRN-UMIN000000723 |
| A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer (APM4074g) | A Randomized, Double-Blind, Phase II Trial of Paclitaxel + Carboplatin + Bevacizumab With or Without PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer | NCT00480831 |
| Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer | A Randomized, Double-Blind, Placebo Controlled, Phase 2 Trial of Paclitaxel in Combination With AMG 386 in Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer | NCT00479817 |
| A Randomized, Open-Label, Phase 3 Trial of NOV-002 in Combination withPaclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for theTreatment of Advanced Non-Small-Cell Lung Cancer (NSCLC) - ND | A Randomized, Open-Label, Phase 3 Trial of NOV-002 in Combination withPaclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for theTreatment of Advanced Non-Small-Cell Lung Cancer (NSCLC) - ND | EUCTR2006-001990-32-IT |
| Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function | A Phase II Study of Gemcitabine, Paclitaxel, and Doxorubicin, With Pegfilgrastim for the Treatment of Patients With Metastatic Transitional Cell Carcinoma and Renal Insufficiency | NCT00478361 |
| A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056) | A Phase II/III Randomized, Double-Blind Study of Paclitaxel Plus Carboplatin in Combination With Vorinostat or Placebo in Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small-Cell Lung Cancer (NSCLC) | NCT00473889 |
| Paclitaxel Coated Balloon Catheter for Prevention of Restenosis in Femoropopliteal Arteries | Paclitaxel Coated Balloon Catheter for Inhibition of Restenosis in Femoropopliteal Arteries (PACCOCATH - FEM I) | NCT00472472 |
| Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer | Randomized Phase II Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer | NCT00481078 |
| A Dose Targeted Phase I/II Study To Evaluate The Feasibility, Safety, And Biological Effects Of Intravenous Administration of A Wild-Type Reovirus (REOLYSIN®) in Combination With Paclitaxel and Carboplatin To Patients With Advanced Malignancies | A Dose Targeted Phase I/II Study To Evaluate The Feasibility, Safety, And Biological Effects Of Intravenous Administration of A Wild-Type Reovirus (REOLYSIN®) in Combination With Paclitaxel and Carboplatin To Patients With Advanced Malignancies | EUCTR2006-006515-76-GB |
| Paclitaxel Eluting Covered Metallic Stent for Unresectable Malignant Bile Duct Obstruction | Randomized Trial of Conventional Covered Self Expandable Metallic Stent Versus Paclitaxel Eluting Covered Self Expandable Metallic Stent in Unresectable Malignant Bile Duct Obstruction | NCT00453076 |
| Phase II Trial of Pulsed Taxol With Concurrent Thoracic Radiotherapy, & Adjuvant Chemo in Stage III NSCLC | Phase II Trial of Pulsed Paclitaxel With Concurrent Radiotherapy,and Adjuvant Chemotherapy in Stage III Non-Small Cell Lung Cancer | NCT00449657 |
| Treatment of in-Stent Restenosis by Paclitaxel Coated PTCA Balloons (PACCOCATH – ISR II) | Treatment of in-Stent Restenosis by Paclitaxel Coated PTCA Balloons (PACCOCATH – ISR II) | NCT00409981 |
| Sequential schedule of platinum then paclitaxel-based chemotherapy for women with epithelial non-mucinous advanced inoperable peritoneal malignancy | A randomised feasibility study of extended chemotherapy with neoadjuvant carboplatin, then surgery followed by adjuvant paclitaxel and gemcitabine versus neoadjuvant gemcitabine and carboplatin, then surgery, followed by adjuvant paclitaxel for women with epithelial non-mucinous advanced inoperable peritoneal malignancy | ISRCTN24742183 |
| HECTOR | Topotecan plus Carboplatin im Vergleich zur Standardtherapie (Paclitaxel plus Carboplatin oder Gemcitabin plus Carboplatin oder pegyliertes liposomales Doxorubicin plus Carboplatin) in der Therapie von Patientinnen mit Platin-sensitivem rezidivierten epithelialen Ovarialkarzinom, Peritonealkarzinom oder TubenkarzinomHECTOR (Hycamtin plus Carboplatin versus Established Regimens for the Treatment of Ovarian Cancer Relapse) | EUCTR2006-004628-34-DE |
| A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment | A Phase I/II Safety, Pharmacodynamic, and Pharmacokinetic Study of Intravenously Administered PXD101 Plus Carboplatin or Paclitaxel or Both in Patients With Advanced Solid Tumours | NCT00421889 |
| Weekly Carboplatin and Taxol with concurrent radiotherapy for locally advanced non small cell lung : Predictive factors for completion of treatment. | Weekly Carboplatin and Taxol with concurrent radiotherapy for locally advanced non small cell lung cancer:Predictive factors for completion of treatment. | ACTRN12607000043437 |
| CoStar™ Paclitaxel-Eluting Coronary Stent Catheter System Evaluation | The PreCiSE Trial: CoStar™ Paclitaxel-Eluting Coronary Stent Catheter System Evaluation | NCT00422435 |
| Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin | Phase I/II Trial of Sequential Paclitaxel/Ifosfamide Followed by Dose-Escalated, Dose-Intensive Carboplatin, Paclitaxel and Ifosfamide With Stem Cell Support in Cisplatin-Resistant Germ Cell Tumor Patients | NCT00423852 |
| A Phase II/III Randomized, Double-Blind Study of Paclitaxel plus Carboplatin in Combination with Vorinostat (MK-0683) or Placebo in Patients with Stage IIIB (with pleural effusion) or Stage IV Non-Small-Cell Lung Cancer (NSCLC) | A Phase II/III Randomized, Double-Blind Study of Paclitaxel plus Carboplatin in Combination with Vorinostat (MK-0683) or Placebo in Patients with Stage IIIB (with pleural effusion) or Stage IV Non-Small-Cell Lung Cancer (NSCLC) | EUCTR2006-005122-23-CZ |
| Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer | A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer | NCT00426556 |
| Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer | A Multicenter Randomized Study Comparing the Dose Dense, G-CSF-Supported Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Women With Axillary Lymph Node Positive Breast Cancer | NCT00431080 |
| Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer | A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer | NCT00433511 |
| Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer | A Phase III Randomized Study of EC Followed by Paclitaxel Versus FEC Followed by Paclitaxel, All Given Either Every 3 Weeks or 2 Weeks Supported by Pegfilgrastim, for Node Positive Breast Cancer Patients | NCT00433420 |
| A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B) | A Multicenter, Phase II, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer | NCT00434356 |
| Multicenter phase II trial of weekly-paclitaxel and oral capecitabine combination therapy for metastatic breast cancer | Multicenter phase II trial of weekly-paclitaxel and oral capecitabine combination therapy for metastatic breast cancer - Phase II study of paclitaxel plus capecitabine (XP) for metastatic breast cancer | JPRN-UMIN000000603 |
| Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction | Dual Arm Factorial Randomized Trial in Patients w/ST Segment Elevation AMI to Compare the Results of Using Anticoagulation With Either Unfractionated Heparin + Routine GP IIb/IIIa Inhibition or Bivalirudin + Bail-out GP IIb/IIIa Inhibition; and Primary Angioplasty With Stent Implantation With Either a Slow Rate-release Paclitaxel-eluting Stent (TAXUS™) or Uncoated Bare Metal Stent (EXPRESS2™) | NCT00433966 |
| A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L) | A Randomized, Controlled, Open-Label, Multicenter, Phase II Study of the Safety and Efficacy of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer | NCT00434226 |
| A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma | A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma | NCT00434252 |
| Safety and Efficacy of Angiotech Vascular Wrap Paclitaxel-Eluting Mesh for Hemodialysis Vascular Access | Trial to Assess the Effectiveness of Maintaining Patency and Safety of the Vascular Wrap Paclitaxel-Eluting Mesh After Surgical Implantation With the Lifespan® ePTFE Vascular Graft in the Upper Extremity for Hemodialysis Vascular Access | NCT00448708 |
| A Phase I open label trial of continuous dosing with BIBW 2992 combined with paclitaxel and BIBW 2992 combined with paclitaxel and bevacizumab in patients with advanced solid tumours - - | A Phase I open label trial of continuous dosing with BIBW 2992 combined with paclitaxel and BIBW 2992 combined with paclitaxel and bevacizumab in patients with advanced solid tumours - - | EUCTR2006-005005-55-GB |
| A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer | A Phase 1/2 Study of HKI-272 in Combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer | NCT00445458 |
| A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Trialof AMG 706 in Combination With Paclitaxel and Carboplatin for AdvancedNon-small Cell Lung Cancer | A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Trialof AMG 706 in Combination With Paclitaxel and Carboplatin for AdvancedNon-small Cell Lung Cancer | EUCTR2006-003784-32-IE |
| Paclitaxel and Capecitabine in Patients With Metastatic/Recurrence Esophageal Cancer | A Phase II Study of Weekly Paclitaxel and Capecitabine in Patients With Metastatic or Recurrent Esophageal Cancer | NCT00453323 |
| A Randomized Phase III Trial of Gemcitabine and Docetaxel versus Gemcitabine and Paclitaxel in Patients with Metastatic Breast Cancer: a comparison of different schedules | A Randomized Phase III Trial of Gemcitabine and Docetaxel versus Gemcitabine and Paclitaxel in Patients with Metastatic Breast Cancer: a comparison of different schedules | EUCTR2005-001545-42-IT |
| A randomized multicenter study of carboplatin-gemcitabine versus carboplatin-paclitaxel in elderly patients with non-small cell lung cancer with emphasis on geriatric assessment and quality of life: The NVALT-3 study. | A randomized multicenter study of carboplatin-gemcitabine versus carboplatin-paclitaxel in elderly patients with non-small cell lung cancer with emphasis on geriatric assessment and quality of life: The NVALT-3 study. | NL-OMON26629 |
| Randomized fase II trial: comparing Cisplatin, Paclitaxel and Gemcitabine vs. Cisplatin, Paclitaxel, Gemcitabine and Avastin in patients with unknown primary tumors | Randomized fase II trial: comparing Cisplatin, Paclitaxel and Gemcitabine vs. Cisplatin, Paclitaxel, Gemcitabine and Avastin in patients with unknown primary tumors | EUCTR2007-000663-18-DK |
| Prospective, Multi-Center, Random. Study of CoStar Paclitaxel-Eluting Coronary Stent(Direct Stenting vs. Pre-Dilatation) | The DECIDE Trial: Prospective, Multi-center, Randomized Study to Evaluate the CoStar Paclitaxel-Eluting Coronary Stent System Using a Direct Stenting Technique Compared to Conventional Stenting With Pre-dilatation Strategy | NCT00440674 |
| Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer | Cetuximab, Paclitaxel, Carboplatin and Radiation for Esophageal, Gastroesophageal Junction and Gastric Cancer BMS#CA225091 | NCT00439608 |
| Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery | Phase II Study of Cardiac Safety and Tolerability of an Adjuvant Chemotherapy Plus Trastuzumab With Lapatinib in Patients With Resected HER2 + Breast Cancer | NCT00436566 |
| Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer | A Pilot Study of Bevacizumab With Dose Dense Doxorubicin and Cyclophosphamide (AC) Followed by Dose Dense Nanoparticle Albumin Bound Paclitaxel for the Treatment of Early Stage Breast Cancer | NCT00436709 |
| Late clinical events after paclitaxel- vs. zotarolimus-eluting stents in patients with small vessel stenting | BAsel Stent Kosten Effektivitäts Trial - late clinical events in patients with SMALL vessel stenting | ISRCTN09125734 |
| Single-Arm, multicenter, phase II clinical study of neoadjuvant tirelizumab combined with albumin paclitaxel cisplatin in patients with borderline resectable esophageal squamous cell carcinoma | Single-Arm, multicenter, phase II clinical study of neoadjuvant tirelizumab combined with albumin paclitaxel cisplatin in patients with borderline resectable esophageal squamous cell carcinoma | ChiCTR2100051514 |
| A Study of Neoadjuvant TCHpy(Pyrotinib ,Trastuzumab,Carboplatin and Paclitaxel)for ER+/HER2+ Breast Cancer | A Multicenter, Single-arm, Prospective Study of Neoadjuvant Pyrotinib Combined With Trastuzumab,Carboplatin and Paclitaxel for ER+/HER2+ Early or Locally Advanced Breast Cancer | NCT06000917 |
| Pembrolizumab/placebo plus paclitaxel with or without bevacizumab for platinum-resistant recurrent ovarian cancer. | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96 / ENGOT-ov65) | EUCTR2020-005027-37-FI |
| A randomized phase II study comparing cisplatin + docetaxel with carboplatin + paclitaxel in patients with Stage III (N 2 positive) non-small-cell lung cancer who receive trimodality treatment consisting of chemoradiotherapy followed by surgery (OLCSG1601) | A randomized phase II study comparing cisplatin + docetaxel with carboplatin + paclitaxel in patients with Stage III (N 2 positive) non-small-cell lung cancer who receive trimodality treatment consisting of chemoradiotherapy followed by surgery (OLCSG1601) - A randomized phase II study comparing cisplatin + docetaxel with carboplatin + paclitaxel in patients with Stage III (N 2 positive) non-small-cell lung cancer who receive trimodality treatment (OLCSG1601) | JPRN-UMIN000024816 |
| Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer | Feasibility Study of Neo-adjuvant Treatment With Carboplatin, Paclitaxel and Pembrolizumab in Primary Stage IV Serous Ovarian Cancer | NCT03126812 |
| A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer | An Open-label, Randomized, Controlled Phase III Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer | NCT03002103 |
| A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer | A Pilot Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer | NCT02999477 |
| The study to compare 2 chemotherapy regimen for high risk carcinoma of penis | An Open label Randomized Trial comparing Paclitaxel and Platinum chemotherapy with 5-FU and Platinum in patients following resection for High Risk Carcinoma of the Penis (â??BACuPâ??-Best Adjuvant Chemotherapy for use in Penile carcinoma) | CTRI/2016/12/007567 |
| Treatment of Coronary In-Stent Restenosis by a Sirolimus (Rapamycin) Coated Balloon or a Paclitaxel Coated Balloon | Treatment of Coronary In-Stent Restenosis by a Sirolimus (Rapamycin) Coated Balloon or a Paclitaxel Coated Balloon | NCT02996318 |
| A RANDOMISED, PARALLEL, DOUBLE BLINDED STUDY TO COMPARE THE EFFICACY AND SAFETY OF FKB238 TO AVASTIN® IN 1ST LINE TREATMENT FOR PATIENTS WITH ADVANCED/RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER IN COMBINATION OF PACLITAXEL AND CARBOPLATIN | A RANDOMISED, PARALLEL, DOUBLE BLINDED STUDY TO COMPARE THE EFFICACY AND SAFETY OF FKB238 TO AVASTIN® IN 1ST LINE TREATMENT FOR PATIENTS WITH ADVANCED/RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER IN COMBINATION OF PACLITAXEL AND CARBOPLATIN | PER-027-16 |
| Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma | Efficacy and Safety of Paclitaxel/Cyclophosphamide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple MyelomaRefractory | NCT02985333 |
| Paclitaxel Liposome for Squamous Non-Small-cell Lung Cancer Study(LIPUSU) | A Multicenter, Randomized, Open-label, Parallel-group Study of Paclitaxel Liposome and Cisplatin Compared With Gemcitabine and Cisplatin as First-line Therapy in Advanced Squamous Non-Small-Cell Lung Cancer | NCT02996214 |
| Phase I Study of TENPA in Advanced Solid Cancer | A Prospective, Open-label, Dose Escalation (Part A), Cohort Expansion (Part B) Phase I Study to Investigate the Safety and to Determine Maximum Tolerated Dose and Recommended Phase 2 Dose of TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel) in Patients With Advanced Solid Tumor | NCT02979392 |
| Efficacy and Safety of TPF Induction Chemotherapy for Borderline-resectable Esophageal Squamous Cell Carcinoma | Paclitaxel In Combination With Cisplatin and 5-fluorouracil(TPF) Induction Chemotherapy for Locally Advanced Borderline-resectable Esophageal Squamous Cell Carcinoma: A Phase II Clinical Trial | NCT02976909 |
| A Study of Hemodialysis Arteriovenous Fistulae Stenosis Treated With APERTO | Evaluation of the Safety and Efficacy of the Paclitaxel Eluting Hemodialysis Shunt Balloon Dilatation Catheter (APERTO) in Treatment of Hemodialysis Arteriovenous Fistulae Stenosis: A Prospective, Multicenter, Randomized, Controlled Clinical Study | NCT02962141 |
| A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer | Nivolumab With or Without Nab-Paclitaxel in Previously Treated, Advanced Stage, Non-small Cell Lung Cancer: A Randomized Phase II Study | NCT02967133 |
| A Study of Below The Knee Arteries' Stenosis or Occlusion Treated With LEGFLOW OTW | Evaluation the Safety and Efficacy of the Paclitaxel Releasing Peripheral Balloon Dilatation Catheter (LEGFLOW)in Treatment of Stenosis or Occlusion in Below The Knee Arteries: A Prospective, Multicenter, Randomized, Controlled Clinical Study | NCT02962232 |
| A Study of The Femoral Popliteal Artery Treated With LEGFLOW OTW | Evaluation of the Safety and Efficacy of the Paclitaxel Releasing Peripheral Balloon Dilatation Catheter (LEGFLOW)in Treatment of Stenosis or Occlusion in Femoral-popliteal Arteries:A Prospective, Multicenter, Randomized, Controlled Clinical Study | NCT02965677 |
| The Effect of Oral Administration of Hesperidin and Diosmin in Reducing Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients | The Effect of Oral Administration of Hesperidin and Diosmin in Reducing Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients | NCT06811220 |
| Phase 2 prospective study of the efficacy of nab-paclitaxel, carboplatin and bevacizumab for the treatment of stage 3B/4 non-squamous cell and non-small cell lung cancer | Phase 2 prospective study of the efficacy of nab-paclitaxel, carboplatin and bevacizumab for the treatment of stage 3B/4 non-squamous cell and non-small cell lung cancer - Phase 2 study of nab-paclitaxel, carboplatin and bevacizumab for the treatment of non-squamous and non-small cell lung cancer | JPRN-UMIN000024610 |
| Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma | Phase II Study of Nab-Paclitaxel in Combination With Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults | NCT02945800 |
| Clinical study on efficacy and safety of Huangqi Guizhi Wuwu decoction bubble bag in paclitaxel related peripheral neuritis of breast cancer patients : A protocol for a randomized, controlled, double-blind trial | Clinical study on efficacy and safety of Huangqi Guizhi Wuwu decoction bubble bag in paclitaxel related peripheral neuritis of breast cancer patients : A protocol for a randomized, controlled, double-blind trial | ITMCTR2200006006 |
| Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy | Multicenter, Open-label Study of Safety and Efficacy of Quisinostat in Combination With Paclitaxel + Carboplatin Chemotherapy in Patients With Metastatic or Locally Advanced Epithelial Ovarian Cancer, Primarily Peritoneal or Fallopian Tube Carcinoma, Resistant to First Line Platinum and Paclitaxel Based Chemotherapy | NCT02948075 |
| Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLC | Study to Evaluate the Efficacy and Safety of IBI305 in Combination With Paclitaxel/Carboplatin Versus Bevacizumab in Combination With Paclitaxel/Carboplatin in Treatment-naïve Patients With Advanced or Recurrent Non-squamous NSCLC | NCT02954172 |
| Outcome of Cisplatin and Vinblastine Versus Paclitaxel and Carboplatin as Sequential Chemotherapy Followed by Radiotherapy in Locally Advanced Non-small Cell Lung Cancer | Outcome of Cisplatin and Vinblastine Versus Paclitaxel and Carboplatin as Sequential Chemotherapy Followed by Radiotherapy in Locally Advanced Non-small Cell Lung Cancer | NCT03092986 |
| Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors | A Randomized Phase III Study of Paclitaxel, Ifosfamide and Cisplatin Versus Vinblastine, Ifosfamide and Cisplatin as Second-Line Therapy for Patients With Relapsed/Resistant Germ Cell Tumors | NCT00072215 |
| Paclitaxel and Carboplatin Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer That Cannot Be Removed During Surgery | A Randomized Phase III Comparative Study of Paclitaxel With Carboplatin Versus Mitomycin, Ifosfamide, Cisplatin (MIC) Chemotherapy in Inoperable Advanced Stage Non-Small Cell Lung Cancer | NCT00004887 |
| Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer | A Randomized Phase II Trial of Taxol/VP-16/Estramustine vs. Ketoconazole/Doxorubicin/Vinblastine/Estramustine in Androgen Independent Prostate Cancer | NCT00003084 |
| A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients | An Open, Non-randomised, Multi-centre Phase I Study to Assess the Safety and Efficacy of Fluzoparib Given in Combination With Apatinib and Paclitaxel in the 2nd Line Treatment of Patients With Recurrent or Metastatic Gastric Cancer | NCT03026881 |
| Combination Chemotherapy in Treating Patients With Bladder Cancer | A Phase III Randomized Trial of Either M-VAC or Paclitaxel + Carboplatin as Postoperative Adjuvant Therapy in Patients With Muscle-Invasive Transitional Cell Carcinoma of the Bladder at High-Risk for Relapse | NCT00003701 |
| Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial | LS1681: A Phase I Trial of AR160 (Abraxane/Rituximab 160nm Nanoparticle) in Relapsed/Refractory B Cell Lymphomas Including Transformed Follicular Lymphoma | NCT03003546 |
| Phase II trial of nab-paclitaxel for the treatment of desmoid tumors and multiply relapsed/refractory desmoplastic small round cell tumors and Ewing sarcoma | Phase II trial of nab-paclitaxel for the treatment of desmoid tumors and multiply relapsed/refractory desmoplastic small round cell tumors and Ewing sarcoma - ABRADES | EUCTR2016-002464-14-ES |
| Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer | A Pilot Study of Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer | NCT03085056 |
| Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma | Phase II Trial of Raltitrexed and Paclitaxel as Second-line Chemotherapy for Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | NCT03083613 |
| A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer | A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer | NCT03086369 |
| A STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER [IMaGYN050] | A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER | JPRN-jRCT2080223474 |
| Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients with Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy | Ramucirumab Plus Irinotecan / Leucovorin / 5-FU Versus Ramucirumab Plus Paclitaxel in Patients with Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed One Prior Line of Palliative Chemotherapy - the Phase II/III RAMIRIS Study | NCT03081143 |
| The aim of this study is to see how well an investigational drug (calledBBI-608) works when it is given in combination with a standard anticancertreatment for people with advanced pancreatic cancer. | A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma. | EUCTR2016-004359-57-DE |
| Clinical study of first-line chemotherapy for ovarian cancer with paclitaxel and carboplatin albumin intravenous chemotherapy | Clinical study of first-line chemotherapy for ovarian cancer with paclitaxel and carboplatin albumin intravenous chemotherapy | ChiCTR-IOR-17010687 |
| Paclitaxel/Radiotherapy/Cisplatino for cervical cancer | Weekly paclitaxel concurrent with radiation therapy/Cisplatin in patients with cervical cancer of clinical stages IIb- IVA: PACORTCC study - PACORTCC | RPCEC00000239 |
| Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC) | A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination With Paclitaxel in Patients With Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry | NCT03057600 |
| A phase II study for the efficacy of bevacizumab with paclitaxel and carboplatin in patient with stage IVB, recurrent or persistant cervical cancer. | A phase II study for the efficacy of bevacizumab with paclitaxel and carboplatin in patient with stage IVB, recurrent or persistant cervical cancer. - JGOG1079 | JPRN-UMIN000026063 |
| Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract | Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract | NCT03051373 |
| Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | Phase II Randomized Trial Comparing Paclitaxel Combined With DDP Plus Concurrent Chemoradiotherapy With DDP Plus Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | NCT03047265 |
| Phase I/II multicenter trial of paclitaxel, ramucirumab and nivolumab for metastatic gastric cancer patients who progressed on chemotherapy with fluoropyrimidine plus platinum | Phase I/II multicenter trial of paclitaxel, ramucirumab and nivolumab for metastatic gastric cancer patients who progressed on chemotherapy with fluoropyrimidine plus platinum - Phase I/II trial of paclitaxel, ramucirumab and nivolumab for advanced gastric cancer patients | JPRN-UMIN000025947 |
| Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer | Assessing the REsponse Rate of Weekly Neo-adjuvanT pacliTAxel (Taxol) in Nigerian Women With Breast Cancer (ARETTA) | NCT03058939 |
| mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA | A Randomized, Parallel Control Trial to Compare mFOLFOX Versus mFOLFIRI Versus FOLFPTX (a Combination of Paclitaxel, Fluorouracil) as First-line Treatment in Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction | NCT03045770 |
| To compare bioavailability of Paclitaxel protein-bound particles of Cipla Ltd.,India with ABRAXANE® in Metastatic Breast cancer patients. | A multicenter, open label, randomized, two treatment, two period, two way crossover, single dose, bioequivalence study of paclitaxel protein-bound particles for injectable suspension (albumin-bound) 100 mg/vial by Cipla Ltd., India with ABRAXANE® for injectable suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) 100 mg/vial by Celgene Corporation, USA in breast cancer patients after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. - CRD/09 | CTRI/2017/01/007746 |
| A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT03038100 |
| Randomized phase II/III trial comparing dose-dense Paclitaxel and Carboplatin (TC) therapy and conventional triweekly TC therapy for newly diagnosed or recurrent uterine carcinosarcoma | Randomized phase II/III trial comparing dose-dense Paclitaxel and Carboplatin (TC) therapy and conventional triweekly TC therapy for newly diagnosed or recurrent uterine carcinosarcoma - Uterine carcinosarcoma dose-dense TC | JPRN-UMIN000025884 |
| Investigating a new combination of chemotherapy (nab-paclitaxel and gemcitabine) for patients with unresectable pancreatic cancer without metastasis. | A nationwide open-label multi-center prospective cohort study of nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer - NABGEM prospective cohort study in LAPC | EUCTR2016-001332-35-NL |
| A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer | A Phase 1b Study of OMP-305B83 Plus Weekly Paclitaxel in Subjects With Platinum Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer | NCT03030287 |
| RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty | RANGER II SFA: A 3:1 Randomized Trial Comparing the Boston Scientific RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty for the Treatment of Superficial Femoral Arteries (SFA) and Proximal Popliteal Arteries (PPA) | NCT03064126 |
| Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063) | A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine | NCT03019588 |
| Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer | LCI-BRE-H2N-PEPP-001: A Pilot Study of Paclitaxel Plus Pembrolizumab in Patients With Metastatic HER2-Negative Breast Cancer (The PePPy Trial) | NCT03018080 |
| A phase I/II study of intravenous gemcitabine and nab-paclitaxel combined with intraperitoneal paclitaxel in pancreatic cancer patients with peritoneal metastasis | A phase I/II study of intravenous gemcitabine and nab-paclitaxel combined with intraperitoneal paclitaxel in pancreatic cancer patients with peritoneal metastasis - Phase I/II study of GnP + IP PTX | JPRN-UMIN000024148 |
| study to compare effectiveness and safety of two regimes in advanced stage non small cell lung cancer. | A Phase III Open label Randomized control study to compare efficacy and safety of Pemetrexed-Carboplatin versus Paclitaxel-Carboplatin as induction regimen in advanced Non-squamous Non-Small-Cell lung cancer | CTRI/2016/12/007605 |
| Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium | Phase III Trial of Methotrexate, Vinblastine, Doxorubicin and Cisplatin vs Carboplatin and Paclitaxel in Advanced Carcinoma of the Urothelium | NCT00003376 |
| Low-dose gemcitabine plus nab-paclitaxel versus standard-dose gemcitabine plus nab-paclitaxel in elderly patients with metastastic pancreatic cancer: A randomized phase II trial | Low-dose gemcitabine plus nab-paclitaxel versus standard-dose gemcitabine plus nab-paclitaxel in elderly patients with metastastic pancreatic cancer: A randomized phase II trial - Low-dose gemcitabine plus nab-paclitaxel versus standard-dose gemcitabine plus nab-paclitaxel in elderly patients with metastastic pancreatic cancer | JPRN-UMIN000024505 |
| Ranger™ and Ranger™ SL (OTW) DCB) in China | Prospective, Non-randomized, Multicenter Clinical Study of the Boston Scientific Paclitaxel-Coated PTA Balloon Catheter (Ranger™ and Ranger™ SL (OTW) DCB) in China | NCT02944071 |
| Efficacy-Safety-Immunogenicity Study of CBT124&EU-sourced Avastin® in Stage 4 NSCLC | Efficacy, Safety & Immunogenicity Study of CBT124 & EU-sourced Avastin® in Combination With Carboplatin and Paclitaxel in First-line Treatment in (NSCLC) | NCT02879097 |
| A Study of nab®-Paclitaxel (Abraxane®) and Carboplatin plus Necitumumab (LY3012211) in Patients with Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) | A Single-Arm, Multicenter, Open-Label, Phase 2 Study of nab®-Paclitaxel (Abraxane®) and Carboplatin Chemotherapy plus Necitumumab (LY3012211) in the First-Line Treatment of Patients with Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) | EUCTR2016-002071-96-ES |
| Liposomal Paclitaxel Combined Nedaplatin in Treatment of Advanced or Recurrent Esophageal Carcinoma | Phase II Study of Liposomal Paclitaxel With Nedaplatin as First-line in Advanced or Recurrent Esophageal Carcinoma | NCT02861690 |
| A Randomised Phase II Study Of nab-paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas | A phase II study to establish if carboplatin and nab-paclitaxel combination is an effective and tolerable chemotherapy treatment for grade 3 advanced gastrointestinal Neuroendocrine Carcinomas. | ACTRN12616000958482 |
| Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy | A Randomized Phase III Trial of Comparing Combination Administration of Paclitaxel and Cisplatin Versus CEF as Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy | NCT02879513 |
| A phase I/ II study to assess the efficacy and safety of ABTL0812 in combination with paclitaxel and carboplatin in patients with advanced endometrial cancer or squamous NSCLC | A phase I/ II, open label study to assess the efficacy and safety of ABTL0812 in combination with paclitaxel and carboplatin in patients with advanced endometrial cancer or squamous NSCLC | EUCTR2016-001352-21-ES |
| Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC). | Phase II Single Arm Study of Combination Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Ovarian, Fallopian Tube, or Peritoneal Carcinoma Receiving Neoadjuvant Chemotherapy | NCT02834975 |
| Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer (JCOG1407, LAPC-mFOLFIRINOX/GnP-rP2) | Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer (JCOG1407, LAPC-mFOLFIRINOX/GnP-rP2) - Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer (JCOG1407, LAPC-mFOLFIRINOX/GnP-rP2) | JPRN-UMIN000023143 |
| A Prospective Observational Study Assessing The Role of IL-6 On The Platelet Protective Effects of Paclitaxel-based Chemotherapy in Patients with Epithelial Ovarian Cancer | A Prospective Observational Study Assessing The Role of IL-6 On The Platelet Protective Effects of Paclitaxel-based Chemotherapy in Patients with Epithelial Ovarian Cancer | ACTRN12616000923460 |
| STREAMER : STent Restenosis And MEdicaments Release | STREAMER : Stent Restenosis and Medicaments Release : Does Local Delivery of Paclitaxel be Safe and Efficient in Stenting of TransAtlantic InterSociety Consensus (TASC) Class C and D Femoropopliteal Artery Lesions | NCT02835586 |
| A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer | A Phase III Randomized, Open-Label Clinical Trial of BBI-608 Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer | NCT02826161 |
| Phase II trial of an alternating regimen consisting of first-line modified FOLFIRINOX and Gemcitabine plus nab-Paclitaxel for patients with metastatic pancreatic cancer | Phase II trial of an alternating regimen consisting of first-line modified FOLFIRINOX and Gemcitabine plus nab-Paclitaxel for patients with metastatic pancreatic cancer - KSCOT-01 | JPRN-UMIN000022936 |
| Phase I trial of intraperitoneal paclitaxel combinated with mFOLFOX6 or CapeOX for colorectal cancer with peritoneal metastasis | Phase I trial of intraperitoneal paclitaxel combinated with mFOLFOX6 or CapeOX for colorectal cancer with peritoneal metastasis - Phase I trial of intraperitoneal paclitaxel combinated with mFOLFOX6 or CapeOX for colorectal cancer with peritoneal metastasis | JPRN-UMIN000022924 |
| A Phase II study of Ramucirumab beyond disease progression in combination with Irinotecan after failure of weekly Paclitaxel plus Ramucirumab in advanced gastric cancer patients previously treated with fluoropyrimidine and platinum | A Phase II study of Ramucirumab beyond disease progression in combination with Irinotecan after failure of weekly Paclitaxel plus Ramucirumab in advanced gastric cancer patients previously treated with fluoropyrimidine and platinum - A Phase II study of Ramucirumab beyond disease progression in combination with Irinotecan after failure of weekly Paclitaxel plus Ramucirumab in advanced gastric cancer patients | JPRN-UMIN000022956 |
| PhaseII study of Nab-paclitaxel followed by EC as neoadjuvant chemotherapy for the operable breast cancer | PhaseII study of Nab-paclitaxel followed by EC as neoadjuvant chemotherapy for the operable breast cancer - PhaseII study of Nab-paclitaxel followed by EC as neoadjuvant chemotherapy for the operable breast cancer | JPRN-UMIN000022931 |
| Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer | Phase Ib Study of Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Patients With Metastatic Breast Cancer | NCT02824575 |
| Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors | A Phase Ib/II Study of Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in Participants With Previously Treated Metastatic and/ or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors | NCT02810418 |
| Randomized controlled trial for endovascular intervention for dysfunctional dialysis access with drug-coated balloon versus plain balloon angioplasty | Paclitaxel-eluting balloon Versus plain angioplasty balloon for dysfunctional dialysis access: a prospective double-blinded randomized controlled trial | ACTRN12616000789460 |
| Phase II study of Paclitaxel and Epirubicin as Neoadjuvant Treatment for locally advanced Breast Cancer. | Phase II study of Paclitaxel and Epirubicin as Neoadjuvant Treatment for locally advanced Breast Cancer. | ACTRN12616000786493 |
| Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma | A Phase I Study of the Mesothelin-Targeted Immunotoxin LMB-100 With or Without Nab-Paclitaxel (Abraxane) in Patients With Malignant Mesothelioma | NCT02798536 |
| Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients | A Multicenter Phase 4 Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients | NCT02812992 |
| Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer | A Randomised, Parallel, Double Blinded Study to Compare the Efficacy and Safety of FKB238 to Avastin® In 1st Line Treatment for Patients With Advanced/Recurrent Non Squamous NSCLC in Combination of Paclitaxel and Carboplatin | NCT02810457 |
| A Phase III Study of atezolizumab or Placebo in Combination With Nab-paclitaxel For Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer[IMpassion130] | A PHASE III MULTICENTER,RANDOMIZED,PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB(ANTI-PD-L1 ANTIBODY)IN COMBINATION WITH NAB-PACLITAXEL COMPARED WITH PLACEBO WITH NAB-PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC TRIPLE-NEGATIVE BREAST CANCER | JPRN-jRCT2080223227 |
| Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer. | Efficacy of Carboplatin and Paclitaxel With Trastuzumab and Pertuzumab (wPCbTP) and Switching to an Anthracycline-based Regimen (AC) in Non-responding Patients in Clinical Stage I-III HER2-positive Breast Cancer. | NCT02789657 |
| Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer | A Randomized, Placebo-Controlled, Double-Blind, Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel (Nab-Paclitaxel, Abraxane®) With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer | NCT02788981 |
| Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer | A Randomized Phase II Study of Neoadjuvant Carboplatin/Paclitaxel (CT) Versus Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen for Newly Diagnosed Primary Triple-Negative Inflammatory Breast Cancer | NCT02876107 |
| A clinical trial intended to compare safety and efficacy of two formulations of paclitaxel protein-bound particles for injectable suspension (albumin-bound) in patients with metastatic breast cancer under fasting conditions. | A Randomized, Open-Label, Two Period, Two-Treatment, Two Sequence, Single-Dose, Crossover, Bioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (albumin-bound) of Panacea Biotec, India with ABRAXANE® (Paclitaxel Protein-bound Particles for Injectable Suspension) (albumin-bound) manufactured for Celgene Corporation, Summit, NJ in Patients with Metastatic Breast Cancer under Fasting Conditions. | CTRI/2016/08/007209 |
| Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma | A Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma | NCT02879318 |
| Paclitaxel and Nortriptyline Hydrochloride in Treating Patients With Relapsed Small Cell Carcinoma | A Phase 1 Study of Weekly Paclitaxel and Nortriptyline for Relapsed Small Cell Carcinoma | NCT02881125 |
| Paclitaxel-coated Peripheral Stents Used in the Treatment of Femoropopliteal Stenoses | Paclitaxel-coated Peripheral Stents Used in the Treatment of Femoropopliteal Stenoses | NCT02936622 |
| Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC | A Phase II One-arm Open-label Neoadjuvant Study of Pembrolizumab in Combination With Nab-paclitaxel Followed by Pembrolizumab in Combination With Epirubicin and Cyclophosphamide in Patients With Triple Negative Breast Cancer | NCT03289819 |
| Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers: the ARMANI Phase III Trial | Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers: the ARMANI Phase III Trial | NCT02934464 |
| Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer | Randomised Phase II Study of the Combination of Oral Vinorelbine With Capecitabine Versus Gemcitabine in Combination With Paclitaxel Versus Gemcitabine in Combination With Docetaxel as First Line Chemotherapy in Patients With Metastatic Breast Cancer | NCT03887130 |
| Phase II study of neoadjuvant chemotherapy of gemcitabine+nab-paclitaxel therapy for patients with borderline resectable pancreatic cancer. | Phase II study of neoadjuvant chemotherapy of gemcitabine+nab-paclitaxel therapy for patients with borderline resectable pancreatic cancer. - Phase II study of neoadjuvant chemotherapy of gemcitabine+nab-paclitaxel therapy for patients with BRPC. | JPRN-UMIN000024154 |
| Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | A Randomized Phase II Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT02923739 |
| Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma | Pilot Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma | NCT02921022 |
| Study of NAC of GA Therapy for Patients With BRPC | Phase II Study of Neoadjuvant Chemotherapy of Gemcitabine+Nab-paclitaxel Therapy for Patients With Borderline Resectable Pancreatic Cancer | NCT02926183 |
| Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002) | A Non-Randomized Phase Ib-II Protocol of Paclitaxel, Carboplatin and the Dual PI3K/mTOR Kinase Inhibitor, PF-05212384, for Patients With Advanced, or Metastatic Non-Small Cell Carcinoma of the Lung | NCT02920450 |
| MEtronomic TrEatment Option in Advanced bReast cAncer | A Randomized Phase II Trial of Metronomic Oral Vinorelbine Plus Cyclophosphamide and Capecitabine (VEX) Versus Weekly Paclitaxel as First-line or Second-line Treatment in Patients With ER-positive/HER2-negative Advanced or Metastatic Breast Cancer | NCT02954055 |
| Phase II study of combination chemotherapy using paclitaxel, carboplatin, and bevacizumab in patients with advanced or recurrent cervical cancer. | Phase II study of combination chemotherapy using paclitaxel, carboplatin, and bevacizumab in patients with advanced or recurrent cervical cancer. - CC-Bev | JPRN-UMIN000024137 |
| A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1) | A Phase II Trial of Pharmacological Ascorbate, Gemcitabine, and Nab-Paclitaxel for Metastatic Pancreatic Cancer (PACMAN 2.1) | NCT02905578 |
| A Phase I-II Trial of Combination Nab-paclitaxel and Nintedanib or Nab-paclitaxel and Placebo in Relapsed Non-Small Cell Lung Cancer Adenocarcinoma - N3 Study | A PHASE I/II TRIAL OF COMBINATION NAB-PACLITAXEL AND NINTEDANIB OR NAB-PACLITAXEL AND PLACEBO IN RELAPSED NSCLC ADENOCARCINOMA - N3 | EUCTR2016-000109-35-GB |
| Addition of Denosumab to two different neoadjuvant treatment schedules of nab-Paclitaxel | Investigating Denosumab as an add-on to neoadjuvant chemotherapy in RANK/L-positive or RANK/L-negative primary breast cancer and two different nab-Paclitaxel schedules in a 2x2 factorial design (GeparX) - GeparX | EUCTR2015-001755-72-DE |
| Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer | A Phase 3, Randomized, International Study Comparing the Efficacy and Safety of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer | NCT02929576 |
| Ramucirumab plus Irinotecan / Leucovorin / 5-FU compared to Ramucirumab plus Paclitaxel in patients with advanced or metastatic gastric cancer who failed one prior chemotherapy - The Phase II/III RAMIRIS STUDY | Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy - The Phase II/III RAMIRIS STUDY - RAMIRIS | EUCTR2015-005171-24-DE |
| Phase II Trial of Neoadjuvant Treatment and Minimal Invasive Surgery for Esophageal and GEJ Cancer | Phase II Trial of Induction Chemotherapy Followed by Chemoradiotherapy With Paclitaxel and Carboplatin Before Minimal Invasive Surgery in Patients With Localized Esophageal and Gastro-esophageal Junction Cancer | NCT02924909 |
| Comparing the Safety and Efficacy of Paclitaxel Controlled Release Balloon Catheter (VasoguardTM) in the Treatment of Small Coronary Vessel Stenosis With a Common Coronary Balloon Catheter (Maverick2) | A Multicenter, Prospective and Randomized Controlled Clinical Study (VasoguardTM Trial I) That Comparing the Safety and Efficacy of Paclitaxel Controlled Release Balloon Catheter (VasoguardTM) in the Treatment of Small Coronary Vessel Stenosis With a Common Coronary Balloon Catheter (Maverick2) | NCT02891005 |
| Comparing the Safety and Efficacy of Paclitaxel Controlled Release Balloon Catheter in the Treatment of In-stent Restenosis of Coronary Artery Lesion With Paclitaxel Release Coronary Balloon Catheter | A Multicenter, Prospective and Randomized Controlled Clinical Study (VasoguardTM Trial II) That Comparing the Safety and Efficacy of Paclitaxel Controlled Release Balloon Catheter (VasoguardTM) in the Treatment of In-stent Restenosis of Coronary Artery Lesion With Paclitaxel Release Coronary Balloon Catheter (SeQuent Please) | NCT02891018 |
| A Study DHP107, a Novel Oral Paclitaxel Formulation, in Patients With Advanced Solid Tumours or Gastric Cancer | A Study of DHP107, a Novel Oral Paclitaxel Formulation, to Determine Maximum Tolerated Dose and Recommended Dose for Phase II Trial in Patients With Advanced Solid Cancer | NCT02890511 |
| Safety Study of Combination of Hormone Therapy, Paclitaxel and Radiation Therapy to Treat Prostate Cancer | Phase I Study of Bi-weekly Taxol and Definitive Radiation in Androgen Ablated Locally Advanced Prostate Cancer | NCT02911350 |
| Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma | Phase II Study of Nanoparticle Albumin-bound Paclitaxel Plus Gemcitabine as First-line Therapy for the Treatment of Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma | NCT02887248 |
| Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer | Randomized Phase 2 Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, With or Without Atezolizumab in Triple Negative Breast Cancer (TNBC) | NCT02883062 |
| A Phase II Study of biweekly Carboplatin, nab-paclitaxel, and concurrent Thoracic radiation therapy for Patients with local advanced Non-small cell Lung Cancer | A Phase II Study of biweekly Carboplatin, nab-paclitaxel, and concurrent Thoracic radiation therapy for Patients with local advanced Non-small cell Lung Cancer - A Phase II Study of biweekly Carboplatin, nab-paclitaxel, and concurrent Thoracic radiation therapy for Patients with local advanced Non-small cell Lung Cancer | JPRN-UMIN000023802 |
| The Phase II study on the efficacy and safety of weekly nab-paclitaxel with 3 rd line therapy or more of advanced or recurrent non-small cell lung cancer after disease progression on 2nd line therapy or more | The Phase II study on the efficacy and safety of weekly nab-paclitaxel with 3 rd line therapy or more of advanced or recurrent non-small cell lung cancer after disease progression on 2nd line therapy or more - The Phase II study on the efficacy and safety of weekly nab-paclitaxel with 3 rd line therapy or more of advanced or recurrent non-small cell lung cancer after disease progression on 2nd line therapy or more | JPRN-UMIN000023763 |
| A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer | A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine | NCT02898077 |
| Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment | Efficacy and Safety Evaluation of IBI308 Versus Paclitaxel/Irinotecan in Patients With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment: a Randomized, Open-label, Multicenter, Phase 2 Study (ORIENT-2) | NCT03116152 |
| Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response | Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response | NCT03096418 |
| Phase I/II Study of Weekly Paclitaxel and Carboplatin with Concurrent Radiation Therapy in Locally Advanced Non-Small-Cell Lung Cancer. Kansai Clinical Oncology Group KCOG T-0401 | Phase I/II Study of Weekly Paclitaxel and Carboplatin with Concurrent Radiation Therapy in Locally Advanced Non-Small-Cell Lung Cancer. Kansai Clinical Oncology Group KCOG T-0401 - Weekly Paclitaxel and Carboplatin with Concurrent Radiation Therapy in Locally Advanced Non-Small-Cell Lung Cancer. | JPRN-UMIN000026606 |
| Pre-Operative Trial (PGHA vs. PGH) for Resectable Pancreatic Cancer | Randomized Phase II Trial of Pre-Operative Gemcitabine, Nab-Paclitaxel, and Hydroxychloroquine With or Without Avelumab (PGHA vs. PGH) | NCT03344172 |
| Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer | A Phase II Study of Neoadjuvant Carboplatin/Paclitaxel Followed by Dose-Dense Doxorubicin/Cyclophosphamide in Patients With Hormone Receptor Negative, HER2 Receptor Negative Breast Cancer | NCT03301350 |
| Effects of scalp cooling on pharmacokinetics of paclitaxel in women treated for advanced cancer | Effects of scalp cooling on pharmacokinetics of paclitaxel in women treated for advanced cancer - Influence of scalp cooling on paclitaxel PK | NL-OMON44910 |
| Phase II Study of bevacizumab combined with chemotherapy (paclitaxel/carboplatin) as postoperative adjuvant therapy for cervical cancer | Phase II Study of bevacizumab combined with chemotherapy (paclitaxel/carboplatin) as postoperative adjuvant therapy for cervical cancer - Phase II Study of bevacizumab combined with chemotherapy (paclitaxel/carboplatin) as postoperative adjuvant therapy for cervical cancer | JPRN-UMIN000029306 |
| Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy | A Multinational, Multicenter, Open-label, Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of Liporaxel® (Oral Paclitaxel) Compared to Taxol® (IV Paclitaxel) as First-line Therapy in Patients With Recurrent or Metastatic HER2 Negative Breast Cancer | NCT03315364 |
| STELLA – A Randomized, Multicenter, Multinational, Double-Blind Study to Assess the Efficacy and Safety of MB02 (Bevacizumab Biosimilar Drug) Versus Avastin® in Combination With Carboplatin and Paclitaxel for the Treatment of Subjects With Stage IIIB/IV Non-squamous Non-Small Cell Lung Cancer (NSCLC) - STELLA | STELLA – A Randomized, Multicenter, Multinational, Double-Blind Study to Assess the Efficacy and Safety of MB02 (Bevacizumab Biosimilar Drug) Versus Avastin® in Combination With Carboplatin and Paclitaxel for the Treatment of Subjects With Stage IIIB/IV Non-squamous Non-Small Cell Lung Cancer (NSCLC) - STELLA | EUCTR2017-001769-26-HU |
| Comparison of efficacy of Paclitaxel with Cisplatin when given weekly along with radiation in patients suffering from Head and Neck cancers. | Comparison of outcomes of weekly Paclitaxel versus weekly Cisplatin in Oral cavity, Oropharyngeal and Hypopharyngeal cancer patients with concurrent Radiation - A Randomized Controlled Trial. | CTRI/2017/09/009864 |
| A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | A Randomized, Multicenter, Multinational, Double-Blind Study to Assess the Efficacy and Safety of MB02 (Bevacizumab Biosimilar Drug) Versus Avastin® in Combination With Carboplatin and Paclitaxel for the Treatment of Subjects With Stage IIIB/IV Non-squamous Non-Small Cell Lung Cancer (NSCLC) | NCT03296163 |
| A Clinical Trial of Ipatasertib plus chemotherapy for Patients with Advanced Triple Negative Breast Cancer or Hormone Receptor–Positive, HER2-Negative Breast Cancer that has a change in the PIK3CA/AKT1/PTEN Gene | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE III STUDY OF IPATASERTIB IN COMBINATION WITH PACLITAXEL AS A TREATMENT FOR PATIENTS WITH PIK3CA/AKT1/PTEN-ALTERED, LOCALLY ADVANCED OR METASTATIC, TRIPLE-NEGATIVE BREAST CANCER OR HORMONE RECEPTOR– POSITIVE, HER2-NEGATIVE BREAST CANCER | EUCTR2017-001548-36-GB |
| Second-line CM082 Combined With Paclitaxel For Patients With Advanced Gastric Cancer | Safety and Preliminary Efficacy of CM082 in Combination With Paclitaxel for Treating Advanced Gastric Cancer Who Progressed on Standard First-line Treatment: a Phase 1, Dose-escalation Study | NCT03286244 |
| MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer | Phase I Study of MCS110 Combined With Neoadjuvant Dose-Dense Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer | NCT03285607 |
| FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma | A Phase II Study of FOLFOX Combined With Nab-Paclitaxel (FOLFOX-A) in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma. Big Ten Cancer Research Consortium: BTCRC-GI15-015 | NCT03283761 |
| Study of the Interest of Pursuing or Not the Chemotherapy for Patients With Metastatic Esophageal Cancer | Phase II Randomized Study Measuring the Interest of Pursuing or Not the CT for Non-progressive Patients With Metastatic Esophageal Squamous-cell Cancer After 6 Weeks of LV5FU2-paclitaxel Given After a 1st Line Fluoropyrimidine/Pt Salt CT | NCT03301454 |
| Effects of (Licochalcone A) and Paclitaxel on Human Oral Squamous Cell Carcinoma Cell Line | Apoptotic and Anti-Proliferative Effects of Licorice Extract (Licochalcone A) and Paclitaxel Chemotherapy on Human Oral Squamous Cell Carcinoma Cell Line | NCT03292822 |
| Phase 2 study in patient with HER2-negative inflammatory breast cancer. | A prospective, multicentre, open-label, randomized, phase II study of Pembrolizumab in combination with neoadjuvante (F)EC-Paclitaxel regimen in HER2-negative inflammatory breast cancer. - PELICAN-IPC2015-016 | EUCTR2016-001868-11-FR |
| Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer Patients | Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer Patients | NCT03278015 |
| Clinical Study of Decitabine and Paclitaxel Combination Therapy | An Open-labelled, Parallel, Multiple Ascending Dose, Phase Ib Clinical Study of Decitabine and Paclitaxel Combination Therapy in Treating Patients With Metastatic and Locally Advanced Breast Cancer | NCT03282825 |
| RESPONSE OF CANCER DRUGS BEFORE SURGERY IN ESOPHAGEAL CANCER AND ALSO COMPARING TWO DIFFERENT CANCER DRUGS COMBINATIONS CISPLATIN PLUS 5FU AND PACLITAXEL AND CARBOPLATIN | Efficacy of Neoadjuvant chemotherapy in carcinoma esophagus A pilot study comparing Cisplatin plus 5FU with Paclitaxel plus Carboplatin | CTRI/2017/09/009658 |
| Stromal TARgeting for PAncreatic Cancer (STAR_PAC) | A Phase 1B Study Repurposing ATRA as Stromal Targeting Agent Along With Gemcitabine and Nab-Paclitaxel for Pancreatic Cancer (STAR_PAC) | NCT03307148 |
| NABGEM study: nab-paclitaxel plus gemcitabine in patients with locally unresectable pancreatic cancer. | NABGEM study: A nationwide open-label multi-center prospective cohort study of nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer | NL-OMON23547 |
| Exploratory Study on the Paclitaxel + S-1 + Oxaliplatin (PSOX) for Locally Advanced or Advanced Gastric Cancer | Exploratory Study on the Efficiency and Safety of Paclitaxel + S-1 + Oxaliplatin Chemotherapy in the Patients With Locally Advanced or Advanced Gastric Cancer | NCT03263741 |
| Does cediranib together with paclitaxel chemotherapy, or cediranib and olaparib, treat advanced endometrial cancer better than paclitaxel chemotherapy? | A 3-Arm Randomised Phase II Evaluation of Cediranib in Combination with Weekly Paclitaxel or Olaparib Versus Weekly Paclitaxel Chemotherapy as Second-Line Therapy for Advanced/ Metastatic Endometrial Carcinoma or for disease relapse within 12 months of adjuvant carboplatin-paclitaxel chemotherapy | ISRCTN16320634 |
| Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC | Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following Induction With Sequential IV Gemcitabine Plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer | NCT03257033 |
| The Efficacy and Safety of Nab-paclitaxel Plus S-1 in First-line Treatment of Advanced Biliary Tract Adenocarcinoma | Phase II Study of Nab-paclitaxel Plus S-1 in First-line Treatment of Advanced Biliary Tract Adenocarcinoma | NCT03830606 |
| A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IMpassion131) | A Phase III, Multicenter, Randomised, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-Pd-L1 Antibody) in Combination With Paclitaxel Compared With Placebo With Paclitaxel for Patients With Previously Untreated Inoperable Locally Advanced or Metastatic Triple Negative Breast Cancer - IMpassion131 | CTRI/2017/10/010010 |
| Is it safe to add cediranib to weekly paclitaxel chemotherapy in women with ovarian cancer who are at risk of developing malignant bowel obstruction? | Evaluation of the safety of CEdiranib in the prevention of Bowel perforation in platinum-resistant Ovarian Cancer | ISRCTN38690336 |
| Does cediranib together with paclitaxel chemotherapy, or cediranib and olaparib, treat advanced endometrial cancer better than paclitaxel chemotherapy? | A 3-Arm Randomised Phase II Evaluation of Cediranib in Combination with Weekly Paclitaxel or Olaparib Versus Weekly Paclitaxel Chemotherapy as Second-Line Therapy for Advanced/Metastatic Endometrial Carcinoma or for disease relapse within 12 months of adjuvant carboplatin-paclitaxel chemotherapy. - COPELIA | EUCTR2016-004617-28-GB |
| Phase I/II trial of S 81694 administered intravenously in;combination with paclitaxel to evaluate the safety,;pharmacokinetic and efficacy in metastatic breast cancer | Phase I/II trial of S 81694 administered intravenously in;combination with paclitaxel to evaluate the safety,;pharmacokinetic and efficacy in metastatic breast cancer - Phase I/II trial of S81694 plus paclitaxel in metastatic Breast Cancer | NL-OMON46450 |
| Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer | Phase 1A/1B Dose Escalation and Expansion Study of SBP-101 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma | NCT03412799 |
| Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer | A Phase II Clinical Trial of Pembrolizumab in Combination With Carboplatin-paclitaxel in Patients With Advanced (Stage III B-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer: MITO28/MANGO OV4 Study | NCT03410784 |
| Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling | An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel Plus Trastuzumab and Pertuzumab in Early Stage HER2-Negative Breast Cancer Patients Selected With a Test Measuring Live Cell HER2 Signaling Transduction (FACT 1) | NCT03412643 |
| Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) | Phase IB/II Trial of High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have No Prior Therapy for Their Metastatic Pancreatic Cancer | NCT03410030 |
| Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic Cancer | Clinical Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin in Patients With Unresectable Locally Advanced Pancreatic Cancer | NCT03585062 |
| A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL) | A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer | NCT03398655 |
| A phase II study of neoadjuvant chemotherapy with nab-paclitaxel followed by FEC in patitents with operable breast cancer | A phase II study of neoadjuvant chemotherapy with nab-paclitaxel followed by FEC in patitents with operable breast cancer - A phase II study of NAC with nab-paclitaxel for breast cancer | JPRN-UMIN000030692 |
| The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer | The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer | NCT03401827 |
| Phase I study of nab-paclitaxel and gemcitabine chemoradiotherapy for borderline resectable and locally advanced unresectable pancreatic ductal adenocarcinoma | Phase I study of nab-paclitaxel and gemcitabine chemoradiotherapy for borderline resectable and locally advanced unresectable pancreatic ductal adenocarcinoma - Phase I study of nab-paclitaxel and gemcitabine CRT for BR and UR-LA PDAC | JPRN-UMIN000030551 |
| Phase II Study of Paclitaxel and TAK-228 in metastatic urothelial carcinoma (UC) and the impact of PI3K-mTOR pathway genomic alterations | Phase II Study of Paclitaxel and TAK-228 in metastatic urothelial carcinoma (UC) and the impact of PI3K-mTOR pathway genomic alterations | EUCTR2017-004486-27-ES |
| Prospective, multi-centre trial to evaluate effectiveness of 45-min and 20-min post-infusion cooling time for patients treated with scalp cooling to prevent paclitaxel-induced alopecia | Prospective, multi-centre trial to evaluate effectiveness of 45-min and 20-min post-infusion cooling time for patients treated with scalp cooling to prevent paclitaxel-induced alopecia - COP | NL-OMON44353 |
| Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3) | Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma | NCT03377491 |
| Comparison of Response and Acute Toxicities of Concurrent Chemoradiation with Weekly Cisplatin Vs. Paclitaxel/Carboplatin in Locally Advanced Squamous Cell Carcinoma of Head & Neck: A Short-term Phase III Clinical Trial. | Comparison of Response and Acute Toxicities of Concurrent Chemoradiation with Weekly Cisplatin Vs. Paclitaxel/Carboplatin in Locally Advanced Squamous Cell Carcinoma of Head & Neck: A Short-term Phase III Clinical Trial. - Shuayb HN CCRT Trial | DRKS00012877 |
| Phase II study of nivolumab + bevacizumab + paclitaxel in patients with HER2-negative metastatic breast cancer Nivolumab Evaluation With BEvacizumab And pacliTaxel (NEWBEAT) study (WJOG9917B) | Phase II study of nivolumab + bevacizumab + paclitaxel in patients with HER2-negative metastatic breast cancer Nivolumab Evaluation With BEvacizumab And pacliTaxel (NEWBEAT) study (WJOG9917B) - Phase II study of nivolumab combination therapy for HER2-negative metastatic breast cancer (WJOG9917B)- NEWBEAT study | JPRN-UMIN000030242 |
| A Study of Ipatasertib in Combination with Paclitaxel as aTreatment for Participants With PIK3CA/AKT1/PTEN-Altered, locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer | A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer | JPRN-jRCT2080223714 |
| Paclitaxel, Cisplatin,5-FU vs. Radiotherapy Plus Paclitaxel, Cisplatin as Preoperative Therapy for Locally Advanced ESC | A Phase III Trial Comparing Paclitaxel, Cisplatin Plus 5-FU (TCF) Versus Radiotherapy With Paclitaxel Plus Cisplatin (TC-RT) as Preoperative Therapy for Locally Advanced Esophageal Squamous Cancer | NCT03366883 |
| Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery | Nivolumab Plus Weekly Carboplatin and Paclitaxel as Induction in Resectable Locally Advanced Head and Neck Cancer | NCT03342911 |
| Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer | Tianjin Medical University Cancer Institute and Hospital | NCT03348098 |
| Regional Cryotherapy in Preventing Paclitaxel Induced Peripheral Neuropathy in Breast Cancer Patients | Regional Cryotherapy in Preventing Paclitaxel Induced Peripheral Neuropathy in Patients With Early and Locally Advanced Breast Cancer | NCT03429972 |
| A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer | A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer | NCT03337724 |
| A multicenter study of adjuvant nab-paclitaxel followed by FEC for early breast cancer | A multicenter study of adjuvant nab-paclitaxel followed by FEC for early breast cancer - A study of adjuvant nab-paclitaxel followed by FEC for early breast cancer | JPRN-UMIN000029836 |
| Study of Paclitaxel in Combination With BOS172722 in Patients With Advanced Nonhaematologic Malignancies | A Phase 1/1b Study of Paclitaxel in Combination With BOS172722, a Monopolar Spindle 1 Kinase Inhibitor, in Patients With Advanced Nonhaematologic Malignancies | NCT03328494 |
| Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer | A Phase II Randomized Trial Evaluating Neoadjuvant Dose-Dense Doxorubicin/Cyclophosphamide Followed by Paclitaxel/Trastuzumab/Pertuzumab (AC THP) and Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) For Early Her2Neu Positive Breast Cancer | NCT03329378 |
| Comparison of efficacy, safety of BCD-021 compared with Avastin® administered in combination with paclitaxel and carboplatin in a first-line treatment of inoperable or advanced non-squamous NSCLC patients. | International multicenter randomized double blind phase III trial comparing safety and efficacy of BCD-021 (CJSC BIOCAD, Russia) and Paclitaxel + carboplatin to Avastin® (F. Hoffmann-La Roche Ltd, Switzerland)and paclitaxel + carboplatin in inoperable or advanced non-squamous non-small-cell lung cancer (NSCLC) patients | CTRI/2017/10/010206 |
| Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer | A Multi-national,Multi-center, Open-label, Phase 2 Clinical Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DHP107 (Liporaxel®,Oral Paclitaxel) Compared to IV Paclitaxel in Patients With Recurrent or Metastatic Breast Cancer(OPERA) | NCT03326102 |
| Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer | Phase 1b Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer | NCT03316599 |
| A Study of CPI-613 With Gemcitabine and Nab-paclitaxel for Patients With Advanced or Metastatic Pancreatic Cancer | A Phase I Study of CPI-613 in Combination With Gemcitabine and Nab-paclitaxel (Abraxane) for Patients With Locally Advanced or Metastatic Pancreatic Cancer | NCT03435289 |
| A phase I trial of biweekly nab-paclitaxel plus ramucirumab in patients with previously treated advanced gastric cancer | A phase I trial of biweekly nab-paclitaxel plus ramucirumab in patients with previously treated advanced gastric cancer - Biweekly nab-paclitaxel plus ramucirumab in patients with previously treated advanced gastric cancer | JPRN-UMIN000021949 |
| Nab-Paclitaxel Versus Paclitaxel Plus Carboplatin in Advanced Squamous Cell Non Small Cell Lung Cancer | The Randomized,Open, Multicenter Phase III Study to Compare the Effectiveness and Safety of Nab-Paclitaxel Versus Paclitaxel Plus Carboplatin First-Line Therapy Advanced Non Small Cell Lung Cancer Squamous Cell Carcinoma | NCT03262948 |
| INTRAPERITONEAL AEROSOLISATION OF ALBUMIN-STABILIZED PACLITAXEL NANOPARTICLES FOR PERITONEAL CARCINOMATOSIS – PHASE I/II STUDY PROTOCOL | INTRAPERITONEAL AEROSOLISATION OF ALBUMIN-STABILIZED PACLITAXEL NANOPARTICLES FOR PERITONEAL CARCINOMATOSIS – PHASE I/II STUDY PROTOCOL | EUCTR2017-001688-20-BE |
| Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma | Multimodality Therapy With Induction Carboplatin/Nab-Paclitaxel/Durvalumab Followed by Surgical Resection and Risk-adapted Adjuvant Therapy for the Treatment of Locally-Advanced and Surgically Resectable Squamous Cell Carcinoma of the Head and Neck | NCT03174275 |
| Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel | Feasibility of a Randomized Controlled Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel | NCT04237090 |
| Vaginal Cuff Brachytherapy Followed by Chemotherapy in Endometrial Cancer | Phase II Trial of Vaginal Cuff Brachytherapy Followed by Adjuvant Chemotherapy With Carboplatin and Dose Dense Paclitaxel in Patients With High-Risk Endometrial Cancer | NCT03189446 |
| Efficacy and Safety of QL1101 and Avastin® Respectively Combined With Paclitaxel and Carboplatin in the First-line Treatment of Non-squamous Non-small Cell Lung Cancer | A Multi-center, Randomized, Double-blind, Parallel, Two-group Phase III Clinical Study of the Efficacy and Safety of QL1101 and Avastin® Respectively Combined With Paclitaxel and Carboplatin in the First-line Treatment of Non-squamous Non-small Cell Lung Cancer | NCT03169335 |
| PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer | A Phase 1b Study of PU-H71 With Nab-paclitaxel (Abraxane) in Patients With HER2-Negative Metastatic Breast Cancer | NCT03166085 |
| Phase II trial of Bi-weeks' liposome-encapsulated paclitaxel combined with Nedaplatin in the treatment of advanced squamous cell lung carcinoma | Phase II trial of Bi-weeks' liposome-encapsulated paclitaxel combined with Nedaplatin in the treatment of advanced squamous cell lung carcinoma | ChiCTR-OIN-17011423 |
| PCB for Long De Novo Lesions of Main Coronary Arteries (D-Lesion Long Trial) | Efficacy and Safety of Paclitaxel-Coated Balloon Catheter in Patients With Long De Novo Lesions of Main Coronary Arteries | NCT03155971 |
| A Study of Atezolizumab with Neoadjuvant Anthracycline/NAB Paclitaxel Based Chemotherapy Compared with Placebo and Chemotherapy in Patients with Primary Invasive Triple-Negative Breast Cancer | A PHASE III RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH NEOADJUVANT ANTHRACYCLINE/NAB-PACLITAXEL-BASED CHEMOTHERAPY COMPARED WITH PLACEBO AND CHEMOTHERAPY IN PATIENTS WITH PRIMARY INVASIVE TRIPLE-NEGATIVE BREAST CANCER | EUCTR2016-004734-22-DE |
| Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors | A Phase 1 Evaluation of the Safety and Tolerability of TAK-228 in Combination With TAK-117 and Paclitaxel in Advanced Solid Tumors | NCT03154294 |
| Phase II study of nab-paclitaxel combined with S-1 in patients with early breast cancer:A multicenter clinical trial | Phase II study of nab-paclitaxel combined with S-1 in patients with early breast cancer:A multicenter clinical trial - nab-paclitaxel + S-1 for early breast cancer | JPRN-UMIN000027216 |
| BCT 1702 (CHARIOT): Patients with high-risk primary triple negative breast cancer who have had anthracycline-based chemotherapy will receive Ipilimumab and Nivolumab with weekly paclitaxel, followed by definitive surgery and further treatment with Nivolumab to evaluate the safety, feasibility and efficacy of this treatment. | BCT 1702 (CHARIOT): A phase II study evaluating efficacy and safety of Ipilimumab and Nivolumab with neoadjuvant weekly paclitaxel after anthracycline based chemotherapy in high-risk primary triple negative breast cancer, followed by definitive surgery and one year total duration of Nivolumab. | ACTRN12617000651381 |
| Pre-operative Treatment for Patients With Untreated Pancreatic Cancer | A Phase II Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Paricalcitol as Pre-operative Treatment in Patients With Untreated Resectable, Borderline Resectable and Locally Advanced Adenocarcinoma of the Pancreas | NCT03138720 |
| A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) | A Phase III, Multicenter, Randomised, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-Pd-L1 Antibody) in Combination With Paclitaxel Compared With Placebo With Paclitaxel for Patients With Previously Untreated Inoperable Locally Advanced or Metastatic Triple Negative Breast Cancer | NCT03125902 |
| PAREO study | PAclitaxel Resistance Explained by pharmacokinetic parameters in patients with Oesophageal cancer | NL-OMON20604 |
| Cetuximab in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Cisplatin Alone for the First-line Treatment of Metastatic Esophageal Squamous Cell Carcinoma | A Phase II, Multicenter, Open-Label, Randomized, Controlled Study to Assess Efficacy and Safety of Cetuximab in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Cisplatin Alone for the First-line Treatment of Chinese Subjects With Metastatic Esophageal Squamous Cell Carcinoma. | NCT03126708 |
| A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF PF-06439535 PLUS PACLITAXEL-CARBOPLATIN AND BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER | A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF PF-06439535 PLUS PACLITAXEL-CARBOPLATIN AND BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER - 9002/0328 (B7391003) | NL-OMON45020 |
| Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer | A Phase I-II Study of Interferon-gamma Plus Weekly Paclitaxel, Trastuzumab and Pertuzumab in Patients With HER-2 Positive Breast Cancer | NCT03112590 |
| Randomized phase II/III study of gemcitabine and nab-paclitaxel therapy versus S-1 and concurrent radiotherapy as neoadjuvant treatment for Borderline resectable pancreatic cancer | Randomized phase II/III study of gemcitabine and nab-paclitaxel therapy versus S-1 and concurrent radiotherapy as neoadjuvant treatment for Borderline resectable pancreatic cancer - GABARNANCE Trial | JPRN-UMIN000026858 |
| Carboplatin with nab-paclitaxel as first-line therapy in patients with advanced non-small-cell lung cancer and idiopathic interstitial pneumonias | Carboplatin with nab-paclitaxel as first-line therapy in patients with advanced non-small-cell lung cancer and idiopathic interstitial pneumonias - Carboplatin with nab-paclitaxel as first-line therapy in patients with advanced non-small-cell lung cancer and idiopathic interstitial pneumonias | JPRN-UMIN000026706 |
| A randomized phse 3 study of carboplatin plus nab-paclitaxel with or without nintedanib for advanced non-small-cell lung cancer with idiopathic pulmonary fibrosis | A randomized phse 3 study of carboplatin plus nab-paclitaxel with or without nintedanib for advanced non-small-cell lung cancer with idiopathic pulmonary fibrosis - Japanese Intergroup Study of Nintedanib for NSCLC with IPF (J-SONIC) | JPRN-UMIN000026799 |
| Local Paclitaxel or Balloon Angioplasty Below the Knee | Does Local Paclitaxel Improve the Efficacy of Balloon Angioplasty Without Stent Implantation for Treatment of Below the Knee Artery Lesions? | NCT03149913 |
| Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer | Pilot Study of Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer | NCT03121352 |
| A multicenter randomized comparison of paclitaxel-coated balloon with plain balloon angioplasty in patients withsmall vessel disease | A multicenter randomized comparison of paclitaxel-coated balloon with plain balloon angioplasty in patients withsmall vessel disease - A multicenter randomized comparison of paclitaxel-coated balloon with plain balloon angioplasty in patients withsmall vessel disease | JPRN-UMIN000026760 |
| Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer | A Phase II Trial of Nivolumab/Nab-paclitaxel/Carboplatin Induction Chemotherapy Followed by Response-stratified Locoregional Therapy for Patients With Locoregionally Advanced HPV-related Oropharyngeal Cancer- the OPTIMA II Trial | NCT03107182 |
| Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer | Single Arm, Phase IIA Clinical Trial Assessing The Safety And Efficacy of Atezolizumab in Combination With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer | NCT03125928 |
| TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer | Phase II Trial to Evaluate the Efficacy of the FASN Inhibitor, TVB-2640, in Combination With Trastuzumab Plus Paclitaxel or Endocrine Therapy in Patients With HER2+ Metastatic Breast Cancer Resistant to Trastuzumab-Based Therapy | NCT03179904 |
| PRIMUS001: A study looking at two different treatments for pancreatic cancer that has spread to other parts of the body | PRIMUS 001: An adaptive phase II study of FOLFOX-A (FOLFOX and nab-paclitaxel) versus AG (nab-paclitaxel and gemcitabine) in patients with metastatic pancreatic cancer, with integrated biomarker evaluation | ISRCTN75002153 |
| Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary | Feasibility IB Trial of Paclitaxel/Carboplatin + Galunisertib (a Small Molecule Inhibitor of the Kinase Domain of Type 1 TGF-B Receptor) in Patients With Newly Diagnosed, Persistent or Recurrent Carcinosarcoma of the Uterus or Ovary | NCT03206177 |
| Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib | The BAROCCO Study (Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib): an Italian Multicenter Randomized Phase II Study of Weekly Paclitaxel vs. Cediranib-Olaparib With Continuous Schedule vs. Cediranib-Olaparib With Intermittent Schedule in Patients With Platinum Resistant High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. | NCT03314740 |
| Phase I study of definitive chemoradiotherapy with paclitaxel, CDDP and 5-FU (PCF-RT) for clinical stage IA-IIIC esophageal cancer | Phase I study of definitive chemoradiotherapy with paclitaxel, CDDP and 5-FU (PCF-RT) for clinical stage IA-IIIC esophageal cancer - Phase I study of definitive CRT with PCF (PCF-RT) for clinical stage IA-IIIC esophageal cancer | JPRN-UMIN000028589 |
| A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer | A Pilot Study of Nivolumab With or Without Ipilimumab in Combination With Front-Line Neoadjuvant Dose Dense Paclitaxel and Carboplatin Chemotherapy and Post-Surgical Dose Dense Paclitaxel and Carboplatin Chemotherapy in Patients With High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT03245892 |
| A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab | A Phase III Clinical Study to Compare the Combination Therapy of Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab (EMERALD) | NCT03264547 |
| Phase II study of chemoradiotherapy combined with gemcitabine and nab-paclitaxel for unresectable locally advanced pancreatic cancer | Phase II study of chemoradiotherapy combined with gemcitabine and nab-paclitaxel for unresectable locally advanced pancreatic cancer - NUPAT 05 | JPRN-UMIN000028116 |
| Treatment of Coronary In-stent Restenosis (ISR) by a Sirolimus Coated or a Paclitaxel Coated Balloon | Treatment of Coronary In-stent Restenosis (ISR) by a Sirolimus Coated SEQUENT® SCB RAPID EXCHANGE PTCA Balloon Catheter or a Paclitaxel Coated SEQUENT® PLEASE PTCA Balloon Catheter | NCT03242096 |
| A Study of Ipatasertib in Combination with Paclitaxel as a Treatment for Patients with PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor–Positive, HER2-Negative Breast Cancer | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE III STUDY OF IPATASERTIB IN COMBINATION WITH PACLITAXEL AS A TREATMENT FOR PATIENTS WITH PIK3CA/AKT1/PTEN-ALTERED, LOCALLY ADVANCED OR METASTATIC, TRIPLE-NEGATIVE BREAST CANCER OR HORMONE RECEPTOR–POSITIVE, HER2-NEGATIVE BREAST CANCER | EUCTR2017-001548-36-ES |
| Nivolumab maintenance as monotherapy after carboplatine plus nab-paclitaxel for first-line treatment of advanced Non-small-cell lung cancer: Feasibility study | Nivolumab maintenance as monotherapy after carboplatine plus nab-paclitaxel for first-line treatment of advanced Non-small-cell lung cancer: Feasibility study - Feasibility Study of nivolumab maintenance therapy | JPRN-UMIN000027985 |
| An Open-label, Randomized Controlled Clinical Study: Neoadjuvant Chemotherapy using Paclitaxel Liposomes in Combination With Tegafur Verus Oxaliplatin Combination With Tegafur in Local Advanced Gastric Cancer | An Open-label, Randomized Controlled Clinical Study: Neoadjuvant Chemotherapy using Paclitaxel Liposomes in Combination With Tegafur Verus Oxaliplatin Combination With Tegafur in Local Advanced Gastric Cancer | ChiCTR-IPR-17012201 |
| A Clinical Trial of Ipatasertib plus chemotherapy for Patients with Advanced Triple-Negative Breast Cancer or Hormone Receptor–Positive, HER2-Negative Breast Cancer that has a change in the PIK3CA/AKT1/PTEN Gene | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE III STUDY OF IPATASERTIB IN COMBINATION WITH PACLITAXEL AS A TREATMENT FOR PATIENTS WITH PIK3CA/AKT1/PTEN-ALTERED, LOCALLY ADVANCED OR METASTATIC, TRIPLE-NEGATIVE BREAST CANCER OR HORMONE RECEPTOR–POSITIVE, HER2-NEGATIVE BREAST CANCER | EUCTR2017-001548-36-DE |
| Cisplatin/Etoposide or Paclitaxel/Carboplatin with Concurrent Radiation Therapy in Stage IIIB Non-Small Cell Lung Cancer: A One-Year Randomized Trial at a Low-Resource Setting | Cisplatin/Etoposide or Paclitaxel/Carboplatin with Concurrent Radiation Therapy in Stage IIIB Non-Small Cell Lung Cancer: A One-Year Randomized Trial at a Low-Resource Setting - Shuayb CCRT Trial | DRKS00012599 |
| A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA) | A Phase III Study to Evaluate the Efficacy and Safety of Fruquintinib in Combination With Paclitaxel Versus Paclitaxel Alone in Second Line Gastric Cancer | NCT03223376 |
| Doxorubicin, Cyclophosphamide followed by Paclitaxel vs. 5-FU, Doxorubicin, Cyclophosphamide in locally advanced Breast Cancer | Doxorubicin, Cyclophosphamide followed by Paclitaxel vs. 5-FU,Doxorubicin, Cyclophosphamide in locally advanced BreastCancer | TCTR20170711001 |
| Multicenter phase II study of neoadjuvant chemotherapy of gemcitabine+nab-paclitaxel therapy for patients with resectable pancreatic cancer. | Multicenter phase II study of neoadjuvant chemotherapy of gemcitabine+nab-paclitaxel therapy for patients with resectable pancreatic cancer. - Multicenter phase II study of neoadjuvant GEM+nab-PTX for resectable pancreatic cancer. | JPRN-UMIN000028101 |
| Phase IB-II, open label, multicentre feasibility study of pazopanib in combination with Paclitaxel and Carboplatin in patients with platinumrefractory/ resistant ovarian, fallopian tube or peritoneal carcinoma. | Phase IB-II, open label, multicentre feasibility study of pazopanib in combination with Paclitaxel and Carboplatin in patients with platinumrefractory/ resistant ovarian, fallopian tube or peritoneal carcinoma. - Pazopanib and weekly paclitaxel/carboplatin in ovarian cancer | NL-OMON45226 |
| Prospective multicenter study regarding the efficacy of Gemcitabine (gemzar) plus nab-Paclitaxel (Abraxane) regimen for locally advanced pancreatic cancer | Prospective multicenter study regarding the efficacy of Gemcitabine (gemzar) plus nab-Paclitaxel (Abraxane) regimen for locally advanced pancreatic cancer - GEAR study | JPRN-UMIN000027775 |
| Single-arm phase II study of induction Gemcitabine+nab-paclitaxel followed by gemcitabine and concurrent radiotherapy for locally advanced pancreatic cancer | Single-arm phase II study of induction Gemcitabine+nab-paclitaxel followed by gemcitabine and concurrent radiotherapy for locally advanced pancreatic cancer - Induction Gem/NabPTX followed by G-CRT for LAPC, sPII | JPRN-UMIN000027756 |
| Assessment of efficacy of weekly paclitaxel chemotherapy in ovarian cancers | Assessment of efficacy of weekly paclitaxel as a neoadjuvant chemotherapy in advanced ovarian cancers | IRCT2017050333789N1 |
| Neo-adjuvant pembrolizumab in primary stage IV ovarian cancer | Exploratory study of neo-adjuvant treatment with carboplatin, paclitaxel and pembrolizumab in primary stage IV serous ovarian cancer | EUCTR2016-004700-56-NL |
| A phase III clinical study to compare the combination therapy of eribulin mesylate + trastuzumab + pertuzumab with paclitaxel or Docetaxel + trastuzumab + pertuzumab | A phase III clinical study to compare the combination therapy of eribulin mesylate + trastuzumab + pertuzumab with paclitaxel or Docetaxel + trastuzumab + pertuzumab - JBCRG-M06 (EMERALD) | JPRN-UMIN000027938 |
| A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer | A Phase III Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Neoadjuvant Anthracycline/Nab-Paclitaxel-Based Chemotherapy Compared With Placebo and Chemotherapy in Patients With Primary Invasive Triple-Negative Breast Cancer | NCT03197935 |
| Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer | Phase I Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer | NCT03246074 |
| Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma | Phase I/Ib Study of Crenolanib With Ramucirumab and Paclitaxel as Second Line Therapy for Advanced Esophagogastric Adenocarcinoma | NCT03193918 |
| TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer | Phase II Clinical Trial of Treatment With TAK-228 and TAK-117 to Inhibit Homologous Recombination (HR) Followed by Cisplatin and Nab Paclitaxel in Patients With Chemotherapy-pretreated Metastatic Triple Negative Breast Cancer | NCT03193853 |
| Pilot study to assess physical exercise intervention in neoadjuvant treatment with nab-paclitaxel in patients with triple negative breast cáncer | Pilot study to assess physical exercise intervention in neoadjuvant treatment with nab-paclitaxel in patients with triple negative breast cancer - OncoExer | EUCTR2016-002435-15-ES |
| Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma | Open-label, Multicenter, Phase 1b/2 Clinical Study to Evaluate the Safety and Efficacy of CD40 Agonistic Monoclonal Antibody (APX005M) Administered Together With Gemcitabine and Nab-Paclitaxel With or Without PD-1 Blocking Antibody (Nivolumab) in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma | NCT03214250 |
| Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women | Phase 3 Study of Weekly Paclitaxel in Combination With Cisplatin as Adjuvant Chemotherapy for Early Stage Human Epidermal Growth Factor Receptor-2 (HER2) Negative Breast Cancer in High-risk Women | NCT03201861 |
| Randomized phase II study of TJ-3020 in patients with unresectable advanced or recurrent pancreatic cancer receiving nab-Paclitaxel plus Gemcitabine | Randomized phase II study of TJ-3020 in patients with unresectable advanced or recurrent pancreatic cancer receiving nab-Paclitaxel plus Gemcitabine - Randomized phase II study of TJ-3020 in patients with unresectable advanced or recurrent pancreatic cancer receiving nab-Paclitaxel plus Gemcitabine | JPRN-UMIN000027631 |
| Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer | A Phase 1b Pilot Clinical Trial of Cirmtuzumab, an Anti-ROR1 Monoclonal Antibody, in Combination With Paclitaxel for the Treatment of Patients With Metastatic, or Locally Advanced, Unresectable Breast Cancer | NCT02776917 |
| A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407) | A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-407) | NCT02775435 |
| [18F]Fluorothymidine (FLT) PET/CT Imaging In Rb+ Metastatic Breast Cancer Patients Undergoing LEE011 And Weekly Paclitaxel Therapy | [18F]Fluorothymidine (FLT) PET/CT Imaging In Rb+ Metastatic Breast Cancer Patients Undergoing LEE011 And Weekly Paclitaxel Therapy | NCT02774473 |
| Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC | AN OPEN-LABEL PHASE IB STUDY OF PALBOCICLIB (ORAL CDK 4/6 INHIBITOR) PLUS ABRAXANE (REGISTERED) (NAB-PACLITAXEL) IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA | NCT02501902 |
| Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer | A Randomized, Open-Label, Phase I Trial of Continuous, Intermittent, and Pulsatile Selumetinib (AZD6244) Plus Paclitaxel as Second-Line Treatment for Stage IIIB or IV Non-small Cell Lung Cancer (NSCLC) | NCT02503358 |
| Phase II study of carboplatin plus weekly paclitaxel for advanced squamous cell lung cancer with idiopathic interstitial pneumonia | Phase II study of carboplatin plus weekly paclitaxel for advanced squamous cell lung cancer with idiopathic interstitial pneumonia - Phase II study of carboplatin plus weekly paclitaxel for advanced squamous cell lung cancer with idiopathic interstitial pneumonia | JPRN-UMIN000018248 |
| A Phase 1b, Dose Finding Study Evaluating AZD1775 in Monotherapy and in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Advanced Solid Tumours | A Phase 1b, Dose Finding Study Evaluating AZD1775 in Monotherapy and in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Advanced Solid Tumours | JPRN-jRCT2080222908 |
| Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol | Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel | NCT02501954 |
| Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer | An Open-label, Multicenter Phase II Study of Afatinib Plus Weekly Taxol as Second Line Treatment for Advanced/Recurrent Gastric and Gastroesophageal Junction Cancer | NCT02501603 |
| Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer | Phase II Study of Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer | NCT02551432 |
| Phase 2 study of Nab-Paclitaxel for patients with previously treated EGFR wild-type non-small-cell lung cancer. | Phase 2 study of Nab-Paclitaxel for patients with previously treated EGFR wild-type non-small-cell lung cancer. - Phase 2 study of Nab-Paclitaxel for patients with previously treated EGFR wild-type non-small-cell lung cancer. | JPRN-UMIN000018233 |
| Phase II study of neoadjuvant FOLFIRINOX or nab-paclitaxel with gemcitabine for borderline resectable pancreatic cancer | Phase II study of neoadjuvant FOLFIRINOX or nab-paclitaxel with gemcitabine for borderline resectable pancreatic cancer - Phase II study of neoadjuvant FOLFIRINOX or nab-paclitaxel with gemcitabine for borderline resectable pancreatic cancer | JPRN-UMIN000017718 |
| Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer | A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer | NCT02488967 |
| PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma | Perioperative Stromal Depletion Strategies in Pancreatic Ductal Adenocarcinoma | NCT02487277 |
| Clinical Trial Testing the efficacy and Safety of Two Ramucirumab DosesGiven as Second Line Treatment to Patients with Stomach Cancer | Protocol I4T-MC-JVCZRandomized Phase 2 Trial Evaluating AlternativeRamucirumab Doses in Combination with Paclitaxel inSecond-Line Metastatic or Locally Advanced, UnresectableGastric or Gastroesophageal Junction Adenocarcinoma | EUCTR2014-005067-32-SE |
| Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer | A Phase 1 Study of Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer | NCT02483104 |
| A Phase III Study of Atezolizumab in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer | A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB (MPDL3280A, ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN+PACLITAXEL WITH OR WITHOUT BEVACIZUMAB COMPARED WITH CARBOPLATIN+PACLITAXEL+BEVACIZUMAB IN CHEMOTHERAPY NAIVE PATIENTS WITH STAGE IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER | JPRN-jRCT2080222890 |
| A Study of Gemcitabine/Nab-paclitaxel and Radiation Therapy Followed by Surgery in Patients With Advanced Pancreatic Cancer | A Phase I/II Study Evaluating the Feasibility and Safety of Neoadjuvant Gemcitabine/Nab-paclitaxel (GA) and Concurrent Gemcitabine and Radiation Therapy Followed By Pancreatic Resection and Major Arterial Resection for Adenocarcinoma of the Pancreas (ARCAP) in Patients With Advanced Disease | NCT02481635 |
| Continuous selumetinib versus continuous or interrupted selumetinib in combination with weekly paclitaxel in metastatic uveal melanoma | A randomised three arm, open label, phase II study of continuous selumetinib versus continuous or interrupted selumetinib in combination with weekly paclitaxel in metastatic uveal melanoma | ISRCTN29621851 |
| ARQ-761 Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Pancreatic Cancer | A Phase I/Ib, Single-Arm, Open-Label, Multi-Center Trial Using ARQ-761 (Beta-Lapachone) Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Metastatic, Unresectable, Or Recurrent Pancreatic Cancer | NCT02514031 |
| Comparison of 2 type of neoadjuvant chemotherpy in breast cancer | Comparison of clinical, radiologic and pathologic response rates of neoadjuvant chemotherapy regimen containing doxorubicin and cyclophosphamide with paclitaxel and gemcitabine in locally advanced breast cancer | IRCT2014051117644N1 |
| Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer | Phase 1b Study of HSP90 Inhibitor, AT13387 (Onalespib) in Combination With Paclitaxel in Patients With Advanced, Triple Negative Breast Cancer | NCT02474173 |
| NAB-PACLITAXEL Plus FOLFOX as Perioperative Chemotherapy in Patients With Operable Oesogastric Adenocarcinoma | Phase II Study of NAB-PACLITAXEL Plus FOLFOX as Perioperative Chemotherapy in Patients With Operable Oesogastric Adenocarcinoma | NCT02486601 |
| EWOC-1 (Elderly Women Ovarian Cancer) Trial: Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients with Stage III-IV Advanced Ovarian Cancer | EWOC-1 (Elderly Women Ovarian Cancer) Trial: Multicenter, randomized trial of carboplatin +/- paclitaxel in vulnerable elderly patients with stage III-IV advanced ovarian cancer. - EWOC-1 | EUCTR2013-000266-11-IE |
| Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects With Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT02470585 |
| Clinical Trial Testing the efficacy and Safety of Two Ramucirumab DosesGiven as Second Line Treatment to Patients with Stomach Cancer | Protocol I4T-MC-JVCZRandomized Phase 2 Trial Evaluating AlternativeRamucirumab Doses in Combination with Paclitaxel inSecond-Line Metastatic or Locally Advanced, UnresectableGastric or Gastroesophageal Junction Adenocarcinoma | EUCTR2014-005067-32-DE |
| Phase II study of carboplatin, weekly paclitaxel and bevacizumab for advanced non-squamous cell, non-small-cell lung cancer with idiopathic interstitial pneumonia | Phase II study of carboplatin, weekly paclitaxel and bevacizumab for advanced non-squamous cell, non-small-cell lung cancer with idiopathic interstitial pneumonia - Phase II study of carboplatin, weekly paclitaxel and bevacizumab for advanced non-squamous cell, non-small-cell lung cancer with idiopathic interstitial pneumonia | JPRN-UMIN000018322 |
| The OPERa study to assess the effectiveness and safety of Olaparib with Paclitaxel, in Western patients with advanced gastric and gastro-oesophageal junction cancer | A Randomised, double-blind, placebo controlled, multi-centre phase II study to assess the Efficacy and safety of 2nd line Olaparib in combination with Paclitaxel, in Western patients with advanced gastric and gastro-oesophageal junction cancer - OPERa | EUCTR2015-001605-14-GB |
| Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid and Fluorouracil for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection | A Prospective, Multi-centric, Phase ?, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine (AG) Versus Oxaliplatin Plus Folinic Acid and Fluorouracil (OFF) for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection | NCT02506842 |
| Phase I/II Study of Nab-paclitaxel and Gemcitabine Followed by AG-mFOLFOX in Patients With Metastatic Pancreatic Adenocarcinoma | A Phase I/II Study of Nab-paclitaxel (Abraxane) and Gemcitabine Followed by Modified FOLFOX (AG-mFOLFOX) in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma | NCT02504333 |
| Bioequivalence study of Paclitaxel protein-bound particles for injectable 100 mg/vial of Cipla Ltd.,India with ABRAXANE® for Injectable Manufacturedfor: Celgene Corporation Summit, USA in Metastatic Breast cancer patients after failure of Chemotherapy /relapse after prior Chemotherapy. | A multicenter, open label, randomized, balanced, two treatment,two period, two sequence, two way crossover, single dose,bioequivalence study of Paclitaxel protein-bound particles forinjectable suspension (albumin-bound) 100 mg/vial of Cipla Ltd.,India with ABRAXANE® for Injectable Suspension (paclitaxelprotein-bound particles for injectable suspension) Manufactured for: Celgene Corporation Summit, USA in Breast cancer patientsafter failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. | CTRI/2015/09/006156 |
| MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma | An Umbrella Study to Evaluate MLN1117 in Combination With Taxanes (Docetaxel or Paclitaxel) and Other Investigational Anticancer Agents for the Treatment of Patients With Previously Treated Advanced and Metastatic Gastric and Gastroesophageal Adenocarcinoma | NCT02551055 |
| Phase I study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 and intraperitoneal infusion of nafamostat mesilate for gastric cancer with peritoneal dissemination | Phase I study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 and intraperitoneal infusion of nafamostat mesilate for gastric cancer with peritoneal dissemination - Phase I study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 and intraperitoneal infusion of nafamostat mesilate for gastric cancer with peritoneal dissemination | JPRN-UMIN000018658 |
| Phase I/II study of Gemcitabine plus nab-paclitaxel and intraperitoneal paclitaxel for pancreas cancer with peritoneal metastasis | Phase I/II study of Gemcitabine plus nab-paclitaxel and intraperitoneal paclitaxel for pancreas cancer with peritoneal metastasis - clinical study for pancreatic cancer with peritoneal metastasis | JPRN-UMIN000018878 |
| A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma | A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of S-1 and Oxaliplatin With or Without Ramucirumab as First-line Therapy Followed by Paclitaxel With Ramucirumab as Second-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | NCT02539225 |
| Oral Paclitaxel for the Treatment of Cancer | A Randomized Crossover Study to Determine the Bioequivalence of Three Consecutive Daily Doses of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel | ACTRN12615000894594 |
| Preoperative gemcitabine plus nab-paclitaxel, concurrent 3D conformal radiation therapy for resectable pancreatic cancer: Phase II study | Preoperative gemcitabine plus nab-paclitaxel, concurrent 3D conformal radiation therapy for resectable pancreatic cancer: Phase II study - GEM/nabPTX CRT for resectable pancreatic cancer | JPRN-UMIN000018803 |
| A Study of MM-141 plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer | A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 plus Nab-paclitaxel and Gemcitabine versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer - A Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer | EUCTR2014-004572-34-ES |
| A Safety Study of Oraxol (HM30181 + oral paclitaxel) in Cancer Patients | A Safety Study of Oraxol (HM30181 + oral paclitaxel) in Cancer Patients | ACTRN12615000881538 |
| Study of Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in Unresectable Gastric Cancer | A Prospective Feasibility Study for Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in Unresectable Gastric Cancer | NCT02529878 |
| Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer | A Phase 1B/2 Study of Taladegib in Combination With Weekly Paclitaxel, Carboplatin, and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction | NCT02530437 |
| A study to evaluate the use of Ibrutinib in combination with nab-paclitaxel and gemcitabine versus placebo in combination with nab-paclitaxel and gemcitabine, in patients with metastatic pancreatic adenocarcinoma | A randomized, multicenter, double-blind, placebo-controlled, Phase 3 study of the Bruton’s Tyrosine Kinase inhibitor ibrutinib in combination with nab-paclitaxel and gemcitabine versus placebo in combination with nab-paclitaxel and gemcitabine, in the first line treatment of patients with metastatic pancreatic adenocarcinoma | EUCTR2015-000905-38-DE |
| The OPC for Optimal Delivery of Paclitaxel for the Prevention of Endovascular Restenosis - Above and Below the Knee | The COPPER-A Trial: The Occlusion Perfusion Catheter for Optimal Delivery of Paclitaxel for the Prevention of Endovascular Restenosis - Above and Below the Knee | NCT02464501 |
| Effectiveness of Paclitaxel-coated Luminor® Balloon Catheter Versus Uncoated Balloon Catheter in the Arteria Femoralis Superficialis | Multicenter Randomized Controlled Trial to Assess the Effectiveness of Paclitaxel-coated Luminor® Balloon Catheter Versus Uncoated Balloon Catheter in the Superficial Femoral and Popliteal Arteries to Prevent Vessel Restenosis or Reocclusion | NCT02540018 |
| Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers | A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers | NCT02525653 |
| MPDL3280A With Chemoradiation for Lung Cancer | DETERRED: PD-L1 blockadE To Evaluate the Safety of Lung CanceR Therapy Using Carboplatin, Paclitaxel, and Radiation CombinEd With MPDL3280A | NCT02525757 |
| A clinical trial to study the effects of Two Humanized Monoclonal Antibodies that Target HER2 Receptors in Combination with Weekly Paclitaxel in Patients with HER2-Positive Metastatic Breast Cancer. | A Randomized, Double-Blind, Multi-Centre, Parallel Group Study Comparing Two Humanized Monoclonal Antibodies that Target HER2 Receptors in Combination with Weekly Paclitaxel Administered as First-Line Treatment in Patients with HER2-Positive Metastatic Breast Cancer (Phase 1/3) | CTRI/2015/08/006085 |
| Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Matched Paired Pharmacodynamics and Feasibility Study of Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer | NCT02520154 |
| Nimotuzumabcombined paclitaxel and cisplatin first-line treatment of metastatic esophageal squamous cell carcinomas of the prospective, multicenter, double-blind, randomized, controlled clinical study | Nimotuzumabcombined paclitaxel and cisplatin first-line treatment of metastatic esophageal squamous cell carcinomas of the prospective, multicenter, double-blind, randomized, controlled clinical study | ChiCTR-IOR-15006875 |
| A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer | Randomized Phase 2 Trial Evaluating Alternative Ramucirumab Doses in Combination With Paclitaxel in Second-Line Metastatic or Locally Advanced, Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma | NCT02514551 |
| A Clinical Study to evaluate the Effectiveness and Safety of Intravenous Infusion of Nanosomal Paclitaxel Lipid Suspension in comparison with Taxol in Breast cancer patients. | An Open Label, Randomized, Multiple-Dose, Parallel Study to Evaluate Efficacy and Safety of Intravenous Infusion of Nanosomal Paclitaxel Lipid Suspension (Intas Pharmaceuticals Ltd.) and Taxol® (Paclitaxel Injection Concentrate, Bristol-Myers Squibb.) in Metastatic Breast Cancer Patients after failure of prior chemotherapy. - NA | CTRI/2015/07/006062 |
| AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer | A Phase II Trial of AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer | NCT02513563 |
| S-1 maintenance therapy after induction therapy with carboplatin and albumin-bound paclitaxel in patients with advanced squamous non-small-cell lung cancer: phase II study (HSR1502) | S-1 maintenance therapy after induction therapy with carboplatin and albumin-bound paclitaxel in patients with advanced squamous non-small-cell lung cancer: phase II study (HSR1502) - S-1 mantenance therapy after CBDCA / nab-PTX in Sq-NSCLC. | JPRN-UMIN000018428 |
| Phase I study of neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel for patients with borderline resectable pancreatic cancer | Phase I study of neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel for patients with borderline resectable pancreatic cancer - NAC-GEMABR | JPRN-UMIN000018382 |
| A Clinical Trial of Standard Chemotherapy (weekly Paclitaxel) +/- a novel agent in recurrent ovarian cancer | OCTOPUS: Ovarian Cancer Trials of Weekly Paclitaxel - Umbrella StudyA Randomised, Phase II Umbrella Trial of a Weekly Paclitxel +/- Novel Agents in Platinum-Resistant Ovarian Cancer - OCTOPUS | EUCTR2014-005221-12-GB |
| Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients | Randomised Phase III Trial of Chemoradiotherapy With or Without Paclitaxel in Patients With Squamous-cell Anal Cancer | NCT02526953 |
| Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer | A Study of the Safety, Immunopharmacodynamics and Anti-tumor Activity of Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Adenocarcinoma | NCT02562898 |
| Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Adjuvant Chemotherapy in the Treatment of the Lymph Node Positive Thoracic Esophageal Squamous Cell Carcinoma | Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma: A Randomized Phase 3 Trial | NCT02461043 |
| A study of neoadjuvant nab-paclitaxel followed by FEC for luminal B-like (HER2-negative) and triple-negative breast cancer | A study of neoadjuvant nab-paclitaxel followed by FEC for luminal B-like (HER2-negative) and triple-negative breast cancer - A study of neoadjuvant nab-paclitaxel followed by FEC for HER2-negative breast cancer | JPRN-UMIN000017675 |
| Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab | A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting | NCT02436993 |
| Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer | "Phase III Clinical Trial: ""Evaluation of the Combination of TRANSKRIP ® Plus Carboplatin and Paclitaxel as First Line Chemotherapy on Survival of Patients With Recurrent - Persistent Cervical Cancer" | NCT02446652 |
| Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery | Phase 2 Study of Preoperative Chemotherapy With Abraxane and Gemcitabine Followed by Chemoradiation for Borderline Resectable or Node-Positive Pancreatic Cancer | NCT02427841 |
| First line TIP in poor prognosis TGCTs | A treatment strategy of the Use of 1st line Chemotherapy in Patients with Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors based on tumor marker decline: A Phase II Trial of paclitaxel, ifosfamid and cisplatin regimen | EUCTR2014-001270-33-SK |
| First Line TIP in Poor Prognosis TGCTs. | A Treatment Strategy of the Use of 1st Line Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors Based on Tumor Marker Decline: A Phase II Trial of Paclitaxel, Ifosfamid and Cisplatin Regimen. | NCT02414685 |
| The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour. | A Phase I, Open Label, 2 Part Study to Determine the Pharmacokinetics of Olaparib 300 mg bd Administered as Monotherapy and Olaparib 100 mg bd as Monotherapy and in Combination With Paclitaxel in Chinese Patients With Advanced Solid Tumours | NCT02430311 |
| A Randomized, Open, Multicenter Trial of Genexol-PM or Paclitaxel Injection combined with Cisplatin for first-line therapy of advanced Non-Small Cell Lung Cancer(NSCLC) | A Randomized, Open, Multicenter Trial of Genexol-PM or Paclitaxel Injection combined with Cisplatin for first-line therapy of advanced Non-Small Cell Lung Cancer(NSCLC) | ChiCTR-IPR-15006252 |
| Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer | Randomized Open Label Phase II Trial of Neoadjuvant Carboplatin Plus Docetaxel or Carboplatin Plus Paclitaxel Followed by Doxorubicin Plus Cyclophosphamide in Stage I-III Triple-negative Breast Cancer | NCT02413320 |
| A phase II neoadjuvant trial of sequential weekly nab-paclitaxel(nanoparticle albumin-bound paclitaxel) (abraxane) in HER2-negative patients, followed by 5-fluorouracil/ epirubicine/ cyclophosphamide (FEC) in operable breast cancer | A phase II neoadjuvant trial of sequential weekly nab-paclitaxel(nanoparticle albumin-bound paclitaxel) (abraxane) in HER2-negative patients, followed by 5-fluorouracil/ epirubicine/ cyclophosphamide (FEC) in operable breast cancer - neo-WABI BC | JPRN-UMIN000017033 |
| A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric Cancer | A Phase Ib/2 Clinical Study to Evaluate the Safety, Pharmacokinetic Characteristics and Preliminary Efficacy of Fruquintinib Combined With Paclitaxel in Patients With Advanced Gastric Cancer | NCT02415023 |
| A clinical studies of concurrent chemoradiotherapy after Pemetrexed and cisplatin or Paclitaxel and cisplatin in stage IIIA/B Non-small Cell Lung Cancer | A clinical studies of induction therapy with Pemetrexed And cisplatin followed by concurrent chemoradiotherapy versus Pinduction therapy with aclitaxel and cisplatin followed by concurrent chemoradiotherapy in patents with stage IIIA/B Non-small Cell Lung Cancer | ChiCTR-IPR-15006245 |
| Phase I/II study of intravenous and intraperitoneal paclitaxel for peritoneal metastasis after resection of pancreatic cancer refractory to gemcitabine and fluoropyrimidine chemotherapy | Phase I/II study of intravenous and intraperitoneal paclitaxel for peritoneal metastasis after resection of pancreatic cancer refractory to gemcitabine and fluoropyrimidine chemotherapy - Intravenous and intraperitoneal paclitaxel for peritoneal metastasis after resection of pancreatic cancer | JPRN-UMIN000016670 |
| Regorafenib in Combination With Paclitaxel in Advanced Oesophagogastric Carcinoma | The REPEAT Trial: Regorafenib in Combination With Paclitaxel in Advanced Oesophagogastric Carcinoma, a Phase 1b Study | NCT02406170 |
| Phase II clinical study of nab-paclitaxel for patients with recurrent advanced non-small cell lung cancer. | Phase II clinical study of nab-paclitaxel for patients with recurrent advanced non-small cell lung cancer. - Phase II clinical study of nab-PTX for patients with recurrent NSCLC | JPRN-UMIN000016932 |
| A randomized, open label, multi centric, 2 treatment, 2 period, 2 sequence, single dose, crossover, BE study of Paclitaxel protein-bound particles for injectable suspension 100mg/vial and Abraxane 100mg/vial (Albumin bound Paclitaxel 260mg/m2) IV infusion in patients with metastatic breast cancer | A randomized, open label, multi centric, two treatment, two period, two sequence, single dose, crossover, bioequivalence study of Paclitaxel protein-bound particles for injectable suspension (albumin-bound) 100 mg/vial manufactured by Sindan Pharma for Actavis LLC, USA and Abraxane 100 mg/vial (Albumin bound Paclitaxel 260 mg/m2) intravenous infusion Abraxis BioScience LLC, New Jersey in patients with metastatic breast cancer | CTRI/2015/03/005653 |
| Ph2 Nab-paclitaxel With Gemcitabine to Determine Efficacy in Advanced Non-squamous NSCLC. | A Phase II Randomized Study of Nab-paclitaxel With Gemcitabine at Two Different Dose Combinations to Determine Efficacy in Patients With Advanced Non- Squamous Non-small Cell Lung Cancer (NSCLC). | NCT02405910 |
| Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen | An Indian Multicentric Open Label Prospective Phase IV Study to Evaluate Safety and Efficacy of Trastuzumab in Her2 Positive, Node Positive or High Risk Node Negative Breast Cancer as Part of a Treatment Regimen Consisting of Doxorubicin, Cyclophosphamide, With Either Docetaxel or Paclitaxel (AC-TH) or Docetaxel and Carboplatin (TCH) | NCT02419742 |
| A trial of MPDL3280A and nab-Paclitaxel in metastatic triple negative breast cancer | A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH NAB-PACLITAXEL COMPARED WITH PLACEBO WITH NAB-PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC TRIPLE-NEGATIVE BREAST CANCER | EUCTR2014-005490-37-BE |
| A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer | A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine Versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer | NCT02399137 |
| A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC | A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Nab®-Paclitaxel (Abraxane®) and Carboplatin Chemotherapy Plus Necitumumab (LY3012211) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) | NCT02392507 |
| Phase I/II trial of combined chemotherapy of S-1, Nab-paclitaxel and Oxaliplatin administered bi-weekly for patients with advanced gastric cancer(HGCSG1404: SNOW study) | Phase I/II trial of combined chemotherapy of S-1, Nab-paclitaxel and Oxaliplatin administered bi-weekly for patients with advanced gastric cancer(HGCSG1404: SNOW study) - HGCSG1404: SNOW study | JPRN-UMIN000016788 |
| Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer | Combining Abraxane With Capecitabine and Radiation Therapy for Consolidation of Treatment Following Induction Chemotherapy for Locally Advanced Pancreatic Cancer | NCT02394535 |
| Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal Cancer Receiving Combination Chemotherapy | Pilot Study of Correlation Between Molecular Phenotype and Response to Two Independent Treatment Regimens, Carboplatin and Paclitaxel vs. 5-Fluorouracil and Oxaliplatin Chemotherapy in Patients With Localized Esophageal Adenocarcinoma | NCT02392377 |
| Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers | A Phase II Study of Gemcitabine, Cisplatin, and Abraxane in Advanced Biliary Cancers | NCT02392637 |
| The COPPER-B Trial | The Occlusion Perfusion Catheter for Optimal Delivery of Paclitaxel for the Prevention of Endovascular Restenosis - Below the Knee | NCT02395744 |
| Phase II study of Nab-paclitaxel plus S-1 followed by FEC as neoadjuvant chemotherapy for the operable breast cancer | Phase II study of Nab-paclitaxel plus S-1 followed by FEC as neoadjuvant chemotherapy for the operable breast cancer - Phase II study of Nab-paclitaxel plus S-1 followed by FEC as neoadjuvant chemotherapy for the operable breast cancer | JPRN-UMIN000017177 |
| Phase II trial of dose dense paclitaxel plus carboplatin in advanced or recurrent uterine corpus cancer | Phase II trial of dose dense paclitaxel plus carboplatin in advanced or recurrent uterine corpus cancer - KCOG-G-1301 trial | JPRN-UMIN000017138 |
| Paclitaxel and carboplatin in patients with completely or optimally resected carcinosarcoma of the uterus: a phase II trial by the Japanese Uterine Sarcoma Group and the Tohoku Gynecologic Cancer Unit. | Paclitaxel and carboplatin in patients with completely or optimally resected carcinosarcoma of the uterus: a phase II trial by the Japanese Uterine Sarcoma Group and the Tohoku Gynecologic Cancer Unit. - Adjuvant chemotherapy (TC) for uterine carcinosarcoma: CS-01 | JPRN-UMIN000017212 |
| A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130) | A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer | NCT02425891 |
| A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer | A Comparison of Paclitaxel in Combination With Cisplatin(TP), Carboplatin(TC) or Fluorouracil(TF) Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Squamous Cell Carcinoma: A Three-Arm Randomized Phase III Trial | NCT02459457 |
| A phase III study comparing nab-paclitaxel with docetaxel in patients with previously treated advanced non-small-cell lung cancer | A phase III study comparing nab-paclitaxel with docetaxel in patients with previously treated advanced non-small-cell lung cancer - nab-PTX vs DTX Phase III | JPRN-UMIN000017487 |
| Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer | A Multicenter Open-Label Single-Arm Phase II Study Evaluating the Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Metastatic, Recurrent or Persistent Cervical Cancer | NCT02467907 |
| Anti EGFR therapy in relapsed/refractory urothelial carcinoma. | An open label, randomized, phase 2 study of Paclitaxel and Panitumumab compared to Paclitaxel alone in patients with relapsed or refractory urothelial cancer. - Anti EGFR therapy in relapsed/refractory urothelial carcinoma. | EUCTR2014-000857-35-IT |
| A RANDOMIZED PHASE III TRIAL COMPARING CONVENTIONAL-DOSE CHEMOTHERAPY USING PACLITAXEL, IFOSFAMIDE, AND CISPLATIN (TIP) WITH HIGH-DOSE CHEMOTHERAPY USING MOBILIZING PACLITAXEL PLUS IFOSFAMIDE FOLLOWED BY HIGH-DOSE CARBOPLATIN AND ETOPOSIDE (TI-CE) AS FIRST SALVAGE TREATMENT IN RELAPSED OR REFRACTORY GERM CELL TUMORS | A RANDOMIZED PHASE III TRIAL COMPARING CONVENTIONAL-DOSE CHEMOTHERAPY USING PACLITAXEL, IFOSFAMIDE, AND CISPLATIN (TIP) WITH HIGH-DOSE CHEMOTHERAPY USING MOBILIZING PACLITAXEL PLUS IFOSFAMIDE FOLLOWED BY HIGH-DOSE CARBOPLATIN AND ETOPOSIDE (TI-CE) AS FIRST SALVAGE TREATMENT IN RELAPSED OR REFRACTORY GERM CELL TUMORS - TIGER | EUCTR2014-003930-17-BE |
| A Study of Trastuzumab in combination with chemotherapy in early Breast Cancer | AN INDIAN MULTICENTRIC OPEN LABEL PROSPECTIVE PHASE IV STUDY TO EVALUATE SAFETY AND EFFICACY OF TRASTUZUMAB IN HER2 POSITIVE, NODE POSITIVE OR HIGH RISK NODE NEGATIVE BREAST CANCER AS PART OF A TREATMENT REGIMEN CONSISTING OF DOXORUBICIN, CYCLOPHOSPHAMIDE, WITH EITHER DOCETAXEL OR PACLITAXEL(ACâ??TH) OR DOCETAXEL AND CARBOPLATIN (TCH) | CTRI/2015/05/005789 |
| Pilot study of nab-Paclitaxel in combination with capecitabine as second line treatment of advanced biliary cancer. | Patients with advanced biliary cancer to be treated with second line combination chemotherapy of NAB Paclitaxel and capecitabine in a single arm pilot study to assess feasibility | ACTRN12615000504516 |
| A Phase III Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous NSCLC | A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (MPDL3280A, ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN + PACLITAXEL OR ATEZOLIZUMAB IN COMBINATION WITH CARBOPLATIN + NAB PACLITAXEL VERSUS CARBOPLATIN + NAB-PACLITAXEL IN CHEMOTHERAPY NAIVE PATIENTS WITH STAGE IV SQUAMOUS NON-SMALL CELL LUNG CANCER | JPRN-jRCT2080222847 |
| Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line Chemotherapy | NCT02449655 | |
| Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy | NCT02451956 | |
| Adjuvant FEC Versus EP in Breast Cancer (MIG5) | Fluorouracil, Epirubicin and Cyclophosphamide Versus Concurrent Epirubicin and Paclitaxel in Node Positive Early Breast Cancer Patients: a Randomized, Phase III Trial of Gruppo Oncologico Nord-Ovest - Mammella Intergruppo Group | NCT02450058 |
| Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy | NCT02448329 | |
| Luminor Registry: Registry of the Results of Angioplasty With Drug-eluting Balloon (Paclitaxel) in the Treatment of Infrainguinal Occlusive Lesions and Restenosis From Prior Endovascular Procedures in This Sector. | Luminor Registry: Registry of the Results of Angioplasty With Drug-eluting Balloon (Paclitaxel) in the Treatment of Infrainguinal Occlusive Lesions (Superficial Femoral Artery (SFA), Popliteal Artery (PA) and Tibial Arteries (ATs)) and Restenosis From Prior Endovascular Procedures in This Sector. | NCT02458911 |
| TOF Versus SOX in Metastatic Gastric Cancer | Paclitaxel/Oxaliplatin/Fluorouracil (TOF) Regimen Versus S-1/Oxaliplatin (SOX) Regimen Metastatic Gastric Cancer Patients | NCT02442362 |
| Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer | Phase 2 Trial of Dose Dense (Weekly) Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Recurrent Ovarian Cancer | NCT02440425 |
| Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE) | A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma | NCT02436668 |
| Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone Lesions | An Open-label, Multi-center, Non-randomized Phase Ib Study to Investigate Safety and Tolerability of Radium Ra 223 Dichloride (BAY88-8223) Administered in Combination With Paclitaxel in Cancer Subjects With Bone Lesions | NCT02442063 |
| A Phase II trial of nab-paclitaxel followed by EC as neoadjuvant chemotherapy for resectable breast cancer. | A Phase II trial of nab-paclitaxel followed by EC as neoadjuvant chemotherapy for resectable breast cancer. - Neo-ABEC trial | JPRN-UMIN000017382 |
| Non-interventional study to evaluate neurotoxicity under therapy with Paclitaxel Omnicare for patients with various tumor entities | Non-interventional study to evaluate neurotoxicity under therapy with Paclitaxel Omnicare for patients with various tumor entities - NEPAL | DRKS00008185 |
| A PHASE III RANDOMIZED CLINICAL TRIAL OF PEMBROLIZUMAB (MK-3475) VERSUS PACLITAXEL, DOCETAXEL OR VINFLUNINE IN SUBJECTS WITH RECURRENT OR PROGRESSIVE METASTATIC UROTHELIAL CANCER | A PHASE III RANDOMIZED CLINICAL TRIAL OF PEMBROLIZUMAB (MK-3475) VERSUS PACLITAXEL, DOCETAXEL OR VINFLUNINE IN SUBJECTS WITH RECURRENT OR PROGRESSIVE METASTATIC UROTHELIAL CANCER | PER-074-14 |
| Study evaluating Bevacizumab in Combination with Carboplatin and Paclitaxel in Women with Metastatic, Recurrent or Persistent Cervical Cancer | A MULTICENTRE OPEN-LABEL SINGLE-ARM PHASE II STUDY EVALUATING THE SAFETY AND EFFICACY OF BEVACIZUMAB IN COMBINATION WITH CARBOPLATIN AND PACLITAXEL IN PATIENTS WITH METASTATIC, RECURRENT OR PERSISTENT CERVICAL CANCER | EUCTR2014-005491-28-ES |
| TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors | A Multicenter, Prospective, Randomized Trial Comparing Paclitaxel and Carboplatin or Bleomycin, Etoposide and Cisplatin in the Treatment of Malignant Ovarian Germ Cell Tumors | NCT02429687 |
| TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors | A Multicenter, Prospective, Randomized Trial Comparing Paclitaxel and Carboplatin or Bleomycin, Etoposide and Cisplatin in the Treatment of Ovarian Malignant Sex Cord-Stromal Tumors | NCT02429700 |
| A phase II study of concurrent weekly carboplatin and paclitaxel combined with definitive radiotherapy for advanced-stage cervical cancer. | A phase II study of concurrent weekly carboplatin and paclitaxel combined with definitive radiotherapy for advanced-stage cervical cancer. - A phase II study of concurrent weekly carboplatin and paclitaxel combined with definitive radiotherapy for advanced-stage cervical cancer. | JPRN-UMIN000017232 |
| Postoperative concurrent chemoradiotherapy with paclitaxel/carboplatin chemotherapy in patients with high risk early stage cervical cancer. | Postoperative concurrent chemoradiotherapy with paclitaxel/carboplatin chemotherapy in patients with high risk early stage cervical cancer. - Postoperative CCRT using paclitaxel/carboplatin in patients with high risk early stage cervical cancer. | JPRN-UMIN000017231 |
| Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma | A Phase II, Open-Label, Non-Randomized, Pilot Study of Paclitaxel, Carboplatin and Oral Metformin for Patients Newly Diagnosed With Stage II-IV Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma | NCT02437812 |
| Study of Abraxane® and gemcitabine followed by modified FOLFOX in patients with previously untreated, metastatic pancreatic adenocarcinoma | A phase I/II study of nab-paclitaxel (Abraxane®) and gemcitabine followed by modified FOLFOX (AG-mFOLFOX) in patients with previously untreated, metastatic pancreatic adenocarcinoma - SEQUENCE | EUCTR2014-005350-19-ES |
| Phase I/II trial of combined chemotherapy of Nab-paclitaxel, S-1, and Oxaliplatin for gastric cancer patients with peritoneal metastasis (NSOX study) | Phase I/II trial of combined chemotherapy of Nab-paclitaxel, S-1, and Oxaliplatin for gastric cancer patients with peritoneal metastasis (NSOX study) - NSOX study | JPRN-UMIN000030909 |
| Phase I Low Dose WART in Combination With Weekly Paclitaxel for Platinum Resistant Ovarian Cancer | Phase I Study of Low Dose Whole Abdominal Radiation Therapy (LDWART) in Combination With Weekly Paclitaxel for Platinum Resistant Ovarian Cancer With Predominant Non-visceral Abdominal Disease | NCT02545010 |
| Pembro/Carbo/Taxol in Endometrial Cancer | Phase II Study of Pembrolizumab in Combination With Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Adenocarcinoma | NCT02549209 |
| Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer | A Phase II Study With a Limited Safety Lead-In of Enzalutamide in Combination With Carboplatin and Paclitaxel in Advanced Stage or Recurrent Endometrioid Endometrial Cancer | NCT02684227 |
| Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer | A Phase IIB Study of Neoadjuvant ZT Regimen (Enzalutamide Therapy in Combination With Weekly Paclitaxel) for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer | NCT02689427 |
| Observational study of Nab-paclitaxel followed by Anthracycline based regimen as preoperative chemotherapy for ER-negative resectable primary breast cancer | Observational study of Nab-paclitaxel followed by Anthracycline based regimen as preoperative chemotherapy for ER-negative resectable primary breast cancer - Observational study of Nab-paclitaxel followed by Anthracycline based regimen as preoperative chemotherapy for ER-negative resectable primary breast cancer | JPRN-UMIN000020994 |
| Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer | Phase II Study of Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer | NCT02717091 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer | Maintenance Nab-Paclitaxel After Cisplatin-Based Neoadjuvant Chemotherapy in Patients With High Risk Bladder Cancer | NCT02718742 |
| Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma | An Open, Multicenter, Randomized Phase III Clinical Study on Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma | NCT02677597 |
| Study of new oral drug in cancer patients with advance solid tumour. | Phase I Clinical Trial to Establish Maximum Tolerated Dose (MTD), Safety and Pharmacokinetic Profile of Oral Paclitaxel | CTRI/2016/02/006607 |
| Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer | A Phase Ib Trial of LY2157299 (TGFßR1 Kinase Inhibitor) With Paclitaxel in Patients With Triple Negative Metastatic Breast Cancer | NCT02672475 |
| Denosumab as an add-on Neoadjuvant Treatment (GeparX) | Investigating Denosumab as an add-on Neoadjuvant Treatment for RANK-positive or RANK-negative Primary Breast Cancer and Two Different Nab-Paclitaxel Schedules ; 2x2 Factorial Design (GeparX) | NCT02682693 |
| An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin plus 5-fluorouracil versus Carboplatin plus Weekly Paclitaxel in Patients with Inoperable Locally Recurrent or Metastatic Disease | A phase II trial comparing cisplatin plus 5-fluorouracil versus carboplatin plus weekly paclitaxel in patients with inoperable locally recurrent or metastatic anal cancer to demonstrate which is more effective and less toxic for patients with this disease. | ACTRN12616000061437 |
| Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLC | NCT02667743 | |
| A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer | A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer | NCT02661815 |
| Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer | Phase II Study of Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer or Those With Progression on First Line Therapy | NCT02769832 |
| An open label, non-randomized phase I/II study of ramucirumab in combination with nab-paclitaxel as second-line therapy in patients with advanced gastric cancer | An open label, non-randomized phase I/II study of ramucirumab in combination with nab-paclitaxel as second-line therapy in patients with advanced gastric cancer - A phase I/II study of ramucirumab plus nab-paclitaxel as second-line therapy in patients with advanced gastric cancer | JPRN-UMIN000020579 |
| Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery | A Phase II Study of Adjuvant Therapy Using a Regimen of Cyclophosphamide, Paclitaxel With Trastuzumab in Stage I-II HER2/Neu Positive Breast Cancer Patients | NCT02654119 |
| Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer | Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer - Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer | JPRN-UMIN000020475 |
| Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects | A Phase 1 Study of VS-4718, a Focal Adhesion Kinase Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Subjects With Advanced Cancer | NCT02651727 |
| Phase I study to optimize the safe starting dose of weekly paclitaxel | Phase I study to optimize the safe starting dose of weekly paclitaxel - Optimizing the starting dose of paclitaxel | JPRN-UMIN000020357 |
| Phase I/II Study of Chemoradiotherapy with Paclitaxel for Elderly Stage IB-III Esophageal Cancer | Phase I/II Study of Chemoradiotherapy with Paclitaxel for Elderly Stage IB-III Esophageal Cancer - Phase I/II Study of Chemoradiotherapy with Paclitaxel for Elderly Esophageal Cancer | JPRN-UMIN000020397 |
| Exploratory study of intraperitoneal paclitaxel combined with mFOLFOX6 for gastric cancer patients with peritoneal metastasis and inadequate oral intake | Exploratory study of intraperitoneal paclitaxel combined with mFOLFOX6 for gastric cancer patients with peritoneal metastasis and inadequate oral intake - Phase I/II study of FOLFOX+IP PTX | JPRN-UMIN000019206 |
| Phase 2 clinical study of neoadjuvant chemotherapy for HER2-negative primary breast cancer patients using dose dense nab-paclitaxel followed by dose dense Epirubicin and cyclophosphamide | Phase 2 clinical study of neoadjuvant chemotherapy for HER2-negative primary breast cancer patients using dose dense nab-paclitaxel followed by dose dense Epirubicin and cyclophosphamide - Neoadjuvant dose-dense chemotherapy for HER2 negative breast cancer | JPRN-UMIN000019787 |
| A Clinical trial to compare standard of care treatment: Nab-Paclitaxel/Gemcitabine alone or in combination with ACP-196 in patients with previously untreated Metastatic Pancreatic Cancer | A Phase 2, Randomized, Proof-of-Concept Study of Nab-Paclitaxel/Gemcitabine Alone and in Combination with ACP-196 in Subjects with Previously Untreated Metastatic Pancreatic Cancer | EUCTR2015-003428-30-BE |
| A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer | A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer | NCT02637375 |
| Nab-Paclitaxel (Abraxane®) and Gemcitabine as first line therapy in patients with cholangiocarcinoma - The NACHO trial | Nab-Paclitaxel (Abraxane®) and Gemcitabine as first line therapy in patients with cholangiocarcinoma ineligible for cisplatin-based chemotherapy – a pilot studyThe NACHO trial (GEMNABCCC-001) - The NACHO trial | EUCTR2014-004981-52-DE |
| Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase | A Phase I, Open-Label, Non-randomised, Single Centre Study of the Absorption, Metabolism, Excretion and Pharmacokinetics of AZD2014 After a Single Oral Dose of [14C]AZD2014, Followed by Multiple Doses of AZD2014 Either As Monotherapy or In Combination With Either Fulvestrant or Paclitaxel in Patients With Advanced Solid Malignancies | NCT02640755 |
| Study investigating PEGylated Recombinant Human Hyaluronidase (PEGPH20) in previously untreated patients with pancreatic cancer that have high levels of hyaluronan. The study has two groups: all patients will be treated with nab-Paclitaxel plus Gemcitabine. In addition, one group will receive PEGPH20 and the other group will receive an inactive substance. Neither the patient nor the doctor will know the treatment group in which the patient has been randomly assigned to. | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma | EUCTR2015-004068-13-LV |
| _ | Etude prospective de phase II d’évaluation d’une prise en charge multimodale des métastases ganglionnaires inguinales des carcinomes épidermoïdes du pénis par lymphadénectomie bilatérale et chimiothérapie TIP (paclitaxel, ifosfamide et cisplatine). - AFU-GETUG 25 - MEGACEP | EUCTR2014-004678-41-FR |
| A Clinical Trial to test the effect of Carboplatin and Paclitaxel, with or without Debio 1143 in patients with newly diagnosed Advanced Epithelial Ovarian Cancer. | A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Neoadjuvant Carboplatin and Paclitaxel, With or Without Debio 1143 in Patients With Newly Diagnosed Advanced Epithelial Ovarian Cancer. | EUCTR2015-005137-42-ES |
| Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | A Phase II Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | NCT02730247 |
| Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients | A Multinational, Randomized, Phase II Study of the Combination of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab, an IL-6R Inhibitor, as First-line Treatment in Patients With Locally Advanced or Metastatic Pancreatic Cancer. | NCT02767557 |
| Trial of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Cancer | A Phase I/II Trial of Weekly Regimens of Nab-paclitaxel Plus Cispaltin Combined With Concurrent IMRT for Inoperable,Locally Advanced Esophageal Carcinoma | NCT02762474 |
| Nab-Paclitaxel in Combination With Carboplatin as First-line Therapy in Patients With NSCLC | A Non-interventional Study of Nab-paclitaxel (Abraxane®) in Combination With Carboplatin as First Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NEPTUN) | NCT02799862 |
| Phase III study of carboplatin and paclitaxel or nano particle albumin-bound paclitaxel (nab-paclitaxel) with or without pembrolizumab in first line metastatic squamous NSCLC. | A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy with or without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-407) - Carboplatin & paclitaxel with/without pembrolizumab in metastatic Squamous NSCLC | EUCTR2016-000229-38-DE |
| Paclitaxel-coated Balloon Angioplasty Versus Standard Angioplasty for the Treatment of Stenosis of Arteriovenous Fistula | Paclitaxel-coated Balloon Angioplasty Versus Standard Angioplasty for the Treatment of Stenosis of Arteriovenous Fistula | NCT02753998 |
| Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer | Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer | NCT02752685 |
| Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma | A Phase II Pilot Trial of Nivolumab + Albumin-Bound Paclitaxel + Paricalcitol + Cisplatin + Gemcitabine (NAPPCG) In Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma | NCT02754726 |
| Evaluation of the remaining alcohol after intravenous injection of paclitaxel by analysis of expired gas and examination of the method for decreasing the remaining alcohol | Evaluation of the remaining alcohol after intravenous injection of paclitaxel by analysis of expired gas and examination of the method for decreasing the remaining alcohol - Evaluation of the remaining alcohol after intravenous injection of paclitaxel by analysis of expired gas and examination of the method for decreasing the remaining alcohol | JPRN-UMIN000021874 |
| Study to Evaluate CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors | Phase 1/2 Study of CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors | NCT02762981 |
| Evaluation of Paclitaxel in Patients With CLI and Femoropopliteal Occlusive Disease Treated With DCB Angioplasty | Evaluation of Paclitaxel in Patients With CLI (Critical Limb Ischemia) and Femoropopliteal Occlusive Disease Treated With DCB Angioplasty | NCT02758847 |
| Role of Intraperitoneal Intraoperative Chemotherapy With Paclitaxel in the Surgical Treatment of Peritoneal Carcinomatosis From Ovarian Cancer. Hyperthermia Versus Normothermia | Role of Intraperitoneal Intraoperative Chemotherapy With Paclitaxel in the Surgical Treatment of Peritoneal Carcinomatosis From Ovarian Cancer. Hyperthermia Versus Normothermia | NCT02739698 |
| Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer | Phase I Evaluation of Lenvatinib and Weekly Paclitaxel in Patients With Recurrent Endometrial, Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT02788708 |
| A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer | A Multicentre, Open-label Phase II Study of Nab-paclitaxel in Combination With Gemcitabine + Cisplatin as First Line Treatment in Patients With Unresectable Biliary Tract Cancer | NCT02632305 |
| The pilot study of Nintedanib and Carboplatin plus Paclitaxel for advanced non-small cell lung cancer with idiopathic interstitial pneumonia | The pilot study of Nintedanib and Carboplatin plus Paclitaxel for advanced non-small cell lung cancer with idiopathic interstitial pneumonia - The pilot study of Nintedanib and Carboplatin plus Paclitaxel for advanced non-small cell lung cancer with idiopathic interstitial pneumonia | JPRN-UMIN000021591 |
| Phase II study of ramucirumab plus paclitaxel therapy for elderly patients with non-resectable or metastatic gastric cancer (T-CORE1501) | Phase II study of ramucirumab plus paclitaxel therapy for elderly patients with non-resectable or metastatic gastric cancer (T-CORE1501) - Phase II study of ramucirumab plus paclitaxel therapy for elderly patients with gastric cancer (T-CORE1501) | JPRN-UMIN000021728 |
| A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer | A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128+MLN1117 (a PI3Ka Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women With Advanced, Recurrent, or Persistent Endometrial Cancer | NCT02725268 |
| Paclitaxel Detection in NSCLC Treated With TC Regimen | A Clinical Experience Trial to Detect the Plasma Paclitaxel Drug Concentration in Chinese Non -Small Cell Lung Cancer (NSCLC) Patients Treated With a Paclitaxel Plus Carboplatin (TC) Regimens, and Explore Individualized Treatment Using Pharmacokinetically-guided Dosing Strategy | NCT02737709 |
| Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer | Chemotherapy in KRAS Mutated Chemotherapy Naive Non-small Cell Lung Cancer Patients: a Phase III Study Comparing Cisplatin-pemetrexed With Carboplatin-paclitaxel-bevacizumab: NVALT 22 | NCT02743923 |
| A clinical study on regional lymphatic chemotherapy using an activated carbon nanoparticle-chemotherapy drugs in patients with esophageal cancer | A clinical study on regional lymphatic chemotherapy using an activated carbon nanoparticle–paclitaxel in patients with esophageal cancer | ChiCTR-IIR-16008115 |
| Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC | A Single-arm, Phase II Study of Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in Resectable Non-small Cell Lung Cancer (NSCLC) | NCT02716038 |
| Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | A Phase I/II Study of Ruxolitinib With Front-Line Neoadjuvant and Post-Surgical Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT02713386 |
| Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer | A Phase I/II Study of Pembrolizumab in Combination With Nab-Paclitaxel in Patients With Unresectable Stage III or Stage IV Non-Small Cell Lung Carcinoma | NCT02733250 |
| A PHASE III STUDY OF PEMBROLIZUMAB VS. PHYSICIANS’ CHOICE OF DOCETAXEL, PACLITAXEL OR IRINOTECAN IN 2L SUBJECTS WITH ADVANCED/METASTATIC ADENOCARCINOMA AND SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS | A PHASE III RANDOMIZED OPEN-LABEL STUDY OF SINGLE AGENT PEMBROLIZUMAB VS PHYSICIANS´ CHOICE OF SINGLE AGENT DOCETAXEL, PACLITAXEL, OR IRINOTECAN IN SUBJECTS WITH ADVANCED/METASTATIC ADENOCARCINOMA AND SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS THAT HAVE PROGRESSED AFTER FIRST-LINE STANDARD THERAPY (KEYNOTE-181) | PER-068-15 |
| Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer | Phase II Open Label Nonrandomized Trial of the Anti PD 1 Therapy Pembrolizumab With First Line Platinum Based Chemotherapy Followed by 12 Months Pembrolizumab Monotherapy for Patients With Stage III/IV Epithelial Ovarian Cancer | NCT02766582 |
| Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer | Feasibility and Safety of Avoiding Granulocyte Colony-stimulating Factor Prophylaxis During the Paclitaxel Portion of Dose Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen | NCT02698891 |
| Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients | PHASE 1B/2 STUDY OF PF-04136309 IN COMBINATION WITH GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA | NCT02732938 |
| Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery | Phase 1b/2 Clinical Trial of Neoadjuvant Pembrolizumab Plus Concurrent Chemoradiotherapy With Weekly Carboplatin and Paclitaxel in Adult Patients With Resectable, Locally Advanced Adenocarcinoma of the Gastroesophageal Junction or Gastric Cardia | NCT02730546 |
| Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma | A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma | NCT02551991 |
| ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer | Multi-center Phase IB Trial of ACY-1215 (Ricolinostat) Combined With Nab-paclitaxel in Unresectable or Metastatic Breast Cancer | NCT02632071 |
| Topical Cryotherapy in Reducing Pain in Patients With Chemotherapy Induced Peripheral Neuropathy or Paclitaxel Induced Acute Pain Syndrome | Pilot Clinical Trial Evaluating the Utility of Topical Cryotherapy to Decrease Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Paclitaxel-Induced Acute Pain Syndrome (P-APS): A Randomized Controlled Trial | NCT02640053 |
| A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN + PACLITAXEL WITH OR WITHOUT BEVACIZUMAB COMPARED WITH CARBOPLATIN + PACLITAXEL + BEVACIZUMAB IN CHEMOTHERAPY NAÏVE PATIENTS WITH STAGE IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER | A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN + PACLITAXEL WITH OR WITHOUT BEVACIZUMAB COMPARED WITH CARBOPLATIN + PACLITAXEL + BEVACIZUMAB IN CHEMOTHERAPY NAÏVE PATIENTS WITH STAGE IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER | PER-027-15 |
| A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN + PACLITAXEL OR MPDL3280A IN COMBINATION WITH CARBOPLATIN + NAB PACLITAXEL VERSUS CARBOPLATIN + NAB-PACLITAXEL IN CHEMOTHERAPY-NAÏVE PATIENTS WITH STAGE IV SQUAMOUS NON-SMALL CELL LUNG CANCER | A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN + PACLITAXEL OR MPDL3280A IN COMBINATION WITH CARBOPLATIN + NAB PACLITAXEL VERSUS CARBOPLATIN + NAB-PACLITAXEL IN CHEMOTHERAPY-NAÏVE PATIENTS WITH STAGE IV SQUAMOUS NON-SMALL CELL LUNG CANCER | PER-028-15 |
| Phase 2 study of Carboplatin plus nab-Paclitaxel for patients with PS 2 advanced NSCLC(TORG1426) | Phase 2 study of Carboplatin plus nab-Paclitaxel for patients with PS 2 advanced NSCLC(TORG1426) - Phase 2 study of Carboplatin plus nab-Paclitaxel for PS 2 advanced NSCLC (TORG1426) | JPRN-UMIN000019458 |
| Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma | Phase I Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma | NCT02588443 |
| Paclitaxel or S1 Plus Cisplatin in Concurrent Chemoradiotherapy for Squamous Cell Carcinoma of Esophagus | A Phase II Study to Compare Paclitaxel or S1 Plus Cisplatin in Concurrent Chemoradiotherapy for Squamous Cell Carcinoma of Esophagus | NCT02586753 |
| [18F]FLT PET/CT in Rb+ Metastatic Breast Cancer | [18F]Fluorothymidine (FLT) PET/CT Imaging in Rb+ Metastatic Breast Cancer Patients Undergoing LEE011 and Weekly Paclitaxel Therapy | NCT02608216 |
| Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer | Immune Response in Patients With Recurrent or Metastatic Non-small Cell Lung Cancer and Performance Status of 2 Treated With a Combination of Pembrolizumab and Low Dose Weekly Carboplatin/Paclitaxel | NCT02581943 |
| Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer | Single-Arm Phase II Combination Study of Low-Dose Paclitaxel With Pembrolizumab in Platinum-Refractory Urothelial Carcinoma | NCT02581982 |
| A phase II study of weekly paclitaxel in patients with advanced or recurrent esophageal cancer who had previously received docetaxel-containing chemotherapy | A phase II study of weekly paclitaxel in patients with advanced or recurrent esophageal cancer who had previously received docetaxel-containing chemotherapy - A phase II study of weekly paclitaxel in patients with advanced or recurrent esophageal cancer who had previously received docetaxel-containing chemotherapy | JPRN-UMIN000019230 |
| A study in hormone receptor-positive metastatic breast carcinoma patients receiving IMP321 or placebo as adjunctive to a standard chemotherapy treatment regimen of paclitaxel. | AIPAC (Active Immunotherapy PAClitaxel): A multicentre, Phase IIb, randomised, double blind, placebo-controlled study in hormone receptor-positive metastatic breast carcinoma patients receiving IMP321 (LAG-3Ig fusion protein) or placebo as adjunctive to a standard chemotherapy treatment regimen of paclitaxel. - AIPAC | EUCTR2015-002541-63-NL |
| Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC) | "Phase II Non-Randomized Three Arm Trial of Induction Chemotherapy With Nab-Paclitaxel and Cisplatin (AP: Arms 1 and 3) or Single Agent Nab-paclitaxel (A: Arm 2) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC): ""The APA Trial""." | NCT02573493 |
| Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer | A Phase 2, Randomized, Proof-of-Concept Study of Nab-Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Previously Untreated Metastatic Pancreatic Cancer | NCT02570711 |
| Neoadjuvant therapy in TRIPle negative breast cancer with antiPDL1 | Neo-Adjuvant study with the PDL1-directed antibody in Triple Negative, Early High-Risk and Locally Advanced Breast Cancer undergoing treatment with nab-paclitaxel and carboplatin - NeoTRIPaPDL1 | EUCTR2014-005017-23-DE |
| TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors | A Phase I Study Evaluating the Safety and Efficacy of TGR 1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors | NCT02574663 |
| Randomized Phase II/III Trial of Conventional Paclitaxel and Carboplatin with/without Bevacizumab versus Dose-dense Paclitaxel and Carboplatin with/without Bevacizumab in Stage IVB, Recurrent, or Persistent Cervical Carcinoma (JCOG1311, CC-TC/ddTC-P2/3) | Randomized Phase II/III Trial of Conventional Paclitaxel and Carboplatin with/without Bevacizumab versus Dose-dense Paclitaxel and Carboplatin with/without Bevacizumab in Stage IVB, Recurrent, or Persistent Cervical Carcinoma (JCOG1311, CC-TC/ddTC-P2/3) - Randomized Phase II/III Trial of Conventional Paclitaxel and Carboplatin with/without Bevacizumab versus Dose-dense Paclitaxel and Carboplatin with/without Bevacizumab in Stage IVB, Recurrent, or Persistent Cervical Carcinoma (JCOG1311, CC-TC/ddTC-P2/3) | JPRN-UMIN000019191 |
| Primary Patency in Post-angioplasty Dysfunctional Arteriovenous Fistula in Renal Dialysis: Paclitaxel-releasing PTA Balloon Catheter vs PTA Balloon | NCT02565953 | |
| A Phase 3 Randomized, Double-Blind Study of PF-06439535 plus Paclitaxel-Carboplatin and Bevacizumab plus Pacitaxel-Carboplatin for the first-line treatment of patients with advanced non-squamous non-small cell lung cancer. | A Phase 3 Randomized, Double-Blind Study of PF-06439535 plus Paclitaxel-Carboplatin and Bevacizumab plus Pacitaxel-Carboplatin for the first-line treatment of patients with advanced non-squamous non-small cell lung cancer. | PER-029-15 |
| First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine | Induction Treatment With Nab-paclitaxel/Gemcitabine for First-line Treatment of Metastatic Pancreatic Cancer Followed by Either Alternating Application of Gemcitabine Monotherapy and Nab-paclitaxel/Gemcitabine or Continuing Application of Nab-paclitaxel/Gemcitabine: A Randomized Phase II Study | NCT02564146 |
| A Phase III Randomized Open-Label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects With Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus That Have Progressed After First-Line Standard Therapy (KEYNOTE-181) | A Phase III Randomized Open-Label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects With Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus That Have Progressed After First-Line Standard Therapy (KEYNOTE-181) | NCT02564263 |
| S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery | A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma | NCT02562716 |
| QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel | Phase Ib/II Study of ALT-803 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Advanced Pancreatic Cancer | NCT02559674 |
| Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer | Phase II Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Urothelial Cancer | NCT02560038 |
| Study the pharmacokinetics of Paclitaxel in patients from different BMI groups after administration of chemotherapy | A Prospective, open label, non randomized, comparative pharmacokinetic study of Paclitaxel pharmacokinetics in women with different Body Mass Index undergoing chemotherapy for breast and ovarian cancer. - Paclitaxel PK Study | CTRI/2015/09/006193 |
| Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer | A Pilot Study of Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Resectable or Potentially Resectable Pancreatic Adenocarcinoma (PDAC) | NCT02550327 |
| Paclitaxel assisted balloon angioplasty of venous stenosis in haemodialysis access: PAVE trial | Paclitaxel assisted balloon Angioplasty of Venous stenosis in haEmodialysis access: The PAVE trial. A multicentre double-blind randomised controlled trial in haemodialysis patients with a stenosis in a native arteriovenous fistula | ISRCTN14284759 |
| Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer | An Open-Label, Randomized, Multicenter, Phase 3 Study to Determine the Safety, Tolerability, and Tumor Response of Oraxol and Its Comparability to IV Taxol or Generic IV Paclitaxel in Subjects With Metastatic Breast Cancer | NCT02594371 |
| Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC | Women's Triple-Negative First-Line Study: A Phase II Trial of Panitumumab, Carboplatin and Paclitaxel (PaCT) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy | NCT02593175 |
| Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic Analysis | Phase II Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic Analysis | NCT02628951 |
| Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer | Phase I, Open-Label Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer | NCT02630199 |
| Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations | Phase II Randomized Clinical Trial and Biomarker Analysis of Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin as Neoadjuvant Chemotherapy in Locally Advanced HER2-Negative Breast Cancer With TEKT4 Variations | NCT02628613 |
| Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer | Moving PD-1 Blockade With Pembrolizumab Into Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer | NCT02621398 |
| Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer | An Open Label, Multicenter, Single Arm, Phase 1/2 Trial of Metronomic 5-fluorouracil in Combination With Nab-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma. | NCT02620800 |
| Ultrasound to Enhance Paclitaxel Uptake in Critical Limb Ischemia: the PACUS Trial | Use of Local Ultrasound to Enhance Local Paclitaxel Delivery Effect After Femoro-popliteal Percutaneous Transluminal Angioplasty in Patients With Critical Limb Ischemia: the PACUS Trial | NCT02625740 |
| Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer Patients | Study of the Safety, Tolerability and Efficacy of the Investigational Anti PD-L1 Monoclonal Antibody Durvalumab in Combination With Paclitaxel in Patients With Metastatic Triple Negative PD-L1 Positive Breast Cancer | NCT02628132 |
| FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine | Phase II Randomised Multicenter Trial Evaluating a Sequential Treatment With Nab-paclitaxel+Gemcitabine /FOLFIRI.3 vs Nab-paclitaxel + Gemcitabine in First Line Metastatic Pancreatic Cancer | NCT02827201 |
| PI3Kß Selective Inhibitor With Paclitaxel, Advanced Gastric Adenocarcinoma | A Phase Ib/IIa, Open-Label, Dose Finding Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of PI3Kß Selective Inhibitor (GSK2636771) Administered in Combination With Paclitaxel in Advanced Gastric Adenocarcinoma | NCT02615730 |
| Circulating Tumor Cells as Tools for Therapy Response in Nab-paclitaxel Treated Metastatic Pancreatic Cancer Patients | A Novel Therapy for Locally Advanced and Metastatic Pancreatic Cancer Based on Nanoparticle Albumin-bound Paclitaxel and Gemcitabine: Circulating Tumor Cells as a Potential Biomarker for Treatment Monitoring, -Response and Survival | NCT02707159 |
| The Randomized Controlled Trial Study of the Incidence of Paclitaxel Hypersensitivity Reaction as First Line drug in Gynecologic Cancer Patients between 2 Steroid Premedication Type: Hydrocortisone & dexamethasone VS Dexamethasone alone | The Randomized Controlled Trial Study of the Incidence of Paclitaxel Hypersensitivity Reaction as First Line drug in Gynecologic Cancer Patients between 2 Steroid Premedication Type: Hydrocortisone & dexamethasone VS Dexamethasone alone | TCTR20151122001 |
| Carboplatin plus nab-Paclitaxel versus docetaxel for elderly squamous non-small cell lung cancer (CAPITAL study) | Carboplatin plus nab-Paclitaxel versus docetaxel for elderly squamous non-small cell lung cancer (CAPITAL study) - CBDCA+nab-PTX vs DOC for eldery Sq NSCLC Phase III study | JPRN-UMIN000019843 |
| Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor | A Prospective Randomized Multicenter Clinical Control Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor | NCT02639650 |
| A study on the efficacy and safety of chemotherapy with paclitaxel, ifosfamide, cisplatin for metastatic penile cancer | A study on the efficacy and safety of chemotherapy with paclitaxel, ifosfamide, cisplatin for metastatic penile cancer - A study on the efficacy and safety of chemotherapy with paclitaxel, ifosfamide, cisplatin for metastatic penile cancer | JPRN-UMIN000019798 |
| BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer | Phase Ib Study of BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer | NCT02608229 |
| A Study of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP) | A Phase II, Randomized, Multicenter Study to Assess the Efficacy of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP): The AGNOSTOS Trial | NCT02607202 |
| Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy | Open-label Multicenter Multiple Ascending Dose Study to Evaluate Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Gemcitabine + Cisplatin Chemotherapy (Second Line for Patients With Non-small Cell Lung Cancer) or Paclitaxel + Carboplatin Chemotherapy (Second Line for Patients With Non-small-cell Lung Cancer, Second and Subsequent Lines for Patients With Epithelial Ovarian Cancer) | NCT02728492 |
| Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma | An Prospective, Multicenter, Double-blind, Randomized, Controlled Clinical Study of Nimotuzumab Combined With Paclitaxel and Cisplatin as First-line Treatment of Metastatic Esophageal Squamous Cell Carcinomas | NCT02611700 |
| Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib | A Trial of Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib | NCT02607332 |
| IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma | AIPAC (Active Immunotherapy PAClitaxel): A Multicentre, Phase IIb, Randomised,Double Blind, Placebo-controlled Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients Receiving IMP321 (LAG-3Ig Fusion Protein) or Placebo as Adjunctive to a Standard Chemotherapy Treatment Regimen of Paclitaxel | NCT02614833 |
| A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer | A Phase I Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer | NCT02599363 |
| Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma | A Phase II Study of Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma | NCT02617849 |
| Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer | Phase II Study of Neoadjuvant Nab-paclitaxel (PTX) and Trastuzumab for ER Negative and HER2 Positive Breast Cancer | NCT02598310 |
| Phase II trial of nab-paclitaxel and carboplatin with concurrent radiotherapy for patients with locally advanced non-small cell lung cancer | Phase II trial of nab-paclitaxel and carboplatin with concurrent radiotherapy for patients with locally advanced non-small cell lung cancer - Phase II trial of nab-paclitaxel and carboplatin with concurrent radiotherapy for patients with locally advanced non-small cell lung cancer | JPRN-UMIN000019611 |
| Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+ | Phase I Study to Evaluate the Safety of Neratinib in Combination With Paclitaxel, Trastuzumab and Pertuzumab in Women and Men With Advanced or Metastatic HER2+ Solid Tumors | NCT02593708 |
| A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of S-1 and Oxaliplatin With or Without Ramucirumab as First-line Therapy Followed by Paclitaxel With Ramucirumab as Second-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of S-1 and Oxaliplatin With or Without Ramucirumab as First-line Therapy Followed by Paclitaxel With Ramucirumab as Second-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | JPRN-jRCT2080222999 |
| CCRT for Esophageal Cancer. | Long-term Results of Definitive Concurrent Chemoradiotherapy Using Paclitaxel Plus Oxaliplatin in Unresectable Locally Advanced Esophageal Cancer. | NCT02607982 |
| Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer | GUARDIAN-1 Trial: A Phase 1 Study of Ganetespib in Combination With Chemoradiation for Stage II-III Esophageal Carcinoma | NCT02389751 |
| A Study of ABTL0812 in Pancreatic Cancer | A Randomized Phase I/II Open Label Study to Assess the Efficacy and Safety of ABTL0812 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Advanced Metastatic Pancreatic Cancer at First Line Therapy | NCT03417921 |
| A Phase II Study of Durvalumab and Tremelimumab in combination with Neoadjuvant Carboplatin and Paclitaxel in newly diagnosed women with advanced high grade Serous Ovarian, Fallopian Tube and Peritoneal Cancers “iPRIME”. | A Phase II Study of Durvalumab and Tremelimumab in combination with Neoadjuvant Carboplatin and Paclitaxel in newly diagnosed women with advanced high grade Serous Ovarian, Fallopian Tube and Peritoneal Cancers “iPRIME”. | ACTRN12618000109202 |
| A multicenter-center, one-arm exploratory clinical study for Apatinib mesylate combined with albumin-bound taxol in the treatment of patients with recurrent/metastatic nasopharyngeal carcinoma | A multicenter-center, one-arm exploratory clinical study for Apatinib mesylate combined with albumin-bound taxol in the treatment of patients with recurrent/metastatic nasopharyngeal carcinoma | ChiCTR1900026622 |
| A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC | A RANDOMIZED, DOUBLE-BLIND BRIDGING SAFETY AND EFFICACY STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN FOR THE FIRST-LINE TREATMENT OF CHINESE PARTICIPANTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER | NCT04325698 |
| The exploratory study for IV period single peritoneal metastasis with ascites in gastric cancer treated with Injected red cartesian bacteria's cell wall skeleton (N-CWS) combine Paclitaxel and S1 | The exploratory study for IV period single peritoneal metastasis with ascites in gastric cancer treated with Injected red cartesian bacteria's cell wall skeleton (N-CWS) combine Paclitaxel and S1 | ChiCTR1900026541 |
| A randomized controlled trial for the effect and safety of albumin-bound paclitaxel neoadjuvant therapy for triple-negative breast cancer patients | A randomized controlled trial for the effect and safety of albumin-bound paclitaxel neoadjuvant therapy for triple-negative breast cancer patients | ChiCTR1900026501 |
| Albumin-bound paclitaxel combined with carboplatin versus epirubicin combined with docetaxel as neoadjuvant therapy for triple-negative breast cancer: a multicenter randomized controlled phase IV clinical trial | Albumin-bound paclitaxel combined with carboplatin versus epirubicin combined with docetaxel as neoadjuvant therapy for triple-negative breast cancer: a multicenter randomized controlled phase IV clinical trial | ChiCTR1900026499 |
| A multi-center, open-labeled, phase Ia clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and efficacy of paclitaxel medium and long chain fat emulsion injection (Cholesterol Bound) in the treatment of advanced solid tumors | A multi-center, open-labeled, phase Ia clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and efficacy of paclitaxel medium and long chain fat emulsion injection (Cholesterol Bound) in the treatment of advanced solid tumors | ChiCTR2400089373 |
| Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER) | Adjuvant Six Cycles of Docetaxel and Cyclophosphamide or Three Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by Three Cycles of Docetaxel Versus Four Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer | NCT04127019 |
| A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS) | Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First-line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer: An Open, Single-arm, Multicenter, Efficacy and Safety Phase II Clinical Study. | NCT04129996 |
| A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUNAB (MPDL3280A, ANTI*PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN + PACLITAXEL WITH OR WITHOUT BEVACIZUMAB COMPARED WITH CARBOPLATIN + PACLITAXEL + BEVACIZUMAB IN CHEMOTHERAPY-NAiVE PATIENTS WITH STAGE IV NON-SQUAMOUS NON*SMALL CELL LUNG CANCER. | A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUNAB (MPDL3280A, ANTI*PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN + PACLITAXEL WITH OR WITHOUT BEVACIZUMAB COMPARED WITH CARBOPLATIN + PACLITAXEL + BEVACIZUMAB IN CHEMOTHERAPY-NAiVE PATIENTS WITH STAGE IV NON-SQUAMOUS NON*SMALL CELL LUNG CANCER. - GO29436 | NL-OMON47780 |
| Second-line modified FOLFIRINOX for patients with unresectable advanced pancreatic cancer after first-line gemcitabine plus nab-paclitaxel failure | Second-line modified FOLFIRINOX for patients with unresectable advanced pancreatic cancer after first-line gemcitabine plus nab-paclitaxel failure - Second-line modified FOLFIRINOX for patients with unresectable advanced pancreatic cancer | JPRN-UMIN000038211 |
| Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer | A Pilot Study of Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma | NCT04115163 |
| Efficacy and Safety Study of Nab-Paclitaxel Combined With Cisplatin in Second or Later-Line Treatment in Advanced Biliary Tract Cancers | Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin in Second or Later-Line Treatment in Advanced Biliary Tract Cancers: a Prospective, Open Label, Single-arm Phase II Trial | NCT04111380 |
| VQI DELTA Paclitaxel Device Safety Analysis | Vascular Quality Initiative (VQI) - Data Extraction and Longitudinal Trend Analysis (DELTA) Paclitaxel Device Safety Analysis - Phase I Study | NCT04110288 |
| A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC | A Randomized,Controlled,Open-label,Prospective,Single-center Study to Investigate the Neoadjuvant Therapy of SHR-1210 in Combination With Carboplatin and Paclitaxel-albumin in Combination With Carboplatin and Paclitaxel in Resectable NSCLC | NCT04108013 |
| The Effect of Metformin on Neuropathy | The Evaluation of the Preventive Effect of Metformin on Paclitaxel-Induced Peripheral Neuropathy | IRCT20190813044526N1 |
| A prospective, single-center and single-arm Phase II clinical trial for first-line chemotherapy combined SOX and high-dose i.p paclitaxel in gastric cancer with peritoneal metastasis | A prospective, single-center and single-arm Phase II clinical trial for first-line chemotherapy combined SOX and high-dose i.p paclitaxel in gastric cancer with peritoneal metastasis | ChiCTR1900025984 |
| Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum | NCT04095364 |
| Clinical effect of paclitaxel albumin in neoadjuvant chemotherapy for advanced ovarian cancer | Clinical effect of paclitaxel albumin in neoadjuvant chemotherapy for advanced ovarian cancer | ChiCTR1900025940 |
| Clinical efficacy of paclitaxel albumin combined with carboplatin in neoadjuvant chemotherapy for locally advanced cervical cancer and its effect in PDX model of cervical cancer | Clinical efficacy of paclitaxel albumin combined with carboplatin in neoadjuvant chemotherapy for locally advanced cervical cancer and its effect in PDX model of cervical cancer | ChiCTR1900025919 |
| Efficacy and Safety of Albumin Paclitaxel Combined With Cisplatin Chemoradiotherapy for Non-resectable Stage III NSCLC | Department of Oncology, Affiliated Hospital of Guizhou Medical University | NCT04284215 |
| Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones | Phase II Trial of Radium-223 Dichloride in Combination With Paclitaxel in Patients With Bone Metastatic Breast Cancer | NCT04090398 |
| A Study to Assess the Efficacy and Safety of IMAB362 in Combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma | A Phase 2, Open-Label, Randomized Study to Assess the Efficacy and Safety of Zolbetuximab (IMAB362) in Combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma | JPRN-jRCT2080224860 |
| "An ""All-Comers"" Study of the AgentTM MONORAILTM Paclitaxel-Coated PTCA Balloon Catheter Used in Real-World Clinical Practice in Chinese Patients" | Agent DCB Registry | NCT04085445 |
| Intraperitoneal and Intravenous nab-Paclitaxel Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: a Single Group, Single-Centre, Phase 2 Study | Intraperitoneal and Intravenous nab-Paclitaxel Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: a Single Group, Single-Centre, Phase 2 Study | ChiCTR1900025762 |
| A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment | An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas | NCT04083235 |
| Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer | Multicenter Retrospective Analysis for Efficacy and Safety of Second-Line Nab-Paclitaxel Plus Gemcitabine After Progression on 1st-line FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma | NCT04133155 |
| An observational study for the efficacy and safety of apatinib combined with albumin-bound taxol in the second-line treatment of advanced gastric cancer | An observational study for the efficacy and safety of apatinib combined with albumin-bound taxol in the second-line treatment of advanced gastric cancer | ChiCTR1900025574 |
| A study to determine whether the addition of Dostarlimab (TSR-042) delays recurrence of advanced endometrial cancer | A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) plus Carboplatin-paclitaxel versus Placebo Plus Carboplatin-paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer (RUBY) - RUBY | EUCTR2019-001576-11-DE |
| Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer | Albumin-bound Paclitaxel Combined With Carboplatin Versus Epirubicin Combined With Docetaxel as Neoadjuvant Therapy for Triple-negative Breast Cancer: a Multicenter Randomized Controlled Phase IV Clinical Trial | NCT04136782 |
| A Study on Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Urothelial Carcinoma | A Phase II Study to Evaluate the Efficacy and Safety of Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Unresectable Locally Advanced or Metastatic Urothelial Carcinoma | NCT04211012 |
| Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver | A Phase 2 Study of Pevonedistat in Combination With Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma | NCT04175912 |
| A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLC | Efficacy and Safety of Camrelizumab Combined With Nb-Paclitaxel in Patients With Recurrent/Metastatic Non-small-cell Lung Cancer After the Failure of Platinum-based Therapy | NCT04167774 |
| Paclitaxel plus cetuximab for the treatment of recurrentand/or metastatic head and neck cancer after first-line checkpointinhibitor failure: A multicenter, single arm study | Paclitaxel plus cetuximab for the treatment of recurrentand/or metastatic head and neck cancer after first-line checkpointinhibitor failure: A multicenter, single arm study - PACE ACE | EUCTR2019-003114-13-AT |
| Treatment of Metastatic Vulvar Carcinoma With Carboplatin and Paclitaxel Chemotherapy | Treatment of Metastatic Vulvar Carcinoma With Carboplatin and Paclitaxel Chemotherapy (CRAVAT) | NCT04161664 |
| Treatment of Locally Advanced VULvar CArcinoma in a Neoadjuvant Setting With Carboplatin and Paclitaxel Chemotherapy (VULCANize) | Treatment of Locally Advanced VULvar CArcinoma in a Neoadjuvant Setting With Carboplatin and Paclitaxel Chemotherapy (VULCANize) | NCT04192253 |
| AN OPEN-LABEL, PHASE IIIB, SINGLE ARM, MULTICENTER SAFETY STUDY OF ATEZOLIZUMAB (TECENTRIQ) PLUS NABPACLITAXEL OR PACLITAXEL IN THE TREATMENT OF UNRESECTABLE LOCALLY ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER | AN OPEN-LABEL, PHASE IIIB, SINGLE ARM, MULTICENTER SAFETY STUDY OF ATEZOLIZUMAB (TECENTRIQ) PLUS NABPACLITAXEL OR PACLITAXEL IN THE TREATMENT OF UNRESECTABLE LOCALLY ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER | PER-028-19 |
| A single-center and single-arm clinical study of neoadjuvant nab-paclitaxel combined with carboplatin therapy in patients with triple-negative or HER2-positive breast cancer | A single-center and single-arm clinical study of neoadjuvant nab-paclitaxel combined with carboplatin therpy in patients with triple-negative or HER2-positive breast cancer | ChiCTR1900027332 |
| Anthracycline combined with cyclophosphamide sequential nab-paclitaxel or docetaxel for adjuvant treatment of breast cancer: an open, single center, observational clinical study | Anthracycline combined with cyclophosphamide sequential nab-paclitaxel or docetaxel for adjuvant treatment of breast cancer: an open, single center, observational clinical study | ChiCTR1900027327 |
| A Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer. | A Phase III, Double-blind, Placebo-controlled, Randomized Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer. | NCT04177108 |
| Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer | A Phase 1 Study of Gemcitabine, Nab-Paclitaxel, and Bosentan in Patients With Unresectable Pancreatic Cancer | NCT04158635 |
| A single-arm, observational, single-center, open label study for Toripalimab with or without Paclitaxel (albumin bound) plus Tegafur, Gimeracil and Oteracil Potassium Capsules as a Neoadjuvant therapy for esophageal cancer before operation | A single-arm, observational, single-center, open label study for Toripalimab with or without Paclitaxel (albumin bound) plus Tegafur, Gimeracil and Oteracil Potassium Capsules as a Neoadjuvant therapy for esophageal cancer before operation | ChiCTR1900027160 |
| A Clinical Study to Evaluate Efficacy and Safety of HLX10 Combined With Albumin-Bound Paclitaxel in Patients With Advanced Cervical Cancer Who Have Progressive Disease or Intolerable Toxicity After First-Line Standard Chemotherapy | A Single-Arm, Open-Label, Multicentre, Phase II Clinical Study to Evaluate Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) Combined With Albumin-Bound Paclitaxel in Patients With Advanced Cervical Cancer Who Have Progressive Disease or Intolerable Toxicity After First-Line Standard Chemotherapy | NCT04150575 |
| Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer | A Single-arm, Exploratory Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Early or Locally Advanced Breast Cancer and Its Biomarkers | NCT04152057 |
| Treatment of Patients With Atherosclerotic Disease With Paclitaxel-associated to LDL Like Nanoparticles | Treatment of Patients With Coronary and Aortic Atherosclerotic Disease With Paclitaxel-associated to LDL Like Nanoparticles. A Randomized, Double-blind, Placebo-control Trial. | NCT04148833 |
| A Trial of Paclitaxel (Albumin-binding) for Castration-resistant Prostate Cancer | One-arm, Multi-center Clinical Trial of Paclitaxel (Albumin-binding) Combined With Carboplatin for Castration-resistant Prostate Cancer | NCT04148885 |
| Efficacy and safety of paclitaxel (albumin-binding) combined with carboplatin for neoadjuvant therapy for unresectable ovarian cancer in women: a single-center, open, one-arm, phase Ib, and phase II clinical study | Efficacy and safety of paclitaxel (albumin-binding) combined with carboplatin for neoadjuvant therapy for unresectable ovarian cancer in women: a single-center, open, one-arm, phase Ib, and phase II clinical study | ChiCTR1900026893 |
| A placebo-controlled study of Ipatasertib in combination with Atezolizumab and Paclitaxel as a treatment for patients with advanced breast cancer | A phase III, double-blind, placebo-controlled, randomized study of Ipatasertib in combination with Atezolizumab and Paclitaxel as a treatment for patients with locally advanced unresectable or metastatic triple-negative breast cancer | RBR-2x8xh8 |
| Camrellizumab combined with stereotactic radiotherapy, apatinib mesylate and albumin-conjugated paclitaxel for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer with non-sensitive gene mutations: a prospective, single arm, single center, exploratory clinical study | Camrellizumab combined with stereotactic radiotherapy, apatinib mesylate and albumin-conjugated paclitaxel for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer with non-sensitive gene mutations: a prospective, single arm, single center, exploratory clinical study | ChiCTR1900026885 |
| The effect of stopping the H2-antagonist ranitidine in premedication regimens during paclitaxel treatment: ‘The RANISTOP study’ | The effect of stopping the H2-antagonist ranitidine in premedication regimens during paclitaxel treatment. | NL-OMON24209 |
| Sintilimab and Nab-paclitaxel in Second-line Treatment of Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma | Efficacy and Safety of Sintilimab and Nab-paclitaxel in Advanced Gastric and Gastro-esophageal Junction Adenocarcinoma Patients With Progression After Fluoropyrimidine or Platinum, a Multi-center, Phase II, Single Arm Trial | NCT04140318 |
| Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer | Clinical Study of Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer | NCT04138719 |
| Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer | Clinical Study of Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer | NCT04159142 |
| Safety and potential efficacy of combining immunotherapy with chemotherapy and radiation for treatment of borderline resectable, non-resectable locally advanced or metastatic pancreatic cancer | Phase 1/2 study in borderline resectable, locally advanced or metastatic pancreatic cancer to assess safety and potential efficacy of dual checkpoint inhibition in combination with gemcitabine and nab-paclitaxel followed by immune-chemoradiation. - LAPTOP | EUCTR2019-003759-13-DK |
| Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT | Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective Randomized Controlled Clinical Trial | NCT04137653 |
| Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage ? Gastric Cancer | Adjuvant Nab-paclitaxel Plus S-1 Versus Capecitabine Plus Oxaliplatin for Patients With Stage III Gastric Cancer After D2 Gastrectomy : a Randomised,Open-label, Phase III Study | NCT04135781 |
| Nab-Paclitaxel Combined With Gemcitabine Adjuvant Chemotherapy After Radical Resection of Intrahepatic Cholangiocarcinoma | a Single-arm Study of Nab-Paclitaxel Combined With Gemcitabine Adjuvant Chemotherapy After Radical Resection of Intrahepatic Cholangiocarcinoma | NCT04077983 |
| EGFR-targeted Therapy for Gastric Cancer | Anti-EGFR Antibody (GC-1118) in Combination With Weekly Paclitaxel as a Second-line Therapy for Gastric and Gastroesophageal Junction Adenocarcinomas With Amplifications | NCT04077255 |
| A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF IPATASERTIB IN COMBINATION WITH ATEZOLIZUMAB AND PACLITAXEL AS A TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER.. | A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF IPATASERTIB IN COMBINATION WITH ATEZOLIZUMAB AND PACLITAXEL AS A TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER. | PER-018-19 |
| A Two-arm (Phase 2) Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China | A Two-arm (Phase 2) Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China | NCT04015778 |
| SHR- 1210 combined with Paclitaxel (Albumin Bound) and Gemcitabine as first-line therapy in patients with metastatic pancreatic cancer | A prospective, single-armed, exploratory clinical trial to evaluate the efficiency and safety of anti-PD1 antibody SHR- 1210 combined with Paclitaxel(Albumin Bound) and Gemcitabine as first-line therapy in patients with metastatic pancreatic cancer | ChiCTR1900024176 |
| Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma | The Efficacy and Safety of Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil, Concurrent Chemotherapy of Cisplatin and IMRT in Locoregionally Advanced Nasopharyngeal Carcinoma: A Prospective, Multi-centeric, Open, Non-controlled, Phase II Clinical Trial | NCT04004871 |
| Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer | AMELIE: A Phase 3 Randomized, Open-label, Multicenter Trial of Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant or Refractory Ovarian Cancer | NCT04000295 |
| AZD8186 and Paclitaxel in Advanced Gastric Cancer | Phase1b/2 Study of AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer | NCT04001569 |
| Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer | Prospective Validation Trial of Taxane Therapy (Docetaxel or Weekly Paclitaxel) and Risk of Chemotherapy-Induced Peripheral Neuropathy in African American Women | NCT04001829 |
| Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer | A Single-center, Prospective, Single Arm Study of Neoadjuvant Treatment With Pegylated Liposomal Doxorubicin(PLD)Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer | NCT03994107 |
| Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients with Stage I-III Breast Cancer | A Phase Ib/II Study of the Safety and Pharmacology of Nilotinib to Prevent Paclitaxel-Induced Peripheral Neuropathy in Patients with Breast Cancer | NCT04205903 |
| A Study to Determine the Bioequivalence of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel | A Randomized Crossover Study to Determine the Bioequivalence of Three Consecutive Daily Doses of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel | NCT04035473 |
| NP030 clinical trial | Multicenter trial of new coronary artery stenosis with Paclitaxel coated balloon catheter | JPRN-jRCT2080224719 |
| Multicenter randomized controlled study for rmhTNF versus paclitaxel intraperitoneal infusion in the treatment of peritoneal metastasis of gastric cancer | Multicenter randomized controlled study for rmhTNF versus paclitaxel intraperitoneal infusion in the treatment of peritoneal metastasis of gastric cancer | ChiCTR1900023675 |
| Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC | Study of Atezolizumab in Combination With Carboplatin + Paclitaxel +Bevacizumab vs With Pemetrexed + Cisplatin or Carboplatin With Stage IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER With EGFR(+) or ALK(+) | NCT03991403 |
| A clinical trial for apatinib combination with nab-paclitaxel /cisplatin in the treatment of NSCLC | A clinical trial for apatinib combination with nab-paclitaxel /cisplatin in the treatment of NSCLC | ChiCTR1900023657 |
| Singal-arm, prospective and open phase II clinical trial for pyrotinib maleate tablets combined with paclitaxel for injection (albumin-binding) in the treatment of HER-2 positive advanced breast cancer | Singal-arm, prospective and open phase II clinical trial for pyrotinib maleate tablets combined with paclitaxel for injection (albumin-binding) in the treatment of HER-2 positive advanced breast cancer | ChiCTR1900023653 |
| Nab-paclitaxel Combined With S-1 Treating Diffuse Type of Stage ? Gastric Cancer | Phase I Study: Nab-paclitaxel Combined With S-1 Treating Diffuse Type of Stage ? Gastric Cancer as Adjuvant Setting (NORDICA) | NCT03977220 |
| Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy | Phase III Randomized Trial of Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Monthly Carboplatin With Weekly Paclitaxel Chemotherapy | NCT03977194 |
| Carboplatin-Paclitaxel Adjuvant Chemotherapy in the Treatment of Locally Advanced Cervical Cancer | Phase II Trial of Weekly Carboplatin-Paclitaxel Adjuvant Chemotherapy After Intensity Modulated Extended-field Chemoradiation in the Treatment of Locally Advanced Cervical Cancer with Para-aortic Positive Nodes | NCT04016142 |
| PIPAC With Nab-paclitaxel and Cisplatin in Peritoneal Carcinomatosis | A Phase Ib Trial of Intraperitoneal Cisplatin and Nab-paclitaxel Administered by Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in the Treatment of Advanced Malignancies Confined to the Peritoneal Cavity | NCT04000906 |
| S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites | S1 Plus Paclitaxel (IV&IP) Plus Bevacizumab (IP) Versus S1 Plus Oxaliplatin(IV) as First-line Treatment in Gastric or Gastroesophageal Junctional Adenocarcinoma With Malignant Ascites: An Open-label, Multicenter Phase II Study | NCT03990103 |
| Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy | A Phase 2 Study of MLN4924 (Pevonedistat) in Combination With Carboplatin and Paclitaxel in Advanced NSCLC Previously Treated With Immunotherapy | NCT03965689 |
| Phase I Clinical Study for Postoperative Early Stage Cervical Cancer with High Risk Factors Treated by Albumin Paclitaxel and Cisplatin Chemotherapy Combined with Synchronous Local Radiotherapy | Phase I Clinical Study for Postoperative Early Stage Cervical Cancer with High Risk Factors Treated by Albumin Paclitaxel and Cisplatin Chemotherapy Combined with Synchronous Local Radiotherapy | ChiCTR1900023373 |
| Phase I clinical study for albumin paclitaxel and capecitabine chemotherapy combined with local radiotherapy for initial unresectable locally advanced gastric cancer or para-aortic lymph node metastasis | Phase I clinical study for albumin paclitaxel and capecitabine chemotherapy combined with local radiotherapy for initial unresectable locally advanced gastric cancer or para-aortic lymph node metastasis | ChiCTR1900023370 |
| Sintilimab in Combination With Nab-paclitaxel in Patients With HNSCC (Head and Neck Squamous Cell Carcinoma ) | An Exploratory Study of Sintilimab in Combination With Nab-paclitaxel in Patients With Advanced Recurrent or Metastatic HNSCC (Head and Neck Squamous Cell Carcinoma )After 2 or More Prior Lines of Therapy | NCT03975270 |
| Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma | The Effectiveness and Safety of Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin Followed by Surgery Versus Surgery Alone for Locally Advanced Esophageal Squamous Cell Carcinoma | NCT03964753 |
| Paclitaxel Injection (Albumin-bound) for Neoadjuvant Treatment of Breast Cancer | A Real-world Study of Paclitaxel Injection (Albumin-bound) for Neoadjuvant Treatment of Breast Cancer | NCT03959397 |
| VMAT Concurrent Cisplatin Plus Nab-paclitaxel for Local Advanced Cervical Cancer | Study of Radiation Therapy With Concomitant Nab-paclitaxel and Cisplatin Chemotherapy in Patients With Locally Advanced Cervical Cancer | NCT04017377 |
| Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Patients With LA-NPC | Induction Chemotherapy With Nab-paclitaxel and Nedaplatin Followed by Concurrent Chemoradiotherapy in Patients With Locally Advanced Nasopharyngeal Carcinoma | NCT04015661 |
| Phase III study for TRS003 in patients with advanced non-small cell lung cancer | A Phase 3, Multicenter, Randomized and Double Blinded Study to Assess the Similarity in Efficacy and Safety Between TRS003 and China-Approved Bevacizumab Administered in Combination With Paclitaxel-Carboplatin in Subjects With Advanced Non-small Cell Lung Cancer | ChiCTR1900024463 |
| Angioplasty With Paclitaxel-coated Balloon Only Strategy for Coronary de Novo Lesions | Long Term Clinical Outcomes of Angioplasty With Paclitaxel-coated Balloon Only Strategy for Coronary de Novo Lesions: a Single Center Registry Study | NCT04022200 |
| Exploratory clinical study for the neoadjuvant therapy of PD-1 antibody combined with paclitaxel and cisplatin for operable esophageal squamous cell carcinoma | Exploratory clinical study for the neoadjuvant therapy of PD-1 antibody combined with paclitaxel and cisplatin for operable esophageal squamous cell carcinoma | ChiCTR1900025318 |
| Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer | BRE-01: Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel Followed by Doxorubicin and Cyclophosphamide in Triple Negative Breast Cancer | NCT04083963 |
| Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma(ESCC). | Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma: a Single Arm, Multicentre Trial. | NCT04063683 |
| Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer | A Randomised, Multicenter, Open-label, Phase II Study Evaluating Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in Early Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2 - Positive Breast Cancer | NCT04066790 |
| Biweekly chemotherapy with nab-Paclitaxel plus Gemcitabine for elderly patinents of unresectable pancreatic cancer | Single-arm phase II study of biweekly nab-Paclitaxel plus Gemcitabine as first-line therapy for elderly patients of unresectable pancreatic cancer | JPRN-jRCTs051190038 |
| Paclitaxel-binding Albumin and Cisplatin as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer | Paclitaxel-binding Albumin and Cisplatin as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer - A Single-center, Single-arm and Stage II Clinical Study | NCT04060459 |
| Paclitaxel (Albumin-bound) and Oxaliplatin for Advanced Hepatobiliary and Malignant Tumors | Single-center, Single-arm and Phase II/III Clinical Study of Paclitaxel (Albumin-binding) Combined With Oxaliplatin as First-line Treatment for Advanced Hepatobiliary and Malignant Tumors | NCT04060472 |
| Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC | Albumin Bound (Nab)-Paclitaxel Combined With Carboplatin Versus Paclitaxel Combined With Carboplatin Followed by Epirubicin and Cyclophosphamide as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) | NCT04067102 |
| ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer | Phase II Study of ONC201 Plus Weekly Paclitaxel in Patients With Platinum-Resistant Refractory or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT04055649 |
| A study to evaluate the Safety and Efficacy of Nivolumab in Combination with Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric Cancer | An Open Label, Single-Arm, Multi-center Phase Ib/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination with Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric Cancer. | KCT0004186 |
| Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide Chemotherapy | The Efficacy and Safety of IBI308 Combined With Paclitaxel/Albumin-Bound Paclitaxel as Second-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer That Relapsed After Failing to Platinum-Etoposide Chemotherapy | NCT04056949 |
| Safety and Effectiveness of Agent Paclitaxel-Coated PTCA Balloon Catheter. (AGENT Japan SV) | A 2:1 Randomized Trial Comparing the Agent Paclitaxel-Coated PTCA Balloon Catheter vs SeQuent Please Drug Eluting Balloon Catheter for the Treatment of a Small Vessel De Novo Native Coronary Artery Lesion. | NCT04058990 |
| A real world study of gemcitabine combined with nab-paclitaxel in the treatment of locally advanced or metastatic pancreatic cancer | A real world study of gemcitabine combined with nab-paclitaxel in the treatment of locally advanced or metastatic pancreatic cancer | ChiCTR1900027729 |
| Nab-paclitaxel plus capecitabine as first-line treatment of recurrent/metastatic cholangi ocarcinoma: a multi-center, open label, single-arm study | Nab-paclitaxel plus capecitabine as first-line treatment of recurrent/metastatic cholangi ocarcinoma: a multi-center, open label, single-arm study | ChiCTR1900025004 |
| The REPEAT trial: Regorafenib in combination with Paclitaxel in advanced oesophagogastric carcinoma, a phase 1b study | The REPEAT trial: Regorafenib in combination with Paclitaxel in advanced oesophagogastric carcinoma, a phase 1b study - REPEAT | NL-OMON47541 |
| Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer | Phase I Study of Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer | NCT04046575 |
| Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC) | Phase I Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced Pancreatic Ductal Adenocarcinoma (PDAC) | NCT04046887 |
| NEJ043 | A Phase 2 Study of atezolizumab + carboplatin + paclitaxel + bevacizumab for previously-treated patients with NSCLC harboring EGFR mutations. - NEJ043 | JPRN-jRCTs031190066 |
| A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer | An Multi-center, Open-label Phase Ib/II Study of Gentuximab Injection + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer to Evaluate Tolerability, Safety, Efficacy and Pharmacokinetics. | NCT04053205 |
| Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis | A Phase II Study of Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis | NCT04034251 |
| Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment | A Randomized, Double-Blind, Multicenter, Phase III Study of Toripalimab(JS001) in Combination With Nab-Paclitaxel Versus Placebo Plus Nab-Paclitaxel for Patients With Metastatic or Recurrent Triple-Negative Breast Cancer With or Without Systemic Treatment (TORCHLIGHT) | NCT04085276 |
| Efficacy and safety of albumin-bound paclitaxel combined with cisplatin for neoadjuvant chemotherapy in squamous non-small cell lung cancer | Efficacy and safety of albumin-bound paclitaxel combined with cisplatin for neoadjuvant chemotherapy in squamous non-small cell lung cancer | ChiCTR1900024720 |
| Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN) | Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer | NCT04031703 |
| A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC | A Randomized, Double-Blind, Multicenter, Phase III Clinical Study of HLX10 (Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection) + Chemotherapy (Carboplatin Nanoparticle Albumin Bound (Nab)-Paclitaxel) vs Chemotherapy (Carboplatin Nab-Paclitaxel) as First-Line Therapy for Locally Advanced or Metastatic Squamous Non Small Cell Lung Cancer (NSCLC) | NCT04033354 |
| A multi-center, open-label, prospective trial for S-1 plus nab-paclitaxel or Gemcitabine as the first-line chemotherapy for unresctable pancreatic cancer (AvGmPC) | A multi-center, open-label, prospective trial for S-1 plus nab-paclitaxel or Gemcitabine as the first-line chemotherapy for unresctable pancreatic cancer (AvGmPC) | ChiCTR1900024588 |
| Toripalimab Combined With S1 and Albumin Paclitaxel in Patients With Advanced Biliary Tract Cancer | Toripalimab Combined With S1 and Albumin Paclitaxel as First Line in Patients With Advanced Biliary Tract Cancer: a Single-arm,One Center, Phase II Clinical Study | NCT04027764 |
| Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma | The Study of Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Initial Unresectable Local Advanced or Potentially Resectable Metastatic Gastric Adenocarcinoma | NCT04047953 |
| Treatment of metastatic vulvar carcinoma in a neoadjuvant setting with Carboplatin and Paclitaxel chemotherapy | Treatment of metastatic vulvar carcinoma in a neoadjuvant setting with Carboplatin and Paclitaxel chemotherapy - CRAVAT | NL-OMON49490 |
| Treatment of locally advanced VULvar CArcinoma in a Neoadjuvant setting with Carboplatin and Paclitaxel chemotherapy | Treatment of locally advanced VULvar CArcinoma in a Neoadjuvant setting with Carboplatin and Paclitaxel chemotherapy - VULCANize | EUCTR2019-003104-12-NL |
| Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer | Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer | NCT04182724 |
| Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma | Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy Versus Nab-Paclitaxel and Gemcitabine Alone for Locally Advanced Pancreatic Adenocarcinoma | NCT04365049 |
| MARGetuximab Or Trastuzumab (MARGOT) | MARGetuximab Or Trastuzumab (MARGOT): A Phase II Study Comparing Neoadjuvant Paclitaxel/Margetuximab/Pertuzumab to Paclitaxel/Trastuzumab/Pertuzumab in Patients With Stage II-III HER2-positive Breast Cancer | NCT04425018 |
| Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC | A Study of Camrelizumab (SHR-1210) Combined With Apatinib Versus Paclitaxel or Irinotecan in Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma Progressed After First-line Chemotherapy | NCT04342910 |
| Study of Anti-PD-1 Combined With Albumin-Bound Paclitaxel in Patients With Recurrent Cervical Cancer | A Open-label, Single-arm, Multicentre, Phase ? Study of Evaluate Efficacy and Safety of Anti-PD-1 Combined With Albumin-Bound Paclitaxel in Patients With Recurrent Cervical Cancer | NCT04341883 |
| Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma | A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma | NCT04339738 |
| A single arm, open, prospective, multicenter clinical study of albumin binding paclitaxel combined with apatinib mesylate in the treatment of relapsed / refractory small cell lung cancer | A single arm, open, prospective, multicenter clinical study of albumin binding paclitaxel combined with apatinib mesylate in the treatment of relapsed / refractory small cell lung cancer | ChiCTR2000031685 |
| Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable NSCLC | An Explorative Study on Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable Non-small-cell Lung Carcinoma | NCT04338620 |
| Efficacy and safety of induction NAB-paclitaxel and cisplatin followed by concurrent chemoradiotherapy in elderly patients with locally advanced nasopharyngeal carcinoma: a prospective II phase clinical trial | Efficacy and safety of induction NAB-paclitaxel and cisplatin followed by concurrent chemoradiotherapy in elderly patients with locally advanced nasopharyngeal carcinoma: a prospective II phase clinical trial | ChiCTR2000031511 |
| A Phase 1b/2 study of derazantinib as monotherapy and combination therapy with paclitaxel, ramucirumab or atezolizumab in patients with HER2-negative gastric adenocarcinoma harboring FGFR genetic aberrations (FIDES-03) | A Phase 1b/2 study of derazantinib as monotherapy and combination therapy with paclitaxel, ramucirumab or atezolizumab in patients with HER2-negative gastric adenocarcinoma harboring FGFR genetic aberrations (FIDES-03) - DZB-CS-202 | EUCTR2019-004505-27-GB |
| Paclitaxel-Coated versus Plain Balloon Angioplasty for Dysfunctional Autogenous Radiocephalic Arteriovenous Fistulas | Paclitaxel-Coated versus Plain Balloon Angioplasty for Dysfunctional Autogenous Radiocephalic Arteriovenous Fistulas: A Prospective Randomized Controlled Trial | KCT0004870 |
| Study with Afuresertib and Paclitaxel in Platinum Resistant Ovarian | An Open Label Randomized Active Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer | NCT04374630 |
| A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer. | A Multicentre, Open-parallel, Randomized, Controlled Phase ? Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer. | NCT04335006 |
| Efficacy and safety of PD-1 antibody combined with albumin bound paclitaxel in the treatment of recurrent/refractory extra-nodal NK/T cell lymphoma: a multicenter, prospective, single-arm, phase II clinical study | Efficacy and safety of PD-1 antibody combined with albumin bound paclitaxel in the treatment of recurrent/refractory extra-nodal NK/T cell lymphoma: a multicenter, prospective, single-arm, phase II clinical study | ChiCTR2000031158 |
| The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC | The BURAN Study of Buparlisib (AN2025) In Combination With Paclitaxel Compared to Paclitaxel Alone, in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | NCT04338399 |
| A phase II study for Albumin-bound paclitaxel in combination with Nedaplatin in the treatment of patients with Platinum-resistant recurrent epithelial ovarian carcinoma | A phase II study for Albumin-bound paclitaxel in combination with Nedaplatin in the treatment of patients with Platinum-resistant recurrent epithelial ovarian carcinoma | ChiCTR2000030875 |
| Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (RELIANT) | NCT04329949 |
| A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation | A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation (Carboplatin and Taxol) as First Line Treatment for Patients With Local Regional Advanced Gastric Cancer | NCT04308837 |
| A prospective, single-arm, multicentre clinical study of first-line treatment of her2-positive recurrent/metastatic breast cancer with pyrotinib maleate tablet and trastuzumab plus albumin-bound paclitaxel | A prospective, single-arm, multicentre clinical study of first-line treatment of her2-positive recurrent/metastatic breast cancer with pyrotinib maleate tablet and trastuzumab plus albumin-bound paclitaxel | ChiCTR2000030618 |
| A trial exploring the efficacy (how well the treatment works) and tolerability of the combination of two investigational drugs (atezolizumab and bevacizumab), when administered together with one of two different chemotherapy treatments, in patients with non-small cell lung cancer and specific mutations (changes) in the EGFR gene | A randomised non-comparative open label phase II trial of atezolizumab plus bevacizumab, with carboplatin-paclitaxel or pemetrexed,in EGFR mutant non-small cell lung carcinoma with acquired resistance - ABC-lung | EUCTR2019-001687-30-ES |
| a study to assess the effect of iced gloves and socks in prevention of tingling prickling numbness and muscle weakness in hand and foot of breast cancer patients caused by paclitaxel chemotherapy injection in tertiary care cancer hospital | a study to assess the feasibility safety and efficacy of frozen gloves & socks application on prevention of pacllitaxel induced peripheral neuropathy in breast cancer patient in tertiary carecancer hospital | CTRI/2020/03/023762 |
| To Compare Carboplatin/ Paclitaxel with Cisplatin/ Etoposide in advanced Non Small Cell Lung cancer (NSCLC). | Carboplatin/ Paclitaxel Versus Cisplatin/ Etoposide as Definitive ChemoRadiotherapy for LocoRegionally advanced Non ââ?¬â?? Small Lung cancer (NSCLC): A Phase III Randomized Controlled Trial | CTRI/2020/03/023770 |
| Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE) | A Prospective, Single Center, Randomized, Open-labled Stage III Clinical Trial Comparing the Efficacy and Safety of Anthracyclin Followed by Weekly Paclitaxel Versus Dose-dense Anthracyclin Followed by Weekly Paclitaxel Versus Dose-dense Anthracyclin Followed by Weekly Paclitaxel Combined With Carboplatin for High-risk, Triple-negative Early Breast Cancer | NCT04296175 |
| Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer | A Multi-center, Open-label, Randomized Controlled Clinical Study of Nab-paclitaxel Plus SHR-1210(PD-1 Inhibitor)Versus Nab-paclitaxel As Second-line Treatment in Advanced or Recurrent Gastric and Esophagogastric Adenocarcinoma | NCT04294784 |
| A PHASE III STUDY OF IPATASERTIB IN COMBINATION WITH ATEZOLIZUMAB AND PACLITAXEL AS A TREATMENT FOR PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER | A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF IPATASERTIB IN COMBINATION WITH ATEZOLIZUMAB AND PACLITAXEL AS A TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER | JPRN-jRCT2080225093 |
| To study the combination of oral (Metronomic)chemotherapy along with Intravenous chemotherapy (Paclitaxel) in advanced stage head and neck cancer patients | Phase 2-3 trial evaluating the Integration of metronomic methotrexate, celecoxib,erlotinib with maximum tolerable dose chemotherapy in advanced Head and Neck Cancer - PHOENIX | CTRI/2020/02/023616 |
| Efficacy and safety of induction chemotherapy of albumin-bound paclitaxel, cisplatin and capecitabine and sequential concurrent chemoradiotherapy combined with apatinib and camrelizumab for stage N3M0 nasopharyngeal carcinoma: a prospective, single-arm, open labeled phase II clinical trial | Efficacy and safety of induction chemotherapy of albumin-bound paclitaxel, cisplatin and capecitabine and sequential concurrent chemoradiotherapy combined with apatinib and camrelizumab for stage N3M0 nasopharyngeal carcinoma: a prospective, open labeled phase II clinical trial | ChiCTR2000032317 |
| An open-label, single-arm, phase Ib/II study of combination of toripalimab(PD-1 antibody), nab-paclitaxel, and gemcitabine as the first-line treatment for patients with advanced pancreatic ductal adenocarcinoma | An open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with advanced pancreatic ductal adenocarcinoma | ChiCTR2000032293 |
| A trial exploring the efficacy (how well the treatment works) and tolerability of the combination of two investigational drugs (atezolizumab and bevacizumab), when administered together with one of two different chemotherapy treatments, in patients with non-small cell lung cancer and specific mutations (changes) in the EGFR gene | A randomised non-comparative open label phase II trial of atezolizumab plus bevacizumab, with carboplatin-paclitaxel or pemetrexed,in EGFR mutant non-small cell lung carcinoma with acquired resistance - ABC-lung | EUCTR2019-001687-30-DE |
| Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | Phase II Study of Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | NCT04390958 |
| The Safety and Efficacy of the Combination of Raltitrexed for Injection and Nab-Paclitaxel in Advanced Pancreatic Cancer | A Single-arm, Prospective Study to Evaluate the Safety and Efficacy and of the Combination of Raltitrexed for Injection and Nab-Paclitaxel as Second-line Therapy in Treating Patients With Advanced Pancreatic Cancer | NCT04581876 |
| Prospective, II phase clinical study with Nab-paclitaxel plus cisplatin weekly radical concurrent radiochemotherapy regimen for limited stage cervical cancer | Prospective, II phase clinical study with Nab-paclitaxel plus cisplatin weekly radical concurrent radiochemotherapy regimen for limited stage cervical cancer | ChiCTR2000034251 |
| Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel | Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel | NCT04449549 |
| Efficacy and safty of Nab-paclitaxel combined with tissue brachytherapy for recurrent cervical cancer after radiotherapy and chemotherapy: a multicenter, open clinical study | Efficacy and safty of Nab-paclitaxel combined with tissue brachytherapy for recurrent cervical cancer after radiotherapy and chemotherapy: a multicenter, open clinical study | ChiCTR2000034101 |
| EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients | A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients | NCT04444921 |
| Treatment with VB-111 and paclitaxel vs. treatment with paclitaxel and placebo in patients with ovarian cancer. | The OVAL Study: A Randomized, Controlled, Double-Arm,Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer - OVAL | EUCTR2019-003884-23-PL |
| Pancreatic Adenocarcinoma Neoadjuvant Chemotherapy Before Surgery | MFOLFIRINOX or Gemcitabine / Nab-paclitaxel Followed by Pancreatectomy for Patients with Borderline Resectable Pancreatic Adenocarcinoma. a Pilot Feasibility Study. | NCT04452461 |
| Study to assess the efficacy and safety of the study drug atezolizumab in combination with paclitaxel and bevacizumab in patients with previously untreated advanced or metastatic triple negative breast cancer. | PHASE II CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FIRST LINE ATEZOLIZUMAB IN COMBINATION WITH PACLITAXEL AND BEVACIZUMAB (AVASTIN®) IN PATIENTS WITH ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER - Phase II First Line Atezolizumab, PacliTaxel, and Bevacizumab (Avastin®) in mTNBC | EUCTR2019-001503-20-FR |
| Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma | Albumin-bound Paclitaxel Combined With Toripalimab as First-line/Second-line Treatment of Local Advanced or Metastatic Gastric or Gastroesophageal Junction Carcinoma: A Prospective, Open-label, Single-arm Phase II Clinical Study | NCT04443036 |
| A Multinational, Multicenter, Open-label, Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of Oral Paclitaxel (DHP107) Compared to IV Paclitaxel as First-line Therapy in Patients with Recurrent or metastatic HER2 negative Breast Cancer | A Multinational, Multicenter, Open-label, Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of Oral Paclitaxel (DHP107) Compared to IV Paclitaxel as First-line Therapy in Patients with Recurrent or metastatic HER2 negative Breast Cancer | EUCTR2020-000954-86-HU |
| A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients | A Phase 1b/2a Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Patients With Advanced or Metastatic Solid Tumors | NCT04492033 |
| A phase II study for Albumin Bound Paclitaxel plus Camrelizumab (SHR1210) as therapy in patients with unresectable locally advanced or metastatic urothelial carcinoma | A phase II study for Albumin Bound Paclitaxel plus Camrelizumab (SHR1210) as therapy in patients with unresectable locally advanced or metastatic urothelial carcinoma | ChiCTR2000033820 |
| Phase II clinical trial of albumin-bound paclitaxel plus gemcitabine in the treatment of metastatic/locally unresectable soft tissue sarcoma: a single-center, open, single-arm study | Phase II clinical trial of albumin-bound paclitaxel plus gemcitabine in the treatment of metastatic/locally unresectable soft tissue sarcoma: a single-center, open, single-arm study | ChiCTR2000030250 |
| Effect of Melatonin on arthralgia-myalgia of Paclitaxel | The effect of melatonin on incidence and severity of arthralgia-myalgia caused by weekly paclitaxel in patients with breast cancer | IRCT20190630044057N1 |
| A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer. | A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel for Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine | NCT04435652 |
| bioequivalence study with pharmacokinetic endpoints of Paclitaxel Protein-Bound Particles for Injectable Suspension. | A randomized, open label, balanced, multicenter, two-treatment, two-period, two-sequence, two-way crossover, single dose, bioequivalence study with pharmacokinetic endpoints of Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound) 100 mg/vial at a dose of 260 mg/m2 with ABRAXANE® for Injectable Suspension (albumin--bound) 100 mg/vial at a dose of 260 mg/m2 in Breast cancer subjects after failure of combination chemotherapy for metastatic disease. - NA | CTRI/2020/06/025512 |
| dose-dense AC or EC therapy followed by dose-dense Paclitaxel as neoadjuvant chemotherapy for triple negative operable breast cancer | dose-dense AC or EC therapy followed by dose-dense Paclitaxel as neoadjuvant chemotherapy for triple negative operable breast cancer - PerSeUS-BC05 | JPRN-UMIN000040187 |
| A prospective, single-arm clinical study on the safety and efficacy of tislelizumab in combination with liposome paclitaxel + cisplatin in the neoadjuvant therapy of potentially resectable local advanced esophageal squamous cell carcinoma | A prospective, single-arm clinical study on the safety and efficacy of tislelizumab in combination with liposome paclitaxel + cisplatin in the neoadjuvant therapy of potentially resectable local advanced esophageal squamous cell carcinoma | ChiCTR2000033416 |
| Immunotherapy combined with Albumin-bound paclitaxel and lobaplatin-induced chemotherapy in the treatment of locally advanced esophageal cancer | Immunotherapy combined with Albumin-bound paclitaxel and lobaplatin-induced chemotherapy in the treatment of locally advanced esophageal cancer | ChiCTR2000033338 |
| GYNecological cancers treated with NETrin Abs in combination with chemotherapy and/or Pembrolizumab | A randomised, multicentre, open label, Phase I/II study to evaluate the safety (Phase I - safety run in), clinical and biological activity (Phase II) of a humanized monoclonal antibody targeting Netrin-1 (NP137) in combination with carboplatin plus paclitaxel and/or pembrolizumab in patients with locally advanced/metastatic endometrial carcinoma or cervix carcinoma progressing/relapsing after at least one prior systemic chemotherapy. - GYNET | EUCTR2020-000172-38-FR |
| Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients | Neoadjuvant Anthracycline Followed by Toripalimab Combined With Nab-paclitaxel in Patients With Early Triple-negative Breast Cancer | NCT04418154 |
| A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC) | A Randomized, Positive Parallel Controlled, Multicenter Phase III Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC) | NCT04405505 |
| First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC | Phase II Clinical Trial to Evaluate the Efficacy and Safety of First Line Atezolizumab in Combination With Paclitaxel and Bevacizumab (Avastin®) in Patients With Advanced or Metastatic Triple-negative Breast Cancer | NCT04408118 |
| Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer | A Randomised, Multicenter, Open-label, Phase II Study Evaluating Pyrotinib Plus Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in Early Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2 - Positive Breast Cancer | NCT04398914 |
| Prospective, single-arm II phase clinical study for albumin-binding paclitaxel combined with DDP regimen in the treatment of locally advanced cervical cancer in stage IIIB -IVA (18FIGO) | Prospective, single-arm II phase clinical study for albumin-binding paclitaxel combined with DDP regimen in the treatment of locally advanced cervical cancer in stage IIIB -IVA (18FIGO) | ChiCTR2000033027 |
| Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) | A Phase II, Open Label, Randomized, Parallel Arm Study of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy Gemcitabine/Nab-paclitaxel, and Gemcitabine/Nab-paclitaxel Alone in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) | NCT04390763 |
| An exploratory clinical study on the adjuvant treatment of locally advanced esophageal squamous cell carcinoma with carrizumab combined with paclitaxel and nedaplatin | An exploratory clinical study on the adjuvant treatment of locally advanced esophageal squamous cell carcinoma with carrizumab combined with paclitaxel and nedaplatin | ChiCTR2000033761 |
| Comparison of two chemotherapeutic drug combinations for lung cancer. | Treatment response and toxicity profile of Pemetrexed/carboplatin vs Paclitaxel/carboplatin combination chemotherapy schedule in advanced non-small cell lung cancer( adenocarcinoma) patients-A prospective observational study. | CTRI/2019/05/019130 |
| Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in Advanced Gastric Cancer | Phase I / II Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in the Second-line Treatment of Advanced Gastric Cancer | NCT04286711 |
| VB-111 and paclitaxel in patients with ovarian cancer | The OVAL Study: A Randomized, Controlled, Double-Arm,Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer - OVAL | EUCTR2019-003884-23-ES |
| Amlotinib hydrochloride combined with paclitaxel liposome and neda platinum for preoperative neoadjuvant therapy of esophageal squamous cell carcinoma: an exploratory phase II clinical study | Amlotinib hydrochloride combined with paclitaxel liposome and neda platinum for preoperative neoadjuvant therapy of esophageal squamous cell carcinoma: an exploratory phase II clinical study | ChiCTR2000028840 |
| Nab-P and Gem Compared With Gem and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic Cancer | An Exploratory Clinical Trial of Nab-Paclitaxel and Gemcitabine Compared With Gemcitabine and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic Cancer | NCT04216758 |
| Efficacy and Safety of Paclitaxel Liposome and S-1 as First-line Therapy in \ Advanced Pancreatic Cancer Patients | A Single-arm, Prospective Study to Evaluate the Efficacy and Safety of the Combination of Paclitaxel Liposome and S-1 as First-line Therapy in Treating Patients With Advanced Metastatic Pancreatic Cancer | NCT04217096 |
| Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations | A Phase-2, Two-Cohort Trial of Neoadjuvant Nab-Paclitaxel and Alpelisib in Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations | NCT04216472 |
| SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer | SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer | NCT04213898 |
| Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer | The Efficacy and Safety of Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer: A Multicenter, Randomized Controlled Study | NCT04213937 |
| Evaluation of the Efficacy and Safety of a Paclitaxel Eluting PTCA Balloon Catheter in Coronary In-stent Restenosis | Evaluation of the Efficacy and Safety of a Paclitaxel Eluting PTCA Balloon Catheter in Coronary In-stent Restenosis: a Randomized, Open-label, Positive Parallel Controlled, Multicenter Clinical Trial | NCT04213378 |
| A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study | A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study | NCT04215146 |
| Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma | Phase 2 Study of Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma | NCT04209686 |
| A Phase II Study for Nab-paclitaxel plus Cisplatin vs Gemcitabine plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer | A Phase II Study for Nab-paclitaxel plus Cisplatin vs Gemcitabine plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer | ChiCTR1900028328 |
| Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers | Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma | NCT04205968 |
| ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma | A Randomised Non-comparative Open Label Phase II Trial of Atezolizumab Plus Bevacizumab, With Carboplatin-paclitaxel or Pemetrexed, in EGFR-mutant Non-small Cell Lung Carcinoma With Acquired Resistance | NCT04245085 |
| A multicenter, prospective, single-arm, exploratory clinical study of neoadjuvant therapy of her2-positive breast cancer with pyrotinib maleate tablets combined with paclitaxel for injection (albumin bound) | A multicenter, prospective, single-arm, exploratory clinical study of neoadjuvant therapy of her2-positive breast cancer with pyrotinib maleate tablets combined with paclitaxel for injection (albumin bound) | ChiCTR1900028212 |
| Efficacy and Safety of Short-term Nab-paclitaxel plus Carboplatin for the First-line Treatment of Advanced Ovarian Cancer | Efficacy and Safety of Short-term Nab-paclitaxel plus Carboplatin for the First-line Treatment of Advanced Ovarian Cancer: a Non-randomized, Controlled, Multicenter, Open-label, Phase II Study | ChiCTR1900028165 |
| Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast Cancer | Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast Cancer:a Multi-center Study | NCT04194684 |
| Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer | Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer: an Multicenter, Open, Randomized, Controlled Clinical Study | NCT04195828 |
| A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151) | A Phase III, Randomized, Double-Blind Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151) | NCT04194203 |
| Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer | Study Comparing the Efficacy and Safety of Epirubicin Combined With Cyclophosphamide Followed by Docetaxel (EC-T) Verses Paclitaxel Combined With Carboplatin (PCb) in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer | NCT04193059 |
| Pyrotinib in Combination With Albumin–Bound Paclitaxel in HER2-Positive Patients With Advanced Breast Cancer: a Multicentre Phase II Study | Pyrotinib in Combination With Albumin–Bound Paclitaxel in HER2-Positive Patients With Advanced Breast Cancer: a Multicentre Phase II Study | ChiCTR1900027932 |
| Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy | Anti-PD-1 Antibody Camrelizumab Combined With Albumin-bound Paclitaxel for Recurrent and Persistent Advanced Cervical Cancer Refractory to Platinum-based Chemotherapy: A Single Arm, Single Center, Open, Phase II Trial | NCT04188860 |
| Clinical Trial to evaluate the efficacy of immunotherapy in a subset of Hormonal Receptor-positive/HER2-negative advanced breast cancer patients who have progressed to standard therapy. | Targeting non-Luminal disease by PAM50 with pembrolizumab + paclitaxel in Hormone Receptor-positive/HER2-negative advanced/metastatic breast cancer, who have progressed on or after CDK 4/6 inhibitor treatment (TATEN trial) - TATEN | EUCTR2018-003367-58-ES |
| Phase II neoadjuvant trial of nab-Paclitaxel+Pertuzumab+Trastuzumab followed by Anthracycline based regimen in patients with operable Her2 positive breast cancer | Phase II neoadjuvant trial of nab-Paclitaxel+Pertuzumab+Trastuzumab followed by Anthracycline based regimen in patients with operable Her2 positive breast cancer - OMC-BC05 Study | JPRN-UMIN000038715 |
| Gemcitabine/nab-paclitaxel/S-1 triple regimen for patients with locally advanced or advanced pancreatic cancer: A prospective, single-arm, phase I study | Gemcitabine/nab-paclitaxel/S-1 triple regimen for patients with locally advanced or advanced pancreatic cancer: A prospective, single-arm, phase I study | ChiCTR1900027833 |
| Phase II study of modified nab-paclitaxel plus gemcitabine in elderly patients over 75 years with unresectable advanced pancreatic cancer | Phase II study of modified nab-paclitaxel plus gemcitabine in elderly patients over 75 years with unresectable advanced pancreatic cancer - Phase II study of modified nab-paclitaxel plus gemcitabine in elderly patients over 75 years with unresectable advanced pancreatic cancer | JPRN-UMIN000038738 |
| Nab-paclitaxel Compared With Docetaxel Followed by Anthracyclines and Cyclophosphamide in the Neoadjuvant Breast Cancer | Nab-paclitaxel Compared With Docetaxel Followed by Anthracyclines and Cyclophosphamide in the Neoadjuvant Breast Cancer | NCT04182568 |
| Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer | A Phase I Study of Intraperitoneal Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology | NCT04220827 |
| Improving Performance status of Advanced lung cancer patients with Chemotherapy | The feasibility of weekly paclitaxel in improving performance status of advanced NSCLC patients with poor performance status: A single arm phase two trial - ImPACt | CTRI/2020/01/022617 |
| A prospective, single-arm clinical study on the safety and efficacy of calirizumab combined with carboplatin and albumin paclitaxel in the neoadjuvant therapy of potentially resectable stage II-IIIA esophageal squamous cell carcinoma | A prospective, single-arm clinical study on the safety and efficacy of calirizumab combined with carboplatin and albumin paclitaxel in the neoadjuvant therapy of potentially resectable stage II-IIIA esophageal squamous cell carcinoma | ChiCTR2000028900 |
| Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer | A Prospective, Belgian Multi-center, Single-arm, Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer | NCT04224922 |
| Incidence, patterns, risk factors, and management of immediate hypersensitivity reactions in gynecologic cancer patients receiving paclitaxel -based chemotherapy | Incidence, patterns, risk factors, and management of immediate hypersensitivity reactions in gynecologic cancer patients receiving paclitaxel -based chemotherapy | TCTR20200220001 |
| Chemoradiotherapy in Unresectable Esophageal Cancer | A Phase I/II Study of Chemoradiotherapy Using Albumin-Bound Paclitaxel and Cisplatin in Unresectable Esophageal Squamous Cell Carcinomas Based on Nutritional Risk Screening Score (NRS2002) | NCT04278287 |
| OCT- Versus Angiography-guided Paclitaxel Drug-Coated Balloon Angioplasty in De Novo Coronary Artery | OCT- Versus Angiography-guided Paclitaxel Drug-Coated Balloon Angioplasty in De Novo Coronary Artery After Lesion Preparation With Scoring Balloon - A Prospective Multicenter Cohort Study | NCT04276389 |
| Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure | Paclitaxel Plus Cetuximab for the Treatment of Recurrent and/or Metastatic Head and Neck Cancer After First-line Checkpoint Inhibitor Failure: A Multicenter, Single Arm Study | NCT04278092 |
| choice between paclitaxel or carboplatin in cisplatin ineligible advanced urinary bladder cancer | Gemcitabine and Carboplatin versus Gemcitabine and Paclitaxel Chemotherapy in Cisplatin Ineligible Advanced Stage Urothelial Cancers: A Prospective Randomized Control Study. - CAUR CAP | CTRI/2020/02/023402 |
| Comparison of response and toxicity of capecitabine and oxaliplatin chemotherapy regimen with taxol and carboplatin with radiotherapy in esophageal cancer patients | Comparison of response and toxicity of capecitabine and oxaliplatin chemotherapy regimen with taxol and carboplatin with radiotherapy in esophageal cancer patients | IRCT20170306032913N4 |
| Albumin Paclitaxel plus S-1 and Anlotinib as First-Line Chemotherapy for Metastatic or Unresectable Locally Advanced Biliary Tract Carcinomas: a Phase II Clinical Trial | Albumin Paclitaxel plus S-1 and Anlotinib as First-Line Chemotherapy for Metastatic or Unresectable Locally Advanced Biliary Tract Carcinomas: a Phase II Clinical Trial | ChiCTR2000029854 |
| Study to Assess the Efficacy and Safety of Nivolumab in Combination with Paclitaxel in Subjects with Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX) | Phase II Multicenter Randomized Trial to Assess the Efficacy and Safety of First Line Nivolumab in Combination with Paclitaxel in Subjects with R/M HNSCC Unable for Cisplatin-based Chemotherapy (NIVOTAX) | NCT04282109 |
| Study of Pamrevlumab or placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer | A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in combination with either Gemcitabine Plus Nab-paclitaxel or FOLFIRNIOX as Neoadjuvant Treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer - Not available | EUCTR2019-001925-28-DE |
| Atezolizumab Plus CArboplatin Plus Nab-paclitaxel | A Phase II Trial of Atezolizumab Plus CArboplatin Plus Nab-paclitaxel as First-line Therapy in Metastatic Triple-negative PD-L1 Positive Breast Cancer Patients - the GIM25-CAPT Trial | NCT05266937 |
| Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer | A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination With Durvalumab, Followed by Maintenance Durvalumab With or Without Olaparib in Patients With Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E) | NCT04269200 |
| Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLC | Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Patients With Stage IB-IIIA Non-small Cell Lung Cancer (NANE-LC): A Prospective, Single-arm, Multicenter, Phase II Study | NCT04541251 |
| Prospective, Multicenter, Non-randomized, Single Arm Clinical Trial to Evaluate the Safety and Efficacy of e-PTFE Grafts Inner Surface-treated With Paclitaxel as an Access for Hemodialysis in Patients With End-stage Renal Disease. | Prospective, Multicenter, Non-randomized, Single Arm Clinical Trial to Evaluate the Safety and Efficacy of e-PTFE Grafts Inner Surface-treated With Paclitaxel as an Access for Hemodialysis in Patients With End-stage Renal Disease. | NCT04285073 |
| Albumin-bound paclitaxel combined with loplatin versus docetaxel combined with loplatin in the perioperative treatment of advanced gastric cancer | Albumin-bound paclitaxel combined with loplatin versus docetaxel combined with loplatin in the perioperative treatment of advanced gastric cancer | ChiCTR2000029714 |
| Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer | Efficacy and Safety of Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer | NCT04258644 |
| Neoadjuvant Chomotherapy With Paclitaxel-albumin and S-1 for Advanced Gastric Cancer | Neoadjuvant Chomotherapy With Paclitaxel-albumin and S-1 for Advanced Gastric Cancer | NCT04258657 |
| NUVOLA TRIAL Open-label Multicentre Study | The NUVOLA TRIAL: Neoadjuvant Chemotherapy in Unresectable oVarian Cancer With OLAparib and Weekly Carboplatin Plus Paclitaxel: A Phase II Open-label Multicentre Study | NCT04261465 |
| Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss | A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation | NCT04251533 |
| A Multicenter, Open-label, Phase I/II Clinical Trial of Intraperitoneal Paclitaxel and Oral S-1 and Intravenous Oxaliplatin Combination Therapy in Patients with Advanced ll | A Multicenter, Open-label, Phase I/II Clinical Trial of Intraperitoneal Paclitaxel and Oral S-1 and Intravenous Oxaliplatin Combination Therapy in Patients with Advanced or Recurrent Gastric Cancer with Peritoneal metastasis | KCT0004670 |
| A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel | AIPAC-002 (Active Immunotherapy PAClitaxel-002): A Multicentre, Phase Ib Study to Test a New Schedule of Eftilagimod Alpha (a Soluble LAG-3 Protein) as Adjunctive to Weekly Paclitaxel in Hormone Receptor-positive Metastatic Breast Carcinoma Patients | NCT04252768 |
| Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer | A Multicenter, Phase I/II Study of Sequential Epigenetic and Immune Targeting in Combination With Nab-Paclitaxel/Gemcitabine in Patients With Advanced Pancreatic Ductal Adenocarcinoma. | NCT04257448 |
| Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer | Cryoablation and Anti-PD-L1 Immunotherapy for Triple Negative Breast Cancer (TNBC) | NCT04249167 |
| Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer. | LAPTOP: Phase 1/2 Study in Borderline Resectable, Locally Advanced or Metastatic Pancreatic Cancer to Assess Safety and Potential Efficacy of Dual Checkpoint Inhibition in Combination with Gemcitabine and Nab-paclitaxel Followed by Immune-chemoradiation. | NCT04247165 |
| Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread | A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients With Treatment Naïve Metastatic Pancreatic Cancer (GIANT) | NCT04233866 |
| Efficacy and safety of nab-paclitaxel combined with apatinib in the second-line treatment of advanced gastric cancer | Efficacy and safety of nab-paclitaxel combined with apatinib in the second-line treatment of advanced gastric cancer | ChiCTR2000028991 |
| A Phase II clinical research study evaluating the effectiveness of paricalcitol in combination with gemcitabine/nab-paclitaxel in patients with advanced pancreatic cancer. | Paricalcitol Trial: Phase II, Open label clinical trial of Paricalcitol in combination with Gemcitabine/ Nab-Paclitaxel therapy in advanced pancreatic cancer. | EUCTR2020-000073-24-IE |
| Albumin paclitaxel plus platinum and toripalimab as first-line treatment for recurrent/metastatic head and neck squamous cell carcinaoma: Phase II Clinical Trial | Albumin paclitaxel plus platinum and toripalimab as first-line treatment for recurrent/metastatic head and neck squamous cell carcinaoma: Phase II Clinical Trial | ChiCTR2000029713 |
| A clinical trial of ipatasertib in combination with paclitaxel versus placebo and paclitaxel in patients with specific tumor alteration, Locally Advanced or Metastatic, Triple Negative Breast cancer or Hormone Receptor â?? Positive, HER2 â?? Negative Breast Cancer | A Double Blind, Placebo- Controlled, Randomized Phase III Study of IPATASERTIB in combination with Paclitaxel As a treatment for patients with PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple Negative Breast cancer or Hormone Receptor â?? Positive, HER2 â?? Negative Breast Cancer | CTRI/2019/05/019047 |
| Efficacy And Safety of Weekly Nab-Paclitaxel Alone as First-line Chemotherapy for Elderly(=70 years) Advanced Lung Squamous Carcinoma Patients. | Efficacy And Safety of Weekly Nab-Paclitaxel Alone as First-line Chemotherapy for Elderly(=70 years) Advanced Lung Squamous Carcinoma Patients: A Prospective Concurrent Controlled Trial. | ChiCTR1900023062 |
| Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib. | A Phase II Study of Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumor (GIST) With Low P-glycoprotein Expression After Failure of at Least Imatinib, Sunitinib, and Regorafenib. | NCT03944304 |
| Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery | A Randomized Phase II Trial of Carboplatin-Paclitaxel With or Without Ramucirumab in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma | NCT03694002 |
| Survival and quality of life of patients with pancreatic cancer treated with nab-paclitaxel and gemcitabine with or wthout Tocilizumab. | A MULTINATIONAL, RANDOMIZED, PHASE II STUDY OF THE COMBINATION OF NAB-PACLITAXEL AND GEMCITABINE WITH OR WITHOUT IL-6R INHIBITOR, TOCILIZUMAB, AS FIRST-LINE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER. - Study of nab-Paclitaxel and Gemcitabine with or without Tocilizumab in Pancreatic Cancer Patients. | EUCTR2016-000643-13-NO |
| Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma | Nal-IRI/LV5-FU VERSUS PACLITAXEL AS SECOND-LINE THERAPY IN PATIENTS WITH METASTATIC OESOPHAGEAL SQUAMOUS CELL CARCINOMA A Multi-centre, Randomized, Non-comparative Phase II Study | NCT03719924 |
| High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | Phase IB/II Trial of High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have No Prior Therapy for Their Metastatic Pancreatic Cancer | NCT03697239 |
| Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer | PD-1 Antibody SHR-1210 Combined With Paclitaxel and Cisplatin Versus Placebo Combined With Paclitaxel and Cisplatin as First-line Therapy for Advanced Esophageal Cancer: a Randomized, Double-blinded, Controlled, Multi-center Phase III Trial | NCT03691090 |
| Feasibility and potential benefits of preoperative chemotherapy with Gemcitabine+nab/Paclitaxel in patients with resectable pancreatic cancer: a multicenter phase I/II trial (APCS-01 study). | Feasibility and potential benefits of preoperative chemotherapy with Gemcitabine+nab/Paclitaxel in patients with resectable pancreatic cancer: a multicenter phase I/II trial (APCS-01 study). - Multicenter phase I/II study of preoperative chemotherapy with Gemcitabine and nab/Paclitaxel for resectable pancreatic cancer (APCS-01). | JPRN-UMIN000033901 |
| Treatment of In-Stent Restenosis 2 Study | Prospective Randomised Study Comparing Efficacy of Treatment Coronary In-stent Restenosis Using Sirolimus-Eluting and Iopromide-Coated Paclitaxel-Eluting Balloon Catheters | NCT03667313 |
| A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer | A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer - SYNERGY trial | EUCTR2017-004651-23-BE |
| Chemoradiation for advanced unresectable esophageal and gastroesophageal junction cancer | Carboplatin/ paclitaxel versus cisplatin/ 5-fluorouracil as definitive chemoradiotherapy for locoregionally advanced unresectable esophageal and gastroesophageal junction cancer | CTRI/2018/08/015564 |
| A clinical study to assess the comparative blood concentration of two anti-cancer drugs (test and marketed Paclitaxel) in patients with breast cancer | A Randomized, Open Label, Multi Center, Two Treatment,Two Period, Two Sequence, Single Dose, Crossover,Bioequivalence Study of Paclitaxel Protein-Bound Particlesfor Injectable Suspension (Albumin-Bound), 100 mg/vialmanufactured by Teva Pharmachemie, The Netherlands, forTeva Pharmaceuticals USA, and Abraxane® for InjectableSuspension (paclitaxel protein-bound particles for injectablesuspension)(albumin-bound), 100 mg/vial manufactured byAbraxis BioScience LLC, USA for Celgene Corporation,USA in Patients with Metastatic Breast Cancer. | CTRI/2018/08/015506 |
| Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) | An International Multi-centre Randomised Phase II Study to Assess the Efficacy of TAK228 in Combination With Intravenous Weekly Paclitaxel Compared With Weekly Paclitaxel Alone in Women With Advanced/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) | NCT03648489 |
| Comparison of two chemotherapy regimens including carboplatin-paclitaxel and capecitabine-oxaliplatin in neo-adjuvant chemo-radiation of esophageal cancer | Comparison of efficacy and adverse effects of two chemotherapy regimens including carboplatin-paclitaxel and capecitabine-oxaliplatin in neo-adjuvant chemo-radiation of esophageal cancer for patients who were referred to Imam Khomeini cancer institute during year 95-96 | IRCT20140903019036N3 |
| Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer | A Phase 1b/2 Randomized, Controlled Study of AVB-S6-500 in Combination With Pegylated Liposomal Doxorubicin (PLD) or Paclitaxel (Pac) in Patients With Platinum-resistant Recurrent Ovarian Cancer | NCT03639246 |
| A nationwide open-label multi-center prospective cohort study of nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer | A nationwide open-label multi-center prospective cohort study of nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer - NABGEM studie | NL-OMON46852 |
| A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin Paclitaxel Plus Concurrent and Extended Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated, Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT03635489 |
| To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) | Phase II Open-label, Multicentre, Randomized Trial of Neoadjuvant Palbociclib in Combination With Hormonal Therapy and HER2 Blockade Versus Paclitaxel in Combination With HER2 Blockade for Postmenopausal Patients With Hormone Receptor Positive/HER2 Positive Early Breast Cancer | NCT03644186 |
| The Efficacy and Safety of SeQuent® Please in the Treatment of Small Vessel Disease (SVD) Patient | A Randomized, Multicenter Study on the Efficacy and Safety of Paclitaxel-eluting PTCA-Balloon Catheter(SeQuent® Please) Compared to POBA in the Treatment of Small Vessel Disease (SVD) Patient | NCT03625830 |
| Study of the investigational drug Ramucirumab in combination with standard chemotherapy with Nab-paclitaxel and Gemcitabine as initial treatment for advanced pancreatic cancer. | Phase Ib-II study of Ramucirumab combined with standard Nab-paclitaxel and Gemcitabine as first-line treatment in patients with advanced pancreatic adenocarcinoma - RACING | EUCTR2017-004792-30-GR |
| Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6 | Safety and Efficacy of Intraperitoneal Paclitaxel in Gastric Cancer Patients With Peritoneal Metastasis Receiving Systemic Chemotherapy | NCT03618758 |
| Nab-paclitaxel Plus S-1(AS) Versus Nab-paclitaxel Plus Gemcitabine(AG) in Patients With Advanced Pancreatic Cancer | Phase II Trial Comparing Nab-paclitaxel Plus S-1 Versus Nab-paclitaxel Plus Gemcitabine in First-line Treatment of Patients With Advanced Pancreatic Cancer | NCT03636308 |
| Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer | Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoantigen Vaccine Vs. Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab in Patients With Metastatic Triple Negative Breast Cancer | NCT03606967 |
| Paclitaxel Eluting Balloon After Bare Metal Stent Implantation vs. Drug-Eluting Stent in St Elevation Myocardial Infarction | Study to Evaluate the Efficacy and Safety of Paclitaxel Eluting Balloon After Bare Metal Stent Implantation Versus Drug-eluting Stent in St Elevation Myocardial Infarction | NCT03610347 |
| Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy | Phase IB Study of Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy | NCT03607955 |
| Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors | A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors | ACTRN12618001236280 |
| SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer | SHR-1210, a Novel Anti-PD-1 Antibody, in Combination With Apatinib and Irinotecan/Paclitaxel Liposome Plus Nedaplatin in Patients With Previously Untreated Advanced or Metastatic Esophageal Squamous Cell Cancer: a Phase II Study | NCT03603756 |
| Selection trial of paclitaxel in gastric cancer with peritoneal dissemination | WJOG10617G Randomized phase II trial of weekly paclitaxel + ramucirumab versus weekly nab-paclitaxel + ramucirumab for unresectable advanced or recurrent gastric/esophagogastric junction adenocarcinoma with peritoneal dissemination refractory to first-line therapy including a fluoropyrimidine (P-SELECT) - P-SELECT | JPRN-jRCTs031180022 |
| Hypofractionated Radiotherapy With Carboplatin and Paclitaxel in Non-Small Cell Lung Cancer | A Phase II Trial of Hypofractionated Intensity-Modulated Radiation Therapy (IMRT) Utilizing 2.5 Gy/Fraction to PET-avid Disease Combined With Carboplatin and Paclitaxel for Subjects With Stage IIIA or IIIB Non-Small Cell Lung Cancer | NCT03699033 |
| Gemcitabine, Nab-paclitaxel, and Dexamethasone in Patients With Recurrent/refractory peripheral T cell lymphoma | Gemcitabine, Nab-paclitaxel, and Dexamethasone in Patients With Recurrent/refractory peripheral T cell lymphoma | ChiCTR1800018710 |
| Gemcitabine & Nab-Paclitaxel in Pancreatic Adenocarcinoma With Positive Peritoneal Cytology | Gemcitabine and Nab-Paclitaxel in Pancreatic Adenocarcinoma With Positive Peritoneal Cytology as a Sole Metastatic Site, a Pilot Study | NCT03703089 |
| Avelumab + Paclitaxel/ Ramucirumab als Zweitlinientherapie beim gastro-ösophagealen Adenokarzinom: eine Phase-II-Studie der AIO - RAP-Studie | Avelumab + Paclitaxel/ Ramucirumab as second line treatment in gastro-esophageal adenocarcinoma: a phase II trial of the AIO - RAP-Trial | EUCTR2018-002938-20-DE |
| Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer | A Multi-center Phase II Study of Trastuzumab Biosimilar (SB3®) in Combination With Ramucirumab and Paclitaxel in HER2 Positive Metastatic Gastric Cancer Patients | NCT03766607 |
| TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors | A Phase I Study of TAK-659 and Paclitaxel in Patients With Advanced Solid Tumors | NCT03756818 |
| The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast Cancer | A Randomized Study Evaluating the Safety and Effects of the Combination of Palbociclib With Epirubicin and Cyclophosphamide Followed by Paclitaxel as Neoadjuvant Therapy in Triple Negative Breast Cancer | NCT03756090 |
| A clinical trial to evaluate a new medicine (Zolbetuximab) for the treatment of pancreatic cancer | A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma | EUCTR2018-002551-15-ES |
| GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study | Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel in Patients With Metastatic Gastric Cancer After Failure of First-line Chemotherapy, Phase Ib/II | NCT03751761 |
| Randomized study of frozen gloves/socks for the prevention of paclitaxel-induced neuropathy in breast cancer patients | Randomized study of frozen gloves/socks for the prevention of paclitaxel-induced neuropathy in breast cancer patients - Evaluation of frozen gloves/socks for the prevention of paclitaxel-induced neuropathy | JPRN-UMIN000034966 |
| DKN-01/Atezolizumab as Second Line Treatment of biliarY Tract Cancer and in combiNAtion or Not With Paclitaxel as Second Line treatMent of esophagogastrIC Cancer | DKN-01/Atezolizumab as Second Line Treatment of biliarY Tract Cancer and in combiNAtion or Not With Paclitaxel as Second Line treatMent of esophagogastrIC Cancer: a Multi-center Phase II Trial | NCT03760289 |
| Phase II trial of paclitaxel (T) vs Irinotecan(I) in patients with extensive disease (ED) small cell lung cancer (SCLC) as 2nd line chemotherapy | Phase II trial of paclitaxel (T) vs Irinotecan(I) in patients with previously Etoposide/platinum (EP) treated, extensive disease (ED) small cell lung cancer (SCLC) as 2nd line chemotherapy | KCT0003330 |
| Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer | The Efficacy and Safety of Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer :Single Arm, Phase II Clinical Trail | NCT03735082 |
| A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer | NCT03726879 |
| International study that compares a chemotherapy regimen with atezolizumab, paclitaxel and carboplatin versus a regimen with placebo, paclitaxel and carboplatin in patients affected by advanced or recurrent endometrial cancer | AtTEnd: Atezolizumab Trial in Endometrial cancer - Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer. - AtTEnd | EUCTR2018-001072-37-ES |
| A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (MPDL3280A, ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN + PACLITAXEL OR MPDL3280A IN COMBINATION WITH CARBOPLATIN + NAB PACLITAXEL VERSUS CARBOPLATIN + NAB-PACLITAXEL IN CHEMOTHERAPY NAÏVE PATIENTS WITH STAGE IV SQUAMOUS NON-SMALL CELL LUNG CANCER | A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (MPDL3280A, ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN + PACLITAXEL OR MPDL3280A IN COMBINATION WITH CARBOPLATIN + NAB PACLITAXEL VERSUS CARBOPLATIN + NAB-PACLITAXEL IN CHEMOTHERAPY NAÏVE PATIENTS WITH STAGE IV SQUAMOUS NON-SMALL CELL LUNG CANCER - GO29437 | NL-OMON47153 |
| A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer | A Phase II/III Randomized, Open-Label Clinical Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Metastatic Pancreatic Cancer Following Chemotherapy Failure | NCT03721744 |
| A Study of Intraperitoneal and Intravenous Paclitaxel Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells | A Study of Intraperitoneal and Intravenous Paclitaxel Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells | NCT03718624 |
| _ | A Phase III randomized study evaluating gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in Metastatic Pancreatic Ductal Adenocarcinoma. - GEMPAX | EUCTR2018-002886-21-FR |
| Trial evaluating the efficacy and safety of the combination of Durvalumab with carboplatin and paclitaxel as first line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck not eligible to standard chemotherapy | Frail-Immune (GORTEC-2018-03) - A multicenter, prospective, single arm phase II study evaluating the efficacy and safety of the combination of Durvalumab with carboplatin and paclitaxel as first line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck not eligible to standard chemotherapy - Frail-Immune | EUCTR2018-000414-38-FR |
| DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC | DAPHNe: De-escalation to Adjuvant Antibodies Post-pCR to Neoadjuvant THP (Paclitaxel/Trastuzumab/Pertuzumab)-a Pilot Study in HER2-positive Breast Cancer | NCT03716180 |
| A study to determine whether the addition of Dostarlimab (TSR-042) delays recurrence of advanced endometrial cancer | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF DOSTARLIMAB (TSR-042) PLUS CARBOPLATIN-PACLITAXEL VERSUS PLACEBO PLUS CARBOPLATIN-PACLITAXEL IN PATIENTS WITH RECURRENT OR PRIMARY ADVANCED ENDOMETRIAL CANCER (RUBY) - 4010-03-001 | CTIS2023-506551-23-00 |
| FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel | Multicenter Prospective Single Arm Phase II Study Evaluating Efficacy & Safety of Durvalumab With Carboplatin/Paclitaxel as First Line Treatment in Patients With Recurrent/Metastatic SCCHN Not Eligible to Standard Chemotherapy | NCT03723967 |
| ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors | A Phase 1b Study of ALRN-6924 in Combination With Paclitaxel in Wild-Type TP53 Advanced or Metastatic Solid Tumors Including Estrogen-Receptor Positive Breast Cancer | NCT03725436 |
| A Phase IB/II Study to determine efficacy and safety of Durvalumab + Paclitaxel and Durvalumab in Combination with Novel Oncology Therapies with or without Paclitaxel for First-line Metastatic Triple Negative Breast Cancer | A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First line Metastatic Triple Negative Breast Cancer - BEGONIA | EUCTR2018-000764-29-GB |
| Response of chemotherapy with cisplatin and etoposide versus cisplatin and paclitaxel in advanced non-small cell lung cancer patient | Response of chemotherapy with cisplatin and etoposide versus cisplatin and paclitaxel in advanced non-small cell lung cancer patient | TCTR20181011005 |
| A study to compare Cipla product- Paclitaxel with Celgene Corporation product - ABRAXANE® to establish that both are equally effective in treating metastatic breast cancer patients. | A multicenter, open label, randomized, two treatment, four period, replicate crossover, single dose, bioequivalence study of paclitaxel protein-bound particles for injectable suspension (albumin-bound) 100 mg/vial by Cipla Ltd., India with ABRAXANE® for injectable suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) 100 mg/vial by Celgene Corporation, USA in breast cancer patients after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. | CTRI/2018/10/015972 |
| A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer | A Phase I/IIa Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Rivoceranib in Combination With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer | NCT03707028 |
| Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer | Alternating Neoadjuvant Gemcitabine-Nab-Paclitaxel and Nanoliposomal Irinotecan (Nal-IRI) With 5-Fluorouracil and Folinic Acid (Leucovorin) Regimens in Resectable and Borderline Resectable Pancreatic Cancer | NCT03703063 |
| Carboplatin + nab-Paclitaxel treatment for non-small lung cancer with malignant pleural effusion -phase II trial- | Carboplatin + nab-Paclitaxel treatment for non-small lung cancer with malignant pleural effusion -phase II trial- - Carboplatin + nab-Paclitaxel treatment for malignant pleural effusion | JPRN-UMIN000034591 |
| NSOX study | Phase I/II trial of combined chemotherapy of Nab-paclitaxel, S-1, and Oxaliplatin for gastric cancer patients with peritoneal metastasis (NSOX study) - NSOX study | JPRN-jRCTs051180012 |
| Clinical study of apatinib mesylate combined with paclitaxel in second-line and second-line maintenance of advanced gastric cancer | Clinical study of apatinib mesylate combined with paclitaxel in second-line and second-line maintenance therapy for advanced gastric cancer - open, single-arm exploratory study | ChiCTR1800017225 |
| Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients | Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients | NCT03760822 |
| Comparison of a standard paclitaxel therapy with additional medication (Ramucirumab) in one group for patients with squamous-cell carcinoma of the esophagus, refractory or intolerant to combination therapy with Fluoropyrimidine or Platinum-based drugs. | RAMOSA randomized, multicenter open label phase II trial of Paclitaxel + Ramucirumab versus Paclitaxel alone in patients with squamous-cell carcinoma of the esophagus, refractory or intolerant to combination therapy with Fluoropyrimidine or Platinum-based drugs – The RAMOS study - RAMOS | EUCTR2016-003850-33-DE |
| A phase II neoadjuvant trial of sequential nab-paclitaxel followed by 5-fluorouracil/epirubicine/cyclophosphamide (FEC) in operable breast cancer | A phase II neoadjuvant trial of sequential nab-paclitaxel followed by 5-fluorouracil/epirubicine/cyclophosphamide (FEC) in operable breast cancer - A phase II neoadjuvant trial of sequential nab-paclitaxel followed by FEC in operable breast cancer | JPRN-UMIN000032153 |
| Gemcitabine + Oxaliplatin +Nab-paclitaxel in Subjects With Advanced Biliary Tract Cancer | A Multicenter, Phase I-II Trial of Gemcitabine Plus Oxaliplatin and Nab-paclitaxel in Subjects With Advanced (Unresectable or Metastatic) Biliary Tract Cancer | NCT03943043 |
| Chemotherapy with paclitaxel and capecitabine for the treatment of recurrent or metastatic head and neck cancer | Phase II analysis of paclitaxel and capecitabine in the treatment of recurrent or disseminated squamous cell carcinoma of the head and neck region | ISRCTN14555104 |
| Carboplatin, Paclitaxel With or Without Avelumab in Advanced or Recurrent Endometrial Cancer | MITO END-3: A Randomized Phase II Trial of Carboplatin+Paclitaxel Compared to Carboplatin+Paclitaxel+Avelumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer | NCT03503786 |
| BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) | A Phase I/II Study to Evaluate the Tolerability and Efficacy of BMS-813160 (CCR2/5 Inhibitor) With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) | NCT03496662 |
| Efficacy and Safety of Modified Nab-Paclitaxel Plus Gemcitabine Chemotherapy for Metastatic Pancreatic Cancer | Efficacy and Safety of Modified Nab-Paclitaxel Plus Gemcitabine Chemotherapy for Metastatic Pancreatic Cancer: A Single-arm Phase II Clinical Trial | NCT03502343 |
| Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer | A Phase II Trial of Pre-operative Chemotherapy (With Gemcitabine and Nab- Paclitaxel) and Stereotactic Body Radiotherapy Followed by Surgery and Chemotherapy in Patients With Resectable Pancreatic Adenocarcinoma | NCT03492671 |
| The phase 2 study of neoadjuvant chemotherapy of gemcitabine+nab-paclitaxel+S-1 for patients with biological borderline resectable pancreatic cancer. | The phase 2 study of neoadjuvant chemotherapy of gemcitabine+nab-paclitaxel+S-1 for patients with biological borderline resectable pancreatic cancer. - The phase 2 study of neoadjuvant chemotherapy of gemcitabine+nab-paclitaxel+S-1 for patients with biological borderline resectable pancreatic cancer. | JPRN-UMIN000030717 |
| Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer | A Prospective Multicenter Open-label, Randomized Phase II Study of Pembrolizumab in Combination With Neoadjuvant EC-Paclitaxel Regimen in HER2-negative Inflammatory Breast Cancer. | NCT03515798 |
| Nab-paclitaxel in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors | AflacST1603: a Phase 1 Study Using Nab-paclitaxel (Abraxane®) in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors | NCT03507491 |
| A Study of Intraperitoneal Paclitaxel in Combination With SOX Compared With SOX Alone in Gastric Cancer With Malignant Ascites | A Randomized Study of the Effect of First-line Intraperitoneal Paclitaxel in Combination With SOX Versus SOX Alone in Gastric Cancer Patients With Malignant Ascites | NCT03475615 |
| A prospective cohort study of neoadjuvant chemotherapy using carboplatin and dose dense paclitaxel for locally advanced cervical cancer | A prospective cohort study of neoadjuvant chemotherapy using carboplatin and dose dense paclitaxel for locally advanced cervical cancer - CC-NAC | JPRN-UMIN000031670 |
| DICE: An international study to assess the effectiveness of TAK228 in combination with weekly paclitaxel, compared with weekly paclitaxel on its own, in women with advanced/recurrent ovarian, fallopian tube or primary peritoneal cancer that is resistant to platinum-based chemotherapy | An international multi-centre randomised phase II study to assess the efficacy of TAK228 in combination with intravenous weekly paclitaxel compared with weekly paclitaxel alone in women with advanced/recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer (of clear cell, endometrioid and high grade serous type, and carcinosarcoma) - DICE version 1.0 | EUCTR2016-000065-23-GB |
| N-acetyl Cysteine Effect in Peripheral Neuropathy in Cancer Patients | Evaluation of The Effect of N-AcetylCysteine in The Prevention of Paclitaxel-Induced Peripheral Neuropathy in Cancer Patients | NCT03492047 |
| Study to Assess the Efficacy and Safety of MB02 (Bevacizumab Biosimilar Drug) Versus Avastin® in Combination With Carboplatin and Paclitaxel for the Treatment of patients with Stage IIIB/IV Non-squamous Non-Small Cell Lung Cancer (NSCLC) | STELLA â?? A Randomized, Multicenter, Multinational, Double-Blind Study to Assessthe Efficacy and Safety of MB02 (Bevacizumab Biosimilar Drug) Versus Avastin® inCombination With Carboplatin and Paclitaxel for the Treatment of Subjects With StageIIIB/IV Non-squamous Non-Small Cell Lung Cancer (NSCLC) | CTRI/2018/02/012091 |
| Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial Carcinoma | An Open Label, Single-arm, Phase 2 Study of Pembrolizumab and Nanoparticle Albumin-bound Paclitaxel in Patients With Metastatic Urothelial Carcinoma After Chemotherapy Failure; the PEANUT Study | NCT03464734 |
| NK105 Phase II Clinical trial (Breast cancer) | A Randomized Phase II Trial Comparing NK105 and Paclitaxel in Advanced or Recurrent Breast Cancer | JPRN-jRCT2080223812 |
| Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination | A Randomized, Molecular Driven Phase II Trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib, Selected According to HRD Status, in Patients With Advanced (Stage III B-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer Preceded by a Phase I Dose Escalation Study on Rucaparib-Bevacizumab Combination | NCT03462212 |
| A phase II study of weekly nab-paclitaxel plus ramucirumab in patients with previously treated advanced gastric cancer | A phase II study of weekly nab-paclitaxel plus ramucirumab in patients with previously treated advanced gastric cancer - weekly Nab-Paclitaxel+Ramucirumab for unresectable gastric cancer | JPRN-UMIN000031285 |
| Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer | A Phase III, Randomized, Multicenter, Double-blind Study to Compare Efficacy and Safety of EG12014 With Herceptin as Neoadjuvant Treatment in Combination With Anthracycline/Paclitaxel Systemic Therapy in HER2-Positive Early Breast Cancer | NCT03433313 |
| A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies | A Phase 1/2, Open-Label, Study to Evaluate the Safety and Anti-Tumor Activity of FS118, a LAG-3/PD-L1 Bispecific Antibody, as a Monotherapy and in Combination With Paclitaxel, in Patients With Advanced Malignancies | NCT03440437 |
| Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors | A Phase I Study of TAK-228 (MLN0128) in Combination With Carboplatin Plus Paclitaxel in Patients With Advanced Malignancies | NCT03430882 |
| Paclitaxel Eluting Balloon Catheter in Coronary De-novo Lesions Treatment in China | A Real-world Study in China: the Safety and Efficacy of Paclitaxel Eluting Balloon Catheter in Coronary De-novo Lesions Treatment | NCT03466749 |
| Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer | Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer: A Pilot Single Arm Phase II Study | NCT03415802 |
| Induction Chemotherapy Followed by Standard Therapy in Cervical Cancer With Aortic Lymph Node Spread | Phase III Study Comparing Neoadjuvant Chemotherapy With Carboplatin and Paclitaxel Followed by Standard Therapy, With Standard Therapy Alone in Women With Cervical Cancer and Para Aortic Positive Lymph Node. | NCT03534713 |
| Clinical trial study comparing the efficiency of standard treatment, new treatment or in combinaison (sequentially every 2 month) in metastatic pancreatic cancer | Randomized phase II study comparing 5FU/LV+Nal-IRI, gemcitabine+Nab-paclitaxel or a sequential regimen of 2 months 5FU/LV+Nal-IRI followed by two months of gemcitabine+Nab-paclitaxel, in metastatic pancreatic cancer - FUNGEMAX | EUCTR2017-004309-41-FR |
| Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer | Vitamin D Receptor Agonist Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Patients With Metastatic Pancreatic Cancer | NCT03520790 |
| Paclitaxel-Avelumab for Angiosarcoma | Phase II Trial, Multicenter, First Line Paclitaxel-Avelumab Treatment for Inoperable Angiosarcoma | NCT03512834 |
| Phase I Study of EOC202 Plus Paclitaxel in Chinese Patients With Metastatic Breast Cancer | A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of hLAG-3 Fusion Protein, EOC202 (Eftilagimod Alpha) Combined With Paclitaxel in Chinese Patients With Metastatic Breast Cancer | NCT03600090 |
| Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC | A Phase I/II Study of Paclitaxel Plus Carboplatin and Durvalumab (MEDI4736) With or Without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer | NCT03616886 |
| Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | A Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian Cancer | NCT03587311 |
| Concurrent chemoradiotherapy combined with paclitaxel plus cisplatin for locally advanced esophageal squamous cell carcinoma: a phase II clinical trial of 3DCRT/IMRT | Concurrent chemoradiotherapy combined with paclitaxel plus cisplatin for locally advanced esophageal squamous cell carcinoma: a phase II clinical trial of 3DCRT/IMRT | ChiCTR1800017039 |
| A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors | An Open-Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid Tumors | NCT03601897 |
| clinical study for patients with metastatic oesophagus carcinoma | Nal-IRI/LV5-FU VERSUS PACLITAXEL AS SECOND-LINE THERAPY IN PATIENTS WITH METASTATIC OESOPHAGEAL SQUAMOUS CELL CARCINOMA - OESIRI | EUCTR2017-004730-28-FR |
| Chemotherapy plus paricalcitol in patients with untreated, metastatic pancreatic cancer. | A Phase II Pilot Trial Of Paclitaxel Protein BoundPlus Cisplatin Plus Gemcitabine and the Addition Of Paricalcitol Upon Disease Progression in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma - PINBALL | EUCTR2017-004467-13-GB |
| A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer | A Phase 3, Multicenter, Randomized Open-Label Study to Compare the Efficacy and Safety of Tislelizumab (BGB A317, Anti-PD1 Antibody) Combined With Paclitaxel Plus Carboplatin or Nab Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Carboplatin Alone as First-Line Treatment for Untreated Advanced Squamous Non-small Cell Lung Cancer | NCT03594747 |
| Phase 2 Trial of preoperative treatment with Nab-paclitaxel Plus S-1 in Patients With borderline resectable Pancreatic Cancer | Phase 2 Trial of preoperative treatment with Nab-paclitaxel Plus S-1 in Patients With borderline resectable Pancreatic Cancer | ChiCTR1800016899 |
| This trial examines the effectiveness of an angioplasty balloon coated with an anticancer drug (Paclitaxel) compared to an ordinary, uncoated balloon in preventing recurrent hemodialysis fistula narrowings in patients on hemodialysis for renal failure. | A double blinded, multicentre, randomised control trial comparing the effectiveness of the Paclitaxel drug eluting angioplasty balloon with an ordinary angioplasty balloon in preventing restenosis and re-intervention in the treatment of recurrent autogenous hemodialysis fistula stenoses in the hemodialysis population of three participating Australian Hospitals. | ACTRN12618001092280 |
| A Safety Study of Oraxol in Cancer Patients | A Safety Study of Oraxol (HM30181 + oral paclitaxel) in Cancer Patients - A Safety Study of Oraxol in Cancer Patients | EUCTR2017-004578-33-GB |
| Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer | A Single-Arm Feasibility Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk Intrahepatic Cholangiocarcinoma | NCT03579771 |
| Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer | Neoadjuvant Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy (SBRT) for Patients With Locally Advanced Pancreatic Cancer | NCT03600623 |
| Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC | A Phase II Clinical Trial of Combination Nivolumab (Opdivo), Ipilimumab (Yervoy), and Paclitaxel in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (The OPTIMAL Trial) [TOP 1705] | NCT03573947 |
| Neoadjuvant Therapy Followed by Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Pancreatic Cancer | A Single Center Pilot Study: Neoadjuvant Modified FOLFIRINOX or Gemcitabine-nab Paclitaxel Followed by Stereotactic Body Radiotherapy (SBRT) for Patients With Locally Advanced Pancreatic Cancer and Borderline Pancreatic Inoperable Cancers | NCT03641183 |
| CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer | A Phase Ib and Open Label Phase II Study of CFI-402257 in Combination With Weekly Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer | NCT03568422 |
| Randomized controlled multicenter trial of neo adjunvant chemotherapy with combination chemotherapy of LBP orparaplatin plus paclitaxel in the treatment of stage II / III three negative breast cancer | Randomized controlled multicenter trial of neo adjunvant chemotherapy with combination chemotherapy of LBP orparaplatin plus paclitaxel in the treatment of stage II / III three negative breast cancer | ChiCTR1800016272 |
| Real-World Effectiveness of PLD in Platinum- Sensitive Recurrent Ovarian Cancer | Comparison of Real-World Effectiveness of Pegylated Liposomal Doxorubicin Versus Paclitaxel in Platinum- Sensitive Recurrent Ovarian Cancer | NCT03562533 |
| Atezolizumab Trial in Endometrial Cancer - AtTEnd | Phase III Double-blind Randomized Placebo Controlled Trial of Atezolizumab in Combination With Paclitaxel and Carboplatin in Women With Advanced/Recurrent Endometrial Cancer | NCT03603184 |
| The Clinical study of PLD plus trastuzumab and paclitaxel as neoadjuvant therapy for HER2 positive breast cancer | TheClinical study of PLD plus trastuzumab and paclitaxel as neoadjuvant therapy for HER2 positive breast cancer | ChiCTR1800016222 |
| Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix | A Randomized Phase III Trial of Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab Versus Platinum Chemotherapy Plus Paclitaxel and Bevacizumab in Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix | NCT03556839 |
| A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer | A Phase I/II Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan (GAX-CI) in Combination in Metastatic Pancreatic Cancer | NCT03535727 |
| A study to compare weekly Paclitaxel injection with best supportive care in patients with lung cancer | A Randomized study comparing Weekly Paclitaxel plus Best Supportive Care with Best Supportive Care Alone in Patients with small cell lung cancer relapsed on two or more lines of chemotherapy. | CTRI/2018/04/013507 |
| A Feasibility Study of Carboplatin/Paclitaxel/Nivolumab with Concurrent Thoracic Radiotherapy in Patients with Unresectable Locally Advanced Non-Small-Cell Lung Cancer | A Feasibility Study of Carboplatin/Paclitaxel/Nivolumab with Concurrent Thoracic Radiotherapy in Patients with Unresectable Locally Advanced Non-Small-Cell Lung Cancer - A Feasibility Study of Carboplatin/Paclitaxel/Nivolumab with Concurrent Thoracic Radiotherapy in Patients with Unresectable Locally Advanced Non-Small-Cell Lung Cancer | JPRN-UMIN000032376 |
| NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma | NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma. A Multicenter Open-label Single Arm Phase Ib/IIa Trial | NCT03524898 |
| The influence of paclitaxel in drug-drug interaction via hepatic organic anion transporter | The influence of paclitaxel in drug-drug interaction via hepatic organic anion transporter - The influence of paclitaxel to liver organic anion transporter | JPRN-UMIN000032370 |
| Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer | Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer | NCT03579784 |
| SecOnd-line Chemotherapy with RAmucirumab +/- pacliTaxel in Elderly advanced gastric or gastroesophageal junction cancer patients | SecOnd-line Chemotherapy with RAmucirumab +/- pacliTaxel in Elderly advanced gastric or gastroesophageal junction cancer patients - SOCRATE | EUCTR2017-001683-37-FR |
| High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | Phase IB/II Trial of High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Had No Prior Therapy for Their Metastatic Pancreatic Cancer | NCT03797443 |
| Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers | A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers | NCT03768414 |
| Paclitaxel plus cisplatin as adjuvant chemotherapy for advanced cervical cancer | Paclitaxel plus cisplatin as adjuvant chemotherapy after radical hysterectomy for intermediate- and high-risk stage IB-IIB cervical cancer | JPRN-jRCTs051180220 |
| TReAtmeNt of Small Coronary Vessels: MagicTouch Sirolimus Coated Balloon | Magic Touch Sirolimus Coated Balloon (Concept Medical) Versus SeQuent Pease Neo Paclitaxel Coated Balloon (Bbraun) for the Treatment of de Novo Coronary Artery Lesions in Small Vessels | NCT03913832 |
| JGOG1079 | A phase II study for the efficacy of bevacizumab with paclitaxel and carboplatin in patient with stage IVB, recurrent or persistant cervical cancer. - JGOG1079 | JPRN-jRCTs051180157 |
| Phase II study of ramucirumab plus paclitaxel therapy for elderly patients with non-resectable or metastatic gastric cancer (T-CORE1501) | Phase II study of ramucirumab plus paclitaxel therapy for elderly patients with non-resectable or metastatic gastric cancer (T-CORE1501) - Phase II study of ramucirumab plus paclitaxel therapy for elderly patients with non-resectable or metastatic gastric cancer (T-CORE1501) | JPRN-jRCTs021180016 |
| JBCRG-M06(EMERALD) | A phase III clinical study to compare the combination therapy of eribulin mesylate + trastuzumab + pertuzumab with paclitaxel or Docetaxel + trastuzumab + pertuzumab - JBCRG-M06(EMERALD) | JPRN-jRCTs021180027 |
| Evaluation of drug-eluting balloon catheters and paclitaxel-releasing coronary balloon catheters SeQuent Please for the safety and efficacy of patients with coronary in-stent restenosis in a prospective, multicenter, randomized controlled clinical trial | Evaluation of drug-eluting balloon catheters and paclitaxel-releasing coronary balloon catheters SeQuent Please for the safety and efficacy of patients with coronary in-stent restenosis in a prospective, multicenter, randomized controlled clinical trial | ChiCTR1900022034 |
| Randomized Phase III Non-inferiority Study Comparing Two Steroid Premedication Strategy For Weekly Paclitaxel Chemotherapy in Patients with Breast Cancer | Randomized Phase III Non-inferiority Study Comparing Two Steroid Premedication Strategy For Weekly Paclitaxel Chemotherapy in Patients with Breast Cancer | KCT0003651 |
| A multi-center clinical study with patients suffering from pancreatic cancer who will receive a consecutive epigenetic and immune targeted treatment in combination with nab-Paclitaxel/Gemcitabine | A MULTICENTER, PHASE I/II STUDY OF SEQUENTIAL EPIGENETIC AND IMMUNE TARGETING IN COMBINATION WITH NAB-PACLITAXEL/GEMCITABINE IN PATIENTS WITH ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA - SEPION | EUCTR2017-001625-40-DE |
| CBDCA plus PTX for NSCLC (squamous) with IP | Phase II study of carboplatin plus weekly paclitaxel for advanced squamous cell lung cancer with idiopathic interstitial pneumonia - IP001 | JPRN-jRCTs051180149 |
| Safety and Efficacy for Gemcitabine plus nab-paclitaxel with MK615 combination therapy in unresected/recurrent metastatic pancreatic cancer.: Phase I/II study (PC(UR-M) GEM/nab-PTX + MK615) | Safety and Efficacy for Gemcitabine plus nab-paclitaxel with MK615 combination therapy in unresected/recurrent metastatic pancreatic cancer.: Phase I/II study (PC(UR-M) GEM/nab-PTX + MK615) | JPRN-jRCTs061180074 |
| Clinical observation of liposomal paclitaxel combined with Anlotinib Hydrochloride in patients with SCLC after first-line standard chemotherapy | Clinical observation of liposomal paclitaxel combined with Anlotinib Hydrochloride in patients with SCLC after first-line standard chemotherapy | ChiCTR1900021983 |
| Ramucirumab, Paclitaxel, and Trastuzumab biosimilar combination treatment in HER2 positive metastatic gastric cancer patients | A Multi-center Phase II Study of Trastuzumab Biosimilar (SB3®) in Combination with Ramucirumab and Paclitaxel in HER2 positive Metastatic Gastric Cancer Patients | KCT0003638 |
| CBDCA+nab-PTX vs DOC for elderly Sq NSCLC Phase III study | Carboplatin plus nab-Paclitaxel versus docetaxel for elderly squamous non-small cell lung cancer - CAPITAL study | JPRN-jRCTs041180110 |
| GABARNANCE Trial | Randomized phase II/III study of gemcitabine and nab-paclitaxel therapy versus S-1 and concurrent radiotherapy as neoadjuvant treatment for Borderline resectable pancreatic cancer - GABARNANCE Trial | JPRN-jRCTs031180319 |
| Feasibility study evaluating Paclitaxel, Carboplatin and Cetuximab (PCE) as induction chemotherapy followed by chemoradiation in patients with Unresectable Locally advanced Squamous Cell Carcinoma of the Head and Neck | Feasibility study evaluating Paclitaxel, Carboplatin and Cetuximab (PCE) as induction chemotherapy followed by chemoradiation in patients with Unresectable Locally advanced Squamous Cell Carcinoma of the Head and Neck - IC-PCE study | JPRN-jRCTs031180358 |
| Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer | A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple negative Breast Cancer - CAPItello-290 | EUCTR2018-004687-64-SE |
| Japanese Intergroup Study of Nintedanib for NSCLC with IPF | A randomized phase III study of carboplatin plus nab-paclitaxel with or without nintedanib for advanced non-small-cell lung cancer with idiopathic pulmonary fibrosis - J-SONIC | JPRN-jRCTs071180049 |
| Nab-paclitaxel and Gemcitabine in Metastatic Pancreatic Cancer | A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Nab-paclitaxel and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer | NCT03929094 |
| elderly PTX-RT | Phase I/II Study of Chemoradiotherapy with Paclitaxel for Elderly Stage IB-III Esophageal Cancer (elderly PTX-RT Phase I/II ) - elderly PTX-RT (elderly PTX-RT Phase I/II) | JPRN-jRCTs031180283 |
| The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency | Randomized Phase ? Trial Comparing Dose-dense Epirubicin and Cyclophosphamide Followed by Paclitaxel With Paclitaxel Plus Carboplatin as Adjuvant Therapy for Triple-negative Breast Cancer With Homologous Recombination Repair Deficiency | NCT03876886 |
| A clinical trial for nab-paclitaxel and carboplatin compared with sb-paclitaxel and carboplatin in advanced squamous cell lung cancer | A clinical trial for nab-paclitaxel and carboplatin compared with sb-paclitaxel and carboplatin in advanced squamous cell lung cancer | ChiCTR1900021857 |
| A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study | A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-407) | NCT03875092 |
| A prospective multicenter phase II clinical study for neoadjuvant therapy of gemcitabine combined with albumin paclitaxel for resectable pancreatic cancer | A prospective multicenter phase II clinical study for neoadjuvant therapy of gemcitabine combined with albumin paclitaxel for resectable pancreatic cancer | ChiCTR1900021840 |
| The phase I,II study of neoadjuvant chemotherapy of gemcitabine+nab-paclitaxel+S-1 for patients with locally-advanced pancreatic cancer | The phase I,II study of neoadjuvant chemotherapy of gemcitabine+nab-paclitaxel+S-1 for patients with locally-advanced pancreatic cancer - The phase I/II study of neoadjuvant chemotherapy of GAS for locally-advanced pancreatic cancer | JPRN-jRCTs061180045 |
| CBDCA, PTX and BV for NSCLC (non-sq) with IP | Phase II study of carboplatin, weekly paclitaxel and bevacizumab for advanced non-squamous cell, non-small-cell lung cancer with idiopathic interstitial pneumonia - IP002 | JPRN-jRCTs061180046 |
| Phase I study of nab-paclitaxel and gemcitabine CRT for BR and UR-LA PDAC | Phase I study of nab-paclitaxel and gemcitabine chemoradiotherapy for borderline resectable and locally advanced unresectable pancreatic ductal adenocarcinoma - Phase I study of GnP-CRT for BR and UR-LA PDAC | JPRN-jRCTs041180147 |
| Single-arm, prospective and exploratory clinical study for the efficacy of Apatinib combined with Paclitaxel, Tegafur, Gimeracil and Oteracil Potassium chemotherapy regimen in the treatment of gastric hepatoid adenocarcinoma | Single-arm, prospective and exploratory clinical study for the efficacy of Apatinib combined with Paclitaxel, Tegafur, Gimeracil and Oteracil Potassium chemotherapy regimen in the treatment of gastric hepatoid adenocarcinoma | ChiCTR1900022213 |
| Phase Ib trial for Neoadjuvant therapy with PD-1 Antibody (SHR-1210) and albumin-bound paclitaxel plus Gemcitabine on resectable/borderline resectable Pancreatic Cancer | Phase Ib trial for Neoadjuvant therapy with PD-1 Antibody (SHR-1210) and albumin-bound paclitaxel plus Gemcitabine on resectable/borderline resectable Pancreatic Cancer | ChiCTR1900022192 |
| Phase I and II trial of combination therapy using nab-Paclitaxel+Pertuzumab+Trastuzumab for HER2 positive metastatic breast cancer | Phase I and II trial of combination therapy using nab-Paclitaxel+Pertuzumab+Trastuzumab for HER2 positive metastatic breast cancer - Combination therapy of nab-Paclitaxel+Pertuzumab+Trastuzumab | JPRN-UMIN000035869 |
| Paclitaxel in patients with GIST with low P-glycoprotein expression after failure of at least imatinib and sunitinib, and regorafenib. | A phase II study of paclitaxel in patients with metastatic or advanced gastrointestinal stromal tumor (GIST) with low P-glycoprotein expression after failure of at least imatinib, sunitinib, and regorafenib | KCT0003895 |
| Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer | Evaluating the Efficacy and Safety of Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer | NCT03942068 |
| A clinical trial of relacorilant (study drug) with nab-paclitaxel in patients with ovarian, fallopian tube or peritoneal cancer | A Phase 2, Randomized, Open-label, 3-arm Study of Relacorilant in Combination with Nab-Paclitaxel for Patients with Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | EUCTR2018-004186-14-BE |
| Paximusâ?¢ Randomized Controlled Trial | A prospective, multicenter, open label, randomized controlled trial to evaluate safety and performance of Paximusâ?¢ (Paclitaxel Eluting Percutaneous Transluminal Angioplasty Balloon Catheter) versus Mozecâ?¢ PTA Balloon Catheter for treatment of blocked or narrowed below the knee arteries. - Paximusâ?¢ RCT - 1 | CTRI/2019/05/018886 |
| De-Escalation Therapy for Human Papillomavirus Negative Disease | A Phase II Trial of Carboplatin, Paclitaxel, and Nivolumab Induction Therapy Followed by Response-stratified Locoregional Therapy for Patients With Locally Advanced, HPV-negative Head and Neck Cancer. The DEPEND Trial. | NCT03944915 |
| Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study | A Phase III Randomized Open-Label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects With Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus That Have Progressed After First-Line Standard Therapy (KEYNOTE-181) | NCT03933449 |
| Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3) | ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer | NCT03940196 |
| Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer | A Phase Ib Trial of Vaginal Cuff Brachytherapy + Pembrolizumab (MK3475) Followed by 3 Cycles of Dose Dense Paclitaxel/q 21 Day Carboplatin + Pembrolizumab (MK3475) in High Intermediate Risk Endometrial Cancer | NCT03932409 |
| Fibroblast Growth Factor (FGFs) / Fibroblast Growth Factor Receptor (FGFRs) Genetic as a second-line therapy for recurrent / progressive gastric cancer with INCB054828 and paclitaxel a study to evaluate the safety and efficacy of combination therapy. | An Open Label, Single-Arm, Multi-center Phase Ib/II Study to Evaluate the Safety and Efficacy of INCB054828 in Combination with Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer with Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration. | KCT0003844 |
| Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer | Phase II Study of Concurrent and Sequential Carboplatin and Paclitaxel With Adjuvant Radiotherapy for High Risk Endometrial Cancer | NCT03935256 |
| Phase 3 Study of Pembrolizumab with or without Maintenance Olaparib in First-Line Metastatic Squamous NSCLC | A Phase 3 Study of Pembrolizumab in Combination with Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) | EUCTR2018-004721-88-FR |
| Paricalcitol Addition to Chemotherapy in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma | A Phase II Pilot Trial Of Paclitaxel Protein Bound and Gemcitabine Based Chemotherapy and the Addition Of Paricalcitol Upon Attainment of Stable or Progressive Disease in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma | NCT04054362 |
| Phase II study of intraperitoneal paclitaxel combined with S-1 plus cisplatin for advanced gastric cancer with peritoneal metastasis | Phase II study of intraperitoneal paclitaxel combined with S-1 plus cisplatin for advanced gastric cancer with peritoneal metastasis - S-1/CDDP + IP PTX Phase 2 (SP + IP PTX) | JPRN-jRCTs041180079 |
| Clinical study for paclitaxel (albumin-binding) for injection plus gemcitabine combined with neoadjuvant radiotherapy and chemotherapy for unresectable locally advanced pancreatic cancer | Clinical study for paclitaxel (albumin-binding) for injection plus gemcitabine combined with neoadjuvant radiotherapy and chemotherapy for unresectable locally advanced pancreatic cancer | ChiCTR1900022684 |
| AtTEnd | PHASE III DOUBLE-BLIND RANDOMIZED PLACEBO CONTROLLED TRIAL OF ATEZOLIZUMAB IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN IN WOMEN WITH ADVANCED/RECURRENT ENDOMETRIAL CANCER - AtTEnd | JPRN-jRCT2031190013 |
| Induction Paclitaxel Followed by Concurrent Paclitaxel and Radiation Therapy for Cutaneous Angiosarcoma | Induction Paclitaxel Followed by Concurrent Paclitaxel and Radiation Therapy for Cutaneous Angiosarcoma | NCT03921008 |
| JCOG1611: Randomized phase II/III study of gemcitabine plus nab-paclitaxel combination therapy versus modified FOLFIRINOX versus S-IROX for metastatic or recurrent pancreatic cancer | JCOG1611: Randomized phase II/III study of gemcitabine plus nab-paclitaxel combination therapy versus modified FOLFIRINOX versus S-IROX for metastatic or recurrent pancreatic cancer - GENERATE | JPRN-jRCTs031190009 |
| Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory Study | Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory Study | NCT03919253 |
| Nab-paclitaxel Dose Schedual for HER-2 Negative Advanced Breast Cancer | A Single-arm Opened Randomized Phase II Study of Nab-paclitaxel Dose Schedual in Advanced Breast Cancer | NCT04192331 |
| Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer | A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer | NCT03914612 |
| Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer | Neoadjuvant Apatinib Added to Weekly Paclitaxel and Cisplatin in Patient With Locally Advanced or Early Stage HER2 Negative Breast Cancer (APP) : a Open-label, Randomized, Controlled, Trial | NCT03982485 |
| Uterine Serous Carcinoma and Adjuvant Combined Intraperitoneal Chemotherapy and Radiation | A Pilot Phase II Trial of Intravenous Paclitaxel and Intraperitoneal Carboplatin/Taxol Followed by Radiation in Patients With Advanced Stage Uterine Serous Carcinoma | NCT04030000 |
| Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma | A Phase II Trial of Nab-Paclitaxel Plus Cisplatin Plus Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma | NCT03915444 |
| High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | Phase IB/II Trial of High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have No Prior Therapy for Their Metastatic Pancreatic Cancer | NCT03908333 |
| Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer | Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer | NCT03907800 |
| A Phase 2 Study for Albumin Bound Paclitaxel Plus Gemcitabine Versus Carboplatin and Gemcitabine as First-line Therapy in Patients With Cisplatin-ineligible Locally Advanced or Metastatic Urothelial Carcinoma | A single-center, randomized controlled phase II clinical study for Albumin Bound Paclitaxel Plus Gemcitabine Versus Carboplatin and Gemcitabine as First-line Therapy in Patients With Cisplatin-ineligible Locally Advanced or Metastatic Urothelial Carcinoma | ChiCTR1900022615 |
| Safety and Efficacy for Gemcitabine plus nab-paclitaxel with MK615 combination therapy in unresected/recurrent metastatic pancreatic cancer.: Phase I/II study | Safety and Efficacy for Gemcitabine plus nab-paclitaxel with MK615 combination therapy in unresected/recurrent metastatic pancreatic cancer.: Phase I/II study - PC(UR-M) GEM/nab-PTX + MK615 | JPRN-UMIN000035158 |
| A study to evaluate the efficacy of intraperitoneal paclitaxel in combination with systemic S-1 and cisplatin in advanced gastric cancer with peritoneal dissemination and ascites. | A phase II study of first line intraperitoneal paclitaxel in combination with systemic S-1 and cisplatin in advanced gastric cancer with peritoneal dissemination and ascites. | KCT0003607 |
| Phase II study of neoadjuvant chemotherapy of gemcitabine+nab-paclitaxel therapy for patients with BRPC. | Phase II study of neoadjuvant chemotherapy of gemcitabine+nab-paclitaxel therapy for patients with borderline resectable pancreatic cancer. - NAC-GA Trial | JPRN-jRCTs051180104 |
| Nab-paclitaxel Combined With S-1 as Induction Therapy for Locally Advanced Pancreatic Cancer | Phase II Clinical Study of Nab-paclitaxel Combined With S-1 as Induction Therapy for Locally Advanced Pancreatic Cancer | NCT03815461 |
| Phase II ramucirumab/paclitaxel as second-line treatment in metastatic gastric or Gastroesophageal junction adenocarcinoma with integrative genomic analysis | Phase II ramucirumab/paclitaxel as second-line treatment in metastatic gastric or Gastroesophageal junction adenocarcinoma with integrative genomic analysis | KCT0003440 |
| DICE: An international study to assess the effectiveness of TAK228 in combination with weekly paclitaxel, compared with weekly paclitaxel on its own, in women with advanced/recurrent ovarian, fallopian tube or primary peritoneal cancer that is resistant to platinum-based chemotherapy | An international multi-centre randomised phase II study to assess the efficacy of TAK228 in combination with intravenous weekly paclitaxel compared with weekly paclitaxel alone in women with advanced/recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer (of clear cell, endometrioid and high grade serous type, and carcinosarcoma) - DICE version 1.0 | EUCTR2016-000065-23-DE |
| JCOG1407: Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer | JCOG1407: Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer - LAPC-mFOLFIRINOX/GnP-rP2 | JPRN-jRCTs031180085 |
| Belgian-Italian Trial to Evaluate the Efficacy and Safety of Below The Knee (BTK) Treatment With the Luminor 14 Paclitaxel Coated Percutaneous Transluminal Angioplasty Balloon Catheter of iVascular | Belgian-Italian Prospective, Single Arm, Multicentre Study to Evaluate the Efficacy and Safety of BTK Treatment With the Luminor 14 Paclitaxel Coated Percutaneous Transluminal Angioplasty Balloon Catheter of iVascular of 150 Subjects With Critical Limb Ischemia | NCT03845543 |
| Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine For The First Line Treatment of Pancreas Cancer | Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine For The First Line Treatment of Metastatic or Locally Advanced Unresectable Adenocarcinoma of The Pancreas: A Phase II Randomized Study | NCT03807999 |
| First-line therapy of gemcitabine plus albumin-paclitaxel followed by mFOLFIRINOX in patients with locally advanced or advanced pancreatic cancer: A prospective, single-arm, phase II study | First-line therapy of gemcitabine plus albumin-paclitaxel followed by mFOLFIRINOX in patients with locally advanced or advanced pancreatic cancer: A prospective, single-arm, phase II study | ChiCTR1900020538 |
| Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma | A Multi-center, Open-label, Randomized Controlled Study of Albumin-bound Paclitaxel Plus S-1 Versus Oxaliplatin Plus S-1 (SOX) as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma | NCT03801668 |
| A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer | A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer | NCT03800836 |
| Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer | Concurrent Nab--paclitaxel/Carboplatin and Thoracic Radiotherapy in Inoperable Stage III Squamous Cell Lung Cancer | NCT03802058 |
| A prospective, multicenter clinical study for pyrrotinib combined with herceptin plus paclitaxel combined with cisplatin in the preoperative treatment of her2-positive breast cancer | A prospective, multicenter clinical study for pyrrotinib combined with herceptin plus paclitaxel combined with cisplatin in the preoperative treatment of her2-positive breast cancer | ChiCTR1800020449 |
| A real world study for the effectivenss and safety of Nab-paclitaxel in patients with gastric cancer in Anhui Province. | A real world study for the effectivenss and safety of Nab-paclitaxel in patients with gastric cancer in Anhui Province. | ChiCTR1800020429 |
| Comparing the effectiveness of Apatinib combined with Paclitaxel For Injection (Albumin Bound) and Tegafur and Paclitaxel For Injection (Albumin Bound) combined with?Tegafur neoadjuvant therapy for resectable, locally advanced pancreatic cancer patients: A prospective, open-label clinical trial. | Comparing the effectiveness of Apatinib combined with?Paclitaxel For Injection (Albumin Bound) and Tegafur and Paclitaxel For Injection (Albumin Bound) combined with?Tegafur neoadjuvant therapy for resectable, locally advanced pancreatic cancer patients: A prospective, open-label clinical trial. | ChiCTR1800020401 |
| To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung Cancer | to Evaluate SCT510 Compared to Avasitin Respectively Combined Paclitaxel and Carboplatin First-line Treatment of Locally Advanced and Metastatic or Recurrent Squamous Cell Non-small Cell Lung Cancer Efficacy and Safety | NCT03792074 |
| Nab-paclitaxel, Nedaplatin plus Bevacizumab as a first-line therapy in advanced lung adenocarcinoma patients with driven gene negative | A single-arm, phase II study for Nab-paclitaxel, Nedaplatin plus Bevacizumab as a first-line therapy in advanced lung adenocarcinoma patients with driven gene negative | ChiCTR1800020333 |
| A Phase II Trial of Biweekly Nab-PaclitaXel in Combination with Ramcirumab for metastatic Gastric Cancer or Gastro-oesophageal Junction Adenocarcinoma | A Phase II Trial of Biweekly Nab-PaclitaXel in Combination with Ramcirumab for Patients with Previously Treated Advanced Gastric Cancer or Gastro-oesophageal Junction Adenocarcinoma(B-RAX trial) (JACCRO GC-09) | JPRN-jRCTs031180061 |
| Phase I, Open-Label study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in combination with paclitaxel, in refractory cancer | Phase I, Open-Label study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in combination with paclitaxel, in refractory cancer | KCT0003403 |
| paclitaxel (chemotherapy) in combination with tremelimumab (immunotherapy), with or without durvalumab (immunotherapy), for advanced urinary tract cancer (ICRA) | ICRA (Improve Checkpoint-blockade Response in Advanced urothelial cancer), an adaptive clinical study to determine efficacy of combining weekly paclitaxel with tremelimumab +/- durvalumab (MEDI4736) | EUCTR2018-004148-53-NL |
| A Phase IB/II Study to determine efficacy and safety of Durvalumab + Paclitaxel and Durvalumab in Combination with Novel Oncology Therapies with or without Paclitaxel for First-line Metastatic Triple Negative Breast Cancer | A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First line Metastatic Triple Negative Breast Cancer - BEGONIA | EUCTR2018-000764-29-PL |
| Randomized Study of IN.PACT 014 Paclitaxel-Coated Percutaneous Transluminal Angioplasty Balloon Catheter vs. Optimal Percutaneous Transluminal Angioplasty for the treatment of chronic total occlusions in the infrapopliteal arteries. | Randomized Study of IN.PACT 014 Paclitaxel-Coated Percutaneous Transluminal Angioplasty Balloon Catheter vs. Optimal Percutaneous Transluminal Angioplasty for the treatment of chronic total occlusions in the infrapopliteal arteries. - IN.PACT BTK | NL-OMON46468 |
| Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | A Phase 2, Randomized, Open-Label, 3-arm Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT03776812 |
| A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC | A Phase III, Multicenter, Randomized, Placebo-Controlled Study of JS001 (Anti-PD-1 Antibody) in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel as First-line Therapy for Patients With Primarily Diagnose or Recurrent and Metastatic Triple-Negative Breast Cancer | NCT03777579 |
| nab-Paclitaxel plus trastuzumab and pertuzumab followed by EC as a neoadjuvant chemotherapy for HER2-positive operable breast cancer | nab-Paclitaxel plus trastuzumab and pertuzumab followed by EC as a neoadjuvant chemotherapy for HER2-positive operable breast cancer - PerSeUS-BC04 | JPRN-UMIN000035235 |
| A Clinical Study for the Efficacy and Safety of Apatinib Combined with Gemcitabine plus Paclitaxel in Patients with Advanced Hepatosarcomatoid Carcinoma | A Clinical Study for the Efficacy and Safety of Apatinib Combined with Gemcitabine plus Paclitaxel in Patients with Advanced Hepatosarcomatoid Carcinoma | ChiCTR1800019995 |
| The phase 2 study of neoadjuvant chemotherapy of GAS for biological borderline resectable pancreatic cancer. | The phase 2 study of neoadjuvant chemotherapy of gemcitabine+nab-paclitaxel+S-1 for patients with biological borderline resectable pancreatic cancer. - The phase 2 study GAS for biological borderline resectable pancreatic cancer | JPRN-jRCTs061180009 |
| Efficacy and Safety of Paclitaxel for Injection (Albumin-bound) for First-line Chemotherapy of Ovarian Cancer | Efficacy and Safety of Paclitaxel for Injection (Albumin-bound) in Combination With Carboplatin for First-line Chemotherapy of Ovarian Cancer: A Multicenter, Open-label, Single-arm Phase 2 Clinical Study | NCT03818282 |
| The Safety and Efficacy of DIOR Balloon in Coronary Bifurcation Lesions | Comparison of the Safety and Efficacy Between Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR) and Paclitaxel-Eluting Balloon (Bingo) in Coronary Bifurcation Lesions: A Prospective, Multicenter, Randomized, Controlled Trial (BEYOND II) | NCT03820622 |
| Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer | DKN-01/Atezolizumab as Second Line Treatment of biliarY Tract Cancer and in combiNAtion or Not With Paclitaxel as Second Line treatMent of esophagogastrIC Cancer: a Multi-center Phase II Trial | NCT03818997 |
| Weekly nab-Paclitaxel+Carboplatin with Radiotherapy as First Line Therapy in Patients with Advanced Non-Small-Cell Lung Cancer | Weekly nab-Paclitaxel+Carboplatin with Radiotherapy as First Line Therapy in Patients with Advanced Non-Small-Cell Lung Cancer - Weekly nab-Paclitaxel+Carboplatin with Radiotherapy as First Line Therapy in Patients with Advanced Non-Small-Cell Lung Cancer | JPRN-UMIN000031017 |
| Phase II clinical study of nab-PTX for patients with recurrent NSCLC | Phase II clinical study of nab-paclitaxel for patients with recurrent advanced non-small cell lung cancer. | JPRN-jRCTs031180214 |
| A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer | A Phase Ib/II Study to Evaluate Efficacy, Safety and Tolerability of KN046 Monotherapy or in Combination With Nab-paclitaxel in Subjects With Triple-negative Breast Cancer | NCT03872791 |
| A phase II clinical study for anti-PD-1 monoclonal antibody (Sintilimab) combined with short course paclitaxel (albumin-bound paclitaxel) /platinum-based chemotherapy as first-line therapy for locally advanced or metastatic lung squamous cell carcinoma in China | A phase II clinical study for anti-PD-1 monoclonal antibody (Sintilimab) combined with short course paclitaxel (albumin-bound paclitaxel) /platinum-based chemotherapy as first-line therapy for locally advanced or metastatic lung squamous cell carcinoma in China | ChiCTR1900021726 |
| A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer | A Phase III, Randomized, Double-blinded, Multicenter Study of AK105 Combined With Carboplatin and Paclitaxel vs Placebo Combined With Carboplatin and Paclitaxel as First-line Therapy in Patients With Metastatic Squamous Non-small Cell Lung Cancer | NCT03866993 |
| JCOG1311: Randomized Phase II/III Trial of Conventional Paclitaxel and Carboplatin with/without Bevacizumab versus Dose-dense Paclitaxel and Carboplatin with/without Bevacizumab in Stage IVB, Recurrent, or Persistent Cervical Carcinoma | JCOG1311: Randomized Phase II/III Trial of Conventional Paclitaxel and Carboplatin with/without Bevacizumab versus Dose-dense Paclitaxel and Carboplatin with/without Bevacizumab in Stage IVB, Recurrent, or Persistent Cervical Carcinoma - CC-TC+/-Bev/ddTC+/-Bev-P2/3 | JPRN-jRCTs031180007 |
| A study to evaluate the safety and efficacy of Varlitinib in combination with weekly paclitaxel in EGFR/HER2 co-expressing advanced or metastatic gastric cancer. | A TWO PART, PHASE IB/II, OPEN LABEL, SINGLE-ARM, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF VARLITINIB IN COMBINATION WITH WEEKLY PACLITAXEL IN EGFR/HER2 CO-EXPRESSING ADVANCED OR METASTATIC GASTRIC CANCER PATIENTS. | KCT0003583 |
| A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128+MLN1117 (a PI3Ka Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women With Advanced, Recurrent, or Persistent Endometrial Cancer | A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128+MLN1117 (a PI3Ka Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women With Advanced, Recurrent, or Persistent Endometrial Cancer - C31004 | NL-OMON48725 |
| A phase II study for albumin- bound paclitaxel versus mitoxantrone in second-line rescue chemotherapy of metastatic castrated resistant prostate cancer (mCRPC) | A phase II study for albumin- bound paclitaxel versus mitoxantrone in second-line rescue chemotherapy of metastatic castrated resistant prostate cancer (mCRPC) | ChiCTR1900021648 |
| Phase I study of definitive CRT with paclitaxel, CDDP and 5-FU for clinical stage IA-IIIC esophageal cancer.(PCF-RT) | Phase I study of definitive chemoradiotherapy with paclitaxel, CDDP and 5-FU for clinical stage IA-IIIC esophageal cancer.(PCF-RT) - Phase I study of PCF-RT | JPRN-jRCTs051180082 |
| Efficacy and safety of weekly nab-paclitaxel plus CBDCA in patients with CUP | A phase2 study to evaluate the efficacy and safety of weekly nab-paclitaxel in combination with carboplatin in patients with cancer of unknown primary - Efficacy and safety of weekly nab-paclitaxel plus CBDCA in patients with CUP | JPRN-jRCTs051180084 |
| Neoadjuvant Immune-Chemo-Radiotherapy in operable oEsophageal and gastro-oesophageal junction cancers with Carboplatin Paclitaxel Radiotherapy and Avelumab - a Trial assessing feasibility and preliminary Efficacy | Neoadjuvant Immune-Chemo-Radiotherapy in operable oEsophageal and gastro-oesophageal junction cancers with Carboplatin Paclitaxel Radiotherapy and Avelumab - a Trial assessing feasibility and preliminary Efficacy | ACTRN12619000288123 |
| An Open Label, Single-Arm, Multi-center Phase II Study to Evaluate the safety and Efficacy of Herzuma® in Combination with Paclitaxel in HER2-positive Recurrent/Metastatic Urothelial Carcinoma | An Open Label, Single-Arm, Multi-center Phase II Study to Evaluate the safety and Efficacy of Herzuma® in Combination with Paclitaxel in HER2-positive Recurrent/Metastatic Urothelial Carcinoma | KCT0003543 |
| A study for apatinib combined with platinum/paclitaxel as neoadjuvant chemotherapy for esophageal cancer | A study for apatinib combined with platinum/paclitaxel as neoadjuvant chemotherapy for esophageal cancer | ChiCTR1900021783 |
| Nab-paclitaxel and S-1 in Patients With Locally Advanced Pancreatic Cancer | Prospective Phase II Single-arm Study of Nab-paclitaxel and S-1 in Patients With Locally Advanced Pancreatic Cancer. | NCT03885219 |
| Improve Checkpoint-blockade Response in Advanced Urothelial Cancer | ICRA (Improve Checkpoint-blockade Response in Advanced Urothelial Cancer), an Adaptive Clinical Study to Determine Efficacy of Combining Weekly Paclitaxel With Tremelimumab +/- Durvalumab (MEDI4736) | NCT03871036 |
| Safety and efficacy of cisplatin plus paclitaxel in patients with uterine cervical cancer which has risk factors for recurrence | Safety and efficacy of cisplatin plus paclitaxel in patients with uterine cervical cancer which has risk factors for recurrence - Safety and efficacy of cisplatin plus paclitaxel in patients with uterine cervical cancer which has risk factors for recurrence | JPRN-UMIN000035856 |
| Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma | Avelumab + Paclitaxel/ Ramucirumab as Second Line Treatment in Gastro-esophageal Adenocarcinoma: a Phase II Trial of the AIO (The RAP-Trial) | NCT03966118 |
| Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast Cancer | A Phase II, Randomized Study of Paclitaxel Weekly Plus Pembrolizumab Versus Paclitaxel Weekly in ER-positive, Luminal B Metastatic Breast Cancer | NCT03841747 |
| Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women | A Randomized Phase II Trial of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Paclitaxel and Carboplatin in HIV-positive Women With Locally Advanced Cervical Cancer (LACC) | NCT03834571 |
| A study to compare two formulations of Paclitaxel Injectable Suspension in metastatic Breast cancer patients | A randomized, open label, balanced, multicenter, two-treatment, two-period, two-sequence, two-way crossover, single dose, bioequivalence study with pharmacokinetic endpoints of Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound) 100 mg/vial at a dose of 260 mg/m2 of Ningbo Shouzheng Medicinal Research Co., Ltd. with ABRAXANE® for Injectable Suspension (albumin-bound) 100 mg/vial at a dose of 260 mg/m2 of Celgene Corporation, Summit, NJ 07901 in Breast cancer patients after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy under fasting condition - CO180006 | CTRI/2019/02/017445 |
| A multicenter, randomized, controlled, open phase II study for comparing the efficacy and safety of albumin paclitaxel plus bicalutamide and albumin paclitaxel in the treatment of androgen receptor-positive advanced triple-negative breast cancer | Comparison of the efficacy and safety of albumin paclitaxel combined with bicalutamide and albumin paclitaxel in the treatment of androgen receptor-positive advanced triple-negative breast cancer | ChiCTR1900021220 |
| Phase1b/2 study of AZD8186 in combination with paclitaxel in patients with advanced gastric cancer | Phase1b/2 study of AZD8186 in combination with paclitaxel in patients with advanced gastric cancer | KCT0003466 |
| Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer | A Phase I/IB Study of Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Patients With Metastatic Triple Negative Breast Cancer | NCT03853707 |
| Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer | Phase II Trial of Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-Related Oropharynx Cancer | NCT03829722 |
| Doxorubicin Hydrochloride Liposome combined with Cyclophosphamide sequential albumin-bound paclitaxel for neoadjuvant therapy of breast cancer | Doxorubicin Hydrochloride Liposome combined with Cyclophosphamide sequential albumin-bound paclitaxel for neoadjuvant therapy of breast cancer | ChiCTR1900021139 |
| Phase I/II study of GnPipPTX | A phase I/II study of intravenous gemcitabine and nab-paclitaxel combined with intraperitoneal paclitaxel in pancreatic cancer patients with peritoneal metastasis - A phase I/II study of intravenous gemcitabine and nab-paclitaxel combined with intraperitoneal paclitaxel in pancreatic cancer patients with peritoneal metastasis | JPRN-jRCTs031180095 |
| Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer | Prospective Phase II Single-arm Study of Neoadjuvant Nab-Paclitaxel and S-1 in Patients With Borderline Resectable Pancreatic Cancer | NCT03850769 |
| Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer | A Prospective, Single-arm, Phase II Study of Camrelizumab Combined With Pyrotinib Maleate, Nab-paclitaxel and Tegafur Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer | NCT05070598 |
| A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies | A Phase 1, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLN0128 (an Oral mTORC 1/2 Inhibitor) as a Single Agent and in Combination With Paclitaxel in Adult Patients With Advanced Nonhematologic Malignancies | NCT02412722 |
| A phase I/II study of carboplatin in combination with nab-paclitaxel and thoracic radiation in elderly patients with previously untreated non-small cell lung cancer | A phase I/II study of carboplatin in combination with nab-paclitaxel and thoracic radiation in elderly patients with previously untreated non-small cell lung cancer - A phase I/II study of carboplatin in combination with nab-paclitaxel and thoracic radiation in elderly patients with previously untreated non-small cell lung cancer | JPRN-UMIN000016730 |
| ONO-7475-04:A Phase1 study of ONO-7475 in combination with ONO-4538 and gemcitabine plus nab-paclitaxel (GnP), the standard of care, and ONO-7475 in combination with GnP in patients with pancreatic cancer | ONO-7475-04:A Phase1 study to examine tolerability and safety of ONO-7475 in combination with ONO-4538 and gemcitabine plus nab-paclitaxel (GnP), the standard of care, and safety of ONO-7475 in combination with GnP in patients with metastatic pancreatic cancer as first-line treatment | JPRN-jRCT2031230429 |
| Multi-center clinical study of efficacy and safety of Cadonilimab (AK104) combined with albumin-paclitaxel and platinum in first-line treatment of extensive small cell lung cancer (ES-SCLC) | Multi-center clinical study of efficacy and safety of Cadonilimab (AK104) combined with albumin-paclitaxel and platinum in first-line treatment of extensive small cell lung cancer (ES-SCLC) | ChiCTR2300077241 |
| Phase II clinical study of efficacy and safety of Envafolimab combined with albumin-paclitaxel and platinum in first-line treatment of extensive small cell lung cancer (ES-SCLC) | Phase II clinical study of efficacy and safety of Envafolimab combined with albumin-paclitaxel and platinum in first-line treatment of extensive small cell lung cancer (ES-SCLC) | ChiCTR2300077236 |
| The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial. | The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial. | NCT06140576 |
| To evaluate human pharmacokinetics of the drug, paclitaxel in MozecTM PEB for PTA | Mozec PEB PTA PK Study: A prospective, single-arm, multi-centre pharmacokinetic study to evaluate human pharmacokinetics of the drug, paclitaxel in MozecTM PEB for PTA. - N/A | CTRI/2023/10/059285 |
| The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer | Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM) | NCT06115499 |
| Fluzoparib plus nab-paclitaxel for metastatic castration-resistant prostate cancer: a single arm, open label, phase 2 clinical trail | Fluzoparib plus nab-paclitaxel for metastatic castration-resistant prostate cancer: a single arm, open label, phase 2 clinical trail | ChiCTR2300077034 |
| Laser Visual Internal Urethrotomy With Versus Without Paclitaxel Injection | Efficacy of Holmium Laser Urethrotomy Versus in Combination With Intralesional Paclitaxel Injection in the Treatment of Urethral Stricture | NCT06123520 |
| Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer | Phase I Study of the PKMYT1 Inhibitor RP-6306 in Combination With Carboplatin and Paclitaxel for the Treatment of Recurrent TP53 Ovarian and Uterine Cancer | NCT06107868 |
| A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer | A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) | NCT06103864 |
| Combination Chemotherapy of Paclitaxel and Carboplatin With or Without Anthracycline as Aneo Adjuvant Treatment in Advanced Endometrial Carcinoma | Combination Chemotherapy of Paclitaxel and Carboplatin With or Without Anthracycline as Aneo Adjuvant Treatment in Advanced Endometrial Carcinoma | NCT06102252 |
| Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer | A Phase I Study of Xevinapant With Radiation and Concurrent Carboplatin and Paclitaxel in Patients Ineligible for Cisplatin With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck | NCT06110195 |
| A prospective, double-cohort, open-label, phase II clinical study of cadonilimab combined with nab-paclitaxel or disitamab vedotin in the treatment of recurrent or metastatic cervical cancer | A prospective, double-cohort, open-label, phase II clinical study of cadonilimab combined with nab-paclitaxel or disitamab vedotin in the treatment of recurrent or metastatic cervical cancer | ChiCTR2300076740 |
| Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC | A Multicenter, Randomized Trial of Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) Versus Adebrelimab Combined With TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of Triple-negative Breast Cancer | NCT06165900 |
| Investigating the effect of chamomile oral solution on neurological complications caused by chemotherapy regimens containing paclitaxel in cancer patients. | Evaluation of the protective effect of chamomile oral solution on the incidence of neurotoxicity caused by chemotherapy regimens containing paclitaxel in cancer patients | IRCT20200408046990N14 |
| Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | Phase III Trial Of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone For Adults With MammaPrint High 2 Risk (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer | NCT06058377 |
| Efficacy and safety of sintilimab in combination with fruquintinib and albumin-bound paclitaxel in advanced HER-2 negative gastric cancer after first-line checkpoint inhibitor combined with chemotherapy failure: a single-arm, prospective, exploratory clinical study | Efficacy and safety of sintilimab in combination with fruquintinib and albumin-bound paclitaxel in advanced HER-2 negative gastric cancer after first-line checkpoint inhibitor combined with chemotherapy failure: a single-arm, prospective, exploratory clinical study | ChiCTR2300076150 |
| PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC | TAK-676 Alone and in Combination(s) With Carboplatin, 5-Fluorouracil, and Paclitaxel in Patients With Head and Neck Squamous Cell Carcinoma | NCT06062602 |
| The Seven Trial: Exploiting the Unfolded Protein Response | An Open-label, Phase I Trial With Expansion Cohort of Nab-Paclitaxel + Gemcitabine + Cisplatin + Botensilimab (AGEN1811) + Balsilimab (AGEN2034) + Chloroquine + Celecoxib in Patients With Previously Untreated Metastatic Pancreatic Cancer | NCT06076837 |
| Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC | An Exploratory Clinical Study of Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of Locally Advanced Cervical Cancer | NCT06055738 |
| Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer | Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine (PAAG) as First-line Treatment for Advanced Metastatic Pancreatic Cancer: a Prospective, Multicenter, Single-arm, Phase 2 Study | NCT06051851 |
| Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma | A Randomized Phase II Study of Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma | NCT06043427 |
| Cadonilimab+ Paclitaxel (Albumin-bound) Treat Advanced Gastric Adenocarcinoma With PD-(L)1 Inhibitors Resistance | An Open, Multicenter, Phase II Study of Cadonilimab Combined With Paclitaxel (Albumin-bound) in the Treatment of Advanced Gastric Adenocarcinoma or Esophagogastric Junction Adenocarcinoma With PD-(L)1 Inhibitors Resistance | NCT06118645 |
| Sintilimab in Combination With S-1/Oxaliplatin With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites | Sintilimab in Combination With Systemic S-1/Oxaliplatin Chemotherapy With Nab-paclitaxel Intraperitoneal Infusion as First-line Treatment for Advanced Gastric/Gastroesophageal Junction (GC/GEJ) Adenocarcinoma With Malignant Ascites: Open-label, Single-arm, Phase II Trial | NCT06046963 |
| Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Envafolimab and Lenvatinib Combined With Paclitaxel-albumin | An Open and Exploratory Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Envafolimab and Lenvatinib Combined With Paclitaxel-albumin | NCT06030934 |
| Bioequivalence Study of Paclitaxel Protein-boundParticles for Injectable Suspension (Albumin-Bound) of Qilu Pharmaceutical (Hainan) Co., Ltd., China in Patients with Breast Cancer | A Randomized, Open-Label, Two Period, Two-Treatment, Two Sequence, Single Dose, Crossover, Bioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-Bound) of Qilu Pharmaceutical (Hainan) Co., Ltd., China with ABRAXANE® (Paclitaxel Protein-bound Particles for Injectable Suspension) (albumin-bound) manufactured for Celgene Corporation, Summit, NJ 07901 in Patients with Breast Cancer. - NIL | CTRI/2023/11/059593 |
| A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer | A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer | NCT06038578 |
| A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma. | A Multicenter, Open-label, Phase Ib/II Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy Versus Paclitaxel in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma. | NCT06136988 |
| Ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Neoadjuvant Transformation Therapy for Advanced Gastric Cancer | Evaluation of the Efficacy and Safety of Ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Neoadjuvant and Conversion Therapy for Advanced Gastric Cancer (RNPLS-01) | NCT06169410 |
| Phase 3 Study of Pembrolizumab with or without Maintenance Olaparib in First-Line Metastatic Squamous NSCLC | A Phase 3 Study of Pembrolizumab in Combination with Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) - MK-7339-008 | CTIS2023-508449-41-00 |
| A phase II study on the efficacy and safety of Sintilimab combined with nab-paclitaxel and tegio (aTS) as first-line treatment of unresectable locally advanced, recurrent or metastatic adenocarcinoma of the stomach and gastroesophageal junction (CZTU-1) | A phase II study on the efficacy and safety of Sintilimab combined with nab-paclitaxel and tegio (aTS) as first-line treatment of unresectable locally advanced, recurrent or metastatic adenocarcinoma of the stomach and gastroesophageal junction ( CZTU-1) | ChiCTR2400080326 |
| A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer (BRIGHTER) | A Phase III Clinical Trial of BBI608 Plus Weekly Paclitaxel vs. Placebo Plus Weekly Paclitaxel in Adult Patients With Advanced, Previously Treated Gastric and Gastro-Esophageal Junction Adenocarcinoma | JPRN-jRCT2080222639 |
| A Phase I Clinical Study of BBI608 Administered with Paclitaxel in Patients with Previously treated Unresectable/Recurrent Gastric Cancer | A Phase I Clinical Study of BBI608 Administered with Paclitaxel in Patients with Previously treated Unresectable/Recurrent Gastric Cancer | JPRN-jRCT2080222370 |
| Study of ZG005 in Combination With Paclitaxel+Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma | A Phase I/II Study to Evaluate Safety and Pharmacokinetics and Initial Efficacy of ZG005 in Combination With Paclitaxel Plus Cisplatin/Carboplatin ± Bevacizumab in Patients With Advanced Cervical Carcinoma | NCT06241235 |
| Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma | Neoadjuvant Tislelizumab (BGB-A317, Anti-PD-1 Antibody) Plus Nab-Paclitaxel and Carboplatin for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma : A Single-arm, Phase II Trial | NCT06235918 |
| Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA | A Multi-Center, Multi-Cohort Study of the Efficacy and Safety of Anlotinib, TQB2450, and Albumin-bound Paclitaxel in CLDN18.2-regimen-failed Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | NCT06222944 |
| Assessment of prolongation of life with 2 different chemotherapy regimens - Gemcitabine – Cisplatin – Nab-Paclitaxel (GAP) and gemcitabine-platinum (GP) combination in advanced gallbladder cancers. | Gemcitabine-cisplatin-albumin bound paclitaxel (GAP) versus gemcitabine-platinum (GP) in advanced gallbladder cancers (GBC) - a randomized parallel design phase III clinical trial (GAP-GB) - GAP-GB STUDY | CTRI/2024/01/061479 |
| Phase 3 study of Paclitaxel therapy and monolithic systemic chemotherapy in patients with gastric cancer and gastroesophageal border cancer with peritoneal metastasis | Intraperitoneal Paclitaxel Plus Systemic Chemotherapy Versus Systemic Chemotherapy Alone for Advanced or Recurrent Gastric,Gastro-oesophageal Junction Adenocarcinoma with Peritoneal Metastasis a multicenter, randomized, open-label, phase 3 trial (PIPS-GC 003) | KCT0009110 |
| Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab Versus Paclitaxel + Ramucirumab in Patients With PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE) | NCT06203600 |
| Dose Escalation and Dose Expansion Study of GAS in Subjects With Metastatic Pancreatic Adenocarcinoma | A Phase 1b, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of S-1 in Combination With Nab-paclitaxel and Gemcitabine (GAS) in Subjects With Metastatic Pancreatic Adenocarcinoma | NCT06229496 |
| A Phase I/II Study of Intraperitoneal Paclitaxel in Patients with Metastatic Appendiceal Adenocarcinoma | A Phase I/II Study of Intraperitoneal Paclitaxel in Patients with Metastatic Appendiceal Adenocarcinoma | NCT06207305 |
| A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer | A Phase 1b Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer | NCT06199466 |
| Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer | Gemcitabine and Nab-paclitaxel Venous Injection Plus Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer | NCT06196788 |
| Phase 1b/2 trial for venadaparib in combination with paclitaxel and ramucirumab as a second-line therapy for gastric cancer with homologous recombination repair deficiency | Phase 1b/2 trial for venadaparib in combination with paclitaxel and ramucirumab as a second-line therapy for gastric cancer with homologous recombination repair deficiency | KCT0009067 |
| Nanoparticle polymeric micellar paclitaxel combined with gemcitabine in first-line treatment of patients with metastatic pancreatic cancer: a single-arm, Phase II clinical study | Nanoparticle polymeric micellar paclitaxel combined with gemcitabine in first-line treatment of patients with metastatic pancreatic cancer: a single-arm, Phase II clinical study | ChiCTR2300078861 |
| Tislelizumab combined with intraperitoneal and intravenous Nab-Paclitaxel plus S-1 oral chemotherapy in the treatment of gastric cancer with peritoneal metastasis: a single group, single-centre, prospective, phase 2 study | Tislelizumab combined with intraperitoneal and intravenous Nab-Paclitaxel plus S-1 oral chemotherapy in the treatment of gastric cancer with peritoneal metastasis: a single group, single-centre, prospective, phase 2 study | ChiCTR2300078838 |
| A prospective, single-arm, Phase II study of Serplulimab combined with paclitaxel and carboplatin as neoadjuvant therapy for locally advanced resectable esophageal small cell carcinoma | A prospective, single-arm, Phase II study of Serplulimab combined with paclitaxel and carboplatin as neoadjuvant therapy for locally advanced resectable esophageal small cell carcinoma | ChiCTR2300078679 |
| PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer | A Phase I Microtrial With PLZ4-Coated Paclitaxel-Loaded Micelles (PPM) in Patients With Recurrent or Refractory Non-Myoinvasive Bladder Cancer | NCT06173349 |
| A single-arm exploratory clinical study of nab-paclitaxel combined with subcutaneous PD-L1 monoclonal antibody in the treatment of advanced and posterior triple-negative breast cancer | A single-arm exploratory clinical study of nab-paclitaxel combined with subcutaneous PD-L1 monoclonal antibody in the treatment of advanced and posterior triple-negative breast cancer | ChiCTR2300078237 |
| Efficacy and Safety of Bevacizumab (Avastin®) Combined to Weekly Paclitaxel Followed by Bevacizumab (Avastin®) Alone in Patients With Relapsed Ovarian Sex-cord Stromal Tumours (ALIENOR) | A Randomized, Open Label, Phase II Trial of Bevacizumab Plus Weekly Paclitaxel Followed by Bevacizumab Monotherapy Maintenance Versus Weekly Paclitaxel Followed by Observation in Patients With Relapsed Ovarian Sex-cord Stromal Tumours | NCT01770301 |
| A prospective, single-arm clinical study of the efficacy and safety of Icaritin in combination with gemcitabine and nab-paclitaxel in patients with advanced pancreatic ductal adenocarcinoma not previously treated with systemic therapy | A prospective, single-arm clinical study of the efficacy and safety of Icaritin in combination with gemcitabine and nab-paclitaxel in patients with advanced pancreatic ductal adenocarcinoma not previously treated with systemic therapy | ChiCTR2300077907 |
| Weekly Paclitaxel versus weekly Cisplatin in Oral cavity, Oropharyngeal and Hypopharyngeal cancer patients with concurrent Radiation – A Superiority, Phase II/III - Randomised Controlled Trial | Weekly Paclitaxel versus weekly Cisplatin in Oral cavity, Oropharyngeal and Hypopharyngeal cancer patients with concurrent Radiation – A Superiority, Phase II/III - Randomised Controlled Trial - NIL | CTRI/2023/11/060145 |
| ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC) | A Phase I/Ib Trial of ProAgio, an Anti- avß3 Integrin Cytotoxin, in Combination With Gemcitabine and Nab-paclitaxel for Advanced Pancreatic Cancer | NCT06182072 |
| Feasibility Trial of EUS-PCA in IPMN Pancreatic Cysts | Single-arm Intervention Trial of the Feasibility of Endoscopic Ultrasound-guided Pancreatic Cyst Chemoablation (EUS-PCA) Using Gemcitabine and Paclitaxel for Intraductal Papillary Mucinous Neoplasms (IPMN) in Two New Zealand Tertiary Interventional Endoscopy Centres | NCT06162468 |
| Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer | A Randomized, Controlled Phase ? Study of Paclitaxel Polymeric Micelles for Injection Versus Physician's Choice(TPC) in Human Epidermal Growth Factor Receptor 2-negative (HER2-) Metastatic Breast Cancer (MBC) Subjects Who Have Failed at Least Two Previous Chemotherapy Regimens. | NCT06143553 |
| Proglumide With Gemcitabine and Nab-Paclitaxel in PatientsWith Metastatic Pancreatic Ductal Adenocarcinoma | Phase I Study of Proglumide With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic DuctalAdenocarcinoma | NCT06017323 |
| Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients | Efficacy and Safety of Albumin-bound Paclitaxel-Lenvatinib-Pembrolizumab in Advanced Nonsquamous NSCLC Patients After Progression to First-line Anti-PD-1/L1 Inhibitor With Platinum-doublet Chemotherapy | NCT06028633 |
| Study of Different types of chemotherapy in oral cancers | Phase 3 study comparing TPF versus Paclitaxel-Carboplatin and oral metronomic chemotherapy as neoadjuvant chemotherapy for borderline resectable oral cancers - NIL | CTRI/2023/08/056693 |
| Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer | Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Locally Advanced or Borderline Resectable Pancreatic Cancer: An Exploratory Study | NCT05908747 |
| A real-world study of immunotherapy combined with paclitaxel polymer micelles and platinum in the treatment of locally advanced solid tumors | A real-world study of immunotherapy combined with paclitaxel polymer micelles and platinum in the treatment of locally advanced solid tumors | ChiCTR2300071667 |
| Preoperative chemotherapy with paclitaxel in women with HER2-negative high-risk breast cancer | Neoadjuvant chemotherapy with nab-paclitaxel in women with HER2-negative high-risk breast cancer ETNA (Evaluating Treatment with Neoadjuvant Abraxane) - ETNA | EUCTR2012-003481-41-IT |
| A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach | Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel With Trastuzumab in Patients With HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy | NCT01774851 |
| A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2+ Metastatic Breast Cancer Patients | Multicenter Randomized Double-blind Phase III Clinical Trial Comparing Safety and Efficacy of BCD-022 (CJSC BIOCAD, Russia) Used With Paclitaxel to Herceptin® Used With Paclitaxel in the First-line Treatment of HER2+ Metastatic Breast Cancer Patients | NCT01764022 |
| A Study of MM-111 and Paclitaxel with or without Trastuzumab in patients with Metastatic or Locally Advanced Cancer of the Esophagus, Gastroesophageal Junction and Stomach | Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel with orwithout Trastuzumab in Patients with ‘Traditional’ and ‘Non-Traditional’ HER2 Expressing Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy. - Open Label MM-111 in patients with HER2 | EUCTR2012-003798-25-GB |
| nab-Paclitaxel plus trastuzumab and pertuzumab as a neoadjuvant chemotherapy for low-risk HER2-positive breast cancer | nab-Paclitaxel plus trastuzumab and pertuzumab as a neoadjuvant chemotherapy for low-risk HER2-positive breast cancer - PerSeUS-BC06 | JPRN-UMIN000051060 |
| A phase ? study to evaluate the efficacy and safety of Surufatinib ,Zimberelimab combined with nab-paclitaxel in advanced triple-negative breast cancer | A phase ? study to evaluate the efficacy and safety of Surufatinib ,Zimberelimab combined with nab-paclitaxel in advanced triple-negative breast cancer | ChiCTR2300071563 |
| Paclitaxel-bevacizumab in Advanced Lung Cancer | Phase III Study Comparing the Efficacy of Paclitaxel-bevacizumab With Docetaxel in 2nd or 3rd Line of Treatment of Non Squamous Non Small Cells Lung Cancer | NCT01763671 |
| A Study of KX2-391 With Paclitaxel in Patients With Solid Tumors | An Open-label Phase I/II Study of KX2-391 in Combination With Paclitaxel in Patients With Advanced Solid Tumors | NCT01764087 |
| Phase II trial of perioperative chemotherapy with cisplatin and dose dense paclitaxel in patients with stage IB2,IIA2 orIIB uterine cervical cancer SGSG014 | Phase II trial of perioperative chemotherapy with cisplatin and dose dense paclitaxel in patients with stage IB2,IIA2 orIIB uterine cervical cancer SGSG014 - Phase II trial of perioperative dose dense TP in patients with stage IB2,IIA2,IIB uterine cervical cancer (SGSG014) | JPRN-UMIN000009643 |
| A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC | A Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of PM8002 Injection in Combination With Paclitaxel Injection as Second Line Treatment for Small Cell Lung Cancer(SCLC) | NCT05879068 |
| A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer | International Multicenter Randomized Double Blind Phase III Trial Comparing Safety and Efficacy of BCD-021 (CJSC BIOCAD, Russia) and Paclitaxel + Carboplatin to Avastin® (F. Hoffmann-La Roche Ltd, Switzerland) and Paclitaxel + Carboplatin in Inoperable or Advanced Non-squamous Non-small-cell Lung Cancer (NSCLC) Patients | NCT01763645 |
| Carrilizumab Combined With White Purple for Squamous Cell Carcinoma of Skin | Carrellizumab Combined With Albumin-binding Paclitaxel in the Treatment of Locally Late Stage or Relapsed Metastatic Cutaneous Squamous Cell Carcinoma: a Single-arm, Open, Multicenter, Prospective Clinical Study | NCT05886140 |
| Study of combination chemotherapy of Albumin-bound paclitaxel / Cyclophosphamide in recurrent or metastatic breast cancer | Study of combination chemotherapy of Albumin-bound paclitaxel / Cyclophosphamide in recurrent or metastatic breast cancer - Study of combination chemotherapy of Albumin-bound paclitaxel / Cyclophosphamide in recurrent or metastatic breast cancer | JPRN-UMIN000009616 |
| Estudio de seguridad en pacientes ancianos (? 70 años) con cáncer de pulmón no microcítico | Estudio Fase II de seguridad de bevacizumab en combinación con carboplatino y paclitaxel en pacientes ancianos (? 70 años) con cáncer de pulmón no microcítico - GIDO1201 | EUCTR2012-002452-16-ES |
| Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC | A RANDOMIZED PHASE I/II STUDY OF NAB-PACLITAXEL, OR PACLITAXEL, PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY FOLLoWED BY CONSOLIDATION IN PATIENTS WITH FAVORABLE PROGNOSIS INOPERABLE STAGE IIIA/B NON-SMALL CELL LUNG CANCER (NSCLC) | NCT01757288 |
| Trial of Postoperative Chemoradiotherapy With or Without Consolidation Chemotherapy for Cervical Cancer Patients | Phase III Randomized Study of Concurrent Paclitaxel/Cisplatin Chemotherapy and Radiotherapy With or Without Consolidation Chemotherapy in High-Risk Patients With Early-Stage Cervical Cancer Following Radical Hysterectomy | NCT01755845 |
| Weekly paclitaxel in combination with bevacizumab in patient with HER2 nagative breast cancer who were previously treated with taxane - PhaseII - | Weekly paclitaxel in combination with bevacizumab in patient with HER2 nagative breast cancer who were previously treated with taxane - PhaseII - - SBP-05: CARP trial Clinical evaluation of avastin to patients relapsed after taxane | JPRN-UMIN000009582 |
| Pilot study of S-1/Paclitaxel/Trastuzumab combination chemotherapy for HER2-positive Stage IV advanced gastric cancer. | Pilot study of S-1/Paclitaxel/Trastuzumab combination chemotherapy for HER2-positive Stage IV advanced gastric cancer. - KGCSG1201 | JPRN-UMIN000009565 |
| Paclitaxel Plus Radiation With Erlotinib to Treat Esophageal Squamous Carcinoma | A Randomized Phase III Study: Paclitaxel Plus Radiation Therapy With or Without Erlotinib in Treating Patients With Esophageal Squamous Carcinoma | NCT01752205 |
| Neurotoxicity Characterization Study of Nab-paclitaxel Versus Conventional Paclitaxel in Metastatic Breast Cancer | Neurotoxicity Characterization Phase II Randomized Study of Nab-paclitaxel Versus Conventional Paclitaxel as First-line Therapy of Metastatic HER2-negative Breast Cancer. | NCT01763710 |
| Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer | A Phase II Study of Neoadjuvant Chemotherapy With and Without Trastuzumab in Patients With Breast Cancer | NCT01750073 |
| Exploratory study to determine predictive factors of effectiveness of nab-paclitaxel in breast cancer (Expect study) | Exploratory study to determine predictive factors of effectiveness of nab-paclitaxel in breast cancer (Expect study) - Exploratory study to determine predictive factors of effectiveness of nab-paclitaxel in breast cancer (Expect study) | JPRN-UMIN000009526 |
| Carboplatin-Paclitaxel ± Bevacizumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer | A Randomized Phase II Trial of Carboplatin-Paclitaxel Compared to Carboplatin-Paclitaxel-Bevacizumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer | NCT01770171 |
| A prospective, single-arm, exploratory study of the efficacy and safety of penpulimab injection in combination with albumin paclitaxel, and carboplatin as neoadjuvant therapy for triple-negative breast cancer | A prospective, single-arm, exploratory study of the efficacy and safety of penpulimab injection in combination with albumin paclitaxel, and carboplatin as neoadjuvant therapy for triple-negative breast cancer | ChiCTR2300071925 |
| BC001 combined with paclitaxel versus placebo combined with paclitaxel in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma that has failed first-line standard therapy: a randomized, double-blind, parallel-controlled Phase III study | BC001 combined with paclitaxel versus placebo combined with paclitaxel in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma that has failed first-line standard therapy: a randomized, double-blind, parallel-controlled Phase III study | ChiCTR2300071906 |
| Paclitaxel-Coated Pulmonary Balloon for the Treatment of Benign Airway Stenosis | Prospective Trial of Paclitaxel-Coated Pulmonary Balloon for the Treatment of Benign Airway Obstruction (OXYGEN-1 Trial) | NCT05895305 |
| A phase 2 study of nab-Paclitaxel followed by FEC (Fluorouracil, Epirubicin, Cyclophosphamide) as primary therapy for operable breast cancer | A phase 2 study of nab-Paclitaxel followed by FEC (Fluorouracil, Epirubicin, Cyclophosphamide) as primary therapy for operable breast cancer - A phase 2 study of nab-Paclitaxel followed by FEC (Fluorouracil, Epirubicin, Cyclophosphamide) as primary therapy for operable breast cancer | JPRN-UMIN000009733 |
| Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell | Pembrolizumab Plus Albumin Paclitaxel or 5-fluorouracil and Cisplatin Versus 5-fluorouracil and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma: a Prospective, Randomized Controlled Trial Study | NCT06006650 |
| A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer | A Phase Ib/II Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer | NCT06016270 |
| Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT) | Neoadjuvant Chemoimmunotherapy With Tislelizumab, Albumin-bound Paclitaxel, and Cisplatin in Locally Advanced Oral/Oropharyngeal Squamous Cell Carcinoma: A Prospective, Multicenter, Single-arm Study | NCT06009861 |
| Verify Effectiveness and Safety of Paclitaxel-Coated Coronary Balloon Catheters Swide® | Prospective, Multi-center Non-inferiority and Randomized Controlled Clinical Study to Verify Effectiveness and Safety of Paclitaxel-Coated Coronary Balloon Catheters Swide® | NCT06024525 |
| Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma | Fruquintinib Combined With Camrelizumab, Paclitaxel Liposome and Nedaplatin as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma | NCT06010212 |
| Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer | A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix | NCT01281852 |
| Adelbelimab Combination Chemotherapy in Neoadjuvant Therapy for Squamous Cell Carcinoma of the Head and Neck | A Prospective, Single-arm, Phase II Study of Adelbelimab Combined With Carboplatin and Nab-paclitaxel in Neoadjuvant Therapy for Patients With Resectable Locally Advanced Squamous Cell Carcinoma of the Head and Neck | NCT06016413 |
| A clinical trial to assess if drug-coated balloons are an effective treatment for arteriovenous fistulas in patients on haemodialysis | Paclitaxel or sirolimus coated balloons used for ArterioVEnous fistulas - 2 (PAVE-2 trial): a randomised controlled clinical trial to determine the efficacy of paclitaxel or sirolimus coated balloons in arteriovenous fistulas used for haemodialysis | ISRCTN40182296 |
| A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer | A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer | NCT05984602 |
| A single-arm, phase II trial of neoadjuvant SHR-1316 plus nab-paclitaxel and carboplatin for potentially unresectable locally advanced thymic carcinomas | A single-arm, phase II trial of neoadjuvant SHR-1316 plus nab-paclitaxel and carboplatin for potentially unresectable locally advanced thymic carcinomas | ChiCTR2300074152 |
| Clinical study of zimberelimab combined with gemcitabine and albumin-paclitaxel in first-line treatment of patients with relapsed or metastatic pancreatic cancer | Clinical study of zimberelimab combined with gemcitabine and albumin-paclitaxel in first-line treatment of patients with relapsed or metastatic pancreatic cancer | ChiCTR2300074055 |
| A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology | A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology | NCT05977998 |
| Envafolimab combined with Irinotecan or albumin-paclitaxel and Chidamide as second-line therapy in advanced and metastatic gastric cancer: A single-arm, exploratory, phase 2 trial | Envafolimab combined with Irinotecan or albumin-paclitaxel and Chidamide as second-line therapy in advanced and metastatic gastric cancer: A single-arm, exploratory, phase 2 trial | ChiCTR2400080485 |
| Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma | Nimotuzumab Combined With Paclitaxel as Second-line Treatment for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma With EGFR Over-expression: A Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial | NCT05978050 |
| Phase II study of the safety and efficacy of TM5614 in combination with Paclitaxel for cutaneous angiosarcoma | Phase II study of the safety and efficacy of TM5614 in combination with Paclitaxel for cutaneous angiosarcoma | JPRN-jRCT2021230016 |
| Comparison of Weekly Versus Every Three Weeks of Carboplatin Plus Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer | A Non-randomized Control Study Comparing Weekly Versus Every Three Weeks of Carboplatin Plus Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer | NCT05963334 |
| Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients | The Safety and Tolerance of Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in Subjects With Locally Advanced and Metastatic Pancreatic Adenocarcinoma: an Open, One-Armed, Single-Center, Phase ? Study. | NCT05947825 |
| Serplulimab combined with gemcitabine, nab-paclitaxel and stereotactic body radiotherapy as the first-line treatment for patients with metastatic pancreatic adenocarcinoma in China: a multicenter, single-arm, phase II trial (ICSBR) | Serplulimab combined with gemcitabine, nab-paclitaxel and stereotactic body radiotherapy as the first-line treatment for patients with metastatic pancreatic adenocarcinoma in China: a multicenter, single-arm, phase II trial (ICSBR) | ChiCTR2300073237 |
| Prospective study of nituzumab combined with gemcitabine and albumin paclitaxel in first-line treatment of advanced pancreatic cancer | Prospective study of nituzumab combined with gemcitabine and albumin paclitaxel in first-line treatment of advanced pancreatic cancer | ChiCTR2300072843 |
| A Phase 2 study of paclitaxel plus rivoceranib in patients with GIST | A Phase 2 study of paclitaxel plus rivoceranib in patients with GIST with a high P-glycoprotein expression after failure with at least imatinib, sunitinib and regorafenib. | KCT0008554 |
| A phase II trial of SHR-1316 plus nab-paclitaxel and carboplatin as the first line therapy for advanced, unresectable, recurrent or metastatic thymic carcinoma | A phase II trial of SHR-1316 plus nab-paclitaxel and carboplatin as the first line therapy for advanced, unresectable, recurrent or metastatic thymic carcinoma | ChiCTR2300072705 |
| Prospective, one-arm clinical study of adebrelimab combined with Apatinib and albumin-bound paclitaxel in the treatment of recurrent extensive stage small cell lung cancer | Prospective, one-arm clinical study of adebrelimab combined with Apatinib and albumin-bound paclitaxel in the treatment of recurrent extensive stage small cell lung cancer - Prospective, one-arm clinical study of adebrelimab combined with Apatinib and albumin-bound paclitaxel in the treatment of recurrent extensive stage small cell lung cancer | ChiCTR2300072520 |
| A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC | A Phase Ib/II Study of PM8002 Injection Plus Nab-paclitaxel as First Line Therapy for Unresectable, Locally Advanced or Metastatic Triple-negative Breast Cancer | NCT05918133 |
| Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor | A Phase 2 Study of Paclitaxel Plus Rivoceranib in Patients With GIST With a High P-glycoprotein Expression After Failure With at Least Imatinib, Sunitinib and Regorafenib | NCT05905887 |
| Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCC | Prospective, One-arm, Phase II Clinical Study of Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in Patients With Resectable Squamous Cell Carcinoma of the Head and Neck | NCT05941338 |
| 4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC | Safety and Efficacy of Four Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel Versus Two Courses of Neoadjuvant Therapy in Patients With Resectable Head and Neck Squamous Cell Carcinoma (T3 or T4, N0) : An Optimal Efficacy Study (Prospective, Two-arm, Phase II) | NCT05980702 |
| A Study of TXN10128 in Subjects With Solid Tumors | A Multicenter, Open-label, Phase 1 Dose Escalation and Expansion Study of TXN10128, an Inhibitor of ENPP1 as Monotherapy and Combination Therapy With Irinotecan or Paclitaxel in Locally Advanced or Metastatic Solid Tumors | NCT05978492 |
| A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer | A Phase II Study of agenT-797 (Invariant Natural Killer T Cells), Botensilimab, a Novel Fc-enhanced CTLA-4 Inhibitor, Plus Balstilimab (Anti-PD-1) With Ramucirumab and Paclitaxel for Patients With Previously Treated, Advanced Esophageal, Gastric, or Gastro-esophageal Junction Adenocarcinoma | NCT06251973 |
| Neoadjuvant Immunochemotherapy for LAOSCC | Neoadjuvant Immunochemotherapy with Tislelizumab, Albumin Paclitaxel and Cisplatin Followed by Standard Therapy Versus Standard Therapy for Locally Advanced Oral Squamous Cell Carcinoma, a Multicenter Randomized Phase 3 Trial | NCT06258811 |
| A phase II study of weekly paclitaxel for advanced or recurrent esophageal cancer | A phase II study of weekly paclitaxel for advanced or recurrent esophageal cancer - Second line treatment using weekly paclitaxel for esophageal cancer | JPRN-UMIN000009807 |
| Phase 3 Study to Compare Efficacy and Safety of DHP107 vs. Taxol® in Patients With Metastatic or Recurrent Gastric Cancer | A Randomized, Open-label, Multicenter, Phase 3 Study for Efficacy and Safety Assessment of DHP107 (Oral Paclitaxel) vs. Taxol® in Patients With Metastatic or Recurrent Gastric Cancer After Failure of First-line Chemotherapy With Fluoropyrimidine +/- Platinum | NCT01839773 |
| A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer. | A Multicenter, Randomized, Double-blind, Parallel-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of B013 Combined With Paclitaxel in the Treatment of Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer. | NCT06434610 |
| Nab-Paclitaxel Plus Cisplatin With Concurrent Radiotherapy for Patients With Locally Advanced Cervical Cancer: A Multicentre, Single-arm, Phase II Trial. | Nab-Paclitaxel Plus Cisplatin With Concurrent Radiotherapy for Patients With Locally Advanced Cervical Cancer:A Multicentre, Single-arm, Phase II Trial. | NCT06426056 |
| Comparing Two Chemotherapy Treatments for Ovarian Cancer: Albumin-Bound vs. Solvent-Based Paclitaxel-Carboplatin | A Randomized Trial Comparing Albumin-Bound Paclitaxel-Carboplatin to Solvent-Based Paclitaxel-Carboplatin for First-Line Chemotherapy in Stage Ic-IV Ovarian Carcinoma: A Study at a Tertiary Healthcare Institute in the Sub-Himalayan Region - NIL | CTRI/2024/05/067283 |
| PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC | A Multicenter, Randomized, Double-blind Phase III Study of PM8002 or Placebo in Combination With Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer(TNBC) | NCT06419621 |
| Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma | A Randomized Controlled Study of 2nd-line Treatment of Advanced G/GEJ Adenocarcinoma With Fruquintinib and Albumin-paclitaxel in Combination With or Without PD-1 Antibody in Patients Who Have Failed Treatment With PD-1 Antibody | NCT06417892 |
| Effect of foot compression therapy on peripheral neuropathy induced by albumin-binding paclitaxel chemotherapy in patients with breast cancer | Effect of foot compression therapy on peripheral neuropathy induced by albumin-binding paclitaxel chemotherapy in patients with breast cancer | ChiCTR2400084154 |
| TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile Cancer | A Single-center, Single-arm Clinical Study of TIP(Paclitaxel + Ifosfamide + Cisplatin) Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile Cancer | NCT06415318 |
| Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Cadonilimab and Fruquintinib Combined With Paclitaxel-albumin | An Open and Exploratory Study of The Second-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma With Cadonilimab and Fruquintinib Combined With Paclitaxel-albumin | NCT06406426 |
| Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer | Prospective, Single-arm, Phase II Study of Nab-paclitaxel Plus Carboplatin in Combination With Sintilimab for Neoadjuvant Therapy in Elderly, Locally Advanced, Resectable Esophageal Squamous Cell Carcinoma. | NCT06403878 |
| Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma | An Open-Label, Phase II Trial to Assess Efficacy and Safety of Onvansertib in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Previously Untreated, Locally-Advanced or Unresectable Pancreatic Adenocarcinoma | NCT06398587 |
| Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer | A Randomized Phase 1/2 Trial Evaluating the Addition of Tolinapant to Weekly Paclitaxel With or Without Bevacizumab in Patients With Recurrent Epithelial Ovarian Cancer | NCT06393751 |
| A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer | A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer - IJB-SYNERGY-012017 | CTIS2024-511850-34-00 |
| Tongluohuoxue Formula in the Prevention and Management of Paclitaxel-induced Peripheral Neuropathy: a Multicenter, Double-blind, Placebo-controlled Trial | Tongluohuoxue Formula in the Prevention and Management of Paclitaxel-induced Peripheral Neuropathy: a Multicenter, Double-blind, Placebo-controlled Trial | ChiCTR2400083563 |
| A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma | A Study of Paclitaxel (Albumin-bound) Combined With Apatinib and Adebrelimab in the Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma Following Previous Immunotherapy Progression | NCT06415669 |
| Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer | A Prospective Single Arm Trial of Concurrent Chemoradiotherapy (With Albumin-Bound Paclitaxel/Cisplatin) Followed by PD-1 Inhibitor in Locally Advanced Cervical Cancer | NCT06391190 |
| Adebrelimab combined with nab-paclitaxel and nedaplatin in the neoadjuvant treatment of locally advanced resectable esophageal squamous cell carcinoma: a single-arm, exploratory clinical study | Adebrelimab combined with nab-paclitaxel and nedaplatin in the neoadjuvant treatment of locally advanced resectable esophageal squamous cell carcinoma: a single-arm, exploratory clinical study | ChiCTR2400083452 |
| A Study of Zolbetuximab (IMAB362) in Adults with Pancreatic Cancer | A Phase 2, Open-Label, Randomized Study to Assess the Efficacy and Safety of Zolbetuximab (IMAB362) in Combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma - 8951-CL-5201 | CTIS2024-510985-17-00 |
| Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer | Efficacy and Safety of Camrelizumab Plus Albumin-bound Paclitaxel/Carboplatin Followed by Camrelizumab With or Without Fluzoparib Maintenance Therapy for TP-53 Mutated Recurrent or Metastatic Endometrial Cancer: A Phase II Trial | NCT06413992 |
| Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma | Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma: a Study Protocol of Prospective Single-center, Open Label and Exploratory Cohort Study (SNC-01) | NCT06388135 |
| CHemotherapy and Stool Transplant in PDAC (CHASe-PDAC) | An Open-label, Single-arm, Phase 1 Study of the Combination of FMT and Gemcitabine with Nab-paclitaxel As First-line Therapy in Patients with Advanced Pancreatic Ductal Adenocarcinoma. | NCT06393400 |
| Pembrolizumab With or Without Maintenance MK-2870 in Metastatic Squamous NSCLC | A Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer - MK-2870-023 | CTIS2023-510128-66-00 |
| A phase II Randomized controlled trial A comparison of short-course radiation and chemotherapy with or without intraperitoneal paclitaxel for locally advanced, non-metastatic signet-ring cell rectal cancers | A phase II Randomized controlled trial comparing short-course radiation and chemotherapy with or without intraperitoneal paclitaxel for locally advanced, non-metastatic signet-ring cell rectal cancers. - NIL | CTRI/2024/04/065785 |
| Effect of paclitaxel protein-bound particles for injectable suspension in breast cancer patients. | An Open Label, Multicenter, Randomized, Balanced, Single Dose, Two Treatment, Two Sequence, Two Period, Crossover, Bioequivalence Study of Test Product Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-bound), for Intravenous Use (Manufactured by/for: Dr. Reddy’s Laboratories Ltd.) with Reference Product Abraxane® for Injectable Suspension (Paclitaxel Protein-bound Particles for Injectable Suspension) (Albumin-bound), for Intravenous Use (Abraxis BioScience, LLC, USA) in Breast Cancer Patients. - NIL | CTRI/2024/04/065727 |
| Randomized controlled study of rmhTNF versus paclitaxel intraperitoneal perfusion in the treatment of peritoneal metastasis of gastric cancer | Randomized controlled study of rmhTNF versus paclitaxel intraperitoneal perfusion in the treatment of peritoneal metastasis of gastric cancer | ChiCTR2400083006 |
| Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer | Sorafenib Combined With Carboplatin/Paclitaxel and Sorafenib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer: a Single-arm, Multicenter, Exploratory Clinical Study | NCT06437353 |
| Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCC | Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma:a Prospective, Single Arm, Phase 2 Clinical Study | NCT06508229 |
| Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) | A Phase 1/2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of MK-2870 Plus Paclitaxel as the Second-Line Treatment of Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma: Substudy 06D | NCT06445972 |
| Nab-TET | A phase II study of carboplatin plus nab-paclitaxel for advanced thymic epithelial tumors (thymoma, thymic cancer) - Nab-TET | JPRN-jRCTs071240019 |
| RESTORING SENSITIVITY TO IMMUNOTHERAPY IN ADVANCED TRIPLE NEGATIVE BREAST CANCER EXPLOITING CERALASERTIB PRIMING FOLLOWED BY COMBINED DURVALUMAB/NAB-PACLITAXEL: THE ATRiBRAVE TRIAL | RESTORING SENSITIVITY TO IMMUNOTHERAPY IN ADVANCED TRIPLE NEGATIVE BREAST CANCER EXPLOITING CERALASERTIB PRIMING FOLLOWED BY COMBINED DURVALUMAB/NAB-PACLITAXEL: THE ATRiBRAVE TRIAL - IFOM-CPT008/2022/PO0 | CTIS2024-513721-23-00 |
| Irinotecan Liposome,Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer | Irinotecan Liposome Combined With Albumin Paclitaxel and Gemcitabine as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer | NCT06513455 |
| A clinical trial assessing the addition of continuous ketogenic diet therapy to standard chemotherapy and immunotherapy treatment for patients with advanced squamous cell lung cancer | KETO-Lung: Assessing the impact of the adoption of a continuous ketogenic diet therapy on the efficacy of combination chemo-immunotherapy using paclitaxel/carboplatin/pembrolizumab in advanced squamous cell cancer of the lung | ISRCTN73427832 |
| Phase 2 study of first-line carboplatin and paclitaxel in combination with pembrolizumab, followed by maintenance pembrolizumab with or without Nesuparib, in patients with newly diagnosed advanced or recurrent MMR-proficient (pMMR) endometrial cancer | Phase 2 study of first-line carboplatin and paclitaxel in combination with pembrolizumab, followed by maintenance pembrolizumab with or without Nesuparib, in patients with newly diagnosed advanced or recurrent MMR-proficient (pMMR) endometrial cancer | KCT0009641 |
| Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis,an Exploratory, Single-Arm, Multicenter Phase II Clinical Study | Exploratory Single-Arm, Multicenter Phase II Study of Tislelizumab Combined with Nab-Paclitaxel As First Line Treatment for Patients of Triple-negative Breast Cancer(TNBC) with Bone Metastasis | NCT06538896 |
| A clinical trial of relacorilant (study drug) with nab-paclitaxel in patients with ovarian, fallopian tube or peritoneal cancer | A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA) - CORT125134-556 | CTIS2024-514080-25-00 |
| A single-arm, Phase II exploratory clinical study of Sintilimab in combination with albumin-paclitaxel and nedaplatin for neoadjuvant treatment of esophageal cancer | A single-arm, Phase II exploratory clinical study of Sintilimab in combination with albumin-paclitaxel and nedaplatin for neoadjuvant treatment of esophageal cancer | ChiCTR2400086739 |
| An open, single-arm clinical study to explore the safety and efficacy of sintilimab in combination with albumin-paclitaxel/cisplatin for neoadjuvant treatment of esophageal cancer | An open, single-arm clinical study to explore the safety and efficacy of sintilimab in combination with albumin-paclitaxel/cisplatin for neoadjuvant treatment of esophageal cancer | ChiCTR2400086654 |
| A study of the efficacy and safety of sintilimab combined with paclitaxel and cisplatin (TP) in the induction therapy of head and neck squamous cell carcinoma | A study of the efficacy and safety of sintilimab combined with paclitaxel and cisplatin (TP) in the induction therapy of head and neck squamous cell carcinoma | ChiCTR2400086660 |
| Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer | A Phase Ib Randomized Parallel Study of Comparing WH002 With Paclitaxel Both Sequential of Epirubicin and Cyclophosphamide As Neoadjuvant Treatment of Women With HER2-Negative Breast Cancer | NCT06513364 |
| A Clinical Study of Albumin-bound Paclitaxel/granulocyte-based Therapy for Recurrent/metastatic Breast Cancer | A Clinical Study of Albumin-bound Paclitaxel/granulocyte-based Therapy for Recurrent/metastatic Breast Cancer | NCT06496724 |
| Single-arm, Exploratory Clinical Study of Adebrelimab Combined with Linperlisib and Nab-paclitaxel in Advanced NSCLC Progressed on Prior Immunotherapy | Single-arm, Exploratory Clinical Study of Adebrelimab Combined with Linperlisib and Nab-paclitaxel in Advanced NSCLC Progressed on Prior Immunotherapy | ChiCTR2400086436 |
| A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC) | A Phase 2 Study of LVGN6051 Combined With Toripalimab and Paclitaxel for Recurrent/Metastatic HNSCC Rapidly Progressed From Previous Platinum-containing Curative Treatment or Contraindicated for Platinum-containing Treatment | NCT06378177 |
| Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma | A Phase ? Study of Chiauranib Plus Albumin-paclitaxel and Gemcitabine as First-line Therapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma | NCT06492915 |
| Predicting the Efficacy in Advanced Gastric Cancer. | Predicting the Efficacy of Paclitaxel Plus Ramucirumab in Advanced Gastric Cancer. | NCT06490055 |
| Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers | Prevention of Paclitaxel-Induced Peripheral Neuropathy: Randomized Trial of Cryocompression With or Without Cilostazol | NCT06492070 |
| Liposomal Irinotecan Combination Regimen for Second-line Treatment of Advanced Gastric Cancer | Liposomal Irinotecan Combined With Albumin-bound Paclitaxel for Second-line Treatment of Advanced Gastric Cancer: a Single-arm, Single-center Clinical Study | NCT06486545 |
| PRODIGE 55-SOCRATE : A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer | PRODIGE 55-SOCRATE : A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer | CTIS2024-513515-27-00 |
| AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDAC | A Prospective, Single-arm, Phase II Study Assessing the Efficacy of Gemcitabine, Nab-paclitaxel, and Cadonilimab With Sequential Short-course Radiotherapy in Locally Advanced Pancreatic Ductal Adenocarcinoma Patients. | NCT06472037 |
| The efficacy and safety exploration study of sequential administration of albumin-bound paclitaxel and carboplatin with PD-1 monoclonal antibody injection based on immune induction strategy in first-line treatment of advanced squamous non-small cell lung cancer | The efficacy and safety exploration study of sequential administration of albumin-bound paclitaxel and carboplatin with PD-1 monoclonal antibody injection based on immune induction strategy in first-line treatment of advanced squamous non-small cell lung cancer | ChiCTR2400085724 |
| Tirilizumab with Albumin-bound Paclitaxel and Cisplatin for Locally Advanced Resectable Oral Squamous Cell Carcinoma | A Prospective, Randomised Controlled, Phase II Clinical Study of Tirilizumab in Combination with Albumin-bound Paclitaxel with Cisplatin for Neoadjuvant and Adjuvant Treatment of Locally Advanced Resectable Oral Squamous Cell Carcinoma | NCT06470217 |
| Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer | A Phase II Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer | NCT06493019 |
| Predicting Peripheral Neuropathy of Paclitaxel for Gastric Cancer | Predicting Peripheral Neuropathy of Paclitaxel in Second-line Chemotherapy for Gastric Cancer | NCT06490159 |
| Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC | A Phase II Clinical Study of Adabrelimab Combined With Carboplatin, Albumin-bound Paclitaxel, and Recaticimab in Perioperative Treatment of Resectable NSCLC | NCT06467617 |
| An exploratory study of camrelizumab combined with albumin-bound paclitaxel in the second-line treatment of advanced esophageal squamous cell carcinoma | An exploratory study of camrelizumab combined with albumin-bound paclitaxel in the second-line treatment of advanced esophageal squamous cell carcinoma | ChiCTR2400085451 |
| Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel | Subjects With Advanced Basal-like Pancreatic Adenocarcinoma Treated With Gemcitabine, Erlotinib and Nab-paclitaxel (PANGEA) Versus Subjects With Classical Pancreatic Adenocarcinoma Treated With Triplet Standard of Care Therapy. | NCT06483555 |
| Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma :A Single-arm, Prospective, Phase II Trial | Neoadjuvant Tislelizumab Combined With Albumin-paclitaxel, Cisplatin, and Fluorouracil in Patients With Locally Advanced Oral Squamous Cell Carcinoma :A Single-arm, Prospective,Phase II Study | NCT05862168 |
| Phase II study of Bevacizumab in combination with Paclitaxel in metastatic breast cancer patients with asymptomatic brain metastases. | Phase II study of Bevacizumab in combination with Paclitaxel in metastatic breast cancer patients with asymptomatic brain metastases. - Phase II study of Bevacizumab in combination with Paclitaxel in metastatic breast cancer patients with asymptomatic brain metastases. | JPRN-UMIN000010466 |
| Gemcitabine, Cisplatin and Nab-Paclitaxel As Neoadjuvant Treatment for Patients with Resectable or Borderline Resectable Pancreatic Cancer | A Single-Arm Phase II Clinical Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel As Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma | NCT06423326 |
| Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa | Phase II Trial of Paclitaxel Combined With Trastuzumab and Pertuzumab as Pre-Operative Therapy for Inflammatory Breast Cancer | NCT01796197 |
| Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer | A Phase II Study Evaluating Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel in the First Line Treatment of Surgically Unresectable/Metastatic Pancreatic Cancer | NCT01851174 |
| A study to evaluate the safety and feasibility of a new drug-coated balloon treatment for patients with coronary artery narrowing | Clinical feasibility and safety of a novel paclitaxel-coated balloon using shellac and vitamin E excipient for the treatment of de novo coronary artery lesions: a prospective, single-arm pilot study | ISRCTN16327473 |
| A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer | A Multicenter, Randomized, Open-label, Active-controlled, Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine Versus Nab-paclitaxel Plus Gemcitabine as the First-line Treatment in Metastatic Pancreatic Cancer | NCT06361888 |
| A Clinical Study of Adebrelimab Combined With Apatinib and Paclitaxel in Patients With Advanced Gastric Cancer. | A Phase II Clinical Study of Adebrelimab Injection in Combination With Apatinib and Paclitaxel for Injection (Albumin-bound) as Second-line Therapy in Patients With Advanced Gastric Cancer Who Had Previously Received Immunotherapy. | NCT06339216 |
| Bioequivalence (BE) study of Paclitaxel 100mg/vial with ABRAXANE® 100mg/vial in subject with metastatic Breast cancer after failure of combination chemotherapy or relapse within 6 months of adjuvant chemotherapy. | An open label, multi-center, randomized, two-treatment, two period, two-sequence, two-way cross-over, single dose, Bioequivalence (BE) study with pharmacokinetic (PK) endpoints of Paclitaxel 100mg/vial injectable suspension at a dose of 260 mg/m2 of Anbison Lab, China with ABRAXANE® 100mg/vial for Injectable suspension at a dose of 260 mg/m2 of Celgene Corporation Summit, NJ 07901 in subject with metastatic Breast cancer after failure of combination chemotherapy or relapse within 6 months of adjuvant chemotherapy. - NIL | CTRI/2024/03/064383 |
| Phase I Study of Nanoparticle albumin-bound paclitaxel and Cyclophosphamide combination chemotherapy for Patients with Metastatic Breast Cancer(GBCCSG-02) | Phase I Study of Nanoparticle albumin-bound paclitaxel and Cyclophosphamide combination chemotherapy for Patients with Metastatic Breast Cancer(GBCCSG-02) - Phase I Study of AbraC for MBC (GBCCSG-02) | JPRN-UMIN000009973 |
| Low-dose radiotherapy combined with serplulimab and albumin paclitaxel plus cisplatin neoadjuvant therapy for locally advanced esophageal cancer: a single-arm, prospective phase II clinical study | Low-dose radiotherapy combined with serplulimab and albumin paclitaxel plus cisplatin neoadjuvant therapy for locally advanced esophageal cancer: a single-arm, prospective phase II clinical study | ChiCTR2400082050 |
| Role of L-carnitine in treating myopathy and peripheral neuropathy caused by paclitaxel in breast cancer patients. | Effectiveness of L-carnitine on paclitaxel induced myopathy and peripheral neuropathy in breast cancer patients : A randomized, double blind, placebo-controlled trail. - - | CTRI/2024/03/064164 |
| A RANDOMIZED, MULTICENTER, ADAPTIVE PHASE II/III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE (T-DM1) VERSUS TAXANE (DOCETAXEL OR PACLITAXEL) IN PATIENTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC HER2-POSITIVE GASTRIC CANCER, INCLUDING ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION | A RANDOMIZED, MULTICENTER, ADAPTIVE PHASE II/III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE (T-DM1) VERSUS TAXANE (DOCETAXEL OR PACLITAXEL) IN PATIENTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC HER2-POSITIVE GASTRIC CANCER, INCLUDING ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION | PER-118-12 |
| A Phase I trial of AZD2014 in combination with paclitaxel | TAX-TORC: A Phase I multi-centre trial of the combination of AZD2014 (dual TORC1 and TORC2 inhibitor) and weekly paclitaxel in patients with solid tumours - A Phase I trial of AZD2014 in combination with paclitaxel | EUCTR2012-003896-20-GB |
| A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer | A Phase 2, Multicenter, Open-label, Single Arm Study of Dostarlimab Plus Carboplatin-paclitaxel Followed by Dostarlimab Monotherapy in Japanese Patients With Primary Advanced or Recurrent Endometrial Cancer (RUBY-J) | NCT06317311 |
| First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients | A Multicenter,Open-label,Exploratory Study of QL1706 Plus Nab-paclitaxel and Gemcitabine With or Without Bevacizumab as First-line Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer | NCT06313970 |
| A Study to Assess the Safety and Performance of Balloon Catheter in Superficial Femoral and Popliteal Arteries | A Prospective, Multicenter, Single Arm, Post-Market Study to Assess the Clinical Safety and Performance of Peripherics Paclitaxel-coated PTA Balloon Catheter in Superficial Femoral and Popliteal Arteries - Nil | CTRI/2024/03/063744 |
| Sequential Cisplatin/Paclitaxel and Tislelizumab as neoadjuvant therapy for locally advanced cervical cancer: an open-label, single-center, single-arm phase II trial | Sequential Cisplatin/Paclitaxel and Tislelizumab as neoadjuvant therapy for locally advanced cervical cancer: an open-label, single-center, single-arm phase II trial | ChiCTR2400081548 |
| Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors | A Phase Ib/II Study of Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced Solid Tumors | NCT06320405 |
| Phase III Clinical Study of ABI-007 | Randomized, phase III, comparative study of every-3-weeks dosing, weekly dosing of ABI-007, and weekly dosing of the conventional paclitaxel for patients with unresectable/recurrent gastric cancer refractory to prior chemotherapy containing fluoropyrimidines. | JPRN-jRCT2080222013 |
| A Phase II trial of ginisortamab in participants with metastatic pancreatic ductal adenocarcinoma | A Cancer Research UK Phase II open label trial in participants with metastatic pancreatic ductal adenocarcinoma of ginisortamab given intravenously i) with first-line standard of care nab-paclitaxel and gemcitabine, or ii) in combination with MEK inhibitor maintenance therapy | ISRCTN63154609 |
| Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer | Phase II Open-label, Single-arm Trial of Neoadjuvant Pembrolizumab With Carboplatin and Paclitaxel in Triple-negative Breast Cancer | NCT06407310 |
| Effect of Electroacupuncture Combined With Paclitaxel Clinical Efficacy of Patients With Recurrence of High-grade Glioma | Specific Model Electroacupuncture Stimulation Promotes Paclitaxel Delivery Across the BBB for Postoperative Glioma Patients: A Randomized Controlled Study | NCT06330337 |
| A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) | A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) | JPRN-jRCT2061230102 |
| This study is to understand how well an investigational drug (called Napabucasin) works when given in combination with chemotherapy treatment for people with pancreatic cancer after prior chemotherapy. | A Phase II/III Randomized, Open-Label Clinical Study of Napabucasin in Combination with Weekly Paclitaxel and Low-dose Gemcitabine in Patients with Metastatic Pancreatic Cancer Following Chemotherapy Failure - STEMNESS-PANC | CTIS2024-518205-17-00 |
| Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer | A Phase I/Ib Study of Paclitaxel in Combination With VS-6063, a Focal Adhesion Kinase Inhibitor, in Subjects With Advanced Ovarian Cancer | NCT01778803 |
| Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations | A Prospective, Single-arm Study of Adebrelimab in Combination With Paclitaxel for Injection (Albumin Bound) and Platinum Chemotherapy as Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) Harboring Driver Gene Mutations | NCT06299371 |
| A Phase 2 clinical study to assess efficacy of induction carboplatin/paclitaxel + pembrolizumab for locoregionally advanced penile cancer: PRIAM | A Phase 2 clinical study to assess efficacy of induction carboplatin/paclitaxel + pembrolizumab for locoregionally advanced penile cancer: PRIAM - N22APC | CTIS2023-506731-15-00 |
| Phase 1 trial of Nab-paclitaxel and Gemcitabine for metastatic breast cancer | Phase 1 trial of Nab-paclitaxel and Gemcitabine for metastatic breast cancer - Phase 1 trial of Nab-paclitaxel and Gemcitabine for metastatic breast cancer | JPRN-UMIN000010125 |
| A Feasibility Study of Chemo-radiotherapy to Treat Operable Oesophageal Cancer | A Randomised Phase II Study of Two Pre-operative Chemoradiotherapy Regimens (Oxaliplatin and Capecitabine Followed by Radiotherapy With Either Oxaliplatin and Capecitabine or Paclitaxel and Carboplatin) for Resectable Oesophageal Cancer | NCT01843829 |
| Neoadjuvant chemotherapy with Paclitaxel/Bevacizumab followed by FEC (5-Fluorouracil/Epirubicin/Cyclophosphamide) for triple negative operable primary breast cancer | Neoadjuvant chemotherapy with Paclitaxel/Bevacizumab followed by FEC (5-Fluorouracil/Epirubicin/Cyclophosphamide) for triple negative operable primary breast cancer - Neoadjuvant Paclitaxel/Bevacizumab followed by FEC therapy for triple negative breast cancer | JPRN-UMIN000010228 |
| A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma | A Randomized, Double-blind, Phase 3 Study Of Cadonilimab (AK104) Plus Pulocimab (AK109) And Paclitaxel Versus Paclitaxel In Patients With Advanced Gastric Or Gastroesophageal Junction Adenocarcinoma Who Failed First-line Immunochemotherapy | NCT06341335 |
| Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC | Prospective, Single-arm, Phase II Clinical Study of Tirellizumab Combined With Carboplatin and Paclitaxel Polymer Micelles Neoadjuvant Therapy for cN+ Head and Neck Squamous Cell Carcinoma | NCT06366945 |
| Investigating Paclitaxel Toxicity in Breast Cancer: the Roles of Physical Activity and Body Composition. | Dose-limiting Toxicities of Paclitaxel in Breast Cancer Patients: Studying Interactions Between Pharmacokinetics, Physical Activity, and Body Composition: an Observational Pilot Study. | NCT06387901 |
| Real-world Data of Paclitaxel and Ramucirumab Compared to Other Treatment Regimens in Advanced Gastric Cancer | Real-world Efficacy and Toxicity Data of the Combination of Paclitaxel and Ramucirumab Compared to Other Treatment Regimens in Patients With Advanced Gastric Cancer | NCT06666582 |
| A Prospective, Single-arm Study of Adebrelimab in Combination With Paclitaxel for Injection (Albumin Bound) and Platinum Chemotherapy as Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) Harboring Driver Gene Mutations | A Prospective, Single-arm Study of Adebrelimab in Combination With Paclitaxel for Injection (Albumin Bound) and Platinum Chemotherapy as Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) Harboring Driver Gene Mutations | ChiCTR2400082754 |
| PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients | A Phase II Study on the Safety and Efficacy of PD-1 Combined With Nab-paclitaxel/Gemcitabine and PULSAR in the Treatment of Locally Advanced Unresectable Pancreatic Cancer and Local Recurrence After Surgery. | NCT06359275 |
| A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined with Cadonilimab As a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma | A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection and Cisplatin Combined with Cadonilimab As a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma: a Single-Arm, Single-Center, Prospective Clinical Trial (POINTS Trial) | NCT06356688 |
| SPAGO: Sirolimus Paclitaxel Angiographic Gain Objective | Selution Sirolimus Coated Balloon (MedAlliance) Versus SeQuent Please Neo Paclitaxel Coated Balloon (Bbraun) for the Treatment of De Novo Coronary Artery Lesions in Medium-small Size Vessels. | NCT06373601 |
| Neoadjuvant Adebrelimab plus SOX and Nab-paclitaxel in Resectable Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: A Multicentre, Single-arm, Prospective Phase II Trial | Neoadjuvant Adebrelimab plus SOX and Nab-paclitaxel in Resectable Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: A Multicentre, Single-arm, Prospective Phase II Trial | ChiCTR2400082697 |
| Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer | An Exploratory Clinical Study of Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Patients With Locally Advanced Pancreatic Cancer | NCT06361030 |
| A prospective, single arm, multicenter, phase II clinical study of the combination of anlotinib and albumin bound paclitaxel for second-line treatment of advanced gastric cancer | A prospective, single arm, multicenter, phase II clinical study of the combination of anlotinib and albumin bound paclitaxel for second-line treatment of advanced gastric cancer - A clinical study on the combination of anlotinib and albumin bound paclitaxel as second-line treatment for advanced gastric cancer | ChiCTR2400082534 |
| Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer | The Feasibility of Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer | NCT01827163 |
| Nab-paclitaxel Combined With Cadonilimab (AK104) for the Second-line Treatment of Advanced Gastric Cancer | Nab-paclitaxel Combined With Cadonilimab (AK104) for the Second-line Treatment of Advanced Gastric Cancer: A Prospective, Multicenter, Single-arm, Phase II Study | NCT06349967 |
| Study of Dato-DXd With or Without Durvalumab Compared With Investigators Choice of Chemotherapy in Combination With Pembrolizumab as first line therapy for Locally Recurrent Inoperable or Metastatic Breast Cancer | A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigatorâ??s Choice of Chemotherapy (Paclitaxel, Nab paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD L1 Positive Locally Recurrent Inoperable or Metastatic Triple negative Breast Cancer (TROPION Breast- 05) - TROPION Breast- 05 | CTRI/2024/04/065629 |
| Evaluation of Lymphadenectomy and Chemotherapy TIP (paclitaxel, ifosfamide and cisplatin) on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis | MEGACEP_Prospective Phase II Study Evaluating a Multimodal Care of Inguinal Node Metastasis in Squamous Cell Carcinoma of the Penis by Bilateral Lymphadenectomy and Chemotherapy TIP - UC_0160/1406 | CTIS2024-512827-36-00 |
| Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors | Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Weekly Paclitaxel, With or Without Bevacizumab, in Patients With Selected Advanced Solid Tumors | NCT01831089 |
| An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors | A Phase 1b Study of the Safety and Tolerability of Ruxolitinib in Combination With Gemcitabine With or Without Nab-Paclitaxel in Subjects With Advanced Solid Tumors | NCT01822756 |
| IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer | Tailored Neoadjuvant Epirubicin and Cyclophosphamide (EC) and Nanoparticle Albumin Bound (Nab) Paclitaxel for Newly Diagnosed Breast Cancer | NCT01830244 |
| Clinical study of pyrrolitinib maleate tablets combined with albumin paclitaxel in adjuvant treatment of HER2 positive early breast cancer | Single arm, multicenter, phase II clinical study of pyrrolinib maleate tablets combined with albumin paclitaxel in adjuvant treatment of HER2 positive early breast cancer | ChiCTR2400082388 |
| Drug-coated angioplasty balloons for subjects with constriction or blockage in the leg arteries, specifically the Superficial Femoral or Popliteal Arteries: A pharmacokinetic study. | ProspectIve, SingLe-Arm, MuLti-Center, Pharmacokinetic Study to EvalUate TreatMent of Obstructive SupErficial Femoral Artery or Popliteal LesioNs With A Novel PacliTaxel-CoatEd Percutaneous Angioplasty Balloon | ACTRN12613000336785 |
| Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel | A Pilot Randomized, Placebo Controlled, Double Blind Study of Omega-3 Fatty Acids to Prevent Paclitaxel Associated Acute Pain Syndrome | NCT01821833 |
| Phase II study of Carboplatin plus weekly nab-paclitaxel in elderly patients with non-small cell lung cancer | Phase II study of Carboplatin plus weekly nab-paclitaxel in elderly patients with non-small cell lung cancer - CBDCA/ weekly nab-PTX for elderly NSCLC patients | JPRN-UMIN000010324 |
| Paclitaxel Eluting Balloon in St Elevation Myocardial Infarction | Study to Evaluate the Efficacy and Safety of Paclitaxel Eluting Balloon in St Elevation Myocardial Infarction After Bare Metal Stent Insertion | NCT01839890 |
| Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer | A Dose-finding Phase Ib Study Followed by a Randomized, Double-blind Phase II Study of Carboplatin and Paclitaxel With or Without Buparlisib in Patients With Previously Untreated Metastatic Non-small Cell Lung Cancer (NSCLC) of Squamous Histology | NCT01820325 |
| Preventive effect of Vitamin E in Taxol induced neuropathy | Evaluation of the Vitamin E effect in Taxol induced neuropathy reduction among patients with breast cancer | IRCT2015122725716N1 |
| Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer | "Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer "" ETNA (Evaluating Treatment With Neoadjuvant Abraxane)" | NCT01822314 |
| NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer | NeoPHOEBE: Pi3k Inhibition in Her2 OverExpressing Breast cancEr: A Phase II, Randomized, Parallel Cohort, Two Stage, Double-blind, Placebo-controlled Study of Neoadjuvant Trastuzumab Versus Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive, PIK3CA Wild-type and PIK3CA Mutant Primary Breast Cancer | NCT01816594 |
| A study of dostarlimab in combination with carboplatin-paclitaxel in Japanese participants with primary advanced or recurrent endometrial cancer | A phase 2, multicenter, open-label, single arm study of dostarlimab plus carboplatin-paclitaxel followed by dostarlimab monotherapy in Japanese patients with primary advanced or recurrent endometrial cancer (RUBY-J) - RUBY-J | JPRN-jRCT2061230114 |
| Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer | A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Study Comparing Tivozanib Hydrochloride in Combination With Paclitaxel v Placebo in Combination With Paclitaxel in Locally Recurrent and/or Metastatic Triple Negative Breast Cancer | NCT01745367 |
| A randomised Phase II study of two pre-operative chemoradiotherapy regimes (oxaliplatin and capecitabine followed by radiotherapy with either oxaliplatin and capecitabine or paclitaxel and carboplatin) for resectable oesophageal cancer. | A randomised Phase II study of two pre-operative chemoradiotherapy regimes (oxaliplatin and capecitabine followed by radiotherapy with either oxaliplatin and capecitabine or paclitaxel and carboplatin) for resectable oesophageal cancer. - NeoSCOPE: Neo-adjuvant Study of Chemoradiotherapy in OesoPhagEal Cance | EUCTR2012-000640-10-GB |
| A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer | A Phase I-II Study to Assess the Safety, Efficacy and Pharmacokinetic Profile of HM781-36B Combined With Paclitaxel and Trastuzumab in Patients With HER-2 Positive Advanced Gastric Cancer | NCT01746771 |
| Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery (FLORA-5) | A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) In Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma | CTRI/2022/05/042562 |
| A phase II study of PM8002 injection in combination with paclitaxel injection as second line treatment for small cell lung cancer(SCLC) | A phase II study to evaluate efficacy, safety and pharmacokinetics of PM8002 injection in combination with paclitaxel injection as second line treatment for small cell lung cancer(SCLC) | ChiCTR2200059911 |
| Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C) | Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy, a Randomised Comparison of Trastuzumab vs Trastuzumab+Paclitaxel in Women With HER2-positive Early Breast Cancer Receiving Neoadjuvant Treatment | NCT05388500 |
| Onvansertib + Paclitaxel in TNBC | A Phase 1b/2 Study of Onvansertib in Combination with Paclitaxel in Triple-negative Metastatic Breast Cancer Patients | NCT05383196 |
| LOGIK2102 | Phase II trial of carboplatin + nab-paclitaxel + atezolizumab combination therapy for TTF-1 negative advanced non-squamous non-small cell lung cancer - LOGIK2102 | JPRN-jRCTs071220008 |
| A Prospective, Single-arm, Exploratory Clinical Study of Sintilimab Injection in Combination With Paclitaxel (Albumin-bound) and Gemcitabine in Translational Therapy in Patients With Unresectable Locally Advanced Pancreatic Cancer. | A Prospective, Single-arm, Exploratory Clinical Study of Sintilimab Injection in Combination With Paclitaxel (Albumin-bound) and Gemcitabine in Translational Therapy in Patients With Unresectable Locally Advanced Pancreatic Cancer. | NCT05346146 |
| A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer | A Phase Ib/II Multicenter, Open-Label Clinical Trial of SHR-A1811 Injection in Combination With Pyrotinib or Pertuzumab or Adebrelimab or Paclitaxel for Injection (Albumin Bound) in Breast Cancer | NCT05353361 |
| Neoadjuvant Camrelizumab Plus Albumin-Bound Paclitaxel in Resectable Stage II/III Non-Small Cell Lung Cancer (NSCLC) | Neoadjuvant Camrelizumab Plus Albumin-Bound Paclitaxel in Resectable Stage II/III Non-Small Cell Lung Cancer (NSCLC) | ChiCTR2200058819 |
| Phase II trial of neoadjuvant therapy with paclitaxel and carboplatin in operable locally advanced head and neck cancer patients (NEOS) | Phase II trial of neoadjuvant therapy with paclitaxel and carboplatin in operable locally advanced head and neck cancer patients (NEOS) | KCT0007197 |
| Phase II clinical study of PD-1 inhibitor + albumin paclitaxel + bevacizumab in first-line treatment of relapsed or metastatic triple negative breast cancer | Phase II clinical study of PD-1 inhibitor + albumin paclitaxel + bevacizumab in first-line treatment of relapsed or metastatic triple negative breast cancer | ChiCTR2200058567 |
| A Real-world Registry Investigating Sirolimus-coated Balloon Versus Paclitaxel-coated Balloon Angioplasty for the Treatment of Dysfunctional Arteriovenous Fistula | A Real-world Registry Investigating Sirolimus-coated Balloon Versus Paclitaxel-coated Balloon Angioplasty for the Treatment of Dysfunctional Arteriovenous Fistula | NCT05333640 |
| Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Cancer: A Multicenter Study | A Single-arm, Multicenter, Open Clinical Trial of the Efficacy and Safety of Tislelizumab in Combination With Nab-Paclitaxel for the Perioperative Treatment of Muscle-invasive Bladder Cancer | NCT05328336 |
| Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab | Phase I/II Study of the Combination of Irinotecan and POF (Paclitaxel Plus Oxaliplatin Plus 5-fluorouracil Plus Leucovorin) and Tislelizumab | NCT05319639 |
| Effect of Albumin-bound Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Patients Receiving Neoadjuvant Chemotherapy for Advanced Ovarian, Fallopian Tube or Peritoneal Cancer: A Phase 2 Single Center Clinical Trial | Effect of Albumin-bound Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Patients Receiving Neoadjuvant Chemotherapy for Advanced Ovarian, Fallopian Tube or Peritoneal Cancer: A Phase 2 Single Center Clinical Trial | NCT05316376 |
| Phase II Trial of Ubenimex Combined with Pembrolizumab + nab-Paclitaxel + Carboplatin for Untreated Patients with Advanced Squamous Non-Small Cell Lung Cancer: (UBE-Q) | Phase II Trial of Ubenimex Combined with Pembrolizumab + nab-Paclitaxel + Carboplatin for Untreated Patients with Advanced Squamous Non-Small Cell Lung Cancer: (UBE-Q) - UBE-Q | JPRN-jRCT2031210707 |
| Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab | A Phase II Study of Human Epidermal Growth Factor Receptor 2 (HER-2) Directed Dendritic Cell (DC1) Vaccine Plus Weekly Paclitaxel, Trastuzumab and Pertuzumab in Patients With HER-2 Positive Breast Cancer | NCT05325632 |
| PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer | PLD Plus Cyclophosphamide Followed by Nab-paclitaxel (Nab-P) as Primary Chemotherapy Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer: A Single-arm Phase 2 Trial(Brecan Trial) | NCT05346107 |
| A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer | A Randomized, Double-blind, Parallel-controlled Study Comparing the Efficacy and Safety of Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection (SIBP04) and Bevacizumab Injection (Avastin) in Combination With Paclitaxel and Carboplatin Respectively in Patients With Advanced, Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer. | NCT05318443 |
| Concurrent radiotherapy with weekly paclitaxel and cisplatin chemotherapy followed by surgery in potentially resectable thymic tumor | Concurrent radiotherapy with weekly paclitaxel and cisplatin chemotherapy followed by surgery in potentially resectable thymic tumor | ChiCTR2200057827 |
| Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer | A Single-arm Phase II Study of Envafolimab Combined With Endostar and Nab-paclitaxel Plus Gemcitabine for First-line Treatment of Advanced Pancreatic Cancer | NCT05298020 |
| Trial of Neoadjuvant Therapy With Paclitaxel and Carboplatin in Operable Locally Advanced Head and Neck Cancer Patients | Phase II Trial of Neoadjuvant Therapy With Paclitaxel and Carboplatin in Operable Locally Advanced Head and Neck Cancer Patients (NEOS) | NCT05294900 |
| Efficacy and safety of albumin-bound paclitaxel combined with platinum as first-line chemotherapy for patients with residual tumor after initial reduction in advanced ovarian cancer: a prospective one-arm study and mechanism based on PDX model | Efficacy and safety of albumin-bound paclitaxel combined with platinum as first-line chemotherapy for patients with residual tumor after initial reduction in advanced ovarian cancer: a prospective one-arm study and mechanism based on PDX model | ChiCTR2200057542 |
| Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast Cancer | A Study to Assess the Efficacy and Safety of Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast Cancer | NCT05291910 |
| Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer | Phase I/IB Safety and Pharmacodynamic Study of Neoadjuvant (NACT) Paclitaxel and Carboplatin With Ipatasertib as Initial Therapy of Ovarian Cancer PTMA 100805 | NCT05276973 |
| Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study | Adjuvant AC Followed by Albumin-bound Paclitaxel Versus AC Followed by Taxanes in Breast Cancer: a Prospective, Multi-center, Real-world Study | NCT05287308 |
| A Single-arm, Open-label Phase II Study of Fruquintinib Combined with Nab-paclitaxel as Second-line Therapy for Locally Advanced/Metastatic Gastric or Gastro-esophageal Junction Cancer (GC/GEJC) after Failure of Treatment with Anti-PD-1/PD-L1 Monoclonal Antibody-containing Regimen | A Single-arm, Open-label Phase II Study of Fruquintinib Combined with Nab-paclitaxel as Second-line Therapy for Locally Advanced/Metastatic Gastric or Gastro-esophageal Junction Cancer (GC/GEJC) after Failure of Treatment with Anti-PD-1/PD-L1 Monoclonal Antibody-containing Regimen | ChiCTR2200059976 |
| Two-Part, Phase Ib/II, Open Label, Single-Arm, Multi-center Study to Evaluate the Safety and Efficacy of Varlitinib in Combination With Weekly Paclitaxel in EGFR/HER2 Co-expressing Advanced or Metastatic Gastric Cancer Patients | Two-Part, Phase Ib/II, Open Label, Single-Arm, Multi-center Study to Evaluate the Safety and Efficacy of Varlitinib in Combination With Weekly Paclitaxel in EGFR/HER2 Co-expressing Advanced or Metastatic Gastric Cancer Patients | NCT05400915 |
| A prospective clinical study evaluating the efficacy and safety of tislelizumab combined with nab-paclitaxel and cisplatin induction chemotherapy in the treatment of newly treated locally advanced hypopharyngeal carcinoma | A prospective clinical study evaluating the efficacy and safety of tislelizumab combined with nab-paclitaxel and cisplatin induction chemotherapy in the treatment of newly treated locally advanced hypopharyngeal carcinoma | ChiCTR2200060094 |
| A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers | A Phase 1, Open-Label, Dose Finding Study of NI-1801, a Bispecific Mesothelin X CD47 Engaging Antibody, As a Single Agent, in Combination with Anti-PD-1 Antibody, and in Combination with Weekly Paclitaxel (Standard of Care) in Patients with Mesothelin Expressing Ovarian, Pancreatic, Non-Small-Cell-Lung and Triple-Negative Breast Cancers | NCT05403554 |
| A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Cancer. | A Multicenter Study of Penpulimab and Anlotinib in Combination With Nab-paclitaxel Plus Gemcitabine as First-line Therapy in Patients (Pts) With Metastatic Pancreatic Cancer: PAAG. | NCT05493995 |
| A Phase II clinical study of SHR-1701 combined with albumin paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer with malignant pleural effusion | A Phase II clinical study of SHR-1701 combined with albumin paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer with malignant pleural effusion | ChiCTR2200062197 |
| NIRVANA-1 | A Randomized Study of Paclitaxel - Carboplatin followed by maintenance Niraparib compared to Paclitaxel - Carboplatin - Bevacizumab followed by maintenance Niraparib+Bevacizumab in Patients With Advanced Ovarian Cancer, Following a Front-Line Complete Cytoreductive Surgery - NIRVANA-1 | JPRN-jRCT2031220203 |
| A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors | A Phase 2, Multicenter, Open-Label Basket Study of Navicixizumab Monotherapy or in Combination With Paclitaxel or Irinotecan in Patients With Select Advanced Solid Tumors | NCT05453825 |
| A Study to Assess Bioequivalence of Albumin-Bound-Paclitaxel Formulations in Female Participants with Advanced Breast Cancer | A Randomized, Multi-Center, Open-Label, Single-Dose, Two-Way Crossover Study to Assess Bioequivalence of Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound) of Intas Pharmaceuticals Limited, India Compared with Abraxane® in Female Participants with Advanced Breast Cancer | CTRI/2022/07/043652 |
| QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer | A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate QL1706 Plus Paclitaxel-Cisplatin/Carboplatin With or Without Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer | NCT05446883 |
| Safety and efficacy of multimodality treatment for locally advanced PDAC | Safety and efficacy test of multimodality treatment combining proton beam therapy, hyperthermia, and gemcitabine-nab-paclitaxel therapy for locally advanced pancreatic cancer | JPRN-jRCTs031220160 |
| Study to evaluate the impact of VCN-01 on the overall survival of patients with advanced pancreatic cancer treated with standard therapy. | A Phase IIb, Open-label, Randomized Study of Nab-Paclitaxel and Gemcitabine plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer | EUCTR2022-000897-24-DE |
| SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | A Multicenter, Open Phase Ib Study to Evaluate the Efficacy and Safety of SCT-I10A in Combination With SCT200 or SCT200 in Combination With Paclitaxel/Docetaxel in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | NCT05552807 |
| Intraperitoneal Paclitaxel for Patients With Primary Malignant Peritoneal Mesothelioma | Intraperitoneal Paclitaxel for Patients With Primary Malignant Peritoneal Mesothelioma - a Phase I/II Dose Escalation and Safety Study | NCT05449366 |
| Marble study | Phase II trial of atezolizumab (MPDL3280A) plus carboplatin and paclitaxel in patients with metastatic or recurrent thymic carcinoma | JPRN-jRCT2031220144 |
| An exploratory clinical study of penpulimab combined with anlotinib and albumin paclitaxel in the treatment of recurrent and metastatic head and neck squamous cell carcinoma | An exploratory clinical study of penpulimab combined with anlotinib and albumin paclitaxel in the treatment of recurrent and metastatic head and neck squamous cell carcinoma | ChiCTR2200061237 |
| HR Positive, HER2 Negative Advanced Breast Cancer With Progression After Endocrine Therapy | A Phase II Clinical Study to Evaluate the Safety and Efficacy of Recombinant hLAG-3 Fusion Protein (EOC202) Injection Combined With Albumin-bound Paclitaxel in Treatment of the Patients With HR Positive, HER2 Negative Advanced Breast Cancer With Progression After Endocrine Therapy | NCT05322720 |
| Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer | A Phase 1b Trial of ZEN003694 (ZEN-3694) With Pembrolizumab and Nab-Paclitaxel in Patients With Metastatic Triple-Negative Breast Cancer | NCT05422794 |
| A phase II study of rivoceranib in combination with paclitaxel in patients with advanced gastric and gastroesophageal junction carcinoma | A phase II study of rivoceranib in combination with paclitaxel in patients with advanced gastric and gastroesophageal junction carcinoma | KCT0007392 |
| A single-arm, multicenter, prospective, phase II clinical study of camrelizumab combined with anlotinib hydrochloride and albumin paclitaxel in the first-line treatment of advanced triple-negative breast cancer | A single-arm, multicenter, prospective, phase II clinical study of camrelizumab combined with anlotinib hydrochloride and albumin paclitaxel in the first-line treatment of advanced triple-negative breast cancer | ChiCTR2200060859 |
| Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET | A Phase 2 Study of Iadademstat in Combination With Paclitaxel in Relapsed or Refractory Small Cell Lung Cancer and Extrapulmonary High Grade Neuroendocrine Carcinomas | NCT05420636 |
| Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable: a Multi-center Study | An Open Label, Single-arm, Phase 2 Study of Tislelizumab Combined With Nab-Paclitaxel for Patients With High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable: a Multi-center Study | NCT05418309 |
| Restoring sensitivity to immunotherapy in advanced triple negative breast cancer exploiting Ceralasertib priming followed by combined Durvalumab/Nab-paclitaxel: The ATRiBRAVE Trial. | Restoring sensitivity to immunotherapy in advanced triple negative breast cancer exploiting Ceralasertib priming followed by combined Durvalumab/Nab-paclitaxel: The ATRiBRAVE Trial. - ATRiBRAVE Trial | EUCTR2022-001669-11-IT |
| A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unresectable/metastatic Mucosal Melanoma | A Multicenter, Single-arm, Open-label Phase II Study to Evaluate the Efficacy and Safety of YH003 in Combination with Pebolizumab and Albumin Paclitaxel in First-line Treatment of Patients with Unresectable/metastatic Mucosal Melanoma | NCT05420324 |
| Exploratory study of camrelizumab combined with nab-paclitaxel and platinum in neoadjuvant therapy for resectable esophageal squamous cell carcinoma | Exploratory study of camrelizumab combined with nab-paclitaxel and platinum in neoadjuvant therapy for resectable esophageal squamous cell carcinoma | ChiCTR2200060652 |
| Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma | A Phase III, Randomized, Open-Label, Non-Inferiority Study of Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma in Resource-Limited Settings | NCT05411237 |
| iPac-02 trial | Phase II clinical trial of intraperitoneal paclitaxel combined with conventional chemotherapy for colorectal cancer with peritoneal metastases - iPac-02 trial | JPRN-jRCT2031220110 |
| Vascular Effects Through Sirolimus vs. Paclitaxel DCB Implantation | Scientific Proposal to Substantiate Vascular Effects Through Sirolimus vs. Paclitaxel DCB Implantation | NCT05450042 |
| Bevacizumab Plus Nab-paclitaxel and Platinum for Immunotherapy-treated Non-squamous Non-small Cell Lung Cancer | BEvacizumab Plus Nab-pacliTaxel and plaTinum as sEcond-line theRapy for Driver-gene-negative Non-squamous Non-small Cell Lung Cancer Progressed After First-line Immune Checkpoint Inhibitor-based Regimen | NCT05407155 |
| Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) and Electrostatic PIPAC (ePIPAC) With Paclitaxel In Patients With Peritoneal Carcinomatosis | Phase 1 Study of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) and Electrostatic PIPAC (ePIPAC) With Paclitaxel for Peritoneal Carcinomatosis - PIPAC2 Study | NCT05395910 |
| Single center, single arm, phase II clinical trial of albumin-bound paclitaxel combined with cisplatin as neoadjuvant therapy for locally advanced cervical cancer | Single center, single arm, phase II clinical trial of albumin-bound paclitaxel combined with cisplatin as neoadjuvant therapy for locally advanced cervical cancer | ChiCTR2200061128 |
| A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer. | A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer. | NCT05497778 |
| A prospective clinical study evaluating pembrolizumab combined with chemotherapy (cisplatin or carboplatin + nab-paclitaxel) in first-line treatment of patients with recurrent and metastatic squamous cell carcinoma of the nasal cavity and paranasal sinuses | A prospective clinical study evaluating pembrolizumab combined with chemotherapy (cisplatin or carboplatin + nab-paclitaxel) in first-line treatment of patients with recurrent and metastatic squamous cell carcinoma of the nasal cavity and paranasal sinuses | ChiCTR2200057343 |
| Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel in Gastric Cancer | Safety of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel in Gastric Cancer Patients with Peritoneal Metastasis | KCT0007061 |
| Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients | Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in Triple-negative Metastatic Breast Cancer Patients | NCT05174832 |
| A clinic trial of PD-1 blockade combined with albumin paclitaxel and gemcitabine in the hepatic metastasis of pancreatic ductal adenocarcinoma | A clinic trial of PD-1 blockade combined with albumin paclitaxel and gemcitabine in the hepatic metastasis of pancreatic ductal adenocarcinoma | ChiCTR2100054202 |
| Albumin-Bound Paclitaxel Combined with Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC | A Prospective, Randomized, Open Label Clinical Study Evaluating Efficacy and Safety of Albumin-Bound Paclitaxel Combined with Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic Triple Negative Breast Cancer | NCT05192798 |
| Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment | Phase II Trial of Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment | NCT05170438 |
| A prospective, open, single-arm, real-world study comparing the results of the WSG-Adapt HER-2+ series of weekly paclitaxel combined with dual target neoadjuvant therapy for breast cancer with POSITIVE HER-2 | A prospective, open, single-arm, real-world study comparing the results of the WSG-Adapt HER-2+ series of weekly paclitaxel combined with dual target neoadjuvant therapy for breast cancer with POSITIVE HER-2 | ChiCTR2100054127 |
| Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer | Efficacy and Safety of the Combination of Cisplatin Plus Nab-paclitaxel and Nivolumab With Radiotherapy After Maximal Tumor Resection in Non-metastatic Muscle Invasive Bladder Cancer. | NCT05203913 |
| A Multicenter, Randomized, Open, Parallel Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2450 Injection Combined With Androtinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment in the Treatment of Recurrent Platinum-resistant Ovarian Cancer | A Multicenter, Randomized, Open, Parallel Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2450 Injection Combined With Androtinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment in the Treatment of Recurrent Platinum-resistant Ovarian Cancer | NCT05145218 |
| Niraparib with BeVAcizumab After Complete CytoreductioN in Patients with OvArian Cancer | Randomized Study of Paclitaxel-carboplatin Followed by Niraparib Compared to Paclitaxel-carboplatin-bevacizumab Followed by Niraparib+bevacizumab in Patients with Advanced Ovarian Cancer, Following a Front-line Complete Surgery | NCT05183984 |
| A placebo-controlled, double-blind crossover study investigating the ameliorative effect of shakuyakukanzoto on paclitaxel (Tri-weekly)-induced muscle pain and arthralgia | A placebo-controlled, double-blind crossover study investigating the ameliorative effect of shakuyakukanzoto on paclitaxel (Tri-weekly)-induced muscle pain and arthralgia | JPRN-jRCT2041210101 |
| Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC | Neoadjuvant Toripalimab and Albumin Paclitaxel /Cisplatin Versus Docetaxel/ Cisplatin/ 5-fluorouracil (TPF) on Pathological Response in Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma | NCT05125055 |
| Intraperitoneal Paclitaxel-loaded TPM for Treatment of Peritoneal Carcinomatosis | Phase I Trial of Intraperitoneal Paclitaxel-loaded Tumor Penetrating Microparticles (TPM) for Treatment of Peritoneal Carcinomatosis | NCT05159050 |
| A study to compare study medication Sacituzumab Govitecan with Standardof Care medications (Paclitaxel, Docetaxel or Vinflunine) in Metastatic (spread to other locations in the body) or Locally Advanced Unresectable (cannot be removed surgically) Urothelial (urinary system) Cancer which has progressed or returned after prior treatments with platinum containing chemotherapy and immunotherapy | A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer | EUCTR2020-002964-29-IE |
| Study of Navicixizumab Plus Paclitaxel and Navicixizumab Monotherapy in Comparison to Paclitaxel Monotherapy in Patients with Platinum-Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | A Phase 3 Multicenter, Open-Label, Randomized Study of Navicixizumab Plus Paclitaxel and Navicixizumab Monotherapy in Comparison to Paclitaxel Monotherapy in Patients with Platinum-Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer - REVELARE | EUCTR2021-001933-38-ES |
| Preventive effect of Goshajinkigan against CIPN with paclitaxel: an open-label, randomized, phase II study | Preventive effect of Goshajinkigan against peripheral neuropathy induced by paclitaxel-containing chemotherapy: an open-label, randomized, phase II study - OLCSG2101 GJG-trial | JPRN-jRCTs061210047 |
| A phase 1b/2 study of tepotinib in combination with paclitaxel in patients with MET amplified or MET exon 14 alterated advanced gastric and gastroesophageal junction carcinoma | A phase 1b/2 study of tepotinib in combination with paclitaxel in patients with MET amplified or MET exon 14 alterated advanced gastric and gastroesophageal junction carcinoma | KCT0006691 |
| Exploratory clinical study of cindilimab combined with S-1 oral plus paclitaxel injection intravenous and intraperitoneal infusion chemotherapy in the treatment of peritoneal metastasis and transformation of gastric cancer | Exploratory clinical study of cindilimab combined with S-1 oral plus paclitaxel injection intravenous and intraperitoneal infusion chemotherapy in the treatment of peritoneal metastasis and transformation of gastric cancer | ChiCTR2100052478 |
| Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65) | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96/ENGOT-ov65) | NCT05116189 |
| Pharmacokinetic, Safety, and Efficacy Studyof SPARCs Paclitaxel Injection Concentrate for Nano-Dispersion (PICN) in subjects with Solid Tumors and With or Without HepaticImpairment. | A Phase 1, Open Label, Dose-Ranging Pharmacokinetic, Safety, and Efficacy Studyof Paclitaxel Injection Concentrate for Nano-Dispersion (PICN) Administered EveryThree Weeks In Subjects with Solid Tumors and With or Without HepaticImpairment. | CTRI/2021/10/037602 |
| Evaluating the effectiveness of combining intensity-modulated radiotherapy technique and paclitaxel plus cisplatin chemotherapy into the treatment of high-risk inoperable cervical cancer | Concurrent definitive chemoradiation incorporating intensity-modulated radiotherapy followed by adjuvant chemotherapy in high risk locally advanced cervical squamous cancer: A phase II study. | ISRCTN53385401 |
| Efficacy and safety of SHR-1210, Apatinib and nab-paclitaxel in the second-line treatment of recurrent / metastatic cervical cancer: a single arm, exploratory study | Efficacy and safety of SHR-1210 combined with Apatinib and Paclitaxel(albumin bound) in the second-line treatment of recurrent / metastatic cervical cancer: a single arm, exploratory study | ChiCTR2100052395 |
| A prospective, single-center, observational study of PD1 monoclonal antibody in combination with SOX versus albumin paclitaxel in combination with SOX after radical surgery for locally progressive gastric cancer with high TSP | A prospective, single-center, observational study of PD1 monoclonal antibody in combination with SOX versus albumin paclitaxel in combination with SOX after radical surgery for locally progressive gastric cancer with high TSP | ChiCTR2100052315 |
| A Phase I/II Study of necitumumab + carboplatin + nab-paclitaxel + pembrolizumab for previously untreated advanced squamous non-small cell lung cancer study | A Phase I/II Study of necitumumab + carboplatin + nab-paclitaxel + pembrolizumab for previously untreated advanced squamous non-small cell lung cancer study - NEXUS | JPRN-jRCT2031210387 |
| Second-Line treatment of nab-paclitaxel combined with sintilimab in advanced biliary tract cancer: an exploratory study | Second-Line treatment of nab-paclitaxel combined with sintilimab in advanced biliary tract cancer: an exploratory study | ChiCTR2100052118 |
| Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax | Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax | NCT05092373 |
| """Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients""" | """Evaluation of the Effect of Pentoxifylline on the Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients""" | NCT05189535 |
| A single-arm, open-label phase II clinical study of nab-paclitaxel combined with anlotinib in platinum-resistant recurrent ovarian cancer | A single-arm, open-label phase II clinical study of nab-paclitaxel combined with anlotinib in platinum-resistant recurrent ovarian cancer | ChiCTR2100054329 |
| SHR6390 Plus Nab-paclitaxel and Gemcitabine in Advanced/Metastatic Pancreatic Cancer | A Phase II Study of SHR6390 Plus Nab-paclitaxel and Gemcitabine in Unresectable Advanced/Metastatic Pancreatic Ductal Adenocarcinoma | NCT05185869 |
| A single arm, prospective II phase clinical trial of the combination of SintilimAb and albumin bound paclitaxel+capecitabine followed by SintilimAb+capecitabine in the maintenance treatment of the metastatic triple negative breast cancer patients | A single arm, prospective II phase clinical trial of the combination of SintilimAb and albumin bound paclitaxel+capecitabine followed by SintilimAb+capecitabine in the maintenance treatment of the metastatic triple negative breast cancer patients | ChiCTR2100054545 |
| Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer | Phase IV Single-arm Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer | NCT05183126 |
| Phase II trial of pembrolizumab in combination with paclitaxel in the hormone receptor-positive metastatic breast cancer with high tumor mutational burden selected by whole exome sequencing: Korean Cancer Study Group trial | Phase II trial of pembrolizumab in combination with paclitaxel in the hormone receptor-positive metastatic breast cancer with high tumor mutational burden selected by whole exome sequencing: Korean Cancer Study Group trial | KCT0007042 |
| S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC | A Phase 1/2, Open -Label, Multicenter Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antineoplastic Activity of S095033 (MAT2A Inhibitor) in Combination With Paclitaxel in Participants With Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) | NCT05312372 |
| Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCC | Induction Therapy With Nab-paclitaxel, Cisplatin and Pembrolizumab in Untreated Locally Advanced Head and Neck Squamous Cell Carcinoma | NCT05272696 |
| Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma | NCT05256225 |
| A randomized, double-blind, phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) | A randomized, double-blind, phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) - NIS793B12301 | NL-OMON51502 |
| Phase I/II study of Second-lIne therapy of preoperative cheMoradiothERApy with gemcitabine and nab-paclitaxel for locally advanced pancreatic canceR (SIMERAR trial) | Phase I/II study of Second-lIne therapy of preoperative cheMoradiothERApy with gemcitabine and nab-paclitaxel for locally advanced pancreatic canceR (SIMERAR trial) - Phase I/II study of Second-lIne therapy of preoperative cheMoradiothERApy with gemcitabine and nab-paclitaxel for locally advanced pancreatic canceR (SIMERAR trial) | JPRN-UMIN000046618 |
| A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer | A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Stage I-III HER2 Negative Breast Cancer | NCT05275777 |
| Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy | A Phase 2 Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy | NCT05283226 |
| A prospective, open, multi-center clinical study of pyrotinib combined with trastuzumab and nab-paclitaxel in neoadjuvant treatment for stage II-III HER2-positive breast cancer patients | A prospective, open, multi-center clinical study of pyrotinib combined with trastuzumab and nab-paclitaxel in neoadjuvant treatment for stage II-III HER2-positive breast cancer patients | ChiCTR2200056592 |
| Preoperative chemoradiation with cisplatin-irrinotecan compared with carboplatin-paclitaxel in esophageal cancer. | Comparison of the efficacy and the toxicity of two chemoradiation protocols of cisplatin-irinotecan and carboplatin-paclitaxol, in operable esophageal cancer. | IRCT20141102019783N5 |
| Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer | A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel Versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA) | NCT05257408 |
| Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma | Phase II, Neoadjuvant Study of Parasympathetic Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Borderline Resectable Pancreatic Adenocarcinoma | NCT05241249 |
| Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases | Safety of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Biliary Tract Cancer Patients With Peritoneal Metastases | NCT05285358 |
| Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer | An Open-label, Dose-finding, Phase Ib Study to Assess the Safety, Tolerability of JPI-547, a Dual Inhibitor of PARP/Tankyrase, in Combination With Modified FOLFIRINOX (mFOLFIRINOX) or Gemcitabine-nab-paclitaxel (GemAbraxne) in Patients With Locally Advanced and Metastatic Pancreatic Cancer | NCT05257993 |
| Combination of Serabelisib and Insulin Suppressing Diet with or Without Nab-paclitaxel in Subjects with Advanced Solid Tumors with PIK3CA Mutations | A Phase 1b Study of Serabelisib in Combination with an Insulin Suppressing Diet (Study ISD) and with or Without Nab-paclitaxel in Adult Subjects with Advanced Solid Tumors with PIK3CA Mutations with or Without PTEN Loss | NCT05300048 |
| A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients | A Phase ?b/? Clinical Study on the Open-label and Multiple Centers of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients | NCT05214976 |
| To evaluate the efficacy and safety of pabolizumab combined with cisplatin and paclitaxel in the neoadjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma | To evaluate the efficacy and safety of pabolizumab combined with cisplatin and paclitaxel in the neoadjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma | ChiCTR2200055719 |
| Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer | A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma | NCT05254171 |
| Paclitaxel-Coated Balloon Versus Zotarolimus-Eluting Stent for Treatment of De Novo Coronary Artery Lesions | Paclitaxel-Coated Balloon Versus Zotarolimus-Eluting Stent for Treatment of De Novo Coronary Artery Lesions: an Open-label, Multicenter, Randomized, Non-inferiority Trial | NCT05209412 |
| HER2Pro 1B - Addition of prochlorperazine to paclitaxel, trastuzumab, and pertuzumab for previously untreated HER2-positive metastatic breast cancer: a phase 1 dose de-escalation study | Addition of prochlorperazine to paclitaxel, trastuzumab, and pertuzumab for previously untreated HER2-positive metastatic breast cancer: a phase 1 dose de-escalation study | ACTRN12622000016730 |
| Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer | Phase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer | NCT05185947 |
| A single-arm, multicenter, prospective, phase II clinical study of AK105 combined with anlotinib hydrochloride and nab-paclitaxel in the first-line treatment of advanced triple-negative breast cancer | A single-arm, multicenter, prospective, phase II clinical study of AK105 combined with anlotinib hydrochloride and nab-paclitaxel in the first-line treatment of advanced triple-negative breast cancer | ChiCTR2100054980 |
| Albumin-bound Paclitaxel Plus Camrelizumab for Advanced Soft Tissue Sarcoma. | Albumin-bound Paclitaxel Plus Camrelizumab Therapy in Locally Unresectable or Metastatic Soft Tissue Sarcomas After Failure of First Line Chemotherapy: a Single Institution, Open-label, Phase 2 Trial | NCT05189483 |
| JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma | JS001 Combined With Nab-paclitaxel and Cisplatin or Carboplatin as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma : a Prospective, Single Arm, Single Center, Phase II Clinical Trial | NCT05173246 |
| Testing the addition of the immunotherapy drug pembrolizumab to the usual chemotherapy treatment (paclitaxel and carboplatin) in endometrial cancer | A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475) in addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer (NCT # 03914612) - NRG-GY018 | JPRN-jRCT2031210512 |
| To Compare the Efficacy and Safety of BP102 vs. Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLC | To Compare the Efficacy and Safety of BP102 in Combination With Paclitaxel/Carboplatin and Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLC - a Randomized, Double-blind, Positive Parallel Control, Multicentre Phase III Clinical Trial | NCT05169801 |
| Efficacy and safety of intravenous and intraperitoneal paclitaxel plus oral S-1 in gastric cancer patients with peritoneal metastasis | Efficacy and safety of intravenous and intraperitoneal paclitaxel plus oral S-1 in gastric cancer patients with peritoneal metastasis | ChiCTR2200056029 |
| Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis | Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis | NCT06519591 |
| A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma | IntenSify: an Open-label Phase I Trial of the CYP3A Inhibitor Cobicistat and the Cytostatics Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma to Evaluate the Combination's Pharmacokinetics, Safety and Efficacy | NCT05494866 |
| Clinical study of transformation treatment of tislelizumab combined with albumin paclitaxel and S-1 in patients with unresectable locally advanced and metastatic gastric cancer | Clinical study of transformation treatment of tislelizumab combined with albumin paclitaxel and S-1 in patients with unresectable locally advanced and metastatic gastric cancer | ChiCTR2200062653 |
| GEM+Nab-Paclitaxel Plus Losartan Followed by Stereotactic Radiotherapy for Locally Advanced Pancreatic Cancer | Phase II Study of Gemcitabine Plus Nab-Paclitaxel in Combination With Losartan Followed by Stereotactic Radiotherapy for Locally Advanced Pancreatic Cancer: OVERPASS Trial | NCT05861336 |
| Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer | The Efficacy and Safety of Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer | NCT05812430 |
| The AIUR Trial: Surgical Gloves to Prevent Peripheral Neuropathy | A Randomized Controlled Trial Using Surgical Gloves to Prevent Chemotherapy-induced Peripheral Neuropathy by Paclitaxel in Breast Cancer Patients | NCT05771974 |
| A phase II clinical trial evaluating the efficacy and safety of Umustat hydrogen sulfate capsules (LH011) combined with GN (gemcitabine + albumin-bound paclitaxel) in the treatment of patients with locally advanced/metastatic pancreatic cancer | A phase II clinical trial evaluating the efficacy and safety of Umustat hydrogen sulfate capsules (LH011) combined with GN (gemcitabine + albumin-bound paclitaxel) in the treatment of patients with locally advanced/metastatic pancreatic cancer | ChiCTR2300069010 |
| Clinical study on the efficacy and safety of Tumor Treating Fields, atezolizumab, gemcitabine and nab-paclitaxel as first line treatment for metastatic pancreatic carcinoma. | PANOVA-4: Pilot, Single arm Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - PANOVA-4 | EUCTR2022-003157-55-CZ |
| Phase II single-arm clinical study of teriprizumab combined with low-dose paclitaxel for injection (albumin-bound) in the treatment of advanced gastric cancer that failed first-line treatment and advanced colorectal cancer that failed standard treatment | Phase II single-arm clinical study of teriprizumab combined with low-dose paclitaxel for injection (albumin-bound) in the treatment of advanced gastric cancer that failed first-line treatment and advanced colorectal cancer that failed standard treatment | ChiCTR2300068977 |
| A safety and early efficacy study of LSTA1 in combination with durvalumab, gemcitabine and nab-paclitaxel, as first-line treatment in locally advanced pancreatic ductal adenocarcinoma (PDAC) | A Phase 1 single-blind study evaluating LSTA1 in combination with durvalumab, gemcitabine and nab-paclitaxel as a first-line treatment in locally advanced pancreatic ductal adenocarcinoma (PDAC) | ACTRN12623000223639 |
| Efficacy and safety of sintilimab combined with paclitaxel/cisplatin (TP) as neoadjuvant therapy for locally advanced head and neck squamous cell carcinoma (HNSCC) in a prospective real-world study | Efficacy and safety of sintilimab combined with paclitaxel/cisplatin (TP) as neoadjuvant therapy for locally advanced head and neck squamous cell carcinoma (HNSCC) in a prospective real-world study | ChiCTR2300068870 |
| Study of Polymeric Micellar Paclitaxel, Platinum Combined With Sindilizumab Injection for Advanced Non-squamous NSCLC | Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection, Platinum (Cisplatin/Carboplatin) Combined With Sindilizumab Injection in the First-line Treatment of Advanced Non-squamous Non-small Cell Lung Cancer | NCT05782426 |
| A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound) | A Multicenter, Randomized, Double-blind Phase ? Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound) | NCT05753865 |
| A study comparing 2 chemotherapy regimens, Paclitaxel-Carboplatin versus Paclitaxel-Carboplatin plus metronomic chemotherapy in advanced Head and neck cancer | Phase 4 trial evaluating the 2 standard palliative chemotherapy regimens of PC (Paclitaxel+Carboplatin) versus PCm (PC+Oral Metronomic) in advanced Head and neck cancer - PHOENIX | CTRI/2023/02/049962 |
| Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II) | An Early Phase and Phase II Clinical Trial to Evaluate Ganglioside-Monosialic Acid (GM1) for Preventing Paclitaxel-Associated Neuropathy | NCT05751668 |
| HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer | HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate Versus Nab-paclitaxel in Combination With Gemcitabine for First-line Treatment of Advanced Pancreatic Cancer: an Open, Randomized, Multicenter Phase III Trial. | NCT05751850 |
| A study to compare BMS-936558 to the physician’s choice of either dacarbazine or carboplatin and paclitaxel in advanced melanoma patients that have progressed following anti-CTLA-4 therapy | A Randomized Open-Label Phase III Trial of BMS-936558 versus Investigator’s Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 TherapyPharmacogenetics Blood Sample Amendment 01- dated 07-aug-12, version 1.0 | EUCTR2012-001828-35-BE |
| Neoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Breast Cancer | Neoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Locally Advanced HER2-Positive Breast Cancer: a Prospective, Single-arm, Multi-center Phase II Study | NCT05749016 |
| Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel in Non-squamous NSCLC After First-line Treatment | A Prospective, Single-arm, Phase II Trial of Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel in Advanced Non-squamous Non-small Cell Lung Cancer After First-line Immunotherapy Progression | NCT05738317 |
| A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037) | A Randomized Open-Label Phase 3 Trial of BMS-936558 (Nivolumab) Versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy | NCT01721746 |
| Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination with Paclitaxel Chemotherapy | AIPAC-003 (Active Immunotherapy and PAClitaxel): a Randomized, Double-blind, Placebo-controlled Phase 3 Trial Testing Eftilagimod Alpha (soluble LAG-3) in HER2-neg/low Metastatic Breast Cancer Patients Receiving Paclitaxel, Following an Open-label Dose Optimization | NCT05747794 |
| A study comparing two chemotherapy regimens prior to surgery for patients with technically unresectable oral cancers | Phase 3 study comparing TPF versus Paclitaxel-Carboplatin and oral metronomic chemotherapy as neoadjuvant chemotherapy for borderline resectable oral cancers - BordRes | CTRI/2023/02/049406 |
| Genetic population-based pharmacokietics of individualized dosing of albumin-bounded paclitaxel in the treatment of solid tumors | Genetic population-based pharmacokietics of individualized dosing of albumin-bounded paclitaxel in the treatment of solid tumors | ChiCTR2300067853 |
| A clinical trial testing the hormonal drug letrozole alone or in addition to the usual chemotherapy treatment (paclitaxel and carboplatin) in low-grade serous ovarian or peritoneal cancer. | A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum. | EUCTR2022-002877-27-IE |
| CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer | A Phase I Clinical Trial of CA-4948 in Combination With Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma | NCT05685602 |
| A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer | A Feasibility Study of Integrated Delivery of Hypofractionated Pelvic IMRT With Carboplatin and Paclitaxel in Stage III Copy-Number Low and Copy-Number High Subtypes of Endometrial Cancer | NCT05691010 |
| Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer | Phase I Study Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer | NCT05673200 |
| Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer | Nab-paclitaxel Versus Solvent-based Taxanes As First-Line Treatment for Patients with Advanced Ovarian Cancer | NCT05737303 |
| A prospective observational study of Sulfatinib plus albumin paclitaxel and gemcitabine regimen for transformation therapy of locally advanced pancreatic cancer | A prospective observational study of Sulfatinib plus albumin paclitaxel and gemcitabine regimen for transformation therapy of locally advanced pancreatic cancer | ChiCTR2300069581 |
| Phase II clinical study on the first-line treatment of advanced gastric and gastroesophageal junction adenocarcinoma with Camrelizumab combined with albumin-binding paclitaxel and S-1 | Phase II clinical study on the first-line treatment of advanced gastric and gastroesophageal junction adenocarcinoma with Camrelizumab combined with albumin-binding paclitaxel and S-1 | ChiCTR2300069672 |
| Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients | Randomized Phase 2 Study of Valproic Acid combinEd With Simvastatin and Gemcitabine/Nab-paclitaxel-based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients (The VESPA Trial). | NCT05821556 |
| The Efficacy and Safety of Nanoparticle Albumin-bound (NAB)-Paclitaxel Plus Cisolation Versus CEP (Cisplatin, Epirubicin,Cyclophosphamide) in Induction Therapy for Thymoma: a Study for a Single-center Prospective Phase II Randomized Controlled Train. | The Efficacy and Safety of Nanoparticle Albumin-bound (NAB)-Paclitaxel Plus Cisolation Versus CEP (Cisplatin, Epirubicin,Cyclophosphamide) in Induction Therapy for Thymoma: a Study for a Single-center Prospective Phase II Randomized Controlled Train. | NCT05816694 |
| Phase I/II study of S-1 plus intravenous and intraperitoneal paclitaxel for pancreas cancer with peritoneal metastasis | Phase I/II study of S-1 plus intravenous and intraperitoneal paclitaxel for pancreas cancer with peritoneal metastasis - clinical study for pancreatic cancer with peritoneal metastasis | JPRN-UMIN000009446 |
| Neoadjuvant Treatment of Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma | Neoadjuvant Treatment of Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma:A Single-Arm Phase 2 Clinical Trial | NCT05947201 |
| A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer | A Phase II, Randomized Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer | NCT01740336 |
| Exploratory Study on the S-1 + Paclitaxel Chemotherapy for Unresectable Gastric Cancer | Exploratory Study on the S-1 + Paclitaxel Chemotherapy for Creating the Operation Chance in the Patients With Unresectable Gastric Cancer | NCT01756183 |
| Schedules of Nab-Paclitaxel in Metastatic Breast Cancer | A Randomized Phase II Study Evaluating Different Schedules of Nab-Paclitaxel in Metastatic Breast Cancer (SNAP Trial) | NCT01746225 |
| Efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neo-adjuvant treatment | Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neo-adjuvant treatment in patients with operable Triple Negative or luminal B/HER2 normal Breast Cancer - Genevieve | EUCTR2012-003330-16-DE |
| A Study in advanced squamous non small cell lung cancer | A Randomized, Multicenter, Open-Label, Phase 2 Study ofPaclitaxel-Carboplatin Chemotherapy Plus Necitumumab(IMC-11F8) Versus Paclitaxel-Carboplatin ChemotherapyAlone in the First-Line Treatment of Patients WithStage IV Squamous Non-Small Cell Lung Cancer (NSCLC) | EUCTR2012-003214-13-DE |
| Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer | Phase II Prospective Open Label Study of Pertuzumab, Trastuzumab, and Nab-Paclitaxel in Patients With HER-2 Positive Advanced Breast Cancer | NCT01730833 |
| Evaluation of Paclitaxel Eluting Stent vs Paclitaxel Eluting Balloon Treating Peripheral Artery Disease of the Femoral Artery | REAL PTX - Randomized Evaluation of the Zilver PTX Stent vs. Paclitaxel-Eluting Balloons for Treatment of Symptomatic Peripheral Artery Disease of the Femoropopliteal Artery | NCT01728441 |
| A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer | A Phase II, Multicenter, Randomized, Double-Blind Study of Tobemstomig/RO7247669 Combined With Nab-Paclitaxel Compared With Pembrolizumab Combined With Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer | NCT05852691 |
| Study evaluating weekly oral vinorelbine versus weekly paclitaxel in a population of patients with advanced breast cancer. | Randomised phase II study evaluating, as first-line chemotherapy, weekly oral vinorelbine as a single-agent versus weekly paclitaxel as a single-agent in estrogen receptor positive, HER2 negative patients with advanced breast cancer. | EUCTR2012-003530-16-ES |
| Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer | Surgical Conversion of Candonilimab (AK104) Combined With Paclitaxel, S-1 and Apatinib for Unresectable Advanced Gastric(G)/Gastroesophageal Junction(GEJ) Cancer | NCT05853172 |
| Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC) | Phase I Study of Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC) | NCT01721525 |
| A Phase II study of the tumour-targeting human F16IL2 monoclonal antibody-cytokine fusion protein in combination with paclitaxel versus paclitaxel alone in patients with Merkel cell carcinoma. | A Phase II study of the tumour-targeting human F16IL2 monoclonal antibody-cytokine fusion protein in combination with paclitaxel versus paclitaxel alone in patients with Merkel cell carcinoma. - F16IL2 plus paclitaxel in metastatic Merkel cell carcinoma | EUCTR2012-004018-33-DE |
| Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer | A Randomized Controlled Study of a Fasting Mimicking Diet (FMD) in Conjunction With Combination Carboplatin and Paclitaxel in the Treatment of Patients With Advanced or Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancer | NCT05921149 |
| SHR-1701 in combination with albumin paclitaxel and carboplatin for advanced head and neck squamous cell carcinoma | SHR-1701 in combination with albumin paclitaxel and carboplatin for advanced head and neck squamous cell carcinoma | ChiCTR2300070675 |
| First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis) | First-line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas | NCT05832827 |
| A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC. | A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy Followed By Standard Chemoradiation In HPV-Negative or High-risk HPV-Positive Locally Advanced Stage III/IVa/IVb HNSCC | NCT01732640 |
| Neoadjuvant Chemo-Immunotherapy using Carboplatin, Paclitaxel, Oral Metronomic Chemotherapy and Low Dose Nivolumab for Locally Advanced “Borderline Resectable ? Oral Cavity squamous cell carcinoma - A Prospective Study | Neoadjuvant Chemo-Immunotherapy using Carboplatin, Paclitaxel, Oral Metronomic Chemotherapy and Low Dose Nivolumab for Locally Advanced “Borderline Resectable ? Oral Cavity squamous cellcarcinoma - A Prospective Study - NeoLOCUS | CTRI/2023/04/051617 |
| Feasibility study of Anthracycline Based Regimen followed by Nab-Paclitaxel as adjuvant chemotherapy for elderly patients with breast cancer | Feasibility study of Anthracycline Based Regimen followed by Nab-Paclitaxel as adjuvant chemotherapy for elderly patients with breast cancer - FANAC study | JPRN-UMIN000009267 |
| AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer | Phase I/IB of AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer | NCT05826015 |
| Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors | A Single-arm, Open-label, Multicenter Phase II Study of Cadonilimab Combined With Nab -Paclitaxel in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer Previously Treated With Immune Checkpoint Inhibitors | NCT05824494 |
| Randomized phase II study comparing trastuzumab plus weekly paclitaxel with weekly paclitaxel alone for patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. | Randomized phase II study comparing trastuzumab plus weekly paclitaxel with weekly paclitaxel alone for patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. - Trial to Assess the Concept of using Trastuzumab beyond progression | JPRN-UMIN000009297 |
| Study of Paclitaxel and Carboplatin chemotherapy in metastatic breast carcinoma | To compare the efficacy and safety of Paclitaxel vs Paclitaxel and Carboplatin combination regimens in patients with HER2/neu negative metastatic breast carcinoma | CTRI/2023/03/051117 |
| Study evaluating weekly oral vinorelbine versus weekly paclitaxel in a population of patients with advanced breast cancer. | Randomised phase II study evaluating, as first-line chemotherapy, weekly oral vinorelbine as a single-agent versus weekly paclitaxel as a single-agent in estrogen receptor positive, HER2 negative patients with advanced breast cancer. | EUCTR2012-003530-16-AT |
| Treatment of Coronary In-Stent Restenosis | Prospective Randomised Study Comparing Efficacy of Treatment Coronary In-stent Restenosis Using Drug Eluting Paclitaxel-coated Balloon and Drug Eluting Stent With Everolimus. | NCT01735825 |
| A Study of Tobemstomig/RO7247669 Combined with Nab-Paclitaxel Compared with Pembrolizumab Combined with Nab-Paclitaxel in Participants with Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer | A Phase II, Multicenter, Randomized, Double-Blind Study of Tobemstomig/RO7247669 Combined with Nab-Paclitaxel Compared with Pembrolizumab Combined with Nab-Paclitaxel in Participants with Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer - CO44194 | CTIS2022-502457-34-00 |
| Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes | Clinical Efficacy of Carrelizumab, Apatinib Mesylate, Albumin Paclitaxel Combined With Oxaliplatin and S-1 in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes--A Prospective, Multi-center, Randomized Controlled Study | NCT05524974 |
| Role of Paclitaxel in Stricture Urethra | Role of Paclitaxel in Prevention of Stricture Recurrence After Direct Visual Internal Urethrotomy (DVIU); Prospective Clinical Trial | NCT05678413 |
| A Bioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (albumin-bound), 100 mg/vial in Patients with Metastatic Breast Cancer | A Randomized, Open-Label, Two Period, Two-Treatment, Two Sequence, Single-Dose, Crossover, Bioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (albumin-bound), 100 mg/vial of AlembicPharmaceuticals Ltd, India with Abraxane 5 mg/ml powder for dispersion for infusion of Bristol-Myers Squibb Pharma EEIG, Ireland in Patients with Metastatic Breast Cancer under standard diet (non-high-fat) conditions | CTRI/2022/12/048030 |
| Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer | A Phase 2, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial Comparing Chemoimmunotherapy (Paclitaxel-Carboplatin-Oregovomab) Versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) as Neoadjuvant Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma | NCT05605535 |
| A superiority study of comparing oral metronomic therapy with Paclitaxel and Carboplatin Vs. Chemotherapy alone in patients with advanced unresectable Head and Neck cancer patients. | A phase III, randomized, open label study to establish the superiority of metronomic therapy used in addition to the chemotherapy regimen (Paclitaxel and Carboplatin) over the chemotherapy alone for the treatment of advanced unresectable head and neck cancer. - Pacli Carbo OMCT | CTRI/2022/10/046520 |
| Phase I trial of Gemcitabine plus nab-Paclitaxel for metastatic breast cancer | Phase I trial of Gemcitabine plus nab-Paclitaxel for metastatic breast cancer - Phase I trial of Gemcitabine plus nab-Paclitaxel for metastatic breast cancer | JPRN-UMIN000009067 |
| Feasibility Study of Intraperitoneal Paclitaxel | Feasibility Study of Intraperitoneal Paclitaxel With Oxaliplatin and Capecitabine in Patients With Advanced Gastric Cancer | NCT01739894 |
| A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies | A Phase 1, Multicenter, Open-Label, Dose Escalation Study of ASP9853 in Combination With Either Docetaxel or Paclitaxel in Subjects With Advanced Non-hematologic Malignancies | NCT01705483 |
| Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer | A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Chemotherapy Regimens With Weekly Paclitaxel or Eribulin Followed by Doxorubicin and Cyclophosphamide in Women With Locally Advanced HER2-Negative Breast Cancer | NCT01705691 |
| Phase1 Study of nab-paclitaxel plus Cyclophosphamide in Metastatic Breast Cancer | Phase1 Study of nab-paclitaxel plus Cyclophosphamide in Metastatic Breast Cancer - ABC-BC01 | JPRN-UMIN000009046 |
| Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer | Combination Treatment of S-1 With Paclitaxel Versus Paclitaxel+Cisplatin and 5-Fu+Cisplatin as First-line Treatment in Advanced Esophageal Cancer | NCT01704690 |
| Phase II study of neoadjuvant chemotherapy with nab-Paclitaxel followed by EC for resectable primary breast cancer | Phase II study of neoadjuvant chemotherapy with nab-Paclitaxel followed by EC for resectable primary breast cancer - PerSeUS-BC01 | JPRN-UMIN000009035 |
| Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer | Phase II Trial of Lapatinib and Weekly Paclitaxel for Advanced Platinum Refractory Urothelial Cancer | NCT01700010 |
| Paclitaxel injection therapy for pancreatic cyst | Study of endoscopic ultrasonography-guided Paclitaxel injection therapy for patients with pancreatic cystics lesion | JPRN-jRCTs041220072 |
| A Phase II Study to Evaluate the Safety and Efficacy of Sintilimab Combined with Nab-paclitaxel and Gemcitabine for Neoadjuvant and Adjuvant Therapy of Patients with Resectable and Borderline Resectable Pancreatic Cancer | A Phase II Study to Evaluate the Safety and Efficacy of Sintilimab Combined with Nab-paclitaxel and Gemcitabine for Neoadjuvant and Adjuvant Therapy of Patients with Resectable and Borderline Resectable Pancreatic Cancer | ChiCTR2200064424 |
| Chemoimmunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Ovarian, Cancer | A Phase 2, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial Comparing Chemoimmunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) as Neoadjuvant Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma. - FLORA-6 | CTRI/2022/10/046210 |
| Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial | Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants With PTEN/AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial | NCT05554380 |
| Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer | A Phase II/III Study to Evaluate the Efficacy and Safety of B013 in Combination With Nab-Paclitaxel in First-line Treatment for Patients With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer | NCT05555706 |
| Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Fosbretabulin Tromethamine (CA4P) in Combination With Paclitaxel and Carboplatin in Anaplastic Thyroid Carcinoma (FACT2) | NCT01701349 |
| Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial | Nilotinib and Paclitaxel in Patients With Prior Taxane-Treated Solid Tumors: A ComboMATCH Treatment Trial | NCT05554341 |
| Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer | A Phase II Study to Evaluate the Safety and Efficacy of Sintilimab Combined with Nab-paclitaxel and Gemcitabine for Neoadjuvant and Adjuvant Therapy of Patients with Resectable and Borderline Resectable Pancreatic Cancer | NCT05562297 |
| Phase Ib/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric Cancer | Phase Ib/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric Cancer | NCT05535569 |
| Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy | Efficacy and Safety of Serplulimab, Lenvatinib, and Paclitaxel in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma After First-line Immunotherapy: a Prospective, Single-armed Clinical Trial | NCT05585580 |
| A single arm, multi-center, open lable, exploratory study of Tirelizumab combined with Nab-Paclitaxel and Gemcitabine in the treatment of patients with advanced biliary tract cancer | A single arm, multi-center, open lable, exploratory study of Tirelizumab combined with Nab-Paclitaxel and Gemcitabine in the treatment of patients with advanced biliary tract cancer | ChiCTR2200063254 |
| DCB Versus Primary Selective Stenting in TASC C/D Femoropopliteal Artery Disease | Paclitaxel Coated Balloon Angioplasty Versus Primary Selective Stenting in the Treatment of TASC C/D Chronic Femoropopliteal Artery Occlusive Disease: A Multicenter Randomized Clinical Trial | NCT05517291 |
| Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial | Optimal Preoperative Therapy for Intrahepatic Cholangiocarcinoma (OPTIC) | NCT05514912 |
| Fibroblast Growth Factor (FGFs) / Fibroblast Growth Factor Receptor (FGFRs) Genetic as a Second-line Therapy for Recurrent / Progressive Gastric Cancer With INCB054828 and Paclitaxel a Study to Evaluate the Safety and Efficacy of Combination Therapy. | An Open Label, Single-Arm, Multi-center Phase Ib/II Study to Evaluate the Safety and Efficacy of INCB054828 in Combination With Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer With FGFs/FGFRs Genetic Aberration. | NCT05529667 |
| A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) | A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination With Paclitaxel Versus Paclitaxel Alone in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers Who Have Received One Prior Systemic Chemotherapy Regimen | NCT05506943 |
| A phase II neoadjuvant trial of concurrent trastuzumab, paclitaxel and endocrine therapy in women with HER2-positive and hormone receptor-positive breast cancer. | A phase II neoadjuvant trial of concurrent trastuzumab, paclitaxel and endocrine therapy in women with HER2-positive and hormone receptor-positive breast cancer. - HERPLET | JPRN-UMIN000009108 |
| A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer | A Phase I/II Trial of Multiple Dose VB-111 and Weekly Paclitaxel for the Treatment of Recurrent Platinum-Resistant Müllerian Cancer | NCT01711970 |
| Assessment of the effect of a chemotherapy combining two molecules in patients with operable, locally advanced or metastatic pancreas cancer | Evaluation of tumoral perfusion modification by dynamic imaging after chemotherapy combining gemcitabine and nab-paclitaxel (Abraxane) in patients with potentially operable, locally advanced or metastatic pancreatic adenocarcinoma - NEOPAX-001 | EUCTR2012-003592-19-BE |
| Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer | Carboplatin-Paclitaxel Induction Chemotherapy and ABT-888 (Veliparib) - a Phase 1/Randomized Phase 2 Study in Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck | NCT01711541 |
| Advanced or Metastatic Cholangiocarcinoma | A Multicenter Clinical Study of Carralizumab Combined With Albumin Paclitaxel and Apatinib Mesylate in the Second-line Treatment of Advanced or Metastatic Cholangiocarcinoma | NCT05653817 |
| Ensayo de fase II de un régimen secuencial de quimioterapia de inducción con panitumumab y paclitaxel seguida de radioterapia más panitumumab en pacientes con cáncer de cabeza y cuello localmente avanzado que no son candidatos al tratamiento con derivados de platino | Ensayo de fase II de un régimen secuencial de quimioterapia de inducción con panitumumab y paclitaxel seguida de radioterapia más panitumumab en pacientes con cáncer de cabeza y cuello localmente avanzado que no son candidatos al tratamiento con derivados de platino - PANTERA | EUCTR2012-003038-17-ES |
| Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma | A Prospective, Single-arm Study on the Efficacy and Safety of Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma | NCT05664139 |
| EFFECT: A randomized phase II study to evaluate the EFficacy and impact on Function of two different doses of nab-paclitaxEl in elderly patients with advanCed breasT cancer | EFFECT: A randomized phase II study to evaluate the EFficacy and impact on Function of two different doses of nab-paclitaxEl in elderly patients with advanCed breasT cancer - EFFECT | EUCTR2012-002707-18-IT |
| A Phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of bevacizumab, and associated biomarkers, in combination with paclitaxel | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer | JPRN-jRCT2080221950 |
| A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer | Randomized Double Blind Phase III Trial Comparing Safety and Efficacy of Bevacizumab (Mabscale LLC, Russia) + Paclitaxel + Carboplatin to Avastin® + Paclitaxel + Carboplatin in Inoperable or Advanced Non-squamous Non-small-cell Lung Cancer | NCT05654454 |
| Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer | A Randomized Phase II Study of NCI Supplied Cabozantinib (NSC #761968) Versus Weekly Paclitaxel (NSC #673089) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT01716715 |
| Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors | A Phase I Study of Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) in Patients with Advanced Solid Tumors | NCT05653661 |
| Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer | Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer | NCT05653453 |
| Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer | A Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination With Avutometinib (VS-6766) and Defactinib in Patients With Previously Untreated Metastatic Adenocarcinoma of the Pancreas | NCT05669482 |
| Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma | Atezolizumab/Carboplatin/Nab-Paclitaxel vs. Pembrolizumab/Platinum/Pemetrexed in Metastatic TTF-1 Negative Lung Adenocarcinoma | NCT05689671 |
| Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer | A Randomized, Controlled, Multicenter Phase II Study of Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer | NCT05669807 |
| Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation | A Phase II Study of Camrelizumab, Fluzoparib and Nab-paclitaxel in Neoadjuvant Therapy of Her-2 Negative Breast Cancer Patients With HRR Gene Mutation | NCT05761470 |
| IFCT-2201 ADAPTABLE A study evaluating the combination of paclitaxel-bevacizumab ± atezolizumab in patients with advanced lung cancer progressing after immunotherapy and chemotherapy | IFCT-2201 ADAPTABLE A non-comparative randomized phase II trial evaluating the combination of paclitaxel-bevacizumab ± atezolizumab in patients with advanced non-squamous NSCLC progressing after immunotherapy and chemotherapy - IFCT-2201 | CTIS2022-502103-30-00 |
| Neoadjuvant camrelizumab plus albumin paclitaxel and cisplatin in locally advanced oral squamous cell carcinoma: A phase II Clinical Trial | Neoadjuvant camrelizumab plus albumin paclitaxel and cisplatin in locally advanced oral squamous cell carcinoma: A phase II Clinical Trial | ChiCTR2200066119 |
| Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer | A Phase II Study of Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer | NCT05633914 |
| A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer | A Randomized, Open-Label, Phase II Trial of Nab-paclitaxel + Gemcitabine With or Without Botensilimab (AGEN1181) in Patients With Metastatic Pancreatic Cancer Who Have Progressed on Prior 5FU + Leucovorin + Irinotecan + Oxaliplatin (FOLFIRINOX) | NCT05630183 |
| Phase II study of nab-paclitaxel plus ramucirumab in combination with nivolumab in unresectable advanced or recurrent gastric cancer after progression to first-line therapy including fluoropyrimidine, platinum, and anti-PD-1/PD-L1 antibody. | Phase II study of nab-paclitaxel plus ramucirumab in combination with nivolumab in unresectable advanced or recurrent gastric cancer after progression to first-line therapy including fluoropyrimidine, platinum, and anti-PD-1/PD-L1 antibody. - PADDLE | JPRN-jRCT2031220448 |
| A Phase I Dose-finding Trial of Hyperthermic Intraperitoneal Paclitaxel Combined With Cisplatin | A Phase I Dose-finding Trial of Hyperthermic Intraperitoneal Paclitaxel Combined With Cisplatin in Patients With Advanced-stage Ovarian Cancer | NCT05620654 |
| Clinical study of tumor treating fields combined with gemcitabine and albumin-bound paclitaxel in the first-line treatment of locally advanced pancreatic cancer | Clinical study of tumor treating fields combined with gemcitabine and albumin-bound paclitaxel in the first-line treatment of locally advanced pancreatic cancer | ChiCTR2200065543 |
| Low dose cancer drugs for advanced stomach cancer | Efficacy of weekly paclitaxel with fixed dose of oral cyclophosphamide as metronomic chemotherapy in recurrent /refractory gastric carcinoma â?? phase 2 study | CTRI/2022/11/047033 |
| A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma | A Phase II Study of Peri-Operative NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma | NCT05624918 |
| Atezolizumab With Nab-paclitaxel for Patients With Triple-negative Stage IV Breast Cancer | Atezolizumab in Combination With Nab-paclitaxel for Patients With Previously Untreated Metastatic Triple-negative Breast Cancer in a Real World Experience | NCT05609903 |
| Phase II study of FEC followed by Nab-paclitaxel as Neoadjuvant Chemotherapy for Primary Breast Cancer | Phase II study of FEC followed by Nab-paclitaxel as Neoadjuvant Chemotherapy for Primary Breast Cancer - Phase II study of FEC followed by Nab-paclitaxel as Neoadjuvant Chemotherapy for Primary Breast Cancer | JPRN-UMIN000009152 |
| A single-arm, open-label, exploratory study of the efficacy and safety of S-1 + nab-paclitaxel + PD-1 mAb in the treatment of initially unresectable intrahepatic cholangiocarcinoma | Conversion therapy for initially unresectable intrahepatic cholangiocarcinoma | ChiCTR2200065096 |
| Phese 2 trial of weekly nab-paclitaxel in combination with gemcitabine in patients with metastatic breast cancer who have failed prior chemotherapy | Phese 2 trial of weekly nab-paclitaxel in combination with gemcitabine in patients with metastatic breast cancer who have failed prior chemotherapy - Phese 2 trial of weekly nab-paclitaxel in combination with gemcitabine in patients with metastatic breast cancer who have failed prior chemotherapy | JPRN-UMIN000009153 |
| Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy | A Phase 1B/2 Study of Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy (TREAZURE) | NCT05640830 |
| AZD2014 and Weekly Paclitaxel in Squamous NSCLC | A Phase 2a, Multi-centre, Single-arm Trial of the Combination of AZD2014 and Weekly Paclitaxel in Patients With Relapsed or Refractory Squamous Non-Small Cell Lung Cancer After At Least One Line of Prior Therapy | NCT02403895 |
| Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma | A Phase II, Single-arm, Multicenter Clinical Trial of Definitive Treatment With Cadonilimab, Paclitaxel, Cisplatin and Radiation for the Treatment of Locally Recurrent and Oligometastatic Endometrial Carcinoma | NCT06532539 |
| A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy | A First-in-human Open Label Phase Ia/Ib, Multicenter/Multiregional, Dose Escalation Study of BI 765883 Administered Intravenously as Monotherapy and in Combination With Gemcitabine and Nab-paclitaxel in Unselected Patients With Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) or Patients With PDAC Who Have Relapsed After Post-surgery Adjuvant Therapy | NCT06528093 |
| Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer | A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination With Paclitaxel in Patients With Advanced Anaplastic Thyroid Cancer | NCT02152137 |
| Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly | Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+) | NCT02151149 |
| Comparison of Agent™ and SeQuent® Please Paclitaxel Coated Balloon Catheters in Coronary In-stent Restenosis (AGENT-ISR) | A Prospective Randomized Multicenter Non-inferiority Clinical Study to Determine the Safety and Performance of the Agent™ Paclitaxel-Coated PTCA Balloon Catheter (Hemoteq) Compared to the SeQuent® Please Paclitaxel-Releasing Coronary Balloon Catheter (B.Braun) for the Treatment of Coronary In-Stent Restenosis (AGENT-ISR) | NCT02151812 |
| A trial of 3 weekly cabazitaxel versus weekly pactlitaxel for the first treatment of metastatic breast cancer. | A randomised phase II pilot study of 3 weekly Cabazitaxel versus weekly Paclitaxel chemotherapy in the first line treatment of HER2 negative metsastatic breast cancer. - CONCEPT | EUCTR2014-000918-61-GB |
| Olanzapine Against Delayed Nausea and Vomiting in Women Receiving Carboplatin Plus Paclitaxel | Olanzapine for the Prevention of Delayed Nausea and Vomiting in Patients With Gynecologic Cancers Receiving Carboplatin and Paclitaxel-based Chemotherapy and Guideline-directed Prophylactic Anti-emetics | NCT02290470 |
| First-in-man Evaluation of a Novel, Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease (PAX-r) | Prospective, Pivotal, First - in Man Clinical Trial of the Safety and Efficacy of a Novel Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease | NCT02145065 |
| A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer | A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer | NCT02163694 |
| Weekly and Every 3 Week Administration of Paclitaxel Liposome Injection in Metastatic Breast Cancer | NCT02142790 | |
| Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer | A Phase I Trial With Cohort Expansion of Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer | NCT02138383 |
| Weekly Paclitaxel Liposome Injection Plus Cisplatin in Preoperative Treatment of Breast Cancer | NCT02142010 | |
| Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel | An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of Oral BAY1161909 in Combination With Weekly Intravenous Paclitaxel Given in an Intermittent Dosing Schedule in Subjects With Advanced Malignancies | NCT02138812 |
| Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Advanced Pancreatic Cancer | Phase II Trial of Nab-paclitaxel Plus Gemcitabine in First-line Treatment of Chinese Patients With Advanced Pancreatic Cancer | NCT02135822 |
| Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma | Phase 2 Study of Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Patients With Advanced Esophageal Cancer | NCT02133612 |
| Scheduling Nab-paclitaxel With Gemcitabine | Randomised Phase II Trial to Investigate Two Different Schedules of Nab-paclitaxel (Abraxane) Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma | NCT03529175 |
| Inhibition of Neointimal hyperplasia with Paclitaxel-eluting balloon angioplasty in haemodialysis shunts. A multicenter randomized clinical trial of paclitaxel drug-eluting balloon (DEB) versus standard percutaneous transluminal angioplasty (PTA) to reduce restenosis in patients with haemodialysis access stenoses. | Inhibition of Neointimal hyperplasia with Paclitaxel-eluting balloon angioplasty in haemodialysis shunts. A multicenter randomized clinical trial of paclitaxel drug-eluting balloon (DEB) versus standard percutaneous transluminal angioplasty (PTA) to reduce restenosis in patients with haemodialysis access stenoses. - APERTO Trial | NL-OMON45191 |
| Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors | A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors | NCT02134067 |
| Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer | Phase II Trial of Nab-paclitaxel Plus S-1 in First-line Treatment of Patients With Advanced Pancreatic Cancer | NCT02124317 |
| Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN | LCCC 1330 - A Phase II Study of Weekly Carboplatin, Paclitaxel and Cetuximab for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) | NCT02124707 |
| Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast Cancer | A Randomized Prospective Clinical Trial of Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin as First-Line Treatment in Metastatic Breast Cancer | NCT02207361 |
| Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | A Phase 1 Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | NCT02121990 |
| Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE) | Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE) - A Single-centre Phase 2a Study of Gemcitabine Plus Nab-paclitaxel for Borderline Unresectable Locally Advanced Pancreatic Cancer | NCT02124369 |
| Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer | A Pilot Phase II Trial of Intravenous Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation in Patients With Advanced Stage Uterine Serous Carcinoma | NCT02112552 |
| An Open-label, Randomized Cross-over, Pharmacokinetic Study to Determine the Bioavailability, Safety, and Tolerability of Two Consecutive Daily Doses of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel Amendment 1 | Patients with cancer for whom IV paclitaxel (at a dose of 80 mg/m2 IV over 1 hour) is indicated will be treated with intravenous paclitaxel and Oraxol (Paclitaxel + HM30181AK-US) to evaluate bioavailability, safety and tolerability of Oraxol. | ACTRN12614000365662 |
| A Randomized, Open Label,Two Period, Single Dose Bioavailability Study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) and Abraxane® in Patients with Breast Cancer | A Randomized, Open Label, Two Period, Single Dose, Two Way Crossover, Bioavailability Study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) and Abraxane® in Patients with Locally Recurrent or Metastatic Breast Cancer | CTRI/2014/04/004528 |
| Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer | Randomized, Double-Blind, Multicenter, Phase 3 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) | NCT02106546 |
| Lower Dose Decitabine (DAC)-Primed TC (Carboplatin-Paclitaxel) Regimen in Ovary Cancer | Addition of Decitabine to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Phase 2-3, Open-label, Randomised Controlled Trial | NCT02159820 |
| Phase I/II trial of 5-FU, cisplatin, and weekly paclitaxel in patients with esophageal cancer | Phase I/II trial of 5-FU, cisplatin, and weekly paclitaxel in patients with esophageal cancer - Phase I/II trial of 5-FU, cisplatin, and weekly paclitaxel in patients with esophageal cancer | JPRN-UMIN000013627 |
| BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer | A Phase I Trial With Cohort Expansion of BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer | NCT02155088 |
| Feasibility of a chemotherapy with the two agents Carboplatin and Paclitaxel, that is applied heated directly into the abdomen after surgery of patients with advanced cancer of the ovary | Feasibility of intraoperative hyperthermic intraperitoneal chemotherapy with carboplatin and paclitaxel in patients with advanced epithelial ovarian cancer – a combined phase I / II trial - HIPEC-Ovar | EUCTR2012-003244-76-AT |
| Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer | Phase 2 Study of Weekly Paclitaxel in Combination With Cisplatin as Neoadjuvant Therapy for Locally Advanced Breast Cancer Patients | NCT02199418 |
| Phase I/II study of Carboplatin plus Nab-Paclitaxel in patients with advanced non-small-cell lung cancer and a performance status of 2 | Phase I/II study of Carboplatin plus Nab-Paclitaxel in patients with advanced non-small-cell lung cancer and a performance status of 2 - Phase I/II study of Carboplatin plus Nab-Paclitaxel in patients with advanced non-small-cell lung cancer and a performance status of 2 | JPRN-UMIN000014544 |
| Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients | A Prospective, Randomized, Open-label Comparison of Preoperative Weekly Paclitaxel and Cisplatin With or Without Endocrine Therapy in Patients With Operable Hormone Receptor Positive and Triple Negative Locally Advanced Breast Cancer | NCT02221999 |
| Phase III clinical trial comparing safety and efficacy of BCD-022 (CJSC BIOCAD, Russia) used with paclitaxel to Herceptin® used with paclitaxel in the first-line treatment of HER2 positive metastatic breast cancer patients. | Multicenter randomized double blind phase III clinical trial comparing safety and efficacy of BCD-022 (CJSC BIOCAD, Russia) used with paclitaxel to Herceptin® (F. Hoffmann-La Roche Ltd, Switzerland) used with paclitaxel in the first-line treatment of HER2-positive metastatic breast cancer patients. | CTRI/2014/07/004722 |
| Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer | A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination With Paclitaxel vs. Paclitaxel Alone in Patients With Metastatic or Locally Recurrent Breast Cancer | NCT02187991 |
| Nab-Paclitaxel as Salvage Treatment in Locally Advanced or Metastatic Gastric Cancer | A Multicenter, Phase II, Single-Arm Clinical Trial of Nab-Paclitaxel as Salvage Treatment for Patients With Locally Advanced or Metastatic Adenocarcinomas of the Stomach and Gastro-esophageal Junction. | NCT02251951 |
| Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma | A Multi-Institutional, Single Arm, Two-Stage Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma | NCT02181634 |
| A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung Cancer | A Phase I Open Label Dose Escalation Study of Continuous Oral Treatment With BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung Cancer | NCT02182232 |
| Feasibility study evaluating Paclitaxel, Carboplatin and Cetuximab (PCE) as induction chemotherapy followed by chemoradiation in patients with Unresectable Locally advanced Squamous Cell Carcinoma of the Head and Neck | Feasibility study evaluating Paclitaxel, Carboplatin and Cetuximab (PCE) as induction chemotherapy followed by chemoradiation in patients with Unresectable Locally advanced Squamous Cell Carcinoma of the Head and Neck - Feasibility study evaluating Paclitaxel, Carboplatin and Cetuximab (PCE) as induction chemotherapy followed by chemoradiation in patients with Unresectable Locally advanced Squamous Cell Carcinoma of the Head and Neck (IC-PCE) | JPRN-UMIN000014430 |
| Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies | A Phase I Open Label Dose Escalation Study of Oral Treatment With BIBF 1120 in Combination With Standard Treatment of Paclitaxel and Carboplatin in Patients With Advanced Gynaecological Malignancies | NCT02182245 |
| Phase II study of nab-paclitaxel for pretreated NSCLC | Phase II study of nab-paclitaxel for pretreated NSCLC - nab-paclitaxel for pretreated NSCLC | JPRN-UMIN000014357 |
| A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer | A Phase III Clinical Trial of BBI608 Plus Weekly Paclitaxel vs. Placebo Plus Weekly Paclitaxel in Adult Patients With Advanced, Previously Treated Gastric and Gastro-Esophageal Junction Adenocarcinoma | NCT02178956 |
| A Study Evaluating RO5479599 in Combination with Carboplatin and Paclitaxel in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology | OPEN-LABEL PHASE Ib/II, MULTICENTER STUDY OF THE COMBINATION OF RO5479599 WITH CARBOPLATIN AND PACLITAXEL IN PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) OF SQUAMOUS HISTOLOGY WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY OR TARGETED THERAPY FOR NSCLC | EUCTR2014-001498-15-DK |
| Paclitaxel Coated PTA Balloons for Treatment of Dysfunctional AV Fistulae and Grafts | A Prospective, MultiCenter, Single-arm, Post-market Study of Paclitaxel Coated PTA Balloons for Treatment of Dysfunctional AV Fistulae and Grafts (ACCESS) | NCT02183194 |
| Biological Effect of Nab-paclitaxel Combined to Gemcitabine in Metastatic Pancreatic Cancer | A Unicentric, Open Label, Mechanism of Action Trial, on the Biological Effect of Nab-paclitaxel Combined to Gemcitabine, in Patients With Metastatic Pancreatic Adenocarcinoma | NCT02174887 |
| Weekly Paclitaxel in Combination with Bevacizumab in Patients with Non-Squamous Non-Small Cell Lung Cancer Previously Untreated -A Phase II study- | Weekly Paclitaxel in Combination with Bevacizumab in Patients with Non-Squamous Non-Small Cell Lung Cancer Previously Untreated -A Phase II study- - Weekly Paclitaxel in Combination with Bevacizumab in Patients with Non-Squamous Non-Small Cell Lung Cancer Previously Untreated -A Phase II study- | JPRN-UMIN000014345 |
| Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer | Phase Ib Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330), Gemcitabine and Nab-Paclitaxel and Phase II Study of Gemcitabine and Selinexor in Patients With Metastatic Pancreatic Cancer | NCT02178436 |
| Hypofractionated Proton Beam Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Stage II-III Non-Small Cell Lung Cancer | A Phase I Study of Radiation Dose Intensification With Accelerated Hypofractionated Proton Therapy and Chemotherapy for Non-small Cell Lung Cancer | NCT02172846 |
| Phase II study of neoadjuvant chemotherapy of TS-1, CDDP and Paclitaxel for resectable large type 3 or type 4 gastric cancer | Phase II study of neoadjuvant chemotherapy of TS-1, CDDP and Paclitaxel for resectable large type 3 or type 4 gastric cancer - Phase II study of neoadjuvant chemotherapy of TS-1, CDDP and Paclitaxel for advanced gastric cancer | JPRN-UMIN000014332 |
| Comparison of paclitaxel, liposomal doxorubicin (and, i.a. carboplatin) with epirubicin, paclitaxel and cyclophosphamide for neoadjuvant treatment of high-risk early breast cancer | A randomized phase III trial comparing two dose-dense, dose-intensified approaches (ETC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto) - GeparOcto | EUCTR2014-000619-14-DE |
| A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors | A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer | NCT02162719 |
| Study on Neoadjuvant Chemotherapy for Advanced Gastric Cancer | Phase II Study of Paclitaxel Liposome Plus S-1 as Neoadjuvant Chemotherapy for Advanced Gastric Cancer | NCT02163291 |
| A PHASE I/II, MULTICENTRE, STUDY COMPRISING A SAFETY RUN-IN OF AZD5363 WHEN COMBINED WITH PACLITAXEL IN PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER; FOLLOWED BY A RANDOMISED EXPANSION OF AZD5363 WHEN COMBINED WITH PACLITAXEL VS. PACLITAXEL PLUS PLACEBO IN PATIENTS WITH ERPOSITIVE ADVANCED OR METASTATIC BREAST CANCER, STRATIFIED BY PIK3CA MUTATION STATUS (BEECH). | A PHASE I/II, MULTICENTRE, STUDY COMPRISING A SAFETY RUN-IN OF AZD5363 WHEN COMBINED WITH PACLITAXEL IN PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER; FOLLOWED BY A RANDOMISED EXPANSION OF AZD5363 WHEN COMBINED WITH PACLITAXEL VS. PACLITAXEL PLUS PLACEBO IN PATIENTS WITH ERPOSITIVE ADVANCED OR METASTATIC BREAST CANCER, STRATIFIED BY PIK3CA MUTATION STATUS (BEECH) | PER-092-13 |
| Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery | Randomized Phase II Study of AB (Nab-Paclitaxel [Abraxane?], Bevacizumab) Versus Ipilimumab for Therapy of Unresectable Stage IV Metastatic Malignant Melanoma | NCT02158520 |
| A Randomized Study of Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer | Phase II of Randomized Study of Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer | NCT02157870 |
| Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients | Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients After Progression on TKI-treatment; a Pilot-study | NCT02226757 |
| Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies | PHASE 1/2 STUDY OF PF-03084014 IN COMBINATION WITH GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA | NCT02109445 |
| Comparative study of chemotherapy in esophagus carcinoma. | Comparative study for efficacy and safety of Paclitaxel with Platinum analogue versus 5-Fluorouracil with Platinum analogue in resectable carcinoma esophagus | CTRI/2014/04/004516 |
| Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer | Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer | NCT02109341 |
| Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer | A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer | NCT02065687 |
| A Phase II, randomised, placebo-controlled study of paclitaxel in combination with the AKT inhibitor AZD5363 in triple-negative advanced or metastatic breast cancer | A Phase II, double blind, randomised, placebo-controlled study of the AKT inhibitor AZD5363 in combination with paclitaxel in triple-negative advanced or metastatic breast cancer - PAKT | EUCTR2013-001521-43-GB |
| Broncho-Adventitial Delivery of Paclitaxel to Extend Airway Patency in Malignant Airway Obstruction Patients | Broncho-Adventitial Delivery of Paclitaxel to Extend Airway Patency in Malignant Airway Obstruction Patients | NCT02066103 |
| Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor | DOSE FINDING STUDY OF PF-05212384 WITH PACLITAXEL AND CARBOPLATIN IN PATIENTS WITH ADVANCED SOLID TUMOR | NCT02069158 |
| Phase 2 trial of weekly Nab paclitaxel for advanced gastric cancer patients with prior chemotherapy | Phase 2 trial of weekly Nab paclitaxel for advanced gastric cancer patients with prior chemotherapy - Phase 2 trial of weekly Nab paclitaxel for advanced gastric cancer patients with prior chemotherapy | JPRN-UMIN000013105 |
| Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer | A Pilot Study of Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer | NCT02059876 |
| Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases | A Pilot Study of the Combination of Nab-paclitaxel, Temozolomide and Bevacizumab in Patients With Metastatic Melanoma With Brain Metastases | NCT02065466 |
| Strut Coverage After Paclitaxel-Eluting Stent implantation Compared with Bare Metal Stent Implantation in the Superficial Femoral Artery: Optical Frequency Domain Imaging Study | Strut Coverage After Paclitaxel-Eluting Stent implantation Compared with Bare Metal Stent Implantation in the Superficial Femoral Artery: Optical Frequency Domain Imaging Study - Strut Coverage After Paclitaxel-Eluting Stent implantation Compared with Bare Metal Stent Implantation in the Superficial Femoral Artery: Optical Frequency Domain Imaging Study | JPRN-UMIN000012565 |
| F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma | Phase II Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Paclitaxel in Patients With Metastatic Merkel Cell Carcinoma | NCT02054884 |
| Reirradiation With Concurrent Paclitaxel for Breast Cancer | A Phase I Study of Twice Weekly Paclitaxel and Radical Re-irradiation Using Helical Tomotherapy for Aggressive Chest Wall Recurrences of Breast Cancer | NCT02058667 |
| A Phase I/II study of nab-Paclitaxel plus S-1 therapy in previously treated patients with refractory advanced non-small-cell lung cancer | A Phase I/II study of nab-Paclitaxel plus S-1 therapy in previously treated patients with refractory advanced non-small-cell lung cancer - A Phase I/II study of nab-PTX plus S-1 therapy in previously treated patients with refractory advanced NSCLC | JPRN-UMIN000012966 |
| Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer | A Phase I Clinical Trial of Ganetespib (Heat Shock Protein 90 Inhibitor) in Combination With Paclitaxel, Trastuzumab and Pertuzumab in Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Metastatic Breast Cancer | NCT02060253 |
| A Phase 2 study of Paclitaxel and Ifosfamide plus either Cisplatin or Carboplatin for patients with metastatic non-transitional cell carcinoma of the bladder and the urinary tract | A Phase 2 study of Paclitaxel and Ifosfamide plus either Cisplatin or Carboplatin for patients with metastatic non-transitional cell carcinoma of the bladder and the urinary tract | EUCTR2014-000043-32-IT |
| Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | The Use and Safety of Metformin, Carboplatin and Paclitaxel in Non-Diabetic Patients With Recurrent, Platinum Sensitive Ovarian Cancer and the Feasibility of Using a Core Biopsy for RNA-Seq | NCT02050009 |
| Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer | A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer | NCT02050178 |
| Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer | A Phase Ib Study of Dovitinib in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced Solid Tumors and Pancreatic Cancer | NCT02048943 |
| Safety Study of Individual Paclitaxel Dose Adjustment Based on Pharmacokinetics in Non-Small Cell Lung Cancer (NSCLC) | Phase 3, Randomized, Open-label Study of the Safety of Individual Paclitaxel Dose Adjustment Based on Pharmacokinetic Follow up Versus Conventional Dosage in First-line Treatment in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | NCT02058433 |
| Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer | Phase II Trial Of Induction Chemotherapy Followed By Attenuated Chemoradiotherapy For Locally Advanced Head And Neck Squamous Cell Carcinoma Associated With Human Papillomavirus (HPV) | NCT02048020 |
| A phase II study of nab-paclitaxel for pretreated non-small cell lung cancer | A phase II study of nab-paclitaxel for pretreated non-small cell lung cancer - A phase II study of nab-paclitaxel for pretreated non-small cell lung cancer | JPRN-UMIN000012972 |
| Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer | An Open-Label, Phase I Dose Escalation Trial of TH-302 in Combination With Gemcitabine and Nab-Paclitaxel in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma | NCT02047500 |
| A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer | A Phase Ib Open Label Dose Finding Study of BYL719 in Combination With Paclitaxel in Advanced Solid Tumors Followed by Two Expansion Phases in Locally Advanced/Metastatic Chemotherapy Naive HER2 Negative Breast Cancer Patients (HER2- mBC) and in Recurrent and Metastatic Head-and-neck Squamous Cell Carcinoma Patients (HNSCC) Pre-treated With Platinum Based Therapy | NCT02051751 |
| Quality of Life in Locally Advanced or Metastatic Pancreatic Cancer Treated With Gemcitabine and Nab-paclitaxel | Randomized Crossover Trial to Assess the Effects and Quality of Life in Patients With Locally Advanced or Metastatic Pancreatic Cancer Treated With Gemcitabine in Combination With Nab-paclitaxel: QOLINPAC | NCT02106884 |
| A Phase II study of Neoadjuvant chemotherapy in Tri-weekly nab-Paclitaxel followed by FEC with Operable HER2 Negative breast cancer | A Phase II study of Neoadjuvant chemotherapy in Tri-weekly nab-Paclitaxel followed by FEC with Operable HER2 Negative breast cancer - A Phase II study of Neoadjuvant chemotherapy in Tri-weekly nab-Paclitaxel followed by FEC with Operable HER2 Negative breast cancer(KBCSG-TR1315) | JPRN-UMIN000012909 |
| Carboplatin and nab-Paclitaxel as first-line treatment in patients with advanced non-small cell lung cancer with interstitial lung disease (HOT1302) | Carboplatin and nab-Paclitaxel as first-line treatment in patients with advanced non-small cell lung cancer with interstitial lung disease (HOT1302) - Carboplatin and nab-Paclitaxel as first-line treatment in patients with advanced non-small cell lung cancer with interstitial lung disease (HOT1302) | JPRN-UMIN000012901 |
| Paclitaxel for the Treatment of Distal Radial Artery Arteriovenous Access Fistula Stenosis (PaciFIST-2) | The Use of Intravascular Paclitaxel for the Treatment of Distal Radial Artery Arteriovenous Access Fistula Stenosis: A Randomized Study (PaciFIST-2) | NCT02040454 |
| Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer | An Open-label, Randomized, Multi-center, Single-Dose, 2-Sequence, 2-Period, Crossover, Comparative Bioequivalence Study of IG-001 (Cb-paclitaxel) 260 mg/m2 Versus Nab-paclitaxel 260 mg/m2 Administered Intravenously With an Open-Label Extension of IG-001 in Patients With Metastatic or Locally Recurrent Breast Cancer | NCT02064829 |
| Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel | Randomized Open Label PhII Trial of Neoadjuvant Trastuzumab Emtansine (Te) in Combination w/Lapatinib (L) Followed by Abraxane (A) Compared w/Trastuzumab Plus Pertuzumab Followed by Paclitaxel in Her2/Neu Over-Expressed Breast Cancer Patients | NCT02073487 |
| A dual arm factorial randomized trial in patients with ST segment elevation AMI to compare the results of using either anticoagulation with unfractionated heparin plus routine GP IIb/IIIa inhibition with bivalirubin and bail-out GP IIb/IIIa inhibition, and primary angioplasty with stent implantation with either a slow rate-release paclitaxel-eluting stent (TAXUS) or an otherwise identical uncoated bare metal stent (Express) - HORIZONS AMI Trial | A dual arm factorial randomized trial in patients with ST segment elevation AMI to compare the results of using either anticoagulation with unfractionated heparin plus routine GP IIb/IIIa inhibition with bivalirubin and bail-out GP IIb/IIIa inhibition, and primary angioplasty with stent implantation with either a slow rate-release paclitaxel-eluting stent (TAXUS) or an otherwise identical uncoated bare metal stent (Express) - HORIZONS AMI Trial | EUCTR2005-001514-41-AT |
| Phase I/II trial of nab-Paclitaxel,Carboplatin,plus Bevacizumab chemotherapy for patients with advanced Non-Squamous Non-Small Cell Lung Cancer. | Phase I/II trial of nab-Paclitaxel,Carboplatin,plus Bevacizumab chemotherapy for patients with advanced Non-Squamous Non-Small Cell Lung Cancer. - Phase I/II trial of nab-Paclitaxel,Carboplatin,plus Bevacizumab chemotherapy for patients with advanced Non-Squamous Non-Small Cell Lung Cancer. | JPRN-UMIN000013201 |
| NR in Chemo-induced Peripheral Neuropathy | Nicotinamide Riboside (NR) in Paclitaxel-induced Peripheral Neuropathy | NCT03642990 |
| Phase I study of S-1 plus cisplatin and intraperitoneal administration of paclitaxel for gastric cacner with peritoneal metastasis | Phase I study of S-1 plus cisplatin and intraperitoneal administration of paclitaxel for gastric cacner with peritoneal metastasis - Phase I study of S-1 plus cisplatin and intraperitoneal administration of paclitaxel for gastric cacner with peritoneal metastasis | JPRN-UMIN000013528 |
| Gemcitabine plus nab-paclitaxel versus folfirinox in patients with potentially resectable pancreatic carcinoma. | Gemcitabine plus nab-paclitaxel versus folfirinox as neoadjuvant treatment in patients with potentially resectable pancreatic carcinoma. NeoPAN Study - NeoPAN | EUCTR2013-005087-25-ES |
| Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma | A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Preceded by a Dose-finding, Lead-in Phase | NCT02101021 |
| Phase 2 clinical trial of primary systemic therapy for primary breast cancer Sequential regimen of Nab-Paclitaxel followed by EC for HER2 negative breast cancer and concurrent regimen of Docetaxel/Carboplatin/Herceptin for HER2 positive breast cancer | Phase 2 clinical trial of primary systemic therapy for primary breast cancer Sequential regimen of Nab-Paclitaxel followed by EC for HER2 negative breast cancer and concurrent regimen of Docetaxel/Carboplatin/Herceptin for HER2 positive breast cancer - Phase 2 clinical trial of primary systemic therapy for breast cancer Nab-Paclitaxel followed by EC for HER2- breast cancer and Docetaxel/Carboplatin/Herceptin for HER2+ breast cancer | JPRN-UMIN000013513 |
| Study to evaluate the safety and effectivity of adding metformin to standard chemotherapy for advanced ovarian cancer | Phase Ib/II study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced ovarian cancer | EUCTR2012-005050-35-NL |
| Therapy of Angiosarcomas with standard therapy paclitaxel in combination with pazopanib (Votrient) | Phase II, multicenter, open-label, single-arm trial in advanced and relapsed Angiosarcomas, to evaluate the efficacy of pazopanib (Votrient) in combination with standard of care treatment paclitaxel ( Evaluation of Votrient in angiosarcoma - EVA) - EVA (Evaluation of Votrient in angiosarcoma) | EUCTR2012-005846-39-DE |
| Phase II study of weekly nab-paclitaxel in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. | Phase II study of weekly nab-paclitaxel in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. - Phase II study of weekly nab-PTX in patients with NSCLC previously treated with platinum-based chemotherapy. | JPRN-UMIN000013390 |
| Phase II Study of Albumin Bound Paclitaxel With 5-FU and CF as Second Line in Taxanes Naive Advanced Gastric Cancer | Phase II Study of Albumin Bound Paclitaxel With 5-FU and CF as Second Line in Taxanes Naive Advanced Gastric Cancer | NCT02229045 |
| Albumin Bound Paclitaxel Plus S-1 as the First Line Chemotherapy in Advanced or Recurrent Gastric Cancer | Phase II Study of Albumin Bound Paclitaxel Plus S-1 as the First Line Chemotherapy in Advanced or Recurrent Gastric Cancer | NCT02229058 |
| Multicenter Clinical Trial in subjects with HER2-negative primary tumors. The subjects will be evaluated for the presence of HER2 positive Circulating Tumor Cells (CTCs) in blood. In case of at least one HER2-positive CTC in blood, the subject will be randomized to receive either (nabTM)-paclitaxel + trastuzumab (ARM A) or (nabTM)-paclitaxel (ARM B). | A phase II randomized, open-label study evaluating the addition of trastuzumab to (nabTM)-paclitaxel as first line treatment in primary HER2 negative metastatic breast cancer patients with HER2 positive Circulating Tumor Cells (CTCs). - Trastuzumab and (nabTM)-paclitaxel as first line MBC in HER2+ve CTC with primary HER2-ve. | EUCTR2012-005352-41-IT |
| BEECH | A Phase 1, 2 Study of AZD5363 Combined With Paclitaxel in Patients With Advanced or Metastatic Breast Cancer. Comprising a Safety Run-In and a Placebo-controlled Randomised Expansion in ER+ve Patients Stratified by PIK3CA Mutation Status. | JPRN-jRCT2080222418 |
| Phase2 study of Nab-Paclitaxel in patients with unresectable or advanced squamous cell lung cancer | Phase2 study of Nab-Paclitaxel in patients with unresectable or advanced squamous cell lung cancer - Phase2 study of Nab-Paclitaxel in patients with unresectable or advanced squamous cell lung cancer | JPRN-UMIN000014558 |
| Randomized phase II study of carboplatin + paclitaxel + bevacizumab or cisplatin + pemetrexed + bevacizumab in patients with previously untreated locally advanced or metastatic non-squamous non-small cell lung cancer (CLEAR study) | Randomized phase II study of carboplatin + paclitaxel + bevacizumab or cisplatin + pemetrexed + bevacizumab in patients with previously untreated locally advanced or metastatic non-squamous non-small cell lung cancer (CLEAR study) - Randomized phase II study of CBDCA + PTX + BEV or CDDP + PEM + BEV in patients with previously untreated locally advanced or metastatic non-sq NSCLC (CLEAR study) | JPRN-UMIN000013354 |
| PhaseI/II study of carboplatin plus nab-paclitaxel plus bevacizumab administered to advanced non-squamous non-small cell lung cancer. | PhaseI/II study of carboplatin plus nab-paclitaxel plus bevacizumab administered to advanced non-squamous non-small cell lung cancer. - PhaseI/II study of carboplatin plus nab-paclitaxel plus bevacizumab administered to advanced non-squamous non-small cell lung cancer. | JPRN-UMIN000013333 |
| Phase II Study of Nab-paclitaxel and Carboplatin Plus Bevacizumab as First-Line Chemotherapy for Reccurent or stage IIIB and IV Nonsquamous Non-Small-Cell Lung Cancer (ALCT004) | Phase II Study of Nab-paclitaxel and Carboplatin Plus Bevacizumab as First-Line Chemotherapy for Reccurent or stage IIIB and IV Nonsquamous Non-Small-Cell Lung Cancer (ALCT004) - Phase II Study of Nab-PTX and CBDCA Plus Bev With Maintenance Bev As First-Line Chemotherapy for Reccurent or Advanced Non-sq NSCLC (ALCT004) | JPRN-UMIN000013310 |
| Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer | A Phase I/II Study of Indoximod in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Adenocarcinoma of the Pancreas | NCT02077881 |
| Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma | Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma | NCT02075021 |
| Treatment With Nab-paclitaxel in Cutaneous SCC | Phase II Trial of Nab-Paclitaxel as First Line Cytotoxic Chemotherapy in Patients With Unresectable and Metastatic Cutaneous Squamous Cell Carcinoma | NCT02076243 |
| Prospective cohort study for safety and efficacy of low dose nab-paclitaxel | Prospective cohort study for safety and efficacy of low dose nab-paclitaxel - Cohort study of low dose nab-paclitaxel | JPRN-UMIN000013275 |
| Phase 2 Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC) | A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC) | EUCTR2013-003713-18-BE |
| A Phase II Study of Carboplatin plus weekly nab-Paclitaxel in combination with Bevacizumab in chemo-naive patients with stage IIIB and IV non-squamous, non-small cell lung cancer | A Phase II Study of Carboplatin plus weekly nab-Paclitaxel in combination with Bevacizumab in chemo-naive patients with stage IIIB and IV non-squamous, non-small cell lung cancer - Phase II study of CBDCA+weekly nab-PTX+Bev in chemo-naive patients with stage IIIB and IV non-sq, non-small cell lung cancer | JPRN-UMIN000013224 |
| A Phase I Study of Carboplatin and nab-Paclitaxel plus concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer | A Phase I Study of Carboplatin and nab-Paclitaxel plus concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer - Phase I study of CBDCA+nab-PTX+TRT with locally advanced NSCLC | JPRN-UMIN000013223 |
| Peri-operative chemotherapy with intraperitoneal and intravenous Paclitaxel plus TS-1 for serosa positive gastric cancer patients | Peri-operative chemotherapy with intraperitoneal and intravenous Paclitaxel plus TS-1 for serosa positive gastric cancer patients - GAPS study | JPRN-UMIN000013109 |
| efficacy and safety of Gemcitabine plus nab-paclitaxel in unresectable pancreas cancer | efficacy and safety of Gemcitabine plus nab-paclitaxel in unresectable pancreas cancer - Gemcitabine plus nab-paclitaxel treatment for pancreas cancer | JPRN-UMIN000013206 |
| Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer | A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer | NCT02092363 |
| Phase2 study of Carboplatin / Nab-paclitaxel + Bevacizumab to non-small-cell lung cancer (non-squamous cell carcinoma) with malignant pleural efussion | Phase2 study of Carboplatin / Nab-paclitaxel + Bevacizumab to non-small-cell lung cancer (non-squamous cell carcinoma) with malignant pleural efussion - Phase2 study of CBDCA / Nab-PAC + Bevacizumab to non-small-cell lung cancer with malignant pleural efussion | JPRN-UMIN000013329 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery | A Phase I and Randomized Phase II Study of Nab-Paclitaxel/Gemcitabine With or Without AZD1775 for Treatment of Metastatic Adenocarcinoma of the Pancreas | NCT02194829 |
| Evaluation of Votrient in Angiosarcoma | Single-arm, Multicenter, Open Label Phase II Trial to Evaluate the Efficacy of Pazopanib in Combination With Paclitaxel in Advanced and Relapsed Angiosarcoma | NCT02212015 |
| Phase 1/2 study of triple combination chemotherapy with Carboplatin, nab-Paclitaxel, and Bevacizumab for chemotherapy-naïve stageIIIB/IV non- squamous non-small-cell lung cancer (TORG1424/OLCSG1402) | Phase 1/2 study of triple combination chemotherapy with Carboplatin, nab-Paclitaxel, and Bevacizumab for chemotherapy-naïve stageIIIB/IV non- squamous non-small-cell lung cancer (TORG1424/OLCSG1402) - CARboplatin, Nab-paclitaxel and AVAstin for non-small cell Lung cancer(CARNAVAL) (TORG1424/OLCSG1402) | JPRN-UMIN000014560 |
| A phase II study of low dose nab-paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer | A phase II study of low dose nab-paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer - A phase II study of nab-paclitaxel as second-line chemotherapy for gastric cancer | JPRN-UMIN000016196 |
| Feasibility study on dose-dense paclitaxel and carboplatin therapy in combination with bevacizumab as neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer | Feasibility study on dose-dense paclitaxel and carboplatin therapy in combination with bevacizumab as neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer - Feasibility study on ddTC plus Bev therapy (NAC) in ovarian cancer | JPRN-UMIN000016176 |
| Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours | A Phase Ib, Dose Finding Study Evaluating AZD1775 in Monotherapy, in Combination With Carboplatin and Paclitaxel, and in Combination With Only Carboplatin in Adult Asian Patients With Advanced Solid Tumours | NCT02341456 |
| Defining an Exposure Target for Weekly Paclitaxel Infusion in Breast Cancer Patients | Defining an Exposure Target for Weekly Paclitaxel Infusion in Breast Cancer Patients | NCT02338115 |
| Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery | A Pilot Study of Gemcitabine, Abraxane, Metformin and a Standardized Dietary Supplement (DS) in Patients With Unresectable Pancreatic Cancer | NCT02336087 |
| A phase II study of Bevacizumab plus Paclitaxel followed by Eribulin maintenance therapy in patients with HER2-negative metastatic breast cancer. | A phase II study of Bevacizumab plus Paclitaxel followed by Eribulin maintenance therapy in patients with HER2-negative metastatic breast cancer. - A phase II study of Eribulin maintenance therapy in patients with HER2-negative metastatic breast cancer. | JPRN-UMIN000015971 |
| A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies | A Multiarm, Open-label, Phase 1b Study of MLN2480 (an Oral A-, B-, and CRAF Inhibitor) in Combination With MLN0128 (an Oral mTORC 1/2 Inhibitor), or Alisertib (an Oral Aurora A Kinase Inhibitor), or Paclitaxel, or Cetuximab, or Irinotecan, in Adult Patients With Advanced Nonhematologic Malignancies | NCT02327169 |
| A Phase 3 clinical study to evaluate the safety and efficacy of the study medication Rociletinib compared to pemetrexed, gemcitabine, docetaxel, or paclitaxel in subjects with Non-Small Cell Lung Cancer | TIGER-3: A Phase 3, Open-label, Multicenter, Randomized Study of Oral Rociletinib (CO-1686) Monotherapy Versus Single-agent Cytotoxic Chemotherapy in Patients with Mutant EGFR Non-small Cell Lung Cancer (NSCLC) After Failure of at Least 1 Previous EGFR-directed Tyrosine Kinase Inhibitor (TKI) and Platinum-doublet Chemotherapy - TIGER-3 | EUCTR2014-003437-26-GB |
| Phase II trial of weekly Nab-Paclitaxel as second-line chemotherapy for unrecectable or recurrent advanced gastric cancer. | Phase II trial of weekly Nab-Paclitaxel as second-line chemotherapy for unrecectable or recurrent advanced gastric cancer. - Phase II trial of weekly Nab-Paclitaxel as second-line chemotherapy for unrecectable or recurrent advanced gastric cancer. | JPRN-UMIN000015968 |
| Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer | A Phase 1 Study of Talazoparib (BMN 673) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumors | NCT02317874 |
| Gemcitabine/Nab-Paclitaxel With HIGRT in Resectable Pancreatic Cancer | Feasibility Study of Neoadjuvant Gemcitabine/Nab-Paclitaxel and Hypofractionated Image-Guided Intensity Modulated Radiotherapy in Resectable and Borderline Resectable Pancreatic Cancer | NCT02318095 |
| A Study of RO6927005 Either As Monotherapy (Part A) or in Combination With Gemcitabine and Nab-Paclitaxel (Part B) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity in Patients With Mesothelin-positive Metastatic and/or Locally Advanced Malignant Solid Tumors | PHASE IA/IB, OPEN-LABEL, MULTICENTER, MULTIPLE ASCENDING DOSE STUDY FOLLOWED BY AN EXTENSION PHASE TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND ACTIVITY OF RO6927005, AN ANTI-MESOTHELIN (MSLN) RECOMBINANT CYTOLYTIC FUSION PROTEIN (cFP), ADMINISTERED EITHER ALONE (PART A) OR IN COMBINATION WITH GEMCITABINE AND NAB-PACLITAXEL (PART B) IN PATIENTS WITH MESOTHELIN-POSITIVE METASTATIC AND/OR LOCALLY ADVANCED MALIGNANT SOLID TUMORS | NCT02317419 |
| A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF PF-05280014 PLUS PACLITAXEL VERSUS TRASTUZUMAB PLUS PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER | A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF PF-05280014 PLUS PACLITAXEL VERSUS TRASTUZUMAB PLUS PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER | PER-010-14 |
| Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer | Phase II Study of Nab-Paclitaxel and Ramucirumab for the Second-line Treatment of Patients With Metastatic Gastroesophageal Cancer | NCT02317991 |
| Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer | The Use of Glutathione (GSH) for Prevention of Paclitaxel/Carboplatin (TAXOL/CBDCA) Induced Peripheral Neuropathy: A Phase III Randomized, Double-Blind Placebo Controlled Study | NCT02311907 |
| Phase II Study of nab-paclitaxel in Treated Patients with Advanced Non-Small Cell Lung Cancer | Phase II Study of nab-paclitaxel in Treated Patients with Advanced Non-Small Cell Lung Cancer - Phase II Study of nab-paclitaxel in Pretreated Patients with NSCLC | JPRN-UMIN000015841 |
| Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer | A Phase 1, Open-label, Multicenter, Safety Study of Nivolumab (Bms-936558) in Combination With Nab-pacitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-paclitaxel/Carboplatin in Stage Iiib/iv Non-small Cell Lung Cancer or Nab-paclitaxel in Metastastic Breast Cancer | NCT02309177 |
| Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma | Phase I/II,Multicenter,Randomized,Double-blind,Placebo-controlled Trial Evaluating the Efficacy and Safety of Nintedanib/Vargatef in Combination With Paclitaxel Chemotherapy for Treatment of Patients With BRAF Wildtype Metastatic Melanoma | NCT02308553 |
| Impact of Stent Diameter on Vascular Response After Self-expanding Paclitaxel-eluting Stent Implantation in the Superficial Femoral Artery: An Optical Frequency Domain Imaging Study | Impact of Stent Diameter on Vascular Response After Self-expanding Paclitaxel-eluting Stent Implantation in the Superficial Femoral Artery: An Optical Frequency Domain Imaging Study - Optimal Diameter of Self-expanding Paclitaxel-eluting Stent in the Superficial Femoral Artery | JPRN-UMIN000015485 |
| Study of Metformin With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer | Phase Ib Study of Metformin in Combination With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer | NCT02312661 |
| NEOPHOEBE: NEOADJUVANT TRASTUZUMAB + BKM120 IN COMBINATION WITH WEEKLY PACLITAXEL IN HER2- POSITIVE PRIMARY BREAST CANCER | NEOPHOEBE: PI3K INHIBITION IN HER2 OVEREXPRESSING BREAST CANCER: A PHASE II, RANDOMIZED, PARALLEL COHORT, TWO STAGE, DOUBLEBLIND, PLACEBO-CONTROLLED STUDY OF NEOADJUVANT TRASTUZUMAB VERSUS TRASTUZUMAB + BKM120 IN COMBINATION WITH WEEKLY PACLITAXEL IN HER2-POSITIVE, PIK3CA WILD-TYPE AND PIK3CA MUTANT PRIMARY BREAST CANCER. | PER-005-14 |
| Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors | Antitumor Immune Responses in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: a Phase II Study With Trastuzumab and Concomitant Weekly Paclitaxel in Patients With HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors. | NCT02307227 |
| TRIAL OF ABRAXANE AND GEMCITABINE TO TREATMENT PANCREATIC CANCER PATIENTS WHO CAN NOT HAVE SURGERY BECAUSE OF CANCER LOCATION | NAB-PACLITAXEL (ABRAXANE®) PLUS GEMCITABINE IN SUBJECTS WITH LOCALLY ADVANCED PANCREATIC CANCER (LAPC): AN INTERNATIONAL, OPEN-LABEL, MULTI-CENTER, PHASE 2 STUDY (LAPACT) - LAPACT | EUCTR2014-001408-23-IT |
| Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France | Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France | NCT02307812 |
| A phase 2 trial of weekly nab-paclitaxel for advanced non-small cell lung cancer without EGFR mutation nor ALK fusion gene in salvage setting | A phase 2 trial of weekly nab-paclitaxel for advanced non-small cell lung cancer without EGFR mutation nor ALK fusion gene in salvage setting - NICE Salvage study | JPRN-UMIN000016173 |
| Phase I/II study of HB-EGF-specific inhibitor BK-UM plus weekly paclitaxel therapy in gastric cancer with peritoneal metastasis after failure of first line treatment. | Phase I/II study of HB-EGF-specific inhibitor BK-UM plus weekly paclitaxel therapy in gastric cancer with peritoneal metastasis after failure of first line treatment. - Phase I/II study of BK-UM and Paclitaxel combination therapy as second line treatment in gastric cancer with peritoneal metastasis refractory. | JPRN-UMIN000015812 |
| Study of Nab-paclitaxel and Gemcitabine in Elderly Patients with Pancreatic Cancer | A Phase II Study of Nab-paclitaxel and Gemcitabine, in Elderly Patients with Previously Untreated, Metastatic Pancreatic Adenocarcinoma | EUCTR2014-003596-27-ES |
| Endostar Combined With Paclitaxel and Nedaplatin in Treating Patients With Recurrent or Metastatic Esophageal Cancer | A Phase II Trial of Recombinant Human Endostatin Injection (Endostar) Combined With Paclitaxel and Nedaplatin as First-line Therapy in Treating Patients With Recurrent or Metastatic Esophageal Cancer | NCT02350517 |
| Efficacy and safety of nab-paclitaxel plus carboplatin in patients with Carcinoma of unknown primary site | Efficacy and safety of nab-paclitaxel plus carboplatin in patients with Carcinoma of unknown primary site - Efficacy and safety of CBDCA plus nab-PTX in patients with CUP | JPRN-UMIN000016728 |
| A trial of MPDL3280A and nab-Paclitaxel in metastatic triple negative breast cancer | A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH NAB-PACLITAXEL COMPARED WITH PLACEBO WITH NAB-PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC TRIPLE-NEGATIVE BREAST CANCER | EUCTR2014-005490-37-DE |
| Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer | A Randomized Phase II Study of Pazopanib and Weekly Paclitaxel in Patients With Platinum Resistant/Refractory Ovarian Cancer Who Relapse During Bevacizumab Maintenance | NCT02383251 |
| Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors | Phase I Trial of the Combination of Nilotinib and Paclitaxel in Adults and Pediatric Patients With Refractory Solid Tumors | NCT02379416 |
| A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | A Phase Ib/II Study of CRLX101 in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT02389985 |
| Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma | A Phase III, Multicenter Randomized Controlled Study of Neo-adjuvant Chemotherapy Paclitaxel + Cisplatin Versus Surgery Alone for Stage IIA-IIIB Esophageal Squamous Cell Carcinoma | NCT02395705 |
| Clinical Post Market Clinical Follow-up (PMCF) on Peripheral Arteries Treated With SeQuent® Please Over The Wire (OTW) | CONSEQUENT ALL COMERS Clinical PMCF on Peripheral Arteries Treated With SeQuent® Please OTW Paclitaxel Coated Balloon Catheter in an All Comer Patient Population | NCT02460042 |
| The phaseI,II study of neoadjuvant chemotherapy of gemcitabine+nab-paclitaxel+S-1 for patients with locally-advanced pancreatic cancer | The phaseI,II study of neoadjuvant chemotherapy of gemcitabine+nab-paclitaxel+S-1 for patients with locally-advanced pancreatic cancer - GAS Study I/II | JPRN-UMIN000016630 |
| Nab-paclitaxel in Combination With Gemcitabine in Fragile Patients With Advanced Pancreatic Cancer | Phase I/II Study to Assess the Efficacy and Safety of Nab-paclitaxel in Combination With Gemcitabine for the Treatment of Fragile Patients With Advanced or Metastatic Pancreatic Cancer | NCT02382263 |
| Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC | A Phase I/II Study of Carboplatin/Nab-Paclitaxel and Pembrolizumab for Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | NCT02382406 |
| A Phase III Study of Pembrolizumab in Subjects with Gastric Cancer | A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel in Subjects with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma who Progressed after First-Line Therapy with Platinum and Fluoropyrimidine - Pembrolizumab (MK-3475) vs Paclitaxel in 2L Subjects with Advanced Gastric Adenocarcinoma | EUCTR2014-005241-45-FI |
| Intrapleural paclitaxel injection for ovarian and uterine cancer patients with malignant pleural effusions. | Intrapleural paclitaxel injection for ovarian and uterine cancer patients with malignant pleural effusions. - Intrapleural paclitaxel injection for malignant pleural effusions. | JPRN-UMIN000016527 |
| A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer | A Phase II Randomized, Double-Blind, Study of Ipatasertib (GDC-0068), an Inhibitor to AKT, in Combination With Paclitaxel as Neoadjuvant Treatment for Patients With Early Stage Triple Negative Breast Cancer | NCT02301988 |
| Epirubicin/Paclitaxel/Cyclophosphamide-Methotrexate-Fluorouracil (E-T-CMF) as adjuvant chemotherapy in high-risk patients with operable breast cancer | High-risk patients with operable breast cancer treated with adjuvant Epirubicin/Paclitaxel/Cyclophosphamide-Methotrexate-Fluorouracil (E-T-CMF). An observational study of the prognostic role of selected biomarkers on disease free survival and overall survival (HE10/08). | ACTRN12615000161527 |
| A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | A Phase III Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Nab-Paclitaxel for Chemotherapy-Naive Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer | NCT02367781 |
| A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131] | A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel or Atezolizumab in Combination With Carboplatin+Nab-Paclitaxel Versus Carboplatin+Nab-Paclitaxel in Chemotherapy-Naive Patients With Stage IV Squamous Non-Small Cell Lung Cancer | NCT02367794 |
| Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel | An Open-label Randomized Two-arm Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of Oral BAY 1217389 in Combination With Weekly Intravenous Paclitaxel Given in an Intermittent Dosing Schedule in Subjects With Advanced Malignancies | NCT02366949 |
| A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer | NCT02366143 |
| Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors | A Phase 1b Study of Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors | NCT02367352 |
| A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer | A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple- Negative Breast Cancer (FRIDA) | NCT02370238 |
| A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC | A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF PF- 06439535 PLUS PACLITAXEL-CARBOPLATIN AND BEVACIZUMAB PLUS PACLITAXEL -CARBOPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER. | NCT02364999 |
| Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and IIA2 Cervical Cancer Followed by Radical Hysterectomy | Phase II Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and IIA2 Cervical Cancer Followed by Radical Hysterectomy | NCT02432365 |
| A prospective, Belgian multi-center, single-arm, phase II study consists in a pre-surgery weekly paclitaxel and carboplatin chemotherapy treatment followed by epirubicin and cyclophosphamide chemotherapy treatment on the 2 weeks at patients with stage II and III sormono-sensitive breast cancer. | A prospective, Belgian multi-center, single-arm, phase II study of neoadjuvant weekly paclitaxel and carboplatin followed by dose dense epirubicin and cyclophosphamide in stage II and III triple negative breast cancer. | EUCTR2014-003723-21-BE |
| A Phase I/Ib Trial of the Oral Hedgehog inhibitor, LY2940680, in Combination with Weekly Paclitaxel in Patients with Platinum-Resistant, Recurrent Ovarian Cancer or Recurrent, Advanced, Solid Tumours. | A Phase I/Ib Trial of the Oral Hedgehog inhibitor, LY2940680, in Combination with Weekly Paclitaxel in Patients with Platinum-Resistant, Recurrent Ovarian Cancer or Recurrent, Advanced, Solid Tumours: open-label, non-randomised, multi-centre, dose escalation trial | ISRCTN15903698 |
| BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer | Phase I/II Study of BYL719 and Nab-Paclitaxel in Subjects With Locally Recurrent or Metastatic HER-2 Negative Breast Cancer | NCT02379247 |
| Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer | Phase I Study to Evaluate the Tolerability, Safety and Efficacy of BMN-673 in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumor Malignancies That Have BRCA Mutations or Triple Negative Metastatic Breast Cancer | NCT02358200 |
| Dose-confirmation Study of ASLAN001 Combined With Weekly Paclitaxel and Carboplatin in Advanced Solid Tumours, Followed by a Study in Patients With Stage I-III HER2 Positive Breast Cancer | Phase Ib Dose-confirmation Study of ASLAN001 Combined With Weekly Paclitaxel and Carboplatin in Advanced Solid Tumours, Followed by an Open-label Phase II Study in Patients With Stage I-III HER2 Positive Breast Cancer | NCT02396108 |
| Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer | A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer | NCT02037529 |
| Study of Trametinib and Nab-paclitaxel in Patients With Melanoma | Phase I Study of Trametinib and Nab-paclitaxel in Patients With Melanoma | NCT02300935 |
| Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC) | Nab-paclitaxel (Abraxane) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC): An International, Open-label, Multi-center, Phase 2 Study (LAPACT). | NCT02301143 |
| Study on the addition of Nab-paclitaxel (Abraxane) to capecitabine and oxaliplatin in the first-line treatment of metastastasized oesophagogastric carcinoma | A phase Ib/II study on the addition of Nab-paclitaxel (Abraxane) to capecitabine and oxaliplatin in the first-line treatment of metastastasized oesophagogastric carcinoma - ACTION | EUCTR2014-001333-88-NL |
| The Efficacy and Safety of Nab-paclitaxel in Pretreated Patients With Extensive Disease of Small Cell Lung Cancer | Single Arm Phase II Clinical Trial to Investigate the Efficacy and Safety of Nab-paclitaxel as a Single Agent in the Small Cell Lung Cancer Patients With Extensive Disease and Failed to First Line/ Second Line Chemotherapy | NCT02262897 |
| Paclitaxel-trastuzumab in EGFR-mutated NSCLC patients after progression on TKI-treatment; a pilot study | Paclitaxel-trastuzumab in EGFR-mutated NSCLC patients after progression on TKI-treatment; a pilot study - HER2 targeting in EGFR-mutated NSCLC | NL-OMON44719 |
| The effect of curcumin on the prevention of paclitaxel and platinum compounds-induced neuropathy in cancer patients | The effect of curcumin on the prevention of paclitaxel and platinum compounds-induced neuropathy in cancer patients: a randomized double-blinded controlled clinical trial | IRCT20191106045356N6 |
| Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer | An Exploratory Pilot Study of Nab-paclitaxel Based Induction Chemotherapy Followed by Response-Stratified Locoregional Therapy for Patients With Stage III and IV HPV-Related Oropharyngeal Cancer - the OPTIMA HPV Trial | NCT02258659 |
| Phase II study of pre and post operative combination chemotherapy using carboplatin and dose dense paclitaxel (dose dense TC therapy) for locally advanced cervical cancer | Phase II study of pre and post operative combination chemotherapy using carboplatin and dose dense paclitaxel (dose dense TC therapy) for locally advanced cervical cancer - SGSG016 study | JPRN-UMIN000015184 |
| Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE) | An Open Label Pilot Study of the NovoTTF-100L(O) System (NovoTTF Therapy) (200 kHz) Concomitant With Weekly Paclitaxel for Recurrent Ovarian Carcinoma | NCT02244502 |
| Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer | Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer | NCT02243007 |
| Phase II study of Carboplatin + nab-Paclitaxel followed by nab-Paclitaxel with chemotherapy naive advanced Non- Small Cell Lung Cancer | Phase II study of Carboplatin + nab-Paclitaxel followed by nab-Paclitaxel with chemotherapy naive advanced Non- Small Cell Lung Cancer - Phase II study of Carboplatin + nab-Paclitaxel followed by nab-Paclitaxel with chemotherapy naive advanced Non- Small Cell Lung Cancer | JPRN-UMIN000015144 |
| Study of Afuresertib Combined With Paclitaxel in Gastric Cancer | Phase Ib Study of Afuresertib Combined With Paclitaxel in Pre-treated HER2-negative Advanced Gastric Cancer | NCT02240212 |
| Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab plus paclitaxeland carboplatin versus placebo plus paclitaxel and carboplatin | Randomized, Multicenter, Double- Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin versus Placebo in Addition to Paclitaxel and Carboplatin in Subjects with StageIV/Recurrent Non-Small Cell Lung Cancer (NSCLC) with Squamous Histology. | EUCTR2014-002604-25-HU |
| Phase1/2 study of nab-Paclitaxel + trastuzumab therapy in 2nd line treatment for HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. | Phase1/2 study of nab-Paclitaxel + trastuzumab therapy in 2nd line treatment for HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab combined with fluoropyrimidine and platinum. - Phase 1/2 study to assess the the safety of nab-Paclitaxel + trastuzumab therapy and the concept of using trastuzumab beyond progression | JPRN-UMIN000014873 |
| Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer | Phase II Study of Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer | NCT02241551 |
| Efficacy and Safety of TC+AVASTIN Versus TC in Patients With Metastatic Nasopharyngeal Carcinoma | Multi-center, Randomized, Controlled, Open-label Study of Bevacizumab With Carboplatin and Paclitaxel Versus Carboplatin and Paclitaxel in Patients With Metastatic Nasopharyngeal Carcinoma | NCT02250599 |
| Prevention of Paclitaxel Neuropathy With Cryotherapy | Prevention of Paclitaxel Neuropathy With Cryotherapy | NCT02230319 |
| Phase I/II study of biweekly nab-paclitaxel in patients with platinum-pretreated non-small cell lung cancer (NJLCG1402) | Phase I/II study of biweekly nab-paclitaxel in patients with platinum-pretreated non-small cell lung cancer (NJLCG1402) - Biweekly nab-PTX for pretreated NSCLC patients (NJLCG1402) | JPRN-UMIN000014893 |
| Clinical Trial to investigate the efficacy and safety of nintedanib/vargatef when combined with paclitaxel (chemotherapy) for treatment of patients suffering from metastatic melanoma with BRAF wildtyp | A Phase I/II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Nintedanib/Vargatef in Combination With Paclitaxel Chemotherapy for Treatment of Patients with BRAF Wildtype Metastatic Melanoma - Nipawilma | EUCTR2013-004458-34-DE |
| A phase I study of weekly nab-Paclitaxel/Carboplatin with concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer | A phase I study of weekly nab-Paclitaxel/Carboplatin with concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer - A phase I study of weekly nab-Paclitaxel/Carboplatin with concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer | JPRN-UMIN000014764 |
| A prospective study to explore the relationship between SPARC expression and efficacy of nab-paclitaxel as second-line chemotherapy for advanced gastric cancer (SYNAPSE study) | A prospective study to explore the relationship between SPARC expression and efficacy of nab-paclitaxel as second-line chemotherapy for advanced gastric cancer (SYNAPSE study) - A prospective study to explore the relationship between SPARC expression and efficacy of nab-paclitaxel as second-line chemotherapy for advanced gastric cancer (SYNAPSE study) | JPRN-UMIN000014789 |
| MK-3475 vs. paclitaxel, Docetaxel or vinflunine in metastatic urothelial cancer | A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel, Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer - MK-3475 vs. paclitaxel, Docetaxel or vinflunine in metastatic urothelial cancer | EUCTR2014-002009-40-BE |
| A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas | A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas | NCT02215447 |
| Study of hypofractionated radiotherapy with carboplatin and paclitaxel in palliative management of esophageal cancers | Study to assess the safety of hypofractionated radiotherapy with concurrent carboplatin and paclitaxel in palliative management of esophageal cancers. | ACTRN12614000821695 |
| A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer | A Randomized, Open Label, Phase 1/2 Trial of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 as Neoadjuvant Chemotherapy in Locally Advanced, Unresectable Pancreatic Cancer | NCT02210559 |
| A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response | A Prospective, Multicenter, Open-label Comparison of Pre-surgical Myocet/ Cyclophosphamide (MC) q3w Followed by Either MC or Paclitaxel - Depending on Early Response Assessment by Ultrasound or by Toxicity for Elderly Non Frail Primary Breast Cancer Patients With Increased Risk of Relapse. | NCT02214381 |
| A Study of PF-05280014 [Trastuzumab-Pfizer] or Herceptin® [Trastuzumab-EU] Plus Paclitaxel in HER2 Positive First Line Metastatic Breast Cancer Treatment | A phase 3 randomized, double-blind study of PF-05280014 plus paclitaxel versus trastuzumab plus paclitaxel for the first-line treatment of patients with HER2-positive metastatic breast cancer - RACE | CTRI/2014/07/004786 |
| Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer | A Phase 2, Open-Label, Multi-Center Study to Assess Safety and Efficacy of Second/Third-Line Treatment With NAB®-Paclitaxel (ABI-007) In Combination With Epigenetic Modifying Therapy Of CC-486, Or Immunotherapy of Durvalumab (MEDI4736), Or As Monotherapy In Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC): Abound.2L+ | NCT02250326 |
| Phase II pilot study of nab-paclitaxel in patients with metastatic or unresectable urothelial cancer previously treated with cisplatin-based chemotherapy. | Phase II pilot study of nab-paclitaxel in patients with metastatic or unresectable urothelial cancer previously treated with cisplatin-based chemotherapy. - Phase II pilot study of nab-paclitaxel in patients with metastatic or unresectable urothelial cancer previously treated with cisplatin-based chemotherapy. | JPRN-UMIN000015260 |
| Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia | A Phase 1, Multicenter, Open-label, Dose-escalation Study to Investigate the Safety and Pharmacokinetics of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia Secondary to Bile Duct Obstruction | NCT02267707 |
| Phase I open label trial of intraperitoneal paclitaxel in combination with intravenous cisplatin and oral capecitabine in patients with advanced gastric cancer and peritoneal metastases | Phase I open label trial of the safety and tolerability of intraperitoneal paclitaxel in combination with intravenous cisplatin and oral capecitabine in patients with advanced gastric cancer and peritoneal metastases | ACTRN12614001063606 |
| Phase II Study of Carboplatin+nab-Paclitaxel for Non-small Cell Lung Cancer with Interstitial Pneumonitis | Phase II Study of Carboplatin+nab-Paclitaxel for Non-small Cell Lung Cancer with Interstitial Pneumonitis - Phase II Study of Carboplatin+nab-Paclitaxel for Non-small Cell Lung Cancer with Interstitial Pneumonitis | JPRN-UMIN000015662 |
| Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2 | A Phase II, Single Arm, Open-Label, Multicenter, Safety and Tolerability Trial With Nab-Paclitaxel (ABRAXANE®) Plus Carboplatin Followed by Nab-Paclitaxel Monotherapy as First-Line Treatment for Subjects With Locally Advanced or Metastatic Nonsmall Cell Lung Cancer (NSCLC) and an Eastern Cooperative Oncology Group Performance Status of 2 (ABOUND.PS2) | NCT02289456 |
| A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC) | A Phase 1 Dose Escalation and Phase 2 Randomized, Placebo-Controlled Study of the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer (NSCLC) | NCT02412371 |
| A Trial of Weekly Paclitaxel With Oncothermia and Weekly cisPlatin With Oncothermia in Patients With Recurrent or Persistent Ovarian Cancer | A Randomized Phase 1 Trial Evaluating the Safety of Weekly Paclitaxel With Oncothermia and Weekly cisPlatin With Oncothermia in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma | NCT02344095 |
| Phase II trial of a low dose nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unrecectable or recurrent advanced gastric cancer. | Phase II trial of a low dose nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unrecectable or recurrent advanced gastric cancer. - Phase II trial of a low dose nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unrecectable or recurrent advanced gastric cancer. | JPRN-UMIN000015431 |
| A Phase 2, randomized, open-label, multicenter study to assess safety and efficacy of nab®-paclitaxel (ABI-007) with epigenetic modifying therapy of CC-486, and nab®-paclitaxel monotherapy as second-line treatment in subjects with advanced nonsquamous non-small cell lung cancer (NSCLC): ABOUND.2L | A Phase 2, randomized, open-label, multicenter study to assess safety and efficacy of nab®-paclitaxel (ABI-007) with epigenetic modifying therapy of CC-486, and nab®-paclitaxel monotherapy as second-line treatment in subjects with advanced nonsquamous non-small cell lung cancer (NSCLC): ABOUND.2L - ABI-007-NSCL-006 | NL-OMON41094 |
| Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer | A Randomised Phase II Pilot Study of 3 Weekly Cabazitaxel Versus Weekly Paclitaxel Chemotherapy in the First Line Treatment of HER2 Negative Breast Cancer | NCT03048942 |
| Phase II study of nab-paclitaxel in combination with carboplatin in patients with refractory small-cell lung cancer | Phase II study of nab-paclitaxel in combination with carboplatin in patients with refractory small-cell lung cancer - Phase II study of nab-paclitaxel in combination with carboplatin in patients with refractory small-cell lung cancer | JPRN-UMIN000015565 |
| Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer | A Phase 2 Trial of Liposomal Doxorubicin and Carboplatin in Patients With ER, PR, HER2 Negative Breast Cancer (TNBC) | NCT02315196 |
| Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG) | Phase II Study With Pazopanib and Weekly Paclitaxel in Metastatic or Locally Advanced Squamous Penile Carcinoma Patients Previously Treated With Cisplatin Based Chemotherapy | NCT02279576 |
| Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer | Prospective Phase I Study of Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer | NCT02283372 |
| A multicenter, open label, balanced, randomized, two treatment, Two sequence, single dose, crossover biostudy in breast cancer patient. | A MULTICENTER OPEN LABEL, BALANCED, RANDOMIZED, TWO-TREATMENT, TWO-PERIOD, TWO-SEQUENCE, SINGLE-DOSE, CROSSOVER BIOEQUIVALENCE STUDY OF PACLIALL(PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION MANUFACTURED BY PANACEA BIOTEC LTD., INDIA) WITH ABRAXANE® (PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION MANUFACTURED FOR CELGENE CORPORATION,USA) IN BREAST CANCER PATIENTS - PacliAll | CTRI/2014/10/005128 |
| Chemoradiotherapy for Advanced Esophageal Cancer | A Phase 2 Study of Palliative Chemo-Radiotherapy With Carbo-Taxol in Non-Curative Cancer of the Esophagus | NCT02297217 |
| Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC | Phase II Multicenter Trial of Neoadjuvant Cisplatin and Nab-paclitaxel for (N2) Defined Stage IIIA Non-Small Cell Lung Cancer (NSCLC) | NCT02276560 |
| A Study of Chemoradiotherapy Using Gem Plus Nab-paclitaxel for Pancreatic Cancer | A Phase I Study of Chemoradiotherapy Using Gemcitabine Plus Nab-paclitaxel for Unresectable Locally Advanced Pancreatic Adenocarcinoma | NCT02272738 |
| The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma (ACTION) | The ACTION Trial: a Phase Ib/II Study on the Addition of Nab-paclitaxel (Abraxane) to Capecitabine and Oxaliplatin in the First-line Treatment of Metastasized Oesophagogastric Carcinoma. | NCT02273713 |
| A mono-center, open, randomized phase II clinical trial to compare the efficacy of Paclitaxel plus Gemcitabine with Paclitaxel sequential Gemcitabine in the first-lined treatment of recurrent metastatic breast cancer | A mono-center, open, randomized phase II clinical trial to compare the efficacy of Paclitaxel plus Gemcitabine with Paclitaxel sequential Gemcitabine in the first-lined treatment of recurrent metastatic breast cancer | ChiCTR-IPR-14005583 |
| Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma | Phase 2 Single Arm Trial of Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (HNSCC) | NCT02270814 |
| A study to compare the effects of ipatasertib in combination with paclitaxel to placebo in combination with paclitaxel in patients with early stage triple negative breast cancer. | A phase II randomized, double-blind study of ipatasertib (GDC-0068), an inhibitor to Akt in combination with paclitaxel as neoadjuvant treatment for patients with early stage triple negative breast cancer. | EUCTR2014-003029-16-ES |
| Study to evaluate the benefit and safety of a drug, paclitaxel, in the treatment of advanced ovarian cancer by applying intraperitoneally for three hours a day in the days following surgery, in which disease malignant ovarian tumor was removed and chemotherapy was administered hyperthermic intraoperative intraperitoneally. | EFFICACY AND SAFETY OF EARLY POSTOPERATIVE CHEMOTHERAPY INTRAPERITONEAL (EPIC) WITH PACLITAXEL IN THE RADICAL SURGERY TREATMENT OF OVARIAN PERITONEAL CARCINOMATOSIS | EUCTR2014-002850-38-ES |
| Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment | Phase II Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment of HER2 Amplified Advanced Gastric, Gastroesophageal Junction and Esophageal Cancer | NCT02274012 |
| Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers | A Phase 1 Open-label Study of the Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers | NCT02269293 |
| Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers | A Randomized, Open-Label, Multicenter, Phase 3 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers | NCT02264990 |
| Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response | Response, Resistance and Metastasis of Locally Advanced Breast Cancer (LABC, Stage 2B-3C) in a Multiethnic Cohort: A Phase II International Multicentric Study of Concurrent Paclitaxel and Radiation | NCT02280252 |
| Paclitaxel-trastuzumab in Lung cancer-patients with an EGFR mutation | Paclitaxel-trastuzumab in EGFR-mutated NSCLC patients after progression on TKI-treatment; a pilot study - HER2 in NSCLC | EUCTR2014-002238-29-NL |
| Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer | A Phase II, Multicenter, Randomized Trial of Eribulin Plus Gemcitabine (EG) vs.Paclitaxel Plus Gemcitabine (PG) in Patients With HER2-Negative Metastatic Breast Cancer as First -Line Chemotherapy | NCT02263495 |
| A multi-part, clinical study testing the safety and effectiveness of cobimetinib in combination with paclitaxel as initial treatment for patients with triple-negative (HER2 negative, Estrogen receptor negative, and Progesterone receptor negative) breast cancer that has spread. | A MULTISTAGE, PHASE II, STUDY EVALUATING THE SAFETY AND EFFICACY OF COBIMETINIB IN COMBINATION WITH PACLITAXEL AS FIRST-LINE TREATMENT FOR PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER | EUCTR2014-002230-32-ES |
| A Phase I Study of Weekly Nab-Paclitaxel/Carboplatin in Chemotherapy-Naive Patients with Advanced Non-Small-Cell Lung Cancer | A Phase I Study of Weekly Nab-Paclitaxel/Carboplatin in Chemotherapy-Naive Patients with Advanced Non-Small-Cell Lung Cancer - A Phase I Study of Weekly Nab-Paclitaxel/Carboplatin in Chemotherapy-Naive Patients with Advanced Non-Small-Cell Lung Cancer | JPRN-UMIN000012788 |
| Randomized controlled trial for peripheral neuropathy comparing weekly Paclitaxel followed by FEC100 with Eribulin Mesilate followed by FEC100 as neoadjuvant chemotherapy in primary breast cancer patients. | Randomized controlled trial for peripheral neuropathy comparing weekly Paclitaxel followed by FEC100 with Eribulin Mesilate followed by FEC100 as neoadjuvant chemotherapy in primary breast cancer patients. - JONIE 3 Study | JPRN-UMIN000012817 |
| Nab-Paclitaxel to Paclitaxel in Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen. | A Multicentre Randomized Phase II Trial Comparing Nab-Paclitaxel to Paclitaxel in Patients With Advanced Urothelial Cancer Progressing on or After a Platinum Containing Regimen. | NCT02033993 |
| Sequential Paclitaxel and Oxaliplatin HIPEC Followed by XELOX plus Sintilimab in HER2-Negative Peritoneal Metastatic Gastric Cancer (S-HIPEC): A Multicenter, Open-Label, Randomized Trial | Sequential Paclitaxel and Oxaliplatin HIPEC Followed by XELOX plus Sintilimab in HER2-Negative Peritoneal Metastatic Gastric Cancer (S-HIPEC): A Multicenter, Open-Label, Randomized Trial | ChiCTR2500097205 |
| Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast Cancer | An Open-Label, Randomized, Two-stage Study to Determine Dose Optimization, Safety, and Noninferiority of Oral Paclitaxel + Encequidar Compared to IV Paclitaxel in Subjects With HER2 Negative Metastatic Breast Cancer | NCT06835400 |
| The efficacy and safety of paclitaxel polymer micelles and carboplatin in combination with Cadonilimab in the conversion therapy for Stage III unresectable lung squamous cell carcinoma: An open, single-arm Phase II trial | The efficacy and safety of paclitaxel polymer micelles and carboplatin in combination with Cadonilimab in the conversion therapy for Stage III unresectable lung squamous cell carcinoma: An open, single-arm Phase II trial - Prospective Phase II clinical study of chemotherapy combined with immunotransformation in the treatment of stage III unresectable lung squamous cell carcinoma | ChiCTR2500097154 |
| VITUS Post-Market Registry | A Prospective PMCF Study of Paclitaxel Drug-coated Balloon Angioplasty for the Treatment of Symptomatic Peripheral Arterial Disease | NCT06832631 |
| A Single-Center, Single-Arm Exploratory Clinical Study of Adebrelimab Combined with Paclitaxel Liposome and Cisplatin as Neoadjuvant Therapy for Locally Advanced Cervical Cancer | A Single-Center, Single-Arm Exploratory Clinical Study of Adebrelimab Combined with Paclitaxel Liposome and Cisplatin as Neoadjuvant Therapy for Locally Advanced Cervical Cancer | ChiCTR2500096824 |
| Clinical study on the combination of xindilimab, bevacizumab, and albumin paclitaxel for second-line treatment of upper gastrointestinal tract (NEC) | Clinical study on the combination of xindilimab, bevacizumab, and albumin paclitaxel for second-line treatment of upper gastrointestinal tract (NEC) | ChiCTR2500096757 |
| Efficacy and Safety of Sirolimus-coated Coronary Balloon Dilatation Catheter for De Novo Coronary Bifurcation Lesions | A Prospective, Multicenter, Noninferiority, Randomized Controlled Clinical Trial Evaluating the Safety and Efficacy of Sirolimus-coated Coronary Balloon Dilatation Catheter Vs Paclitaxel-coated Balloon Catheter for the Treatment of De Novo Coronary Bifurcation Lesions | NCT06822712 |
| Phase 2 study of neoadjuvant tri-weekly Nab-paclitaxel and Trastuzumab followed by FEC(5-FU/epirubicin/cyclophosphamide) in patients for HER2 positive breast cancer. | Phase 2 study of neoadjuvant tri-weekly Nab-paclitaxel and Trastuzumab followed by FEC(5-FU/epirubicin/cyclophosphamide) in patients for HER2 positive breast cancer. - Phase 2 study of neoadjuvant tri-weekly Nab-paclitaxel and Trastuzumab followed by FEC(5-FU/epirubicin/cyclophosphamide) in patients for HER2 positive breast cancer. | JPRN-UMIN000010579 |
| An open, single-arm, single-center Phase II trial of the efficacy and safety of pazopanib in combination with TGI/CIV for the treatment of recurrent or refractory rhabdomyosarcoma in children or children or adolescents | Evaluation of efficacy and safety of pazopanib combined with TGI/CIV(nab?Paclitaxel+ gemcitabine + isocyclophosphamide/cyclophosphamide +Irinotecan + vinorelbine) in the treatment for children or adolescents with recurrent/refractory rhabdomyosarcoma ——an open-label, single-arm, single-center,phase II clinical trial | ChiCTR2500096689 |
| An open label, multicenter, randomized, balanced, two treatment, two sequence, two period, crossover, single dose, pharmacokinetic, bioequivalence study of Paclitaxel protein-bound particles for injectable suspension (albumin-bound) 100 mg/vial in metastatic breast cancer patients. | A multicenter, open label, randomized, balanced, two treatment, two sequence, two period, crossover, single dose, bioequivalence study of Paclitaxel protein-bound particles for injectable suspension (albumin-bound) 100 mg/vial of Hetero Labs Limited, India with ABRAXANE® for injectable suspension (Paclitaxel protein-bound particles for injectable suspension) (albumin-bound) 100 mg/vial by Celgene Corporation Summit, NJ 07901 in metastatic breast cancer patients. - PAC | CTRI/2025/02/079937 |
| A single-arm, single-center phase II clinical study on the clinical efficacy and safety of Paclitaxel Polymeric Micelles for Injection combined with Fruquintinib Capsules in the second-line treatment of patients with advanced gastric cancer | A single-arm, single-center phase II clinical study on the clinical efficacy and safety of Paclitaxel Polymeric Micelles for Injection combined with Fruquintinib Capsules in the second-line treatment of patients with advanced gastric cancer | ChiCTR2500096559 |
| Adebrelimab Combined With Nab-paclitaxel, Oxaliplatin and Tegafur (AOS) for Perioperative Treatment of Locally Advanced Resectable GC/GEJ | A Phase II Clinical Trial of Adebrelimab Combined With Nab-paclitaxel, Oxaliplatin and Tegafur Gimeracil Oteracil Potassium Capsule for Perioperative Treatment of Locally Advanced Resectable Gastric/Gastroesophageal Adenocarcinoma | NCT06808971 |
| Low-dose Radiotherapy Combined With Chemotherapy and AK112 as Second-line Treatment in Patients With Advanced G/GEJ Cancer | Low-dose Radiotherapy Combined With Albumin-bound Paclitaxel and AK112 as Second-line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction(G.GEJ)Cancer Who Failed First-line Therapy:a Single,Phase II Trial | NCT06791148 |
| Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer | Randomized Phase II Clinical Study of Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Locally Advanced or Metastatic Pancreatic Cancer | NCT06789679 |
| CRISTAL-APC - a trial of chemokine receptor inhibition for patients with pancreatic cancer | A multi-centre, open-label Phase I/randomised Phase II study of VP-002, a C-C motif chemokine receptor 1 (CCR1) inhibitor, given orally in combination with nab-paclitaxel and gemcitabine (nPG) to patients with advanced pancreatic ductal adenocarcinoma | ISRCTN16463547 |
| T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) | A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial) | NCT01853748 |
| A clinical study of patritumab deruxtecan in people with breast cancer | An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) - MK-1022-010 | CTIS2024-514376-40-00 |
| A Phase 2 Study of Relacorilant in Combination with Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (BELLA) | A Phase 2 Study of Relacorilant in Combination with Nab-Paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (BELLA) - CORT125134-557 | CTIS2024-517432-21-00 |
| Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer | Comparing Second-Line NABPLAGEM vs. Nab-paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma | NCT06783140 |
| Adjuvant S-1 and inserted paclitaxel in patients with stage II-III gastric or gastroesophageal junction adenocarcinoma:a prospective, single arm, single center, phase II, exploratory IIT clinical study | Adjuvant S-1 and inserted paclitaxel in patients with stage II-III gastric or gastroesophageal junction adenocarcinoma:a prospective, single arm, single center, phase II, exploratory IIT clinical study | ChiCTR2500095699 |
| AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer | A Randomized, Controlled, Multi-center Phase III Clinical Study of AK112 Plus Nab-paclitaxel Versus Placebo Plus Nab-paclitaxel as First-line Treatment for Locally Advanced Unresectable or Metastatic Triple-negative Breast Cancer | NCT06767527 |
| A study on the Combination of Gemcitabine, Cisplatin, Nab-Paclitaxel, and Tislelizumab in Treatment-Naïve Patients with Biliary Tract Cancer | A multicenter Phase 1b/2 Trial Investigating the Efficacy and Toxicity of the Combination of Gemcitabine, Cisplatin, Nab-Paclitaxel, and Tislelizumab in Treatment-Naïve Patients with Unresectable, Locally Advanced, or Metastatic Biliary Tract Cancers (GemCiNT) | KCT0010102 |
| A single-arm, open-label Phase II clinical study on the efficacy and safety of Ivosidenib combined with Nab-paclitaxel sequentially followed by spatially fractionated radiotherapy in the treatment of advanced solid tumors | A single-arm, open-label Phase II clinical study on the efficacy and safety of Ivosidenib combined with Nab-paclitaxel sequentially followed by radiotherapy in the treatment of advanced solid tumors | ChiCTR2400094961 |
| A multi-center, randomized, open, parallel-group, positive drug-controlled phase III clinical trial for evaluating the efficacy and safety of paclitaxel polymeric micelles for injection plus gemcitabine and paclitaxel for injection (albumin-bound) plus gemcitabine for injection in the first-line treatment of metastatic pancreatic cancer | A multi-center, randomized, open, parallel-group, positive drug-controlled phase III clinical trial for evaluating the efficacy and safety of paclitaxel polymeric micelles for injection plus gemcitabine and paclitaxel for injection (albumin-bound) plus gemcitabine for injection in the first-line treatment of metastatic pancreatic cancer | ChiCTR2400094707 |
| Efficacy and safety of PEG-rhG-CSF Combined with Camrelizumab and Chemotherapy in the Treatment of advanced squamous non-small cell lung cancer | The Efficacy and Safety of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor or Placebo Combined with Camrelizumab, Paclitaxel and Platinum-based Chemotherapy in the First-line Treatment of Advanced Squamous Cell Carcinoma of the Lung: A Phase II Randomized Controlled Trial | ChiCTR2400094635 |
| Second-line Immunotherapy for ES-SCLC | Selinexor Combined With Nab-paclitaxel and Adebrelimab as Second-line Treatment for ES-SCLC:A Prospective, Single-center, Single-arm Clinical Study | NCT06853678 |
| Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. | TTCC-2022-02: A Phase II, Multicenter, Randomized Study of Cetuximab Plus/ Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (ERBIOTAX) | NCT06856213 |
| Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer | Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer | NCT06910072 |
| SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC | SHR-A1811 Plus Pertuzumab in Combination With or Without Albumin-paclitaxel as Neoadjuvant Treatment for Early or Locally Advanced HER2-positive Breast Cancer:A Prospective, Randomized, Open-label, Phase II Trial. | NCT06927180 |
| Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer | Efficacy and Safety of Neoadjuvant Nab-Paclitaxel Combined With Oxaliplatin, S-1, and Sintilimab in Patients With Locally Advanced Resectable Early-onset Gastric Cancer: A Phase II, Single-Arm, Open-Label Clinical Trial | NCT07018063 |
| Neoadjuvant Low-Dose Radiotherapy Combined With Adebrelimab and Single-Agent Albumin-Bound Paclitaxel Chemotherapy for Early-Stage Oral Squamous Cell Carcinoma: A Prospective, Single-Arm Clinical Trial | Neoadjuvant Low-Dose Radiotherapy Combined With Adebrelimab and Single-Agent Albumin-Bound Paclitaxel Chemotherapy for Early-Stage Oral Squamous Cell Carcinoma: A Prospective, Single-Arm Clinical Trial | NCT07007364 |
| Glutamine combined with albumin-bound paclitaxel and gemcitabine in the treatment of advanced pancreatic cancer with KRAS G12D mutation | Glutamine combined with albumin-bound paclitaxel and gemcitabine as first-line treatment for advanced pancreatic cancer with KRAS G12D mutation: A prospective study | ChiCTR2500103114 |
| Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis | Intraperitoneal Paclitaxel With Standard Systemic NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis: Prospective Pilot Trial | NCT07030283 |
| A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS) | A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS) | NCT06992882 |
| Neoadjuvant pyrotinib plus trastuzumab combined with albumin-bound paclitaxel and carboplatin in patients with HER2+/HR+ early breast cancer: a single-arm multicenter phase 2 trail | Neoadjuvant pyrotinib plus trastuzumab combined with albumin-bound paclitaxel and carboplatin in patients with HER2+/HR+ early breast cancer: a single-arm multicenter phase 2 trail | ChiCTR2500102478 |
| A Clinical Trial of two drugs Paclitaxel (Test) and Abraxane (Reference) to study the pharmacokinetics and safety in patients with metastatic breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy | A Multicenter, Open Label, Randomized, Single Dose, Two Treatment, Two period, Two sequence, Crossover Bioequivalence Study of Paclitaxel Protein bound Particles for Injectable Suspension (Albumin bound) 100 mg per vial (Test) of Amneal EU, Limited, Ireland with Abraxane for Injectable Suspension (paclitaxel protein bound particles for injectable suspension) (albumin bound) 100 mg per Vial (Reference) of Abraxis BioScience, LLCs, in patients with metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy under fasting conditions - NIL | CTRI/2025/05/086951 |
| A multicenter, randomized, double-blind, parallel-positive control of the efficacy and safety of recombinant humanized anti-vascular endothelial growth factor monoclonal antibody injection (HOT-1010) versus bevacizumab in combination with carboplatin/paclitaxel in the treatment of advanced, metastatic or recurrent non-squamous cell non-small cell lung cancer | A multicenter, randomized, double-blind, parallel-positive control of the efficacy and safety of recombinant humanized anti-vascular endothelial growth factor monoclonal antibody injection (HOT-1010) versus bevacizumab in combination with carboplatin/paclitaxel in the treatment of advanced, metastatic or recurrent non-squamous cell non-small cell lung cancer | ChiCTR2500102299 |
| This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy. | Optimizing Neoadjuvant Therapy for HER2-Positive Breast Cancer Based on Dynamic Efficacy Monitoring: A Trial of Trastuzumab Plus Pyrotinib and Albumin-Bound Paclitaxel Followed by SHR-A1811 Plus Pertuzumab(OnThePath Trial) | NCT06973525 |
| Phase III study of Combined Intraperitoneal Paclitaxel and Systemic Chemotherapy Compared to Conventional Treatment in Gastric Cancer Patients with Peritoneal Metastasis | Randomized Controlled Trial of Combined Intraperitoneal Paclitaxel and Systemic Chemotherapy Compared to Conventional Treatment in Gastric Cancer Patients with Peritoneal Metastasis | KCT0010456 |
| Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer | A Randomized, Placebo-controlled, Parallel-group, Open-label Trial to Evaluate the Efficacy of Proactive Immune Tolerance Induction to Paclitaxel and Carboplatin in Patients With Gynecologic Cancer | NCT06977594 |
| Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer | Randomized Phase II Study of Pembrolizumab + Paclitaxel +/- Bevacizumab in Patients With Recurrent Triple-Negative Breast Cancer Who Received Perioperative Immunotherapy | NCT06976944 |
| Single-arm, Phase II clinical study of cardonilizumab combined with albumin-paclitaxel and cisplatin neoadjuvant therapy for locally advanced cervical cancer | Single-arm, Phase II clinical study of cardonilizumab combined with albumin-paclitaxel and cisplatin neoadjuvant therapy for locally advanced cervical cancer | ChiCTR2400094554 |
| A study of the effectiveness of pressurized hypothermia in improving paclitaxel combined with platinum-associated peripheral neuropathy in lung cancer patients | A study of the effectiveness of pressurized hypothermia in improving paclitaxel combined with platinum-associated peripheral neuropathy in lung cancer patients | ChiCTR2500101439 |
| A comparative study of paclitaxel-based concurrent radiotherapy and cisplatin combined with fluorouracil in the treatment of locally advanced esophageal squamous cell carcinoma, phase III clinical trial | Comparative study of paclitaxel-based concurrent radiotherapy and cisplatin combined with fluorouracil concurrent radiotherapy for locally advanced esophageal squamous cell carcinoma | ChiCTR2500100712 |
| Preoperative single arm, multicenter, prospective clinical study of pyrotinib maleate tablets combined with albumin paclitaxel and trastuzumab in the treatment of HER2 positive early or locally advanced breast cancer | Preoperative single arm, multicenter, prospective clinical study of pyrotinib maleate tablets combined with albumin paclitaxel and trastuzumab in the treatment of HER2 positive early or locally advanced breast cancer | ChiCTR2500100648 |
| DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer | A Phase 1b Study of BCL-XL Degrader DT2216 in Combination With Weekly Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer | NCT06964009 |
| Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer | Phase II, Single-Arm, Multicenter Clinical Study of Iparomlimab and Tuvonralimab in Combination With Paclitaxel Plus Cisplatin/Carboplatin and Radiotherapy for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer | NCT06942416 |
| Ivonescimab (AK112) Plus Paclitaxel as Second-line Therapy in Patients With Advanced G/GEJ Cancer | A Randomized, Controlled, Multi-center Phase II Study of Ivonescimab (AK112) Plus Paclitaxel Versus Paclitaxel With or Without Ramucirumab as Second-line Therapy in Subjects With Advanced Gastric or Gastroesophageal Junction(G.GEJ)Cancer Who Failed Immunochemotherapy | NCT06904300 |
| Ontegimod and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma | Phase I/II Clinical Trial of Ontegimod and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma: Reprogramming Tumor-associated Myeloid Cells | NCT06904378 |
| Screening of regimens to prevent neurotoxicity due to breast cancer treated with albumin-bound paclitaxel | Screening of regimens to prevent neurotoxicity due to breast cancer treated with albumin-bound paclitaxel | ChiCTR2500099237 |
| Combination Therapy of GCNT and Tislelizumab in Advanced Biliary Tract Cancer (GemCiNT) | A Multicenter Phase 1b/2 Trial Investigating the Efficacy and Toxicity of the Combination of Gemcitabine, Cisplatin, Nab-Paclitaxel, and Tislelizumab in Treatment Naïve Patients With Unresectable, Locally Advanced, or Metastatic Biliary Tract Cancers (GemCiNT) | NCT06893380 |
| Tautopathic treatment of cancer patients | A multicentric, double-blind, randomized, placebo-controlled, phase III study to evaluate the role of potentized (Tautopathy) form of chemotherapy in patients to determine the reduction in the pre-identified side effects of non-potentised chemotherapy drugs cisplatin, docetaxel, paclitaxel, carboplatin, epirubicin, gemcitabine, cyclophosphamide and adriamycin on cancer patients to enhance tolerance to chemotherapy regimen. | CTRI/2025/03/082132 |
| Paclitaxel Lipid Suspension for Patients with Platinum-Resistant /Refractory Ovarian Cancer | A Phase-3, Randomized, Parallel Group, Open-label, Multicenter, Two-Arm Treatment Study to Evaluate the Efficacy and Safety of Weekly Paclitaxel Lipid Suspension Compared with Weekly Conventional Paclitaxel in the Patients with Platinum-Resistant/Refractory Recurrent High-grade Serous Epithelial Ovarian Cancer Including Fallopian Tube And/or Primary Peritoneal Cancer | NCT06867562 |
| Phase II study of weekly nanoparticle albumin-bound paclitaxel for patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. (KTOSG1301) | Phase II study of weekly nanoparticle albumin-bound paclitaxel for patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. (KTOSG1301) - Phase II study of weekly nanoparticle albumin-bound paclitaxel for patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. (KTOSG1301) | JPRN-UMIN000010532 |
| Comparative Study of Adjuvant Therapy for Postoperative Cervical Gastric-type Adenocarcinoma | A Multicenter Randomized Study Comparing Paclitaxel and Platinum-based Concurrent Chemoradiotherapy With Short-term Adjuvant Chemotherapy Versus Platinum-based Monotherapy Concurrent Chemoradiotherapy in Patients With Postoperative Cervical Gastric-type Adenocarcinoma With High-risk Factors for Recurrence. | NCT06870565 |
| QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer | Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chidamide, Albumin-bound Paclitaxel and Gemcitabine as First-line Treatment for Metastatic Pancreatic Cancer | NCT06951997 |
| Phase 1/2a study of pressurized intraperitoneal aerosol chemotherapy using paclitaxel for mutli-drug resistant recurrent ovarian cancer | A Phase 1/2a Study to Evaluate the Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel for Platinum-resistant Recurrent Ovarian Cancer With Peritoneal Metastasis (PIPAC-OvPac 1/2a) | KCT0010597 |
| Efficacy and Safety of Ivonescimab Injection Combined with Nab-Paclitaxel Plus Lobaplatin as Neoadjuvant Therapy for Triple-Negative Breast Cancer in Stages II-III: A Prospective, Multicenter, Single-Arm Study | Efficacy and Safety of Ivonescimab Injection Combined with Nab-Paclitaxel Plus Lobaplatin as Neoadjuvant Therapy for Triple-Negative Breast Cancer in Stages II-III: A Prospective, Multicenter, Single-Arm Study | ChiCTR2400094426 |
| Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer | A Multi-center, Randomized, Open, Parallel-group, Positive Drug-controlled Phase III Clinical Trial for Evaluating the Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection Plus Gemcitabine and Paclitaxel for Injection (Albumin-bound) Plus Gemcitabine for Injection in the First-line Treatment of Metastatic Pancreatic Cancer | NCT06752811 |
| Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer | Neoadjuvant Phase II Study of Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer (The TELESCOPE Study) | NCT06604858 |
| Gemcitabine plus nab-PAclitaxel as switch maiNTEnance versus cONtinuation of modified FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: the PANThEON phase III Trial | Gemcitabine plus nab-PAclitaxel as switch maiNTEnance versus cONtinuation of modified FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: the PANThEON phase III Trial. - PANThEON | CTIS2024-515214-41-00 |
| PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer | A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Combined With Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Previously Untreated Pancreatic Cancer | NCT01839487 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer | Nab-Paclitaxel-based Re-induction Chemotherapy Followed by Response-stratified Chemoradiotherapy in Patients With Previously Treated Squamous Cell Carcinoma of the Head and Neck. | NCT01847326 |
| Study with carboplatin-cyclophosphamide versus paclitaxel with or without atezolizumab in advanced breast cancer | Biomarker discovery randomized phase IIb trial with carboplatin-cyclophosphamide versus paclitaxel with or without atezolizumaB as first-line treatment in advanced triple negative Breast cancer - Triple-B study | EUCTR2013-001484-23-NL |
| Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients with Locally Advanced or Metastatic Gallbladder Cancer | A Phase II Study of Gemcitabine, Cisplatin, Nab-Paclitaxel, and Durvalumab in Locally Advanced or Metastatic Gallbladder Cancer | NCT06591650 |
| Phase II study of neoadjuvant chemotherapy with the FEC followed by weekly nab-Paclitaxel(nanoparticle albumin-bound paclitaxel) for the operable breast cancer (KSCOG-BC07) | Phase II study of neoadjuvant chemotherapy with the FEC followed by weekly nab-Paclitaxel(nanoparticle albumin-bound paclitaxel) for the operable breast cancer (KSCOG-BC07) - Phase II study of neoadjuvant chemotherapy with the FEC followed by weekly nab-Paclitaxel for the operable breast cancer (KSCOG-BC07) | JPRN-UMIN000010504 |
| The BURAN Study of Buparlisib (AN2025) In Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | The BURAN Study of Buparlisib (AN2025) In Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma - AN2025H0301 | CTIS2024-517251-12-00 |
| Inetetamab Combined With Paclitaxel With/Without Pertuzumab for Previously Treated HER2-positive Advanced Breast Cancer | The Real World Study of First Line Treatment of HER2 Positive Recurrent/Metastatic Breast Cancer With Inetetamab Combined With Paclitaxel With/Without Pertuzumab(INTPOWER) | NCT06578299 |
| A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC | Camrelizumab Plus Nab-paclitaxel and Anti-histamine Drug Levocetirizine in Metastatic or Recurrent Triple-negative Breast Cancer: a Randomized, Double-arm, Phase 2 Randomized Controlled Trial | NCT06632405 |
| Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer | Treatment of Patients With Metastatic Pancreatic Cancer With Gemcitabine and Nab-Paclitaxel and Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) | NCT06576115 |
| Phase II trial of Combination with Paclitaxel, Carboplatin and Cetuximab (PCE) as a first line treatment in patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck | Phase II trial of Combination with Paclitaxel, Carboplatin and Cetuximab (PCE) as a first line treatment in patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck - Phase II trial of Combination with Paclitaxel, Carboplatin and Cetuximab (PCE) as a first line treatment in patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (CSPOR-HN 02) | JPRN-UMIN000010507 |
| Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Pain, Anxiety and Depression in Patients With Resectable Head and Neck Squamous Cell Carcinoma | Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Pain, Anxiety and Depression in Patients With Resectable Head and Neck Squamous Cell Carcinoma | NCT06575322 |
| Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Cognitive Function in Patients With Resectable Head and Neck Squamous Cell Carcinoma | Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Cognitive Function in Patients With Resectable Head and Neck Squamous Cell Carcinoma: a Prospective Cohort Study | NCT06576180 |
| Polymeric micellar paclitaxel plus cisplatin combined with tislelizumab as the first-line treatment of advanced unresectable esophageal squamous cell carcinoma: a phase II study | Polymeric micellar paclitaxel plus cisplatin combined with tislelizumab as the first-line treatment of advanced unresectable esophageal squamous cell carcinoma: a single-center phase II study | ChiCTR2400088576 |
| Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig in Resectable iCCA | Perioperative Therapy With Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig for Patients With Resectable Intrahepatic Cholangiocarcinoma (iCCA) - A Phase II Trial | NCT06569225 |
| A randomized controlled trial to evaluate if the use of a combination of chemotherapy and immunotherapy results in an increased surgical resection rate for patients with unresectable oral cavity cancers when compared to standard chemotherapy. | A Phase II randomized trial of neoadjuvant Carboplatin, Paclitaxel, low dose Nivolumab and metronomic therapy compared to standard chemotherapy in technically unresectable oral cavity squamous cancer - NIL | CTRI/2024/08/072823 |
| A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer | A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator’s Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer - Tropion-Breast05 | CTIS2023-503675-24-00 |
| A Prospective randomized study to compare haematological toxicities and response between two different chemotherapy regimens in chemoradiotherapy treatment of carcinoma of uterine cervix. | A Prospective randomized study to evaluate toxicities and locoregional response between two different concomitant chemoradiotherapy regimens using weekly cisplatin versus weekly cisplatin and paclitaxel in carcinoma of uterine cervix. - NIL | CTRI/2024/08/072198 |
| EORTC-1407-GUCG: A randomized phase III trial comparing conventional-dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) with high-dose chemotherapy using mobilizing paclitaxel plus ifosfamide followed by high-dose carboplatin and etoposide (TI-CE) as first salvage treatment in relapsed or refractory germ cell tumors (TIGER) | EORTC-1407-GUCG: A randomized phase III trial comparing conventional-dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) with high-dose chemotherapy using mobilizing paclitaxel plus ifosfamide followed by high-dose carboplatin and etoposide (TI-CE) as first salvage treatment in relapsed or refractory germ cell tumors (TIGER) - 1407-GUCG | CTIS2024-513509-30-00 |
| Chidamide in Combination With Carboplatin and Paclitaxel in Advanced Non-small Cell Lung Cancer | A Phase II Study of Chidamide or Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer | NCT01836679 |
| QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer | A Multicenter Phase I/II Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel With or Without NPC-1C in Patients With Metastatic or Locally Advanced Pancreatic Cancer Previously Treated With FOLFIRINOX | NCT01834235 |
| The Efficacy and Safety of Drug-Coated Balloon Versus Drug-Eluting Stent in Treating Chronic Total Occlusion of Coronary Arteries: A Multi-center, Randomized, Controlled, Non-inferiority Clinical Trial | Evaluation of the Safety and Efficacy of Paclitaxel Drug-coated Balloons Compared to Zotarolimus-eluting Stents in De Novo Chronic Total Occlusion: A Multicenter, Randomized, Controlled, Non-inferiority Trial | ChiCTR2400087491 |
| An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer | An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer | NCT06538207 |
| A Phase?Study of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer | A Phase?Study to Examine Tolerability and Safety of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and Safety of ONO-7475 in Combination With GnP in Patients With Metastatic Pancreatic Cancer as First-line Treatment | NCT06532331 |
| BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer | A Phase 1/2, Open-label Clinical Trial to Evaluate Safety and Efficacy of Combination Paclitaxel and BMX-001, in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer | NCT06620029 |
| A multicenter, single-arm clinical study of enlonstobart combined with nab-paclitaxel and platinum drugs neoadjuvant therapy for locally advanced cervical cancer (ENLONG-001) | A multicenter, single-arm clinical study of enlonstobart combined with nab-paclitaxel and platinum drugs neoadjuvant therapy for locally advanced cervical cancer (ENLONG-001) | ChiCTR2400090024 |
| PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer | A Multicenter, Open-lable, Randomized Phase III Study of PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer | NCT06616532 |
| Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal Carcinoma | A Phase I Study of Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal Carcinoma | NCT06611150 |
| A single-arm, open-label, single-center phase II clinical trial to evaluate the efficacy and safety of cadonilimab plus albumin-bound paclitaxel versus gemcitabine in patients with unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) | A single-arm, open-label, single-center phase II clinical trial to evaluate the efficacy and safety of cadonilimab plus albumin-bound paclitaxel versus gemcitabine in patients with unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) | ChiCTR2400093744 |
| Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma | A Single-Arm, Prospective Phase II Clinical Study on the Neoadjuvant Tislelizumab -Cetuximab - TP(cisplatin and Albumin-paclitaxel) Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma | NCT06728618 |
| STAR-PAK Study: Evaluating the Safety and Efficacy of PAK® (Paclitaxel Coated Balloon) in Treating Atherosclerotic Femoro-Popliteal Lesions | STAR-PAK Study: Evaluating the Safety and Efficacy of PAK® (Paclitaxel Coated Balloon) in Treating Atherosclerotic Femoro-Popliteal Lesions | NCT06734221 |
| A single-arm study on the neoadjuvant therapy of triple-negative breast cancer, combining albumin-bound paclitaxel, doxorubicin liposome, and cyclophosphamide. | A single-arm study on the neoadjuvant therapy of triple-negative breast cancer, combining albumin-bound paclitaxel, doxorubicin liposome, and cyclophosphamide. | ChiCTR2400093248 |
| Randomized phase II trial of Carboplatin plus weekly nab-Paclitaxel versus Cisplatin plus Gemcitabine in patients with chemo-naive stage IIIB/IV or postoperative recurrent squamous cell lung cancer | Randomized phase II trial of Carboplatin plus weekly nab-Paclitaxel versus Cisplatin plus Gemcitabine in patients with chemo-naive stage IIIB/IV or postoperative recurrent squamous cell lung cancer - NJLCG1302 CBDCA + weekly nab-PTX vs CDDP + GEM for SQ-NSCLC patients | JPRN-UMIN000010443 |
| A Single-arm, Single-center Phase II Clinical Study on the Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection Combined With Fruquintinib Capsules in the Second-line Treatment of Patients With Advanced Gastric Cancer | A Single-arm, Single-center Phase II Clinical Study on the Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection Combined With Fruquintinib Capsules in the Second-line Treatment of Patients With Advanced Gastric Cancer | NCT06706895 |
| Pucotenlimab, nab-paclitaxel and carboplatin versus pucotenlimab monotherapy for resected stage III acral melanoma: A prospective phase 2 randomized controlled trial | Pucotenlimab, nab-paclitaxel and carboplatin versus pucotenlimab monotherapy for resected stage III acral melanoma: A prospective phase 2 randomized controlled trial | ChiCTR2400092697 |
| “A Phase II trial of atezolizumab plus CArboplatin plus nab-Paclitaxel as first-line Therapy in metastatic triple-negative PD-L1 positive breast cancer patients” | A Phase II Trial of atezolizumab plus carboplatin plus nab-paclitaxel as first-line therapy in metastatic Triple-negative PD-L1 positive breast cancer patients - GIM25-CAPT | CTIS2024-519514-31-00 |
| Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors | Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors | NCT06684327 |
| Phase III randomized trial of atezolizumab in elderly patients with advanced Non-Small-Cell Lung Cancer and receiving monthly carboplatin with weekly paclitaxel chemotherapy | IFCT-1805 ELDERLY Phase III randomized trial of atezolizumab in elderly patients with advanced Non-Small-Cell Lung Cancer and receiving monthly carboplatin with weekly paclitaxel chemotherapy - IFCT-1805 | CTIS2024-515946-17-00 |
| A multicenter, randomized controlled, open-label phase II clinical study of the efficacy and safety of evoximab (AK112) combined with nab-paclitaxel versus nab-paclitaxel in second-line patients with extensive-stage small cell lung cancer | A multicenter, randomized controlled, open-label phase II clinical study of the efficacy and safety of evoximab (AK112) combined with nab-paclitaxel versus nab-paclitaxel in second-line patients with extensive-stage small cell lung cancer | ChiCTR2400092048 |
| Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases | Phase 1 Trial of Nab-Paclitaxel PIPAC (Pressurized Intraperitoneal Aerosolized Chemotherapy) Given in Combination With Second-Line Therapy for Gastric Cancer With Peritoneal Metastases | NCT06675136 |
| Bioequivalence Study of Paclitaxel for Injection (Albumin Bound) in Subjects With Breast Cancer | A Randomized, Open-label, Single-dose, Two-period, Two-way Crossover Bioequivalence Study of Paclitaxel for Injection (Albumin Bound) in Subjects With Breast Cancer | NCT06765590 |
| Comparision of the tolerability, response rates and cost analysis among the breast cancer patients receiving neoadjuvant chemotherapy - a randomized control trial | Comparision of the tolerability, response rates and cost analysis among the patients receiving weekly paclitaxel versus three weekly docetaxel as a part of neo adjuvant chemotherapy for breast cancer patients-a randomized control trial - NIL | CTRI/2024/11/076131 |
| A prospective clinical study on the first-line treatment of advanced thymic cancer with the combination of Tislelizumab and paclitaxel-albumin/carboplatin | A prospective clinical study on the first-line treatment of advanced thymic cancer with the combination of Tislelizumab and paclitaxel-albumin/carboplatin | ChiCTR2400091626 |
| Biolimus-Coated Balloon in de Novo Large Vessel Coronary Lesions | A Randomized Trial Comparing the Biolimus-coated Balloon and Paclitaxel-coated Balloon in de Novo Large Vessel Coronary Lesions | NCT06669793 |
| A prospective, multicenter, multi-cohort phase II clinical study:To evaluate the efficacy and safety of pembrolizumab in combination with cisplatin and paclitaxel in the neoadjuvant treatment of locally advanced head and neck squamous cell carcinoma | Prospective research and clinical trials of standardized and individualized treatment mode for head and neck squamous cell carcinoma | ChiCTR2400091507 |
| Cetuximab With or Without Paclitaxel After Pembrolizumab-Chemotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck. | A Phase II, Multicenter, Randomized Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (ERBIOTAX) - TTCC-2022-02 | CTIS2024-514953-31-00 |
| Imatinib combined with albumin paclitaxel, gemcitabine for clinical studies in advanced pancreatic ductal adenocarcinoma | Imatinib combined with albumin paclitaxel, gemcitabine for clinical studies in advanced pancreatic ductal adenocarcinoma | ChiCTR2400091331 |
| A clinical trial to study the prevention of pain syndrome caused by chemotherapy paclitaxel in cancer patients by oral drug duloxetine compared to placebo. | Randomized, double-blind, placebo-controlled study of oral duloxetine in the prevention of acute pain syndrome in patients receiving paclitaxel - NIL | CTRI/2024/10/075636 |
| YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer | A Randomized, Open, Parallel-controlled, Multi-center , Phase Ib/? Clinical Trial of YL-13027 and/or HY-0102 Combined With AG(Nab-paclitaxel and Gemcitabine) Regimen Chemotherapy for Metastatic Pancreatic Cancer | NCT06662669 |
| IN10018 with Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 Trial | IN10018 Plus Nab-Paclitaxel and Cadonilimab for Metastatic, Recurrent, or Persistent Gastric-Type Adenocarcinoma of the Cervix: a Multicenter, Single-Arm, Phase II Trial | NCT06654011 |
| Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer | A Phase 1b Trial of Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer | NCT06639724 |
| QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC | QL1706 Plus Nab-paclitaxel +/- Bevacizumab As 1L Treatment in Recurrent or Metastatic Triple-Negative Breast Cancer: a Non-randomized, Multicenter Phase II Study | NCT06786026 |
| Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer | Pilot Trial of the IL-4 Receptor Antagonist Dupilumab Plus Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer | NCT06637306 |
| A Clinical Study of Paclitaxel Cationic Liposomes for the Treatment of Patients With Advanced Solid Tumors | A Phase I Clinical Study Evaluating the Safety, Tolerability, and Pharmacokinetic Characteristics of Paclitaxel Cationic Liposome for Injection in the Treatment of Patients With Advanced Solid Tumors Via Transcatheter Arterial Infusion Therapy. | NCT06632574 |
| Adebrelimab combined with chemotherapy followed by adebrelimab plus albumin-bound paclitaxel/apatinib/fluzoparib as first-line treatment for extensive-stage small cell lung cancer: a prospective, multicenter, open, parallel cohort study | Adebrelimab combined with chemotherapy followed by adebrelimab plus albumin-bound paclitaxel/apatinib/fluzoparib as first-line treatment for extensive-stage small cell lung cancer: a prospective, multicenter, open, parallel cohort study | ChiCTR2400091715 |
| Carboplatin + Paclitaxel + Cetuximab (PCC) after failure of first line Pembrolizumab with or wothout chemotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck: CARPACCIO (CARboplatin PAClitaxel Cetuximab IO immuno-oncology) | Carboplatin + Paclitaxel + Cetuximab (PCC) after failure of first line Pembrolizumab with or without chemotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck: CARPACCIO (CARboplatin PAClitaxel Cetuximab IO immuno-oncology) | CTIS2024-512297-96-01 |
| The efficacy and safety of neoadjuvant Ineteramab, Pertuzumab, Toripalimab and Paclitaxel in Patients With Her2-Positive Breast Cancer (A Single-Center Clinical Trial) | The efficacy and safety of neoadjuvant Ineteramab, Pertuzumab, Toripalimab and Paclitaxel in Patients With Her2-Positive Breast Cancer (A Single-Center Clinical Trial) | ChiCTR2500104075 |
| Phase I trial of biweekly Carboplatin plus nab-Paclitaxel with concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer | Phase I trial of biweekly Carboplatin plus nab-Paclitaxel with concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer - Phase I trial of biweekly CBDCA + nab-PTX +TRT for LA-NSCLC | JPRN-UMIN000010480 |
| A phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic adenocarcinoma | A phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic adenocarcinoma - A phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic adenocarcinoma | JPRN-UMIN000012254 |
| First Line Chemotherapy for Advanced Cancer | Pase 2 Study of Albumin-bounded Paclitaxel Plus S-1 as First-line Chemotherapy for Locally Advanced or Metastatic Gastric or Gastro-esophageal Adenocarcinoma | NCT01980810 |
| A phase2 study to evaluate the efficacy and safety of weekly nab-paclitaxel in combination with carboplatin in patients with cancer of unknown primary | A phase2 study to evaluate the efficacy and safety of weekly nab-paclitaxel in combination with carboplatin in patients with cancer of unknown primary - Efficacy and safety of weekly nab-paclitaxel plus CBDCA in patients with CUP | JPRN-UMIN000012204 |
| Phase Ib/II Study of LY2780301 in Combination With Weekly PACLITAXEL in HER2-metastatic Breast Cancer | A Prospective, Multicentre, Uncontrolled, Phase Ib/II Study of LY2780301 in Combination With Weekly Paclitaxel in HER2-negative Metastatic or Locally Advanced Breast Cancer in Patients With and Without PI3/AKT/S6 Pathway Activation. - TAKTIC-IPC 2012-008 | NCT01980277 |
| Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer | Bevacizumab Plus Paclitaxel Optimization Study With Interventional Maintenance Endocrine Therapy in Advanced or Metastatic ER-positive HER2-negative Breast Cancer -BOOSTER Trial, a Multicenter Randomized Phase II Study- | NCT01989780 |
| Dose Escalation and Pharmacokinetic Study of Paclitaxel Liposome Injection in Treating Patients With Advanced Solid Tumor After Failure From Conventional Treatments | Dose Escalation and Pharmacokinetic Study of Paclitaxel Liposome Injection in Treating Patients With Advanced Solid Tumor After Failure From Conventional Treatments | NCT01994031 |
| Bevacizumab plus paclitaxel optimization study with interventional maintenance endocrine therapy in advanced or metastatic ER-positive HER2-negative breast cancer-BOOSTER trial, a multicenter randomized phase II study | Bevacizumab plus paclitaxel optimization study with interventional maintenance endocrine therapy in advanced or metastatic ER-positive HER2-negative breast cancer-BOOSTER trial, a multicenter randomized phase II study - JBCRG-M04 (BOOSTER) | JPRN-UMIN000012179 |
| Cisplatin vs Paclitaxel for Triple Negative Breast Cancer | A Randomized Phase II Study of Preoperative Cisplatin Versus Paclitaxel in Patients With Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker | NCT01982448 |
| A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer | A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Breast Cancer | NCT01973309 |
| Phase II study of nab-paclitaxel in patients with previously treated non-small cell lung cancer | Phase II study of nab-paclitaxel in patients with previously treated non-small cell lung cancer - Phase II study of nab-paclitaxel in patients with previously treated non-small cell lung cancer | JPRN-UMIN000012114 |
| Clinical Trial on Peripheral Arteries Treated With SeQuent® Please P Paclitaxel Coated Balloon Catheter | Clinical Trial on Peripheral Arteries Treated With SeQuent® Please P Paclitaxel Coated Balloon Catheter | NCT01970579 |
| Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA) | A Phase II Study of TTFields (150 kHz) Concomitant With Gemcitabine and TTFields Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma | NCT01971281 |
| Nab-paclitaxel as Second-line Therapy in Locally Advanced or Metastatic Squamous Lung Cancer | A Phase II Trial of Nab-paclitaxel as Second-line Therapy in Locally Advanced or Metastatic Squamous Lung Cancer After Failure of Platinum Doublet (Except Pemetrexed) Therapy | NCT01969955 |
| Pilot study of low-dose Nab-paclitaxel as adjuvant chemotherapy in patients with breast cancer | Pilot study of low-dose Nab-paclitaxel as adjuvant chemotherapy in patients with breast cancer - Pilot study of low-dose Nab-paclitaxel as adjuvant chemotherapy in patients with breast cancer | JPRN-UMIN000012047 |
| Phase II study of Carboplatin plus weekly nab-paclitaxel in elderly patients with non-small cell lung cancer using MNA | Phase II study of Carboplatin plus weekly nab-paclitaxel in elderly patients with non-small cell lung cancer using MNA - OSAKA-LCSG1305 | JPRN-UMIN000012051 |
| Phase II study of low-dose Nab-paclitaxel for advanced breast cancer | Phase II study of low-dose Nab-paclitaxel for advanced breast cancer - Phase II study of low-dose Nab-paclitaxel for advanced breast cancer | JPRN-UMIN000012048 |
| Chemotherapy Plus Bevacizumab in Elderly Non-small Cell Lung Cancer Patients | Phase II Trial of Geriatric Evaluation as Selection Criteria and Predictive Factor of Safety in Elderly Patients (= 70 Years) With Non-small Cell Lung Cancer (NSCLC)That Can be Treated With Bevacizumab, Carboplatin and Paclitaxel | NCT01980472 |
| "Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the ""Apact"" Study)" | A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma | NCT01964430 |
| Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | A Phase I/II Trial of Weekly Paclitaxel In Combination With Ganetespib In Patients With Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT01962948 |
| Randomized phase II study of 3 vs 6 courses of neoadjuvant carboplatin-paclitaxel chemotherapy in stage IIIC or IV epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinoma | Randomized phase II study of 3 vs 6 courses of neoadjuvant carboplatin-paclitaxel chemotherapy in stage IIIC or IV epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinoma | EUCTR2013-002520-17-IT |
| LDE225 in combination with gemcitabine and nab-paclitaxel in patients with locally advanced or metastasized pancreatic cancer | Phase I/II study of LDE225 in combination with gemcitabine and nab-paclitaxel in patients with locally advanced or metastasized pancreatic cancer - MATRIX | EUCTR2013-002370-51-NL |
| Cannabidiol for Prevention of Chemotherapy-induced Peripheral Neuropathy | A Phase II Trial of Cannabidiol for Prevention of Chemotherapy-induced Peripheral Neuropathy in Patients Receiving Oxaliplatin or Paclitaxel Based Chemotherapy | NCT04582591 |
| "ENGOT-cx1/BGOG-cx1: ""Randomized double-blind Phase II study comparing 3-weekly carboplatin + paclitaxel with or without concomitant and maintenance nintedanib (NINTEDANIB) in advanced or recurrent cervical carcinoma.""" | "ENGOT-cx1/BGOG-cx1: ""Randomized double-blind Phase II study comparing 3-weekly carboplatin (AUC 5) + paclitaxel 175 mg/m2 with or without concomitant and maintenance nintedanib (NINTEDANIB) in advanced or recurrent cervical carcinoma."" - ENGOT-cx1/BGOG-cx1: 3 weekly Carboplatin/Paclitaxel with or without nintedanib in cervix cancer" | EUCTR2012-004076-19-BE |
| FREERIDE STUDY, Freeway Paclitaxel Coated Balloon Catheter to Treat Peripheral Artery Disease | Phase III FREERIDE STUDY Freeway Randomized Angioplasty Study | NCT01960647 |
| Phase 2 trial of weekly Nab paclitaxel for advanced gastric cancer patients with prior chemotherapy | Phase 2 trial of weekly Nab paclitaxel for advanced gastric cancer patients with prior chemotherapy - Phase 2 trial of weekly Nab paclitaxel for advanced gastric cancer patients with prior chemotherapy | JPRN-UMIN000011882 |
| Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC) | Phase Ib Pilot Study to Evaluate Reparixin in Combination With Chemotherapy With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC) | NCT02001974 |
| Paclitaxel Liposome and Cisplatin as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer | Paclitaxel Liposome and Cisplatin as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer: an Open-label, Randomised Phase 3 Trial. | NCT01998347 |
| Phase II study of nab-paclitaxel for relapsed non-small cell lung cancer (NLCTG1302) | Phase II study of nab-paclitaxel for relapsed non-small cell lung cancer (NLCTG1302) - Phase II study of nab-PTX for relapsed NSCLC(NLCTG1302) | JPRN-UMIN000012343 |
| EWOC-1 Trial: Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer | EWOC-1 Trial: Multicenter, Randomized Trial of Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer | NCT02001272 |
| An investigator initiated, open label, prospective, randomized phase II study to compare the efficacy and safety of Paclitaxel plus Epirubicin with Paclitaxel plus Carboplatin as new adjunctive therapy on patients with local advanced breast cancer | An investigator initiated, open label, prospective, randomized phase II study to compare the efficacy and safety of Paclitaxel plus Epirubicin with Paclitaxel plus Carboplatin as new adjunctive therapy on patients with local advanced breast cancer | ChiCTR-TRC-14004142 |
| Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer | A Phase III, Randomized, Open-Label, Multi-Center, Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane®) as Maintenance Treatment After Induction With Nab-Paclitaxel Plus Carboplatin in Subjects With Squamous Cell Non-Small Cell Lung Cancer (NSCLC) | NCT02027428 |
| A phase II study of nab-Paclitaxel therapy in reductive dose for patients with advanced/recurrent gastric cancer after prior treatments including fluoropyrimidine (OGSG 1302) | A phase II study of nab-Paclitaxel therapy in reductive dose for patients with advanced/recurrent gastric cancer after prior treatments including fluoropyrimidine (OGSG 1302) - A phase II study of nab-Paclitaxel therapy in reductive dose for patients with advanced/recurrent gastric cancer after prior treatments including fluoropyrimidine (OGSG 1302) | JPRN-UMIN000012701 |
| Clinical research study comparing anti-tumor acitivty of an investigational drug (neratinib) plus paclitaxel and a combination therapy of trastuzumab (Herceptin) plus paclitaxel in patients with erbB-2 positive locally recurrent or metastatic breast cancer | A Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer - NeferTT | EUCTR2008-007803-10-GB |
| Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer | A Randomized, Open-Label, Two-Arm Study Of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel As First-Line Treatment For ErbB-2-Positive Locally Recurrent Or Metastatic Breast Cancer | NCT00915018 |
| A phase I/II study of chemoradiation with use of carboplatin/nab-paclitaxel and concurrent radiotherapy for local advanced non-small cell lung cancer | A phase I/II study of chemoradiation with use of carboplatin/nab-paclitaxel and concurrent radiotherapy for local advanced non-small cell lung cancer - A phase I/II study of chemoradiation with use of carboplatin/nab-paclitaxel and concurrent radiotherapy for local advanced non-small cell lung cancer | JPRN-UMIN000012719 |
| Gold | A Randomized, Double-blinded, Placebo Controlled, Multicentre Phase 3 Study to Assess the Efficacy and Safety of Olaparib (AZD2281) in Combination With Paclitaxel, Compared to Placebo in Combination With Paclitaxel, in Asian Patients With Advanced Gastric Cancer (Including the Gastro-oesophageal Junction) Who Have Progressed Following First Line Therapy | JPRN-jRCT2080222339 |
| Nab-paclitaxel Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection | A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Nab-paclitaxel and Gemcitabine in Treating Patients With Pancreatic Cancer After Curative Resection | NCT02023021 |
| Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal Melanoma | A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma | NCT02023710 |
| Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers | Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex) | NCT02020707 |
| Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Squamous Cell Carcinoma of Esophagus | A Phase II Trial of Neoadjuvant Chemotherapy With Nanoparticle Albumin-bound Paclitaxel and Fluorouracil Followed by Surgery in Patients With Locally Advanced Squamous Cell Carcinoma of Esophagus | NCT02033538 |
| An experimental study in women with cervical cancer to test the safety and activation of the patient's own immune system after treatment with chemotherapy in combination with a vaccine directed against an infection with Human Papilloma Virus Type 16 (HPV16). | A multicenter, open label Phase I/II study to determine the safety and immune modulating effects of the therapeutic Human Papilloma Virus Type 16 (HPV16) E6/E7 Synthetic Long Peptides Vaccine (ISA101) at different doses with or without interferon alpha as combination therapy with carboplatin and paclitaxel in women with HPV16 positive advanced or recurrent cervical cancer who have no curative treatment options. - CervISA | EUCTR2013-001804-12-NL |
| Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors | A Phase 1/2, Multicenter, Open-label, Dose-finding Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent or Refractory Solid Tumors. | NCT01962103 |
| A clinical trial to study the effects of combined therapy with Paclitaxel and Doxorubicin in comparison to Taxol® and Doxorubicin in female patients with metastatic breast cancer after failure of standard combination therapy.â?? | Open-label, comparative clinical study of the efficacy and safety of combined therapy with Paclitaxel (Biosyntez Laboratories Private Limited, India) and Doxorubicin in comparison to Taxol® (Bristol-Myers Squibb S.r.L., Italy) and Doxorubicin in female patients with metastatic breast cancer after failure of standard combination therapy. | CTRI/2013/12/004208 |
| A study in patients with metastatic pancreatic ductal adenocarcinoma, where abraxane and gemcitabine chemotherapy will be administered either on the same day, or abraxane will be administered 24 hours before gemcitabine. | Scheduling nab-paclItaxEl with GEmcitabine (SIEGE): Randomised phase II trial to investigate two different schedules of nab-paclitaxel (Abraxane) combined with gemcitabine as first line treatment for metastatic pancreatic ductal adenocarcinoma - SIEGE | EUCTR2013-001868-40-GB |
| Sequential Paclitaxel Plus Cisplatin Chemotherapy and Radiotherapy as 1st Line Treatment for Esophageal Squamous Cell Cancer | Sequential Paclitaxel Plus Cisplatin Chemotherapy and Radiotherapy as First Line Treatment for Metastatic Esophageal Squamous Cell Cancer:: a Phase II Single Center Prospective Clinical Trial | NCT02016274 |
| Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Lung Cancer | Phase II Study of Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin/Cisplatin in Stage ? B and IIIA Non-small Cell Lung Cancer Patients | NCT02016209 |
| Sequential Paclitaxel Chemotherapy and Radiotherapy as 1st Line Treatment for Elderly Esophageal Squamous Cell Cancer | Sequential Paclitaxel Chemotherapy and Radiotherapy as First Line Treatment for Elderly Metastatic Esophageal Squamous Cell Cancer:: a Phase II Single Center Prospective Clinical Trial | NCT02016287 |
| Feasibility study of adjuvant chemotherapy with nab-paclitaxel and carboplatin in patients with completely resected pathological IB squamous cell lung cancer, II and IIIA non-small cell lung cancer | Feasibility study of adjuvant chemotherapy with nab-paclitaxel and carboplatin in patients with completely resected pathological IB squamous cell lung cancer, II and IIIA non-small cell lung cancer - Feasibility study of adjuvant nab-PTX/CBDCA for StageIB SqLC, II and IIIA NSCLC | JPRN-UMIN000012505 |
| Safety and Efficacy Study of Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Cancer | A PHASE 2, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ABI-007 PLUS GEMCITABINE IN CHINESE PATEINTS WITH METASTATIC PANCREATIC ADENOCARCINOMA | NCT02017015 |
| A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer | A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer | NCT02005315 |
| A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Metastatic or Locally Advanced Breast Cancer | 'A Study of the Effect of First Line Treatment With Paclitaxel and Myocet in Combination With Herceptin on Overall Tumor Response in Patients With Metastatic or Locally Advanced Breast Cancer and HER2 Overexpression.' | NCT02015676 |
| GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer | A Two-part, Multicentre, International Phase I and II Trial Assessing the Safety and Efficacy of the Hsp90 Inhibitor Ganetespib in Combination With Paclitaxel Weekly in Women With High-grade Serous, High-grade Endometrioid, or Undifferentiated, Platinum-resistant Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT02012192 |
| A feasibility study of Anthracycline-based regimen followed by Nab-Paclitaxel as adjuvant chemotherapy for breast cancer.(SBCCSG-32) | A feasibility study of Anthracycline-based regimen followed by Nab-Paclitaxel as adjuvant chemotherapy for breast cancer.(SBCCSG-32) - A feasibility study of Anthracycline-based regimen followed by Nab-Paclitaxel as adjuvant chemotherapy for breast cancer.(SBCCSG-32) | JPRN-UMIN000012428 |
| Phase II study of nab-paclitaxel as second-line chemotherapy prior fluoropyrimidine resistance for metastatic or recurrent gastric cancer considering dose reduction on early points | Phase II study of nab-paclitaxel as second-line chemotherapy prior fluoropyrimidine resistance for metastatic or recurrent gastric cancer considering dose reduction on early points - Phase II study of nab-paclitaxel as second-line chemotherapy for metastatic or recurrent gastric cancer considering dose reduction on early points (CCOG1303) | JPRN-UMIN000012247 |
| A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer | A Randomized, Open-label Study of the Effect of Paclitaxel, Doxorubicin, and CMF Neoadjuvant Chemotherapy, With and Without Herceptin, on Tumor Response in Women With HER2-positive Breast Cancer | NCT01998906 |
| A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab | A Multi-part, Phase 1, Multi-center, Open-label Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel or Pembrolizumab in Patients With Relapsed or Refractory Esophagogastric Malignancies | NCT02013154 |
| Efficacy of Chinese original immune preparation combined with albumin paclitaxel and carboplatin in neoadjuvant treatment of triple negative breast cancer and exploration of immune sensitive subtypes | Efficacy of Chinese original immune preparation combined with albumin paclitaxel and carboplatin in neoadjuvant treatment of triple negative breast cancer and exploration of immune sensitive subtypes | ChiCTR2500104560 |
| Phase I/II study of Paclitaxel+Trastuzumab therapy in 2nd line treatment for advanced or recurrent gastric cancer with HER2 positive. | Phase I/II study of Paclitaxel+Trastuzumab therapy in 2nd line treatment for advanced or recurrent gastric cancer with HER2 positive. - PTX+Tmab(2nd) | JPRN-UMIN000011863 |
| An international multicentre clinical trial comparing two chemotherapy regimens in patients with advanced anal cancer | An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin plus 5-fluorouracil versus Carboplatin plus Weekly Paclitaxel in Patients with Inoperable Locally Recurrent or Metastatic Disease - InterAACT A Multicentre Randomised Phase II Advanced Anal Cancer Trial | EUCTR2013-001949-13-GB |
| Phase II trial of capecitabine (Xeloda®) + nab-paclitaxel (Abraxane®) in patients with metastatic pancreatic cancer | Phase II trial of capecitabine (Xeloda®) + nab-paclitaxel (Abraxane®) in patients with metastatic pancreatic cancer - Met.Panc.01 | EUCTR2013-001714-15-AT |
| Phase I trial of weekly nab-paclitaxel plus cyclophosphamide for metastatic breast cancer | Phase I trial of weekly nab-paclitaxel plus cyclophosphamide for metastatic breast cancer - Phase I trial of weekly nab-paclitaxel plus cyclophosphamide for metastatic breast cancer | JPRN-UMIN000010945 |
| Phase I study of combination chemotherapy with nab-paclitaxel and Nedaplatin as first-line treatment in patients with advanced squamous cell lung cancer. | Phase I study of combination chemotherapy with nab-paclitaxel and Nedaplatin as first-line treatment in patients with advanced squamous cell lung cancer. - Phase I study of combination chemotherapy with nab-paclitaxel and Nedaplatin as first-line treatment in patients with advanced squamous cell lung cancer. | JPRN-UMIN000010963 |
| Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) | A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly Nab®-Paclitaxel in Combination With Gemcitabine or Carboplatin, Compared to Gemcitabine/Carboplatin, as First Line Treatment in Subjects With ER, PgR, and HER2 Negative (Triple Negative) Metastatic Breast Cancer | NCT01881230 |
| Investigation of anti-tumoral effect and safety of combination therapy LD-GP (low dose gemcitabine and paclitaxel) therapy and sorafenib in patients with cisplatin-resistant advanced urothelial cancer. | Investigation of anti-tumoral effect and safety of combination therapy LD-GP (low dose gemcitabine and paclitaxel) therapy and sorafenib in patients with cisplatin-resistant advanced urothelial cancer. - Efficacy and safety of combination therapy of low dose gemcitabine and paclitaxeltherapy with sorafenib in patients with cisplatin-resistant urothelial cancer. | JPRN-UMIN000010957 |
| Clinical study for patients with breast cancer that has spread to other parts of the body and that does not respond to hormonal or anti-HER2 therapy ('triple negative disease'), comparing a chemotherapy treatment (carboplatin + gemcitabine) with an experimental treatment of nab-paclitaxel plus chemotherapy (carboplatin OR gemcitabine). | A PHASE 2/3, MULTI-CENTER, OPEN-LABEL, RANDOMIZED STUDY OF WEEKLY nab®-PACLITAXEL IN COMBINATION WITH GEMCITABINE OR CARBOPLATIN, COMPARED TO GEMCITABINE/CARBOPLATIN, AS FIRST LINE TREATMENT IN SUBJECTS WITH ER, PgR, AND HER2 NEGATIVE (TRIPLE NEGATIVE) METASTATIC BREAST CANCER - TNACITY | EUCTR2013-000113-20-AT |
| Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors | Randomized Phase II Trial of Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-Risk Germ Cell Tumors | NCT01873326 |
| Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling | Multi-arm, Non-randomized, Open-Label Phase IB Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated FGF Pathway Signaling | NCT01868022 |
| Paclitaxel for the Treatment of Upper-Extremity Arteriovenous Access Fistula Stenosis | The Use of Intravascular Paclitaxel for the Treatment of Upper-Extremity Arteriovenous Access Fistula Stenosis: A Randomized Study | NCT01868984 |
| A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer | NCT01862081 | |
| Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients | A Phase I/II Study of AZD5363 Combined With Paclitaxel in Patients With Advanced or Metastatic Breast Cancer. Comprising a Safety Run-In and a Placebo-controlled Randomised Expansion in ER+ve Patients Stratified by PIK3CA Mutation Status | NCT01625286 |
| A study to evaluate the addition of the tested drug (BKM120) to standard therapy (trastuzumab and paclitaxel) in the treatment of type HER2 positive early breast cancer before the surgery | NeoPHOEBE: Pi3k inhibition in Her2 OverExpressing Breast cancErA phase II, randomized, parallel cohort, two stage, double-blind, placebo-controlled study of neoadjuvant trastuzumab versus trastuzumab + BKM120 in combination with weekly paclitaxel in HER2-positive, PIK3CA wild-type and PIK3CA mutant primary breast cancer - NeoPHOEBE | EUCTR2012-000738-21-AT |
| Study comparing the efficacy of paclitaxel-bevacizumab with docetaxel in 2nd or 3rd treatment of lung cancer | Phase III study comparing the efficacy of paclitaxel-bevacizumab with docetaxel in 2nd or 3rd line of treatment of non squamous Non Small Cells Lung Cancer - Ultimate | EUCTR2012-004524-38-FR |
| Phase II study of EC followed by Nab-paclitaxel as neoadjuvant chemotherapy for HER2 negative with lymph node metastases | Phase II study of EC followed by Nab-paclitaxel as neoadjuvant chemotherapy for HER2 negative with lymph node metastases - Phase II study of EC followed by Nab-paclitaxel as neoadjuvant chemotherapy for HER2 negative with lymph node metastases | JPRN-UMIN000010685 |
| Phase II Study for Efficacy and Safety of nab-paclitaxel for Previously Treated Advanced Non-small Cell Lung Cancer | Phase II Study for Efficacy and Safety of nab-paclitaxel for Previously Treated Advanced Non-small Cell Lung Cancer - Phase II study of nab-PTX for previously treated adnvaced NSCLC | JPRN-UMIN000010737 |
| Phase II study for efficacy and safety of nab-paclitaxel and carboplatin combination chemotherapy for Previously untreated advanced non-small cell lung cancer | Phase II study for efficacy and safety of nab-paclitaxel and carboplatin combination chemotherapy for Previously untreated advanced non-small cell lung cancer - Phase II study of nab-PTX/CBDCA for elderly advanced NSCLC | JPRN-UMIN000010738 |
| Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors | A Phase 1b, Open-Label, Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Patients With Solid Tumors | NCT01862328 |
| Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel/Carboplatin vs. Paclitaxel /Carboplatin in Stage ? B and IIIA Squamous Cell Carcinoma of the Lung | Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel/Carboplatin vs. Paclitaxel /Carboplatin in Stage ? B and IIIA Squamous Cell Carcinoma of the Lung: Parallel Control and Single Center | NCT01872403 |
| Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors | Official Title: A Phase 1B/2 Study of the Safety and Tolerability of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors | NCT01858883 |
| Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer | Single Arm, Neoadjuvant, Phase II Trial of Pertuzumab and Trastuzumab Administered Concomitantly With Weekly Paclitaxel and FEC for Clinical Stage I-II HER2-Positive Breast Cancer | NCT01855828 |
| Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy | Double Blind, Placebo Controlled Study Assessing the Efficacy of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Patients With Platinum Pre-treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) | NCT01852292 |
| Pivotal Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon | ILLUMENATE Pivotal: ProspectIve, Randomized, SingLe-Blind, U.S. MuLti-Center Study to EvalUate TreatMent of Obstructive SupErficial Femoral Artery or Popliteal LesioNs With A Novel PacliTaxel-CoatEd Percutaneous Angioplasty Balloon | NCT01858428 |
| ILLUMENATE EU Randomized Clinical Trial | Prospective, Randomized, Multi-center, Single-blinded Study for the Treatment of Subjects Presenting With De Novo Occluded/Stenotic or Re-occluded/Restenotic Lesions of the Superficial Femoral or Popliteal Arteries Using Paclitaxel or Bare Percutaneous Transluminal Angioplasty Balloon Catheter | NCT01858363 |
| ILLUMENATE Global (ProspectIve, SingLe-Arm, Global MuLti-Center Study to EvalUate TreatMent of Obstructive SupErficial Femoral Artery or Popliteal LesioNs With A Novel PacliTaxel-CoatEd Percutaneous Angioplasty Balloon) | ILLUMENATE Global: Prospective, single-arm, global multi-center study to evaluate the safety and performance of the CVI paclitaxel-coated percutaneous angioplasty balloon catheter in the treatment of de novo or restenotic lesions (excluding in-stent lesions) in the superficial and/or popliteal arteries to establish blood flow and to maintain vessel patency. | ACTRN12613000511730 |
| Paclitaxol Every 2 Week Versus Paclitaxol Every 1 Week in the Adjuvant Treatment of Breast Cancer | An Open, Randomized, Parallel-group, Multicenter Clinical Study to Evaluate Efficacy and Safety of Paclitaxel Every 2 Weeks Compared Weekly in Adjuvant Treatment of Breast Cancer | NCT01848197 |
| clinical study for pediatric patients with solid tumors that have come back after disappearing or that don’t respond to any treatment, designed to find the safest and most tolerable dose of nab ®-paclitaxel and to asses the preliminary efficacy of the treatment. | A Phase 1/2, multicenter, open-label, dose-finding study to assess the safety, tolerability, and preliminary efficacy of weekly nab-paclitaxel in pediatric patients with recurrent or refractory solid tumors. | EUCTR2013-000144-26-IT |
| Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid Malignancies | A Phase I Study to Evaluate the Safety and Determine the Maximum Tolerated Dose (MTD) of Debio 1143 Combined With Carboplatin and Paclitaxel in Patients With Squamous Non-Small Cell Lung Cancer (NSCLC), Platinum-refractory Ovarian Cancer, and Basal-like/Claudin Low Triple Negative Breast Cancer (TNBC) | NCT01930292 |
| Phase II study of Nab-paclitaxel followed by FEC as neoadjuvant chemotherapy for the operable breast cancer | Phase II study of Nab-paclitaxel followed by FEC as neoadjuvant chemotherapy for the operable breast cancer - Phase II study of Nab-paclitaxel followed by FEC as neoadjuvant chemotherapy for the operable breast cancer | JPRN-UMIN000011048 |
| Phase IIa Open Label, Randomized Clinical Trial to Study Vintafolide and Paclitaxel in Subjects with Advanced Triple Negative Breast Cancer Using SPECT/CT scan with Etarfolatide (EC20) for Subject Selection | A Phase IIa Open Label, Randomized Clinical Trial to Study the Safety and Efficacy of Vintafolide and the Combination of Vintafolide and Paclitaxel Compared to Paclitaxel in Subjects with Advanced Triple Negative Breast Cancer Using Etarfolatide (EC20) Subject Selection - Vintafolide and vintafolide plus paclitaxel compared to paclitaxel alone in subjects with TNBC using | EUCTR2012-005170-65-SE |
| Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast Cancer | Neoadjuvant Phase II Trial of Paclitaxel in Combination With BKM120 in Endocrine Resistant Clinical Stage II or III Estrogen Receptor-Positive and HER2 Negative Breast Cancer | NCT01953445 |
| LDE225 and Paclitaxel in Solid Tumors | LDE225 in Combination With Paclitaxel in Patients With Advanced Solid Tumors - A Multicenter Phase I Trial | NCT01954355 |
| A phase I/II study of weekly nab-Paclitaxel/Cisplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer | A phase I/II study of weekly nab-Paclitaxel/Cisplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer - A phase I/II study of weekly nab-Paclitaxel/Cisplatin in NSCLC | JPRN-UMIN000011776 |
| PhaseII study of nab-paclitaxel for elderly patients for the recurrence or Stage IIIB/IV with non-small cell lung cancer. | PhaseII study of nab-paclitaxel for elderly patients for the recurrence or Stage IIIB/IV with non-small cell lung cancer. - PhaseII study of nab-paclitaxel for elderly patients for the recurrence or Stage IIIB/IV with non-small cell lung cancer. | JPRN-UMIN000011714 |
| Phase I open label trial of Abraxane (nab-paclitaxel) administered concurrently with radiotherapy in patients with locally advanced inoperable pancreatic adenocarcinoma. | Phase I open label trial of Abraxane (nab-paclitaxel) administered concurrently with radiotherapy in patients with locally advanced inoperable pancreatic adenocarcinoma. | ACTRN12613001013752 |
| DOUBLE-BLIND STUDY OF PF-05280014 PLUS PACLITAXEL VERSUS TRASTUZUMAB PLUS PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER | A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF PF-05280014 PLUS PACLITAXEL VERSUS TRASTUZUMAB PLUS PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER | EUCTR2013-001352-34-CZ |
| Phase II study of nab-paclitaxel and carboplatin with concurrent thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer | Phase II study of nab-paclitaxel and carboplatin with concurrent thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer - Phase II study of ABI + CBDCA + TRT for unresectable LA-NSCLC | JPRN-UMIN000011681 |
| Treatment of Patients With Advanced Pancreatic Cancer After Gemcitabine Failure. | A Prospective Study to Evaluate the Combination of Metformin With Paclitaxel in the Treatment of Patients With Advanced Pancreatic Cancer After Gemcitabine Failure. | NCT01971034 |
| BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors | An Open Label Phase I Dose Finding Study of BI 860585 Administered Orally in a Continuous Dosing Schedule as Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumours | NCT01938846 |
| Evaluating the Effectiveness of Paclitaxel-eluting Balloons for Below-the-knee Angioplasty in Patients With Critical Limb Ischemia | NCT01938872 | |
| The Feasibility Study of Adjuvant nab-paclitaxel+Carboplatin in Patients with Resected Stage IB-IIIA Non-Small-Cell Lung Cance | The Feasibility Study of Adjuvant nab-paclitaxel+Carboplatin in Patients with Resected Stage IB-IIIA Non-Small-Cell Lung Cance - The Feasibility Study of Adjuvant nab-paclitaxel+Carboplatin in Patients with Resected Stage IB-IIIA Non-Small-Cell Lung Cance | JPRN-UMIN000011315 |
| Phase II study of nab-paclitaxel and carboplatin for elderly patients with non-small cell lung cancer. (KRSG1303) | Phase II study of nab-paclitaxel and carboplatin for elderly patients with non-small cell lung cancer. (KRSG1303) - Phase II study of nab-paclitaxel and carboplatin for elderly patients with non-small cell lung cancer. (KRSG1303) | JPRN-UMIN000011534 |
| The Effect of Cannabidiol on Lean Body Mass in Patients Receiving Chemotherapy | The Effect of Medical Cannabidiol on Lean Body Mass in Patients Receiving Oxaliplatin or Paclitaxel Based Chemotherapy | NCT04585841 |
| Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer | Phase I Trial of the Proapoptotic Agonist, LCL161, and Gemcitabine Plus Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer | NCT01934634 |
| Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. | A Randomized, Double-blinded, Placebo Controlled, Multicentre Phase III Study to Assess the Efficacy and Safety of Olaparib (AZD2281) in Combination With Paclitaxel, Compared to Placebo in Combination With Paclitaxel, in Asian Patients With Advanced Gastric Cancer (Including the Gastro-oesophageal Junction) Who Have Progressed Following First Line Therapy | NCT01924533 |
| High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery | A Phase II Randomized Trial Evaluating the Addition of High or Standard Intensity Radiation to Gemcitabine and Nab-paclitaxel for Locally Advanced Pancreatic Cancer | NCT01921751 |
| A study evaluating the effect of a chemotherapy regimen on the menstrual and ovarian functions of young breast cancer patients | TRIUMPH TrialA phase II TRial evalUating the Menstrual and ovarian function of young breast cancer patients treated with a cycloPHosphamide-free regimen composed of doxorubicin and paclitaxel - TRIUMPH | EUCTR2013-000173-77-BE |
| Phase I-II trial of gemcitabine plus nab-paclitaxel (GemBrax) followed by FOLFIRINOX as first-line treatment of patients with metastatic pancreatic adenocarcinoma - GABRINOX | Phase I-II trial of gemcitabine plus nab-paclitaxel (GemBrax) followed by FOLFIRINOX as first-line treatment of patients with metastatic pancreatic adenocarcinoma - GABRINOX | EUCTR2012-003678-13-FR |
| A Phase II Trial of Adjuvant Radiotherapy Combined With Chemotherapy for Patients With High-risk Endometrial Cancer | A Phase II Clinical Trial of Adjuvant Postoperative Irradiation Combined With Paclitaxel/Carboplatin(TP) or Cisplatin/Doxorubicin/Cyclophosphamide (CAP) Chemotherapy for Patients With High-risk Endometrial Cancer | NCT01918124 |
| clinical study for pediatric patients with solid tumors that have come back after disappearing or that don’t respond to any treatment, designed to find the safest and most tolerable dose of nab ®-paclitaxel and to asses the preliminary efficacy of the treatment. | A Phase 1/2, multicenter, open-label, dose-finding study to assess the safety, tolerability, and preliminary efficacy of weekly nab-paclitaxel in pediatric patients with recurrent or refractory solid tumors. | EUCTR2013-000144-26-GB |
| A Study of MEHD7945A in Combination With Cisplatin and 5-Fluorouracil (5-FU) or Paclitaxel and Carboplatin in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) | A Phase 1b Open-Label Study of the Safety and Pharmacokinetics of MEHD7945A in Combination With Either Cisplatin and 5-FU or Paclitaxel and Carboplatin in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | NCT01911598 |
| Feasibility study of postoperative adjuvant carboplatin plus nab-paclitaxel for complete resected pathological stage II/IIIA non-small cell lung cancer | Feasibility study of postoperative adjuvant carboplatin plus nab-paclitaxel for complete resected pathological stage II/IIIA non-small cell lung cancer - FASTnab | JPRN-UMIN000011225 |
| Feasibility study of adjuvant chemotherapy with nanoparticle albumin-bound (nab)- paclitaxel and carboplatin in patients with completely resected pathological IB non small cell lung cancer | Feasibility study of adjuvant chemotherapy with nanoparticle albumin-bound (nab)- paclitaxel and carboplatin in patients with completely resected pathological IB non small cell lung cancer - Feasibility study of adjuvant chemotherapy with nanoparticle albumin-bound (nab)- paclitaxel and carboplatin in patients with completely resected pathological IB non small cell lung cancer | JPRN-UMIN000011215 |
| A multicenter, open label Phase I/II study to determine the safety and immune modulating effects of the therapeutic Human Papilloma Virus Type 16 (HPV16) E6/E7 Synthetic Long Peptides Vaccine (ISA101/ISA101b) immunotherapy in combination with standard of care therapy (carboplatin and paclitaxel with or without bevacizumab) in women with HPV16 positive advanced or recurrent cervical cancer who have no curative treatment options. | A multicenter, open label Phase I/II study to determine the safety and immune modulating effects of the therapeutic Human Papilloma Virus Type 16 (HPV16) E6/E7 Synthetic Long Peptides Vaccine (ISA101/ISA101b) immunotherapy in combination with standard of care therapy (carboplatin and paclitaxel with or without bevacizumab) in women with HPV16 positive advanced or recurrent cervical cancer who have no curative treatment options. - CervISA: ISA-HPV-01-12 | NL-OMON45132 |
| A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein | Phase IB, Open-Label, Multicenter, Dose-Escalation Study Followed by an Extension Phase to Evaluate the Safety, Pharmacokinetics and Activity of RO5479599, a Glycoengineered Antibody Against HER3, Administered in Combination With Pertuzumab and Paclitaxel in Patients With Metastatic Breast Cancer Expressing HER3 & HER2 Protein | NCT01918254 |
| Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA | A Phase 1b/2 Pilot Trial of Nab-Paclitaxel Plus Cisplatin Plus Gemcitabine (Nabplagem) in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDA) | NCT01893801 |
| RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND PHASE 1B/2 STUDY OF U3-1287 (AMG 888) IN COMBINATION WITH TRASTUZUMAB PLUS PACLITAXEL IN NEWLY DIAGNOSED HER2-POSITIVE METASTATIC BREAST CANCER (MBC) | RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND PHASE 1B/2 STUDY OF U3-1287 (AMG 888) IN COMBINATION WITH TRASTUZUMAB PLUS PACLITAXEL IN NEWLY DIAGNOSED HER2-POSITIVE METASTATIC BREAST CANCER (MBC) | PER-021-13 |
| Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors | A Phase 1 Study of ABT-888 (Veliparib) in Combination With Weekly Carboplatin and Paclitaxel in Advanced Solid Tumors | NCT01281150 |
